(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATING

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 15 March 2001 (15.03.2001)

(51) International Patent Classification7:

G01N 33/574

(10) International Publication Number WO 01/18542 A2

(US). (21) International Application Number: PCT/US00/24199 (22) International Filing Date:

. 1 September 2000 (01.09.2000)

(25) Filing Language: English

English (26) Publication Language:

(30) Priority Data: US 60/152,547 3 September 1999 (03.09.1999) 60/190,347 16 March 2000 (16.03.2000) US 60/191,321 21 March 2000 (21.03.2000) US 60/208,382 31 May 2000 (31.05.2000) US 60/220,467 20 July 2000 (20.07.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

60/152,547 (CON)
3 September 1999 (03.09.1999)
60/190,347 (CON)
16 March 2000 (16.03.2000)
60/191,321 (CON)
21 March 2000 (21.03.2000)
60/208,382 (CON)
31 May 2000 (31.05.2000)
60/220,467 (CON)
20 July 2000 (20.07.2000)

(71) Applicant (for all designated States except US): MIL-LENNIUM PREDICTIVE MEDICINE, INC. [US/US]; One Kendall Square Bldg. 700, Cambridge, MA 02139

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LEE, John [US/US]: 119 Walnut Street, Somerville, MA 02145 (US). THOMP-SHO, Pamela [US/US]; 83 Beech Street #2, Belmont, MA 02478 (US). LILLIE, James [US/US]; 119 Walnut Street, Somerville, MA 02145 (US).
- (74) Agent: SMITH, DeAnn, F.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THER-APY OF OVARIAN CANCER

(57) Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.

-1-

COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF OVARIAN CANCER

5 RELATED APPLICATIONS

The present application claims priority to U.S. provisional patent application serial no. 60/152,547, filed on September 3, 1999, U.S. provisional patent application serial no. 60/190,347, filed on March 16, 2000, U.S. provisional patent application serial no. 60/191,321, filed on March 21, 2000, U.S. provisional patent application serial no. 60/208,382, filed on May 31, 2000 and U.S. provisional patent application serial no. 60/220,467, filed on July 20, 2000, all of which are expressly incorporated by reference.

FIELD OF THE INVENTION

The field of the invention is ovarian cancer, including diagnosis, characterization, management, and therapy of ovarian cancer.

15

20

BACKGROUND OF THE INVENTION

Ovarian cancer is responsible for significant morbidity and mortality in populations around the world. Ovarian cancer is classified, on the basis of clinical and pathological features, in three groups, namely epithelial ovarian cancer (EOC; >90% of ovarian cancer in Western countries), germ cell tumors (circa 2-3% of ovarian cancer), and stromal ovarian cancer (circa 5% of ovarian cancer; Ozols et al., 1997, Cancer Principles and Practice of Oncology, 5th ed., DeVita et al., Eds. pp. 1502). Relative to EOC, germ cell tumors and stromal ovarian cancers are more easily detected and treated at an early stage, translating into higher/better survival rates for patients afflicted with these two types of ovarian cancer.

There are numerous types of ovarian tumors, some of which are benign, and others of which are malignant. Treatment (including non-treatment) options and predictions of patient outcome depend on accurate classification of the ovarian cancer. Ovarian cancers are named according to the type of cells from which the cancer is derived and whether the ovarian cancer is benign or malignant. Recognized histological tumor types include, for example, serous, mucinous, endometrioid, and clear cell

20

25

- 2 -

PCT/US00/24199

tumors. In addition, ovarian cancers are classified according to recognized grade and stage scales.

In grade I, the tumor tissue is well differentiated from normal ovarian tissue. In grade II, tumor tissue is moderately well differentiated. In grade III, the tumor tissue is poorly differentiated from normal tissue, and this grade correlates with a less favorable prognosis than grades I and II. Stage I is generally confined within the capsule surrounding one (stage IA) or both (stage IB) ovaries, although in some stage I (i.e. stage IC) cancers, malignant cells may be detected in ascites, in peritoneal rinse fluid, or on the surface of the ovaries. Stage II involves extension or metastasis of the tumor 10 from one or both ovaries to other pelvic structures. In stage IIA, the tumor extends or has metastasized to the uterus, the fallopian tubes, or both. Stage IIB involves extension of the tumor to the pelvis. Stage IIC is stage IIA or IIB in which malignant cells may be detected in ascites, in peritoneal rinse fluid, or on the surface of the ovaries. In stage III, the tumor comprises at least one malignant extension to the small bowel or the omentum, has formed extrapelvic peritoneal implants of microscopic (stage IIIA) or macroscopic (< 2 centimeter diameter, stage IIIB; > 2 centimeter diameter, stage IIIC) size, or has metastasized to a retroperitoneal or inguinal lymph node (an alternate indicator of stage IIIC). In stage IV, distant (i.e. non-peritoneal) metastases of the tumor can be detected.

The durations of the various stages of ovarian cancer are not presently known, but are believed to be at least about a year each (Richart et al., 1969, Am. J. Obstet. Gynecol. 105:386). Prognosis declines with increasing stage designation. For example, 5-year survival rates for patients diagnosed with stage I, II, III, and IV ovarian cancer are 80%, 57%, 25%, and 8%, respectively.

Despite being the third most prevalent gynecological cancer, ovarian cancer is the leading cause of death among those afflicted with gynecological cancers. The disproportionate mortality of ovarian cancer is attributable to a substantial absence of symptoms among those afflicted with early-stage ovarian cancer and to difficulty diagnosing ovarian cancer at an early stage. Patients afflicted with ovarian cancer most often present with non-specific complaints, such as abnormal vaginal bleeding, gastrointestinal symptoms, urinary tract symptoms, lower abdominal pain, and generalized abdominal distension. These patients rarely present with paraneoplastic

symptoms or with symptoms which clearly indicate their affliction. Presently, less than about 40% of patients afflicted with ovarian cancer present with stage I or stage II.

Management of ovarian cancer would be significantly enhanced if the disease could be

- 3 -

Ovarian cancer may be diagnosed, in part, by collecting a routine medical history from a patient and by performing physical examination, x-ray examination, and chemical and hematological studies on the patient. Hematological tests which may be indicative of ovarian cancer in a patient include analyses of serum levels of proteins designated CA125 and DF3 and plasma levels of lysophosphatidic acid (LPA).

detected at an earlier stage, when treatments are much more generally efficacious.

Palpation of the ovaries and ultrasound techniques (particularly including endovaginal ultrasound and color Doppler flow ultrasound techniques) can aid detection of ovarian tumors and differentiation of ovarian cancer from benign ovarian cysts. However, a definitive diagnosis of ovarian cancer typically requires performing exploratory laparotomy of the patient.

15

20

Potential tests for the detection of ovarian cancer (e.g., screening, reflex or monitoring) may be characterized by a number of factors. The "sensitivity" of an assay refers to the probability that the test will yield a positive result in an individual afflicted with ovarian cancer. The "specificity" of an assay refers to the probability that the test will yield a negative result in an individual not afflicted with ovarian cancer. The "positive predictive value" (PPV) of an assay is the ratio of true positive results (i.e. positive assay results for patients afflicted with ovarian cancer) to all positive results (i.e. positive assay results for patients afflicted with ovarian cancer + positive assay results for patients not afflicted with ovarian cancer). It has been estimated that in order for an assay to be an appropriate population-wide screening tool for ovarian cancer the assay must have a PPV of at least about 10% (Rosenthal et al., 1998, Sem. Oncol. 25:315-325). It would thus be desirable for a screening assay for detecting ovarian cancer in patients to have a high sensitivity and a high PPV. Monitoring and reflex tests would also require appropriate specifications.

Owing to the cost, limited sensitivity, and limited specificity of known methods
of detecting ovarian cancer, screening is not presently performed for the general
population. In addition, the need to perform laparotomy in order to diagnose ovarian
cancer in patients who screen positive for indications of ovarian cancer limits the

-4-

PCT/US00/24199

desirability of population-wide screening, such that a PPV even greater than 10% would be desirable.

Prior use of serum CA125 level as a diagnostic marker for ovarian cancer indicated that this method exhibited insufficient specificity for use as a general screening method. Use of a refined algorithm for interpreting CA125 levels in serial retrospective samples obtained from patients improved the specificity of the method without shifting detection of ovarian cancer to an earlier stage (Skakes, 1995, Cancer 76:2004). Screening for LPA to detect gynecological cancers including ovarian cancer exhibited a sensitivity of about 96% and a specificity of about 89%. However, CA125based screening methods and LPA-based screening methods are hampered by the presence of CA125 and LPA, respectively, in the serum of patients afflicted with conditions other than ovarian cancer. For example, serum CA125 levels are known to be associated with menstruation, pregnancy, gastrointestinal and hepatic conditions such as colitis and cirrhosis, pericarditis, renal disease, and various non-ovarian malignancies. Serum LPA is known, for example, to be affected by the presence of non-ovarian gynecological malignancies. A screening method having a greater specificity for ovarian cancer than the current screening methods for CA125 and LPA could provide a population-wide screening for early stage ovarian cancer.

stage III or stage IV cancers. Treatment at these stages is largely limited to cytoreductive surgery (when feasible) and chemotherapy, both of which aim to slow the spread and development of metastasized tumor. Substantially all late stage ovarian cancer patients currently undergo combination chemotherapy as primary treatment, usually a combination of a platinum compound and a taxane. Median survival for responding patients is about one year. Combination chemotherapy involving agents such as doxorubicin, cyclophosphamide, cisplatin, hexamethylmelamine, paclitaxel, and methotrexate may improve survival rates in these groups, relative to single-agent therapies. Various recently-developed chemotherapeutic agents and treatment regimens have also demonstrated usefulness for treatment of advanced ovarian cancer. For example, use of the topoisomerase I inhibitor topectan, use of amifostine to minimize chemotherapeutic side effects, and use of intraperitoneal chemotherapy for patients having peritoneally implanted tumors have demonstrated at least limited utility.

Presently, however, the 5-year survival rate for patients afflicted with stage III ovarian cancer is 25%, and the survival rate for patients afflicted with stage IV ovarian cancer is 8%.

In summary, the earlier ovarian cancer is detected, the aggressiveness of therapeutic intervention and the side effects associated with therapeutic intervention are minimized. More importantly, the earlier the cancer is detected, the survival rate and quality of life of ovarian cancer patients is enhanced. Thus, a pressing need exists for methods of detecting ovarian cancer as early as possible. There also exists a need for methods of detecting recurrence of ovarian cancer as well as methods for predicting and monitoring the efficacy of treatment. The present invention satisfies these needs.

SUMMARY OF THE INVENTION

10

15

20

25

30

The invention relates to a method of assessing whether a patient is afflicted with ovarian cancer. This method comprises the step of comparing the level of expression of a marker in a patient sample, wherein the marker is listed in Tables 1-11, and the normal level of expression of the marker in a control, e.g., a sample from a patient without ovarian cancer. A significant difference between the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with ovarian cancer. In a preferred embodiment, the marker is listed in Tables 2B or 2C (which are subsets of the markers listed in Table 2A), in Tables 3B or 3C (which are subsets of the markers listed in Table 3A), in Tables 4A or 5A (which are subsets of the markers listed in Tables 4 and 5, respectively), in Table 6A, in Tables 7A-7E or in Table 8. Preferably, a protein corresponding to the marker is a secreted protein or is predicted to correspond to a secreted protein (see, e.g. Tables 2D, 4A, 7A-7E). Alternatively, the marker can correspond to a protein which is normally expressed in ovarian tissue at a detectable level, to one having an extracellular portion, or both (see e.g., Table 8).

In one method, the marker(s) are preferably selected such that the positive predictive value of the method is at least about 10%. Also preferred are embodiments of the method wherein the marker is over- or under-expressed by at least two-fold in at least about 20% of stage I ovarian cancer patients, stage II ovarian cancer patients, stage III ovarian cancer patients, grade I ovarian cancer patients, grade I ovarian cancer patients, epithelial

5

15

20

25

ovarian cancer patients, stromal ovarian cancer patients, germ cell ovarian cancer patients, malignant ovarian cancer patients, benign ovarian patients, serous neoplasm ovarian cancer patients, mucinous neoplasm ovarian cancer patients, endometrioid neoplasm ovarian cancer patients and/or clear cell neoplasm ovarian cancer patients.

-6-

In one embodiment of the methods of the present invention, the patient sample is an ovary-associated body fluid. Such fluids include, for example, blood fluids, lymph, ascitic fluids, gynecological fluids, cystic fluids, urine, and fluids collected by peritoneal rinsing. In another embodiment, the sample comprises cells obtained from the patient. In this embodiment, the cells may be found in a fluid selected from the group consisting of a fluid collected by peritoneal rinsing, a fluid collected by uterine rinsing, a uterine fluid, a uterine exudate, a pleural fluid, and an ovarian exudate. In another embodiment, the patient sample is in vivo.

In accordance with the methods of the present invention, the level of expression of the marker in a sample can be assessed, for example, by detecting the presence in the sample of:

- a protein corresponding to the marker or a fragment of the protein (e.g. using a reagent, such as an antibody, an antibody derivative, or an antibody fragment, which binds specifically with the protein)
- a metabolite which is produced directly (i.e., catalyzed) or indirectly by a protein corresponding to the marker
- a transcribed polynucleotide (e.g. an mRNA or a cDNA), or fragment thereof, having at least a portion with which the marker is substantially homologous (e.g. by contacting a mixture of transcribed polynucleotides obtained from the sample with a substrate having one or more of the markers listed in Tables 1-11 fixed thereto at selected positions)
- a transcribed polynucleotide or fragment thereof, wherein the polynucleotide anneals with the marker under stringent hybridization conditions.

The methods of the present invention are particularly useful for patients with an identified pelvic mass or symptoms associated with ovarian cancer. The methods of the present invention can also be of particular use with patients having an enhanced risk of developing ovarian cancer (e.g., patients having a familial history of ovarian cancer,

5

20

25

patients identified as having a mutant oncogene, and patients at least about 50 years of age). The methods of the present invention may further be of particular use in monitoring the efficacy of treatment of an ovarian cancer patient (e.g. the efficacy of chemotherapy).

The methods of the present invention may be performed using a plurality (e.g. 2, 3, 5, or 10 or more) of markers. According to a method involving a plurality of markers, the level of expression in the sample of each of a plurality of markers independently selected from the markers listed in Tables 1-11 is compared with the normal level of expression of each of the plurality of markers in samples of the same type obtained from control humans not afflicted with ovarian cancer. A significantly enhanced level of expression of one or more of the markers listed in Tables 1, 1A, 2A, 4 and 6, 6A, 7A, 7B, 7D and 8, a significantly reduced level of expression of one or more of the markers listed in Tables 3A, 5, 7C and 7E, or some combination thereof, in the sample, relative to the corresponding normal levels, is an indication that the patient is afflicted with ovarian cancer. The markers of Tables 1-11 may also be used in combination with known ovarian cancer markers in the methods of the present invention.

In a preferred method of assessing whether a patient is afflicted with ovarian cancer (e.g., new detection ("screening"), detection of recurrence, reflex testing), the method comprises comparing:

a) the level of expression of a marker in a patient sample, wherein at least one marker is selected from the markers of Tables 1-11 and,

b) the normal level of expression of the marker in a control non-ovarian cancer sample.

A significant difference between the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with ovarian cancer.

The methods of the present invention further include a method of assessing the efficacy of a test compound for inhibiting ovarian cancer in a patient. This method comprises comparing:

a) expression of a marker in a first sample obtained from the patient and maintained in the presence of the test compound, wherein the marker is selected from the group consisting of the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8, and

PCT/US00/24199

5

WO 01/18542

b) expression of the marker in a second sample obtained from the patient and maintained in the absence of the test compound.

A significantly lower level of expression of the marker in the first sample, relative to the second sample, is an indication that the test compound is efficacious for inhibiting ovarian cancer in the patient. For example, the first and second samples can be portions of a single sample obtained from the patient or portions of pooled samples obtained from the patient.

The invention still further includes a method of assessing the efficacy of a test compound for inhibiting ovarian cancer in a patient. This method comprises comparing:

a) expression of a marker in a first sample obtained from the patient and maintained in the presence of the test compound, wherein the marker is selected from the group consisting of the markers listed in Tables 3A, 5, 7C and 7E, and

- b) expression of the marker in a second sample obtained from the patient and maintained in the absence of the test compound.
- A significantly enhanced level of expression of the marker in the first sample, relative to the second sample, is an indication that the test compound is efficacious for inhibiting the ovarian cancer in the patient.

The invention further relates to a method of assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient. This method comprises comparing:

25

30

15

- a) expression of a marker in a first sample obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the marker is selected from the group consisting of the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8, and
- b) expression of the marker in a second sample obtained from the patient following provision of the portion of the therapy.

PCT/US00/24199

A significantly lower level of expression of the marker in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer in the patient.

The invention further includes a method of assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient, comprising comparing: 5

> a) expression of a marker in a first sample obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the marker is selected from the group consisting of the markers listed in Tables 3A, 5, 7C and 7E, and

> b) expression of the marker in a second sample obtained from the patient following provision of the portion of the therapy.

A significantly enhanced level of expression of the marker in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer in the patient.

10

15

20

25

It will be appreciated that in these methods the "therapy" may be any traditional therapy for treating ovarian cancer including, but not limited to, chemotherapy, radiation therapy and surgical removal of tissue, e.g., an ovarian tumor. Thus, the methods of the invention may be used to evaluate a patient before, during and after therapy, for example, to evaluate the reduction in tumor burden.

The present invention therefore further comprises a method for monitoring the progression of ovarian cancer in a patient, the method comprising:

- a) detecting in a patient sample at a first time point, the expression of a marker, wherein the marker is selected from the group consisting of the markers listed in Tables 1-11;
 - b) repeating step a) at a subsequent time point in time; and
- c) comparing the level of expression detected in steps a) and b), and therefrom monitoring the progression of ovarian cancer in the patient.

The invention also includes a method of selecting a composition for inhibiting ovarian cancer in a patient. This method comprises the steps of:

a) obtaining a sample comprising cancer cells from the patient; 30 b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;

5

10

15

20

25

30

- 10 -

c) comparing expression of a marker listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8 in each of the aliquots; and

PCT/US00/24199

d) selecting one of the test compositions which induces a lower level of expression of the marker in the aliquot containing that test composition, relative to other test compositions.

The invention further includes a method of selecting a composition for inhibiting ovarian cancer in a patient. This method comprises the steps of:

- a) obtaining a sample comprising cancer cells from the patient;
 - b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
 - c) comparing expression of a marker listed in Tables 3A, 5, 7C and 7E in each of the aliquots; and
 - d) selecting one of the test compositions which induces an enhanced level of expression of the marker in the aliquot containing that test composition, relative to other test compositions.

In addition, the invention includes a method of inhibiting ovarian cancer in a patient. This method comprises the steps of:

- a) obtaining a sample comprising cancer cells from the patient;
 - b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
 - c) comparing expression of a marker listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8 in each of the aliquots; and
 - d) administering to the patient at least one of the test compositions which induces a lower level of expression of the marker in the aliquot containing that test composition, relative to other test compositions.

The invention also includes a method of inhibiting ovarian cancer in a patient. This method comprises the steps of:

- a) obtaining a sample comprising cancer cells from the patient;
 - b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
 - c) comparing expression of a marker listed in Tables 3A, 5, 7C and 7E, in each of the aliquots; and

-11-

d) administering to the patient at least one of the test compositions which induces an enhanced of expression of the marker in the aliquot containing that test composition, relative to other test compositions.

The invention also includes a kit for assessing whether a patient is afflicted with ovarian cancer. This kit comprises reagents for assessing expression of a marker listed in Tables 1-11.

In another aspect, the invention relates to a kit for assessing the suitability of each of a plurality of compounds for inhibiting an ovarian cancer in a patient. The kit comprises a reagent for assessing expression of a marker listed in Tables 1-11, and may also comprise a plurality of compounds.

10

15

20

In another aspect, the invention relates to a kit for assessing the presence of ovarian cancer cells. This kit comprises an antibody, wherein the antibody binds specifically with a protein corresponding to a marker listed in Tables 1-11. The kit may also comprise a plurality of antibodies, wherein the plurality binds specifically with a protein corresponding to a different marker listed in Tables 1-11.

The invention also includes a kit for assessing the presence of ovarian cancer cells, wherein the kit comprises a nucleic acid probe. The probe binds specifically with a transcribed polynucleotide corresponding to a marker listed in Tables 1-11. The kit may also comprise a plurality of probes, wherein each of the probes binds specifically with a transcribed polynucleotide corresponding to a different marker listed in Tables 1-11.

The invention further relates to a method of making an isolated hybridoma which produces an antibody useful for assessing whether a patient is afflicted with ovarian cancer. The method comprises isolating a protein corresponding to a marker listed in Tables 1-11, immunizing a mammal using the isolated protein, isolating splenocytes from the immunized mammal, fusing the isolated splenocytes with an immortalized cell line to form hybridomas, and screening individual hybridomas for production of an antibody which specifically binds with the protein to isolate the hybridoma. The invention also includes an antibody produced by this method.

- 12 -

The invention further includes a method of assessing the ovarian carcinogenic potential of a test compound. This method comprises the steps of:

- a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and
- 5 b) comparing expression of a marker in each of the aliquots.

The marker is selected from those listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8. A significantly enhanced level of expression of the marker in the aliquot maintained in the presence of (or exposed to) the test compound, relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses ovarian carcinogenic potential.

The invention includes another method of assessing the ovarian carcinogenic potential of a test compound. This method comprises the steps of:

- a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and
- b) comparing expression of a marker in each of the aliquots.

10

20

In this method, the marker is selected from those listed in Tables 3A, 5, 7C and 7E. A significantly lower level of expression of the marker in the aliquot maintained in the presence of the test compound, relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses ovarian carcinogenic potential.

Additionally, the invention includes a kit for assessing the ovarian carcinogenic potential of a test compound. The kit comprises ovarian cells and a reagent for assessing expression of a marker in each of the aliquots. The marker is selected from those listed in Tables 1-11.

The invention further relates to a method of treating a patient afflicted with ovarian cancer. This method comprises providing to cells of the patient a protein corresponding to a marker listed in Tables 3A, 5, 7C and 7E. The protein can be provided to the cells, for example, by providing a vector comprising a polynucleotide encoding the protein to the cells.

- 13 -

The invention includes another method of treating a patient afflicted with ovarian cancer. This method comprises providing to cells of the patient an antisense oligonucleotide complementary to a polynucleotide corresponding to a marker listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8.

The invention includes a method of inhibiting ovarian cancer in a patient at risk for developing ovarian cancer. This method comprises inhibiting expression or overexpression of a gene corresponding to a marker listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8.

The invention includes another method of inhibiting ovarian cancer in a patient at risk for developing ovarian cancer. This method comprises enhancing expression of a gene corresponding to a marker listed in Tables 3A, 5, 7C and 7E.

It will be appreciated that the methods and kits of the present invention may also include known cancer markers including known ovarian cancer markers. It will further be appreciated that the methods and kits may be used to identify cancers other than ovarian cancer.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to newly discovered correlations between expression of certain markers and the cancerous state of ovarian cells. It has been discovered that the level of expression of individual markers and combinations of markers described herein correlates with the presence of ovarian cancer in a patient. Methods are provided for detecting the presence of ovarian cancer in a sample, the absence of ovarian cancer in a sample, the stage of an ovarian cancer, and with other characteristics of ovarian cancer that are relevant to prevention, diagnosis, characterization, and therapy of ovarian cancer in a patient.

Definitions

5

15

20

25

As used herein, each of the following terms has the meaning associated with it in this section.

The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

20

30

A "marker" of the invention is a naturally-occurring polymer corresponding to at least one of the nucleic acids listed in Tables 1-11. In particular, a marker of the invention may be a nucleic acid molecule comprising a sequence listed in Tables 1-11 or a sequence which hybridizes under high stringency conditions with a polynucleotide sequence listed in Tables 1-11 ("nucleic acid marker"). Nucleic acid markers include, without limitation, sense and anti-sense strands of genomic DNA (*i.e.* including any introns occurring therein), RNA generated by transcription of genomic DNA (*i.e.* prior to splicing), RNA generated by splicing of RNA transcribed from genomic DNA, and proteins generated by translation of spliced RNA (*i.e.* including proteins both before and after cleavage of normally cleaved regions such as transmembrane signal sequences). As used herein, "marker" may also include a cDNA made by reverse transcription of an RNA generated by transcription of genomic DNA (including spliced RNA). A marker

- 14 -

PCT/US00/24199

The term "probe" refers to any molecule which is capable of selectively binding to a specifically intended target molecule, for example a marker of the invention. Probes can be either synthesized by one skilled in the art, or derived from appropriate biological preparations. For purposes of detection of the target molecule, probes may be specifically designed to be labeled, as described herein. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic monomers.

of the invention also may be a protein encoded by, for example, a nucleic acid marker.

An "ovary-associated" body fluid is a fluid which, when in the body of a patient, contacts or passes through ovarian cells or into which cells or proteins shed from ovarian cells *e.g.*, ovarian epithelium, are capable of passing. Exemplary ovary-associated body fluids include blood fluids, lymph, ascites, gynecological fluids, cystic fluid, urine, and fluids collected by peritoneal rinsing.

The "normal" level of expression of a marker is the level of expression of the marker in ovarian cells of a patient, e.g. a human, not afflicted with ovarian cancer.

"Over-expression" and "under-expression" of a marker refer to expression of the marker of a patient at a greater or lesser level, respectively, than normal level of expression of the marker (e.g. at least two-fold greater or lesser level).

As used herein, the term "promoter/regulatory sequence" means a nucleic acid sequence which is required for expression of a gene product operably linked to the promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product. The promoter/regulatory sequence may, for example, be one which expresses the gene product in a tissue-specific manner.

A "constitutive" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a living human cell under most or all physiological conditions of the cell.

An "inducible" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a living human cell substantially only when an inducer which corresponds to the promoter is present in the cell.

15

20

25

30

A "tissue-specific" promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a living human cell substantially only if the cell is a cell of the tissue type corresponding to the promoter.

A "transcribed polynucleotide" is a polynucleotide (e.g. an RNA, a cDNA, or an analog of one of an RNA or cDNA) which is complementary to or homologous with all or a portion of a mature RNA made by transcription of a genomic DNA corresponding to a marker of the invention and normal post-transcriptional processing (e.g. splicing), if any, of the transcript.

"Complementary" refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds ("base pairing") with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to

10

20

25

- 16 -

PCT/US00/24199

a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an antiparallel fashion, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues of the first portion are capable of base pairing with nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.

"Homologous" as used herein, refers to nucleotide sequence similarity between two regions of the same nucleic acid strand or between regions of two different nucleic acid strands. When a nucleotide residue position in both regions is occupied by the same nucleotide residue, then the regions are homologous at that position. A first region is homologous to a second region if at least one nucleotide residue position of each region is occupied by the same residue. Homology between two regions is expressed in terms of the proportion of nucleotide residue positions of the two regions that are occupied by the same nucleotide residue. By way of example, a region having the nucleotide sequence 5'-TATGCC-3' and a region having the nucleotide sequence 5'-TATGGC-3' share 50% homology. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residue positions of each of the portions are occupied by the same nucleotide residue. More preferably, all nucleotide residue positions of each of the portions are occupied by the same nucleotide residue.

A marker is "fixed" to a substrate if it is covalently or non-covalently associated with the substrate such the substrate can be rinsed with a fluid (e.g. standard saline citrate, pH 7.4) without a substantial fraction of the marker dissociating from the substrate.

As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g. encodes a natural protein).

WO 01/18542 - 17 -

Expression of a marker in a patient is "significantly" higher or lower than the normal level of expression of a marker if the level of expression of the marker is greater or less, respectively, than the normal level by an amount greater than the standard error of the assay employed to assess expression, and preferably at least twice, and more preferably three, four, five or ten times that amount. Alternately, expression of the marker in the patient can be considered "significantly" higher or lower than the normal level of expression if the level of expression is at least about two, and preferably at least about three, four, or five times, higher or lower, respectively, than the normal level of

PCT/US00/24199

Ovarian cancer is "inhibited" if at least one symptom of the cancer is alleviated, terminated, slowed, or prevented. As used herein, ovarian cancer is also "inhibited" if recurrence or metastasis of the cancer is reduced, slowed, delayed, or prevented.

A kit is any manufacture (e.g. a package or container) comprising at least one reagent, e.g. a probe, for specifically detecting a marker of the invention, the manufacture being promoted, distributed, or sold as a unit for performing the methods of the present invention.

Description

10

15

20

25

30

expression of the marker.

The present invention is based, in part, on identification of markers which are expressed at a different level in ovarian cancer cells than they are in normal (*i.e.* non-cancerous) ovarian cells. The markers of the invention correspond to nucleic acid and polypeptide molecules which can be detected in one or both of normal and cancerous ovarian cells. The presence, absence, or level of expression of one or more of these markers in ovarian cells is herein correlated with the cancerous state of the tissue. The invention thus includes compositions, kits, and methods for assessing the cancerous state of ovarian cells (*e.g.* cells obtained from a human, cultured human cells, archived or preserved human cells and *in vivo* cells).

The compositions, kits, and methods of the invention have the following uses, among others:

- 1) assessing whether a patient is afflicted with ovarian cancer;
- assessing the stage of ovarian cancer in a human patient;
- 3) assessing the grade of ovarian cancer in a patient;

- 18 -

PCT/US00/24199

	4)	assessing the benign or malignant nature of ovarian cancer in a
		patient;
	5)	assessing the histological type of neoplasm (e.g. serous,
		mucinous, endometroid, or clear cell neoplasm) associated with
5		ovarian cancer in a patient;
	6)	making an isolated hybridoma which produces an antibody useful
		for assessing whether a patient is afflicted with ovarian cancer;
	7)	assessing the presence of ovarian cancer cells;
	8)	assessing the efficacy of one or more test compounds for
10		inhibiting ovarian cancer in a patient;
	9)	assessing the efficacy of a therapy for inhibiting ovarian cancer
		in a patient;
	10)	monitoring the progression of ovarian cancer in a patient;
	11)	selecting a composition or therapy for inhibiting ovarian cancer in
15		a patient;
	12)	treating a patient afflicted with ovarian cancer;
	13)	inhibiting ovarian cancer in a patient;
		14) assessing the ovarian carcinogenic potential of a test
		compound; and
20		15) inhibiting an ovarian cancer in a patient at risk for
		developing ovarian cancer.

The invention thus includes a method of assessing whether a patient is afflicted with ovarian cancer. This method comprises comparing the level of expression of a marker in a patient sample and the normal level of expression of the marker in a control, e.g., a non-ovarian cancer sample. A significant difference between the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with ovarian cancer. The marker is selected from the group consisting of the markers listed in Tables 1-11. The markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8 are expressed at a greater level in ovarian cancer cells than in normal ovarian cells. The markers listed in Tables 3A, 5, 7C and 7E are expressed at a lower level in ovarian cancer cells than in normal ovarian cells. Although one or more

- 19 -

molecules corresponding to the markers listed in Tables 1-11 may have been described by others, the significance of the level of expression of these markers with regard to the cancerous state of ovarian cells has not previously been recognized.

Tables 1 and 1A list markers that were identified in subtractive libraries and which are preferentially expressed in ovarian cancer cells over normal (i.e., non-cancerous) ovarian cells.

Table 2A lists markers, expression of which was increased by at least 5-fold in at least one of twenty-three ovarian cancer samples tested, relative to its expression in normal (*i.e.* non-cancerous) ovarian samples. Table 2B lists markers, expression of which was increased by at least 2-fold in all twenty-three ovarian cancer samples tested, relative to its expression in normal ovarian samples. Table 2C lists markers, expression of which was increased by at least 5-fold in at least 6 of the 23 ovarian cancer samples tested, relative to its expression in normal ovarian cells. Table 2D lists markers, expression of which was increased by at least 5-fold in at least 6 of the 23 ovarian cancer samples, relative to expression in normal ovarian samples. In a preferred embodiment, proteins corresponding to the markers of Table 2D as well as fragments of the proteins, serve as antigens for antibody production, based upon proteomic studies, sequence analysis and/or literature references

15

20

25

Table 3A lists markers, expression of which was decreased by at least 5-fold in at least one of twenty-three ovarian cancer samples tested, relative to its expression in normal (i.e., non-cancerous) ovarian cells. Table 3B lists markers, expression of which was decreased by at least 2-fold in all twenty-three ovarian cancer samples tested, relative to its expression in normal ovarian cells. Table 3C lists markers, expression of which was decreased by at least 5-fold in at least 6 of the 23 ovarian cancer samples tested, relative to its expression in normal ovarian cells.

Tables 4 and 5 list markers, expression of which was either increased (Table 4) or decreased (Table 5) in ovarian cancer samples, relative to expression in normal (*i.e.*, non-cancerous) ovarian samples. In particular, expression of the markers in 37 tumors (7 endometroid tumors, 5 clear cell tumors and 25 serous tumors) was evaluated. A ranking system based on the sum of the number of tumors multiplied by the fold regulation (for 2-fold, 3-fold, 5-fold and 10-fold regulation), divided by the total number

- 20 -

of tumors, was employed. A rank score was generated for four categories, endometroid tumors, clear cell tumors, serous tumors and overall.

For example, for # 19109 in Table 4A (first marker listed):

of tumors > 2-fold: $36 = (2 \times 0) = 0$

of tumors > 3-fold: $36 = (3 \times 1) = 3$

5

10

20

25

of tumors > 5-fold: $35 = (5 \times 3) = 15$

of tumors > 10-fold: $32 = (10 \times 32) = 320$

The sum is 3 plus 15 plus 320, which equals 338. The score is therefore 338 divided by 37, which equals 9.1.

The markers of Table 4 had a score of greater than 1.5 for endometroid tumors, greater than 1.5 for clear cell tumors, greater than 1 for serous tumors, or greater than 0.8 overall. Table 4A shows the markers of Table 4 with a score of greater than 3 in any of the four categories.

The markers of Table 5 had a score of greater than 2.5 for endometroid tumors, greater than 2.5 for clear cell tumors, greater than 2 for serous tumors, or greater than 1.75 overall. Table 5A shows the markers of Table 5 with a score of greater than 3 in any of the four categories.

Tables 6 and 6A list markers that were identified in subtractive libraries and which are preferentially expressed in ovarian cancer cells over normal (i.e., non-cancerous) ovarian cells.

Tables 7A-7E list markers that were identified in proteomic studies. The markers of Table 7A are secreted or membrane proteins, expression of which was increased at least 5-fold in two or more ovarian cancer samples or cell lines, relative to at least a 10-fold decrease in expression in normal ovarian samples.

The markers of Table 7B are secreted or membrane proteins, expression of which was increased in one ovarian cancer sample cell line, relative to expression in normal ovarian samples, where the medium expression of normals equaled 0 (the expression level of the ovarian cancer sample and cell lines was divided by 0.001, rather than 0).

The markers of Table 7C are preferred secreted or membrane proteins, expression of which was decreased in ovarian cancer samples and cell lines, relative to expression in normal ovarian samples.

PCT/US00/24199

The markers of Table 7D are secreted or membrane proteins present in ovarian cancer cell supernatants.

The markers of Table 7E are secreted or membrane proteins present in normal cell supernatants.

Table 8 lists novel genes that are overexpressed in ovarian cancer samples, relative to expression in normal ovarian samples.

Table 9 summarizes TaqMan® expression data for the novel genes of Table 8.

Tables 10A-10N summarize Northern Blot analysis of the novel genes of Table 8.

Table 11 summarizes LightCycler data and RT-PCR data for various markers of the present invention.

15

20

25

Any marker or combination of markers listed in Tables 1-11, as well as any known markers in combination with the markers set forth in Tables 1-11, may be used in the compositions, kits, and methods of the present invention. Use of markers listed in Tables 2B, 2C, 2D, 3B, 3C, 4A, 5A, 6A, 7A-7E and 8 are preferred, wherein use of markers listed in Tables 2C, 2D, 3C, 6A, 7A-7C and 8 are more preferred. In general, it is preferable to use markers for which the difference between the level of expression of the marker in ovarian cancer cells and the level of expression of the same marker in normal ovarian cells is as great as possible. Although this difference can be as small as the limit of detection of the method for assessing expression of the marker, it is preferred that the difference be at least greater than the standard error of the assessment method, and preferably a difference of at least 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 100-, 500-, 1000-fold or greater.

It is recognized that certain markers correspond to proteins which are secreted from ovarian cells (*i.e.* one or both of normal and cancerous cells) to the extracellular space surrounding the cells (see, *e.g.* Tables 2D, 7A-7E and 8). These markers are preferably used in certain embodiments of the compositions, kits, and methods of the invention, owing to the fact that the protein corresponding to each of these markers can be detected in an ovary-associated body fluid sample, which may be more easily collected from a human patient than a tissue biopsy sample. In addition, preferred *in vivo* techniques for detection of a protein corresponding to a marker of the invention include introducing into a subject a labeled antibody directed against the protein. For

example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

- 22 -

Although not every marker corresponding to a secreted protein is indicated as such in the Tables herein, it is a simple matter for the skilled artisan to determine whether any particular marker corresponds to a secreted protein. In order to make this determination, the protein corresponding to a marker is expressed in a test cell (e.g. a cell of an ovarian cell line), extracellular fluid is collected, and the presence or absence of the protein in the extracellular fluid is assessed (e.g. using a labeled antibody which binds specifically with the protein).

The following is an example of a method which can be used to detect secretion 10 . of a protein corresponding to a marker of the invention. About 8×10^5 293T cells are incubated at 37°C in wells containing growth medium (Dulbecco's modified Eagle's medium {DMEM} supplemented with 10% fetal bovine serum) under a 5% (v/v) CO₂, 95% air atmosphere to about 60-70% confluence. The cells are then transfected using a standard transfection mixture comprising 2 micrograms of DNA comprising an expression vector encoding the protein and 10 microliters of LipofectAMINE™ (GIBCO/BRL Catalog no. 18342-012) per well. The transfection mixture is maintained for about 5 hours, and then replaced with fresh growth medium and maintained in an air atmosphere. Each well is gently rinsed twice with DMEM which does not contain methionine or cysteine (DMEM-MC; ICN Catalog no. 16-424- 54). About 1 milliliter of DMEM-MC and about 50 microcuries of Trans-³⁵S™ reagent (ICN Catalog no. 51006) are added to each well. The wells are maintained under the 5% CO_2 atmosphere described above and incubated at 37°C for a selected period. Following incubation, 150 microliters of conditioned medium is removed and centrifuged to remove floating cells and debris. The presence of the protein in the supernatant is an indication that the protein is secreted.

15

20

25

30

Examples of ovary-associated body fluids include blood fluids (e.g. whole blood, blood serum, blood having platelets removed therefrom, etc.), lymph, ascitic fluids, gynecological fluids (e.g. ovarian, fallopian, and uterine secretions, menses, vaginal douching fluids, fluids used to rinse cervical cell samples, etc.), cystic fluid, urine, and fluids collected by peritoneal rinsing (e.g. fluids applied and collected during laparoscopy or fluids instilled into and withdrawn from the peritoneal cavity of a human

- 23 -

patient). In these embodiments, the level of expression of the marker can be assessed by assessing the amount (e.g. absolute amount or concentration) of the marker in an ovary-associated body fluid obtained from a patient. The fluid can, of course, be subjected to a variety of well-known post-collection preparative and storage techniques (e.g. storage, freezing, ultrafiltration, concentration, evaporation, centrifugation, etc.) prior to assessing the amount of the marker in the fluid.

Many ovary-associated body fluids (i.e. usually excluding urine) can have ovarian cells, e.g. ovarian epithelium, therein, particularly when the ovarian cells are cancerous, and, more particularly, when the ovarian cancer is metastasizing. Cellcontaining fluids which can contain ovarian cancer cells include, but are not limited to, peritoneal ascites, fluids collected by peritoneal rinsing, fluids collected by uterine rinsing, uterine fluids such as uterine exudate and menses, pleural fluid, and ovarian exudates. Thus, the compositions, kits, and methods of the invention can be used to detect expression of markers corresponding to proteins having at least one portion which is displayed on the surface of cells which express it. Examples of such proteins are indicated in the Tables herein. Although not every protein having at least one cellsurface portion is indicated in the Tables, it is a simple matter for the skilled artisan to determine whether the protein corresponding to any particular marker comprises a cellsurface protein. For example, immunological methods may be used to detect such proteins on whole cells, or well known computer-based sequence analysis methods (e.g. the SIGNALP program; Nielsen et al., 1997, Protein Engineering 10:1-6) may be used to predict the presence of at least one extracellular domain (i.e. including both secreted proteins and proteins having at least one cell-surface domain). Expression of a marker corresponding to a protein having at least one portion which is displayed on the surface of a cell which expresses it may be detected without necessarily lysing the cell (e.g. using a labeled antibody which binds specifically with a cell-surface domain of the protein).

15

20

25

Expression of a marker of the invention may be assessed by any of a wide variety of well known methods for detecting expression of a transcribed molecule or its corresponding protein. Non-limiting examples of such methods include immunological methods for detection of secreted, cell-surface, cytoplasmic, or nuclear proteins, protein purification methods, protein function or activity assays, nucleic acid hybridization

10

20

methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods.

- 24 -

In a preferred embodiment, expression of a marker is assessed using an antibody (e.g. a radio-labeled, chromophore-labeled, fluorophore-labeled, or enzyme-labeled antibody), an antibody derivative (e.g. an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair {e.g. biotin-streptavidin}), or an antibody fragment (e.g. a single-chain antibody, an isolated antibody hypervariable domain, etc.) which binds specifically with a protein corresponding to the marker, such as the protein encoded by the open reading frame corresponding to the marker or such a protein which has undergone all or a portion of its normal post-translational modification.

In another preferred embodiment, expression of a marker is assessed by preparing mRNA/cDNA (i.e. a transcribed polynucleotide) from cells in a patient sample, and by hybridizing the mRNA/cDNA with a reference polynucleotide which is a complement of a polynucleotide comprising the marker, and fragments thereof. cDNA can, optionally, be amplified using any of a variety of polymerase chain reaction methods prior to hybridization with the reference polynucleotide; preferably, it is not amplified. Expression of one or more markers can likewise be detected using quantitative PCR to assess the level of expression of the marker(s). Alternatively, any of the many known methods of detecting mutations or variants (e.g. single nucleotide polymorphisms, deletions, etc.) of a marker of the invention may be used to detect occurrence of a marker in a patient.

In a related embodiment, a mixture of transcribed polynucleotides obtained from the sample is contacted with a substrate having fixed thereto a polynucleotide complementary to or homologous with at least a portion (e.g. at least 7, 10, 15, 20, 25, 30, 40, 50, 100, 500, or more nucleotide residues) of a marker of the invention. If polynucleotides complementary to or homologous with are differentially detectable on the substrate (e.g. detectable using different chromophores or fluorophores, or fixed to different selected positions), then the levels of expression of a plurality of markers can be assessed simultaneously using a single substrate (e.g. a "gene chip" microarray of polynucleotides fixed at selected positions). When a method of assessing marker expression is used which involves hybridization of one nucleic acid with another, it is preferred that the hybridization be performed under stringent hybridization conditions.

- 25 -

Because the compositions, kits, and methods of the invention rely on detection of a difference in expression levels of one or more markers of the invention, it is preferable that the level of expression of the marker is significantly greater than the minimum detection limit of the method used to assess expression in at least one of normal ovarian cells and cancerous ovarian cells.

Preferably, at least one of the marker(s) used in the compositions, kits, and methods of the invention is a marker for which the "Tissue Prominence," as indicated in the Tables herein, includes, without limitation, an epithelial tissue such as ovarian, stomach, foreskin, colon, uterus, esophagus, synovial membrane, small intestine, breast, skin, cervix, adrenal gland, eye, gall bladder, lung, placenta, prostate and retina tissues. Preferably, the marker is one for which ovary is listed among the Tissue Prominence tissues in one or more of the Tables.

15

20

25

30

The chromosomal location corresponding to each of a number of the markers listed in the Tables herein is known and is also listed in the Tables. In addition, the chromosomal locations of a number of loci and chromosomal regions associated with ovarian cancers are known (Lynch et al., 1998, Sem. Oncol. 25:265-280). For example, AKT2 is located on chromosome 19 at q13.1-13.2, copy number increases have been observed at 8q24, 20q13.2-qter, 3q26.3, 1q32, 20p, 9p21-pter, 12p, and 5p14-pter, DNA amplifications have been observed at 8q24, 3q26.3, and 20q13.3, c- MYC is located at 8q24, MYBL2 is located at 20q13.1, EVII is located at 3q26, loss of heterozygosity has been observed on chromosomes 6, 9, 13q, 17, 18q, 19p, 22q and Xp, including at locations 17p(p13.3, 13.1), 17q(q21, q22-q23), 18q (q21.3-qter), 6q(q26-q27), 11q(q23.3-qter), and 11p(p13-p15.5), TP53 is located at 17p13.1, BRCA1 is located at 17q21, the prohibitin gene and NM23 are both located at 17q23-24, NF1 is located at 17q11, and ERBB2 is located at 17q21. At least one previously unidentified gene which contributes to development of ovarian cancer has been suggested to reside on chromosome 17 (Lynch et al., supra), particularly on 17p, and more particularly in the vicinity of 17p13.3. Thus, markers which map to one or more of these chromosomal locations, or to a location relatively near one of these locations are preferred for use in the compositions, kits, and methods of the invention.

- 26 -

WO 01/18542

It is understood that by routine screening of additional patient samples using one or more of the markers of the invention, it will be realized that certain of the markers are over- or under-expressed in cancers of various types, including specific ovarian cancers, as well as other cancers such as breast cancer, cervical cancer, etc. For example, it will be confirmed that some of the markers of the invention are over- or under-expressed in most (i.e. 50% or more) or substantially all (i.e. 80% or more) of ovarian cancer. Furthermore, it will be confirmed that certain of the markers of the invention are associated with ovarian cancer of various stages (i.e. stage I, II, III, and IV ovarian cancers, as well as subclassifications IA, IB, IC, IIA, IIB, IIC, IIIA, IIIB, and IIIC, using the FIGO Stage Grouping system for primary carcinoma of the ovary; 1987, Am. J. 10 Obstet. Gynecol. 156:236), of various histologic subtypes (e.g. serous, mucinous, endometroid, and clear cell subtypes, as well as subclassifications and alternate classifications adenocarcinoma, papillary adenocarcinoma, papillary cystadenocarcinoma, surface papillary carcinoma, malignant adenofibroma, cystadenofibroma, adenocarcinoma, cystadenocarcinoma, adenoacanthoma, endometrioid stromal sarcoma, mesodermal (Müllerian) mixed tumor, mesonephroid tumor, malignant carcinoma, Brenner tumor, mixed epithelial tumor, and undifferentiated carcinoma, using the WHO/FIGO system for classification of malignant ovarian tumors; Scully, Atlas of Tumor Pathology, 3d series, Washington DC), and various grades (i.e. grade I {well differentiated}, grade II {moderately well 20 differentiated), and grade III {poorly differentiated from surrounding normal tissue}). In addition, as a greater number of patient samples are assessed for expression of the markers of the invention and the outcomes of the individual patients from whom the samples were obtained are correlated, it will also be confirmed that altered expression of certain of the markers of the invention are strongly correlated with malignant cancers and that altered expression of other markers of the invention are strongly correlated with benign tumors. The compositions, kits, and methods of the invention are thus useful for characterizing one or more of the stage, grade, histological type, and benign/malignant nature of ovarian cancer in patients. In addition, these compositions, kits, and methods can be used to detect and differentiate epithelial, stromal, and germ cell ovarian cancers.

PCT/US00/24199

- 27 -

When the compositions, kits, and methods of the invention are used for characterizing one or more of the stage, grade, histological type, and benign/malignant nature of ovarian cancer in a patient, it is preferred that the marker or panel of markers of the invention is selected such that a positive result is obtained in at least about 20%, and preferably at least about 40%, 60%, or 80%, and more preferably in substantially all patients afflicted with an ovarian cancer of the corresponding stage, grade, histological type, or benign/malignant nature. Preferably, the marker or panel of markers of the invention is selected such that a PPV of greater than about 10% is obtained for the general population (more preferably coupled with an assay specificity greater than 99.5%).

10

15

20

25

When a plurality of markers of the invention are used in the compositions, kits, and methods of the invention, the level of expression of each marker in a patient sample can be compared with the normal level of expression of each of the plurality of markers in non-cancerous samples of the same type, either in a single reaction mixture (i.e. using reagents, such as different fluorescent probes, for each marker) or in individual reaction mixtures corresponding to one or more of the markers. In one embodiment, a significantly enhanced level of expression of more than one of the plurality of markers in the sample, relative to the corresponding normal levels, is an indication that the patient is afflicted with ovarian cancer. In another embodiment, a significantly lower level of expression in the sample of each of the plurality of markers, relative to the corresponding normal levels, is an indication that the patient is afflicted with ovarian cancer. In yet another embodiment, a significantly enhanced level of expression of one or more marks and a significantly lower level of expression of one or more markers in a sample relative to the corresponding normal levels, is an indication that the patient is afflicted with ovarian cancer. When a plurality of markers is used, it is preferred that 2, 3, 4, 5, 8, 10, 12, 15, 20, 30, or 50 or more individual markers be used, wherein fewer markers are preferred.

In order to maximize the sensitivity of the compositions, kits, and methods of the invention (i.e. by interference attributable to cells of non-ovarian origin in a patient sample), it is preferable that the marker of the invention used therein be a marker which has a restricted tissue distribution, e.g., normally not expressed in a non-epithelial tissue, and more preferably a marker which is normally not expressed in a non-ovarian tissue.

- 28 -

Only a small number of markers are known to be associated with ovarian cancers (e.g. AKT2, Ki-RAS, ERBB2, c-MYC, RBI, and TP53; Lynch, supra). These markers are not, of course, included among the markers of the invention, although they may be used together with one or more markers of the invention in a panel of markers, for example.

It is well known that certain types of genes, such as oncogenes, tumor suppressor genes, growth factor-like genes, protease-like genes, and protein kinase-like genes are often involved with development of cancers of various types. Thus, among the markers of the invention, use of those which correspond to proteins which resemble known proteins encoded by known oncogenes and tumor suppressor genes, and those which correspond to proteins which resemble growth factors, proteases, and protein kinases are preferred.

Known oncogenes and tumor suppressor genes include, for example, abl, abr, akt2, apc, bcl2α, bcl2β, bcl3, bcr, brca1, brca2, cbl, ccnd1, cdc42, cdk4, crk- II, csf1r/fms, dbl, dcc, dpc4/smad4, e-cad, e2f1/rbap, egfr/erbb-1, elk1, elk3, eph, erg, ets1, ets2, fer, fgr/src2, fli1/ergb2, fos, fps/fes, fra1, fra2, fyn, hck, hek, her2/erbb- 2/neu, her3/erbb-3, her4/erbb-4, hras1, hst2, hstf1, igfbp2, ink4a, ink4b, int2/fgf3, jun, junb, jund, kip2, kit, kras2a, kras2b, lck, lyn, mas, max, mcc, mdm2, met, mlh1, mmp10, mos, msh2, msh3, msh6, myb, myba, mybb, myc, mycl1, mycn, nf1, nf2, nme2, nras, p53, pdgfb, phb, pim1, pms1, pms2, ptc, pten, raf1, rap1a, rb1, rel, ret, ros1, ski, src1, tal1, tgfbr2, tgfb3, tgfbr3, thra1, thrb, tiam1, timp3, tjp1, tp53, trk, vav, vhl, vil2, waf1, wnt1, wnt2, wt1, and yes1 (Hesketh, 1997, In: The Oncogene and Tumour Suppressor Gene Facts Book, 2nd Ed., Academic Press; Fishel et al., 1994, Science 266:1403-1405).

Known growth factors include platelet-derived growth factor alpha, platelet-derived growth factor beta (simian sarcoma viral {v-sis} oncogene homolog), thrombopoietin (myeloproliferative leukemia virus oncogene ligand, megakaryocyte growth and development factor), erythropoietin, B cell growth factor, macrophage stimulating factor 1 (hepatocyte growth factor-like protein), hepatocyte growth factor (hepapoietin A), insulin-like growth factor 1 (somatomedia C), hepatoma-derived growth factor, amphiregulin (schwannoma-derived growth factor), bone morphogenetic proteins 1, 2, 3, 3 beta, and 4, bone morphogenetic protein 7 (osteogenic protein 1), bone morphogenetic protein 8 (osteogenic protein 2), connective tissue growth factor, connective tissue activation peptide 3, epidermal growth factor (EGF), teratocarcinoma-derived growth factor 1, endothelin, endothelin 2, endothelin 3, stromal cell-derived

10

20

- 29 -

factor 1, vascular endothelial growth factor (VEGF), VEGF-B, VEGF-C, placental growth factor (vascular endothelial growth factor-related protein), transforming growth factor alpha, transforming growth factor beta 1 and its precursors, transforming growth factor beta 2 and its precursors, fibroblast growth factor 1 (acidic), fibroblast growth factor 2 (basic), fibroblast growth factor 5 and its precursors, fibroblast growth factor 6 and its precursors, fibroblast growth factor 7 (keratinocyte growth factor), fibroblast growth factor 8 (androgen-induced), fibroblast growth factor 9 (glia-activating factor), pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1), brain-derived neurotrophic factor, and recombinant glial growth factor 2.

Known proteases include interleukin-1 beta convertase and its precursors, Mch6 and its precursors, Mch2 isoform alpha, Mch4, Cpp32 isoform alpha, Lice2 gamma cysteine protease, Ich-1S, Ich-1L, Ich-2 and its precursors, TY protease, matrix metalloproteinase 1 (interstitial collagenase), matrix metalloproteinase 2 (gelatinase A, 72kD gelatinase, 72kD type IV collagenase), matrix metalloproteinase 7 (matrilysin), matrix metalloproteinase 8 (neutrophil collagenase), matrix metalloproteinase 12 (macrophage elastase), matrix metalloproteinase 13 (collagenase 3), metallopeptidase 1, cysteine-rich metalloprotease (disintegrin) and its precursors, subtilisin-like protease Pc8 and its precursors, chymotrypsin, snake venom-like protease, cathepsin I, cathepsin D (lysosomal aspartyl protease), stromelysin, aminopeptidase N, plasminogen, tissue plasminogen activator, plasminogen activator inhibitor type II, and urokinase-type plasminogen activator.

Known protein kinases include DAP kinase, serine/threonine protein kinases NIK, PK428, Krs-2, SAK, and EMK, interferon-inducible double stranded RNA dependent protein kinase, FAST kinase, AIM1, IPL1-like midbody-associated protein kinase-1, NIMA-like protein kinase 1 (NLK1), the cyclin-dependent kinases (cdk1-10), checkpoint kinase Chk1, Nek3 protein kinase, BMK1 beta kinase, Clk1, Clk2, Clk3, extracellular signal-regulated kinases 1, 3, and 6, cdc28 protein kinase 1, cdc28 protein kinase 2, pLK, Myt1, c-Jun N-terminal kinase 2, Cam kinase 1, the MAP kinases, insulin-stimulated protein kinase 1, beta-adrenergic receptor kinase 2, ribosomal protein S6 kinase, kinase suppressor of ras-1 (KSR1), putative serine/threonine protein kinase Prk, PkB kinase, cAMP-dependent protein kinase, cGMP-dependent protein kinase, type II cGMP-dependent protein kinase, protein kinases Dyrk2, Dyrk3, and Dyrk4, Rho-

20

30

- 30 -

PCT/US00/24199

associated coiled-coil containing protein kinase p160ROCK, protein tyrosine kinase t-Rorl, Ste20-related kinases, cell adhesion kinase beta, protein kinase 3, stress-activated protein kinase 4, protein kinase Zpk, serine kinase hPAK65, dual specificity mitogenactivated protein kinases 1 and 2, casein kinase I gamma 2, p21-activated protein kinase Pak1, lipid-activated protein kinase PRK2, focal adhesion kinase, dual-specificity tyrosine-phosphorylation regulated kinase, myosin light chain kinase, serine kinases SRPK2, TESK1, and VRK2, B lymphocyte serine/threonine protein kinase, stressactivated protein kinases JNK1 and JNK2, phosphorylase kinase, protein tyrosine kinase Tec, Jak2 kinase, protein kinase Ndr, MEK kinase 3, SHB adaptor protein (a Src homology 2 protein), agammaglobulinaemia protein-tyrosine kinase (Atk), protein kinase ATR, guanylate kinase 1, thrombopoeitin receptor and its precursors, DAG kinase epsilon, and kinases encoded by oncogenes or viral oncogenes such as v-fgr (Gardner-Rasheed), v-abl (Abelson murine leukemia viral oncogene homolog 1), v-arg (Abelson murine leukemia viral oncogene homolog, Abelson-related gene), v-fes and v-15 fps (feline sarcoma viral oncogene and Fujinami avian sarcoma viral oncogene homologs), proto-oncogene c-cot, oncogene pim-1, and oncogene mas1.

Previously known proteins (and, of course, the genes, transcripts, mRNAs, etc. corresponding to those proteins) designated NES1, HE4, and neurosin, are included as markers. NES1 protein is also known as protease serine-like 1 and normal epithelial cell-specific protein, and has been assigned Swiss-Prot accession number O43240 and GenBank accession number AF024605. The amino acid sequence of NES1 protein and the nucleotide sequence of a cDNA encoding it have also been described in U.S. Patent 5,736,377. Association of NES1 protein expression and occurrence of cancer has been described, for example, in U.S. Patent 5,843,694. However, these references (and others, e.g. Liu et al., 1996, Cancer Res. 56:3371-3379; Luo et al., 1998, Biochem. Biophys. Res. Comm. 247:580-586; Goyal et al., 1998, Cancer Res. 58:4782-4786) indicate that NES1 expression is down-regulated in cancer patients. In contrast, the present inventors have discovered that NES1 expression is up- regulated in ovarian cancer samples (e.g. in later stage {i.e. stage 3 or 4} ovarian cancer cell lines).

HE4 protein is also known as major epididymis-specific protein E4 and epididymal secretory protein E4, and has been assigned Swiss-Prot accession number Q14508 and GenBank accession number X63187. The amino acid sequence and the

corresponding cDNA nucleotide sequence were also disclosed in Kirchhoff et al. (1991) Biol. Reprod. 45:350-357. A possible association between expression of HE4 and occurrence of ovarian cancer was disclosed, for example in Wang et al. (1999) Gene 229:101-108.

Neurosin is also known as protease M, zyme, and SP59, and has been assigned Swiss-Prot accession number Q92876 and GenBank accession number U62801. The amino acid sequence of neurosin and the corresponding cDNA nucleotide sequence were also disclosed in Anisowicz *et al.* (1996) *Mol. Med.* 2:624-636. The same reference discloses a possible association between expression of neurosin and occurrence of ovarian cancer.

5

10

15

20

It is recognized that the compositions, kits, and methods of the invention will be of particular utility to patients having an enhanced risk of developing ovarian cancer and their medical advisors. Patients recognized as having an enhanced risk of developing ovarian cancer include, for example, patients having a familial history of ovarian cancer, patients identified as having a mutant oncogene (i.e. at least one allele), and patients of advancing age (i.e. women older than about 50 or 60 years).

The level of expression of a marker in normal (i.e. non-cancerous) human ovarian tissue can be assessed in a variety of ways. In one embodiment, this normal level of expression is assessed by assessing the level of expression of the marker in a portion of ovarian cells which appears to be non-cancerous and by comparing this normal level of expression with the level of expression in a portion of the ovarian cells which is suspected of being cancerous. For example, when laparoscopy or other medical procedure, reveals the presence of a lump on one portion of a patient's ovary, but not on another portion of the same ovary or on the other ovary, the normal level of expression of a marker may be assessed using one or both or the non-affected ovary and a non-affected portion of the affected ovary, and this normal level of expression may be compared with the level of expression of the same marker in an affected portion (i.e. the lump) of the affected ovary. Alternately, and particularly as further information becomes available as a result of routine performance of the methods described herein, population-average values for normal expression of the markers of the invention may be used. In other embodiments, the 'normal' level of expression of a marker may be determined by assessing expression of the marker in a patient sample obtained from a

25

- 32 -

PCT/US00/24199

non-cancer-afflicted patient, from a patient sample obtained from a patient before the suspected onset of ovarian cancer in the patient, from archived patient samples, and the like.

The invention includes compositions, kits, and methods for assessing the presence of ovarian cancer cells in a sample (e.g. an archived tissue sample or a sample obtained from a patient). These compositions, kits, and methods are substantially the same as those described above, except that, where necessary, the compositions, kits, and methods are adapted for use with samples other than patient samples. For example, when the sample to be used is a parafinized, archived human tissue sample, it can be necessary to adjust the ratio of compounds in the compositions of the invention, in the kits of the invention, or the methods used to assess levels of marker expression in the sample. Such methods are well known in the art and within the skill of the ordinary artisan.

The invention includes a kit for assessing the presence of ovarian cancer cells (e.g. in a sample such as a patient sample). The kit comprises a plurality of reagents, each of which is capable of binding specifically with a nucleic acid or polypeptide corresponding to a marker of the invention. Suitable reagents for binding with a polypeptide corresponding to a marker of the invention include antibodies, antibody derivatives, antibody fragments, and the like. Suitable reagents for binding with a nucleic acid (e.g. a genomic DNA, an mRNA, a spliced mRNA, a cDNA, or the like) include complementary nucleic acids. For example, the nucleic acid reagents may include oligonucleotides (labeled or non-labeled) fixed to a substrate, labeled oligonucleotides not bound with a substrate, pairs of PCR primers, molecular beacon probes, and the like.

The kit of the invention may optionally comprise additional components useful for performing the methods of the invention. By way of example, the kit may comprise fluids (e.g. SSC buffer) suitable for annealing complementary nucleic acids or for binding an antibody with a protein with which it specifically binds, one or more sample compartments, an instructional material which describes performance of a method of the invention, a sample of normal ovarian cells, a sample of ovarian cancer cells, and the like.

- 33 -

The invention also includes a method of making an isolated hybridoma which produces an antibody useful for assessing whether patient is afflicted with an ovarian cancer. In this method, a protein corresponding to a marker of the invention or a fragment of the protein is isolated (e.g. by purification from a cell in which it is expressed or by transcription and translation of a nucleic acid encoding the protein in vivo or in vitro using known methods). A vertebrate, preferably a mammal such as a mouse, rat, rabbit, or sheep, is immunized using the isolated protein or fragment thereof. The vertebrate may optionally (and preferably) be immunized at least one additional time with the isolated protein or fragment, so that the vertebrate exhibits a robust immune response to the protein. Splenocytes are isolated from the immunized vertebrate and fused with an immortalized cell line to form hybridomas, using any of a variety of methods well known in the art. Hybridomas formed in this manner are then screened using standard methods to identify one or more hybridomas which produce an antibody which specifically binds with the protein. The invention also includes hybridomas made by this method and antibodies made using such hybridomas. An antibody of the invention may also be used as a therapeutic agent for treating cancers, particularly ovarian cancers (see e.g., Table 8).

15

20

30

The invention also includes a method of assessing the efficacy of a test compound for inhibiting ovarian cancer cells. As described above, differences in the level of expression of the markers of the invention correlate with the cancerous state of ovarian cells. Although it is recognized that changes in the levels of expression of certain of the markers of the invention likely result from the cancerous state of ovarian cells, it is likewise recognized that changes in the levels of expression of other of the markers of the invention induce, maintain, and promote the cancerous state of those cells. Thus, compounds which inhibit an ovarian cancer in a patient will cause the level of expression of one or more of the markers of the invention to change to a level nearer the normal level of expression for that marker (*i.e.* the level of expression for the marker in non-cancerous ovarian cells).

This method thus comprises comparing expression of a marker in a first ovarian cell sample and maintained in the presence of the test compound and expression of the marker in a second ovarian cell sample and maintained in the absence of the test compound. A significant increase in the level of expression of a marker listed in Table

15

20

25

3A, 5, 7C and/or 7E, or a significant decrease in the level of expression of a marker listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and/or 8, is an indication that the test compound inhibits ovarian cancer. The ovarian cell samples may, for example, be aliquots of a single sample of normal ovarian cells obtained from a patient, pooled samples of normal ovarian cells obtained from a patient, cells of a normal ovarian cell line, aliquots of a single sample of ovarian cancer cells obtained from a patient, pooled samples of ovarian cancer cells obtained from a patient, cells of an ovarian cancer cell line, or the like. In one embodiment, the samples are ovarian cancer cells obtained from a patient and a plurality of compounds known to be effective for inhibiting various ovarian cancers are tested in order to identify the compound which is likely to best inhibit the ovarian cancer in the patient.

- 34 -

PCT/US00/24199

This method may likewise be used to assess the efficacy of a therapy for inhibiting ovarian cancer in a patient. In this method, the level of expression of one or more markers of the invention in a pair of samples (one subjected to the therapy, the other not subjected to the therapy) is assessed. As with the method of assessing the efficacy of test compounds, if the therapy induces a significant decrease in the level of expression of a marker listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and/or 8, or blocks induction of a marker listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and/or 8, or if the therapy induces a significant enhancement of the level of expression of a marker listed in Tables 3A, 5, 7C and 7E, then the therapy is efficacious for inhibiting ovarian cancer. As above, if samples from a selected patient are used in this method, then alternative therapies can be assessed *in vitro* in order to select a therapy most likely to be efficacious for inhibiting ovarian cancer in the patient.

As described herein, ovarian cancer in patients is associated with an increase in the level of expression of one or more markers listed in either or both of Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and/or 8, with a decrease in the level of expression of one or more markers listed in Table 3A, 5, 7C and 7E, or with both. While, as discussed above, some of these changes in expression level result from occurrence of the ovarian cancer, others of these changes induce, maintain, and promote the cancerous state of ovarian cancer cells. Thus, ovarian cancer characterized by an increase in the level of expression of one or more markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and/or 8 can be inhibited by inhibiting expression of those markers. Likewise, ovarian

5

15

20

25

cancer characterized by a decrease in the level of expression of one or more markers listed in Table 3A, 5, 7C and 7E can be inhibited by enhancing expression of those markers.

Expression of a marker listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8 can be inhibited in a number of ways generally known in the art. For example, an antisense oligonucleotide can be provided to the ovarian cancer cells in order to inhibit transcription, translation, or both, of the marker(s). Alternately, a polynucleotide encoding an antibody, an antibody derivative, or an antibody fragment which specifically binds the protein corresponding to the marker, and operably linked with an appropriate promoter/regulator region, can be provided to the cell in order to generate intracellular antibodies which will inhibit the function or activity of the protein. The expression and/or function of a marker may also be inhibited by treating the ovarian cancer cell with a heterologous antibody or antibody derivative that specifically binds the protein corresponding to the marker. Using the methods described herein, a variety of molecules, particularly including molecules sufficiently small that they are able to cross the cell membrane, can be screened in order to identify molecules which inhibit expression of the marker(s). The compound so identified can be provided to the patient in order to inhibit expression of the marker(s) in the ovarian cancer cells of the patient.

Expression of a marker listed in Tables 3A, 5, 7C and 7E can be enhanced in a number of ways generally known in the art. For example, a polynucleotide encoding the marker and operably linked with an appropriate promoter/regulator region can be provided to ovarian cancer cells of the patient in order to induce enhanced expression of the protein (and mRNA) corresponding to the marker therein. Alternatively, if the protein is capable of crossing the cell membrane, inserting itself in the cell membrane, or is normally a secreted protein, then expression of the protein can be enhanced by providing the protein (e.g. directly or by way of the bloodstream or another ovary-associated fluid) to ovarian cancer cells in the patient.

As described above, the cancerous state of human ovarian cells is correlated with changes in the levels of expression of the markers of the invention. Thus, compounds which induce increased expression of one or more of the markers listed in either or both of Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8, decreased expression of one or more of the markers listed in either or both of Tables 3A, 5, 7C and 7E, or both, can induce

ovarian cell carcinogenesis. The invention includes a method for assessing the human ovarian cell carcinogenic potential of a test compound. This method comprises maintaining separate aliquots of human ovarian cells in the presence and absence of the test compound. Expression of a marker of the invention in each of the aliquots is compared. A significant increase in the level of expression of a marker listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8, or a significant decrease in the level of expression of a marker listed in Tables 3A, 5, 7C and 7E in the aliquot maintained in the presence of the test compound (relative to the aliquot maintained in the absence of the test compound) is an indication that the test compound possesses human ovarian cell carcinogenic potential. The relative carcinogenic potentials of various test compounds can be assessed by comparing the degree of enhancement or inhibition of the level of expression of the relevant markers, by comparing the number of markers for which the level of expression is enhanced or inhibited, or by comparing both.

- 36 -

Various aspects of the invention are described in further detail in the following subsections.

I. Isolated Nucleic Acid Molecules

15

20

30

One aspect of the invention pertains to isolated nucleic acid molecules that correspond to a marker of the invention, including nucleic acids which encode a polypeptide corresponding to a marker of the invention or a portion of such a polypeptide. Isolated nucleic acids of the invention also include nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules that correspond to a marker of the invention, including nucleic acids which encode a polypeptide corresponding to a marker of the invention, and fragments of such nucleic acid molecules, *e.g.*, those suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

- 37 -

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Preferably, an "isolated" nucleic acid molecule comprises a protein-coding sequence and is free of sequences which naturally flank the coding sequence in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kB, 4 kB, 3 kB, 2 kB, 1 kB, 0.5 kB or 0.1 kB of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid encoding a protein corresponding to a marker listed in one or more of Tables 1-11, can be isolated using standard molecular biology techniques and the sequence information in the database records described herein. Using all or a portion of such nucleic acid sequences, nucleic acid molecules of the invention can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., ed., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

15

20

A nucleic acid molecule of the invention can be amplified using cDNA, mRNA, or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which has a nucleotide sequence complementary to the nucleotide sequence of a nucleic acid corresponding to a marker of the invention or to the nucleotide sequence of a nucleic acid encoding a protein which corresponds to a marker of the invention. A nucleic acid molecule which is

- 38 -

WO 01/18542

20

25

complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.

PCT/US00/24199

Moreover, a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence, wherein the full length nucleic acid sequence comprises a marker of the invention or which encodes a polypeptide corresponding to a marker of the invention. Such nucleic acids can be used, for example, as a probe or primer. The probe/primer typically is used as one or more substantially purified oligonucleotides. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 7, preferably about 15, more preferably about 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 or more consecutive nucleotides of a nucleic acid of the invention.

Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences corresponding to one or more markers of the invention. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which misexpress the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

The invention further encompasses nucleic acid molecules that differ, due to degeneracy of the genetic code, from the nucleotide sequence of nucleic acids encoding a protein which corresponds to a marker of the invention, and thus encode the same protein.

In addition to the nucleotide sequences described in the GenBank and IMAGE Consortium database records described herein, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. In addition, it will be appreciated that DNA polymorphisms that affect

5

15

20

25

30

PCT/US00/24199

RNA expression levels can also exist that may affect the overall expression level of that gene (e.g., by affecting regulation or degradation).

As used herein, the phrase "allelic variant" refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide corresponding to a marker of the invention. Such natural allelic variations can typically result in 0.1 –0.5 % variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.

In another embodiment, an isolated nucleic acid molecule of the invention is at least 7, 15, 20, 25, 30, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or more nucleotides in length and hybridizes under stringent conditions to a nucleic acid corresponding to a marker of the invention or to a nucleic acid encoding a protein corresponding to a marker of the invention. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 75% (80%, 85%, preferably 90%) identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in sections 6.3.1-6.3.6 of Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989). A preferred, non-limiting example of stringent hybridization conditions for annealing two single-stranded DNA each of which is at least about 100 bases in length and/or for annealing a single-stranded DNA and a single-stranded RNA each of which is at least about 100 bases in length, are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50-65°C. Further preferred hybridization conditions are taught in Lockhart, et al., Nature Biotechnology, Volume 14, 1996 August:1675-1680; Breslauer, et al., Proc. Natl. Acad.

5

15

20

30

- 40 -

Sci. USA, Volume 83, 1986 June: 3746-3750; Van Ness, et al., Nucleic Acids Research, Volume 19, No. 19, 1991 September: 5143-5151; McGraw, et al., BioTechniques, Volume 8, No. 6 1990: 674-678; and Milner, et al., Nature Biotechnology, Volume 15, 1997 June: 537-541, all expressly incorporated by reference.

In addition to naturally-occurring allelic variants of a nucleic acid molecule of the invention that can exist in the population, the skilled artisan will further appreciate that sequence changes can be introduced by mutation thereby leading to changes in the amino acid sequence of the encoded protein, without altering the biological activity of the protein encoded thereby. For example, one can make nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are not conserved or only semi-conserved among homologs of various species may be non-essential for activity and thus would be likely targets for alteration. Alternatively, amino acid residues that are conserved among the homologs of various species (e.g., murine and human) may be essential for activity and thus would not be likely targets for alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from the naturally-occurring proteins which correspond to the markers of the invention, yet retain biological activity. In one embodiment, such a protein has an amino acid sequence that is at least about 40% identical, 50%, 60%, 70%, 80%, 90%, 95%, or 98% identical to the amino acid sequence of one of the proteins which correspond to the markers of the invention.

An isolated nucleic acid molecule encoding a variant protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of nucleic acids of the invention, such that one or more amino acid residue substitutions, additions, or deletions are introduced into the encoded protein.

Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are

-41 -

made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

15

20

25

30

The present invention encompasses antisense nucleic acid molecules, *i.e.*, molecules which are complementary to a sense nucleic acid of the invention, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule corresponding to a marker of the invention or complementary to an mRNA sequence corresponding to a marker of the invention. Accordingly, an antisense nucleic acid of the invention can hydrogen bond to (*i.e.* anneal with) a sense nucleic acid of the invention. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof, *e.g.*, all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can also be antisense to all or part of a noncoding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention. The non-coding regions ("5' and 3' untranslated regions") are the 5' and 3' sequences which flank the coding region and are not translated into amino acids.

An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the

- 42 -

PCT/US00/24199

molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. 15 Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been sub-cloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection). 20

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a polypeptide corresponding to a selected marker of the invention to thereby inhibit expression of the marker, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. Examples of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site or infusion of the antisense nucleic acid into an ovary-associated body fluid. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense

10

15

30

molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector

To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

An antisense nucleic acid molecule of the invention can be an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual α-units, the strands run parallel to each other (Gaultier *et al.*, 1987, *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.*, 1987, *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, *FEBS Lett.* 215:327-330).

The invention also encompasses ribozymes. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach, 1988, Nature 334:585-591) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of the protein encoded by the mRNA. A ribozyme having specificity for a nucleic acid molecule encoding a polypeptide corresponding to a marker of the invention can be designed based upon the nucleotide sequence of a cDNA corresponding to the marker. For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved (see Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742). Alternatively, an mRNA encoding a polypeptide of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules (see, e.g., Bartel and Szostak, 1993, Science 261:1411-1418).

The invention also encompasses nucleic acid molecules which form triple helical structures. For example, expression of a polypeptide of the invention can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the gene

5

10

15

20

25

- 44 -

PCT/US00/24199

encoding the polypeptide (e.g., the promoter and/or enhancer) to form triple helical structures that prevent transcription of the gene in target cells. See generally Helene (1991) Anticancer Drug Des. 6(6):569-84; Helene (1992) Ann. N.Y. Acad. Sci. 660:27-36; and Maher (1992) Bioassays 14(12):807-15.

In various embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al., 1996, Bioorganic & Medicinal Chemistry 4(1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996), supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93:14670-675.

PNAs can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup (1996), supra; or as probes or primers for DNA sequence and hybridization (Hyrup, 1996, supra; Perry-O'Keefe et al., 1996, Proc. Natl. Acad. Sci. USA 93:14670-675).

In another embodiment, PNAs can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated which can combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNASE H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity.

- 45 -

PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup, 1996, *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), *supra*, and Finn *et al.* (1996) *Nucleic Acids Res.* 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs. Compounds such as 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite can be used as a link between the PNA and the 5' end of DNA (Mag *et al.*, 1989, *Nucleic Acids Res.* 17:5973-88). PNA monomers are then coupled in a step-wise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn *et al.*, 1996, *Nucleic Acids Res.* 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser *et al.*, 1975, *Bioorganic Med. Chem. Lett.* 5:1119-11124).

In other embodiments, the oligonucleotide can include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. USA 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol et al., 1988, Bio/Techniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

15

20

25

The invention also includes molecular beacon nucleic acids having at least one region which is complementary to a nucleic acid of the invention, such that the molecular beacon is useful for quantitating the presence of the nucleic acid of the invention in a sample. A "molecular beacon" nucleic acid is a nucleic acid comprising a pair of complementary regions and having a fluorophore and a fluorescent quencher associated therewith. The fluorophore and quencher are associated with different portions of the nucleic acid in such an orientation that when the complementary regions are annealed with one another, fluorescence of the fluorophore is quenched by the

- 46 -

quencher. When the complementary regions of the nucleic acid are not annealed with one another, fluorescence of the fluorophore is quenched to a lesser degree. Molecular beacon nucleic acids are described, for example, in U.S. Patent 5,876,930.

PCT/US00/24199

5 II. Isolated Proteins and Antibodies

WO 01/18542

15

25

One aspect of the invention pertains to isolated proteins which correspond to individual markers of the invention, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a polypeptide corresponding to a marker of the invention. In one embodiment, the native polypeptide corresponding to a marker can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, polypeptides corresponding to a marker of the invention are produced by recombinant DNA techniques. Alternative to recombinant expression, a polypeptide corresponding to a marker of the invention can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.

- 47 -

Biologically active portions of a polypeptide corresponding to a marker of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein corresponding to the marker (e.g., the amino acid sequence listed in the GenBank and IMAGE Consortium database records described herein), which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding protein. A biologically active portion of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of a polypeptide of the invention.

Preferred polypeptides have the amino acid sequence listed in the one of the GenBank and IMAGE Consortium database records described herein. Other useful proteins are substantially identical (e.g., at least about 40%, preferably 50%, 60%, 70%, 80%, 90%, 95%, or 99%) to one of these sequences and retain the functional activity of the protein of the corresponding naturally-occurring protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.

15

20

30

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions (e.g., overlapping positions) x100). In one embodiment the two sequences are the same length.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of

- 48 -

Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-Blast can be 10 used to perform an iterated search which detects distant relationships between molecules. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, (1988) Comput Appl Biosci, 4:11-7. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap 20 penalty of 4 can be used. Yet another useful algorithm for identifying regions of local sequence similarity and alignment is the FASTA algorithm as described in Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448. When using the FASTA algorithm for comparing nucleotide or amino acid sequences, a PAM120 weight residue table can, for example, be used with a k-tuple value of 2.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

25

The invention also provides chimeric or fusion proteins corresponding to a marker of the invention. As used herein, a "chimeric protein" or "fusion protein" comprises all or part (preferably a biologically active part) of a polypeptide corresponding to a marker of the invention operably linked to a heterologous polypeptide (*i.e.*, a polypeptide other than the polypeptide corresponding to the marker).

- 49 -

Within the fusion protein, the term "operably linked" is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the amino-terminus or the carboxyl-terminus of the polypeptide of the invention.

One useful fusion protein is a GST fusion protein in which a polypeptide corresponding to a marker of the invention is fused to the carboxyl terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.

5

20

25

30

In another embodiment, the fusion protein contains a heterologous signal

sequence at its amino terminus. For example, the native signal sequence of a
polypeptide corresponding to a marker of the invention can be removed and replaced
with a signal sequence from another protein. For example, the gp67 secretory sequence
of the baculovirus envelope protein can be used as a heterologous signal sequence
(Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, NY,
15 1992). Other examples of eukaryotic heterologous signal sequences include the
secretory sequences of melittin and human placental alkaline phosphatase (Stratagene;
La Jolla, California). In yet another example, useful prokaryotic heterologous signal
sequences include the phoA secretory signal (Sambrook et al., supra) and the protein A
secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

In yet another embodiment, the fusion protein is an immunoglobulin fusion protein in which all or part of a polypeptide corresponding to a marker of the invention is fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane-bound) and a protein on the surface of a cell (receptor), to thereby suppress signal transduction *in vivo*. The immunoglobulin fusion protein can be used to affect the bioavailability of a cognate ligand of a polypeptide of the invention. Inhibition of ligand/receptor interaction can be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (e.g. promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against a

15

30

polypeptide of the invention in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of receptors with ligands.

- 50 -

PCT/US00/24199

Chimeric and fusion proteins of the invention can be produced by standard recombinant DNA techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see, e.g., Ausubel et al., supra). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide of the invention.

A signal sequence can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. Thus, the invention pertains to the described polypeptides having a signal sequence, as well as to polypeptides from which the signal sequence has been proteolytically cleaved (i.e., the cleavage products). In one embodiment, a nucleic acid sequence encoding a signal sequence can be operably linked in an expression vector to a protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.

The present invention also pertains to variants of the polypeptides corresponding to individual markers of the invention. Such variants have an altered amino acid sequence which can function as either agonists (mimetics) or as antagonists. Variants

can be generated by mutagenesis, e.g., discrete point mutation or truncation. An agonist can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the protein. An antagonist of a protein can inhibit one or more of the activities of the naturally occurring form of the protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the protein of interest. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the protein.

- 51 -

Variants of a protein of the invention which function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the protein of the invention for agonist or antagonist activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods which can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, 1983, Tetrahedron 39:3; Itakura et al., 1984, Annu. Rev. Biochem. 53:323; Itakura et al., 1984, Science 198:1056; Ike et al., 1983 Nucleic Acid Res. 11:477).

20

25

In addition, libraries of fragments of the coding sequence of a polypeptide corresponding to a marker of the invention can be used to generate a variegated population of polypeptides for screening and subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions

5

10

20

25

30

- 52 -

from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes amino terminal and internal fragments of various sizes of the protein of interest.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan, 1992, Proc. Natl. Acad. Sci. 15 USA 89:7811-7815; Delgrave et al., 1993, Protein Engineering 6(3):327-331).

An isolated polypeptide corresponding to a marker of the invention, or a fragment thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. The full-length polypeptide or protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens. The antigenic peptide of a protein of the invention comprises at least 8 (preferably 10, 15, 20, or 30 or more) amino acid residues of the amino acid sequence of one of the polypeptides of the invention, and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with a marker of the invention to which the protein corresponds. Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, e.g., hydrophilic regions. Hydrophobicity sequence analysis, hydrophilicity sequence analysis, or similar analyses can be used to identify hydrophilic regions.

An immunogen typically is used to prepare antibodies by immunizing a suitable (i.e. immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. An appropriate immunogenic preparation can contain, for example,

- 53 -

recombinantly-expressed or chemically-synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.

Accordingly, another aspect of the invention pertains to antibodies directed against a polypeptide of the invention. The terms "antibody" and "antibody substance" as used interchangeably herein refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the invention, e.g., an epitope of a polypeptide of the invention. A molecule which specifically binds to a given polypeptide of the invention is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope.

Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a polypeptide of the invention as an immunogen. Preferred polyclonal antibody compositions are ones that have been selected for antibodies directed against a polypeptide or polypeptides of the invention. Particularly preferred polyclonal antibody preparations are ones that contain only antibodies directed against a polypeptide or polypeptides of the invention. Particularly preferred immunogen compositions are those that contain no other human proteins such as, for example, immunogen compositions made using a non-human host cell for recombinant expression of a polypeptide of the invention. In such a manner, the only human epitope or epitopes recognized by the resulting antibody compositions raised against this immunogen will be present as part of a polypeptide or polypeptides of the invention.

20

30

The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules can be harvested or

- 54 -

polypeptide of the invention.

WO 01/18542

isolated from the subject (e.g., from the blood or serum of the subject) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. Alternatively, antibodies specific for a protein or polypeptide of the invention can be selected or (e.g., partially purified) or purified by, e.g., affinity chromatography.

PCT/US00/24199

For example, a recombinantly expressed and purified (or partially purified) protein of the invention is produced as described herein, and covalently or non-covalently coupled to a solid support such as, for example, a chromatography column. The column can then be used to affinity purify antibodies specific for the proteins of the invention from a sample containing antibodies directed against a large number of different epitopes, thereby generating a substantially purified antibody composition, *i.e.*, one that is

thereby generating a substantially purified antibody composition, *i.e.*, one that is substantially free of contaminating antibodies. By a substantially purified antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those of the desired protein or polypeptide of the invention, and preferably at most 20%, yet more preferably at most 10%, and most preferably at most 5% (by dry weight) of the sample is contaminating antibodies. A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or

At an appropriate time after immunization, e.g., when the specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497, the human B cell hybridoma technique (see Kozbor et al., 1983, Immunol. Today 4:72), the EBV-hybridoma technique (see Cole et al., pp. 77-96 In Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985) or trioma techniques. The technology for producing hybridomas is well known (see generally Current Protocols in Immunology, Coligan et al. ed., John Wiley & Sons, New York, 1994). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, e.g., using a standard ELISA assay.

- 55 -

PCT/US00/24199

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide of interest. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. 10 WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum. Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EMBO J. 12:725-734. 15

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. A chimeric antibody is a molecule in which different portions are derived 20 from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; and Boss et al., U.S. Patent No. 4,816,397, which are incorporated herein by reference in their entirety.) Humanized antibodies are antibody molecules from non-human species having one or more complementarily determining 25 regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, e.g., Queen, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Patent No. 4,816,567; European Patent Application 125,023; Better et al. (1988) Science 240:1041-

- 56 -

1043; Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Cancer Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559); Morrison (1985) Science 229:1202-1207; Oi et al. (1986) Bio/Techniques 4:214; U.S. Patent 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol. 141:4053-4060.

Antibodies of the invention may be used as therapeutic agents in treating cancers. In a preferred embodiment, completely human antibodies of the invention are used for therapeutic treatment of human cancer patients, particularly those having an ovarian cancer. Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide corresponding to a marker of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995) Int. Rev. Immunol. 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., U.S. Patent 5,625,126; U.S. Patent 5,633,425; U.S. Patent 5,569,825; U.S. Patent 5,661,016; and U.S. Patent 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont, CA), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a murine antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers et al., 1994, Bio/technology 12:899-903).

20

25

30

An antibody directed against a polypeptide corresponding to a marker of the invention (e.g., a monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the marker (e.g., in a cellular lysate or cell supernatant) in order to evaluate the level and pattern of expression of the marker. The antibodies can also be used diagnostically to monitor protein levels in tissues or body fluids (e.g. in an ovary-associated body fluid) as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. 10 Examples of detectable substances include various enzymes, prosthetic groups. fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, \u03b3-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, 15 rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

Further, an antibody (or fragment thereof) can be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and

doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, .alpha.-interferon, .beta.-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophase colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Techniques for conjugating such therapeutic moiety to antibodies are well
known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs
In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al.
(eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug
Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53
(Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer
Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical
Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future
Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in
Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp.
303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic
Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

Accordingly, in one aspect, the invention provides substantially purified antibodies or fragments thereof, and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of the present invention, an amino acid sequence encoded by the cDNA of the present invention, a

10

15

fragment of at least 15 amino acid residues of an amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to the amino acid sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C. In various embodiments, the substantially purified antibodies of the invention, or fragments thereof, can be human, non-human, chimeric and/or humanized antibodies.

- 59 -

In another aspect, the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of: the amino acid sequence of the present invention, an amino acid sequence encoded by the cDNA of the present invention, a fragment of at least 15 amino acid residues of the amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to the amino acid sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C. Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the nonhuman antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.

In still a further aspect, the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of the present invention, an amino acid sequence encoded by the cDNA of the

- 60 -

present invention, a fragment of at least 15 amino acid residues of an amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to an amino acid sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.

The substantially purified antibodies or fragments thereof may specifically bind to a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain or cytoplasmic membrane of a polypeptide of the invention. In a particularly preferred embodiment, the substantially purified antibodies or fragments thereof, the non-human antibodies or fragments thereof, and/or the monoclonal antibodies or fragments thereof, of the invention specifically bind to a secreted sequence or an extracellular domain of the amino acid sequences of the present invention.

10

15

20

25

Any of the antibodies of the invention can be conjugated to a therapeutic moiety or to a detectable substance. Non-limiting examples of detectable substances that can be conjugated to the antibodies of the invention are an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

The invention also provides a kit containing an antibody of the invention conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition contains an antibody of the invention, a therapeutic moiety, and a pharmaceutically acceptable carrier.

Still another aspect of the invention is a method of making an antibody that specifically recognizes a polypeptide of the present invention, the method comprising immunizing a mammal with a polypeptide. The polypeptide used as an immungen comprises an amino acid sequence selected from the group consisting of the amino acid

sequence of the present invention, an amino acid sequence encoded by the cDNA of the nucleic acid molecules of the present invention, a fragment of at least 15 amino acid residues of the amino acid sequence of the present invention, an amino acid sequence which is at least 95% identical to the amino acid sequence of the present invention (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present invention, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C.

- 61 -

PCT/US00/24199

After immunization, a sample is collected from the mammal that contains an antibody that specifically recognizes the polypeptide. Preferably, the polypeptide is recombinantly produced using a non-human host cell. Optionally, the antibodies can be further purified from the sample using techniques well known to those of skill in the art. The method can further comprise producing a monoclonal antibody- producing cell from the cells of the mammal. Optionally, antibodies are collected from the antibody-producing cell.

III. Recombinant Expression Vectors and Host Cells

10

20

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a polypeptide corresponding to a marker of the invention (or a portion of such a polypeptide). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, namely expression vectors, are capable of directing the expression of genes to which they are

- 62 -

operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

10

20

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, Methods in Enzymology: Gene Expression Technology vol.185, Academic Press, San Diego, CA (1991). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.

The recombinant expression vectors of the invention can be designed for expression of a polypeptide corresponding to a marker of the invention in prokaryotic (e.g., E. coli) or eukaryotic cells (e.g., insect cells {using baculovirus expression vectors}, yeast cells or mammalian cells). Suitable host cells are discussed further in Goeddel, supra. Alternatively, the recombinant expression vector can be transcribed

10

20

25

- 63 -

and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988, *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, 1988, *Gene* 69:301-315) and pET 11d (Studier *et al.*, p. 60-89, In *Gene Expression Technology: Methods in Enzymology* vol.185, Academic Press, San Diego, CA, 1991). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, p. 119-128, In *Gene Expression Technology: Methods in Enzymology* vol. 185, Academic Press, San Diego, CA, 1990. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized

- 64 -

WO 01/18542

15

20

in E. coli (Wada et al., 1992, Nucleic Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

PCT/US00/24199

In another embodiment, the expression vector is a yeast expression vector.

Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari *et al.*, 1987, *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz, 1982, *Cell* 30:933-943), pJRY88 (Schultz *et al.*, 1987, *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and pPicZ (Invitrogen Corp, San Diego, CA).

Alternatively, the expression vector is a baculovirus expression vector.

10 Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., 1983, Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers, 1989, Virology 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987, *Nature* 329:840) and pMT2PC (Kaufman *et al.*, 1987, *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook *et al.*, *supra*.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al., 1987, Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton, 1988, Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989, EMBO J. 8:729-733) and immunoglobulins (Banerji et al., 1983, Cell 33:729-740; Queen and Baltimore, 1983, Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989, Proc. Natl. Acad. Sci. USA 86:5473-5477), pancreas-specific promoters (Edlund et al., 1985, Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No.

5

15

20

30

- 65 -

4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss, 1990, *Science* 249:374-379) and the α-fetoprotein promoter (Camper and Tilghman, 1989, *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operably linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to the mRNA encoding a polypeptide of the invention.

Regulatory sequences operably linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue-specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub *et al.*, 1986, *Trends in Genetics*, Vol. 1(1).

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic (e.g., E. coli) or eukaryotic cell (e.g., insect cells, yeast or mammalian cells).

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized

5

10

15

techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*supra*), and other laboratory manuals.

- 66 -

PCT/US00/24199

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a polypeptide corresponding to a marker of the invention. Accordingly, the invention further provides methods for producing a polypeptide corresponding to a marker of the invention using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the marker is produced. In another embodiment, the method further comprises isolating the marker polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a sequences encoding a polypeptide corresponding to a marker of the invention have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous sequences encoding a marker protein of the invention have been introduced into their genome or homologous recombinant animals in which endogenous gene(s) encoding a polypeptide corresponding to a marker of the invention sequences have been altered. Such animals are useful for studying the function and/or activity of the polypeptide corresponding to the marker and for identifying and/or evaluating modulators of polypeptide activity. As

used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

- 67 -

A transgenic animal of the invention can be created by introducing a nucleic acid encoding a polypeptide corresponding to a marker of the invention into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the polypeptide of the invention to 20 particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan, Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA encoding the transgene in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying the transgene can further be bred to other transgenic animals 30 carrying other transgenes.

- 68 -

PCT/US00/24199

To create an homologous recombinant animal, a vector is prepared which contains at least a portion of a gene encoding a polypeptide corresponding to a marker of the invention into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the gene. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous protein). In the homologous 10 recombination vector, the altered portion of the gene is flanked at its 5' and 3' ends by additional nucleic acid of the gene to allow for homologous recombination to occur between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell. The additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see, e.g., Thomas and Capecchi, 1987, Cell 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected (see, e.g., Li et al., 1992, Cell 20 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see, e.g., Bradley, Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, Ed., IRL, Oxford, 1987, pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) Current Opinion in Bio/Technology 2:823-829 and in PCT Publication NOS. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

- 69 -

PCT/US00/24199

In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso et al. (1992) Proc. Natl. Acad. Sci. USA 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al., 1991, Science 251:1351-1355). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut *et al.* (1997) *Nature* 385:810-813 and PCT Publication NOS. WO 97/07668 and WO 97/07669.

IV. Pharmaceutical Compositions

15

30

The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") corresponding to a marker of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a polypeptide or nucleic acid corresponding to a marker of the invention. Such methods comprise formulating a pharmaceutically

acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid corresponding to a marker of the invention. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid corresponding to a marker of the invention and one or more additional active compounds.

- 70 -

PCT/US00/24199

The invention also provides methods (also referred to herein as "screening assays") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, peptoids, small molecules or other drugs) which (a) bind to the marker, or (b) have a modulatory (*e.g.*, stimulatory or inhibitory) effect on the activity of the marker or, more specifically, (c) have a modulatory effect on the interactions of the marker with one or more of its natural substrates (*e.g.*, peptide, protein, hormone, co-factor, or nucleic acid), or (d) have a modulatory effect on the expression of the marker. Such assays typically comprise a reaction between the marker and one or more assay components. The other components may be either the test compound itself, or a combination of test compound and a natural binding partner of the marker.

The test compounds of the present invention may be obtained from any available source, including systematic libraries of natural and/or synthetic compounds. Test compounds may also be obtained by any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive; see, e.g., Zuckermann et al., 1994, J. Med. Chem. 37:2678-85); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library and peptoid library approaches are limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997, Anticancer Drug Des. 12:145).

- 71 -

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med. Chem. 37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and in Gallop et al. (1994) J. Med. Chem. 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten, 1992, Biotechniques 13:412-421), or on beads (Lam, 1991, Nature 354:82-84), chips (Fodor, 1993, Nature 364:555-556), bacteria and/or spores, (Ladner, USP 5,223,409), plasmids (Cull et al, 1992, Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith, 1990, Science 249:386-390; Devlin, 1990, Science 249:404-406; Cwirla et al, 1990, Proc. Natl. Acad. Sci. 87:6378-6382; Felici, 1991, J. Mol. Biol. 222:301-310; Ladner, supra.).

In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of a marker or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to a marker or biologically active portion thereof. Determining the ability of the test compound to directly bind to a marker can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound to the marker can be determined by detecting the labeled marker compound in a complex. For example, compounds (e.g., marker substrates) can be labeled with ¹²⁵I, ³⁵S, ¹⁴C, or ³H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, assay components can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

In another embodiment, the invention provides assays for screening candidate or test compounds which modulate the activity of a marker or a biologically active portion thereof. In all likelihood, the marker can, *in vivo*, interact with one or more molecules, such as but not limited to, peptides, proteins, hormones, cofactors and nucleic acids. For the purposes of this discussion, such cellular and extracellular molecules are referred to herein as "binding partners" or marker "substrate".

- 72 -

One necessary embodiment of the invention in order to facilitate such screening is the use of the marker to identify its natural *in vivo* binding partners. There are many ways to accomplish this which are known to one skilled in the art. One example is the use of the marker protein as "bait protein" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al, 1993, Cell 72:223-232; Madura et al, 1993, J. Biol. Chem. 268:12046-12054; Bartel et al, 1993, Biotechniques 14:920-924; Iwabuchi et al, 1993 Oncogene 8:1693-1696; Brent WO94/10300) in order to identify other proteins which bind to or interact with the marker (binding partners) and, therefore, are possibly involved in the natural function of the marker. Such marker binding partners are also likely to be involved in the propagation of signals by the marker or downstream elements of a marker-mediated signaling pathway. Alternatively, such marker binding partners may also be found to be inhibitors of the marker.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that encodes a marker protein fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a marker-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be readily detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the marker protein.

20

In a further embodiment, assays may be devised through the use of the invention for the purpose of identifying compounds which modulate (e.g., affect either positively or negatively) interactions between a marker and its substrates and/or binding partners. Such compounds can include, but are not limited to, molecules such as antibodies, peptides, hormones, oligonucleotides, nucleic acids, and analogs thereof. Such compounds may also be obtained from any available source, including systematic

5

20

libraries of natural and/or synthetic compounds. The preferred assay components for use in this embodiment is an ovarian cancer marker identified herein, the known binding partner and/or substrate of same, and the test compound. Test compounds can be supplied from any source.

- 73 -

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the marker and its binding partner involves preparing a reaction mixture containing the marker and its binding partner under conditions and for a time sufficient to allow the two products to interact and bind, thus forming a complex. In order to test an agent for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound can be initially included in the reaction mixture, or can be added at a time subsequent to the addition of the marker and its binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the marker and its binding partner is then detected. The formation of a complex in the control reaction, but less or no such formation in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the marker and its binding partner. Conversely, the formation of more complex in the presence of compound than in the control reaction indicates that the compound may enhance interaction of the marker and its binding partner.

The assay for compounds that interfere with the interaction of the marker with its binding partner may be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the marker or its binding partner onto a solid phase and detecting complexes anchored to the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the markers and the binding partners (e.g., by competition) can be identified by conducting the reaction in the presence of the test substance, i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the marker and its interactive binding partner. Alternatively, test compounds that disrupt preformed complexes, e.g., compounds with higher binding constants that displace one of the components from the complex, can be tested by adding

PCT/US00/24199 WO 01/18542

the test compound to the reaction mixture after complexes have been formed. The various formats are briefly described below.

- 74 -

In a heterogeneous assay system, either the marker or its binding partner is anchored onto a solid surface or matrix, while the other corresponding non-anchored 5 component may be labeled, either directly or indirectly. In practice, microtitre plates are often utilized for this approach. The anchored species can be immobilized by a number of methods, either non-covalent or covalent, that are typically well known to one who practices the art. Non-covalent attachment can often be accomplished simply by coating the solid surface with a solution of the marker or its binding partner and drying. Alternatively, an immobilized antibody specific for the assay component to be anchored can be used for this purpose. Such surfaces can often be prepared in advance and stored.

In related embodiments, a fusion protein can be provided which adds a domain that allows one or both of the assay components to be anchored to a matrix. For example, glutathione-S-transferase/marker fusion proteins or glutathione-Stransferase/binding partner can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and either the non-adsorbed marker or its binding partner, and the mixture incubated under conditions conducive to complex formation (e.g., physiological conditions). Following incubation, the beads or microtiter plate wells are washed to remove any unbound assay components, the immobilized complex assessed either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of marker binding or activity determined using standard techniques.

15

20

25

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either a marker or a marker binding partner can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated marker protein or target molecules can be prepared from biotin-NHS (N-hydroxysuccinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In certain embodiments, the protein-immobilized surfaces can be prepared in 30 advance and stored.

- 75 -

In order to conduct the assay, the corresponding partner of the immobilized assay component is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted assay components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, can be directly labeled or indirectly labeled with, e.g., a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which modulate (inhibit or enhance) complex formation or which disrupt preformed complexes can be detected.

In an alternate embodiment of the invention, a homogeneous assay may be used. This is typically a reaction, analogous to those mentioned above, which is conducted in a liquid phase in the presence or absence of the test compound. The formed complexes are then separated from unreacted components, and the amount of complex formed is determined. As mentioned for heterogeneous assay systems, the order of addition of reactants to the liquid phase can yield information about which test compounds modulate (inhibit or enhance) complex formation and which disrupt preformed complexes.

15

20

25

In such a homogeneous assay, the reaction products may be separated from unreacted assay components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In differential centrifugation, complexes of molecules may be separated from uncomplexed molecules through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P., *Trends Biochem Sci* 1993 Aug;18(8):284-7). Standard chromatographic techniques may also be utilized to separate complexed molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger

- 76 -

WO 01/18542

complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge properties of the complex as compared to the uncomplexed molecules may be exploited to differentially separate the complex from the remaining individual reactants, for example through the use of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard, 1998, J Mol. Recognit. 11:141-148; Hage and Tweed, 1997, J. Chromatogr. B. Biomed. Sci. Appl., 699:499-525). Gel electrophoresis may also be employed to separate complexed molecules from unbound species (see, e.g., Ausubel et al (eds.), In: Current Protocols in Molecular Biology, J. Wiley & Sons, 10 New York. 1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process, nondenaturing gels in the absence of reducing agent are typically preferred, but conditions appropriate to the particular interactants will be well known to one skilled in the art. Immunoprecipitation is another common technique utilized for the isolation of a protein-protein complex from solution (see, e.g., Ausubel et 15 al (eds.), In: Current Protocols in Molecular Biology, J. Wiley & Sons, New York. 1999). In this technique, all proteins binding to an antibody specific to one of the binding molecules are precipitated from solution by conjugating the antibody to a polymer bead that may be readily collected by centrifugation. The bound assay components are released from the beads (through a specific proteolysis event or other 20 technique well known in the art which will not disturb the protein-protein interaction in the complex), and a second immunoprecipitation step is performed, this time utilizing antibodies specific for the correspondingly different interacting assay component. In this manner, only formed complexes should remain attached to the beads. Variations in complex formation in both the presence and the absence of a test compound can be compared, thus offering information about the ability of the compound to modulate interactions between the marker and its binding partner.

PCT/US00/24199

Also within the scope of the present invention are methods for direct detection of interactions between the marker and its natural binding partner and/or a test compound in a homogeneous or heterogeneous assay system without further sample manipulation. For example, the technique of fluorescence energy transfer may be utilized (see, e.g., Lakowicz et al, U.S. Patent No. 5,631,169; Stavrianopoulos et al, U.S. Patent No.

4,868,103). Generally, this technique involves the addition of a fluorophore label on a first 'donor' molecule (e.g., marker or test compound) such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, 'acceptor' molecule (e.g., marker or test compound), which in turn is able to fluoresce due to the absorbed energy.

- 77 -

Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter). A test substance which either enhances or hinders participation of one of the species in the preformed complex will result in the generation of a signal variant to that of background. In this way, test substances that modulate interactions between a marker and its binding partner can be identified in controlled assays.

In another embodiment, modulators of marker expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA or protein, corresponding to a marker in the cell, is determined. The level of expression of mRNA or protein in the presence of the candidate compound is compared to the level of expression of mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of marker expression based on this comparison. For example, when expression of marker mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of marker mRNA or protein expression. Conversely, when expression of marker mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of marker mRNA or protein expression. The level of marker mRNA or protein expression in the cells can be determined by methods described herein for detecting marker mRNA or protein.

20

WO 01/18542

5

15

20

25

In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell free assay, and the ability of the agent to modulate the activity of a marker protein can be further confirmed *in vivo*, *e.g.*, in a whole animal model for cellular transformation and/or tumorigenesis.

- 78 -

PCT/US00/24199

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., an marker modulating agent, an antisense marker nucleic acid molecule, an marker-specific antibody, or an marker-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

It is understood that appropriate doses of small molecule agents and protein or polypeptide agents depends upon a number of factors within the knowledge of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of these agents will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the agent to have upon the nucleic acid or polypeptide of the invention. Exemplary doses of a small molecule include milligram or microgram amounts per kilogram of subject or sample weight (e.g. about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram). Exemplary doses of a protein or polypeptide include gram, milligram or microgram amounts per kilogram of subject or sample weight (e.g. about 1 microgram per kilogram to about 5 grams per kilogram, about 100 micrograms per kilogram to about 500 milligrams per kilogram, or about 1 milligram per kilogram to about 50 milligrams per kilogram). It is furthermore understood that appropriate doses of one of these agents depend upon the potency of the agent with respect to the expression or activity to be modulated. Such appropriate doses - 79 -

WO 01/18542

10

can be determined using the assays described herein. When one or more of these agents is to be administered to an animal (e.g. a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher can, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific agent employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

PCT/US00/24199

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for

WO 01/18542

20

example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.

- 80 -

PCT/US00/24199

Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium, and then incorporating the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a

WO 01/18542

5

15

- 81 -

PCT/US00/24199

lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes having monoclonal antibodies incorporated therein or thereon) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in
dosage unit form for ease of administration and uniformity of dosage. Dosage unit form
as used herein refers to physically discrete units suited as unitary dosages for the subject
to be treated; each unit containing a predetermined quantity of active compound

calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

For antibodies, the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the ovarian epithelium). A method for lipidation of antibodies is described by Cruikshank et al. (1997) J. Acquired Immune Deficiency Syndromes and Human Retrovirology 14:193.

The nucleic acid molecules corresponding to a marker of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Patent 5,328,470), or by stereotactic injection (see, e.g., Chen et al., 1994, Proc. Natl. Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

V. Predictive Medicine

10

15

20

25

The present invention pertains to the field of predictive medicine in which
diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trails
are used for prognostic (predictive) purposes to thereby treat an individual
prophylactically. Accordingly, one aspect of the present invention relates to diagnostic

WO 01/18542

- 83 -

PCT/US00/24199

assays for determining the level of expression of polypeptides or nucleic acids corresponding to one or more markers of the invention, in order to determine whether an individual is at risk of developing ovarian cancer. Such assays can be used for prognostic or predictive purposes to thereby prophylactically treat an individual prior to the onset of the cancer.

Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs or other compounds administered either to inhibit ovarian cancer or to treat or prevent any other disorder {i.e. in order to understand any ovarian carcinogenic effects that such treatment may have}) on the expression or activity of a marker of the invention in clinical trials. These and other agents are described in further detail in the following sections.

A. Diagnostic Assays

5

10

15

20

25

30

An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid corresponding to a marker of the invention in a biological sample involves obtaining a biological sample (e.g. an ovary-associated body fluid) from a test subject and contacting the biological sample with a compound or an agent capable of detecting the polypeptide or nucleic acid (e.g., mRNA, genomic DNA, or cDNA). The detection methods of the invention can thus be used to detect mRNA, protein, cDNA, or genomic DNA, for example, in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of a polypeptide corresponding to a marker of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of a polypeptide corresponding to a marker of the invention include introducing into a subject a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

A general principle of such diagnostic and prognostic assays involves preparing a sample or reaction mixture that may contain a marker, and a probe, under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind,

- 84 -

thus forming a complex that can be removed and/or detected in the reaction mixture.

These assays can be conducted in a variety of ways.

For example, one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, a sample from a subject, which is to be assayed for presence and/or concentration of marker, can be anchored onto a carrier or solid phase support. In another embodiment, the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay.

There are many established methods for anchoring assay components to a solid phase. These include, without limitation, marker or probe molecules which are immobilized through conjugation of biotin and streptavidin. Such biotinylated assay components can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In certain embodiments, the surfaces with immobilized assay components can be prepared in advance and stored.

Other suitable carriers or solid phase supports for such assays include any material capable of binding the class of molecule to which the marker or probe belongs. Well-known supports or carriers include, but are not limited to, glass, polystyrene, nylon, polypropylene, nylon, polyethylene, dextran, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

In order to conduct assays with the above mentioned approaches, the non-immobilized component is added to the solid phase upon which the second component is anchored. After the reaction is complete, uncomplexed components may be removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase. The detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein.

25

10

20

- 85 -

WO 01/18542

5

20

In a preferred embodiment, the probe, when it is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art.

PCT/US00/24199

It is also possible to directly detect marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (see, for example, Lakowicz et al., U.S. Patent No. 5,631,169; Stavrianopoulos, et al., U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent energy will be absorbed by a fluorescent label on a second 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

In another embodiment, determination of the ability of a probe to recognize a marker can be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C., 1991, Anal. Chem. 63:2338-2345 and Szabo et al., 1995, Curr. Opin. Struct. Biol. 5:699-705). As used herein, "BIA" or "surface plasmon resonance" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

- 86 -

Alternatively, in another embodiment, analogous diagnostic and prognostic assays can be conducted with marker and probe as solutes in a liquid phase. In such an assay, the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential 5 centrifugation, chromatography, electrophoresis and immunoprecipitation. In differential centrifugation, marker/probe complexes may be separated from uncomplexed assay components through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P., 1993, Trends Biochem Sci. 18(8):284-7). Standard chromatographic techniques may also be utilized to separate complexed 10 molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge properties of the marker/probe complex as compared to the uncomplexed components may be exploited to differentiate the complex from uncomplexed components, for example through the utilization of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard, N.H., 1998, J. Mol. Recognit. Winter 11(1-6):141-8; Hage, D.S., and Tweed, S.A. J Chromatogr B Biomed Sci Appl 1997 Oct 20 10;699(1-2):499-525). Gel electrophoresis may also be employed to separate complexed assay components from unbound components (see, e.g., Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1987-1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process, non-denaturing gel matrix materials and conditions in the absence of reducing agent are typically preferred. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art.

In a particular embodiment, the level of mRNA corresponding to the marker can
be determined both by *in situ* and by *in vitro* formats in a biological sample using
methods known in the art. The term "biological sample" is intended to include tissues,
cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues,

cells and fluids present within a subject. Many expression detection methods use isolated RNA. For *in vitro* methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from ovarian cells (see, *e.g.*, Ausubel *et al.*, ed., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York 1987-1999). Additionally, large numbers of tissue samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Patent No. 4,843,155).

- 87 -

The isolated mRNA can be used in hybridization or amplification assays that

include, but are not limited to, Southern or Northern analyses, polymerase chain reaction
analyses and probe arrays. One preferred diagnostic method for the detection of mRNA
levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that
can hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe
can be, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide
of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to
specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding
a marker of the present invention. Other suitable probes for use in the diagnostic assays
of the invention are described herein. Hybridization of an mRNA with the probe
indicates that the marker in question is being expressed.

In one format, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the markers of the present invention.

20

25

An alternative method for determining the level of mRNA corresponding to a marker of the present invention in a sample involves the process of nucleic acid amplification, e.g., by rtPCR (the experimental embodiment set forth in Mullis, 1987, U.S. Patent No. 4,683,202), ligase chain reaction (Barany, 1991, Proc. Natl. Acad. Sci. USA, 88:189-193), self sustained sequence replication (Guatelli et al., 1990, Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al., 1989,

5

15

25

- 88 -

Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al., 1988, Bio/Technology 6:1197), rolling circle replication (Lizardi et al., U.S. Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

For *in situ* methods, mRNA does not need to be isolated from the ovarian cells prior to detection. In such methods, a cell or tissue sample is prepared/processed using known histological methods. The sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the marker.

As an alternative to making determinations based on the absolute expression level of the marker, determinations may be based on the normalized expression level of the marker. Expression levels are normalized by correcting the absolute expression level of a marker by comparing its expression to the expression of a gene that is not a marker, e.g., a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene, or epithelial cell-specific genes. This normalization allows the comparison of the expression level in one sample, e.g., a patient sample, to another sample, e.g., a non-ovarian cancer sample, or between samples from different sources.

Alternatively, the expression level can be provided as a relative expression level. To determine a relative expression level of a marker, the level of expression of the marker is determined for 10 or more samples of normal versus cancer cell isolates, preferably 50 or more samples, prior to the determination of the expression level for the sample in question. The mean expression level of each of the genes assayed in the larger number of samples is determined and this is used as a baseline expression level

5

10

20

25

for the marker. The expression level of the marker determined for the test sample (absolute level of expression) is then divided by the mean expression value obtained for that marker. This provides a relative expression level.

- 89 -

Preferably, the samples used in the baseline determination will be from ovarian cancer or from non-ovarian cancer cells of ovarian tissue. The choice of the cell source is dependent on the use of the relative expression level. Using expression found in normal tissues as a mean expression score aids in validating whether the marker assayed is ovarian specific (versus normal cells). In addition, as more data is accumulated, the mean expression value can be revised, providing improved relative expression values based on accumulated data. Expression data from ovarian cells provides a means for grading the severity of the ovarian cancer state.

In another embodiment of the present invention, a polypeptide corresponding to a marker is detected. A preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide corresponding to a marker of the invention, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

Proteins from ovarian cells can be isolated using techniques that are well known to those of skill in the art. The protein isolation methods employed can, for example, be such as those described in Harlow and Lane (Harlow and Lane, 1988, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

A variety of formats can be employed to determine whether a sample contains a protein that binds to a given antibody. Examples of such formats include, but are not limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis and enzyme linked immunoabsorbant assay (ELISA). A skilled artisan can

- 90 -

readily adapt known protein/antibody detection methods for use in determining whether ovarian cells express a marker of the present invention.

In one format, antibodies, or antibody fragments, can be used in methods such as Western blots or immunofluorescence techniques to detect the expressed proteins. In such uses, it is generally preferable to immobilize either the antibody or proteins on a solid support. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

10

15

20

One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present invention. For example, protein isolated from ovarian cells can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support such as nitrocellulose. The support can then be washed with suitable buffers followed by treatment with the detectably labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means.

The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid corresponding to a marker of the invention in a biological sample (e.g. an ovary-associated body fluid such as a urine sample). Such kits can be used to determine if a subject is suffering from or is at increased risk of developing ovarian cancer. For example, the kit can comprise a labeled compound or agent capable of detecting a polypeptide or an mRNA encoding a polypeptide corresponding to a marker of the invention in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for interpreting the results obtained using the kit.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide corresponding to a marker of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable label.

- 91 -

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide corresponding to a marker of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule corresponding to a marker of the invention. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can further comprise components necessary for detecting the detectable label (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.

B. Pharmacogenomics

treatment of the individual.

10

20

Agents or modulators which have a stimulatory or inhibitory effect on expression of a marker of the invention can be administered to individuals to treat (prophylactically or therapeutically) ovarian cancer in the patient. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens.

Accordingly, the level of expression of a marker of the invention in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic

Pharmacogenomics deals with clinically significant variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Linder (1997) Clin. Chem. 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body are referred to as "altered drug action." Genetic

5

10

15

conditions transmitted as single factors altering the way the body acts on drugs are referred to as "altered drug metabolism". These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

- 92 -

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the level of expression of a marker of the invention in an individual can be
determined to thereby select appropriate agent(s) for therapeutic or prophylactic
treatment of the individual. In addition, pharmacogenetic studies can be used to apply
genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the
identification of an individual's drug responsiveness phenotype. This knowledge, when
applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure
and thus enhance therapeutic or prophylactic efficiency when treating a subject with a
modulator of expression of a marker of the invention.

C. Monitoring Clinical Trials

Monitoring the influence of agents (e.g., drug compounds) on the level of expression of a marker of the invention can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent to affect marker expression can be monitored in clinical trials of subjects receiving treatment for ovarian cancer. In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of one or more selected markers of the invention in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression of the marker(s) in the post-administration samples; (v) comparing the level of expression of the marker(s) in the pre-administration sample with the level of expression of the marker(s) in the post-administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent can be desirable to increase expression of the marker(s) to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent can be desirable to decrease expression of the marker(s) to lower levels than detected, i.e., to decrease the effectiveness of the agent.

D. Surrogate Markers

The markers of the invention may serve as surrogate markers for one or more

disorders or disease states or for conditions leading up to disease states, and in
particular, ovarian cancer. As used herein, a "surrogate marker" is an objective
biochemical marker which correlates with the absence or presence of a disease or
disorder, or with the progression of a disease or disorder (e.g., with the presence or
absence of a tumor). The presence or quantity of such markers is independent of the
disease. Therefore, these markers may serve to indicate whether a particular course of
treatment is effective in lessening a disease state or disorder. Surrogate markers are of
particular use when the presence or extent of a disease state or disorder is difficult to

- 94 -

WO 01/18542

assess through standard methodologies (e.g., early stage tumors), or when an assessment of disease progression is desired before a potentially dangerous clinical endpoint is reached (e.g., an assessment of cardiovascular disease may be made using cholesterol levels as a surrogate marker, and an analysis of HIV infection may be made using HIV RNA levels as a surrogate marker, well in advance of the undesirable clinical outcomes of myocardial infarction or fully-developed AIDS). Examples of the use of surrogate markers in the art include: Koomen et al. (2000) J. Mass. Spectrom. 35: 258-264; and James (1994) AIDS Treatment News Archive 209.

PCT/US00/24199

The markers of the invention are also useful as pharmacodynamic markers. As used herein, a "pharmacodynamic marker" is an objective biochemical marker which 10 correlates specifically with drug effects. The presence or quantity of a pharmacodynamic marker is not related to the disease state or disorder for which the drug is being administered; therefore, the presence or quantity of the marker is indicative of the presence or activity of the drug in a subject. For example, a 15 pharmacodynamic marker may be indicative of the concentration of the drug in a biological tissue, in that the marker is either expressed or transcribed or not expressed or transcribed in that tissue in relationship to the level of the drug. In this fashion, the distribution or uptake of the drug may be monitored by the pharmacodynamic marker. Similarly, the presence or quantity of the pharmacodynamic marker may be related to 20 the presence or quantity of the metabolic product of a drug, such that the presence or quantity of the marker is indicative of the relative breakdown rate of the drug in vivo. Pharmacodynamic markers are of particular use in increasing the sensitivity of detection of drug effects, particularly when the drug is administered in low doses. Since even a small amount of a drug may be sufficient to activate multiple rounds of marker transcription or expression, the amplified marker may be in a quantity which is more readily detectable than the drug itself. Also, the marker may be more easily detected due to the nature of the marker itself; for example, using the methods described herein, antibodies may be employed in an immune-based detection system for a protein marker, or marker-specific radiolabeled probes may be used to detect a mRNA marker. Furthermore, the use of a pharmacodynamic marker may offer mechanism-based 30 prediction of risk due to drug treatment beyond the range of possible direct

observations. Examples of the use of pharmacodynamic markers in the art include:

Matsuda et al. US 6,033,862; Hattis et al. (1991) Env. Health Perspect. 90: 229-238; Schentag (1999) Am. J. Health-Syst. Pharm. 56 Suppl. 3: S21-S24; and Nicolau (1999) Am, J. Health-Syst. Pharm. 56 Suppl. 3: S16-S20.

The markers of the invention are also useful as pharmacogenomic markers. As used herein, a "pharmacogenomic marker" is an objective biochemical marker which correlates with a specific clinical drug response or susceptibility in a subject (see, e.g., McLeod et al. (1999) Eur. J. Cancer 35(12): 1650-1652). The presence or quantity of the pharmacogenomic marker is related to the predicted response of the subject to a specific drug or class of drugs prior to administration of the drug. By assessing the presence or quantity of one or more pharmacogenomic markers in a subject, a drug therapy which is most appropriate for the subject, or which is predicted to have a greater degree of success, may be selected. For example, based on the presence or quantity of RNA or protein for specific tumor markers in a subject, a drug or course of treatment may be selected that is optimized for the treatment of the specific tumor likely to be present in the subject. Similarly, the presence or absence of a specific sequence mutation in marker DNA may correlate with drug response. The use of pharmacogenomic markers therefore permits the application of the most appropriate treatment for each subject without having to administer the therapy.

E. Computer Readable Means and Arrays

5

Computer readable media comprising a marker of the present invention is also provided. As used herein, "computer readable media" refers to any medium that can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. The skilled artisan will readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising computer readable medium having recorded thereon a marker of the present invention.

WO 01/18542

5

As used herein, "recorded" refers to a process for storing information on computer readable medium. Those skilled in the art can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising the markers of the present invention.

- 96 -

PCT/US00/24199

A variety of data processor programs and formats can be used to store the marker information of the present invention on computer readable medium. For example, the nucleic acid sequence corresponding to the markers can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database 10 application, such as DB2, Sybase, Oracle, or the like. Any number of dataprocessor structuring formats (e.g., text file or database) may be adapted in order to obtain computer readable medium having recorded thereon the markers of the present invention.

By providing the markers of the invention in computer readable form, one can routinely access the marker sequence information for a variety of purposes. For example, one skilled in the art can use the nucleotide or amino acid sequences of the present invention in computer readable form to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of the sequences of the invention which match a particular target sequence or target motif.

The invention also includes an array comprising a marker of the present invention. The array can be used to assay expression of one or more genes in the array. In one embodiment, the array can be used to assay gene expression in a tissue to ascertain tissue specificity of genes in the array. In this manner, up to about 7600 genes can be simultaneously assayed for expression. This allows a profile to be developed showing a battery of genes specifically expressed in one or more tissues.

In addition to such qualitative determination, the invention allows the quantitation of gene expression. Thus, not only tissue specificity, but also the level of expression of a battery of genes in the tissue is ascertainable. Thus, genes can be grouped on the basis of their tissue expression per se and level of expression in that tissue. This is useful, for example, in ascertaining the relationship of gene expression between or among tissues. Thus, one tissue can be perturbed and the effect on gene

expression in a second tissue can be determined. In this context, the effect of one cell type on another cell type in response to a biological stimulus can be determined. Such a determination is useful, for example, to know the effect of cell-cell interaction at the level of gene expression. If an agent is administered therapeutically to treat one cell type but has an undesirable effect on another cell type, the invention provides an assay to determine the molecular basis of the undesirable effect and thus provides the opportunity to co-administer a counteracting agent or otherwise treat the undesired effect. Similarly, even within a single cell type, undesirable biological effects can be determined at the molecular level. Thus, the effects of an agent on expression of other than the target gene can be ascertained and counteracted.

In another embodiment, the array can be used to monitor the time course of expression of one or more genes in the array. This can occur in various biological contexts, as disclosed herein, for example development and differentiation, tumor progression, progression of other diseases, *in vitro* processes, such a cellular transformation and senescence, autonomic neural and neurological processes, such as, for example, pain and appetite, and cognitive functions, such as learning or memory.

The array is also useful for ascertaining the effect of the expression of a gene on the expression of other genes in the same cell or in different cells. This provides, for example, for a selection of alternate molecular targets for therapeutic intervention if the ultimate or downstream target cannot be regulated.

The array is also useful for ascertaining differential expression patterns of one or more genes in normal and abnormal cells. This provides a battery of genes that could serve as a molecular target for diagnosis or therapeutic intervention.

25 VI. Experimental Protocol

20

30

A. Subtracted Libraries

Subtracted libraries are generated using a PCR based method that allows the isolation of clones expressed at higher levels in one population of mRNA (tester) compared to another population (driver). Both tester and driver mRNA populations are converted into cDNA by reverse transcription, and then PCR amplified using the SMART PCR kit from Clontech. Tester and driver cDNAs are then hybridized using

- 98 -

WO 01/18542

25

the PCR-Select cDNA subtraction kit from Clontech. This technique results in both subtraction and normalization, which is an equalization of copy number of low-abundance and high-abundance sequences. After generation of the subtractive libraries, a group of 96 or more clones from each library is tested to confirm differential

PCT/US00/24199

5 expression by reverse Southern hybridization.

A first group of regular cDNA libraries was constructed. Library johOa was constructed from a pool of 5 normal ovarian epithelial cell cultures. Library johOb was constructed from a pool of 5 ascites short cultured samples from ovarian cancer patients. Library johOc was constructed from a pool of 6 serous late stage (III/IV) tumor samples. Three subtracted libraries were generated from these libraries: johOd, johOe and johOf. The johOd library was a subtracted ascites library, where the tester was johOb, and the driver was johOa. The johOe and johOf libraries were both subtracted stage III/IV serous tumor libraries. The tester for both of these libraries was johOc, and the driver was a pooled RNA from normal tissues. The tissues used for this driver pool were: kidney, small intestine, prostate, lung, heart, muscle, spleen, pancreas, liver, and 15 lymphocyte. . Library cMhOg was the same as the johOc and johOf libraries, with the exception that normal ovary was added to the driver. cMhOh, i, j, and k are all stage I/II subtracted libraries made from pooled tumor RNAs of different histological types (h=serous, I-endometriod, j=clear cell, k=mucinous). The driver was the same for these 4 libraries. It consisted of normal ovarian epithelial RNA and PBML RNA. 20

SEQ ID NOS: 1-2795 (Tables 1 and 1A) were identified through the above-described subtractive library hybridization techniques. In Tables 1 and 1A, SEQ ID NOS: 1-773 were from Library johOd; SEQ ID NOS: 774-1331 were from Library johOe; SEQ ID NOS: 1332-2795 were from Libraries johOf.

SEQ ID NOS: 2796-10795 (Table 6) and 10796-10808 (Table 6A) were also identified through the above-described subtractive library hybridization techniques. In Table 6, SEQ ID NOS: 2796-3789 were from Library cMhOg; SEQ ID NOS: 3790-6301 were from Library cMhoh; SEQ ID NOS: 6302-8108 were from Libraries cMhoi; SEQ ID NOS: 8109-9981 were from Library cMhoj; SEQ ID NOS: 9982-10795 were from Libraries cMhok.

- 99 -

B. Transcript Profiling

5

15

Nylon arrays were prepared by spotting purified PCR product onto a nylon membrane using a robotic gridding system linked to a sample database. Several thousand clones were spotted on each nylon filter.

RNA or DNA from clinical samples (tumor and normal), and cell lines as well as from subtracted libraries, were used for hybridization against the nylon arrays. The RNA or DNA is labeled utilizing an *in vitro* reverse transcription reaction that contains a radiolabeled nucleotide that is incorporated during the reaction. Hybridization experiments were carried out by combining labeled RNA or DNA samples with nylon filters in a hybridization chamber. Duplicate, independent hybridization experiments were performed to generate transcriptional profiling data. See, *Nature Genetics*, 21 (1999).

C. Proteomics

Proteins that are secreted by normal and transformed cells in culture are analyzed to identify those proteins that are likely to be secreted by cancerous cells into body fluids. Supernatants are isolated and MWT-CO filters are used to simplify the mixture of proteins. The proteins are then digested with trypsin. The tryptic peptides are loaded onto a microcapillary HPLC column where they are separated, and eluted directly into an ion trap mass spectrometer, through a custom-made electrospray ionization source. Throughout the gradient, sequence data is acquired through fragmentation of the four most intense ions (peptides) that elute off the column, while dynamically excluding those that have already been fragmented. In this way, approximately 2000 scans worth of sequence data are obtained, corresponding to approximately 50 to 200 different proteins in the sample. These data are searched against databases using correlation analysis tools, such as MS-Tag, to identify the proteins in the supernatants.

The markers of Tables 7A-7E were identified through the above-described proteomics protocol. In particular, the proteins set forth in Tables 7A-7E were identified and their expression was analyzed in seven short term cultures of ovarian cancer cells (jov891N, jov915N, jov915p6N, jov928N, jov860N, jov908N and jov926N) and six

WO 01/18542

5

10

- 100 -

PCT/US00/24199

ovarian cancer cell lines (ov17TotN, ov167TotN, ov177TotN, ov202TotN, ov207TotN and ov266TotN).

D. Identification of Novel Genes

Sequences which displayed an increase in expression in [any one of] twelve late stage ovarian tumor samples over the corresponding average expression of four nontumor samples were blasted against both public and proprietary sequence databases in order to identify other sequences with significant overlap. Contiguous sequences were then assembled into full length genes (cDNAs). Those cDNAs in which the potential open reading frame was still open at the 5' end were experimentally extended by either 5' RACE PCR or extracted from full length cDNA libraries by a PCR reaction between the vector and 5'end of the assembled electronic sequence. To predict whether an assembled gene encodes a potential integral membrane protein or not, hydropathy predictions of the predicted open reading frame was performed. If the open reading frame contained a predicted signal peptide in the N-terminal portion and a single 15 membrane spanning domain, it was labeled as being a potential type I transmembrane protein. If the predicted amino acid sequence contained a transmembrane domain in the N-terminal portion of the protein, it was labeled as being a potential type II transmembrane protein. If the predicted amino acid sequence was a short hydrophobic protein (<50 amino acids), such as CD52 (CAMPATH), it was labeled as a potential 20 integral membrane protein. If the predicted amino acid sequence contained multiple membrane spanning regions it was labeled as a type III transmembrane protein.

The novel genes of Table 8 were identified through the above-described procedure.

25

E. Northern Blot Analysis

Northern blots were performed for several of the genes of Table 8 to analyze for expression in normal human tissues. A clone was picked and served as a template for generation of probes for Northern blots. The probes were radiolabeled using ³²PdCTP using standard procedures and hybridized to Clontech (Palo Alto, California) human multiple tissue northerns. Clontech Human MTN blot (catalog # 7760-1) contains heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Human 12-Lane

- 101 -

MTN blot (catalog # 7780-1) contains brain, heart, skeletal muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, lung, peripheral blood leukocytes. Human MTN blot II (#7759-1) contains spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes. The hybridization and wash conditions used were as described in the Clontech Multiple Tissue Northern (MTN) Blot User Manual (Catalogue number PT1200-1). Kodak biomax film was exposed to the Northern blot membrane for 10-72 hours, which were then developed.

Tables 10A-10N summarize the Northern blot analysis performed for several of the novel genes of Table 8.

10

20

30

F. Gene Expression Analysis

Total RNA from normal human tissue was obtained from commercial sources. The integrity of the RNA was verified by agarose gel electrophoresis and ethidium bromide staining. Cell lines were purchased from ATCC and grown under the conditions recommended by ATCC. Total RNA from a number of various breast, ovarian and prostate adenocarcinoma cell lines was prepared using commercial kits (Qiagen). First strand cDNA was prepared using oligo-dT primer and standard conditions. Each RNA preparation was treated with DNase I (Ambion) at 37°C for I hour.

Novel gene expression was measured by TaqMan[®] quantitative PCR (Perkin Elmer Applied Biosystems) in cDNA prepared from the following normal human tissues: prostate, cerebellum, breast, ovary, kidney, trachea, adipose, small intestine, thyroid, testis, placenta, spinal cord, cervix, esophagus, spleen, thymus, brain, lung, skeletal muscle, heart, mammary gland, salivary gland, stomach, uterus, adrenal gland, bladder, medulla hippocampus, and liver from one or two adult donors. Furthermore, novel gene expression was analyzed in the following cell lines: ZR-75-30, CAMA-1, MDA-MB-157, MDA-MB-175VII, MDA-MB-231, MDA-MB-361, SK-BR-3, BT-483, BT-549, DU4475, Hs578Bst, Hs578T, MDA-MB-453, T-47D, ES-2, Caov-3, SK-OV-3, NIH:OVCAR-3, HTB-78, CRL-1572, CRL-10303, CA-HPV-10, CA-HPV-7, DU145, MCF-7 and MDA-MB-468.

- 102 -

PCR Probes were designed by PrimerExpress software (PE Biosystems) based on the disclosed sequences of each novel human kinase gene. The primers and probes for expression analysis of the novel genes in Table 8 are given below:

5 Marker 10

Forward primer: F GATGACTTGAGAGAAGGTGCACAGT
Reverse primer: R AAGGACAAGTGTGTTTGGCTTCA
TaqMan probe: P TTTGATGCAGGCTGCTGGTCTTGG

10 Marker 15

Forward primer: F TGCAGCAGCCTGTGTATGC

Reverse primer: R AAACAGCGACAGGACA

TaqMan probe: P TTGGCTCCGGTATCGTCAACACGG

15 Marker 19

Forward primer: F AGTTCATCACGATATCAGGGAAGAT

Reverse primer: R TGAATGATTACTGCCGATGTAGCT

TaqMan probe: P CAAAGAGCCGTACGTCCACTGCCAGA

20 Marker 5

Forward primer: F GGCTGCTTTGCTGCAACTG

Reverse primer: R CAGAGCGGCAGCAGAATA

TaqMan Probe P ACCCCGCACAGACAAGCCTTACTCC

25 Marker 8

Forward primer

Reverse primer R TCTCCATGGCTGGTTTCCA

TagMan Probe P TTCTTACACGTCAGGTATTTGTAATCGCCCT

TGTGTGCTGAAGGCTACATGTTG

30 Marker 25

Forward Primer F CTCCCACCCCTTCTTCAATG

Reverse primer R AGCTGTACTCTGCCGGTTTCTC

TaqMan Probe P ACCTTCGACTATGACATCGCGCTGCT

- 103 -

Marker 39

WO 01/18542

Forward primer F CCCGGAATGTGGTTTATGGTATT

Reverse primer R GACCGTCTTGTTGTGGAGTGAAG

TagMan Probe P CCTTTCCTTGACCTCTATCGCAACCCGAA

5

An internal reference gene 18S rRNA was used. Primers and probe were purchased pretested from PE Applied Biosystems. Each gene probe was labeled using FAM (6-carboxyfluorescein), and the β2-microglobulin reference probe was labeled with a different fluorescent dye, VIC. The differential labeling of the target gene and internal reference gene thus enabled measurement in same well. Forward and reverse - 10 primers and the probes for both 18S rRNA and target gene were added to the TaqMan® Universal PCR Master Mix (PE Applied Biosystems). Although the final concentration of primer and probe could vary, each was internally consistent within a given experiment. A typical experiment contained 900 nM of forward and reverse primers plus 250nM probe for the target gene whereas primers and probe for 18S rRNA were used according to manufacturer's recommendations. TaqMan matrix experiments were carried out on an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems). The thermal cycler conditions were as follows: hold for 2 min at 50°C and 10 min at 95°C, followed by two-step PCR for 40 cycles of 95°C for 15 sec followed by 60°C for 1 min. 20

PCT/US00/24199

The following method was used to quantitatively calculate gene expression in the various tissues relative to 18S rRNA expression in the same tissue. The threshold cycle (Ct) value is defined as the cycle at which a statistically significant increase in flourescence is detected. A lower Ct value is indicative of a higher mRNA concentration. The Ct value of a given gene (Ct_{marker}) is normalized by subtracting the Ct value of the 18S rRNA gene to obtain a ΔCt value using the following formula: ΔCt=Ct_{marker} - Ct β18S rRNA. Expression is then calibrated against a no template control sample. The ΔCt value for the calibrator sample is then subtracted from ΔCt for each tissue sample according to the following formula: ΔΔCt=ΔCt-sample - ΔCt-calibrator. Relative expression is then calculated using the arithmetic formula given by 2-ΔΔCt. Table 9 graphically represents the results of the TaqMan® expression study.

WO 01/18542

20

30

- 104 -

PCT/US00/24199

G. LightCycler

The LightCycler Instrument from Boehringer Mannheim GmbH, Mannheim is a thermocycler for the rapid analysis of PCR applications. Fluorimetric analysis of the PCR products formed is performed as "real time" measurement either continuously or at a specifically defined time during each PCR cycle. The three detection channels of the LightCycler are fitted with filter combinations which allow analysis at the given emission wavelengths, thereby enabling exact sample measurement to be carried out in parallel with the fluorophores. SYBR Green I is a dye specific for double-stranded DNA. Its inherent fluorescence is enhanced by binding to the minor groove to ds DNA. The addition of SYBR Green I to PCR reactions allows the detection of PCR products 10 formed by the binding of this flurophore during each phase of DNA synthesis. The point of time of fluorimetric measurement is determined at the end of the elongation phase. The LightCycler- FastStart DNA Master SYBR Green I kit manufactured by Roche was used in order to quantify the copy number of a specific target. A panel of tumors and normal tissues were used to detect the expression levels of specific markers of the present invention in ovarian tumor samples compared to normal. The results are set forth in Table 11.

H. RT-PCR

The Gibco BRL Superscript first strand synthesis system was used for RT-PCR to synthesize first strand cDNA from total RNA of ovarian tumors as well as normal ovary. Gene specific primers were designed for clones of the present invention using software program Oligo5.1. Finished sequence for these clones was available by in house sequencing efforts. Following the use of this system, target cDNA was amplified with the gene specific primers. Presence of a band in a sample indicates that the gene is upregulated in that particular tissue or tumor. Table 11 summarizes the RT-PCR data.

VII. Summary of the Data Provided in the Tables

The level of expression of numerous potential markers (i.e. "the markers of the invention") in cells obtained from seven patients afflicted with ovarian cancer, and in cells of six ovarian cancer cell lines (i.e. a total of thirteen sample sources) were

5

25

compared with levels of expression of the same markers in non-cancerous ovarian cell samples. Markers for which significant differences in the levels of expression in cancer-related samples and non-cancerous samples were observed are listed in the Tables.

- 105 -

Tables 1 and 1A list markers that were identified in subtractive libraries and which are preferentially expressed in ovarian cancer cells over normal (i.e. non-cancerous) ovarian cells.

Table 2A lists markers, expression of which was increased by at least 5-fold in at least one of twenty-three ovarian cancer samples tested, relative to its expression in normal (*i.e.* non-cancerous) ovarian samples. Table 2B lists markers, expression of which was increased by at least 2-fold in all twenty-three ovarian cancer samples tested, relative to its expression in normal ovarian samples. Table 2C lists markers, expression of which was increased by at least 5-fold in at least 6 of the 23 ovarian cancer samples tested, relative to its expression in normal ovarian cells. Table 2D lists markers, expression of which was increased by at least 5-fold in at least 6 of the 23 ovarian cancer samples, relative to expression in normal ovarian samples, and which can serve as antigens for embodiments of the invention based upon proteomic studies, sequence analysis and/or literature references.

Table 3A lists markers, expression of which was decreased by at least 5-fold in at least one of twenty-three ovarian cancer samples tested, relative to its expression in normal (i.e. non-cancerous) ovarian cells. Table 3B lists markers, expression of which was decreased by at least 2-fold in all twenty-three ovarian cancer samples tested, relative to its expression in normal ovarian cells. Table 3C lists markers, expression of which was decreased by at least 5-fold in at least 6 of the 23 ovarian cancer samples tested, relative to its expression in normal (i.e. non-cancerous) ovarian cells.

Tables 4 and 5 list markers, expression of which was either increased (Table 4) or decreased (Table 5) in ovarian cancer samples, relative to expression in normal (i.e., non-cancerous) ovarian samples. In particular, expression of the markers in 37 tumors (7 endometroid tumors, 5 clear cell tumors and 25 serous tumors) was evaluated. A ranking system based on the sum of the number of tumors multiplied by the fold regulation (for 2-fold, 3-fold, 5-fold and 10-fold regulation), divided by the total number of tumors, was employed. A rank score was generated for four categories, endometroid tumors, clear cell tumors, serous tumors and overall.

10

WO 01/18542

5

15

20

- 106 -

PCT/US00/24199

The markers of Table 4 had a score of greater than 1.5 for endometroid tumors, greater than 1.5 for clear cell tumors, greater than 1 for serous tumors, or greater than 0.8 overall. Table 4A shows the markers of Table 4 with a score of greater than 3 in any of the four categories.

The markers of Table 5 had a score of greater than 2.5 for endometroid tumors, greater than 2.5 for clear cell tumors, greater than 2 for serous tumors, or greater than 1.75 overall. Table 5A shows the markers of Table 5 with a score of greater than 3 in any of the four categories.

Tables 6 and 6A list markers that were identified in subtractive libraries and which are preferentially expressed in ovarian cancer cells over normal (i.e. non-cancerous ovarian cells).

Table 7A-7E show markers of the present invention obtained through proteomic analysis as described in Section VI., subsection C., above.

Table 8 lists the nucleotide sequences of 24 novel genes identified as described in Section VI., subsection D, above.

Table 9 depicts the results of the TaqMan® expression analysis obtained as described in Section VI., subsection F, above.

Tables 10A-10N contain Northern blot analysis data obtained as described in Section VI., subsection E, above.

Table 10A shows Marker 5 expression in normal human tissue samples. The highest level of expression is seen in placenta, followed by trachea, prostate, mammary gland, and lung, with lower levels in kidney, salivary gland, small intestine, and bladder, and an even lower level of expression in normal ovary tissue.

Table 10B shows that Marker 5 is expressed in several cancer cell lines. The highest level of expression is seen in SK-BR-3, followed by T-47D, BT-483, and ZR-75-30.

Table 10C shows Marker 8 expression in wide range of normal human tissue samples. The highest level of expression was seen in cerebllum, followed by placenta, prostate, and lung. Lower levels of expression were seen in kidney, spleen, testis, whole brain, and trachea, followed by mammary gland, small intestine, and thymus, which were higher than the level of expression in normal ovary tissue.

Table 10D shows that Marker 8 is expressed in all the cancer cell lines tested, with the highest levels of expression in DU4475, followed by MDA-MB-361line.

Table 10E shows Marker 10 expression was detected in all tissue samples tested. The highest level of expression was seen in trachea, followed by testis and prostate.

Lower levels of expression were seen in whole brain, salivary gland, cerebellum, and small intesting. Expression in normal ovary tissue was among the lowest levels observed.

10

15

20

25

30

Table 10F shows that Marker 10 expression was detected in all cancer cell lines tested, with the highest levels of expression in MDA-MB-361, followed by MDA-MB-468, and HTB-78.

Table 10G shows a limited distribution of expression of Marker 15 in the panel of normal tissues tested, with significant expression only in placenta, and much lower levels of expression in whole brain, cerebellum, and prostate. No detectable levels of expression were seen in normal ovarian tissue.

Table 10H shows that Marker 15 expression was detected in all cancer cell lines tested, with the highest levels of expression seen in HTB-78, followed by MDA-MB-361, SK-BR-3, Caov-3, and MDA-MB-231.

Table 10I shows that expression of Marker 19 in the panel of normal human tissues tested was much higher in testis than in prostate and whole brain. Lower, but detectable, levels of expression were seen in a number of other tissues, with ovary among the lowest.

Table 10J shows that expression of Marker 19 was seen in 22 of the 26 cancer cell lines tested. The highest levels of expression were seen in BT549 and DU145, followed by NIH-Ovcar-3 and HTB-78. Lower levels of expression were seen in MDA-MB-453, MDA-MB-361, and T-470.

Table 10K shows that high levels of expression of Marker 25 in the panel of normal human tested were seen in placenta, prostate, and trachea, followed by kidney, lung, and small intestine. Lower levels of expression were seen in salivery gland, spleen, thymus, and bladder. Expression in normal ovarian tissue was just above background.

WO 01/18542

5

10

15

20

25

- 108 -

PCT/US00/24199

Table 10L shows that expression of Marker 25 was detected in 20 of the 26 cancer cell lines tested. The highest level of expression was seen in T-470, followed by S-BR-3. Lower levels of expression were seen in Caov-3, MDA-MB-468, and HTB-78, followed by MDA-MB-453, MDA-MB-361, BT-483, DU4475, and NIH-Ovcar-3.

Table 10M shows that the highest level of expression of Marker 039 was seen in whole brain, followed by cerebellum, with a lower level in prostate. Even lower levels were seen in a number of tissues, including kidney, liver, spleen, testis, thymus, trachea, and lung. Expression in normal ovarian tissue was among the lowest.

Table 10N shows that Marker 39 expression was detected in most of the cancer cell lines tested, with the highest level seen in SK-BR-3, followed by MDA-MB-361 and T470. Lower levels of expression were seen in all other cell lines tested, except for MDA-MB-157, Hs578Bst, Hs578T, and ES-2, in which no expression was detected.

Table 11 depicts the results of LightCycler data and RT-PCR data obtained as described in Section VI., subsections G. and H., respectively, above.

Tables 1-1, 2A-1, 2D-1, 3A-1, 4-1, 5-1 and 6-1 depict the accession number ("ACC Num") and database ("DATABASE") of the markers of the present invention with the corresponding GenBank GI number ("GI NBR"). One skilled in the art may thus obtain from the Tables of the invention, both GenBank accession number as well as the GenBank GI number for a marker of the present invention, thereby identifying the nucleotide and/or polypeptide sequence of that marker. For example, the markers of Tables 1 and 1A are referenced in Table 1-1 by both GenBank accession number and GenBank GI number.

Those skilled in the art will readily understand the data set forth in the Tables of the present invention. In particular, the following definitions will be understood to mean:

- 1) "ID #" or "#" is an arbitrary designation assigned to the marker.
- 2) "Image Clone ID" is the identification number assigned to the marker by the IMAGE Consortium (Lennon *et al.*, 1996, *Genomics* 33:151-152; see, *e.g.*, "http://www-bio.llnl.gov/bbrp/image/image.html" for further information). All referenced Image Clone sequences are expressly incorporated by reference.
- 3) "GenBank Accession Number" or "Accession No." or "acc" or "Accession #" or "Acc Num" is the identification number assigned to the marker in the relevant database

- (see, e.g. "http://www.ncbi.nlm.nih.gov/genbank/ query_form.html" and "www.derwent.com" for further information). "GenBank Gi "" or "GI NB"" is the GI identification number assigned to the marker in the GenBank database (see supra). All referenced database sequences are expressly incorporated herein by reference.
- 5 4) "Secreted?" or "Secreted" indicates whether the protein corresponding to the marker has been demonstrated to be secreted in protein profiling experiments.
 - 5) "Secretion Predicted?" indicates whether the protein corresponding to the marker is predicted, using the SIGNALP computer software described herein, to have at least one portion which is exposed to the extracellular medium upon expression of the protein.
- 6) "Ave-Normal-Exp" indicates the average marker expression in the non-cancerous samples.
 - 7) "Max expression" and "Min-expression" indicates the highest (or lowest) marker expression value of all samples.
 - 8) "Max fold up" and "Max fold-up down" indicates the highest fold positive (or negative) induction of regulation of the marker of all samples.
 - 9) "Count-up tumors" and "Count-down tumors" indicate the total number of the twenty-three tumor samples that the marker was up (or down) regulated.
 - 10) "Count-up cell lines" and "Count-down cell lines" indicated the total number of the six cell lines where the marker was up (or down) regulated.
- 20 11) "Chromosome" indicates the chromosome on which the genomic sequence corresponding to the marker is located, where this location is known.
 - 12) "Location" indicates the location on the chromosome at which the genomic sequence corresponding to the marker is located, where this location is known. The genes were mapped using radiation hybrid panel data that can be found in the art, for
- 25 example at "http://www.sanger.ac.uk/HGP/Rhmap/" and at "http://www.ncbi.nlm.nih.gov/genemap99/".

30

13) "Tissue Prominence" indicates up to three tissues in which expression of the marker is predicted, based on expression in the predicted tissues, of expressed sequence tags located in close proximity to the marker. The marker may also, or instead, be expressed in tissues that are not listed in this section (i.e. this list is not exhaustive).

- 110 -

14) "Database" or "dbase" refers to the relevant database where the nucleotide sequence may be found according to its accession number. These public databases include GenBank, dbEST (a division of GenBank), and NUCPATENT (a GENESEQ database, available through Derwent). For examples, see

http://www.ncbi.nlm.nih.gov/Entrez/nucleotide.html for GenBank and www.derwent.com for GENESEQ. All referenced database sequences are expressly incorporated herein by reference.

The contents of all references, patents, published patent applications, and database records including, GenBank, IMAGE consortium and GENESEQ database records, cited throughout this application are hereby incorporated by reference.

Other Embodiments

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed is:

- 111 -

Claims

1. A method of assessing whether a patient is afflicted with ovarian cancer, the method comprising comparing:

- a) the level of expression of a marker in a patient sample, wherein the marker is selected from the group consisting of the markers listed in Tables 1-11, and
 - b) the normal level of expression of the marker in a control non-ovarian cancer sample,

wherein a significant difference between the level of expression of the marker in
the patient sample and the normal level is an indication that the patient is afflicted with
ovarian cancer.

2. The method of claim 1, wherein the marker is selected from the group consisting of the markers listed in Table 2C.

15

5

- 3. The method of claim 1, wherein the marker is selected from the group consisting of the markers listed in Table 2D.
- 4. The method of claim 1, wherein the marker is selected from the group consisting of the markers listed in Table 3C.
 - 5. The method of claim 1, wherein the marker is selected from the group consisting of the markers listed in Table 4A.
- 6. The method of claim 1, wherein the marker is selected from the group consisting of the markers listed in Table 5A.
 - 7. The method of claim 1, wherein the marker is selected from the group consisting of the markers listed in Tables 6 and 6A.

30

8. The method of claim 1, wherein the marker is selected from the group consisting of the markers listed in Table 8.

- 112 -

9. The method of claim 1, wherein the marker is selected from the group consisting of the markers listed in Tables 7A-7E.

PCT/US00/24199

- 10. The method of claim 1, wherein the marker corresponds to a secreted protein.
 - 11. The method of claim 10, wherein the marker is selected from the group consisting of the markers listed in Tables 7A-7E.
- 12. The method of claim 1, wherein the marker corresponds to a transcribed polynucleotide or portion thereof, wherein the polynucleotide comprises the marker.
 - 13. The method of claim 1, wherein at least one tissue corresponding to the marker in the Tables is an epithelial tissue.

15

WO 01/18542

- 14. The method of claim 13, wherein at least one tissue corresponding to the marker in the Tables is an ovarian tissue.
- 15. The method of claim 1, wherein the marker is over- or under-expressed by at least two-fold in at least about 20% of ovarian cancer patients.
 - 16. The method of claim 1, wherein the marker is not significantly expressed in non-ovarian tissues.
- 25 17. The method of claim 1, wherein the patient sample is an ovary-associated body fluid.
 - 18. The method of claim 13, wherein the ovary-associated body fluid is selected from the group consisting of blood fluid, lymph, ascitic fluid, gynecological fluid, cystic fluid, urine, and a fluid collected by peritoneal rinsing.

- 113 -

- 19. The method of claim 1, wherein the sample comprises cells obtained from the patient.
- 20. The method of claim 19, wherein the cells are in a fluid selected from the group consisting of a fluid collected by peritoneal rinsing, a fluid collected by uterine rinsing, a uterine fluid, a uterine exudate, a pleural fluid, a cystic fluid, and an ovarian exudate.
- 21. The method of claim 1, wherein the level of expression of the marker in the sample is assessed by detecting the presence in the sample of a protein corresponding to the marker.
 - 22. The method of claim 21, wherein the marker is selected from the group consisting of the markers listed in Tables 7A-7E and 8.

15

25

- 23. The method of claim 21, wherein the presence of the protein is detected using a reagent which specifically binds with the protein.
- 24. The method of claim 23, wherein the reagent is selected from the groupconsisting of an antibody, an antibody derivative, and an antibody fragment.
 - 25. The method of claim 1, wherein the level of expression of the marker in the sample is assessed by detecting the presence in the sample of a transcribed polynucleotide or portion thereof, wherein the transcribed polynucleotide comprises the marker.
 - 26. The method of claim 25, wherein the transcribed polynucleotide is an mRNA.
 - 27. The method of claim 25, wherein the transcribed polynucleotide is a cDNA.

- 114 -

28. The method of claim 25, wherein the step of detecting further comprises amplifying the transcribed polynucleotide.

- 29. The method of claim 1, wherein the level of expression of the marker in the sample is assessed by detecting the presence in the sample of a transcribed polynucleotide which anneals with the marker or anneals with a portion of a polynucleotide wherein the polynucleotide comprises the marker, under stringent hybridization conditions.
- 30. The method of claim 1, wherein the level of expression of the marker in the sample differs from the normal level of expression of the marker in a patient not afflicted with ovarian cancer by a factor of at least about 2.
- 31. The method of claim 1, wherein the level of expression of the marker in the sample differs from the normal level of expression of the marker in a patient not afflicted with ovarian cancer by a factor of at least about 5.
 - 32. The method of claim 1, comprising comparing:

20

- a) the level of expression in the sample of each of a plurality of markers independently selected from the markers listed in Tables 1-11, and
- b) the normal level of expression of each of the plurality of markers in samples of the same type obtained from control humans not afflicted with ovarian cancer,

wherein the level of expression of more than one of the markers is significantly altered, relative to the corresponding normal levels of expression of the markers, is an indication that the patient is afflicted with ovarian cancer.

- 33. The method of claim 32, wherein the plurality comprises at least three of the markers.
- 30 34. The method of claim 32, wherein the plurality comprises at least five of the markers.

WO 01/18542

5

10

- 115 -

PCT/US00/24199

35. A method of assessing whether a patient is afflicted with ovarian cancer, the method comprising comparing:

- a) the level of expression of a marker in a sample obtained from the patient, wherein the marker is selected from the group consisting of the markers listed in Tables 1-11 and
- b) the normal level of expression of the marker in samples of the same type obtained from control humans not afflicted with ovarian cancer,

wherein a significantly different level of expression of the marker in the sample, relative to the normal level, is an indication that the patient is afflicted with ovarian cancer.

- 36. A method for monitoring the progression of ovarian cancer in a patient, the method comprising:
- a) detecting in a patient sample at a first point in time, the expression of a
 marker, wherein the marker is selected from the group consisting of the markers listed in Tables 1-11;
 - b) repeating step a) at a subsequent point in time; and
 - c) comparing the level of expression detected in steps a) and b), and therefrom monitoring the progression of ovarian cancer in the patient.

- 37. The method of claim 36, wherein the marker is selected from the group consisting of the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8.
- 38. The method of claim 36, wherein the marker is selected from the group consisting of the markers listed in Tables 3A, 5, 7C and 7E.
 - 39. The method of claim 36, wherein the marker corresponds to a secreted protein.
- 40. The method of claim 36, wherein marker corresponds to a transcribed polynucleotide or portion thereof, wherein the polynucleotide comprises the marker.

WO 01/18542 - 116 -

41. The method of claim 36, wherein the patient sample is an ovary-associated body fluid.

PCT/US00/24199

- 42. The method of claim 36, wherein the sample comprises cells obtained from5 the patient.
 - 43. The method of claim 36, wherein between the first point in time and the subsequent point in time, the patient has undergone surgery to remove a tumor.
- 44. A method of assessing the efficacy of a test compound for inhibiting an ovarian cancer in a patient, the method comprising comparing:
- a) expression of a marker in a first sample obtained from the patient and maintained in the presence of the test compound, wherein the marker is selected from the group consisting of the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and
 8, and
 - b) expression of the marker in a second sample obtained from the patient and maintained in the absence of the test compound,

wherein a significantly lower level of expression of the marker in the first sample, relative to the second sample, is an indication that the test compound is efficacious for inhibiting ovarian cancer in the patient.

- 45. The method of claim 44, wherein the first and second samples are portions of a single sample obtained from the patient.
- 25 46. The method of claim 44, wherein the first and second samples are portions of pooled samples obtained from the patient.

- 117 -

47. A method of assessing the efficacy of a test compound for inhibiting ovarian cancer in a patient, the method comprising comparing:

- a) expression of a marker in a first sample obtained from the patient and maintained in the presence of the test compound, wherein the marker is selected from the group consisting of the markers listed in Tables 3A, 5, 7C and 7E, and
- b) expression of the marker in a second sample obtained from the patient and maintained in the absence of the test compound,

wherein a significantly enhanced level of expression of the marker in the first sample, relative to the second sample, is an indication that the test compound is efficacious for inhibiting ovarian cancer in the patient.

10

- 48. A method of assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient, the method comprising comparing:
- a) expression of a marker in the first sample obtained from the patient prior to 15 providing at least a portion of the therapy to the patient, wherein the marker is selected from the group consisting of the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8, and
 - b) expression of the marker in a second sample obtained from the patient following provision of the portion of the therapy,
 - wherein a significantly lower level of expression of the marker in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer in the patient.
 - 49. A method of assessing the efficacy of a therapy for inhibiting ovarian cancer5 in a patient, the method comprising comparing:
 - a) expression of a marker in the first sample obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the marker is selected from the group consisting of the markers listed in Tables 3A, 5, 7C and 7E, and

- 118 -

b) expression of the marker in a second sample obtained from the patient following provision of the portion of the therapy,

wherein a significantly enhanced level of expression of the marker in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer in the patient.

- 50. A method of selecting a composition for inhibiting ovarian cancer in a patient, the method comprising:
 - a) obtaining a sample comprising cancer cells from the patient;
- b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
 - c) comparing expression of a marker in each of the aliquots, wherein the marker is selected from the group consisting of the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8; and
- d) selecting one of the test compositions which induces a lower level of expression of the marker in the aliquot containing that test composition, relative to other test compositions.
- 51. A method of selecting a composition for inhibiting ovarian cancer in a patient, the method comprising:
 - a) obtaining a sample comprising cancer cells from the patient;
 - b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
- c) comparing expression of a marker in each of the aliquots, wherein the marker is selected from the group consisting of the markers listed in Tables 3A, 5, 7C and 7E; and
 - d) selecting one of the test compositions which induces an enhanced level of expression of the marker in the aliquot containing that test composition, relative to other test compositions.

.

WO 01/18542

15

- 119 -

52. A method of inhibiting ovarian cancer in a patient, the method comprising:

PCT/US00/24199

- a) obtaining a sample comprising cancer cells from the patient;
- b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
- c) comparing expression of a marker in each of the aliquots, wherein the marker is selected from the group consisting of the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8, and
- d) administering to the patient at least one of the test compositions which induces a lower level of expression of the marker in the aliquot containing that test composition,
 relative to other test compositions.
 - 53. A method of selecting a composition for inhibiting ovarian cancer in a patient, the method comprising:
 - a) obtaining a sample comprising cancer cells from the patient;
 - b) separately maintaining aliquots of the sample in the presence of a plurality of test compositions;
 - c) comparing expression of a marker in each of the aliquots, wherein the marker is selected from the group consisting of the markers listed in Tables 3A, 5, 7C and 7E, and
- d) administering to the patient at least one of the test compositions which induces an enhanced level of expression of the marker in the aliquot containing that test composition, relative to other test compositions.
- 54. A kit for assessing the suitability of each of a plurality of compounds for inhibiting ovarian cancer in a patient, the kit comprising:
 - a) the plurality of compounds; and
 - b) a reagent for assessing expression of a marker selected from the group consisting of the markers listed in Tables 1-11.
- 55. A kit for assessing whether a patient is afflicted with ovarian cancer, the kit comprising reagents for assessing expression of a marker selected from the group consisting of the markers listed in Tables 1-11.

- 120 -

- 56. A method of making an isolated hybridoma which produces an antibody useful for assessing whether a patient is afflicted with ovarian cancer, the method comprising:
- isolating a protein corresponding to a marker selected from the group consisting of the markers listed in Tables 1-11;

immunizing a mammal using the isolated protein;

isolating splenocytes from the immunized mammal;

fusing the isolated splenocytes with an immortalized cell line to form

10 hybridomas; and

screening individual hybridomas for production of an antibody which specifically binds with the protein to isolate the hybridoma.

- 57. The method of claim 56, wherein the marker is selected from the group consisting of the members listed in Tables 7A-7E and 8.
 - 58. An antibody produced by a hybridoma made by the method of claim 56.
- 59. A kit for assessing the presence of human ovarian cancer cells, the kit comprising an antibody, wherein the antibody specifically binds with a protein corresponding to a marker selected from the group consisting of the markers listed in Tables 1-11.
- 60. A kit for assessing the presence of ovarian cancer cells, the kit comprising a nucleic acid probe wherein the probe specifically binds with a transcribed polynucleotide corresponding to a marker selected from the group consisting of the markers listed in Tables 1-11.

WO 01/18542

10

15

- 121 -

PCT/US00/24199

- 61. A method of assessing the ovarian cell carcinogenic potential of a test compound, the method comprising:
- a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and
- b) comparing expression of a marker in each of the aliquots, wherein the marker is selected from the group consisting of the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8, and

wherein a significantly enhanced level of expression of the marker in the aliquot maintained in the presence of the test compound, relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses human ovarian cell carcinogenic potential.

- 62. A method of assessing the ovarian cell carcinogenic potential of a test compound, the method comprising:
- a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and
- b) comparing expression of a marker in each of the aliquots, wherein the marker is selected from the group consisting of the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8, and
- wherein a significantly lower level of expression of the marker in the aliquot maintained in the presence of the test compound, relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses ovarian cell carcinogenic potential.
- 25 63. A kit for assessing the ovarian cell carcinogenic potential of a test compound, the kit comprising ovarian cells and a reagent for assessing expression of a marker, wherein the marker is selected from the group consisting of the markers listed in Tables 1-11.
- 64. A method of treating a patient afflicted with ovarian cancer, the method comprising providing to cells of the cancer a protein corresponding to a marker selected from the markers listed in Tables 3A, 5, 7C and 7E.

- 122 -

WO 01/18542

20

25

65. The method of claim 62, wherein the protein is provided to the cells by providing a vector comprising a polynucleotide encoding the protein to the cells.

PCT/US00/24199

- 66. A method of treating a patient afflicted with ovarian cancer, the method comprising providing to cells of the patient an antisense oligonucleotide complementary to a polynucleotide corresponding to a marker selected from the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and 8.
- 67. A method of inhibiting ovarian cancer in a patient at risk for developing

 10 ovarian cancer, the method comprising inhibiting expression of a gene corresponding to

 a marker selected from the markers listed in Tables 1, 1A, 2A, 4, 6, 6A, 7A, 7B, 7D and

 8.
- 68. A method of inhibiting ovarian cancer in a patient at risk for developing ovarian cancer, the method comprising enhancing expression of a gene corresponding to a marker selected from the markers listed in Tables 3A, 5, 7C and 7E.
 - 69. An isolated nucleic acid molecule selected from the group consisting of:
 - a) a nucleic acid molecule comprising a nucleotide sequence which is at least 90% homologous to a nucleotide sequence of Table 8, or a complement thereof;
 - b) a nucleic acid molecule comprising a fragment of a nucleic acid molecule comprising the nucleotide sequence of Table 8, or a complement thereof; and
 - c) a nucleic acid molecule comprising the nucleotide sequence of Table 8, or a complement thereof.
 - 70. A vector which contains a nucleic acid molecule of claim 69.
 - 71. A host cell which contains a nucleic acid molecule of claim 69.

- 72. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% homologous to a nucleic acid comprising the nucleotide sequence of Table 8.
- 5 73. An antibody which selectively binds to a polypeptide of claim 72.

Datont Coguence	Accession	Sequence 50	AA111907
Patent Sequence Number	Number	Sequence 51	AA112043
Hulliber	140111561	Sequence 52	AA112308
Sequence 1	AA001066	Sequence 53	AA112375
Sequence 2	AA007157	Sequence 54	AA113860
Sequence 3	AA010954	Sequence 55	AA114120
Sequence 4	AA015792	Sequence 56	AA115118
Sequence 5	AA019769	Sequence 57	AA115368
Sequence 6	AA019948	Sequence 58	AA122286
Sequence 7	AA022925	•	AA122348
Sequence 8	AA022937	Sequence 59	AA126109
Sequence 9	AA024405	Sequence 60	AA127105
Sequence 10	AA029750	Sequence 61	AA127132
Sequence 11	AA031509	Sequence 62	AA127418
Sequence 12	AA033876	Sequence 63	AA128305
Sequence 13	AA034237	Sequence 64	
Sequence 14	AA039967	Sequence 65	AA129461
Sequence 15	AA040073	Sequence 66	AA130252
Sequence 16	AA040122	Sequence 67	AA130547
Sequence 17	AA045732	Sequence 68	AA130786
Sequence 18	AA045861	Sequence 69	AA131041
Sequence 19	AA046835	Sequence 70	AA131065
Sequence 20	AA047026	Sequence 71	AA131104
Sequence 21	AA047417	Sequence 72	AA131155
Sequence 22	AA053486	Sequence 73	AA131160
Sequence 23	AA054658	Sequence 74	AA132182
Sequence 24	AA055606	Sequence 75	AA132568
Sequence 25	AA056113	Sequence 76	AA132598
Sequence 26	AA056176	Sequence 77	AA133351
Sequence 27	AA056363	Sequence 78	AA133927
Sequence 28	AA056431	Sequence 79	AA134105
•	AA065336	Sequence 80	AA134210
Sequence 29 Sequence 30	AA069781	Sequence 81	AA135032
	AA069784	Sequence 82	AA135919
Sequence 31	AA069839	Sequence 83	AA136383
Sequence 32	AA069983	Sequence 84	AA136789
Sequence 33	AA071255	Sequence 85	AA143609
Sequence 34	AA075135	Sequence 86	AA146773
Sequence 35		Sequence 87	AA147806
Sequence 36	AA081655	Sequence 88	AA148160
Sequence 37	AA082245	Sequence 89	AA148268
Sequence 38	AA083471	Sequence 90	AA148771
Sequence 39	AA083510	Sequence 91	AA149056
Sequence 40	AA085862	Sequence 92	AA150307
Sequence 41	AA085872	Sequence 93	AA151310
Sequence 42*	AA085947	Sequence 94	AA151775
Sequence 43	AA088770	Sequence 95	AA152037
Sequence 44	AA100333	Sequence 96	AA152416
Sequence 45	AA100719	Sequence 97	AA155853
Sequence 46	AA100793	Sequence 98	AA155926
Sequence 47	AA100852	Sequence 99	AA157405
Sequence 48	AA101270	Sequence 100	AA157725
Sequence 49	AA101561	Sequence 101	AA157788

Sequence 102	AA158165	Sequence 154	AA301631
Sequence 103	AA158171	Sequence 155	AA304669
Sequence 104	AA159272	Sequence 156	AA304961
Sequence 105	AA160114	Sequence 157	AA305193
Sequence 106	AA160685	Sequence 158	AA305438
Sequence 107	AA161410	Sequence 159	AA306542
Sequence 108	AA164405	Sequence 160	AA306708
Sequence 109	AA164465	Sequence 161	AA306945
Sequence 110	AA165083	Sequence 162	AA307239
Sequence 111	AA165629	Sequence 163	AA307477
Sequence 112	AA166973	Sequence 164	AA307504
Sequence 113	AA171510	Sequence 165	AA307697
Sequence 114	AA173031	Sequence 166	AA307779
Sequence 115	AA173470	Sequence 167	AA308062
Sequence 116	AA173630	Sequence 168	AA308801
Sequence 117	AA179462	Sequence 169	AA309028
Sequence 118	AA187003	Sequence 170	AA309988
Sequence 119	AA187958	Sequence 171	AA311006
Sequence 120	AA188591	Sequence 172	AA311481
Sequence 121	AA192108	Sequence 173	AA312012
Sequence 122	AA199710	Sequence 174	AA313684
Sequence 123	AA203224	Sequence 175	AA314146
Sequence 124	AA203284	Sequence 176	AA315049
Sequence 125	AA205851	Sequence 177	AA315308
Sequence 126	AA209431	Sequence 178	AA315426
Sequence 127	AA209531	Sequence 179	AA316682
Sequence 128	AA214075	Sequence 180	AA319958
Sequence 129	AA216612	Sequence 181	AA320346
Sequence 130	AA224230	Sequence 182	AA320991
Sequence 131	AA224985	Sequence 183	AA328544
Sequence 132	AA226502	Sequence 184	AA330457
Sequence 133	AA229225	Sequence 185	AA338793
Sequence 134	AA232626	Sequence 186	AA340069
Sequence 135	AA233843	Sequence 187	AA341170
Sequence 136	AA242891	Sequence 188	AA342394
Sequence 137	AA250725	Sequence 189	AA348250
Sequence 138	AA250982	Sequence 190	AA349148
Sequence 139	AA256959	Sequence 191	AA351443
Sequence 140	AA259077	Sequence 192	AA351880
Sequence 141	AA262440	Sequence 193	AA356158
Sequence 142	AA263110	Sequence 194	AA356187
Sequence 143	AA283165	Sequence 195	AA356195
Sequence 144	AA285260	Sequence 196	AA357374
Sequence 145	AA287112	Sequence 197	AA367446
Sequence 146	AA292191	Sequence 198	AA375236
Sequence 147	AA292334	Sequence 199	AA377718
Sequence 148	AA292385	Sequence 200	AA380997
Sequence 149	AA292771	Sequence 201	AA383917
Sequence 150	AA293273	Sequence 202	AA385147
Sequence 151	AA293572	Sequence 203	AA389641
Sequence 152	AA295348	Sequence 204	AA393164
Sequence 153	AA295485	Sequence 205	AA393236

PCT/US00/24199 3

Sequence 206	AA394242	Sequence 258	AA568217
Sequence 207	AA398732	Sequence 259	AA573742
Sequence 208	AA401864	Sequence 260	AA573893
Sequence 209	AA410508	Sequence 261	AA574237
Sequence 210	AA410580	Sequence 262	AA576866
Sequence 211	AA410942	Sequence 263	AA579034
Sequence 212	AA411334	Sequence 264	AA579816
Sequence 213	AA411599	Sequence 265	AA581220
Sequence 214	AA418061	Sequence 266	AA581264
Sequence 215	AA418473	Sequence 267	AA582093
Sequence 216	AA418970	Sequence 268	AA583091
Sequence 217	AA420789	Sequence 269	AA584411
Sequence 218	AA421682	Sequence 270	AA586776
Sequence 219	AA421850	Sequence 271	AA587110
Sequence 220	AA424529	Sequence 272	AA587233
Sequence 221	AA428421	Sequence 273	AA587700
Sequence 222	AA429754	Sequence 274	AA609259
Sequence 223	AA441787	Sequence 275	AA609837
Sequence 224	AA451633	Sequence 276	AA613907
Sequence 225	AA453309	Sequence 277	AA614529
Sequence 226	AA453559	Sequence 278	AA618033
Sequence 227	AA453570	Sequence 279	AA628487
Sequence 228	AA454871	Sequence 280	AA631204
Sequence 229	AA454913	Sequence 281	AA631811
Sequence 230	AA456892	Sequence 282	AA640901
Sequence 231	AA457048	Sequence 283	AA641841
Sequence 232	AA463426	Sequence 284	AA642215
Sequence 233	AA465039	Sequence 285	AA643602
Sequence 234	AA477173	Sequence 286	AA651720
Sequence 235	AA480921	Sequence 287	AA664996
Sequence 236	AA484050	Sequence 288	AA668297
Sequence 237	AA484756	Sequence 289	AA668836
Sequence 238	AA487483	Sequence 290	AA675923
Sequence 239	AA489640	Sequence 291	AA687833
Sequence 240	AA493886	Sequence 292	AA704992
Sequence 241	AA494493	Sequence 293	AA732702
Sequence 242	AA496518	Sequence 294	AA745241
Sequence 243	AA501749	Sequence 295	AA746481
Sequence 244	AA501822	Sequence 296	AA758889
Sequence 245	AA501945	Sequence 297	AA772570
Sequence 246	AA504490	Sequence 298	AA772790
Sequence 247	AA507234	Sequence 299	AA776709
Sequence 248	AA513640	Sequence 300	AA776811
Sequence 249	AA526227	Sequence 301	AA777384
Sequence 250	AA526889	Sequence 302	AA778116
Sequence 251	AA527139	Sequence 303	AA779868
Sequence 252	AA527188	Sequence 304	AA781343
Sequence 253	AA531428	Sequence 305	AA809984
Sequence 254	AA532633	Sequence 306	AA810945
Sequence 255	AA535471	Sequence 307	AA811200
Sequence 256	AA554757	Sequence 308	AA825768
Sequence 257	AA565996	Sequence 309	AA828073

Sequence 310	AA828722	Sequence 362	AF035316
Sequence 311	AA843176	Sequence.363	AF037204
Sequence 312	AA843661	Sequence 364	AF038451
Sequence 313	AA876526	Sequence 365	AF038662
Sequence 314	AA883255	Sequence 366	AF038963
Sequence 315	AA906652	Sequence 367	AF043431
Sequence 316	AA917638	Sequence 368	AF044956
Sequence 317	AA927734	Sequence 369	AF045941
Sequence 318	AA954939	Sequence 370	AF046997
Sequence 319	AA962622	Sequence 371	AF051894
Sequence 320	AA991285	Sequence 372	AF052124
Sequence 321	AB000115	Sequence 373	AF052578
Sequence 322	AB004047	Sequence 374	AF053233
Sequence 323	AB006746	Sequence 375	AF054838
Sequence 324	AB007619	Sequence 376	AF055012
Sequence 325	AB007860	Sequence 377	AF061736
Sequence 326	AB007965	Sequence 378	AF061738
Sequence 327	AB011101	Sequence 379	AF064603
Sequence 328	AB011169	Sequence 380	AF064854
Sequence 329	AB012701	Sequence 381	AF065388
Sequence 330	AB014536	Sequence 382	AF067168
Sequence 331	AB014565	Sequence 383	AF067174
Sequence 332	AB019568	Sequence 384	AF067817
Sequence 333	AB020623	Sequence 385	AF070523
Sequence 334	AB020629	Sequence 386	AF070561
Sequence 335	AB020693	Sequence 387	AF070562
Sequence 336		Sequence 388	AF070596
Sequence 337	AB022663	Sequence 389	AF070664
Sequence 338		Sequence 390	AF070674
Sequence 339		Sequence 391	AF077048
Sequence 340		Sequence 392	AF077051
Sequence 341	AC03653	Sequence 393	AF077200
Sequence 342		Sequence 394	AF077671
Sequence 343		Sequence 395	AF080246
Sequence 344		Sequence 396	AF081484
Sequence 345		Sequence 397	AF083470
Sequence 346		Sequence 398	AF084523
Sequence 347		Sequence 399	AF085355
Sequence 348		Sequence 400	AF086003
Sequence 349		Sequence 401	AF086080
Sequence 350		Sequence 402	AF086183
Sequence 351		Sequence 403	AF086545
Sequence 352		Sequence 404	AF091263
Sequence 353		Sequence 405	AF111713
Sequence 354		Sequence 406	AF118023
Sequence 355		Sequence 407	AF124438
Sequence 356		Sequence 408	AF124439
Sequence 357		Sequence 409	AF131808
Sequence 358		Sequence 410	AF131820
Sequence 359		Sequence 411	AF131848
Sequence 360		Sequence 412	AF132966
Sequence 361		Sequence 413	AF132968
4 - 5 - 7 - 6 - 6 - 6 - 6 - 6 - 6 - 6 - 6 - 6	00000	204001100 410	

WO 01/18542 PCT/US00/24199 · · 5

0	AE146077	Sequence 466	AI382020
Sequence 414	AF146277 AF147331	Sequence 467	AI400372
Sequence 415		Sequence 468	Al417973
Sequence 416	AF150100	Sequence 469	Al431963
Sequence 417	AF150266	Sequence 409 Sequence 470	Al453405
Sequence 418	AF151873		Al457157
Sequence 419	AF151877	Sequence 471	
Sequence 420	AF151978	Sequence 472	Al457624
Sequence 421	AF167160	Sequence 473	AI459679
Sequence 422	Al023413	Sequence 474	AI460010
Sequence 423	AI027888	Sequence 475	AI469095
Sequence 424	Al031811	Sequence 476	Al469715
Sequence 425	AI033687	Sequence 477	Al471539
Sequence 426	AI042140	Sequence 478	AI476335
Sequence 427	AI075324	Sequence 479	Al479289
Sequence 428	AI075876	Sequence 480	Al499285
Sequence 429	AI126802	Sequence 481	AI521180
Sequence 430	Al127556	Sequence 482	AI538061
Sequence 431	AI129360	Sequence 483	AI567204
Sequence 432	Al139456	Sequence 484	AI587104
Sequence 433	Al140291	Sequence 485	AI587328
Sequence 434	Al144215	Sequence 486	Al609624
Sequence 435	Al161378	Sequence 487	AI610607
Sequence 436	Al188638	Sequence 488	AI612873
Sequence 437	Al215617	Sequence 489	A1627444
Sequence 438	Al216969	Sequence 490	AI632869
Sequence 439	Al241578	Sequence 491	Al633164
Sequence 440	Al250167	Sequence 492	AI636014
Sequence 441	AI253330	Sequence 493	AI637620
Sequence 442	Al253335	Sequence 494	AI676218
Sequence 443	AI253369	Sequence 495	A1683871
Sequence 444	Al253436	Sequence 496	AI684170
Sequence 445	Al261671	Sequence 497	AI693877
Sequence 446	AI262264	Sequence 498	AI694088
Sequence 447	Al267162	Sequence 499	AI732534
Sequence 448	AI267379	Sequence 500	AI743595
Sequence 449	AI267502	Sequence 501	A1744489
Sequence 450	Al267622	Sequence 502	AI745058
Sequence 451	AI279131	Sequence 503	AI753108
Sequence 452	AI285943	Sequence 504	AI791322
Sequence 453	AI289173	Sequence 505	AI798474
Sequence 454	AI290876	Sequence 506	AI803838
Sequence 455	AI292104	Sequence 507	AI811960
Sequence 456	Al300033	Sequence 508	AI813617
Sequence 457	Al300074	Sequence 509	AI815829
Sequence 458	Al312113	Sequence 510	AI826957
Sequence 459	AI336032	Sequence 511	AI831002
Sequence 460	AI337069	Sequence 512	AI863041
Sequence 461	AI340262	Sequence 513	AI867294
Sequence 462	Al346975	Sequence 514	AI912076
Sequence 463	Al354639	Sequence 515	AI915553
Sequence 464	AI366381	Sequence 516	. AJ001381
Sequence 465	Al369024	Sequence 517	AJ003401
ocquence 400	,	23420.000011	

PCT/US00/24199

Sequence 518	AJ010071	Sequence 570	D90311
Sequence 519	AJ132502	Sequence 571	D90453
Sequence 520	AL044356	Sequence 572	E01197
Sequence 521	AL044825	Sequence 573	E01198
Sequence 522	AL047024	Sequence 574	E01630
Sequence 523	AL048393	Sequence 575	E01954
Sequence 524	AL049313	Sequence 576	E01971
Sequence 525	AL049923	Sequence 577	E01972
Sequence 526	AL049954	Sequence 578	E02628
Sequence 527	AL050024	Sequence 579	E03569
Sequence 528	AL050272	Sequence 580	E03879
Sequence 529	AL050395	Sequence 581	E08663
Sequence 530	AL096714	Sequence 582	F06593
Sequence 531	AL096748	Sequence 583	F28779
Sequence 532	AL096842	Sequence 584	H25806
Sequence 533	AL110124	Sequence 585	H47546
Sequence 534	C17346	Sequence 586	H48873
Sequence 535	D00017	Sequence 587	H66467
Sequence 536	D00068	Sequence 588	H88415
Sequence 537	D11960	Sequence 589	J00196
Sequence 538	D12502	Sequence 590	J03575
Sequence 539	D12763	Sequence 591	J03858
Sequence 540	D13380	Sequence 592	J03909
Sequence 541	D13645	Sequence 593	J04164
Sequence 542	D13866	Sequence 594	K00422
Sequence 543	D14697	Sequence 595	K01763
Sequence 544	D21260	Sequence 596	L00693
Sequence 545	D23660	Sequence 597	L02426
Sequence 546	D26155	Sequence 598	L06328
Sequence 547	D26599	Sequence 599	L09159
Sequence 548	D28759	Sequence 600	L10413
Sequence 549	D29640	Sequence 601	L11066
Sequence 550	D31763	Sequence 602	L20688
Sequence 551	D31767	Sequence 603	L20941
Sequence 552	D31883	Sequence 604	L28997
Sequence 553	D38524	Sequence 605	L38995
Sequence 554	D42040	Sequence 606	L41490
Sequence 555	D45248	Sequence 607	M10119
Sequence 556	D49396	Sequence 608	M13536
Sequence 557	D50372	Sequence 609	M14328
Sequence 558	D50420	Sequence 610	M14764
Sequence 559	D55653	Sequence 611	M15329
Sequence 560	D81522	Sequence 612	M16660
Sequence 561	D83077	Sequence 613	M17017
Sequence 562	D83767	Sequence 614	M18216
Sequence 563	. D86958	Sequence 615	M19723
Sequence 564	D86979	Sequence 616	M22918
Sequence 565	D87666	Sequence 617	M23613
Sequence 566	D87667	Sequence 618	M24194
Sequence 567	D87735	Sequence 619	M24594
Sequence 568	D88532	Sequence 620	M26152
Sequence 569	D89053	Sequence 621	M29540

Sequence 622	M29541	Sequence 674	U03886
Sequence 623	M29551	Sequence 675	U04313
Sequence 624	M33146	Sequence 676	U07550
Sequence 625	M34064	Sequence 677	U07857
Sequence 626	M34455	Sequence 678	U08815
Sequence 627	M35198	Sequence 679	U09559
Sequence 628	M36693	Sequence 680	U09847
Sequence 629	M37716	Sequence 681	U10439
Sequence 630	M55268	Sequence 682	U14966
Sequence 631	M55542	Sequence 683	U18321
Sequence 632	M55543	Sequence 684	U19878
Sequence 633	M57567	Sequence 685	U23942
Sequence 634	M60333	Sequence 686	U25789
Sequence 635	M61715	Sequence 687	U28249
Sequence 636	M62831	Sequence 688	U28964
Sequence 637	M63121	Sequence 689	U32500
Sequence 638	M63838	Sequence 690	U32944
Sequence 639	. M68520	Sequence 691	U33760
Sequence 640	M77945	Sequence 692	U37230
Sequence 641	M80563	Sequence 693	U37518
Sequence 642	M81757	Sequence 694	U38292
Sequence 643	M83248	Sequence 695	U38784
Sequence 644	M83654	Sequence 696	U41371
Sequence 645	M86553	Sequence 697	U41515
Sequence 646	M87284	Sequence 698	U52513
Sequence 647	M87434	Sequence 699	U56255
Sequence 648	M87503	Sequence 700	U57847
Sequence 649	M92357	Sequence 701	U61083
Sequence 650	M96982	Sequence 702	U68758
Sequence 651	M97501	Sequence 703	U73524
Sequence 652	M97935	Sequence 704	U77085
Sequence 653	N36346	Sequence 705	U78722
Sequence 654	N51262	Sequence 706	U79751
Sequence 655	N57413	Sequence 707	U94586
Sequence 656	N78477	Sequence 708	V00572
Sequence 657	N92060	Sequence 709	V00594
Sequence 658	Q21065	Sequence 710	V04202
Sequence 659	Q94780	Sequence 711	V17906
Sequence 660	R13925	Sequence 712	V36078
Sequence 661	R51732	Sequence 713	V68140
Sequence 662	R56461	Sequence 714	V86134
Sequence 663	R66489	Sequence 715	W02908
Sequence 664	R75621	Sequence 716	W05711
Sequence 665	S45630	Sequence 717	W07308
Sequence 666	S70290	Sequence 718	W25547
Sequence 667	S75295	Sequence 719	W28837
Sequence 668	S76638	Sequence 720	W37272
Sequence 669	T34641	Sequence 721	W38644
Sequence 670	T50925	Sequence 722	W39262
Sequence 671	T52715	Sequence 723	W39498
Sequence 672	T54951	Sequence 724	W52254
Sequence 673	T70793	Sequence 725	W74319

Sequence 726	W77987	Sequence 778	AA022965
Sequence 727	W80480	Sequence 779	AA024522
Sequence 728	X00637	Sequence 780	AA028164
Sequence 729	X01742	Sequence 781	AA035775
Sequence 730	X02530	Sequence 782	AA037294
Sequence 731	X02661	Sequence 783	AA039967
Sequence 732	X04316	Sequence 784	AA045637
Sequence 733	X04371	Sequence 785	AA046815
Sequence 734	X04470	Sequence 786	AA046853
Sequence 735	X05908	Sequence 787	AA047052
Sequence 736	X07819	Sequence 788	AA047213
Sequence 737	X13238	Sequence 789	AA057071
Sequence 738	X15674	Sequence 790	AA058933
Sequence 739	X15729	Sequence 791	AA064952
Sequence 740	X16354	Sequence 792	AA075089
Sequence 741	X16356	Sequence 793	AA076291
Sequence 742	X16455	Sequence 794	AA078508
Sequence 743	X17025	Sequence 795	AA080864
Sequence 744	X20432	Sequence 796	AA083345
Sequence 745	X30167	Sequence 797	AA083693
Sequence 746	X33937	Sequence 798	AA085497
Sequence 747	X35726	Sequence 799	AA086463
Sequence 748	X41105	Sequence 800	AA093935
Sequence 749	X51841	Sequence 801	AA100291
Sequence 750	X54941	Sequence 802	AA101207
Sequence 751		Sequence 803	AA102403
Sequence 752		Sequence 804	AA111856
Sequence 753	X59710	Sequence 805	AA115174
Sequence 754	X65614	Sequence 806	AA122134
Sequence 755	X67951	Sequence 807	AA122291
Sequence 756	X68060	Sequence 808	AA125780
Sequence 757	X68277	Sequence 809	AA127322
Sequence 758	X72790	Sequence 810	AA130432
Sequence 759	X76488	Sequence 811	AA131801
Sequence 760	X83544	Sequence 812	AA132445
Sequence 761	X85134	Sequence 813	AA134109
Sequence 762	X87949	Sequence 814	AA135924
Sequence 763	3 X93036	Sequence 815	AA136322
Sequence 764	X99699	Sequence 816	AA143034
Sequence 765	5 X99920	Sequence 817	AA150057
Sequence 766	Y09267	Sequence 818	AA151651
Sequence 767	7 Y13323	Sequence 819	AA156335
Sequence 768	3 Y17392	Sequence 820	AA157333
Sequence 769	212830	Sequence 821	AA158987
Sequence 770	Z36815	Sequence 822	AA165439
Sequence 77	1 Z47087	Sequence 823	AA165632
Sequence 772		Sequence 824	AA166618
Sequence 773		Sequence 825	AA172067
Sequence 774		Sequence 826	AA173031
Sequence 77		Sequence 827	AA178870
Sequence 77		Sequence 828	AA181874
Sequence 77		Sequence 829	AA195194
•	· -	7	

Sequence 830	AA203206	Sequence 882	AA446099
Sequence 831	AA203289	Sequence 883	AA446403
Sequence 832	AA204768	Sequence 884	AA447735
Sequence 833	AA206621	Sequence 885	AA449054
Sequence 834	AA213914	Sequence 886	AA449205
Sequence 835	AA218919	Sequence 887	AA449520
Sequence 836	AA224050	Sequence 888	AA452273
Sequence 837	AA224244	Sequence 889	AA455007
Sequence 838	AA227596	Sequence 890	AA455104
Sequence 839	AA229018	Sequence 891	AA459527
Sequence 840	AA229161	Sequence 892	AA460226
Sequence 841	AA236445	Sequence 893	AA461287
Sequence 842	AA236680	Sequence 894	AA464526
Sequence 843	AA243537	Sequence 895	AA468398
Sequence 844	AA252436	Sequence 896	AA469135
Sequence 845	AA252869	Sequence 897	AA469453
Sequence 846	AA256330	Sequence 898	AA470690
Sequence 847	AA262700	Sequence 899	AA479427
Sequence 848	AA278358	Sequence 900	AA480336
Sequence 849	AA287076	Sequence 901	AA483454
Sequence 850	AA291551	Sequence 902	AA487669
Sequence 851	AA293273	Sequence 903	AA488423
Sequence 852	AA295982	Sequence 904	AA488635
Sequence 853	AA301675	Sequence 905	AA488843
Sequence 854	AA301722	Sequence 906	AA489772
Sequence 855	AA302964	Sequence 907	AA503972
Sequence 856	AA303199	Sequence 908	AA508506
Sequence 857	AA304927	Sequence 909	AA513550
Sequence 858	AA305042	Sequence 910	AA513783
Sequence 859	AA305635	Sequence 911	AA514989
Sequence 860	AA315030	Sequence 912	AA516400
Sequence 861	AA315943	Sequence 913	AA520993
Sequence 862	AA317144	Sequence 914	AA521110
Sequence 863	AA326060	Sequence 915	AA523639
Sequence 864	AA327358	Sequence 916	AA523697
Sequence 865	AA336387	Sequence 917	AA528106
Sequence 866	AA346413	Sequence 918	AA528190
Sequence 867	AA352580	Sequence 919	AA528226
Sequence 868	AA363162	Sequence 920	AA534830
Sequence 869	AA375754	Sequence 921	AA548722
Sequence 870	AA399230	Sequence 922	AA551236
Sequence 871	AA400249	Sequence 923	AA551243
Sequence 872	AA401629	Sequence 924	AA558778
Sequence 873	AA402885	Sequence 925	AA563834
Sequence 874	AA406401	Sequence 926	AA576432
Sequence 875	AA421682	Sequence 927	AA580069
Sequence 876	AA422057	Sequence 928	AA580294
Sequence 877	AA424445	Sequence 929	AA582588
Sequence 878	AA424901	Sequence 930	AA584304
Sequence 879	AA424984	Sequence 931	AA588772
Sequence 880	AA425182	Sequence 932	AA593075
Sequence 881	AA428607	Sequence 933	AA595585

Sequence 934	AA601895	Sequence 986	AA897461
Sequence 935	AA628700	Sequence 987	AA902582
Sequence 936	AA630326	Sequence 988	AA902644
Sequence 937	AA630642	Sequence 989	AA909144
Sequence 938	AA631178	Sequence 990	AA913281
Sequence 939	AA631218	Sequence 991	AA916756
Sequence 940	AA633550	Sequence 992	AA922420
Sequence 941	AA634808	Sequence 993	AA927283
Sequence 942	AA639199	Sequence 994	AA933075
Sequence 943	AA639791	Sequence 995	AA935979
Sequence 944	AA644273	Sequence 996	AA937947
Sequence 945	AA648897	Sequence 997	AA948295
Sequence 946	AA664732	Sequence 998	AA969131
Sequence 947	AA677550	Sequence 999	AA971881
Sequence 948	AA687308	Sequence 1000	AA973019
Sequence 949	AA705002	Sequence 1001	AA988923
Sequence 950	AA706685	Sequence 1002	AA989465
Sequence 951	AA708266	Sequence 1003	AA994023
Sequence 952	AA713687	Sequence 1004	AB002310
Sequence 953	AA719618	Sequence 1005	AB002330
Sequence 954	AA719674	Sequence 1006	AB007944
Sequence 955	AA720572	Sequence 1007	AB012911
Sequence 956	AA721752	Sequence 1008	AB017019
Sequence 957	AA723612	Sequence 1009	AB018266
Sequence 958	AA730571	Sequence 1010	AB018305
Sequence 959	AA742282	Sequence 1011	AB018347
Sequence 960	AA748437	Sequence 1012	AB019568
Sequence 961	AA749187	Sequence 1013	AB023158
Sequence 962	AA761602	Sequence 1014	AB028976
Sequence 963	AA768355	Sequence 1015	AB029005
Sequence 964	AA769127	Sequence 1016	AC28164
Sequence 965	AA774030	Sequence 1017	AD001528
Sequence 966	AA774247	Sequence 1018	AF000231
Sequence 967	AA779631	Sequence 1019	AF006088
Sequence 968	AA808747	Sequence 1020	AF006516
Sequence 969	AA809854	Sequence 1021	AF012072
Sequence 970	AA810859	Sequence 1022	AF026947
Sequence 971	AA825673	Sequence 1023	AF028832
Sequence 972	AA825768	Sequence 1024	AF030424
Sequence 973	AA826517	Sequence 1025	AF031379
Sequence 974	AA827331	Sequence 1026	AF035287
Sequence 975	AA827764	Sequence 1027	AF035309
Sequence 976	AA829511	Sequence 1028	AF038197
Sequence 977		Sequence 1029	AF038404
Sequence 978	AA836991	Sequence 1030	AF043431
Sequence 979		Sequence 1031	AF044670
Sequence 980		Sequence 1032	AF044958
Sequence 981	AA846840	Sequence 1033	AF047184
Sequence 982		Sequence 1034	AF052164
Sequence 983		Sequence 1035	AF052496
Sequence 984		Sequence 1036	AF052578
Sequence 985		Sequence 1037	AF054990
•		•	

PCT/US00/24199

Sequence 1038	AF059524	Sequence 1090	Al338977
	AF070561	Sequence 1091	Al339946
Sequence 1039	AF070626	Sequence 1092	Al373032
Sequence 1040	AF070655	Sequence 1093	Al374954
Sequence 1041		Sequence 1094	AI380539
Sequence 1042	AF070674	Sequence 1095	Al417583
Sequence 1043	AF075040	Sequence 1096	Al432644
Sequence 1044	AF077030		Al433157
Sequence 1045	AF078847	Sequence 1097	Al457792
Sequence 1046	AF080246	Sequence 1098	Al469112
Sequence 1047	AF081282	Sequence 1099	Al471114
Sequence 1048	AF081484	Sequence 1100	Al471114 Al471534
Sequence 1049	AF084523	Sequence 1101	
Sequence 1050	AF086163	Sequence 1102	AI473927
Sequence 1051	AF095791	Sequence 1103	AI479305
Sequence 1052	AF100756	Sequence 1104	AI499243
Sequence 1053	AF107406	Sequence 1105	AI525796
Sequence 1054	AF119297	Sequence 1106	AI525843
Sequence 1055	AF131858	Sequence 1107	AI537677
Sequence 1056	AF132940	Sequence 1108	AI541029
Sequence 1057	AF151857	Sequence 1109	AI560129
Sequence 1058	AI028733	Sequence 1110	AI583108
Sequence 1059	Al031901	Sequence 1111	AI584068
Sequence 1060	AI033739	Sequence 1112	AI587208
Sequence 1061	AI040324	Sequence 1113	AI589867
Sequence 1062	AI051172	Sequence 1114	Al610676
Sequence 1063	AI076805	Sequence 1115	AI630362
Sequence 1064	AI087005	Sequence 1116	AI633006
Sequence 1065	AI089913	Sequence 1117	AI634443
Sequence 1066	A1092007	Sequence 1118	Al635096
Sequence 1067	Al127326	Sequence 1119	Al682105
Sequence 1068	Al147251	Sequence 1120	AI683338
Sequence 1069	AI148933	Sequence 1121	AI684800
Sequence 1070	Al149846	Sequence 1122	Al684991
Sequence 1071	AI167855	00400	AI689369
Sequence 1072	Al183965	Sequence 1124	AI689617
Sequence 1073	AI189258	Sequence 1125	AI689883
Sequence 1074	Al220148	Sequence 1126	AI693745
Sequence 1075	Al224374	Sequence 1127	AI701001
Sequence 1076	AI240095	Sequence 1128	A1733038
Sequence 1077	AI246677	Sequence 1129	AI735638
Sequence 1078	AI248538	Sequence 1130	AI741506
Sequence 1079	AI266582	Sequence 1131	AI742722
Sequence 1080	Al268864	Sequence 1132	AI742738
Sequence 1081	AI270183	Sequence 1133	AI743552
Sequence 1082	Al271795	Sequence 1134	AI753784
Sequence 1083	AI273008	Sequence 1135	AI754296
Sequence 1084	Al273841	Sequence 1136	A1754652
Sequence 1085	AI274756	Sequence 1137	AI754732
Sequence 1086	Al275528	Sequence 1138	AI765975
Sequence 1087	Al283096	Sequence 1139	AI769970
Sequence 1088	Al298059	Sequence 1140	AI819225
Sequence 1089	Al335653	Sequence 1141	AI820563
50450.100 1000		•	

PCT/US00/24199 WO 01/18542 12

Sequence 1142	AI827818	Sequence 1194	D30655
Sequence 1143	A1828682	Sequence 1195	D50310
Sequence 1144	AI830067	Sequence 1196	D51497
Sequence 1145	AI861989	Sequence 1197	D53031
Sequence 1146	AI887129	Sequence 1198	D62116
Sequence 1147	AI887632	Sequence 1199	D63878
Sequence 1148	AI890281	Sequence 1200	D78611
Sequence 1149	AI924046	Sequence 1201	D82348
Sequence 1150	AI924096	Sequence 1202	D83032
Sequence 1151	AI924823	Sequence 1203	D85433
Sequence 1152	AI963471	Sequence 1204	D87437
Sequence 1153	AI963604	Sequence 1205	D87667
Sequence 1154	A1972556	Sequence 1206	D89092
Sequence 1155	AI979048	Sequence 1207	D90041
Sequence 1156	Al984656	Sequence 1208	E02628
Sequence 1157	AJ010442	Sequence 1209	E05732
Sequence 1158	AJ132694	Sequence 1210	F00551
Sequence 1159	AJ224442	Sequence 1211	H08920
Sequence 1160	AL036299	Sequence 1212	H25080
Sequence 1161	AL042979	Sequence 1213	H30306
Sequence 1162	AL047305	Sequence 1214	H44647
Sequence 1163	AL049247	Sequence 1215	H81376
Sequence 1164	AL049313	Sequence 1216	H93521
Sequence 1165	AL049381	Sequence 1217	H94496
Sequence 1166	AL049932	Sequence 1218	J03464
Sequence 1167	AL050041	Sequence 1219	J03799
Sequence 1168	AL050161	Sequence 1220	J04027
Sequence 1169	AL050265	Sequence 1221	J04177
Sequence 1170	AL050268	Sequence 1222	K01228
Sequence 1171	AL050367	Sequence 1223	K01566
Sequence 1172	AL079286	Sequence 1224	L07395
Sequence 1173	AL079312	Sequence 1225	L09159
Sequence 1174	AL079314	Sequence 1226	L11315
Sequence 1175	AL080113	Sequence 1227	L13806
Sequence 1176	AL110164	Sequence 1228	L15702
Sequence 1177	AL117412	Sequence 1229	L16510
Sequence 1178	AL117612	Sequence 1230	L24804
Sequence 1179	AL119009	Sequence 1231	L25931
Sequence 1180	AW014693	Sequence 1232	L28809
Sequence 1181	AW014985	Sequence 1233	M10036
Sequence 1182	AW021794	Sequence 1234	M10905
Sequence 1183	C01521	Sequence 1235	M11353
Sequence 1184	D01096	Sequence 1236	M12267
Sequence 1185	D13119	Sequence 1237	M13536
Sequence 1186	D13627	Sequence 1238	M14483
Sequence 1187	D13630	Sequence 1239	M14630
Sequence 1188	D13639	Sequence 1240	M17885
Sequence 1189	D13665	Sequence 1241	M18366
Sequence 1190	D14530	Sequence 1242	M21575
Sequence 1191	D21260	Sequence 1243	M23254
Sequence 1192	D25278	Sequence 1244	M24194
Sequence 1193	D26361	Sequence 1245	M24486

Sequence 1246	M26512	Sequence 1298	V24305
Sequence 1247	M28372	Sequence 1299	V81394
Sequence 1248	M31159	Sequence 1300	V84510
Sequence 1249	M32220	Sequence 1301	W19427
Sequence 1250	M36341	Sequence 1302	W65357
Sequence 1251	M36693	Sequence 1303	W75963
Sequence 1252	M38690	Sequence 1304	W80525
Sequence 1253	M58485	Sequence 1305	X01630
Sequence 1254	M59849	Sequence 1306	X04098
Sequence 1255	M62831	Sequence 1307	X04408
Sequence 1256	M64241	Sequence 1308	X06700
Sequence 1257	M69043	Sequence 1309	X14420
Sequence 1258	M77142	Sequence 1310	X51742
Sequence 1259	M77830	Sequence 1311	X60111
Sequence 1260	M86667	Sequence 1312	X69398
Sequence 1261	M88108	Sequence 1313	X72755
Sequence 1262	M93651	Sequence 1314	X74979
Sequence 1263	M95542	Sequence 1315	X76180
Sequence 1264	N43970	Sequence 1316	X78627
Sequence 1265	Q12759	Sequence 1317	X79067
Sequence 1266	Q14635	Sequence 1318	X80910
Sequence 1267	R11045	Sequence 1319	X87949
Sequence 1268	R76376	Sequence 1320	Y00052
Sequence 1269	R84450	Sequence 1321	Y00062
Sequence 1270	S74728	Sequence 1322	Y00282
Sequence 1271	S82081	Sequence 1323	Y00503
Sequence 1272	T07459	Sequence 1324	Y15286
Sequence 1273	T19883	Sequence 1325	Y17171
Sequence 1274	T21168	Sequence 1326	Z13009
Sequence 1275	T22605	Sequence 1327	Z24724
Sequence 1276	T37405	Sequence 1328	Z29083
Sequence 1277	T67129	Sequence 1329	Z29331
Sequence 1278	T69703	Sequence 1330	Z46606
Sequence 1279	T78615	Sequence 1331	Z48501
Sequence 1280	T89937	Sequence 1332	AA001460
Sequence 1281	U03851	Sequence 1333	AA001543
Sequence 1282	U12404	Sequence 1334	AA001792
Sequence 1283	U14967	Sequence 1335	AA004925
Sequence 1284	U14971	Sequence 1336	AA010897
Sequence 1285	U20659	Sequence 1337	AA017162
Sequence 1286	U25789	Sequence 1338	AA019019
Sequence 1287	U30825	Sequence 1339	AA022980
Sequence 1288	U47077	Sequence 1340	AA024595
Sequence 1289	U49844	Sequence 1341	AA024940
Sequence 1290	U63846	Sequence 1342	AA024996
Sequence 1291	U65928	Sequence 1343	AA025750
Sequence 1292	U72516	Sequence 1344	AA026598
Sequence 1293	U79282	Sequence 1345	AA029271
Sequence 1294	U90716	Sequence 1346	AA029725
Sequence 1295	U90904	Sequence 1347	AA029930
Sequence 1296	U94364	Sequence 1348	AA033832
Sequence 1297	V20437	Sequence 1349	AA035471

14

Table 1

PCT/US00/24199

Sequence 1350	AA035616	Sequence 1402	AA088344
Sequence 1351	AA036752	Sequence 1403	AA088351
Sequence 1352	AA037377	Sequence 1404	AA088693
Sequence 1353	AA039778	Sequence 1405	AA088783
Sequence 1354	AA039948	Sequence 1406	AA088829
Sequence 1355	AA040688	Sequence 1407	AA090106
Sequence 1356	AA040820	Sequence 1408	AA096032
Sequence 1357	AA041259	Sequence 1409	AA099819
Sequence 1358	AA043477	Sequence 1410	AA099923
Sequence 1359	AA044209	Sequence 1411	AA099976
Sequence 1360	AA044233	Sequence 1412	AA100764
Sequence 1361	AA044791	Sequence 1413	AA101010
Sequence 1362	AA045054	Sequence 1414	AA102013
Sequence 1363	AA045147	Sequence 1415	AA102564
Sequence 1364	AA045768	Sequence 1416	AA102830
Sequence 1365	AA046848	Sequence 1417	AA112186
Sequence 1366	AA053021	Sequence 1418	AA112645
Sequence 1367	AA053316	Sequence 1419	AA113305
Sequence 1368	AA053919	Sequence 1420	AA115218
Sequence 1369	AA054069	Sequence 1421	AA115315
Sequence 1370	AA055479	Sequence 1422	AA121656
Sequence 1371	AA055591	Sequence 1423	AA121718
Sequence 1372	AA055637	Sequence 1424	AA125809
Sequence 1373	AA057243	Sequence 1425	AA125939
Sequence 1374	AA058712	Sequence 1426	AA126452
Sequence 1375	AA059128	Sequence 1427	AA126718
Sequence 1376	AA065169	Sequence 1428	AA127436
Sequence 1377	AA069850	Sequence 1429	AA127666
Sequence 1378	AA071167	Sequence 1430	AA128063
Sequence 1379	AA075158	Sequence 1431	AA128636
Sequence 1380	AA075515	Sequence 1432	AA128641
Sequence 1381	AA075663	Sequence 1433	AA130778
Sequence 1382	AA076397	Sequence 1434	AA130982
Sequence 1383	AA076421	Sequence 1435	AA131827
Sequence 1384	AA078387	Sequence 1436	AA132056
Sequence 1385	AA078570	Sequence 1437	AA132163
Sequence 1386	AA078872	Sequence 1438	AA132574
Sequence 1387	AA079480	Sequence 1439	AA132992
Sequence 1388	AA080889	Sequence 1440	AA133351
Sequence 1389	AA081073	Sequence 1441	AA133474
Sequence 1390	AA081608	Sequence 1442	AA134460
Sequence 1391	AA081834	Sequence 1443	AA134527
Sequence 1392	AA081917	Sequence 1444	AA134589
Sequence 1393	AA082258	Sequence 1445	AA135696
Sequence 1394	AA082441	Sequence 1446	AA137017
Sequence 1395	AA083270	Sequence 1447	AA142941
Sequence 1396	AA083345	Sequence 1448	AA143001
Sequence 1397	AA083522	Sequence 1449	AA143074
Sequence 1398	AA083573	Sequence 1450	AA143746
Sequence 1399	AA083638	Sequence 1451	AA146900
Sequence 1400	AA083774	Sequence 1452	AA147200
Sequence 1401	AA088318	Sequence 1453	AA147247

Sequence 1454	AA147781	Sequence 1506	AA188826
Sequence 1455	AA148027	Sequence 1507	AA190873
Sequence 1456	AA148136	Sequence 1508	AA191422
Sequence 1457	AA149810	Sequence 1509	AA192094
Sequence 1458	AA150377	Sequence 1510	AA193308
Sequence 1459	AA150837	Sequence 1511	AA194577
Sequence 1460	AA150928	Sequence 1512	AA195246
Sequence 1461	AA151274	Sequence 1513	AA195865
Sequence 1462	AA151594	Sequence 1514	AA196424
Sequence 1463	AA151755	Sequence 1515	AA196982
Sequence 1464	AA152476	Sequence 1516	AA203691
Sequence 1465	AA155754	Sequence 1517	AA204867
Sequence 1466	AA156066	Sequence 1518	AA206578
Sequence 1467	AA157163	Sequence 1519	AA206991
Sequence 1468	AA157993	Sequence 1520	AA209508
Sequence 1469	AA158738	Sequence 1521	AA216753
Sequence 1470	AA159110	Sequence 1522	AA219665
Sequence 1471	AA159576	Sequence 1523	AA223121
Sequence 1472	AA161003	Sequence 1524	AA223820
Sequence 1473	AA161076	Sequence 1525	AA224109
Sequence 1474	AA161467	Sequence 1526	AA224407
Sequence 1475	AA164193	Sequence 1527	AA227118
Sequence 1476	AA164473	Sequence 1528	AA229325
Sequence 1477	AA164729	Sequence 1529	AA229611
Sequence 1478	AA164873	Sequence 1530	AA232959
Sequence 1479	AA165027	Sequence 1531	AA233835
Sequence 1480	AA165068	Sequence 1532	AA233843
Sequence 1481	AA165087	Sequence 1533	AA234092
Sequence 1482	AA165174	Sequence 1534	AA234307
Sequence 1483	AA165282	Sequence 1535	AA236776
Sequence 1484	AA165293	Sequence 1536	AA242985
Sequence 1485	AA165638	Sequence 1537	AA243338
Sequence 1486	AA166618	Sequence 1538	AA244342
Sequence 1487	AA167041	Sequence 1539	AA249154
Sequence 1488	AA167750	Sequence 1540	AA255502
Sequence 1489	AA171630	Sequence 1541	AA256591
Sequence 1490	AA173506	Sequence 1542	AA261990
Sequence 1491	AA174097	Sequence 1543	AA262939
Sequence 1492	AA179187	Sequence 1544	AA278445
Sequence 1493	AA180137	Sequence 1545	AA278482
Sequence 1494	AA180224	Sequence 1546	AA278642
Sequence 1495	AA180383	Sequence 1547	AA278956
Sequence 1496	AA181075	Sequence 1548	AA279048
Sequence 1497	AA181258	Sequence 1549	AA280099
Sequence 1498	AA181684	Sequence 1550	AA280221
Sequence 1499	AA182415	Sequence 1551	AA280828
Sequence 1500	AA182540	Sequence 1552	AA282915
Sequence 1501	AA186577	Sequence 1553	AA284334
Sequence 1502	AA187817	Sequence 1554	AA284555
Sequence 1503	AA188045	Sequence 1555	AA284670
Sequence 1504	AA188140	Sequence 1556	AA284671
Sequence 1505	AA188384	Sequence 1557	AA284870
•			

PCT/US00/24199 WO 01/18542 16

Sequence 1558	AA284906	Sequence 1610	AA314872
Sequence 1559	AA285290	Sequence 1611	AA315363
Sequence 1560	AA286699	Sequence 1612	AA315379
Sequence 1561	AA286872	Sequence 1613	AA317243
Sequence 1562	AA287219	Sequence 1614	AA317393
Sequence 1563	AA287642	Sequence 1615	AA318969
Sequence 1564	AA287815	Sequence 1616	AA327201
Sequence 1565	AA291438	Sequence 1617	AA331991
Sequence 1566	AA291485	Sequence 1618	AA332672
Sequence 1567	AA291971	Sequence 1619	AA333358
Sequence 1568	AA292334	Sequence 1620	AA335273
Sequence 1569	AA293127	Sequence 1621	AA336666
Sequence 1570	AA293133	Sequence 1622	AA337192
Sequence 1571	AA293273	Sequence 1623	AA337489
Sequence 1572	AA293286	Sequence 1624	AA338793
Sequence 1573	AA293353	Sequence 1625	AA339957
Sequence 1574	AA293572	Sequence 1626	AA340341
Sequence 1575	AA293629	Sequence 1627	AA341446
Sequence 1576	AA293759	Sequence 1628	AA341465
Sequence 1577	AA293804	Sequence 1629	AA342969
Sequence 1578	AA296780	Sequence 1630	AA343629
Sequence 1579	AA297402	Sequence 1631	AA344084
Sequence 1580	AA298505	Sequence 1632	AA345329
Sequence 1581	AA299640	Sequence 1633	AA346393
Sequence 1582	AA301062	Sequence 1634	AA346698
Sequence 1583	AA301800	Sequence 1635	AA347887
Sequence 1584	AA303461	Sequence 1636	AA350059
Sequence 1585	AA303568	Sequence 1637	AA351507
Sequence 1586	AA306718	Sequence 1638	AA355003
•	AA306862	Sequence 1639	AA356682
Sequence 1587	AA306876	Sequence 1640	AA357574
Sequence 1588	AA307198	Sequence 1641	AA358887
Sequence 1589	AA307325	Sequence 1642	AA359705
Sequence 1590	AA308065	Sequence 1643	AA364352
Sequence 1591	AA308274	Sequence 1644	AA367451
Sequence 1592	AA308744	Sequence 1645	AA367773
Sequence 1593	AA310739	Sequence 1646	AA368542
Sequence 1594	AA310771	Sequence 1647	AA369400
Sequence 1595		Sequence 1648	AA373230
Sequence 1596	AA311228 AA311460	Sequence 1649	AA374754
Sequence 1597		Sequence 1650	AA375312
Sequence 1598	AA311571	Sequence 1651	AA375815
Sequence 1599	AA311801	Sequence 1652	AA393525
Sequence 1600	AA311848	Sequence 1653	AA394115
Sequence 1601	AA311905	Sequence 1654	AA398443
Sequence 1602	AA312218	Sequence 1655	AA398585
Sequence 1603	AA312240		AA398739
Sequence 1604	AA312435	Sequence 1656	AA399165
Sequence 1605	AA313108	Sequence 1657	AA399628
Sequence 1606	AA313223	Sequence 1658	AA401329
Sequence 1607	AA313653	Sequence 1659	AA401329 AA401334
Sequence 1608	AA313994	Sequence 1660	AA401334 AA402191
Sequence 1609	AA314431	Sequence 1661	7V74UZ 13 I

Sequence 1662	AA402289	Sequence 1714	AA476522
Sequence 1663	AA402775	Sequence 1715	AA477018
Sequence 1664	AA403319	Sequence 1716	AA477567
Sequence 1665	AA404613	Sequence 1717	AA477973
Sequence 1666	AA405124	Sequence 1718	AA478230
Sequence 1667	AA406239	Sequence 1719	AA479646
Sequence 1668	AA410580	Sequence 1720	AA479648
Sequence 1669	AA410982	Sequence 1721	AA479848
Sequence 1670	AA411021	Sequence 1722	AA481078
Sequence 1671	AA411252	Sequence 1723	AA481710
Sequence 1672	AA411764	Sequence 1724	AA482430
Sequence 1673	AA417794	Sequence 1725	AA482432
Sequence 1674	AA419263	Sequence 1726	AA482779
Sequence 1675	AA419284	Sequence 1727	AA483258
Sequence 1676	AA420751	Sequence 1728	AA483726
Sequence 1677	AA420758	Sequence 1729	AA483858
Sequence 1678	AA421248	Sequence 1730	AA484181
Sequence 1679	AA421682	Sequence 1731	AA486047
Sequence 1680	AA422060	Sequence 1732	AA486859
Sequence 1681	AA422143	Sequence 1733	AA488141
Sequence 1682	AA425004	Sequence 1734	AA488385
Sequence 1683	AA425468	Sequence 1735	AA488517
Sequence 1684	AA425737	Sequence 1736	AA489323
Sequence 1685	AA429794	Sequence 1737	AA489380
•	AA430400	Sequence 1738	AA489382
Sequence 1686	AA430436	Sequence 1739	AA491204
Sequence 1687	AA431428	Sequence 1740	AA492143
Sequence 1688		Sequence 1741	AA493371
Sequence 1689	AA433988	Sequence 1742	AA494321
Sequence 1690	AA436315	Sequence 1742	AA494552
Sequence 1691	AA436411	Sequence 1744	AA501657
Sequence 1692	AA443024	Sequence 1745	AA502136
Sequence 1693	AA449394	Sequence 1745	AA505780
Sequence 1694	AA451779	Sequence 1747	AA512933
Sequence 1695	AA453878	Sequence 1747 Sequence 1748	AA514395
Sequence 1696	AA454668	Sequence 1740 Sequence 1749	AA514974
Sequence 1697	AA454953	•	AA515143
Sequence 1698	AA454962	Sequence 1750	AA516376
Sequence 1699	AA455245	Sequence 1751	AA521006
Sequence 1700	AA455785	Sequence 1752	AA523522
Sequence 1701	AA456454	Sequence 1753	AA524748
Sequence 1702	AA456557	Sequence 1754	AA524746 AA524950
Sequence 1703	AA457255	Sequence 1755	
Sequence 1704	AA457579	Sequence 1756	AA525141
Sequence 1705	AA459167	Sequence 1757	AA526028
Sequence 1706	AA459210	Sequence 1758	AA527275
Sequence 1707	AA459527	Sequence 1759	AA527557
Sequence 1708	AA460570	Sequence 1760	AA533506
Sequence 1709	AA460816	Sequence 1761	AA534349
Sequence 1710	AA461005	Sequence 1762	AA534586
Sequence 1711	AA468657	Sequence 1763	AA534608
Sequence 1712	AA469447	Sequence 1764	AA535496
Sequence 1713	AA469453	Sequence 1765	AA541651

PCT/US00/24199 WO 01/18542 18

Sequence 1766	AA548056	Sequence 1818	AA628536
Sequence 1767	AA548600	Sequence 1819	AA628547
Sequence 1768	AA550854	Sequence 1820	AA630611
Sequence 1769	AA550855	Sequence 1821	AA631326
Sequence 1770	AA551351	Sequence 1822	AA633909
Sequence 1771	AA551391	Sequence 1823	AA634260
Sequence 1772	AA554437	Sequence 1824	AA634298
Sequence 1773	AA554735	Sequence 1825	AA640505
Sequence 1774	AA555102	Sequence 1826	AA641289
Sequence 1775	AA564272	Sequence 1827	AA644625
Sequence 1776	AA564870	Sequence 1828	AA648944
Sequence 1777	AA565420	Sequence 1829	AA651720
Sequence 1778	AA568936	Sequence 1830	AA652478
Sequence 1779	AA569816	Sequence 1831	AA652505
Sequence 1780	AA569851	Sequence 1832	AA653775
Sequence 1781	AA569916	Sequence 1833	AA658374
Sequence 1782	AA573761	Sequence 1834	AA663005
Sequence 1783	AA573787	Sequence 1835	AA669154
Sequence 1784	AA577537	Sequence 1836	AA677560
Sequence 1785	AA578881	Sequence 1837	AA677750
Sequence 1786	AA579591	Sequence 1838	AA678185
Sequence 1787	AA579890	Sequence 1839	AA678251
Sequence 1788	AA580835	Sequence 1840	AA687495
Sequence 1789	AA582093	Sequence 1841	AA703208
Sequence 1790	AA582866	Sequence 1842	AA703667
Sequence 1791	AA583055	Sequence 1843	AA703907
Sequence 1792	AA583498	Sequence 1844	AA704208
Sequence 1793	AA583567	Sequence 1845	AA706347
Sequence 1794	AA583773	Sequence 1846	AA714010
Sequence 1795	AA584921	Sequence 1847	AA715984
Sequence 1796	AA586755	Sequence 1848	AA716651
Sequence 1797	AA587140	Sequence 1849	AA719530
Sequence 1798	AA587315	Sequence 1850	AA721642
Sequence 1799	AA587873	Sequence 1851	AA729381
Sequence 1800	AA593983	Sequence 1852	AA731946
Sequence 1801	AA594366	Sequence 1853	AA736817
Sequence 1802	AA595624	Sequence 1854	AA742713
Sequence 1803	AA595771	Sequence 1855	AA743278
Sequence 1804	AA599454	Sequence 1856	AA744681
Sequence 1805	AA600227	Sequence 1857	AA745953
Sequence 1806	AA600771	Sequence 1858	AA759195
Sequence 1807	AA601172	Sequence 1859	AA767779
Sequence 1808	AA602395	Sequence 1860	AA769697
Sequence 1809	AA602871	Sequence 1861	AA773998
Sequence 1810	AA603125	Sequence 1862	AA775058
Sequence 1811	AA603177	Sequence 1863	AA776593
Sequence 1812	AA604324	Sequence 1864	AA777384
Sequence 1813	AA604853	Sequence 1865	AA778672
Sequence 1814	AA610279	Sequence 1866	AA779949
Sequence 1815	AA610476	Sequence 1867	AA781487
Sequence 1816	AA610734	Sequence 1868	AA788907
Sequence 1817	AA614482	Sequence 1869	AA806278
q		•	

Sequence 1870	AA806735	Sequence 1922	AB007867
Sequence 1871	AA808769	Sequence 1923	AB007900
Sequence 1872	AA810149	Sequence 1924	AB007916
Sequence 1873	AA811609	Sequence 1925	AB007923
Sequence 1874	AA813604	Sequence 1926	AB007957
Sequence 1875	AA826307	Sequence 1927	AB011103
Sequence 1876	AA833766	Sequence 1928	AB011143
Sequence 1877	AA833900	Sequence 1929	AB011151
Sequence 1878	AA837457	Sequence 1930	AB011166
Sequence 1879	AA843531	Sequence 1931	AB014533
Sequence 1880	AA845737	Sequence 1932	AB014542
Sequence 1881	AA846698	Sequence 1933	AB014560
Sequence 1882	AA846856	Sequence 1934	AB015630
Sequence 1883	AA852896	Sequence 1935	AB015856
Sequence 1884	AA856902	Sequence 1936	AB018281
Sequence 1885	AA857824	Sequence 1937	AB018284
Sequence 1886	AA857882	Sequence 1938	AB018285
Sequence 1887	AA861665	Sequence 1939	AB018289
Sequence 1888	AA865960	Sequence 1940	AB018305
Sequence 1889	AA868529	Sequence 1941	AB018327
Sequence 1890	AA873271	Sequence 1942	AB018331
Sequence 1891	AA877189	Sequence 1943	AB018337
Sequence 1892	AA884922	Sequence 1944	AB019409
Sequence 1893	AA886453	Sequence 1945	AB019563
Sequence 1894	AA906652	Sequence 1946	AB019568
Sequence 1895	AA906865	Sequence 1947	AB019691
Sequence 1896	AA918993	Sequence 1948	AB020682
Sequence 1897	AA926926	Sequence 1949	AB020718
Sequence 1898	AA928934	Sequence 1950	AB021288
Sequence 1899	AA932501	Sequence 1951	AB023154
Sequence 1900	AA933987	Sequence 1952	AB023219
Sequence 1901	AA935947	Sequence 1953	AB024704
Sequence 1902	AA937302	Sequence 1954	AB027467
Sequence 1903	AA937773	Sequence 1955	AB028069
Sequence 1904	AA947835	Sequence 1956	AB028624
Sequence 1905	AA954939	Sequence 1957	AB028969
Sequence 1906	AA962587	Sequence 1958	AB028986
Sequence 1907	AA962632	Sequence 1959	AB029000
Sequence 1908	AA972525	Sequence 1960	AB029004
Sequence 1909	AA976489	Sequence 1961	AB029028
Sequence 1910	AA983380	Sequence 1962	AC03044
Sequence 1911	AA984586	Sequence 1963	AC31479
Sequence 1912	AA992596	Sequence 1964	AF000670
Sequence 1913	AB002305	Sequence 1965	AF000974
Sequence 1914	AB002330	Sequence 1966	AF001893
Sequence 1915	AB002357	Sequence 1967	AF004562
Sequence 1916	AB002806	Sequence 1968	AF006043
Sequence 1917	AB003476	Sequence 1969	AF007135
Sequence 1918	AB004066	Sequence 1970	AF007151
Sequence 1919	AB006077	Sequence 1971	AF007170
Sequence 1920	AB006534	Sequence 1972	AF009615
Sequence 1921	AB006755	Sequence 1973	AF013759
Sequence 1321	70000100	Sequence 1910	

			. =000040
Sequence 1974	AF013988	Sequence 2026	AF062318
Sequence 1975	AF015283	Sequence 2027	AF063611
Sequence 1976	AF015767	Sequence 2028	AF064019
Sequence 1977	AF016507	Sequence 2029	AF068235
Sequence 1978	AF016582	Sequence 2030	AF068846
Sequence 1979	AF017790	Sequence 2031	AF070523
Sequence 1980	AF019767	Sequence 2032	AF070537
Sequence 1981	AF021351	Sequence 2033	AF070555
Sequence 1982	AF021819	Sequence 2034	AF070561
Sequence 1983	AF022229	Sequence 2035	AF070596
Sequence 1984	AF023266	Sequence 2036	AF070600
Sequence 1985	AF025439	Sequence 2037	AF070626
Sequence 1986	AF026166	Sequence 2038	AF070649
Sequence 1987	AF026939	Sequence 2039	AF070662
Sequence 1988	AF027205	Sequence 2040	AF070672
Sequence 1989	AF031385	Sequence 2041	AF071202
Sequence 1990	AF034607	Sequence 2042	AF071219
Sequence 1991	AF035286	Sequence 2043	AF071593
Sequence 1992	AF035309	Sequence 2044	AF073298
Sequence 1993	AF035313	Sequence 2045	AF075587
Sequence 1994	AF037204	Sequence 2046	AF077030
Sequence 1995	AF038661	Sequence 2047	AF077045
Sequence 1996	AF039019	Sequence 2048	AF077200
Sequence 1997	AF039291	Sequence 2049	AF077202
Sequence 1998	AF039843	Sequence 2050	AF077207
Sequence 1999	AF040990	Sequence 2051	AF081192
Sequence 2000	AF041483	Sequence 2052	AF081484
Sequence 2001	AF042385	Sequence 2053	AF083190
Sequence 2002	AF042729	Sequence 2054	AF085355
Sequence 2003	AF044588	Sequence 2055	AF086003
Sequence 2004	AF045184	Sequence 2056	AF086116
Sequence 2005	AF047438	Sequence 2057	AF086178
Sequence 2006	AF047472	Sequence 2058	AF086205
Sequence 2007	AF048977	Sequence 2059	AF086207
Sequence 2008	AF050171	Sequence 2060	AF086336
Sequence 2009	AF050199	Sequence 2061	AF086517
Sequence 2010	AF050639	Sequence 2062	AF087135
Sequence 2011	AF052124	Sequence 2063	AF087990
Sequence 2012	AF052135	Sequence 2064	AF088036
Sequence 2013	AF052149	Sequence 2065	AF091076
Sequence 2014	AF052164	Sequence 2066	AF092563
Sequence 2015	AF052169	Sequence 2067	AF095287
Sequence 2016	AF052180	Sequence 2068	AF095791
Sequence 2017	AF052514	Sequence 2069	AF097709
Sequence 2018	AF054183	Sequence 2070	AF100741
Sequence 2019	AF054187	Sequence 2071	AF100756
Sequence 2020	AF054840	Sequence 2072	AF100928
Sequence 2021	AF055012	Sequence 2073	AF104222
Sequence 2022	AF055033	Sequence 2074	AF104913
Sequence 2023	AF057299	Sequence 2075	AF104923
Sequence 2024	AF059252	Sequence 2076	AF107405
Sequence 2025	AF061258	Sequence 2077	AF120334
Sequence 2023	, 00 1200	- 54501100 8071	

Sequence 2078	AF124438	Sequence 2130	AI090524
Sequence 2079	AF124439	Sequence 2131	AI090623
Sequence 2080	AF125525	Sequence 2132	Al091425
Sequence 2081	AF131799	Sequence 2133	AI092971
Sequence 2082	AF131814	Sequence 2134	AI095477
Sequence 2083	AF139461	Sequence 2135	Al123229
Sequence 2084	AF139658	Sequence 2136	AI125642
Sequence 2085	AF144755	Sequence 2137	Al125874
Sequence 2086	AF147331	Sequence 2138	AI127013
Sequence 2087	AF150962	Sequence 2139	Al127556
Sequence 2088	AF151832	Sequence 2140	Al140291
Sequence 2089	AF151868	Sequence 2141	AI141130
Sequence 2090	AF151898	Sequence 2142	Al141847
Sequence 2091	AF151907	Sequence 2143	AI143899
Sequence 2092	AF152097	Sequence 2144	AI144100
Sequence 2093	AF159295	Sequence 2145	AI148251
Sequence 2094	AF176702	Sequence 2146	AI149429
Sequence 2095	AF190744	Sequence 2147	Al149592
Sequence 2096	AI004664	Sequence 2148	AI186028
Sequence 2097	Al004915	Sequence 2149	Al186042
Sequence 2098	AI016073	Sequence 2150	Al190341
Sequence 2099	AI016323	Sequence 2151	Al192367
Sequence 2100	AI016323	Sequence 2152	AI192629
Y	AI018451	Sequence 2153	AI198930
Sequence 2101	AI018625	Sequence 2154	Al216969
Sequence 2102	AI016025 AI022779	Sequence 2155	AI217003
Sequence 2103		Sequence 2156	Al223292
Sequence 2104	AI023799	Sequence 2157	AI241706
Sequence 2105	AI026164	Sequence 2158	Al251743
Sequence 2106	AI027516	Sequence 2159	Al252466
Sequence 2107	AI031636	Sequence 2160	AI253330
Sequence 2108	AI033037	Sequence 2161	Al253335
Sequence 2109	AI034115	Sequence 2162	AI253338
Sequence 2110	AI037859	•	AI253335
Sequence 2111	AI041670	Sequence 2163 Sequence 2164	Al253379
Sequence 2112	AI042034	Sequence 2165	AI253436
Sequence 2113	AI042290	•	Al262380
Sequence 2114	AI051971	Sequence 2166	AI262360
Sequence 2115	AI056917	Sequence 2167	Al267162
Sequence 2116	AI057124	Sequence 2168	Al267185
Sequence 2117	AI066419	Sequence 2169	
Sequence 2118	AI078041	Sequence 2170	Al267209
Sequence 2119	AI081116	Sequence 2171	Al267289
Sequence 2120	AI081472	Sequence 2172	AI267307
Sequence 2121	AI081913	Sequence 2173	Al267321
Sequence 2122	AI082244	Sequence 2174	AI267454
Sequence 2123	AI082648	Sequence 2175	A1267502
Sequence 2124	AI084731	Sequence 2176	AI268293
Sequence 2125	AI085381	Sequence 2177	Al269060
Sequence 2126	AI087291	Sequence 2178	Al269369
Sequence 2127	AI087819	Sequence 2179	AI270183
Sequence 2128	AI088178	Sequence 2180	A1270472
Sequence 2129	AI089981	Sequence 2181	Al271786

0	41070007	C 2224	AI589301
Sequence 2182	AI272827	Sequence 2234	Al597938
Sequence 2183	AI274047	Sequence 2235	Al608591
Sequence 2184	AI276341	Sequence 2236	Al608787
Sequence 2185	AI276839	Sequence 2237	
Sequence 2186	AI278611	Sequence 2238	Al608968 Al609193
Sequence 2187	AI280022	Sequence 2239	
Sequence 2188	AI283548	Sequence 2240	Al609281
Sequence 2189	AI288965	Sequence 2241	AI623804
Sequence 2190	Al290565	Sequence 2242	AI628689
Sequence 2191	Al291683	Sequence 2243	AI636635
Sequence 2192	Al292286	Sequence 2244	AI650837
Sequence 2193	Al298472	Sequence 2245	AI654096
Sequence 2194	Al298941	Sequence 2246	AI660245
Sequence 2195	Al304857	Sequence 2247	AI669253
Sequence 2196	Al308959	Sequence 2248	AI670084
Sequence 2197	Al312552	Sequence 2249	AI674313
Sequence 2198	Al333055	Sequence 2250	AI678152
Sequence 2199	Al333116	Sequence 2251	Al678703
Sequence 2200	Al335249	Sequence 2252	AI679044
Sequence 2201	Al336326	Sequence 2253	Al679321
Sequence 2202	Al345325	Sequence 2254	Al683140
Sequence 2203	Al366549	Sequence 2255	AI683338
Sequence 2204	AI367850	Sequence 2256	AI683793
Sequence 2205	Al375624	Sequence 2257	AI688798
Sequence 2206	Al376561	Sequence 2258	AI692866
Sequence 2207	Al399636	Sequence 2259	AI694087
Sequence 2208	Al417384	Sequence 2260	Al696819
Sequence 2209	Al421720	Sequence 2261	AI697501
Sequence 2210	AI424841	Sequence 2262	AI734922
Sequence 2211	AI431507	Sequence 2263	AI735069
Sequence 2212	AI433180	Sequence 2264	AI739337
Sequence 2213	AI434084	Sequence 2265	AI739377
Sequence 2214	Al434401	Sequence 2266	AI743595
Sequence 2215	AI436016	Sequence 2267	AI743691
Sequence 2216	AI436448	Sequence 2268	AI750198
Sequence 2217	AI446503	Sequence 2269	AI750909
Sequence 2218	AI453199	Sequence 2270	AI751119
Sequence 2219	AI459028	Sequence 2271	AI751364
Sequence 2220	Al469237	Sequence 2272	AI751565
Sequence 2221	AI492520	Sequence 2273	AI752319
Sequence 2222	AI492769	Sequence 2274	AI752553
Sequence 2223	AI494344	Sequence 2275	AI752929
Sequence 2224	AI523940	Sequence 2276	AI753108
Sequence 2225	AI524677	Sequence 2277	AI753671
Sequence 2226	AI538682	Sequence 2278	AI754437
Sequence 2227	AI557059	Sequence 2279	AI755181
Sequence 2228	AI561260	Sequence 2280	AI758869
Sequence 2229	AI567988	Sequence 2281	AI761927
Sequence 2230	AI569715	Sequence 2282	AI763126
Sequence 2231	AI581291	Sequence 2283	AI791906
Sequence 2232	AI583211	Sequence 2284	AI793120
Sequence 2233	AI583570	Sequence 2285	AI799521
•		•	

Sequence 2286	A1804346	Sequence 2338	AL049959
Sequence 2287	Al808109	Sequence 2339	AL049987
Sequence 2288	AI811021	Sequence 2340	AL049999
Sequence 2289	AI811845	Sequence 2341	AL050011
Sequence 2290	AI814139	Sequence 2342	AL050089
Sequence 2291	AI814674	Sequence 2343	AL050141
Sequence 2292	AI815868	Sequence 2344	AL050171
Sequence 2293	AI822030	Sequence 2345	AL050187
Sequence 2294	AI827641	Sequence 2346	AL050198
Sequence 2295	Al859619	Sequence 2347	AL050217
Sequence 2296	A1864580	Sequence 2348	AL050392
Sequence 2297	A1878968	Sequence 2349	AL080062
Sequence 2298	AI879179	Sequence 2350	AL080186
Sequence 2299	AI879367	Sequence 2351	AL080235
Sequence 2300	A1879992	Sequence 2352	AL096857
Sequence 2301	AI888377	Sequence 2353	AL096858
Sequence 2302	Al911704	Sequence 2354	AL110197
Sequence 2303	AI911997	Sequence 2355	AL110235
Sequence 2304	AI912084	· Sequence 2356	AL:117237
Sequence 2305	Al916284	Sequence 2357	AL117499
Sequence 2306	Al916584	Sequence 2358	AL117534
Sequence 2307	AI923224	Sequence 2359	AL118999
Sequence 2308	Al924096	Sequence 2360	AL119085
Sequence 2309	Al928185	Sequence 2361	AL119157
Sequence 2310	AI929819	Sequence 2362	AW020479
Sequence 2311	AI936748	Sequence 2363	AW044114
Sequence 2312	AI950087	Sequence 2364	AW102841
Sequence 2313	AI955808	Sequence 2365	C02094
Sequence 2314	AJ001258	Sequence 2366	C16886
Sequence 2315	AJ002030	Sequence 2367	C18886
Sequence 2316	AJ006026	Sequence 2368	D00017
Sequence 2317	AJ011001	Sequence 2369	D00022
Sequence 2318	AJ011915	Sequence 2370	D00068
Sequence 2319	AJ012499	Sequence 2371	D00099
Sequence 2320	AJ223183	Sequence 2372	D00422
Sequence 2321	AL035802	Sequence 2373	D10495
Sequence 2322	AL035987	Sequence 2374	D13119
Sequence 2323	AL036801	Sequence 2375	D13287
Sequence 2324	AL037646	Sequence 2376	D13665
Sequence 2325	AL038985	Sequence 2377	D13866
Sequence 2326	AL039150	Sequence 2378	D14662
Sequence 2327	AL041780	Sequence 2379	D14697
Sequence 2328	AL044019	Sequence 2380	D14710
Sequence 2329	AL046804	Sequence 2381	D14812
Sequence 2330	AL049055	Sequence 2382	D15049
Sequence 2331	AL049227	Sequence 2383	D16431
Sequence 2332	AL049229	Sequence 2384	D16937
Sequence 2333	AL049296	Sequence 2385	D17188
Sequence 2334	AL049464	Sequence 2386	D17268
Sequence 2335	AL049953	Sequence 2387	D17409
Sequence 2336	AL049954	Sequence 2388	D17793
Sequence 2337	AL049955	Sequence 2389	D21063

Sequence 2390	D23660	Sequence 2442	E01650
Sequence 2391	D25542	Sequence 2443	E01797
Sequence 2392	D28759	Sequence 2444	E01813
Sequence 2393	D29677	Sequence 2445	E01827
	D31767	Sequence 2446	E01979
Sequence 2394	D31784	Sequence 2447	E02628
Sequence 2395	D31764	Sequence 2448	E02651
Sequence 2396		Sequence 2449	E03569
Sequence 2397	D31890	Sequence 2450	E06721
Sequence 2398	D37991	Sequence 2451	E07218
Sequence 2399	D38491	Sequence 2452	F28779
Sequence 2400	D38583	Sequence 2453	F30276
Sequence 2401	D43948	Sequence 2454	F31082
Sequence 2402	D43950	Sequence 2455	H03854
Sequence 2403	D45248	Sequence 2456	H05412
Sequence 2404	D45887		H08994
Sequence 2405	D45915	Sequence 2457	H13339
Sequence 2406	D49489	Sequence 2458	H16426
Sequence 2407	D49547	Sequence 2459	
Sequence 2408	D50310	Sequence 2460	H39960
Sequence 2409	D50371	Sequence 2461	H48742
Sequence 2410	D55192	Sequence 2462	H59372
Sequence 2411	D55649	Sequence 2463	H60722
Sequence 2412	D56120	Sequence 2464	H69238
Sequence 2413	D59253	Sequence 2465	H72481
Sequence 2414	D78586	Sequence 2466	H75695
Sequence 2415	D79826	Sequence 2467	H78517
Sequence 2416	D79983	Sequence 2468	H79084
Sequence 2417	D79986	Sequence 2469	H84729
Sequence 2418	D79997	Sequence 2470	H85709
Sequence 2419	D80006	Sequence 2471	H89654
Sequence 2420	D80012	Sequence 2472	J00269
Sequence 2421	D80087	Sequence 2473	J02621
Sequence 2422	D80253	Sequence 2474	J03005
Sequence 2423	D81635	Sequence 2475	J03040
Sequence 2424	D82128	Sequence 2476	J03171
Sequence 2425	D82348	Sequence 2477	J03191
Sequence 2426	D83197	Sequence 2478	J03210
Sequence 2427	D83327	Sequence 2479	J03464
Sequence 2428	D83784	Sequence 2480	J03473
Sequence 2429	D86227	Sequence 2481	J03799
Sequence 2430	D87437	Sequence 2482	J04080
Sequence 2431	D87442	Sequence 2483	J04164
Sequence 2432	D87470	Sequence 2484	J04177
Sequence 2433	D87666	Sequence 2485	J04765
Sequence 2434	D87667	Sequence 2486	J05013
Sequence 2435	D87682	Sequence 2487	J05021
Sequence 2436	D87735	Sequence 2488	J05192
Sequence 2437	D87969	Sequence 2489	J05633
Sequence 2438	D89052	Sequence 2490	K00558
Sequence 2439	D90226	Sequence 2491	K01566
Sequence 2440	D90373	Sequence 2492	K02765
Sequence 2441	E00882	Sequence 2493	L00160
•			

		2212	4404404
Sequence 2494	L02547	Sequence 2546	M24194
Sequence 2495	L05092	Sequence 2547	M25246
Sequence 2496	L05186	Sequence 2548	M26041
Sequence 2497	L07633	Sequence 2549	M26152
Sequence 2498	L11066	Sequence 2550	M26325
Sequence 2499	L11932	Sequence 2551	M27913
Sequence 2500	L12711	Sequence 2552	M27971
Sequence 2501	L13848	Sequence 2553	M28373
Sequence 2502	L14599	Sequence 2554	M31159
Sequence 2503	L19161	Sequence 2555	M31212
Sequence 2504	L19184	Sequence 2556	M31899
Sequence 2505	L19597	Sequence 2557	M32110
Sequence 2506	L20941	Sequence 2558	M32790
Sequence 2507	L23959	Sequence 2559	M32798
Sequence 2508	L26081	Sequence 2560	M33308
Sequence 2509	L27560	Sequence 2561	M34064
Sequence 2510	L28010	Sequence 2562	M37583
Sequence 2511	L28809	Sequence 2563	M38106
Sequence 2512	L33404	Sequence 2564	M55409
Sequence 2513	L33930	Sequence 2565	M55542
Sequence 2514	L:34155	Sequence 2566	M58485
Sequence 2515	L34839	Sequence 2567	M60457
Sequence 2516	L38486	Sequence 2568	M60854
Sequence 2517	L42024	Sequence 2569	M62403
Sequence 2518	L43575	Sequence 2570	M62810
Sequence 2519	L44349	Sequence 2571	M64241
Sequence 2520	L54057	Sequence 2572	M67468
Sequence 2521	M10036	Sequence 2573	M69181
Sequence 2522	M10119	Sequence 2574	M74002
Sequence 2523	M10905	Sequence 2575	M75126
Sequence 2524	M11146	Sequence 2576	M76729
Sequence 2525	M13573	Sequence 2577	M78113
Sequence 2526	M13955	Sequence 2578	M81757
Sequence 2527	M14083	Sequence 2579	M83248
Sequence 2528	M14483	Sequence 2580	M84739
Sequence 2529	M14630	Sequence 2581	M87503
Sequence 2530	M14631	Sequence 2582	M88279
Sequence 2531	M15182	Sequence 2583	M92357
Sequence 2532	M15800	Sequence 2584	N20576
Sequence 2533	M16247	Sequence 2585	N34255
Sequence 2534	M16553	Sequence 2586	N35187
Sequence 2535	M16660	Sequence 2587	N35421
Sequence 2536	M16937	Sequence 2588	N39717
Sequence 2537	M17597	Sequence 2589	N40823
Sequence 2538	M17885	Sequence 2590	N40852
Sequence 2539	M20372	Sequence 2591	N67927
Sequence 2540	M22146	Sequence 2592	N76180
Sequence 2541	M22382	Sequence 2593	N76677
Sequence 2542	M22590	Sequence 2594	N77080
Sequence 2543	M22918	Sequence 2595	N84497
Sequence 2544	M22920	Sequence 2596	N86776
Sequence 2545	M23613	Sequence 2597	N91638
ocquerioe 2040		•	

Sequence 2598	N92086	Sequence 2650	U20896
Sequence 2599	N99205	Sequence 2651	U22431
Sequence 2600	Q37741	Sequence 2652	U22815
Sequence 2601	Q48043	Sequence 2653	U24105
Sequence 2602	Q65676	Sequence 2654	U24153
Sequence 2603	Q90526	Sequence 2655	U27768
Sequence 2604	R06046	Sequence 2656	U33760
Sequence 2605	R17092	Sequence 2657	U33833
Sequence 2606	R47228	Sequence 2658	U34877
Sequence 2607	R55150	Sequence 2659	U39361
Sequence 2608	R55398	Sequence 2660	U41515
Sequence 2609	R68132	Sequence 2661	U46570
Sequence 2610	R72676	Sequence 2662	U5 073 3
Sequence 2611	R73306	Sequence 2663	U51586
Sequence 2612	R78333	Sequence 2664	U56255
Sequence 2613	R92367	Sequence 2665	U59305
Sequence 2614	R93637	Sequence 2666	U60975
Sequence 2615	R99649	Sequence 2667	U61083
Sequence 2616	S41458	Sequence 2668	U61397
Sequence 2617	S42303	Sequence 2669	U63846
Sequence 2618	S54005	Sequence 2670	U67784
Sequence 2619	S66431	Sequence 2671	U68723
Sequence 2620	S70154	Sequence 2672	U68727
Sequence 2621	S70290	Sequence 2673	U68758
Sequence 2622	S79895	Sequence 2674	U70735
Sequence 2623	S82076	Sequence 2675	U 7 7085
Sequence 2624	T02792	Sequence 2676	U79258
Sequence 2625	T24119	Sequence 2677	U79274
Sequence 2626	T49314	Sequence 2678	U79278
Sequence 2627	T53479	Sequence 2679	U80213
Sequence 2628	T58797	Sequence 2680	U81234
Sequence 2629	T64560	Sequence 2681	U82130
Sequence 2630	T66112	Sequence 2682	U86602
Sequence 2631	T92160	Sequence 2683	U87309
Sequence 2632	T92396	Sequence 2684	U90028
Sequence 2633	U00947	Sequence 2685	U90441
Sequence 2634	U04815	Sequence 2686	U90902
Sequence 2635	U07151	Sequence 2687	U90917
Sequence 2636	U07857	Sequence 2688	U94831
Sequence 2637	U08470	Sequence 2689	V00478
Sequence 2638	U10323	Sequence 2690	V00503
Sequence 2639	U10439	Sequence 2691	V05728
Sequence 2640	U12465	Sequence 2692	V11636
Sequence 2641	U13665	Sequence 2693	V57903
Sequence 2642	U13877	Sequence 2694	V59662
Sequence 2643	U14550	Sequence 2695	V59746
•	U14966	Sequence 2696	V84428
Sequence 2644	U15008	Sequence 2697	V86232
Sequence 2645	U16306	Sequence 2698	V87930
Sequence 2646	U17104	Sequence 2699	W07215
Sequence 2647	U17496	Sequence 2700	W19127
Sequence 2648	U19769	Sequence 2700 Sequence 2701	W19407
Sequence 2649	013703	Coquence 2701	

Sequence 2702	W19441	Sequence 2754	X71087
Sequence 2703	W25547	Sequence 2755	X73608
Sequence 2704	W26197	Sequence 2756	X73902
Sequence 2705	W38952	Sequence 2757	X74039
Sequence 2706	W56388	Sequence 2758	X74801
Sequence 2707	W68015	Sequence 2759	X74979
Sequence 2708	W73140	Sequence 2760	X76013
Sequence 2709	W73168	Sequence 2761	X76180
Sequence 2710	W76204	Sequence 2762	X78627
Sequence 2711	W87522	Sequence 2763	X81109
Sequence 2712	W87891	Sequence 2764	X82676
Sequence 2713	X00351	Sequence 2765	X84939
Sequence 2714	X00497	Sequence 2766	X85373
Sequence 2715	X01742	Sequence 2767	X93036
Sequence 2716	X01924	Sequence 2768	X93207
Sequence 2717	X03084	Sequence 2769	X94323
Sequence 2718	X04098	Sequence 2770	X94754
Sequence 2719	X04408	Sequence 2771	X97324
Sequence 2720	X04470	Sequence 2772	X99920
Sequence 2721	X05276	Sequence 2773	Y00503
Sequence 2722	X05908	Sequence 2774	Y00757
Sequence 2723	X06700	Sequence 2775	Y00815
Sequence 2724	X07819	Sequence 2776	Y09188
Sequence 2725	X13425	Sequence 2777	Y11435
Sequence 2726	X14420	Sequence 2778	Y12065
Sequence 2727	X15729	Sequence 2779	Y13247
Sequence 2728	X15880	Sequence 2780	Y13286
Sequence 2729	X16869	Sequence 2781	Y15286
Sequence 2730	X17206	Sequence 2782	Y17114
Sequence 2731	X24068	Sequence 2783	Z18538
Sequence 2732	X37385	Sequence 2784	Z18954
Sequence 2733	X37509	Sequence 2785	Z19054
Sequence 2734	X40178	Sequence 2786	Z21507
Sequence 2735	X51466	Sequence 2787	Z26317
Sequence 2736	X53505	Sequence 2788	Z29093
Sequence 2737	X54304	Sequence 2789	Z31696
Sequence 2738	X54941	Sequence 2790	Z32564
Sequence 2739	X55110	Sequence 2791	Z36531
Sequence 2740	X55885	Sequence 2792	Z37986
Sequence 2741	X56932	Sequence 2793	Z46629
Sequence 2742	X56998	Sequence 2794	Z47087
Sequence 2743	X56999	Sequence 2795	Z74615
Sequence 2744	X57766	·	
Sequence 2745	X62744		
Sequence 2746	X63432		
Sequence 2747	X66360		
Sequence 2748	X67698		
Sequence 2749	X68277		
Sequence 2750	X68880		
Sequence 2751	X69398		
Sequence 2752	X69838		
Sequence 2753	X70340		
•			

Sequence 340: found in patent publication W098/39446
AGGCGTNCCTCTGACTGCCCACTCAGTGGCNNCACCNGGGAGCTGNTTTGGNGCTTTGGG
GANCCTNAACANTTNCNTCTTTCAAAACTNACTGGC

Sequence 341: found in patent publication W099/039941
CCCTTAGCGNGGTCGCGGCCGAGGCACAATTCGATTATTCACANGAAAGGGCAAACTGTT
NNTGTTNGCTGGCAGGAGNAGGTGCATATATACCAGCACTTCAAGTNNGGTATTTCCATT
CAGGACATTTTATCTCTGTGCAAAGACCGGAGTAGAAGCTGATGAGTGGATCAAGATATT
ACGCTGGAAATTGTCACAAATAAGAAAACAGCTCAACCAAGGGGAAGGCACCGATCCGAT
CTCGGTCGTTCATCTTTAAATAGATCTTTCTTGCCAAGGAATGCTCTGGCCCAGGAGCAA
GGTGGAATGCTTCCCTGACGCTGCGATCTGCAGCAGACTNCAAATGAAAACCGACTAAGG
ATTTTCTTTCAAAAACAAATCAGAAGCAGATGCTGATTGGGACCCATATACCACGTTGCT
GACTCACCGTTGCTGCCCTTNCATGGATGTTGCCATCTGCTTGAGAACACTGAAGCAATC
ACCATTCTNGATANGAAAGTGCTTAAACCCCCACTCTTAGGGCTGCTCACTTCTTAGAAC
ACACAAAGGGAAGAGGAAAGGGGT

Sequence 1016: found in patent publication W099/38881
CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCCGCG
TCCGTGATAAACTACTTTTGGGTTTTATTTCATTGAGGCACTTTTTTTATTGTTTGAATG
ATTCCGGCTTGTAATATATCAGCCTCTACAATGAAATGCAGAAGAGTTCATTTTCTAG
ATCTGTTTTTCATTAGAAATATTGACAAATAACACATTGTCAACCTGGATCCTTTGACA
TTTACTTAACTCTGGCATGTTCACAAAAAGTAGAAACTCTAAGAGACCATTACCATTTT
TCACAGATGTATAGGGGATGTATTCTAAAAACTGACAGAAAAGAGAAATNTGATAGTCAAC
ACTGTTAACTTTTACTGNGTAATTGCCAAATACACTTTTCCAAATTTGTCCCAACAGCC
TNTAAGCCAGCTTTCTTCTATATTTATAA

PCT/US00/24199

TABLE 1A

30

			_		
patent seq name	acc	dbase	Sequence 52	AA112308	dbEST
Sequence 1	AA001066	dbEST	Sequence 53	AA112375	dbEST
Sequence 2	AA007157	dbEST	Sequence 54	AA113860	dbEST
Sequence 3	AA010954	dbEST	Sequence 55	AA114120	dbEST
Sequence 4	AA015792	dbEST	Sequence 56	AA115118	dbEST
Sequence 5	AA019769	dbEST	Sequence 57	AA115368	dbEST
Sequence 6	AA019948	dbEST	Sequence 58	AA122286	dbEST
Sequence 7	AA022925	dbEST	Sequence 59	AA122348	dbEST
Sequence 8	AA022937	dbEST	Sequence 60	AA126109	dbEST
Sequence 9	AA024405	dbEST	Sequence 61	AA127105	dbEST
Sequence 10	AA029750	dbEST	Sequence 62	AA127132	dbEST
Sequence 11	AA031509	dbEST	Sequence 63	AA127418	dbEST
Sequence 12	AA033876	dbEST	Sequence 64	AA128305	dbEST
Sequence 13	AA034237	dbEST	Sequence 65	AA129461	dbEST
Sequence 14	AA039967	dbEST	Sequence 66	AA130252	dbEST
Sequence 15	AA040073	dbEST	Sequence 67	AA130547	dbEST
Sequence 16	AA040122	dbEST	Sequence 68	AA130786	dbEST
Sequence 17	AA045732	dbEST	Sequence 69	AA131041	dbEST
Sequence 18	AA045861	dbEST	Sequence 70	AA131065	dbEST
Sequence 19	AA046835	dbEST	Sequence 71	AA131104	dbEST
Sequence 20	AA047026	dbEST	Sequence 72	AA131155	dbEST
Sequence 21	AA047417	dbEST	Sequence 73	AA131160	dbEST
Sequence 22	AA053486	dbEST	Sequence 74	AA132182	dbEST
Sequence 23	AA054658	dbEST	Sequence 75	AA132568	dbEST
Sequence 24	AA055606	dbEST	Sequence 76	AA132598	dbEST
Sequence 25	AA056113	dbEST	Sequence 77	AA133351	dbEST
Sequence 26	AA056176	dbEST	Sequence 78	AA133927	dbEST
Sequence 27	AA056363	dbEST	Sequence 79	AA134105	dbEST
Sequence 28	AA056431	dbEST	Sequence 80	AA134210	dbEST
Sequence 29	AA065336	dbEST	Sequence 81	AA135032	dbEST
Sequence 30	AA069781	dbEST	Sequence 82	AA135919	dbEST
Sequence 31	AA069784	dbEST	Sequence 83	AA136383	dbEST
Sequence 32	AA069839	dbEST	Sequence 84	AA136789	dbEST
Sequence 33	AA069983	dbEST	Sequence 85	AA143609	dbEST
Sequence 34	AA071255	dbEST	Sequence 86	AA146773	dbEST
Sequence 35	AA075135	dbEST	Sequence 87	AA147806	dbEST
Sequence 36	AA081655	dbEST	Sequence 88	AA148160	dbEST
Sequence 37	AA082245	dbEST	Sequence 89	AA148268	dbEST
Sequence 38	AA083471	dbEST	Sequence 90	AA148771	dbEST
Sequence 39	AA083510	dbEST	Sequence 91	AA149056	dbEST
Sequence 40	AA085862	dbEST	Sequence 92	AA150307	dbEST
Sequence 41	AA085872	dbEST	Sequence 93	AA151310	dbEST
Sequence 42	AA085947	dbEST	Sequence 94	AA151775	dbEST
Sequence 43	AA088770	dbEST	Sequence 95	AA152037	dbEST
Sequence 44	AA100333	dbEST	Sequence 96	AA152416	dbEST
Sequence 45	AA100719	dbEST	Sequence 97	AA155853	dbEST
Sequence 46	AA100793	dbEST	Sequence 98	AA155926	dbEST
Sequence 47	AA100852	dbEST	Sequence 99	AA157405	dbEST
Sequence 48	AA101270	dbEST	Sequence 100	AA157725	dbEST
Sequence 49	AA101561	dbEST	Sequence 101	AA157788	dbEST
Sequence 50	AA111907	dbEST	Sequence 102	AA158165	dbEST
Sequence 51	AA112043	dbEST	Sequence 103	AA158171	dbEST
-					

Sequence 104	AA159272	dbEST	Sequence 156	AA304961	dbEST
Sequence 105	AA160114	dbEST	Sequence 157	AA305193	dbEST
Sequence 106	AA160685	dbEST	Sequence 158	AA305438	dbEST
Sequence 107	AA161410	dbEST	Sequence 159	AA306542	dbEST
Sequence 108	AA164405	dbEST	Sequence 160	AA306708	dbEST
Sequence 109	AA164465	dbEST	Sequence 161	AA306945	dbEST
Sequence 110	AA165083	dbEST	Sequence 162	AA307239	dbEST
Sequence 111	AA165629	dbEST	Sequence 163	AA307477	dbEST
Sequence 112	AA166973	dbEST	Sequence 164	AA307504	dbEST
Sequence 113	AA171510	dbEST	Sequence 165	AA307697	dbEST
Sequence 114	AA173031	dbEST	Sequence 166	AA307779	dbEST
Sequence 115	AA173470	dbEST	Sequence 167	AA308062	dbEST
Sequence 116	AA173630	dbEST	Sequence 168	AA308801	dbEST
Sequence 117	AA179462	dbEST	Sequence 169	AA309028	dbEST
Sequence 118	AA187003	dbEST	Sequence 170	AA309988	dbEST
Sequence 119	AA187958	dbEST	Sequence 171	AA311006	dbEST
Sequence 120	AA188591	dbEST	Sequence 172	AA311481	dbEST
Sequence 121	AA192108	dbEST	Sequence 173	AA312012	dbEST
Sequence 122	AA199710	dbEST	Sequence 174	AA313684	dbEST
Sequence 123	AA203224	dbEST	Sequence 175	AA314146	dbEST
Sequence 124	AA203284	dbEST	Sequence 176	AA315049	dbEST
Sequence 125	AA205851	dbEST	Sequence 177	AA315308	dbEST
Sequence 126	AA209431	dbEST	Sequence 178	AA315426	dbEST
Sequence 127	AA209531	dbEST	Sequence 179	AA316682	dbEST
Sequence 128	AA214075	dbEST	Sequence 180	AA319958	dbEST
Sequence 129	AA216612	dbEST	Sequence 181	AA320346	dbEST
Sequence 130	AA224230	dbEST	Sequence 182	AA320991	dbEST
Sequence 131	AA224985	dbEST	Sequence 183	AA328544	dbEST
Sequence 132	AA226502	dbEST	Sequence 184	AA330457	dbEST
Sequence 133	AA229225	dbEST	Sequence 185	AA338793	dbEST
Sequence 134	AA232626	dbEST	Sequence 186	AA340069	dbEST
Sequence 135	AA233843	dbEST	Sequence 187	AA341170	dbEST
Sequence 136	AA242891	dbEST	Sequence 188	AA342394	dbEST
Sequence 137	AA250725	dbEST	Sequence 189	AA348250	dbEST
Sequence 138	AA250982	dbEST	Sequence 190	AA349148	dbEST
Sequence 139	AA256959	dbEST	Sequence 191	AA351443	dbEST
Sequence 140	AA259077	dbEST	Sequence 192	AA351880	dbEST
Sequence 141	AA262440	dbEST	Sequence 193	AA356158	dbEST
Sequence 142	AA263110	dbEST	Sequence 194	AA356187	dbEST
Sequence 143	AA283165	dbEST	Sequence 195	AA356195	dbEST
Sequence 144	AA285260	dbEST	Sequence 196	AA357374	dbEST
Sequence 145	AA287112	dbEST	Sequence 197	AA367446	dbEST
Sequence 146	AA292191	dbEST	Sequence 198	AA375236	dbEST
Sequence 147	AA292334	dbEST	Sequence 199	AA377718	dbEST
Sequence 148	AA292385	dbEST	Sequence 200	AA380997	dbEST
Sequence 149	AA292771	dbEST	Sequence 201	AA383917	dbEST
Sequence 150	AA293273	dbEST	Sequence 202	AA385147	dbEST
Sequence 151	AA293572	dbEST	Sequence 203	AA389641	dbEST
Sequence 152	AA295348	dbEST	Sequence 204	AA393164	dbEST
Sequence 153	AA295485	dbEST	Sequence 205	AA393236	dbEST
Sequence 154	AA301631	dbEST	Sequence 206	AA394242	dbEST
Sequence 155	AA304669	dbEST	Sequence 207	AA398732	dbEST
- 7					

Sequence 208	AA401864	dbEST	Sequence 260	AA573893	dbEST
Sequence 209	AA410508	dbEST	Sequence 261	AA574237	dbEST
Sequence 210	AA410580	dbEST	Sequence 262	AA576866	dbEST
Sequence 211	AA410942	dbEST	Sequence 263	AA579034	dbEST
Sequence 212	AA411334	dbEST	Sequence 264	AA579816	dbEST
Sequence 213	AA411599	dbEST	Sequence 265	AA581220	dbEST
Sequence 214	AA418061	dbEST	Sequence 266	AA581264	dbEST
Sequence 215	AA418473	dbEST	Sequence 267	AA582093	dbEST
Sequence 216	AA418970	dbEST	Sequence 268	AA583091	dbEST
Sequence 217	AA420789	dbEST	Sequence 269	AA584411	dbEST
Sequence 218	AA421682	dbEST	Sequence 270	AA586776	dbEST
Sequence 219	AA421850	dbEST	Sequence 271	AA587110	dbEST
Sequence 220	AA424529	dbEST	Sequence 272	AA587233	dbEST
Sequence 221	AA428421	dbEST	Sequence 273	AA587700	dbEST
Sequence 222	AA429754	dbEST	Sequence 274	AA609259	dbEST
Sequence 223	AA441787	dbEST	Sequence 275	AA609837	dbEST
Sequence 224	AA451633	dbEST	Sequence 276	AA613907	dbEST
Sequence 225	AA453309	dbEST	Sequence 277	AA614529	dbEST
Sequence 226	AA453559	dbEST	Sequence 278	AA618033	dbEST
Sequence 227	AA453570	dbEST	Sequence 279	AA628487	dbEST
Sequence 228	AA454871	dbEST	Sequence 280	AA631204	dbEST
Sequence 229	AA454913	dbEST	Sequence 281	AA631811	dbEST
Sequence 230	AA456892	dbEST	Sequence 282	AA640901	dbEST
Sequence 231	AA457048	dbEST	Sequence 283	AA641841	dbEST
Sequence 232	AA463426	dbEST	Sequence 284	AA642215	dbEST
Sequence 233	AA465039	dbEST	Sequence 285	AA643602	dbEST
Sequence 234	AA477173	dbEST	Sequence 286	AA651720	dbEST
Sequence 235	AA480921	dbEST	Sequence 287	AA664996	dbEST
Sequence 236	AA484050	dbEST	Sequence 288	AA668297	dbEST
Sequence 237	AA484756	dbEST	Sequence 289	AA668836	dbEST
Sequence 238	AA487483	dbEST	Sequence 290	AA675923	dbEST
Sequence 239	AA489640	dbEST	Sequence 291	AA687833	dbEST
Sequence 240	AA493886	dbEST	Sequence 292	AA704992	dbEST
Sequence 241	AA494493	dbEST	Sequence 293	AA732702	dbEST
Sequence 242	AA496518	dbEST	Sequence 294	AA745241	dbEST
Sequence 243	AA501749	dbEST	Sequence 295	AA746481	dbEST
Sequence 244	AA501822	dbEST	Sequence 296	AA758889	dbEST
Sequence 245	AA501945	dbEST	Sequence 297	AA772570	dbEST
Sequence 246	AA504490	dbEST	Sequence 298	AA772790	dbEST
Sequence 247	AA507234	dbEST	Sequence 299	AA776709	dbEST
Sequence 248	AA513640	dbEST	Sequence 300	AA776811	dbEST
Sequence 249	AA526227	dbEST	Sequence 301	AA777384	dbEST
Sequence 250	AA526889	dbEST	Sequence 302	AA778116	dbEST
Sequence 251	AA527139	dbEST	Sequence 303	AA779868	dbEST
Sequence 252	AA527188	dbEST	Sequence 304	AA781343	dbEST
Sequence 253	AA531428	dbEST	Sequence 305	AA809984	dbEST
Sequence 254	AA532633	dbEST	Sequence 306	AA810945	dbEST
Sequence 255	AA535471	dbEST	Sequence 307	AA811200	dbEST
Sequence 256	AA554757	dbEST	Sequence 308	AA825768	dbEST
Sequence 257	AA565996	dbEST	Sequence 309	AA828073	dbEST
Sequence 258	AA568217	dbEST	Sequence 310	AA828722	dbEST
Sequence 259	AA573742	dbEST	Sequence 311	AA843176	dbEST
	-		•		-

Sequence 312	AA843661	dbEST	Sequence 364	AF038451	ANUC
Sequence 313	AA876526	dbEST	Sequence 365	AF038662	ANUC
Sequence 314	AA883255	dbEST	Sequence 366	AF038963	ANUC
Sequence 315	AA906652	dbEST	Sequence 367	AF043431	ANUC
Sequence 316	AA917638	dbEST	Sequence 368	AF044956	ANUC
Sequence 317	AA927734	dbEST	Sequence 369	AF045941	ANUC
Sequence 318	AA954939	dbEST	Sequence 370	AF046997	ANUC
Sequence 319	AA962622	dbEST	Sequence 371	AF051894	ANUC
Sequence 320	AA991285	dbEST	Sequence 372	AF052124	ANUC
Sequence 321	AB000115	ANUC	Sequence 373	AF052578	ANUC
Sequence 322	AB004047	ANUC	Sequence 374	AF053233	ANUC
Sequence 323	AB006746	ANUC	Sequence 375	AF054838	ANUC
Sequence 324	AB007619	ANUC	Sequence 376	AF055012	ANUC
Sequence 325	AB007860	ANUC	Sequence 377	AF061736	ANUC
Sequence 326	AB007965	ANUC	Sequence 378	AF061738	ANUC
Sequence 327	AB011101	ANUC	Sequence 379	AF064603	ANUC
Sequence 328	AB011169	ANUC	Sequence 380	AF064854	ANUC
Sequence 329	AB012701	ANUC	Sequence 381	AF065388	ANUC
Sequence 330	AB014536	ANUC	Sequence 382	AF067168	ANUC
Sequence 331	AB014565	ANUC	Sequence 383	AF067174	ANUC
Sequence 332	AB019568	ANUC	Sequence 384	AF067817	ANUC
Sequence 333	AB020623	ANUC	Sequence 385	AF070523	ANUC
Sequence 334	AB020629	ANUC	Sequence 386	AF070561	ANUC
Sequence 335	AB020693	ANUC	Sequence 387	AF070562	ANUC
Sequence 336	AB021288	ANUC	Sequence 388	AF070596	ANUC
Sequence 337	AB022663	ANUC	Sequence 389	AF070664	ANUC
Sequence 338	AB023214	ANUC	Sequence 390	AF070674	ANUC
Sequence 339	AB023230	ANUC	Sequence 391	AF077048	ANUC
Sequence 340	AC02059	PREPATNUC	Sequence 392	AF077051	ANUC
Sequence 341	AC03653	PREPATNUC	Sequence 393	AF077200	ANUC
Sequence 342	AC13415	PREPATNUC	Sequence 394	AF077671	ANUC
Sequence 343	AF000982	ANUC	Sequence 395	AF080246	ANUC
Sequence 344	AF002985	ANUC	Sequence 396	AF081484	ANUC
Sequence 345	AF005654	ANUC	Sequence 397	AF083470	ANUC
Sequence 346	AF006086	ANUC	Sequence 398	AF084523	ANUC
_ ·	AF007791	ANUC	Sequence 399	AF085355	ANUC
Sequence 347 Sequence 348	AF013758	ANUC	Sequence 400	AF086003	ANUC
Sequence 349	AF013988	ANUC	Sequence 401	AF086080	ANUC
•	AF021232	ANUC	Sequence 402	AF086183	ANUC
Sequence 350	AF021232 AF026939	ANUC	Sequence 403	AF086545	ANUC
Sequence 351	AF026941	ANUC	Sequence 403	AF091263	ANUC
Sequence 352	AF026941	ANUC	Sequence 405	AF111713	ANUC
Sequence 353			Sequence 405 Sequence 406	AF118023	ANUC
Sequence 354	AF026943 AF026944	ANUC	Sequence 400	AF124438	ANUC
Sequence 355		ANUC	•	AF124439	ANUC
Sequence 356	AF028832	ANUC	Sequence 408 Sequence 409	AF124439 AF131808	ANUC
Sequence 357	AF030455	ANUC	*		ANUC
Sequence 358	AF030514	ANUC	Sequence 410	AF131820	ANUC
Sequence 359	AF031469	ANUC	Sequence 411	AF131848	
Sequence 360	AF033095	ANUC	Sequence 412	AF132966	ANUC
Sequence 361	AF035286	ANUC	Sequence 413	AF132968	ANUC
Sequence 362	AF035316	ANUC	Sequence 414	AF146277	ANUC
Sequence 363	AF037204	ANUC	Sequence 415	AF147331	ANUC

Sequence 416	AF150100	ANUC	Sequence 468	Al417973	dbEST
Sequence 417	AF150266	dbEST	Sequence 469	Al431963	dbEST
Sequence 418	AF151873	ANUC	Sequence 470	AI453405	dbEST
Sequence 419	AF151877	ANUC	Sequence 471	Al457157	dbEST
Sequence 420	AF151978	ANUC	Sequence 472	Al457624	dbEST
Sequence 421	AF167160	ANUC	Sequence 473	Al459679	dbEST
Sequence 422	AI023413	dbEST	Sequence 474	Al460010	dbEST
Sequence 423	AI027888	dbEST	Sequence 475	Al469095	dbEST
Sequence 424	Al031811	dbEST	Sequence 476	Al469715	dbEST
Sequence 425	AI033687	dbEST	Sequence 477	Al471539	dbEST
Sequence 426	AI042140	dbEST	Sequence 478	AI476335	dbEST
Sequence 427	AI075324	dbEST	Sequence 479	Al479289	dbEST
Sequence 428	AI075876	dbEST	Sequence 480	Al499285	dbEST
Sequence 429	AI126802	dbEST	Sequence 481	AI521180	dbEST
Sequence 430	AI127556	dbEST	Sequence 482	AI538061	dbEST
Sequence 431	AI129360	dbEST	Sequence 483	AI567204	dbEST
Sequence 432	AI139456	dbEST	Sequence 484	AI587104	dbEST
Sequence 433	AI140291	dbEST	Sequence 485	Al587328	dbEST
Sequence 434	AI144215	dbEST	Sequence 486	AI609624	dbEST
Sequence 435	AI161378	dbEST	Sequence 487	AI610607	dbEST
Sequence 436	AI188638	dbEST	Sequence 488	Al612873	dbEST
Sequence 437	AI215617	dbEST	Sequence 489	Al627444	dbEST
Sequence 438	AI216969	dbEST	Sequence 490	Al632869	dbEST
Sequence 439	Al241578	dbEST	Sequence 491	Al633164	dbEST
Sequence 440	AI250167	dbEST	Sequence 492	Al636014	dbEST
Sequence 441	AI253330	dbEST	Sequence 493	Al637620	dbEST
Sequence 442	AI253335	dbEST	Sequence 494	AI676218	dbEST
Sequence 443	AI253369	dbEST	Sequence 495	AI683871	dbEST
Sequence 444	AI253436	dbEST	Sequence 496	Al684170	dbEST
Sequence 445	Al261671	dbEST	Sequence 497	AI693877	dbEST
Sequence 446	Al262264	dbEST	Sequence 498	Al694088	dbEST
Sequence 447	Al267162	dbEST	Sequence 499	AJ732534	dbEST
Sequence 448	Al267379	dbEST	Sequence 500	AI743595	dbEST
Sequence 449	AI267502	dbEST	Sequence 501	AI744489	dbEST
Sequence 450	Al267622	dbEST	Sequence 502	AI745058	dbEST
Sequence 451	Al279131	dbEST	Sequence 503	AI753108	dbEST
Sequence 452	Al285943	dbEST	Sequence 504	AJ791322	dbEST
Sequence 453	Al289173	dbEST	Sequence 505	AI798474	dbEST
Sequence 454	AI290876	dbEST	Sequence 506	A1803838	dbEST
Sequence 455	Al292104	dbEST	Sequence 507	AI811960	dbEST
Sequence 456	Al300033	dbEST	Sequence 508	AI813617	dbEST
Sequence 457	Al300074	dbEST	Sequence 509	AI815829	dbEST
Sequence 458	Al312113	dbEST	Sequence 510	AI826957	dbEST
Sequence 459	Al336032	dbEST	Sequence 511	AI831002	dbEST
Sequence 460	Al337069	dbEST	Sequence 512	AI863041	dbEST
Sequence 461	Al340262	dbEST	Sequence 513	AI867294	dbEST
Sequence 462	Al346975	dbEST	Sequence 514	Al912076	dbEST
Sequence 463	Al354639	dbEST	Sequence 515	AI915553	dbEST
Sequence 464	Al366381	dbEST	Sequence 516	AJ001381	ANUC
Sequence 465	Al369024	dbEST	Sequence 517	AJ003401	dbEST
Sequence 466	Al382020	dbEST	Sequence 518	AJ010071	ANUC
Sequence 467	AI400372	dbEST	Sequence 519	AJ132502	ANUC
•					

Sequence 520	AL044356	dbEST	Sequence 572	E01197	ANUC
Sequence 521	AL044825	dbEST	Sequence 573	E01198	ANUC
Sequence 522	AL047024	dbEST	Sequence 574	E01630	ANUC
Sequence 523	AL048393	dbEST	Sequence 575	E01954	ANUC
Sequence 524	AL049313	ANUC	Sequence 576	E01971	ANUC
Sequence 525	AL049923	ANUC	Sequence 577	E01972	ANUC
Sequence 526	AL049954	ANUC	Sequence 578	E02628	ANUC
Sequence 527	AL050024	ANUC	Sequence 579	E03569	ANUC
Sequence 528	AL050272	ANUC	Sequence 580	E03879	ANUC
Sequence 529	AL050395	ANUC	Sequence 581	E08663	ANUC
Sequence 530	AL096714	ANUC	Sequence 582	F06593	dbEST
Sequence 531	AL096748	ANUC	Sequence 583	F28779	dbEST
Sequence 532	AL096842	ANUC	Sequence 584	H25806	dbEST
Sequence 533	AL110124	ANUC	Sequence 585	H47546	dbEST
Sequence 534	C17346	dbEST	Sequence 586	H48873	dbEST
Sequence 535	D00017	ANUC	Sequence 587	H66467	dbEST
Sequence 536	D00068	ANUC	Sequence 588	H88415	dbEST
Sequence 537	D11960	dbEST	Sequence 589	J00196	ANUC
Sequence 538	D12502	ANUC	Sequence 590	J03575	ANUC
Sequence 539	D12763	ANUC	Sequence 591	J03858	ANUC
Sequence 540	D13380	ANUC	Sequence 592	J03909	ANUC
Sequence 541	D13645	ANUC	Sequence 593	J04164	ANUC
Sequence 542	D13866	ANUC	Sequence 594	K00422	ANUC
Sequence 543	D14697	ANUC	Sequence 595	K01763	ANUC
Sequence 544	D21260	ANUC	Sequence 596	L00693	ANUC
Sequence 545	D23660	ANUC	Sequence 597	L02426	ANUC
Sequence 546	D26155	ANUC	Sequence 598	L06328	ANUC
Sequence 547	D26599	ANUC	Sequence 599	L 0 9159	ANUC
Sequence 548	D28759	ANUC	Sequence 600	L10413	ANUC
Sequence 549	D29640	ANUC	Sequence 601	L11066	ANUC
Sequence 550	D31763	ANUC	Sequence 602	L20688	ANUC
Sequence 551	D31767	ANUC	Sequence 603	L20941	ANUC
Sequence 552	D31883	ANUC	Sequence 604	L28997	ANUC
Sequence 553	D38524	ANUC	Sequence 605	L38995	ANUC
Sequence 554	D42040	ANUC	Sequence 606	L41490	ANUC
Sequence 555	D45248	ANUC	Sequence 607	M10119	ANUC
Sequence 556	D49396	ANUC	Sequence 608	M13536	ANUC
Sequence 557	D50372	ANUC	Sequence 609	M14328	ANUC
Sequence 558	D50420	ANUC	Sequence 610	M14764	ANUC
Sequence 559	D55653	ANUC	Sequence 611	M15329	ANUC
Sequence 560	D81522	dbEST	Sequence 612	M16660	ANUC
Sequence 561	D83077	ANUC	Sequence 613	M17017	ANUC
Sequence 562	D83767	ANUC	Sequence 614	M18216	ANUC
Sequence 563	D86958	ANUC	Sequence 615	M19723	ANUC
Sequence 564	D86979	ANUC	Sequence 616	M22918	ANUC
Sequence 565	D87666	ANUC	Sequence 617	M23613	ANUC
Sequence 566	D87667	ANUC	Sequence 618	M24194	ANUC
Sequence 567	D87735	ANUC	Sequence 619	M24594	ANUC
Sequence 568	D88532	ANUC	Sequence 620	M26152	ANUC
Sequence 569	D89053	ANUC	Sequence 621	M29540	ANUC
Sequence 570	D90311	ANUC	Sequence 622	M29541	ANUC
Sequence 571	D90453	ANUC	Sequence 623	M29551	ANUC

Sequence 624	M33146	ANUC	Sequence 676	U07550	ANUC
Sequence 625	M34064	ANUC	Sequence 677	U07857	ANUC
Sequence 626	M34455	ANUC	Sequence 678	U08815	ANUC
Sequence 627	M35198	ANUC	Sequence 679	U09559	ANUC .
Sequence 628	M36693	ANUC	Sequence 680	U09847	ANUC
Sequence 629	M37716	ANUC	Sequence 681	U10439	ANUC
Sequence 630	M55268	ANUC	Sequence 682	U14966	ANUC
Sequence 631	M55542	ANUC	Sequence 683	U18321	ANUC
Sequence 632	M55543	ANUC	Sequence 684	U19878	ANUC
Sequence 633	M57567	ANUC	Sequence 685	U23942	ANUC
Sequence 634	M60333	ANUC	Sequence 686	U25789	ANUC
Sequence 635	M61715	ANUC	Sequence 687	U28249	ANUC
Sequence 636	M62831	ANUC	Sequence 688	U28964	ANUC
Sequence 637	M63121	ANUC	Sequence 689	U32500	ANUC
Sequence 638	M63838	ANUC	Sequence 690	U32944	ANUC
Sequence 639	M68520	ANUC	Sequence 691	U33760	ANUC
Sequence 640	M77945	dbEST	Sequence 692	U37230	ANUC
Sequence 641	M80563	ANUC	Sequence 693	U37518	ANUC
Sequence 642	M81757	ANUC	Sequence 694	U38292	ANUC
Sequence 643	M83248	ANUC	Sequence 695	U38784	ANUC
Sequence 644	M83654	ANUC	Sequence 696	U41371	ANUC
Sequence 645	M86553	ANUC	Sequence 697	U41515	ANUC
Sequence 646	M87284	ANUC	Sequence 698	U52513	ANUC
Sequence 647	M87434	ANUC	Sequence 699	U56255	ANUC
Sequence 648	M87503	ANUC	Sequence 700	U57847	ANUC
Sequence 649	M92357	ANUC	Sequence 701	U61083	ANUC
Sequence 650	M96982	ANUC	Sequence 702	U68758	ANUC
Sequence 651	M97501	ANUC	Sequence 703	U73524	ANUC
Sequence 652	M97935	ANUC	Sequence 704	U77085	ANUC
Sequence 653	N36346	dbEST	Sequence 705	U78722	ANUC
Sequence 654	N51262	dbEST	Sequence 706	U79751	ANUC
Sequence 655	N57413	dbEST	Sequence 707	U94586	ANUC
Sequence 656	N78477	dbEST	Sequence 708	V00572	ANUC
Sequence 657	N92060	dbEST	Sequence 709	V00594	ANUC
Sequence 658	Q21065	NUCPATENT	Sequence 710	V04202	NUCPATENT
Sequence 659	Q94780	NUCPATENT	Sequence 711	V17906	NUCPATENT
Sequence 660	R13925	dbEST	Sequence 712	V36078	NUCPATENT
Sequence 661	R51732	dbEST	Sequence 713	V68140	NUCPATENT
Sequence 662	R56461	dbEST	Sequence 714	V86134	NUCPATENT
Sequence 663	R66489	dbEST	Sequence 715	W02908	dbEST
Sequence 664	R75621	dbEST	Sequence 716	W05711	dbEST
Sequence 665	S45630	ANUC	Sequence 717	W07308	dbEST
Sequence 666	S70290	ANUC	Sequence 718	W25547	dbEST
Sequence 667	S75295	ANUC	Sequence 719	W28837	dbEST
Sequence 668	S76638	ANUC	Sequence 720	W37272	dbEST
Sequence 669	T34641	dbEST	Sequence 721	W38644	dbEST
Sequence 670	T50925	NUCPATENT	Sequence 722	W39262	dbEST
Sequence 671	T52715	dbEST	Sequence 723	W39498	dbEST
Sequence 672	T54951	dbEST	Sequence 724	W52254	dbEST
Sequence 673	T70793	dbEST	Sequence 725	W74319	dbEST
Sequence 674	U03886	ANUC	Sequence 726	W77987	dbEST
Sequence 675	U04313	ANUC	Sequence 727	W80480	dbEST
•					

Sequence 728	X00637	ANUC	Sequence 780	AA028164	dbEST
Sequence 729	X01742	ANUC	Sequence 781	AA035775	dbEST
Sequence 730	X02530	ANUC	Sequence 782	AA037294	dbEST
Sequence 731	X02661	ANUC	Sequence 783	AA039967	dbEST
Sequence 732	X04316	NUCPATENT	Sequence 784	AA045637	dbEST
Sequence 733	X04371	ANUC	Sequence 785	AA046815	dbEST
Sequence 734	X04470	ANUC	Sequence 786	AA046853	dbEST
Sequence 735	X05908	ANUC	Sequence 787	AA047052	dbEST
Sequence 736	X07819	ANUC	Sequence 788	AA047213	dbEST
Sequence 737	X13238	ANUC	Sequence 789	AA057071	dbEST
Sequence 738	X15674	ANUC	Sequence 790	AA058933	dbEST
Sequence 739	X15729	ANUC	Sequence 791	AA064952	dbEST
Sequence 740	X16354	ANUC	Sequence 792	AA075089	dbEST
Sequence 741	X16356	ANUC	Sequence 793	AA076291	dbEST
Sequence 742	X16455	ANUC	Sequence 794	AA078508	dbEST
Sequence 743	X17025	ANUC	Sequence 795	AA080864	dbEST
Sequence 744	X20432	NUCPATENT	Sequence 796	AA083345	dbEST
Sequence 745	X30167	NUCPATENT	Sequence 797	AA083693	dbEST
Sequence 746	X33937	NUCPATENT	Sequence 798	AA085497	dbEST
Sequence 747	X35726	NUCPATENT	Sequence 799	AA086463	dbEST
Sequence 748	X41105	NUCPATENT	Sequence 800	AA093935	dbEST
Sequence 749	X51841	ANUC	Sequence 801	AA100291	dbEST
Sequence 750	X54941	ANUC	Sequence 802	AA101207	dbEST
Sequence 751	X56932	ANUC	Sequence 803	AA102403	dbEST
Sequence 752	X57351	ANUC	Sequence 804	AA111856	dbEST
Sequence 753	X59710	ANUC	Sequence 805	AA115174	dbEST
Sequence 754	X65614	ANUC	Sequence 806	AA122134	dbEST
Sequence 755	X67951	ANUC	Sequence 807	AA122291	dbEST
Sequence 756	X68060	ANUC	Sequence 808	AA125780	dbEST
Sequence 757	X68277	ANUC	Sequence 809	AA127322	dbEST
Sequence 758	X72790	ANUC	Sequence 810	AA130432	dbEST
Sequence 759	X76488	ANUC	Sequence 811	AA131801	dbEST
Sequence 760	X83544	ANUC	Sequence 812	AA132445	dbEST
Sequence 761	X85134	ANUC	Sequence 813	AA134109	dbEST
Sequence 762	X87949	ANUC	Sequence 814	AA135924	dbEST
Sequence 763	X93036	ANUC	Sequence 815	AA136322	dbEST
Sequence 764	X99699	ANUC	Sequence 816	AA143034	dbEST
Sequence 765	X99920	ANUC	Sequence 817	AA150057	dbEST
Sequence 766	Y09267	ANUC	Sequence 818	AA151651	dbEST
Sequence 767	Y13323	ANUC	Sequence 819	AA156335	dbEST
Sequence 768	Y17392	ANUC	Sequence 820	AA157333	dbEST
Sequence 769	Z12830	ANUC	Sequence 821	AA158987	dbEST
Sequence 770	Z36815	ANUC	Sequence 822	AA165439	dbEST
Sequence 771	Z47087	ANUC	Sequence 823	AA165632	dbEST
Sequence 772	Z48570	ANUC	Sequence 824	AA166618	dbEST
Sequence 773	Z 71389	ANUC	Sequence 825	AA172067	dbEST
Sequence 774	AA002223	dbEST	Sequence 826	AA173031	dbEST
Sequence 775	AA018843	dbEST	Sequence 827	AA178870	dbEST
Sequence 776	AA021647	dbEST	Sequence 828	AA181874	dbEST
Sequence 777	AA022842	dbEST	Sequence 829	AA195194	dbEST
Sequence 778	AA022965	dbEST	Sequence 830	AA203206	dbEST
Sequence 779	AA024522	dbEST	Sequence 831	AA203289	dbEST

Sequence 832	AA204768	dbEST	Sequence 884	AA447735	dbEST
Sequence 833	AA206621	dbEST	Sequence 885	AA449054	dbEST
Sequence 834	AA213914	dbEST	Sequence 886	AA449205	dbEST
Sequence 835	AA218919	dbEST	Sequence 887	AA449520	dbEST
Sequence 836	AA224050	dbEST	Sequence 888	AA452273	dbEST
Sequence 837	AA224244	dbEST	Sequence 889	AA455007	dbEST
Sequence 838	AA227596	dbEST	Sequence 890	AA455104	dbEST
Sequence 839	AA229018	dbEST	Sequence 891	AA459527	dbEST
Sequence 840	AA229161	dbEST	Sequence 892	AA460226	dbEST
Sequence 841	AA236445	dbEST	Sequence 893	AA461287	dbEST
Sequence 842	AA236680	dbEST	Sequence 894	AA464526	dbEST
Sequence 843	AA243537	dbEST	Sequence 895	AA468398	dbEST
Sequence 844	AA252436	dbEST	Sequence 896	AA469135	dbEST
Sequence 845	AA252869	dbEST	Sequence 897	AA469453	dbEST
Sequence 846	AA256330	dbEST	Sequence 898	AA470690	dbEST
Sequence 847	AA262700	dbEST	Sequence 899	AA479427	dbEST
Sequence 848	AA278358	dbEST	Sequence 900	AA480336	dbEST
Sequence 849	AA287076	dbEST	Sequence 901	AA483454	dbEST
Sequence 850	AA291551	dbEST	Sequence 902	AA487669	dbEST
Sequence 851	AA293273	dbEST	Sequence 903	AA488423	dbEST
Sequence 852	AA295982	dbEST	Sequence 904	AA488635	dbEST
Sequence 853	AA301675	dbEST	Sequence 905	AA488843	dbEST
Sequence 854	AA301722	dbEST	Sequence 906	AA489772	dbEST
Sequence 855	AA302964	dbEST	Sequence 907	AA503972	dbEST
Sequence 856	AA303199	dbEST	Sequence 908	AA508506	dbEST
Sequence 857	AA304927	dbEST	Sequence 909	AA513550	dbEST
Sequence 858	AA305042	dbEST	Sequence 910	AA513783	dbEST
Sequence 859	AA305635	dbEST	Sequence 911	AA514989	dbEST
Sequence 860	AA315030	dbEST	Sequence 912	AA516400	dbEST
Sequence 861	AA315943	dbEST	Sequence 913	AA520993	dbEST
Sequence 862	AA317144	dbEST	Sequence 914	AA521110	dbEST
Sequence 863	AA326060	dbEST	Sequence 915	AA523639	dbEST
Sequence 864	AA327358	dbEST	Sequence 916	AA523697	dbEST
Sequence 865	AA336387	dbEST	Sequence 917	AA528106	dbEST
Sequence 866	AA346413	dbEST	Sequence 918	AA528190	dbEST
Sequence 867	AA352580	dbEST	Sequence 919	AA528226	dbEST
Sequence 868	AA363162	dbEST	Sequence 920	AA534830	dbEST
Sequence 869	AA375754	dbEST	Sequence 921	AA548722	dbEST
Sequence 870	AA399230	dbEST	Sequence 922	AA551236	dbEST
Sequence 871	AA400249	dbEST	Sequence 923	AA551243	dbEST
Sequence 872	AA401629	dbEST	Sequence 924	AA558778	dbEST
Sequence 873	AA402885	dbEST	Sequence 925	AA563834	dbEST
Sequence 874	AA406401	dbEST	Sequence 926	AA576432	dbEST
Sequence 875	AA421682	dbEST	Sequence 927	AA580069	dbEST
Sequence 876	AA422057	dbEST	Sequence 928	AA580294	dbEST
Sequence 877	AA424445	dbEST	Sequence 929	AA582588	dbEST
Sequence 878	AA424901	dbEST	Sequence 930	AA584304	dbEST
Sequence 879	AA424984	dbEST	Sequence 931	AA588772	dbEST
Sequence 880	AA425182	dbEST	Sequence 932	AA593075	dbEST
Sequence 881	AA428607	dbEST	Sequence 933	AA595585	dbEST
Sequence 882	AA446099	dbEST	Sequence 934	AA601895	dbEST
Sequence 883	AA446403	dbEST	Sequence 935	AA628700	dbEST
504601100 000		,	•		

Sequence 936	AA630326	dbEST	Sequence 988	AA902644	dbEST
Sequence 937	AA630642	dbEST	Sequence 989	AA909144	dbEST
Sequence 938	AA631178	dbEST	Sequence 990	AA913281	dbEST
Sequence 939	AA631218	dbEST	Sequence 991	AA916756	dbEST
Sequence 940	AA633550	dbEST	Sequence 992	AA922420	dbEST
Sequence 941	AA634808	dbEST	Sequence 993	AA927283	dbEST
Sequence 942	AA639199	dbEST	Sequence 994	AA933075	dbEST
Sequence 943	AA639791	dbEST	Sequence 995	AA935979	dbEST
Sequence 944	AA644273	dbEST	Sequence 996	AA937947	dbEST
Sequence 945	AA648897	dbEST	Sequence 997	AA948295	dbEST
Sequence 946	AA664732	dbEST	Sequence 998	AA969131	dbEST
Sequence 947	AA677550	dbEST	Sequence 999	AA971881	dbEST
Sequence 948	AA687308	dbEST	Sequence 1000	AA973019	dbEST
Sequence 949	AA705002	dbEST	Sequence 1001	AA988923	dbEST
Sequence 950	AA706685	dbEST	Sequence 1002	AA989465	dbEST
Sequence 951	AA708266	dbEST	Sequence 1003	AA994023	dbEST
Sequence 952	AA713687	dbEST	Sequence 1004	AB002310	ANUC
Sequence 953	AA719618	dbEST	Sequence 1005	AB002330	ANUC
Sequence 954	AA719674	dbEST	Sequence 1006	AB007944	ANUC
Sequence 955	AA720572	dbEST	Sequence 1007	AB012911	ANUC
Sequence 956	AA721752	dbEST	Sequence 1008	AB017019	ANUC
Sequence 957	AA723612	dbEST	Sequence 1009	AB018266	ANUC
Sequence 958	AA730571	dbEST	Sequence 1010	AB018305	ANUC
Sequence 959	AA742282	dbEST	Sequence 1011	AB018347	ANUC
Sequence 960	AA748437	dbEST	Sequence 1012	AB019568	ANUC
Sequence 961	AA749187	dbEST	Sequence 1013	AB023158	ANUC
Sequence 962	AA761602	dbEST	Sequence 1014	AB028976	ANUC
Sequence 963	AA768355	dbEST	Sequence 1015	AB029005	ANUC
Sequence 964	AA769127	dbEST	Sequence 1016	AC28164	PREPATNUC
Sequence 965	AA774030	dbEST	Sequence 1017	AD001528	ANUC
Sequence 966	AA774247	dbEST	Sequence 1018	AF000231	ANUC
Sequence 967	AA779631	dbEST	Sequence 1019	AF006088	ANUC
Sequence 968	AA808747	dbEST	Sequence 1020	AF006516	ANUC
Sequence 969	AA809854	dbEST	Sequence 1021	AF012072	ANUC
Sequence 970	AA810859	dbEST	Sequence 1022	AF026947	ANUC
Sequence 971	AA825673	dbEST	Sequence 1023	AF028832	ANUC
Sequence 972	AA825768	dbEST	Sequence 1024	AF030424	ANUC
Sequence 973	AA826517	dbEST	Sequence 1025	AF031379	ANUC
Sequence 974	AA827331	dbEST	Sequence 1026	AF035287	ANUC
Sequence 975	AA827764	dbEST	Sequence 1027	AF035309	ANUC
Sequence 976	AA829511	dbEST	Sequence 1028	AF038197	ANUC
Sequence 977	AA831603	dbEST	Sequence 1029	AF038404	ANUC
Sequence 978	AA836991	dbEST	Sequence 1030	AF043431	ANUC
Sequence 979	AA837254	dbEST	Sequence 1031	AF044670	ANUC
Sequence 980	AA846480	dbEST	Sequence 1032	AF044958	ANUC
Sequence 981	AA846840	dbEST	Sequence 1033	AF047184	ANUC
Sequence 982	AA853515	dbEST	Sequence 1034	AF052164	ANUC
Sequence 983	AA883212	dbEST	Sequence 1035	AF052496	dbEST
Sequence 984	AA886885	dbEST	Sequence 1036	AF052578	ANUC
Sequence 985	AA889485	dbEST	Sequence 1037	AF054990	ANUC
Sequence 986	AA897461	dbEST	Sequence 1038	AF059524	ANUC
Sequence 987	AA902582	dbEST	Sequence 1039	AF070561	ANUC

Sequence 1040	AF070626	ANUC	Sequence 1092	Al373032	dbEST
Sequence 1041	AF070655	ANUC	Sequence 1093	Al374954	dbEST
Sequence 1042	AF070674	ANUC	Sequence 1094	AI380539	dbEST
Sequence 1043	AF075040	ANUC	Sequence 1095	Al417583	dbEST
Sequence 1044	AF077030	ANUC	Sequence 1096	Al432644	dbEST
Sequence 1045	AF078847	ANUC	Sequence 1097	Al433157	dbEST
Sequence 1046	AF080246	ANUC	Sequence 1098	Al457792	dbEST
Sequence 1047	AF081282	ANUC	Sequence 1099	AJ469112	dbEST
Sequence 1048	AF081484	ANUC	Sequence 1100	Al471114	dbEST
Sequence 1049	AF084523	ANUC	Sequence 1101	AJ471534	dbEST
Sequence 1050	AF086163	ANUC	Sequence 1102	AI473927	dbEST
Sequence 1051	AF095791	ANUC	Sequence 1103	AI479305	dbEST
Sequence 1052	AF100756	ANUC	Sequence 1104	Al499243	dbEST
Sequence 1053	AF107406	ANUC	Sequence 1105	Al525796	dbEST
Sequence 1054	AF119297	ANUC	Sequence 1106	AI525843	dbEST
Sequence 1055	AF131858	ANUC	Sequence 1107	AI537677	dbEST
Sequence 1056	AF132940	ANUC	Sequence 1108	AI541029	dbEST
Sequence 1057	AF151857	ANUC	Sequence 1109	AI560129	dbEST
Sequence 1058	AI028733	dbEST	Sequence 1110	AI583108	dbEST
Sequence 1059	AI031901	dbEST	Sequence 1111	AI584068	dbEST
Sequence 1060	AI033739	dbEST	Sequence 1112	AI587208	dbEST
Sequence 1061	AI040324	dbEST	Sequence 1113	AI589867	dbEST
Sequence 1062	AI051172	dbEST	Sequence 1114	AI610676	dbEST
Sequence 1063	AI076805	dbEST	Sequence 1115	Al630362	dbEST
Sequence 1064	AI087005	dbEST	Sequence 1116	Al633006	dbEST
Sequence 1065	AI089913	dbEST	Sequence 1117	AI634443	dbEST
Sequence 1066	AI092007	dbEST	Sequence 1118	Al635096	dbEST
Sequence 1067	Al127326	dbEST	Sequence 1119	Al682105	dbEST
Sequence 1068	AI147251	dbEST	Sequence 1120	Al683338	dbEST
Sequence 1069	Al148933	dbEST	Sequence 1121	Al684800	dbEST
Sequence 1070	AI149846	dbEST	Sequence 1122	Al684991	dbEST
Sequence 1071	AI167855	dbEST	Sequence 1123	AI689369	dbEST
Sequence 1072	AI183965	dbEST	Sequence 1124	AI689617	dbEST
Sequence 1073	Al189258	dbEST	Sequence 1125	AI689883	dbEST
Sequence 1074	Al220148	dbEST	Sequence 1126	Al693745	dbEST
Sequence 1075	Al224374	dbEST	Sequence 1127	AI701001	dbEST
Sequence 1076	Al240095	dbEST	Sequence 1128	AI733038	dbEST
Sequence 1077	Al246677	dbEST	Sequence 1129	AI735638	dbEST
Sequence 1078	Al248538	dbEST	Sequence 1130	AI741506	dbEST
Sequence 1079	Al266582	dbEST	Sequence 1131	AI742722	dbEST
Sequence 1080	Al268864	dbEST	Sequence 1132	AI742738	dbEST
Sequence 1081	Al270183	dbEST	Sequence 1133	AI743552	dbEST
Sequence 1082	Al271795	dbEST	Sequence 1134	AI753784	dbEST
Sequence 1083	Al273008	dbEST	Sequence 1135	AI754296	dbEST
Sequence 1084	Al273841	dbEST	Sequence 1136	AI754652	dbEST
Sequence 1085	Al274756	dbEST	Sequence 1137	AI754732	dbEST
Sequence 1086	Al275528	dbEST	Sequence 1138	AI765975	dbEST
Sequence 1087	Al283096	dbEST	Sequence 1139	AI769970	dbEST
Sequence 1088	Al298059	dbEST	Sequence 1140	AI819225	dbEST
Sequence 1089	Al335653	dbEST	Sequence 1141	AI820563	dbEST
Sequence 1090	Al338977	dbEST	Sequence 1142	AJ827818	dbEST
Sequence 1091	Al339946	dbEST	Sequence 1143	AI828682	dbEST

Sequence 1144	AI830067	dbEST	Sequence 1196	D51497	dbEST
Sequence 1145	Al861989	dbEST	Sequence 1197	D53031	dbEST
Sequence 1146	AI887129	dbEST	Sequence 1198	D62116	dbEST
Sequence 1147	AI887632	dbEST	Sequence 1199	D63878	ANUC
Sequence 1148	AI890281	dbEST	Sequence 1200	D78611	ANUC
Sequence 1149	Al924046	dbEST	Sequence 1201	D82348	ANUC
Sequence 1150	Al924096	dbEST	Sequence 1202	D83032	ANUC
Sequence 1151	Al924823	dbEST	Sequence 1203	D85433	ANUC
Sequence 1152	Al963471	dbEST	Sequence 1204	D87437	ANUC
Sequence 1153	Al963604	dbEST	Sequence 1205	D87667	ANUC
Sequence 1154	Al972556	dbEST	Sequence 1206	D89092	ANUC
Sequence 1155	Al979048	dbEST	Sequence 1207	D90041	71100
Sequence 1156	Al984656	dbEST	Sequence 1208	E02628	ANUC
Sequence 1157	AJ010442	ANUC	Sequence 1209	E05732	ANUC
Sequence 1158	AJ132694	ANUC	Sequence 1210	F00551	dbEST
Sequence 1159	AJ224442	ANUC	Sequence 1211	H08920	dbEST
Sequence 1160	AL036299	dbEST	Sequence 1212	H25080	dbEST
Sequence 1161	AL042979	dbEST	Sequence 1213	H30306	dbEST
Sequence 1162	AL047305	dbEST	Sequence 1214	H44647	dbEST
Sequence 1163	AL049247	ANUC	Sequence 1215	H81376	dbEST
Sequence 1164	AL049313	ANUC	Sequence 1216	H93521	dbEST
Sequence 1165	AL049381	ANUC	Sequence 1217	H94496	dbEST
Sequence 1166	AL049932	ANUC	Sequence 1218	J03464	ANUC
Sequence 1167	AL050041	ANUC	Sequence 1219	J03799	ANUC
Sequence 1168	AL050161	ANUC	Sequence 1220	J04027	ANUC
Sequence 1169	AL050265	ANUC	Sequence 1221	J04177	ANUC
Sequence 1170	AL050268	ANUC	Sequence 1222	K01228	ANUC
Sequence 1171	AL050367	ANUC	Sequence 1223	K01566	ANUC
Sequence 1172	AL079286	ANUC	Sequence 1224	L07395	ANUC
Sequence 1173	AL079312	ANUC	Sequence 1225	L09159	ANUC
Sequence 1174	AL079314	ANUC	Sequence 1226	L11315	ANUC
Sequence 1175	AL080113	ANUC	Sequence 1227	L13806	ANUC
Sequence 1176	AL110164	ANUC	Sequence 1228	L15702	ANUC
Sequence 1177	AL117412	ANUC	Sequence 1229	L16510	ANUC
Sequence 1178	AL117612	ANUC	Sequence 1230	L24804	ANUC
Sequence 1179	AL119009	dbEST	Sequence 1231	L25931	ANUC
Sequence 1180	AW014693	dbEST	Sequence 1232	L28809	ANUC
Sequence 1181	AW014985	dbEST	Sequence 1233	M10036	ANUC
Sequence 1182	AW021794	dbEST	Sequence 1234	M10905	ANUC
Sequence 1183	C01521	dbEST	Sequence 1235	M11353	ANUC
Sequence 1184	D01096	ANUC	Sequence 1236	M12267	ANUC
Sequence 1185	D13119	ANUC	Sequence 1237	M13536	ANUC
Sequence 1186	D13627	ANUC	Sequence 1238	M14483	ANUC
Sequence 1187	D13630	ANUC	Sequence 1239	M14630	ANUC
Sequence 1188	D13639	ANUC	Sequence 1240	M17885	ANUC
Sequence 1189	D13665	ANUC	Sequence 1241	M18366	ANUC
Sequence 1190	D14530	ANUC	Sequence 1242	M21575	ANUC
Sequence 1191	D21260	ANUC	Sequence 1243	M23254	ANUC
Sequence 1192	D25278	ANUC	Sequence 1244	M24194	ANUC
Sequence 1193	D26361	ANUC	Sequence 1245	M24486	ANUC
Sequence 1194	D30655	ANUC	Sequence 1246	M26512	ANUC
Sequence 1195	D50310	ANUC	Sequence 1247	M28372	ANUC

PCT/US00/24199 WO 01/18542 42

Sequence 1248	M31159	ANUC	Sequence 1300	V84510	NUCPATENT
Sequence 1249	M32220	ANUC	Sequence 1301	W19427	dbEST
Sequence 1250	M36341	ANUC	Sequence 1302	W65357	dbEST
Sequence 1251	M36693	ANUC	Sequence 1303	W75963	dbEST
Sequence 1252	M38690	ANUC	Sequence 1304	W80525	dbEST ,
Sequence 1253	M58485	ANUC	Sequence 1305	X01630	ANUC
Sequence 1254	M59849	ANUC	Sequence 1306	X04098	ANUC
Sequence 1255	M62831	ANUC	Sequence 1307	X04408	ANUC
Sequence 1256	M64241	ANUC	Sequence 1308	X06700	ANUC
Sequence 1257	M69043	ANUC	Sequence 1309	X14420	ANUC
Sequence 1258	M77142	ANUC	Sequence 1310	X51742	NUCPATENT
Sequence 1259	M77830	ANUC	Sequence 1311	X60111	ANUC
Sequence 1260	M86667	ANUC	Sequence 1312	X69398	ANUC
Sequence 1261	M88108	ANUC	Sequence 1313	X72755	ANUC
Sequence 1262	M93651	ANUC	Sequence 1314	X74979	ANUC
Sequence 1263	M95542	ANUC	Sequence 1315	X76180	ANUC
Sequence 1264	N43970	dbEST	Sequence 1316	X78627	ANUC
Sequence 1265	Q12759	NUCPATENT	Sequence 1317	X79067	ANUC
Sequence 1266	Q14635	NUCPATENT	Sequence 1318	X80910	ANUC
Sequence 1267	R11045	dbEST	Sequence 1319	X87949	ANUC
Sequence 1268	R76376	dbEST	Sequence 1320	Y00052	ANUC
•	R84450	dbEST	Sequence 1321	Y00062	ANUC
Sequence 1269	S74728	ANUC	Sequence 1322	Y00282	ANUC
Sequence 1270	S82081	ANUC	Sequence 1323	Y00503	ANUC
Sequence 1271		dbEST	Sequence 1324	Y15286	ANUC
Sequence 1272	T07459	NUCPATENT	Sequence 1325	Y17171	ANUC
Sequence 1273	T19883	NUCPATENT	Sequence 1326	Z13009	ANUC
Sequence 1274	T21168	NUCPATENT	Sequence 1327	Z24724	ANUC
Sequence 1275	T22605		Sequence 1328	Z29083	ANUC
Sequence 1276	T37405	NUCPATENT	Sequence 1329	Z29331	ANUC
Sequence 1277	T67129	dbEST	Sequence 1330	Z46606	ANUC
Sequence 1278	T69703	dbEST	Sequence 1331	Z48501	ANUC
Sequence 1279	T78615	dbEST	Sequence 1332	AA001460	dbEST
Sequence 1280	T89937	dbEST	Sequence 1333	AA001543	dbEST
Sequence 1281	U03851	ANUC	Sequence 1334	AA001792	dbEST
Sequence 1282	U12404	ANUC	•	AA004925	dbEST
Sequence 1283	U14967	ANUC	Sequence 1335	AA010897	dbEST
Sequence 1284	U14971	ANUC	Sequence 1336	AA017162	dbEST
Sequence 1285	U20659	ANUC	Sequence 1337	AA019019	dbEST
Sequence 1286	U25789	ANUC	Sequence 1338	AA022980	dbEST
Sequence 1287	U30825	ANUC	Sequence 1339		dbEST
Sequence 1288	U47077	ANUC	Sequence 1340	AA024595 AA024940	dbEST
Sequence 1289	U49844	ANUC	Sequence 1341		
Sequence 1290	U63846	ANUC	Sequence 1342	AA024996	dbEST
Sequence 1291	U65928	ANUC	Sequence 1343	AA025750	dbEST
Sequence 1292	U72516	ANUC	Sequence 1344	AA026598	dbEST
Sequence 1293	U79282	ANUC	Sequence 1345	AA029271	dbEST
Sequence 1294	U90716	ANUC	Sequence 1346	AA029725	dbEST
Sequence 1295	U90904	ANUC	Sequence 1347	AA029930	dbEST
Sequence 1296	U94364	ANUC	Sequence 1348	AA033832	dbEST
Sequence 1297	V20437	NUCPATENT	Sequence 1349	AA035471	dbEST
Sequence 1298	V24305	NUCPATENT	Sequence 1350	AA035616	dbEST
Sequence 1299	V81394	NUCPATENT	Sequence 1351	AA036752	dbEST

Sequence 1352	AA037377	dbEST	Sequence 1404	AA088693	dbEST
Sequence 1353	AA039778	dbEST	Sequence 1405	AA088783	dbEST
Sequence 1354	AA039948	dbEST	Sequence 1406	AA088829	dbEST
Sequence 1355	AA040688	dbEST	Sequence 1407	AA090106	dbEST
Sequence 1356	AA040820	dbEST	Sequence 1408	AA096032	dbEST
Sequence 1357	AA041259	dbEST	Sequence 1409	AA099819	dbEST
Sequence 1358	AA043477	dbEST	Sequence 1410	AA099923	dbEST
Sequence 1359	AA044209	dbEST	Sequence 1411	AA099976	dbEST
Sequence 1360	AA044233	dbEST	Sequence 1412	AA100764	dbEST
Sequence 1361	AA044791	dbEST	Sequence 1413	AA101010	dbEST
Sequence 1362	AA045054	dbEST	Sequence 1414	AA102013	dbEST
Sequence 1363	AA045147	dbEST	Sequence 1415	AA102564	dbEST
Sequence 1364	AA045768	dbEST	Sequence 1416	AA102830	dbEST
Sequence 1365	AA046848	dbEST	Sequence 1417	AA112186	dbEST
Sequence 1366	AA053021	dbEST	Sequence 1418	AA112645	dbEST
Sequence 1367	AA053316	dbEST	Sequence 1419	AA113305	dbEST
Sequence 1368	AA053919	dbEST	Sequence 1420	AA115218	dbEST
Sequence 1369	AA054069	dbEST	Sequence 1421	AA115315	dbEST
Sequence 1370	AA055479	dbEST	Sequence 1422	AA121656	dbEST
Sequence 1371	AA055591	dbEST	Sequence 1423	AA121718	dbEST
Sequence 1372	AA055637	dbEST	Sequence 1424	AA125809	dbEST
Sequence 1373	AA057243	dbEST	Sequence 1425	AA125939	dbEST
Sequence 1374	AA058712	dbEST	Sequence 1426	AA126452	dbEST
Sequence 1375	AA059128	dbEST	Sequence 1427	AA126718	dbEST
Sequence 1376	AA065169	dbEST	Sequence 1428	AA127436	dbEST
Sequence 1377	AA069850	dbEST	Sequence 1429	AA127666	dbEST
Sequence 1378	AA071167 [*]	dbEST	Sequence 1430	AA128063	dbEST
Sequence 1379	AA075158	dbEST	Sequence 1431	AA128636	dbEST
Sequence 1380	AA075515	dbEST	Sequence 1432	AA128641	dbEST
Sequence 1381	AA075663	dbEST	Sequence 1433	AA130778	dbEST
Sequence 1382	AA076397	dbEST	Sequence 1434	AA130982	dbEST
Sequence 1383	AA076421	dbEST	Sequence 1435	AA131827	dbEST
Sequence 1384	AA078387	dbEST	Sequence 1436	AA132056	dbEST
Sequence 1385	AA078570	dbEST	Sequence 1437	AA132163	dbEST
Sequence 1386	AA078872	dbEST	Sequence 1438	AA132574	dbEST
Sequence 1387	AA079480	dbEST	Sequence 1439	AA132992	dbEST
Sequence 1388	AA080889	dbEST	Sequence 1440	AA133351	dbEST
Sequence 1389	AA081073	dbEST	Sequence 1441	AA133474	dbEST
Sequence 1390	AA081608	dbEST	Sequence 1442	AA134460	dbEST
Sequence 1391	AA081834	dbEST	Sequence 1443	AA134527	dbEST
Sequence 1392	AA081917	dbEST	Sequence 1444	AA134589	dbEST
Sequence 1393	AA082258	dbEST	Sequence 1445	AA135696	dbEST
Sequence 1394	AA082441	dbEST	Sequence 1446	AA137017	dbEST
Sequence 1395	AA083270	dbEST	Sequence 1447	AA142941	dbEST
Sequence 1396	AA083345	dbEST	Sequence 1448	AA143001	dbEST
Sequence 1397	AA083522	dbEST	Sequence 1449	AA143074	dbEST
Sequence 1398	AA083573	dbEST	Sequence 1450	AA143746	dbEST
Sequence 1399	AA083638	dbEST	Sequence 1451	AA146900	dbEST
Sequence 1400	AA083774	dbEST	Sequence 1452	AA147200	dbEST
Sequence 1401	AA088318	dbEST	Sequence 1453	AA147247	dbEST
Sequence 1402	AA088344	dbEST	Sequence 1454	AA147781	dbEST
Sequence 1403	AA088351	dbEST	Sequence 1455	AA148027	dbEST
·			•		

					4L COT
Sequence 1456	AA148136	dbEST	Sequence 1508	AA191422	dbEST
Sequence 1457	AA149810	dbEST	Sequence 1509	AA192094	dbEST
Sequence 1458	AA150377	dbEST	Sequence 1510	AA193308	dbEST
Sequence 1459	AA150837	dbEST	Sequence 1511	AA194577	dbEST
Sequence 1460	AA150928	dbEST	Sequence 1512	AA195246	dbEST
Sequence 1461	AA151274	dbEST	Sequence 1513	AA195865	dbEST
Sequence 1462	AA151594	dbEST	Sequence 1514	AA196424	dbEST
Sequence 1463	AA151755	dbEST	Sequence 1515	AA196982	dbEST
Sequence 1464	AA152476	dbEST	Sequence 1516	AA203691	dbEST
Sequence 1465	AA155754	dbEST	Sequence 1517	AA204867	dbEST
Sequence 1466	AA156066	dbEST	Sequence 1518	AA206578	dbEST
Sequence 1467	AA157163	dbEST	Sequence 1519	AA206991	dbEST
Sequence 1468	AA157993	dbEST	Sequence 1520	AA209508	dbEST
Sequence 1469	AA158738	dbEST	Sequence 1521	AA216753	dbEST
Sequence 1470	AA159110	dbEST	Sequence 1522	AA219665	dbEST
Sequence 1471	AA159576	dbEST	Sequence 1523	AA223121	dbEST
Sequence 1472	AA161003	dbEST	Sequence 1524	AA223820	dbEST
Sequence 1473	AA161076	dbEST	Sequence 1525	AA224109	dbEST
Sequence 1474	AA161467	dbEST	Sequence 1526	AA224407	dbEST
Sequence 1475	AA164193	dbEST	Sequence 1527	AA227118	dbEST
Sequence 1476	AA164473	dbEST	Sequence 1528	AA229325	dbEST
Sequence 1477	AA164729	dbEST	Sequence 1529	AA229611	dbEST
Sequence 1478	AA164873	dbEST	Sequence 1530	AA232959	dbEST
Sequence 1479	AA165027	dbEST	Sequence 1531	AA233835	dbEST
Sequence 1480	AA165068	dbEST	Sequence 1532	AA233843	dbEST
Sequence 1481	AA165087	dbEST	Sequence 1533	AA234092	dbEST
Sequence 1482	AA165174	dbEST	Sequence 1534	AA234307	dbEST
Sequence 1483	AA165282	dbEST	Sequence 1535	AA236776	dbEST
Sequence 1484	AA165293	dbEST	Sequence 1536	AA242985	dbEST
Sequence 1485	AA165638	dbEST	Sequence 1537	AA243338	dbEST
Sequence 1486	AA166618	dbEST	Sequence 1538	AA244342	dbEST
Sequence 1487	AA167041	dbEST	Sequence 1539	AA249154	dbEST
Sequence 1488	AA167750	dbEST	Sequence 1540	AA255502	dbEST
Sequence 1489	AA171630	dbEST	Sequence 1541	AA256591	dbEST
Sequence 1490	AA173506	dbEST	Sequence 1542	AA261990	dbEST
Sequence 1491	AA174097	dbEST	Sequence 1543	AA262939	dbEST
Sequence 1492	AA179187	dbEST	Sequence 1544	AA278445	dbEST
Sequence 1493	AA180137	dbEST	Sequence 1545	AA278482	dbEST
Sequence 1494	AA180224	dbEST	Sequence 1546	AA278642	dbEST
Sequence 1495	AA180383	dbEST	Sequence 1547	AA278956	dbEST
Sequence 1496	AA181075	dbEST	Sequence 1548	AA279048	dbEST
Sequence 1497	AA181258	dbEST	Sequence 1549	AA280099	dbEST
Sequence 1498	AA181684	dbEST	Sequence 1550	AA280221	dbEST
Sequence 1499	AA182415	dbEST	Sequence 1551	AA280828	dbEST
Sequence 1500	AA182540	dbEST	Sequence 1552	AA282915	dbEST
Sequence 1501	AA186577	dbEST	Sequence 1553	AA284334	dbEST
Sequence 1502	AA187817	dbEST	Sequence 1554	AA284555	dbEST
Sequence 1503	AA188045	dbEST	Sequence 1555	AA284670	dbEST
Sequence 1504	AA188140	dbEST	Sequence 1556	AA284671	dbEST
•	AA188384	dbEST	Sequence 1557	AA284870	dbEST
Sequence 1505 Sequence 1506	AA188826	dbEST	Sequence 1558	AA284906	dbEST
•	AA190873	dbEST	Sequence 1559	AA285290	dbEST
Sequence 1507	W 190019	UDLO	2542000 .000		

Sequence 1560	AA286699	dbEST	Sequence 1612	AA315379	dbEST
Sequence 1561	AA286872	dbEST	Sequence 1613	AA317243	dbEST
Sequence 1562	AA287219	dbEST	Sequence 1614	AA317393	dbEST
Sequence 1563	AA287642	dbEST	Sequence 1615	AA318969	dbEST
Sequence 1564	AA287815	dbEST	Sequence 1616	AA327201	dbEST
Sequence 1565	AA291438	dbEST	Sequence 1617	AA331991	dbEST
Sequence 1566	AA291485	dbEST	Sequence 1618	AA332672	dbEST
Sequence 1567	AA291971	dbEST	Sequence 1619	AA333358	dbEST
Sequence 1568	AA292334	dbEST	Sequence 1620	AA335273	dbEST
Sequence 1569	AA293127	dbEST	Sequence 1621	AA336666	dbEST
Sequence 1570	AA293133	dbEST	Sequence 1622	AA337192	dbEST
Sequence 1571	AA293273	dbEST	Sequence 1623	AA337489	dbEST
Sequence 1572	AA293286	dbEST	Sequence 1624	AA338793	dbEST
Sequence 1573	AA293353	dbEST	Sequence 1625	AA339957	dbEST
Sequence 1574	AA293572	dbEST	Sequence 1626	AA340341	dbEST
Sequence 1575	AA293629	dbEST	Sequence 1627	AA341446	dbEST
Sequence 1576	AA293759	dbEST	Sequence 1628	AA341465	dbEST
Sequence 1577	AA293804	dbEST	Sequence 1629	AA342969	dbEST
Sequence 1578	AA296780	dbEST	Sequence 1630	AA343629	dbEST
Sequence 1579	AA297402	dbEST	Sequence 1631	AA344084	dbEST
Sequence 1580	AA298505	dbEST	Sequence 1632	AA345329	dbEST
Sequence 1581	AA299640	dbEST	Sequence 1633	AA346393	dbEST
Sequence 1582	AA301062	dbEST	Sequence 1634	AA346698	dbEST
Sequence 1583	AA301800	dbEST	Sequence 1635	AA347887	dbEST
Sequence 1584	AA303461	dbEST	Sequence 1636	AA350059	dbEST
Sequence 1585	AA303568	dbEST	Sequence 1637	AA351507	dbEST
Sequence 1586	AA306718	dbEST	Sequence 1638	AA355003	dbEST
Sequence 1587	AA306862	dbEST	Sequence 1639	AA356682	dbEST
Sequence 1588	AA306876	dbEST	Sequence 1640	AA357574	dbEST
Sequence 1589	AA307198	dbEST	Sequence 1641	AA358887	dbEST
Sequence 1590	AA307325	dbEST	Sequence 1642	AA359705	dbEST
Sequence 1591	AA308065	dbEST	Sequence 1643	AA364352	dbEST
Sequence 1592	AA308274	dbEST	Sequence 1644	AA367451	dbEST
Sequence 1593	AA308744	dbEST	Sequence 1645	AA367773	dbEST
Sequence 1594	AA310739	dbEST	Sequence 1646	AA368542	dbEST
Sequence 1595	AA310771	dbEST	Sequence 1647	AA369400	dbEST
Sequence 1596	AA311228	dbEST	Sequence 1648	AA373230	dbEST
Sequence 1597	AA311460	dbEST	Sequence 1649	AA374754	dbEST
Sequence 1598	AA311571	dbEST	Sequence 1650	AA375312	dbEST
Sequence 1599	AA311801	dbEST	Sequence 1651	AA375815	dbEST
Sequence 1600	AA311848	dbEST	Sequence 1652	AA393525	dbEST
Sequence 1601	AA311905	dbEST	Sequence 1653	AA394115	dbEST
Sequence 1602	AA312218	dbEST	Sequence 1654	AA398443	dbEST
Sequence 1603	AA312240	dbEST	Sequence 1655	AA398585	dbEST
Sequence 1604	AA312435	dbEST	Sequence 1656	AA398739	dbEST
Sequence 1605	AA313108	dbEST	Sequence 1657	AA399165	dbEST
Sequence 1606	AA313223	dbEST	Sequence 1658	AA399628	dbEST
Sequence 1607	AA313653	dbEST	Sequence 1659	AA401329	dbEST
Sequence 1608	AA313994	dbEST		AA401334	dbEST
Sequence 1609	AA314431	dbEST		AA402191	dbEST
Sequence 1610	AA314872	dbEST		AA402289	dbEST
Sequence 1611	AA315363	dbEST	Sequence 1663	AA402775	dbEST

			2	AA477567	dbEST
Sequence 1664	,	dbEST	Sequence 1716	,	dbEST
Sequence 1665	,	dbEST	Sequence 1717	,	dbEST
Sequence 1666	, , , , , , , , , , , , , , , , , , , ,	dbEST	Sequence 1718	,	dbEST
Sequence 1667	AA406239	dbEST	Sequence 1719	AA479648	dbEST
Sequence 1668	AA410580	dbEST	Sequence 1720		dbEST
Sequence 1669	AA410982	dbEST	Sequence 1721	AA479848 AA481078	dbEST
Sequence 1670	AA411021	dbEST	Sequence 1722		dbEST
Sequence 1671	AA411252	dbEST	Sequence 1723	AA481710 AA482430	dbEST
Sequence 1672	AA411764	dbEST	Sequence 1724		dbEST
Sequence 1673	AA417794	dbEST	Sequence 1725	AA482432	dbEST
Sequence 1674	AA419263	dbEST	Sequence 1726	AA482779	dbEST
Sequence 1675	AA419284	dbEST	Sequence 1727	AA483258	dbEST
Sequence 1676	AA420751	dbEST	Sequence 1728	AA483726	dbEST
Sequence 1677	AA420758	dbEST	Sequence 1729	AA483858	dbEST
Sequence 1678	AA421248	dbEST	Sequence 1730	AA484181	dbEST
Sequence 1679	AA421682	dbEST	Sequence 1731	AA486047	dbEST
Sequence 1680	AA422060	dbEST	Sequence 1732	AA486859	dbEST
Sequence 1681	AA422143	dbEST	Sequence 1733	AA488141	
Sequence 1682	AA425004	dbEST	Sequence 1734	AA488385	dbEST
Sequence 1683	AA425468	dbEST	Sequence 1735	AA488517	dbEST dbEST
Sequence 1684	AA425737	dbEST	Sequence 1736	AA489323	dbEST
Sequence 1685	AA429794	dbEST	Sequence 1737	AA489380	dbEST
Sequence 1686	AA430400	dbEST	Sequence 1738	AA489382	dbEST
Sequence 1687	AA430436	dbEST	Sequence 1739	AA491204	dbEST
Sequence 1688	AA431428	dbEST	Sequence 1740	AA492143	dbEST
Sequence 1689	AA433988	dbEST	Sequence 1741	AA493371	dbEST
Sequence 1690	AA436315	dbEST	Sequence 1742	AA494321 AA494552	dbEST
Sequence 1691	AA436411	dbEST	Sequence 1743	AA494552 AA501657	dbEST
Sequence 1692	AA443024	dbEST	Sequence 1744	AA501037 AA502136	dbEST
Sequence 1693	AA449394	dbEST	Sequence 1745	AA505780	dbEST
Sequence 1694	AA451779	dbEST	Sequence 1746	AA512933	dbEST
Sequence 1695	AA453878	dbEST	Sequence 1747	AA514395	dbEST
Sequence 1696	AA454668	dbEST	Sequence 1748	AA514974	dbEST
Sequence 1697	AA454953	dbEST	Sequence 1749	AA515143	dbEST
Sequence 1698	AA454962	dbEST	Sequence 1750	AA516376	dbEST
Sequence 1699	AA455245	dbEST	Sequence 1751	AA521006	dbEST
Sequence 1700	AA455785	dbEST	Sequence 1752	AA523522	dbEST
Sequence 1701	AA456454	dbEST	Sequence 1753	AA524748	dbEST
Sequence 1702	AA456557	dbEST	Sequence 1754	AA524950	dbEST
Sequence 1703	AA457255	dbEST	Sequence 1755	AA525141	dbEST
Sequence 1704	AA457579	dbEST	Sequence 1756 Sequence 1757	AA526028	dbEST
Sequence 1705	AA459167	dbEST	Sequence 1758	AA527275	dbEST
Sequence 1706	AA459210		Sequence 1759	AA527557	dbEST
Sequence 1707	AA459527	dbEST	Sequence 1760	AA533506	dbEST
Sequence 1708	AA460570		Sequence 1761	AA534349	dbEST
Sequence 1709	AA460816		Sequence 1762	AA534586	dbEST
Sequence 1710	AA461005		Sequence 1763	AA534608	
Sequence 1711	AA468657		Sequence 1764	AA535496	
Sequence 1712	AA469447		Sequence 1765	AA541651	
Sequence 1713	AA469453		Sequence 1766	AA548056	
Sequence 1714	AA476522		Sequence 1767	AA548600	
Sequence 1715	AA477018	dbEST	004801100 1101		

Sequence 1768	AA550854	dbEST	Sequence 1820	AA630611	dbEST
Sequence 1769	AA550855	dbEST	Sequence 1821	AA631326	dbEST
Sequence 1770	AA551351	dbEST	Sequence 1822	AA633909	dbEST
Sequence 1771	AA551391	dbEST	Sequence 1823	AA634260	dbEST
Sequence 1772	AA554437	dbEST	Sequence 1824	AA634298	dbEST
Sequence 1773	AA554735	dbEST	Sequence 1825	AA640505	dbEST
Sequence 1774	AA555102	dbEST	Sequence 1826	AA641289	dbEST
Sequence 1775	AA564272	dbEST	Sequence 1827	AA644625	dbEST
Sequence 1776	AA564870	dbEST	Sequence 1828	AA648944	dbEST
Sequence 1777	AA565420	dbEST	Sequence 1829	AA651720	dbEST
Sequence 1778	AA568936	dbEST	Sequence 1830	AA652478	dbEST
Sequence 1779	AA569816	dbEST	Sequence 1831	AA652505	dbEST
Sequence 1780	AA569851	dbEST	Sequence 1832	AA653775	dbEST
Sequence 1781	AA569916	dbEST	Sequence 1833	AA658374	dbEST
Sequence 1782	AA573761	dbEST	Sequence 1834	AA663005	dbEST
Sequence 1783	AA573787	dbEST	Sequence 1835	AA669154	dbEST
Sequence 1784	AA577537	dbEST	Sequence 1836	AA677560	dbEST
Sequence 1785	AA578881	dbEST	Sequence 1837	AA677750	dbEST
Sequence 1786	AA579591	dbEST	Sequence 1838	AA678185	dbEST
Sequence 1787	AA579890	dbEST	Sequence 1839	AA678251	dbEST
Sequence 1788	AA580835	dbEST	Sequence 1840	AA687495	dbEST
Sequence 1789	AA582093	dbEST	Sequence 1841	AA703208	dbEST
Sequence 1790	AA582866	dbEST	Sequence 1842	AA703667	dbEST
Sequence 1791	AA583055	dbEST	Sequence 1843	AA703907	dbEST
Sequence 1792	AA583498	dbEST	Sequence 1844	AA704208	dbEST
Sequence 1793	AA583567	dbEST	Sequence 1845	AA706347	dbEST
Sequence 1794	AA583773	dbEST	Sequence 1846	AA714010	dbEST
Sequence 1795	AA584921	dbEST	Sequence 1847	AA715984	dbEST
Sequence 1796	AA586755	dbEST	Sequence 1848	AA716651	dbEST
Sequence 1797	AA587140	dbEST	Sequence 1849	AA719530	dbEST
Sequence 1798	AA587315	dbEST	Sequence 1850	AA721642	dbEST
Sequence 1799	AA587873	dbEST	Sequence 1851	AA729381	dbEST
Sequence 1800	AA593983	dbEST	Sequence 1852	AA731946	dbEST
Sequence 1801	AA594366	dbEST	Sequence 1853	AA736817	dbEST
Sequence 1802	AA595624	dbEST	Sequence 1854	AA742713	dbEST
Sequence 1803	AA595771	dbEST	Sequence 1855	AA743278	dbEST
Sequence 1804	AA599454	dbEST	Sequence 1856	AA744681	dbEST
Sequence 1805	AA600227	dbEST	Sequence 1857	AA745953	dbEST
Sequence 1806	AA600771	dbEST	Sequence 1858	AA759195	dbEST
Sequence 1807	AA601172	dbEST	Sequence 1859	AA767779	dbEST
Sequence 1808	AA602395	dbEST	Sequence 1860	AA769697	dbEST
Sequence 1809	AA602871	dbEST	Sequence 1861	AA773998	dbEST
Sequence 1810	AA603125	dbEST	Sequence 1862	AA775058	dbEST
Sequence 1811	AA603177	dbEST	Sequence 1863	AA776593	dbEST
Sequence 1812	AA604324	dbEST	Sequence 1864	AA777384	dbEST
Sequence 1813	AA604853	dbEST	Sequence 1865	AA778672	dbEST
Sequence 1814	AA610279	dbEST	Sequence 1866	AA779949	dbEST
Sequence 1815	AA610476	dbEST	Sequence 1867	AA781487	dbEST
Sequence 1816	AA610734	dbEST	Sequence 1868	AA788907	dbEST
Sequence 1817	AA614482	dbEST	•	AA806278	dbEST
Sequence 1818	AA628536	dbEST	Sequence 1870	AA806735	dbEST
Sequence 1819	AA628547	dbEST	Sequence 1871	AA808769	dbEST

PCT/US00/24199 WO 01/18542 48

Sequence 1872	AA810149	dbEST	Sequence 1924	,	ANUC
Sequence 1873		dbEST	Sequence 1925	, 1000.000	ANUC
Sequence 1874	AA813604	dbEST	Sequence 1926	,	ANUC
Sequence 1875	AA826307	dbEST	Sequence 1927		ANUC
Sequence 1876	AA833766	dbEST	Sequence 1928	,	ANUC
Sequence 1877	AA833900	dbEST	Sequence 1929		ANUC
Sequence 1878	AA837457	dbEST	Sequence 1930		ANUC
Sequence 1879	AA843531	dbEST	Sequence 1931	AB014533	ANUC
Sequence 1880	AA845737	dbEST	Sequence 1932	AB014542	ANUC
Sequence 1881	AA846698	dbEST	Sequence 1933	AB014560	ANUC
Sequence 1882	AA846856	dbEST	Sequence 1934	AB015630	ANUC
Sequence 1883	AA852896	dbEST	Sequence 1935	AB015856	ANUC
Sequence 1884	AA856902	dbEST	Sequence 1936	AB018281	ANUC
Sequence 1885	AA857824	dbEST	Sequence 1937	AB018284	ANUC
	AA857882	dbEST	Sequence 1938	AB018285	ANUC
Sequence 1886	AA861665	dbEST	Sequence 1939	AB018289	ANUC
Sequence 1887	AA865960	dbEST	Sequence 1940	AB018305	ANUC
Sequence 1888	AA868529	dbEST	Sequence 1941	AB018327	ANUC
Sequence 1889	AA873271	dbEST	Sequence 1942	AB018331	ANUC
Sequence 1890	AA877189	dbEST	Sequence 1943	AB018337	ANUC
Sequence 1891	AA884922	dbEST	Sequence 1944	AB019409	ANUC
Sequence 1892	AA886453	dbEST	Sequence 1945	AB019563	ANUC
Sequence 1893	AA906652	dbEST	Sequence 1946	AB019568	ANUC
Sequence 1894	AA906865	dbEST	Sequence 1947	AB019691	ANUC
Sequence 1895	AA918993	dbEST	Sequence 1948	AB020682	ANUC
Sequence 1896	AA926926	dbEST	Sequence 1949	AB020718	ANUC
Sequence 1897	AA928934	dbEST	Sequence 1950	AB021288	ANUC
Sequence 1898	AA932501	dbEST	Sequence 1951	AB023154	ANUC
Sequence 1899	AA933987	dbEST	Sequence 1952	AB023219	ANUC
Sequence 1900	AA935947	dbEST	Sequence 1953	AB024704	ANUC
Sequence 1901	AA937302	dbEST	Sequence 1954	AB027467	ANUC
Sequence 1902	AA937773	dbEST	Sequence 1955	AB028069	ANUC
Sequence 1903	AA947835	dbEST	Sequence 1956	AB028624	ANUC
Sequence 1904	AA954939	dbEST	Sequence 1957	AB028969	ANUC
Sequence 1905	AA962587	dbEST	Sequence 1958	AB028986	ANUC
Sequence 1906	AA962632	dbEST	Sequence 1959	AB029000	ANUC
Sequence 1907	AA972525	dbEST	Sequence 1960	AB029004	ANUC
Sequence 1908	AA976489	dbEST	Sequence 1961	AB029028	ANUC
Sequence 1909	AA983380	dbEST	Sequence 1962	AC03044	PREPATNUC
Sequence 1910	AA984586	dbEST	Sequence 1963	AC31479	PREPATNUC
Sequence 1911	AA992596	dbEST	Sequence 1964	AF000670	ANUC
Sequence 1912	AB002305		Sequence 1965	AF000974	ANUC
Sequence 1913	AB002330		Sequence 1966	AF001893	ANUC
Sequence 1914	AB002357	_	Sequence 1967	AF004562	ANUC
Sequence 1915	AB002806		Sequence 1968	AF006043	ANUC
Sequence 1916	AB002806 AB003476		Sequence 1969	AF007135	ANUC
Sequence 1917	AB003476 AB004066		Sequence 1970	AF007151	ANUC
Sequence 1918			Sequence 1971	AF007170	ANUC
Sequence 1919	AB006077		Sequence 1972	AF009615	ANUC
Sequence 1920	AB006534		Sequence 1973	AF013759	
Sequence 1921	AB006755		Sequence 1974	AF013988	ANUC
Sequence 1922	AB007867		Sequence 1975	AF015283	ANUC
Sequence 1923	AB007900	, AIIUU			

Sequence 1976	AF015767	ANUC	Sequence 2028	AF064019	ANUC
Sequence 1977	AF016507	ANUC	Sequence 2029	AF068235	ANUC
Sequence 1978	AF016582	ANUC	Sequence 2030	AF068846	ANUC
Sequence 1979	AF017790	ANUC	Sequence 2031	AF070523	ANUC
Sequence 1980	AF019767	ANUC	Sequence 2032	AF070537	ANUC
Sequence 1981	AF021351	ANUC	Sequence 2033	AF070555	ANUC
Sequence 1982	AF021819	ANUC	Sequence 2034	AF070561	ANUC
Sequence 1983	AF022229	ANUC	Sequence 2035	AF070596	ANUC
Sequence 1984	AF023266	ANUC	Sequence 2036	AF070600	ANUC
Sequence 1985	AF025439	ANUC	Sequence 2037	AF070626	ANUC
Sequence 1986	AF026166	ANUC	Sequence 2038	AF070649	ANUC
Sequence 1987	AF026939	ANUC	Sequence 2039	AF070662	ANUC
Sequence 1988	AF027205	ANUC	Sequence 2040	AF070672	ANUC
Sequence 1989	AF031385	ANUC	Sequence 2041	AF071202	ANUC
Sequence 1990	AF034607	ANUC	Sequence 2042	AF071219	ANUC
Sequence 1991	AF035286	ANUC	Sequence 2043	AF071593	ANUC
Sequence 1992	AF035309	ANUC	Sequence 2044	AF073298	ANUC
Sequence 1993	AF035313	ANUC	Sequence 2045	AF075587	ANUC
Sequence 1994	AF037204	ANUC	Sequence 2046	AF077030	ANUC
Sequence 1995	AF038661	ANUC	Sequence 2047	AF077045	ANUC
Sequence 1996	AF039019	ANUC	Sequence 2048	AF077200	ANUC
Sequence 1997	AF039291	ANUC	Sequence 2049	AF077202	ANUC
Sequence 1998	AF039843	ANUC	Sequence 2050	AF077207	ANUC
Sequence 1999	AF040990	ANUC	Sequence 2051	AF081192	ANUC
Sequence 2000	AF041483	ANUC	Sequence 2052	AF081484	ANUC
Sequence 2001	AF042385	ANUC	Sequence 2053	AF083190	ANUC
Sequence 2002	AF042729	ANUC	Sequence 2054	AF085355	ANUC
Sequence 2003	AF044588	ANUC	Sequence 2055	AF086003	ANUC
Sequence 2004	AF045184	ANUC	Sequence 2056	AF086116	ANUC
Sequence 2005	AF047438	ANUC	Sequence 2057	AF086178	ANUC
Sequence 2006	AF047472	ANUC	Sequence 2058	AF086205	ANUC
Sequence 2007	AF048977	ANUC	Sequence 2059	AF086207	ANUC
Sequence 2008	AF050171	ANUC	Sequence 2060	AF086336	ANUC
Sequence 2009	AF050199	ANUC	Sequence 2061	AF086517	ANUC
Sequence 2010	AF050639	ANUC	Sequence 2062	AF087135	ANUC
Sequence 2011	AF052124	ANUC	Sequence 2063	AF087990	ANUC
Sequence 2012	AF052135	ANUC ·	Sequence 2064	AF088036	ANUC
Sequence 2013	AF052149	ANUC	Sequence 2065	AF091076	ANUC
Sequence 2014	AF052164	ANUC	Sequence 2066	AF092563	ANUC
Sequence 2015	AF052169	ANUC	Sequence 2067	AF095287	ANUC
Sequence 2016	AF052180	ANUC	Sequence 2068	AF095791	ANUC
Sequence 2017	AF052514	ANUC	Sequence 2069	AF097709	ANUC
Sequence 2018	AF054183	ANUC	Sequence 2070	AF100741	ANUC
Sequence 2019	AF054187	ANUC	Sequence 2071	AF100756	ANUC
Sequence 2020	AF054840	ANUC	Sequence 2072	AF100928	ANUC
Sequence 2021	AF055012	ANUC	Sequence 2073	AF104222	ANUC
Sequence 2022	AF055033	ANUC	Sequence 2074	AF104913	ANUC
Sequence 2023	AF057299	ANUC	Sequence 2075	AF104923	ANUC
Sequence 2024	AF059252	ANUC	Sequence 2076	AF107405	ANUC
Sequence 2025	AF061258	ANUC	Sequence 2077	AF120334	ANUC
Sequence 2026	AF062318	ANUC	Sequence 2078	AF124438	ANUC
Sequence 2027	AF063611	ANUC	Sequence 2079	AF124439	ANUC

PCT/US00/24199 WO 01/18542 **50**

	A E 4 0 E E 0 E	ANULC	Sequence 2132	AI091425	dbEST
Sequence 2080	AF125525	ANUC ANUC	Sequence 2133	AI092971	dbEST
Sequence 2081	AF131799		Sequence 2134	AI095477	dbEST
Sequence 2082	AF131814	ANUC	Sequence 2135	Al123229	dbEST
Sequence 2083	AF139461	ANUC	Sequence 2136	AI125642	dbEST
Sequence 2084	AF139658	ANUC	Sequence 2137	AI125874	dbEST
Sequence 2085	AF144755	ANUC	Sequence 2138	Al127013	dbEST
Sequence 2086	AF147331	ANUC	Sequence 2139	Al127556	dbEST
Sequence 2087	AF150962	ANUC	Sequence 2140	Al140291	dbEST
Sequence 2088	AF151832	ANUC	Sequence 2141	Al141130	dbEST
Sequence 2089	AF151868	ANUC	Sequence 2142	AI141847	dbEST
Sequence 2090	AF151898	ANUC		Al143899	dbEST
Sequence 2091	AF151907	ANUC	Sequence 2143	AI144100	dbEST
Sequence 2092	AF152097	ANUC	Sequence 2144	AI148251	dbEST
Sequence 2093	AF159295	ANUC	Sequence 2145	Al149429	dbEST
Sequence 2094	AF176702	ANUC	Sequence 2146	Al149592	dbEST
Sequence 2095	AF190744	ANUC	Sequence 2147	Al186028	dbEST
Sequence 2096	AI004664	dbEST	Sequence 2148	AI186042	dbEST
Sequence 2097	Al004915	dbEST	Sequence 2149	AI190341	dbEST
Sequence 2098	AI016073	dbEST	Sequence 2150	Al190341 Al192367	dbEST
Sequence 2099	AI016323	dbEST	Sequence 2151		dbEST
Sequence 2100	AI016791	dbEST	Sequence 2152	Al192629	dbEST
Sequence 2101	AI018451	dbEST	Sequence 2153	Al198930 Al216969	dbEST
Sequence 2102	AI018625	dbEST	Sequence 2154	Al217003	dbEST
Sequence 2103	AI022779	dbEST	Sequence 2155	Al217003 Al223292	dbEST
Sequence 2104	AI023799	dbEST	Sequence 2156		dbEST
Sequence 2105	AI026164	dbEST	Sequence 2157	Al241706 Al251743	dbEST
Sequence 2106	AI027516	dbEST	Sequence 2158	Al251743 Al252466	dbEST
Sequence 2107	AI031636	dbEST	Sequence 2159		dbEST
Sequence 2108	AI033037	dbEST	Sequence 2160	Al253330 Al253335	dbEST
Sequence 2109	AI034115	dbEST	Sequence 2161	Al253338	dbEST
Sequence 2110	AI037859	dbEST	Sequence 2162	Al253375	dbEST
Sequence 2111	AI041670	dbEST	Sequence 2163	Al253379	dbEST
Sequence 2112	AI042034	dbEST	Sequence 2164	Al253436	dbEST
Sequence 2113	AI042290	dbEST	Sequence 2165	Al262380	dbEST
Sequence 2114	AI051971	dbEST	Sequence 2166	Al263674	dbEST
Sequence 2115	AI056917	dbEST	Sequence 2167	Al267162	dbEST
Sequence 2116	AI057124	dbEST	Sequence 2168		dbEST
Sequence 2117	AI066419	dbEST	Sequence 2169	Al267185 Al267209	dbEST
Sequence 2118	AI078041	dbEST	Sequence 2170	Al267289	dbEST
Sequence 2119	AI081116	dbEST	Sequence 2171	Al267209 Al267307	dbEST
Sequence 2120	AI081472	dbEST	Sequence 2172	Al267307 Al267321	dbEST
Sequence 2121	AI081913	dbEST	Sequence 2173	Al267321	dbEST
Sequence 2122	AI082244	dbEST	Sequence 2174		dbEST
Sequence 2123	AI082648	dbEST	Sequence 2175	A1267502	dbEST
Sequence 2124	AI084731	dbEST	Sequence 2176	A1268293	dbEST
Sequence 2125	AI085381	dbEST	Sequence 2177	AI269060	
Sequence 2126	AI087291	dbEST	Sequence 2178	AI269369	dbEST
Sequence 2127	AI087819	dbEST	Sequence 2179	AI270183	dbEST
Sequence 2128	Al088178	dbEST	Sequence 2180	AI270472	dbEST
Sequence 2129	AI089981	dbEST	Sequence 2181	AI271786	dbEST
Sequence 2130	Al090524	dbEST	Sequence 2182	AI272827	dbEST
Sequence 2131	AI090623	dbEST	Sequence 2183	Al274047	dbEST

Sequence 2184	AI276341	dbEST	Sequence 2236	Al608591	dbEST
Sequence 2185	AI276839	dbEST	Sequence 2237	AI608787	dbEST
Sequence 2186	Al278611	dbEST	Sequence 2238	Al608968	dbEST
Sequence 2187	Al280022	dbEST	Sequence 2239	Al609193	dbEST
Sequence 2188	AI283548	dbEST	Sequence 2240	Al609281	dbEST
Sequence 2189	Al288965	dbEST	Sequence 2241	AI623804	dbEST
Sequence 2190	Al290565	dbEST	Sequence 2242	AI628689	dbEST
Sequence 2191	Al291683	dbEST	Sequence 2243	AI636635	dbEST
Sequence 2192	Al292286	dbEST	Sequence 2244	AI650837	dbEST
Sequence 2193	Al298472	dbEST	Sequence 2245	AI654096	dbEST
Sequence 2194	Al298941	dbEST	Sequence 2246	AI660245	dbEST
Sequence 2195	Al304857	dbEST	Sequence 2247	AI669253	dbEST
Sequence 2196	Al308959	dbEST	Sequence 2248	Al670084	dbEST
Sequence 2197	Al312552	dbEST	Sequence 2249	AI674313	dbEST
Sequence 2198	Al333055	dbEST	Sequence 2250	AI678152	dbEST
Sequence 2199	Al333116	dbEST	Sequence 2251	AI678703	dbEST
Sequence 2200	Al335249	dbEST	Sequence 2252	Al679044	dbEST
Sequence 2201	Al336326	dbEST	Sequence 2253	Al679321	dbEST
Sequence 2202	AI345325	dbEST	Sequence 2254	Al683140	dbEST
Sequence 2203	AI366549	dbEST	Sequence 2255	AI683338	dbEST
Sequence 2204	AI367850	dbEST	Sequence 2256	Al683793	dbEST
Sequence 2205	Al375624	dbEST	Sequence 2257	AI688798	dbEST
Sequence 2206	Al376561	dbEST	•	A1692866	dbEST
Sequence 2207	Al399636	dbEST	Sequence 2259	AI694087	dbEST
Sequence 2208	Al417384	dbEST	Sequence 2260	AI696819	dbEST
Sequence 2209	Al421720	dbEST	Sequence 2261	Al697501	dbEST
Sequence 2210	Al424841	dbEST	Sequence 2262	AI734922	dbEST
Sequence 2211	Al431507	dbEST	Sequence 2263	AI735069	dbEST
Sequence 2212	Al433180	dbEST	Sequence 2264	AI739337	dbEST
Sequence 2213	Al434084	dbEST	Sequence 2265	AI739377	dbEST
Sequence 2214	Al434401	dbEST	Sequence 2266	AI743595	dbEST
Sequence 2215	Al436016	dbEST	Sequence 2267	AI743691	dbEST
Sequence 2216	Al436448	dbEST	Sequence 2268	AI750198	dbEST
Sequence 2217	Al446503	dbEST	Sequence 2269	AI750909	dbEST
Sequence 2218	Al453199	dbEST	Sequence 2270	AI751119	dbEST
Sequence 2219	Al459028	dbEST	Sequence 2271	AI751364	dbEST
Sequence 2220	Al469237	dbEST	Sequence 2272	AI751565	dbEST
Sequence 2221	Al492520	dbEST	Sequence 2273	AI752319	dbEST
Sequence 2222	Al492769	dbEST	Sequence 2274	AI752553	dbEST
Sequence 2223	Al494344	dbEST	Sequence 2275	AI752929	dbEST
Sequence 2224	AI523940	dbEST	Sequence 2276	AI753108	dbEST
Sequence 2225	AI524677	dbEST	Sequence 2277	AI753671	dbEST
Sequence 2226	AI538682	dbEST	Sequence 2278	AI754437	dbEST
Sequence 2227	AI557059	dbEST	Sequence 2279	AI755181	dbEST
Sequence 2228	Al561260	dbEST	Sequence 2280	AI758869	dbEST
Sequence 2229	AI567988	dbEST	Sequence 2281	AI761927	dbEST
Sequence 2230	AI569715	dbEST	Sequence 2282	AI763126	dbEST
Sequence 2231	Al581291	dbEST	Sequence 2283	AI791906	dbEST
Sequence 2232	Al583211	dbEST	Sequence 2284	AI793120	dbEST
Sequence 2233	AI583570	dbEST	Sequence 2285	AI799521	dbEST
Sequence 2234	AI589301	dbEST	Sequence 2286	AI804346	dbEST
Sequence 2235	AI597938	dbEST	Sequence 2287	AI808109	dbEST

PCT/US00/24199 WO 01/18542 52

Sequence 2288	AI811021	dbEST	Oodaoee ma	AL049999	ANUC
Sequence 2289	AI811845	dbEST	0042000 20	AL050011	ANUC
Sequence 2290	AI814139	dbEST	Ocque.ior =- i=	AL050089	ANUC
Sequence 2291	AI814674	dbEST	0040000	AL050141	ANUC
Sequence 2292	AI815868	dbEST	Sequence 2344	AL050171	ANUC
Sequence 2293	AI822030	dbEST	Sequence 2345	AL050187	ANUC
Sequence 2294	AI827641	dbEST	Sequence 2346	AL050198	ANUC
Sequence 2295	AI859619	dbEST	Sequence 2347	AL050217	ANUC
Sequence 2296	AI864580	dbEST	Sequence 2348	AL050392	ANUC -
Sequence 2297	AI878968	dbEST	Sequence 2349	AL080062	ANUC
Sequence 2298	AI879179	dbEST	Sequence 2350	AL080186	ANUC
Sequence 2299	AI879367	dbEST	Sequence 2351	AL080235	ANUC
Sequence 2300	AI879992	dbEST	Sequence 2352	AL096857	ANUC
	AI888377	dbEST	Sequence 2353	AL096858	ANUC
Sequence 2301	AI911704	dbEST	Sequence 2354	AL110197	ANUC
Sequence 2302	Al911997	dbEST	Sequence 2355	AL110235	ANUC
Sequence 2303	Al912084	dbEST	Sequence 2356	AL117237	ANUC
Sequence 2304	Al916284	dbEST	Sequence 2357	AL117499	ANUC
Sequence 2305	Al916584	dbEST	Sequence 2358	AL117534	ANUC
Sequence 2306	Al923224	dbEST	Sequence 2359	AL118999	dbEST
Sequence 2307		dbEST	Sequence 2360	AL119085	dbEST
Sequence 2308	AI924096	dbEST	Sequence 2361	AL119157	dbEST
Sequence 2309	AI928185	dbEST	Sequence 2362	AW020479	dbEST
Sequence 2310	AI929819	dbEST	Sequence 2363	AW044114	dbEST
Sequence 2311	AI936748	dbEST	Sequence 2364	AW102841	dbEST
Sequence 2312	AI950087	dbEST	Sequence 2365	C02094	dbEST
Sequence 2313	AI955808	ANUC	Sequence 2366	C16886	dbEST
Sequence 2314	AJ001258	ANUC	Sequence 2367	C18886	dbEST
Sequence 2315	AJ002030	ANUC	Sequence 2368	D00017	ANUC
Sequence 2316	AJ006026	ANUC	Sequence 2369	D00022	ANUC
Sequence 2317	AJ011001	ANUC	Sequence 2370	D00068	ANUC
Sequence 2318	AJ011915	ANUC	Sequence 2371	D00099	ANUC
Sequence 2319	AJ012499	ANUC	Sequence 2372	D00422	ANUC
Sequence 2320	AJ223183 AL035802	dbEST	Sequence 2373	D10495	ANUC
Sequence 2321	AL035802 AL035987	dbEST	Sequence 2374	D13119	ANUC
Sequence 2322		dbEST	Sequence 2375	D13287	ANUC
Sequence 2323	AL036801 AL037646	dbEST	Sequence 2376	D13665	ANUC
Sequence 2324		dbEST	Sequence 2377	D13866	ANUC
Sequence 2325	AL038985 AL039150	dbEST	Sequence 2378	D14662	ANUC
Sequence 2326	AL041780	dbEST	Sequence 2379	D14697	ANUC
Sequence 2327	AL044019	dbEST	Sequence 2380	D14710	ANUC
Sequence 2328	AL044019 AL046804	dbEST	Sequence 2381	D14812	ANUC
Sequence 2329		dbEST	Sequence 2382	D15049	ANUC
Sequence 2330	AL049055	ANUC	Sequence 2383	D16431	ANUC
Sequence 2331	AL049227	ANUC	Sequence 2384	D16937	ANUC
Sequence 2332	AL049229	ANUC	Sequence 2385	D17188	ANUC
Sequence 2333	AL049296		Sequence 2386	D17268	ANUC
Sequence 2334	AL049464	ANUC	Sequence 2387	D17409	ANUC
Sequence 2335	AL049953	ANUC	Sequence 2388	D17793	ANUC
Sequence 2336	AL049954	ANUC	Sequence 2389	D21063	ANUC
Sequence 2337	AL049955		Sequence 2390	D23660	ANUC
Sequence 2338	AL049959		Sequence 2391	D25542	ANUC
Sequence 2339	AL049987	MINOC	22400.00 -001	-	

PCT/US00/24199 WO 01/18542 53

Sequence 2392	D28759	ANUC	Sequence 2444	E01813	ANUC
Sequence 2393	D29677	ANUC	Sequence 2445	E01827	ANUC
Sequence 2394	D31767	ANUC	Sequence 2446	E01979	ANUC
Sequence 2395	D31784	ANUC	Sequence 2447	E02628	ANUC
Sequence 2396	D31764	ANUC	Sequence 2448	E02651	ANUC
Sequence 2397	D31890	ANUC	Sequence 2449	E03569	ANUC
•	D37991	ANUC	Sequence 2450	E06721	ANUC
Sequence 2398		ANUC	Sequence 2451	E07218	ANUC
Sequence 2399	D38491		Sequence 2452	F28779	dbEST
Sequence 2400	D38583	ANUC	•	F30276	dbEST
Sequence 2401	D43948	ANUC	Sequence 2453	F30270	dbEST
Sequence 2402	D43950	ANUC	Sequence 2454	H03854	dbEST
Sequence 2403	D45248	ANUC	Sequence 2455	H05412	dbEST
Sequence 2404	D45887	ANUC	Sequence 2456		dbEST
Sequence 2405	D45915	ANUC	Sequence 2457	H08994	
Sequence 2406	D49489	ANUC	Sequence 2458	H13339	dbEST
Sequence 2407	D49547	ANUC	Sequence 2459	H16426	dbEST
Sequence 2408	D50310	ANUC	Sequence 2460	H39960	dbEST
Sequence 2409	D50371	ANUC	Sequence 2461	H48742	dbEST
Sequence 2410	D55192	dbEST	Sequence 2462	H59372	dbEST
Sequence 2411	D55649	ANUC	Sequence 2463	H60722	dbEST
Sequence 2412	D56120	dbEST	Sequence 2464	H69238	dbEST
Sequence 2413	D59253	ANUC	Sequence 2465	H72481	dbEST
Sequence 2414	D78586	ANUC	Sequence 2466	H75695	dbEST
Sequence 2415	D79826	dbEST	Sequence 2467	H78517	dbEST
Sequence 2416	D79983	ANUC	Sequence 2468	H79084	dbEST
Sequence 2417	D79986	ANUC	Sequence 2469	H84729	dbEST
Sequence 2418	D79997	ANUC	Sequence 2470	H85709	dbEST
Sequence 2419	D80006	ANUC	Sequence 2471	H89654	dbEST
Sequence 2420	D80012	ANUC	Sequence 2472	J00269	ANUC
Sequence 2421	D80087	dbEST	Sequence 2473	J02621	ANUC
Sequence 2422	D80253	dbEST	Sequence 2474	J03005	ANUC
Sequence 2423	D81635	dbEST	Sequence 2475	J03040	ANUC
Sequence 2424	D82128	dbEST	Sequence 2476	J03171	ANUC
Sequence 2425	D82348	ANUC	Sequence 2477	J03191	ANUC
Sequence 2426	D83197	ANUC	Sequence 2478	J03210	ANUC
Sequence 2427	D83327	ANUC	Sequence 2479	J03464	ANUC
Sequence 2428	D83784	ANUC	Sequence 2480	J03473	ANUC
Sequence 2429	D86227	ANUC	Sequence 2481	J03799	ANUC
Sequence 2430	D87437	ANUC	Sequence 2482	J04080	ANUC
Sequence 2431	D87442	ANUC	Sequence 2483	J04164	ANUC
Sequence 2432	D87470	ANUC	Sequence 2484	J04177	ANUC
Sequence 2433	D87666	ANUC	Sequence 2485	J04765	ANUC
Sequence 2434	D87667	ANUC	Sequence 2486	J05013	ANUC
Sequence 2435	D87682	ANUC	Sequence 2487	J05021	ANUC
Sequence 2436	D87735	ANUC	Sequence 2488	J05192	ANUC
Sequence 2437	D87969	ANUC	Sequence 2489	J05633	ANUC
Sequence 2438	D89052	ANUC	Sequence 2490	K00558	ANUC
Sequence 2439	D90226	ANUC	Sequence 2491	K01566	ANUC
Sequence 2440	D90220	ANUC	Sequence 2492	K02765	ANUC
Sequence 2441	E00882	ANUC	Sequence 2493	L00160	ANUC
Sequence 2442	E01650	ANUC	Sequence 2494	L02547	ANUC
•	E01797	ANUC	Sequence 2495	L05092	ANUC
Sequence 2443	LVIIJI	/1110C	Coquence 2700		• •

0.400	1.05400	AA11.10	Comunes 2549	M26041	ANUC
Sequence 2496	L05186	ANUC	Sequence 2548	M26152	ANUC
Sequence 2497	L07633	ANUC	Sequence 2549	M26325	ANUC
Sequence 2498	L11066	ANUC	Sequence 2550	M27913	ANUC
Sequence 2499	L11932	ANUC	Sequence 2551		ANUC
Sequence 2500	L12711	ANUC	Sequence 2552	M27971	ANUC
Sequence 2501	L13848	ANUC	Sequence 2553	M28373	
Sequence 2502	L14599	ANUC	Sequence 2554	M31159	ANUC
Sequence 2503	L19161	ANUC	Sequence 2555	M31212	ANUC
Sequence 2504	L19184	ANUC	Sequence 2556	M31899	ANUC
Sequence 2505	L19597	ANUC	Sequence 2557	M32110	ANUC
Sequence 2506	L20941	ANUC	Sequence 2558	M32790	ANUC
Sequence 2507	L23959	ANUC	Sequence 2559	M32798	ANUC
Sequence 2508	L26081	ANUC	Sequence 2560	M33308	ANUC
Sequence 2509	L27560	ANUC	Sequence 2561	M34064	ANUC
Sequence 2510	L28010	ANUC	Sequence 2562	M37583	ANUC
Sequence 2511	L28809	ANUC	Sequence 2563	M38106	ANUC
Sequence 2512	L33404	ANUC	Sequence 2564	M55409	ANUC
Sequence 2513	L33930	ANUC	Sequence 2565	M55542	ANUC
Sequence 2514	L34155	ANUC	Sequence 2566	M58485	ANUC
Sequence 2515	L34839	ANUC	Sequence 2567	M60457	ANUC
Sequence 2516	L38486	ANUC	Sequence 2568	M60854	ANUC
Sequence 2517	L42024	ANUC	Sequence 2569	M62403	ANUC
Sequence 2518	L43575	ANUC	Sequence 2570	M62810	ANUC
Sequence 2519	L44349	dbEST	Sequence 2571	M64241	ANUC
Sequence 2520	L54057	ANUC	Sequence 2572	M67468	ANUC
Sequence 2521	M10036	ANUC	Sequence 2573	M69181	ANUC
Sequence 2522	M10119	ANUC	Sequence 2574	M74002	ANUC
Sequence 2523	M10905	ANUC	Sequence 2575	M75126	ANUC
Sequence 2524	M11146	ANUC	Sequence 2576	M76729	ANUC
Sequence 2525	M13573	ANUC	Sequence 2577	M78113	dbEST
Sequence 2526	M13955	ANUC	Sequence 2578	M81757	ANUC
Sequence 2527	M14083	ANUC	Sequence 2579	M83248	ANUC
Sequence 2528	M14483	ANUC	Sequence 2580	M84739	ANUC
Sequence 2529	M14630	ANUC	Sequence 2581	M87503	ANUC
Sequence 2530	M14631	ANUC	Sequence 2582	M88279	ANUC
Sequence 2531	M15182	ANUC	Sequence 2583	M92357	ANUC
Sequence 2532	M15800	ANUC	Sequence 2584	N20576	dbEST
Sequence 2533	M16247	ANUC	Sequence 2585	N34255	dbEST
Sequence 2534	M16553	ANUC	Sequence 2586	N35187	dbEST
Sequence 2535	M16660	ANUC	Sequence 2587	N35421	dbEST
Sequence 2536	M16937	ANUC	Sequence 2588	N39717	dbEST
Sequence 2537	M17597	ANUC	Sequence 2589	N40823	dbEST
Sequence 2538	M17885	ANUC	Sequence 2590	N40852	dbEST
Sequence 2539	M20372	ANUC	Sequence 2591	N67927	dbEST
Sequence 2540	M22146	ANUC	Sequence 2592	N76180	dbEST
Sequence 2541	M22382	ANUC	Sequence 2593	N76677	dbEST
Sequence 2542	M22590	ANUC	Sequence 2594	N77080	dbEST
•	M22918	ANUC	Sequence 2595	N84497	dbEST
Sequence 2543	M22910	ANUC	Sequence 2596	N86776	dbEST
Sequence 2544		ANUC	Sequence 2597	N91638	dbEST
Sequence 2545	M23613	ANUC	Sequence 2598	N92086	dbEST
Sequence 2546	M24194	ANUC	Sequence 2599	N99205	dbEST
Sequence 2547	M25246	MADE	Gequence 2033	1103200	45201

Sequence 2600	Q37741	NUCPATENT	Sequence 2652	U22815	ANUC
Sequence 2601	Q48043	NUCPATENT	Sequence 2653	U24105	ANUC
Sequence 2602	Q65676	NUCPATENT	Sequence 2654	U24153	ANUC
Sequence 2603	Q90526	NUCPATENT	Sequence 2655	U27768	ANUC
Sequence 2604	R06046	dbEST	Sequence 2656	U33760	ANUC
Sequence 2605	R17092	dbEST	Sequence 2657	U33833	ANUC
Sequence 2606	R47228	dbEST	Sequence 2658	U34877	ANUC
Sequence 2607	R55150	dbEST	Sequence 2659	U39361	ANUC
Sequence 2608	R55398	dbEST	Sequence 2660	U41515	ANUC
Sequence 2609	R68132	dbEST	Sequence 2661	U46570	ANUC
Sequence 2610	R72676	dbEST	Sequence 2662	U50733	ANUC
Sequence 2611	R73306	dbEST	Sequence 2663	U51586	ANUC
Sequence 2612	R78333	dbEST	Sequence 2664	U56255	ANUC
Sequence 2613	R92367	dbEST	Sequence 2665	U59305	ANUC
Sequence 2614	R93637	dbEST	Sequence 2666	U60975	ANUC
Sequence 2615	R99649	dbEST	Sequence 2667	U61083	ANUC
Sequence 2616	S41458	ANUC	Sequence 2668	U61397	ANUC
Sequence 2617	S42303	ANUC	Sequence 2669	U63846	ANUC
Sequence 2618	S54005	ANUC	Sequence 2670	U67784	ANUC
Sequence 2619	S66431	ANUC	Sequence 2671	U68723	ANUC
Sequence 2620	S70154	ANUC	Sequence 2672	U68727	ANUC
•	S70134 S70290	ANUC	Sequence 2673	U68758	ANUC
Sequence 2621	S79895	ANUC	Sequence 2674	U70735	ANUC
Sequence 2622	S82076	ANUC	Sequence 2675	U77085	ANUC
Sequence 2623	T02792	NUCPATENT	Sequence 2676	U79258	ANUC
Sequence 2624	T24119	dbEST	Sequence 2677	U79274	ANUC
Sequence 2625	T49314	dbEST	Sequence 2678	U79278	ANUC
Sequence 2626	T53479	dbEST	Sequence 2679	U80213	ANUC
Sequence 2627	T58797	dbEST	Sequence 2680	U81234	ANUC
Sequence 2628	T64560	dbEST	Sequence 2681	U82130	ANUC
Sequence 2629	T66112	NUCPATENT	Sequence 2682	U86602	ANUC
Sequence 2630	T92160	NUCPATENT	Sequence 2683	U87309	ANUC
Sequence 2631	T92396	dbEST	Sequence 2684	U90028	ANUC
Sequence 2632	U00947	ANUC	Sequence 2685	U90441	ANUC
Sequence 2633 Sequence 2634	U04815	ANUC	Sequence 2686	U90902	ANUC
•	U07151	ANUC	Sequence 2687	U90917	ANUC
Sequence 2635 Sequence 2636	U07857	ANUC	Sequence 2688	U94831	ANUC
•	U08470	ANUC	Sequence 2689	V00478	ANUC
Sequence 2637 Sequence 2638	U10323	ANUC	Sequence 2690	V00503	ANUC
Sequence 2639	U10439	ANUC	Sequence 2691	V05728	NUCPATENT
Sequence 2640	U12465	ANUC	Sequence 2692	V11636	NUCPATENT
Sequence 2641	U13665	ANUC	Sequence 2693	V57903	NUCPATENT
Sequence 2642	U13877	ANUC	Sequence 2694	V59662	NUCPATENT
Sequence 2643	U14550	ANUC	Sequence 2695	V59746	NUCPATENT
•	U14966	ANUC	Sequence 2696	V84428	NUCPATENT
Sequence 2644	U15008	ANUC	Sequence 2697	V86232	NUCPATENT
Sequence 2645			Sequence 2698	V87930	NUCPATENT
Sequence 2646	U16306	ANUC	•	W07215	dbEST
Sequence 2647	U17104	ANUC	Sequence 2699	W19127	dbEST
Sequence 2648	U17496	ANUC	Sequence 2700	W19407	dbEST
Sequence 2649	U19769	ANUC	Sequence 2701	W19441	dbEST
Sequence 2650	U20896	ANUC	Sequence 2702	W25547	dbEST
Sequence 2651	U22431	ANUC	Sequence 2703	442534 <i>1</i>	UDES I

WO 01/18542 56

TABLE 1A

PCT/US00/24199

•					
Sequence 2704	W26197	dbEST	Sequence 2756	X73902	ANUC
Sequence 2705	W38952	dbEST	Sequence 2757	X74039	ANUC
Sequence 2706	W56388	dbEST	Sequence 2758	X74801	ANUC
Sequence 2707	W68015	dbEST	Sequence 2759	X74979	ANUC .
Sequence 2708	W73140	dbEST	Sequence 2760	X76013	ANUC
Sequence 2709	W73168	dbEST	Sequence 2761	X76180	ANUC
Sequence 2710	W76204	dbEST	Sequence 2762	X78627	ANUC
Sequence 2711	W87522	dbEST	Sequence 2763	X81109	ANUC
Sequence 2712	W87891	dbEST	Sequence 2764	X82676	ANUC
Sequence 2713	X00351	ANUC	Sequence 2765	X84939	NUCPATENT
Sequence 2714	X00497	ANUC	Sequence 2766	X85373	ANUC
Sequence 2715	X01742	ANUC	Sequence 2767	X93036	ANUC
Sequence 2716	X01924	NUCPATENT	Sequence 2768	X93207	ANUC
Sequence 2717	X03084	ANUC	Sequence 2769	X94323	ANUC
Sequence 2718	X04098	ANUC	Sequence 2770	X94754	ANUC
Sequence 2719	X04408	ANUC	Sequence 2771	X97324	ANUC
Sequence 2720	X04470	ANUC	Sequence 2772	X99920	ANUC
Sequence 2721	X05276	ANUC	Sequence 2773	Y00503	ANUC
Sequence 2722	X05908	ANUC	Sequence 2774	Y00757	ANUC
Sequence 2723	X06700	ANUC	Sequence 2775	Y00815	ANUC
Sequence 2724	X07819	ANUC	Sequence 2776	Y09188	ANUC
Sequence 2725	X13425	ANUC	Sequence 2777	Y11435	ANUC
Sequence 2726	X14420	ANUC	Sequence 2778	Y12065	ANUC
Sequence 2727	X15729	ANUC	Sequence 2779	Y13247	ANUC
Sequence 2728	X15880	ANUC	Sequence 2780	Y13286	ANUC
Sequence 2729	X16869	ANUC	Sequence 2781	Y15286	ANUC
Sequence 2730	X17206	ANUC	Sequence 2782	Y17114	ANUC
Sequence 2731	X24068	NUCPATENT	Sequence 2783	Z18538	ANUC
Sequence 2732	X37385	NUCPATENT	Sequence 2784	Z18954	ANUC
Sequence 2733	X37509	NUCPATENT	Sequence 2785	Z19054	ANUC
Sequence 2734	X40178	NUCPATENT	Sequence 2786	Z21507	ANUC
Sequence 2735	X51466	ANUC	Sequence 2787	Z26317	ANUC
Sequence 2736	X53505	ANUC	Sequence 2788	Z29093	ANUC
Sequence 2737	X54304	ANUC	Sequence 2789	Z31696	ANUC
Sequence 2738	X54941	ANUC	Sequence 2790	Z32564	ANUC
Sequence 2739	X55110	ANUC	Sequence 2791	Z36531	ANUC
Sequence 2740	X55885	ANUC	Sequence 2792	Z37986	ANUC
Sequence 2741	X56932	ANUC	Sequence 2793	Z46629	ANUC
Sequence 2742	X56998	ANUC	Sequence 2794	Z47087	ANUC
Sequence 2743	X56999	ANUC	Sequence 2795	Z74615	ANUC
Sequence 2744	X57766	ANUC			
Sequence 2745	X62744	ANUC			
Sequence 2746	X63432	ANUC			
Sequence 2747	X66360	ANUC			
Sequence 2748	X67698	ANUC			
Sequence 2749	X68277	ANUC			
Sequence 2750	X68880	ANUC			
Sequence 2751	X69398	ANUC			
Sequence 2752	X69838	ANUC			
Sequence 2753	X70340	ANUC			
Sequence 2754	X71087	ANUC			
Sequence 2755	X73608	ANUC			

57

TABLE 1A

Sequence 340: found in patent publication W098/39446
AGGCGTNCCTCTGACTGCCCACTCAGTGGCNNCACCNGGGAGCTGNTTTGGNGCTTTGGG
GANCCTNAACANTTNCNTCTTTCAAAACTNACTGGC

Sequence 1962: found in patent publication W098/42738

Sequence 341: found in patent publication W099/039941

CCCTTAGCGNGGTCGCGGCCGAGGCACAATTCGATTATTCACANGAAAGGGCAAACTGTT
NNTGTTNGCTGGCAGGAGNAGGTGCATATATACCAGCACTTCAAGTNNGGTATTTCCATT
CAGGACATTTTATCTCTGTGCAAAGACCGGAGTAGAAGCTGATGAGTGGATCAAGATATT
ACGCTGGAAATTGTCACAAATAAGAAAACAGCTCAACCAAGGGGAAGGCACCGATCCGAT
CTCGGTCGTTCATCTTTAAATAGATCTTTCTTGCCAAGGAATGCTCTGGCCCAGGAGCAA
GGTGGAATGCTTCCCTGACGCTGCGATCTGCAGCAGACTNCAAATGAAAACCGACTAAGG
ATTTTCTTTCAAAAACAAATCAGAAGCAGATGCTGATTGGGACCCATATACCACGTTGCT
GACTCACCGTTGCTGCCCTTNCATGGATGTTGCCATCTGCTTGAGAACACTGAAGCAATC
ACCATTCTNGATANGAAAGTGCTTAAACCCCCCACTCTTAGGGCTGCTCACTTCTTAGAAC
ACACAAAGGGAAGAGAGAAAGGGGT

Sequence 342: found in patent publication W099/18126

Sequence 1016: found in patent publication W099/38881

CTACTTAGGGCGAATTGGAGCTCCCCGCGGTGGCGGCCGAGGTCAAGCTTCGACCCCGCG
TCCGTGATAAACTACTTTTGGGTTTTATTTCATTGAGGCACTTTTTTTATTGTTTGAATG
ATTCCGGCTTGTAATATATCAGCCTCTACAATGAAATGCAGAAGAGTTCATTTTTCTAG
ATCTGTTTTTCATTAGAAATATTGACAAATAACACATTGTCAACCTGGATCCTTTGACA
TTTACTTAACTCTGGCATGTTCACAAAAAGTAGAAACTCTAAGAGACCATTACCATTTT
TCACAGATGTATAGGGGATGTATTCTAAAAACTGACAGAAAAGAGAAATTTGTCCCAACAGCC
ACTGTTAACTTTTACTGNGTAATTGCCAAATACACTTTTCCAAATTTGTCCCAACAGCC
TNTAAGCCAGCTTTCTTCTATATTTATAA

TABLE IA

ACC NUM	DATABASE	GI NBR
AA001066	DBEst	1437265
AA007157	DBEst	1463141
AA010954	DBEst	1472001
AA015792	DBEst	1476959
AA019769	DBEst	1483105
AA019948	DBEst	1483755
AA022925	DBEst	1487005
AA022937	DBEst	1487036
AA024405	DBEst	1489413
AA024403 AA029750	DBEst	1496068
	DBEst	1501463
AA031509		
AA033876	DBEst	1505694 1506265
AA034237	DBEst	
AA039967	DBEst	1516280
AA040073	DBEst	1516350
AA040122	DBEst	1516400
AA045732	DBEst	1525626
AA045861	DBEst	1525757
AA046835	DBEst	1524734
AA047026	DBEst	1525061
AA047417	DBEst	1525463
AA053486	DBEst	1544124
AA054658	DBEst	1545600
AA055606	DBEst	1547963
AA056113	DBEst	1548469
AA056176	DBEst	1548514
AA056363	DBEst	1548703
AA056431	DBEst	1548771
AA065336	DBEst	1929216
AA069781	DBEst	1577149
AA069784	DBEst	1577152
AA069839	DBEst	1577199
AA069983	DBEst	1577343
AA071255	DBEst	1578610
AA075135	DBEst	1615139
AA081655	DBEst	1623857
AA082245	DBEst	1624304
AA083471	DBEst	1625557
AA083510	DBEst	1625570
AA085862	DBEst	1629449
AA085872	DBEst	1629244
AA085947	DBEst	1629482
AA088770	DBEst	1634335
AA100333	DBEst	1646685
AA100719	DBEst	1647074
AA100793	DBEst	1647210
AA100852	DBEst	1647269
AA101270	DBEst	1647951
AA101561	DBEst	1648449
AA111907	DBEst	1663978
AA112043	DBEst	1664189
AA112308	DBEst	1664577
AA112306 AA112375	DBEst	1664785
AA112375 AA113860	DBEst	1667753
AA114120		1667996
	DREST	1669966
AA115118	DBEst	1670548
AA115368	DBEst	
AA122286	DBEst	1678525
AA122348	DBEst	1678587
AA126109	DBEst	1685775
AA127105	DBEst	1686466
AA127132	DBEst	1686492
AA127418	DBEst	1686707

TABLE 1-1

ACC NUM	DATABASE	GI NBR
AA128305	DBEst	1688355
AA129461	DBEst	1689332
AA130252	DBEst	1691414
AA130547	DBEst	1692100
AA130786	DBEst	1692452
AA131041	DBEst	1692593
AA131065	DBEst	1692555
AA131104	DBEst	1692612
AA131155	DBEst	1692646
AA131160	DBEst	1692668
AA132182	DBEst	1693860
AA132568	DBEst	1694075
AA132598	DBEst	1694087
AA133351	DBEst	1690319
AA133927	DBEst	1690994
AA134105	DBEst	1691317
AA134210	DBEst	1691566
AA135032	DBEst	1696143
AA135919	DBEst	1697105
AA136383	DBEst	1697611
AA136789	DBEst	1697998
AA143609	DBEst	1713177
AA146773	DBEst	1716163
AA147806	DBEst	1717195
AA148160	DBEst	1717542
AA148268	DBEst	1717666
AA148771 AA149056	DBEst	1721626
AA150307	DBEst DBEst	1719347
AA151310	DBESt	1721837 1719502
AA151775	DBEst	1719502
AA152037	DBEst	1720875
AA152416	DBEst	1718626
	DBEst	1727471
	DBEst	1727544
	DBEst	1729013
	DBEst	1729350
AA157788	DBEst	1732599
AA158165	DBEst	1732959
	DBEst	1732965
	DBEst	1734074
AA160114	DBEst	1734680
	DBEst	1736087
	DBEst	1735771
	DBEst	1740715
	DBEst	1740624
	DBEst	1740311
	DBEst	1741662
	DBEst	1745366
	DBEst	1750569
	DBESt	1754310
	DBEst	1753798
	DBEST	1753763
	DBEST DBEST	1760830
_	DBEst DBEst	1775129
		1774167
	DBEst DBEst	1775616 1781932
	DBESt	1795418
	DBESt	1798950
	DBESt	1798930
	DBEst	1801222
	DBEst	1807445
	- 	-001233

ACC NUM	DATABASE	GI NBR
AA209531	DBEst	1807492
AA214075	DBEst	1812697
AA216612	DBEst	1817292
AA224230	DBEst	1844755
AA224985	DBEst	1846276
AA226502	DBEst	1847857
AA229225	DBEst	1851057
AA232626	DBEst DBEst	1855763 1856920
AA233843 AA242891	DBEst	1873684
AA250725	DBEst	1885707
AA250725 AA250982	DBEst	1885943
AA256959	DBEst	1891227
AA259077	DBEst	1894348
AA262440	DBEst	1897800
AA263110	DBEst	1898920
AA283165	DBEst	1926099
AA285260	DBEst	1929570
AA287112	DBEst	1934119
AA292191	DBEst	1940291
AA292334	DBEst	1940314
AA292385	DBEst	1940380
AA292771	DBEst	1941593
AA293273	DBEst	1941423
AA293572	DBEst	1941239
AA295348	DBEst	1947743
AA295485	DBEst	1947839
AA301631	DBEst	1954115 1957001
AA304669 AA304961	DBEst DBEst	1957288
AA304961 AA305193	DBEst	1957520
AA305193 AA305438	DBEst	1957763
AA306542	DBEst	1958871
AA306708	DBEst	1959036
AA306945	DBEst	1959275
AA307239	DBEst	1959567
AA307477	DBEst	1960025
AA307504	DBEst	1959872
AA307697	DBEst	1960187
AA307779	DBEst	1960177
AA308062	DBEst	1960391
AA308801	DBEst	1961131
AA309028	DBEst	1961354
AA309988	DBEst	1962337 1963405
AA311006	DBEst	1963975
AA311481 AA312012	DBEst DBEst	1964341
AA312012 AA313684	DBEst	1966083
AA314146	DBEst	1966495
AA314140 AA315049	DBEst	1967529
AA315308	DBEst	1967637
AA315426	DBEst	1967755
AA316682	DBEst	1969010
AA319958	DBEst	1972449
AA320346	DBEst	1972675
AA320991	DBEst	1973319
AA328544	DBEst	1980860
AA330457	DBEst	1982700
AA338793	DBEst	1991103
AA340069	DBEst	1992307
AA341170	DBEst	1993406
AA342394	DBEst	1994715
AA348250	DBEst	2000486

TABLE 1-1

ACC NUM	DATABASE	GI NBR
AA349148	DBEst	2001385
AA351443	DBEst	2003763
AA351880	DBEst	2004198
AA356158	DBEst	2008784
AA356187	DBEst	2008516
AA356195	DBEst	2008524
AA357374	DBEst	2009714
AA367446	DBEst	2019764
AA375236	DBEst	2027555
AA377718 AA380997	DBEst	2030037
AA383917	DBEst DBEst	2033336
AA385147	DBESt	2036256 2037466
AA389641	DBEst	2037466
AA393164	DBESt	2042627
AA393236	DBEst	2046205
AA394242	DBEst	2047227
AA398732	DBEst	2051854
AA401864	DBEst	2055883
AA410508	DBEst	2069614
AA410580	DBEst	2069686
AA410942	DBEst	2070196
AA411334	DBEst	2068883
AA411599	DBEst	2069132
AA418061	DBEst	2079935
AA418473 AA418970	DBEst	2080273
AA420789	DBEst DBEst	2080798
AA421682	DBEst	2094677 2100499
AA421850	DBEst	2100499
AA424529	DBEst	2103499
AA428421	DBEst	2112235
AA429754	DBEst	2112972
AA441787	DBEst	2153671
AA451633	DBEst	2165302
AA453309	DBEst	2166978
AA453559 AA453570	DBEst	2167228
AA453570 AA454871	DBEst DBEst	2167239
AA454913	DBESt	2177647 2177689
AA456892	DBEst	2179612
AA457048	DBEst	2179768
AA463426	DBEst	2188310
AA465039	DBEst	2189923
AA477173	DBEst	2205857
AA480921	DBEst	2210473
AA484050	DBEst	2212863
AA484756	DBEst	2214141
AA487483 AA489640	DBEst	2217647
AA493886	DBEst	2219242
AA494493	DBEst DBEst	2223727
AA496518	DBESt	2224280
AA501749	DBESt	2229839 2236716
AA501822	DBESt	2236716
AA501945	DBEst	2236912
AA504490	DBEst	2240650
AA507234	DBEst	2243673
AA513640	DBEst	2252052
AA526227	DBEst	2268296
AA526889	DBEst	2268958
AA527139	DBEst	2269208
AA527188	DBEst	2269257

ACC NUM	DATABASE	GI NBR
AA531428	DBEst	2274134
AA532633	DBEst	2276887 2279724
AA535471 AA554757	DBEst DBEst	2325296
AA565996	DBESt	2337635
AA568217	DBEst	2341271
AA573742	DBEst	2348257
AA573893	DBEst	2348408
AA574237	DBEst	2348752
AA576866	DBEst	2354340
AA579034	DBEst	2357218
AA579816	DBEst	2358000
AA581220	DBEst	2358992
AA581264	DBEst	2359036
AA582093	DBEst	2360771 2360451
AA583091 AA584411	DBEst DBEst	2369020
AA584411 AA586776	DBEst	2397590
AA587110	DBEst	2397924
AA587233	DBEst	2398047
AA587700	DBEst	2401875
AA609259	DBEst	2457687
AA609837	DBEst	2458265
AA613907	DBEst	2466041
AA614529	DBEst	2466725
AA618033	DBEst	2505238
AA628487	DBEst	2540874 2553815
AA631204 AA631811	DBEst DBEst	2554422
AA640901	DBEst	2566151
AA641841	DBEst	2567059
AA642215	DBEst	2567433
AA643602	DBEst	2568820
AA651720	DBEst	2583372
AA664996	DBEst	2619609
AA668297 AA668836	DBEst DBEst	2629796 2630335
AA675923	DBESt	2775270
AA687833	DBEst	2674739
AA704992	DBEst	2714910
AA732702	DBEst	2753309
AA745241	DBEst	2785227
AA746481	DBEst	2786467
AA758889	DBEst	2806752
AA772570	DBEst	2824353 2825632
AA772790 AA776709	DBEst DBEst	2836043
AA776709 AA776811	DBEst	2836142
AA777384	DBEst	2836715
AA778116	DBEst	2837517
AA779868	DBEst	2839199
AA781343	DBEst	2840674
AA809984	DBEst	2879390
AA810945	DBEst	2880556
AA811200	DBEst	2880811
AA825768	DBEst DBEst	2899080 2900436
AA828073 AA828722	DBESt	2900436
AA843176	DBESt	2929694
AA843661	DBEst	2930179
AA876526	DBEst	2985603
AA883255	DBEst	2992785
AA906652	DBEst	3042238

ACC NUM	DATABASE	GI NBR
AA917638	DBEst	3057528
AA927734	DBEst	3076554
AA954939	DBEst	3118634
AA962622	DBEst	3134786
AA991285	DBEst	3177774
AB000115	GenBank	2564034
AB004047	GenBank	2116654
AB006746	GenBank	3510296
AB007619	GenBank	2465179
AB007860 AB007965	GenBank	2662080
AB007905 AB011101	GenBank GenBank	3413940 3043581
AB011101 AB011169	GenBank	3043581
AB011103 AB012701	GenBank	6714554
AB014536	GenBank	3327085
AB014565	GenBank	3327143
AB019568	GenBank	3885371
AB020623	GenBank	3985929
AB020629	GenBank	4240129
AB020693	GenBank	4240260
AB021288	GenBank	4038732
AB022663	GenBank	5019617
AB023214	GenBank	4589637
AB023230	GenBank	4589675
AC02059	N/A	N/A
AC03653	N/A	N/A
AC13415	N/A	N/A
AF000982 AF002985	GenBank	2580549
AF005654	GenBank GenBank	2580585
AF006086	GenBank	2337951 2282037
AF007791	GenBank	3779196
AF013758	GenBank	3046899
AF013988	GenBank	2318114
AF021232	GenBank	3452182
AF026939	GenBank	2612967
	GenBank	2612970
AF026942	GenBank	2612971
AF026943	GenBank	2612972
	GenBank	2612973
AF028832	GenBank	3287488
AF030455	GenBank	3169829
	GenBank	3219692
	GenBank	4104081 2645728
	GenBank GenBank	2645728
	Genbank GenBank	2661078
	GenBank	2906012
	GenBank	3779225
	GenBank	3132899
	GenBank	4405794
	GenBank	3452280
AF044956	GenBank	5326827
	GenBank	3893854
	GenBank	3170363
	GenBank	3095110
	GenBank	3360431
	GenBank	2967847
	GenBank	2996191
	GenBank	2997740
	GenBank	3005735
	GenBank GenBank	4335936 4335940
AL VUI/JU	GENDANK	4333740

PCT/US00/24199 WO 01/18542 65

ACC NUM	DATABASE	GI NBR
AF064603	GenBank	3152659
AF064854	GenBank	4206066
AF065388	GenBank	3152700
AF067168	GenBank	4894369
AF067174	GenBank	4894381
AF067817	GenBank	3928846
AF070523	GenBank	3764088
AF070561	GenBank	3387928
AF070562	GenBank	3387930
AF070596	GenBank	3387973
AF070664	GenBank	4454703
AF070674	GenBank	3978243
AF077048	GenBank	4689143
AF077051	GenBank	4689149
AF077200	GenBank	4679013
AF077671	GenBank	3386485
AF080246	GenBank	3406799
AF081484	GenBank	3420928
AF083470	GenBank	3719293
AF084523	GenBank	3550342
AF085355	GenBank	5114044
AF086003	GenBank	3483348
AF086080	GenBank	3483425
AF086183	GenBank	3483528
AF086545	GenBank	3483890
AF091263	GenBank	4140646
AF111713	GenBank	5326796
AF118023	GenBank	4836400
AF124438	GenBank	4838431
AF124439	GenBank	4838433
AF131808	GenBank	4406640
AF131820	GenBank	4406655
AF131848	GenBank	4406690
AF132966	GenBank	4680702
AF132968	GenBank	4680706
AF146277	GenBank	4960046
AF147331	GenBank	4761682
AF150100	GenBank	5107187
AF150266	DBEst	5133702
AF151873	GenBank	4929698
AF151877	GenBank GenBank	4929706 5732679
AF151978	•	5733691
AF167160	GenBank DBEst	3239819
AI023413 AI027888		3246587
AI027888 AI031811	DBEst	3250023
	DBEst DBEst	3254640
AI033687 AI042140	DBEst	3281334
AI042140 AI075324	DBEst	3399895
A1075324 A1075876	DBEst	3405054
AI126802	DBEst	3595316
AI120002 AI127556	DBEst	3596070
AI129360	DBEst	3597874
AI139456	DBEst	3645428
AI140291	DBEst	3647748
AI140251 AI144215	DBEst	3666024
AI144213 AI161378	DBEst	3693062
AI188638	DBEst	3739847
AI215617	DBEst	3784658
A1216969	DBEst	3789623
AI241578	DBEst	3836975
AI250167	DBEst	3846696
AI253330	DBEst	3850451

TABLE 1-1

ACC NUM	DATABASE	GI NBR
AI253335 AI253369	DBEst	3850456
AI253436	DBEst DBEst	3850490 3850391
AI261671	DBEst	3869874
AI262264	DBEst	3870467
AI267162	DBEst	3886329
AI267379	DBEst	3886546
AI267502 AI267622	DBEst	3886669
A1267622 A1279131	DBEst DBEst	3886789 3917365
AI285943	DBESt	3924176
AI289173	DBEst	3932437
AI290876	DBEst	3933650
AI292104	DBEst	3934878
AI300033	DBEst	3959379
AI300074 AI312113	DBEst DBEst	3959420
AI336032	DBESt	4017718 4072959
AI337069	DBEst	4073996
AI340262	DBEst	4077189
AI346975	DBEst	4084181
AI354639	DBEst	4094792
AI366381 AI369024	DBEst DBEst	4126070
AI382020	DBESt	4147777 4194801
AI400372	DBEst	4243459
AI417973	DBEst	4261477
AI431963	DBEst	4306858
AI453405 AI457157	DBEst	4281647
AI457624	DBEst DBEst	4310026 4310493
AI459679	DBEst	4312560
AI460010	DBEst	4312891
AI469095	DBEst	4331185
AI469715	DBEst	4331805
AI471539 AI476335	DBEst DBEst	4333629
AI479289	DBEst	4329380 4372457
AI499285	DBEst	4391267
AI521180	DBEst	4435315
AI538061	DBEst	4452196
AI567204 AI587104	DBEst	4525656
AI587328	DBEst DBEst	4573545 4573769
AI609624	DBEst	4618791
AI610607	DBEst	4619774
AI612873	DBEst	4622040
AI627444	DBEst	4664244
AI632869 AI633164	DBEst DBEst	4684199 4684494
AI636014	DBEst	4684494
AI637620	DBEst	4689854
AI676218	DBEst	4876698
AI683871	DBEst	4894053
AI684170	DBEst	4895464
AI693877 AI694088	DBEst	4971217
AI732534	DBEst DBEst	4971428 5053647
AI743595	DBEst	5111883
AI744489	DBEst	5112777
AI745058	DBEst	5113346
AI753108	DBEst	5131372
AI791322	DBEst	5339038

TABLE 1-1

ACC NUM	DATABASE	GI NBR
A1798474	DBEst	5363946
AI803838	DBEst	5369310
AI811960	DBEst	5398526
AI813617	DBEst	5424832
AI815829	DBEst	5431375
AI826957	DBEst	5447628
AI831002	DBEst	5451673
AI863041	DBEst	5527148
AI867294	DBEst	5540310
AI912076	DBEst	5631931
AI915553	DBEst	5635408 2764616
AJ001381	GenBank	2769433
AJ003401 AJ010071	DBEst GenBank	3483016
AJ132502	GenBank	5629914
AD132302 AL044356	DBEst	5432578
AL044825	DBEst	5433037
AL047024	DBEst	5435080
AL048393	DBEst	5936479
AL049313	GenBank	4500086
AL049923	GenBank	4884169
AL049954	GenBank	4884203
AL050024	GenBank	4884093
AL050272	GenBank	4886498
AL050395	GenBank	4914616
AL096714	GenBank	5419847
AL096748	GenBank	5419879
AL096842	GenBank	5524930
AL110124	GenBank	5817017
C17346	DBEst	1572053
D00017	GenBank	219909
D00068	GenBank	220080 2148277
D11960 D12502	DBEst GenBank	219494
D12302 D12763	GenBank	220076
D13380	GenBank	220073
D13645	GenBank	286008
D13866	GenBank	433410
D14697	GenBank	285964
D21260	GenBank	434760
D23660	GenBank	432358
D26155	GenBank	505086
D26599	GenBank	565648
D28759	GenBank	633074
D29640	GenBank	473930
D31763	GenBank	498151
D31767	GenBank	505091
D31883	GenBank	505093
D38524	GenBank	633070 577292
D42040	GenBank GenBank	1008914
D45248	GenBank	682747
D49396 D50372	GenBank	2605593
D50372 D50420	GenBank	2618577
D55653	GenBank	871882
D81522	DBEst	1179399
D83077	GenBank	1304131
D83767	GenBank	1913784
D86958	GenBank	1503989
D86979	GenBank	6634000
D87666	GenBank	1620016
D87667	GenBank	1620019
D87735	GenBank	1620021

ACC NUM	DATABASE	GI NBR
D88532	GenBank	1661000
D89053 D90311	GenBank GenBank	4165017
D90453	GenBank	219496 219897
E01197	GenBank	2169456
E01198	GenBank	2169457
E01630	GenBank	2169883
E01954	GenBank	2170202
E01971	GenBank	2170219
E01972	GenBank	2170220
E02628	GenBank	2170856
E03569	GenBank	2171785
E03879	GenBank	2172093
E08663	GenBank	2176776
F06593 F28779	DBEst	672186
H25806	DBEst DBEst	4814405 894929
H47546	DBEst	923598
H48873	DBEst	988713
H66467	DBEst	1025207
Н88415	DBEst	1070675
J00196	GenBank	188242
J03575	GenBank	189737
J03858	GenBank	179439
J03909	GenBank	186264
J04164	GenBank	177801
K00422 K01763	GenBank GenBank	184322
L00693	GenBank	184316 180228
L02426	GenBank	403455
L06328	GenBank	340200
L09159	GenBank	307374
L10413	GenBank	388755
L11066	GenBank	307322
L20688	GenBank	404044
L20941 L28997	GenBank GenBank	507251
L38995	GenBank	607027 704415
L41490	GenBank	927064
M10119	GenBank	182517
M13536	GenBank	180248
M14328	GenBank	182113
M14764	GenBank	189204
M15329	GenBank	186277
M16660 M17017	GenBank	184420
M18216	GenBank GenBank	179579 178690
M19723	GenBank	186726
M22918	GenBank	189019
M23613	GenBank	189271
M24194	GenBank	187701
M24594	GenBank	186262
M26152	GenBank	1160968
M29540	GenBank	180222
M29541	GenBank	189103
M29551 M33146	GenBank ConBank	180708
M34064	GenBank GenBank	181070 416292
M34455	GenBank GenBank	185790
M35198	GenBank	9446401
M36693	GenBank	338285
M37716	GenBank	338266
M55268	GenBank	177837

ACC NUM	DATABASE	GI NBR
M55542	GenBank	183001
M55543	GenBank	829176 178986
M57567	GenBank GenBank	188268
M60333	GenBank	340367
M61715	GenBank	182260
M62831 M63121	GenBank	339755
M63121 M63838	GenBank	184568
M68520	GenBank	180177
M77945	DBEst	273682
M80563	GenBank	179916
M81757	GenBank	337732
M83248	GenBank	189150
M83654	GenBank	179660
M86553	GenBank	179958
M87284	GenBank	338651
M87434	GenBank	338653
M87503	GenBank	184652
м92357	GenBank	306463
м96982	GenBank	338262
м97501	GenBank	180621
M97935	GenBank	2281070 1157488
N36346	DBEst DBEst	1192428
N51262 N57413	DBEst	1201303
N78477	DBEst	1241178
N92060	DBEst	1264369
Q21065	N/A	N/A
Q94780	N/A	N/A
R13925	DBEst	767001
R51732	DBEst	813634
R56461	DBEst	826567
R66489	DBEst	839127
R75621	DBEst	850303
S45630	GenBank	256398
\$70290	GenBank	546602
\$75295 \$76638	GenBank GenBank	913392 243420
S76638 T34641	DBEst	616739
T50925	DBEst	652785
T52715	DBEst	654575
T54951	DBEst	656812
T70793	DBEst	685314
U03886	GenBank	458225
U04313	GenBank	453368
U07550	GenBank	469170
U07857	GenBank	469048
U08815	GenBank	508722
U09559	GenBank	791184
U09847	GenBank	495565
U10439	GenBank	577169
U14966	GenBank GenBank	550012 603763
U18321	GenBank	755465
U19878 U23942	GenBank	1698395
U25789	GenBank	808089
U28249	GenBank	897916
U28964	GenBank	899458
U32500	GenBank	1000750
U32944	GenBank	1209060
U33760	GenBank	995823
U37230	GenBank	1574941
U37518	GenBank	1149557

ACC NUM	DATABASE	GI NBR
U38292	GenBank	1790879
U38784	GenBank	1574947
U41371	GenBank	1173904
U41515	GenBank	1209723
U52513	GenBank	1777781
U56255	GenBank	1399688
U57847	GenBank	1373420
U61083	GenBank	4097430
U68758	GenBank	4097815
U73524	GenBank	1644401
U77085	GenBank	1684789
U78722	GenBank	1699000
U79751	GenBank	2257753
U94586	GenBank	1946691
V00572	GenBank	35434
V00594.	GenBank	37120
V04202	N/A	N/A
V17906	N/A	N/A
V36078	N/A	N/A
V68140	N/A	N/A
V86134	N/A	N/A
W02908	DBEst	1274885
W05711	DBEst	1278502
W07308 W25547	DBEst DBEst	1281506 1303421
W28837	DBESt	1303421
W37272	DBEst	1318866
W38644	DBEst	1320349
W39262	DBEst	1320979
W39498	DBEst	1321206
W52254	DBEst	1349394
W74319	DBEst	1384468
W77987	DBEst	1388521
W80480	DBEst	1391538
X00637	GenBank	32429
X01742	GenBank	35324
X02530	GenBank	33917
X02661	GenBank	23795
X04316	N/A	N/A
X04371	GenBank	23792
X04470 X05908	GenBank GenBank	28638
X07819	GenBank GenBank	34387 35798
X13238	GenBank	1200056
X15674	GenBank	35995
X15729	GenBank	38317
X16354	GenBank	37197
X16356	GenBank	37203
X16455	GenBank	29854
X17025	GenBank	488749
X20432	N/A	N/A
X30167	N/A	N/A
X33937	N/A	N/A
X35726	N/A	N/A
X41105	N/A	N/A
X51841	GenBank	33910
X54941	GenBank	29976
X56932	GenBank	23690
X57351	GenBank	311373
X59710	GenBank	35049
X65614	GenBank GenBank	36177
X67951 X68060	GenBank GenBank	287640 37230
A00000	GCIIDAIIA	31230

ACC NUM	DATABASE	GI NBR
X68277	GenBank	29980
x72790	GenBank	311401
X76488	GenBank	434305
x83544	GenBank	1089849
X85134	GenBank	755749 1143491
x87949	GenBank	1085025
X93036 X99699	GenBank GenBank	1869900
X99099 X99920	GenBank	1694827
Y09267	GenBank	1834492
Y13323	GenBank	5042231
Y17392	GenBank	3212109
z12830	GenBank	551637
Z36815	GenBank	533929
247087	GenBank	860989
Z48570	GenBank	695580
Z71389	GenBank	2239127
AA002223	DBEst	1445158
AA018843	DBEst	1482235
AA021647	DBEst	1485308
AA022842	DBEst	1487015
AA022965	DBEst	1487064
AA024522	DBEst	1489238
AA028164	DBEst	1494289 1507603
AA035775 AA037294	DBEst DBEst	1512438
AA039967	DBESt	1516280
AA045637	DBEst	1525513
AA046815	DBEst	1524920
AA046853	DBEst	1524752
AA047052	DBEst	1524950
AA047213	DBEst	1525113
AA057071	DBEst	1549810
AA058933	DBEst	1551788
AA064952	DBEst	1559216
AA075089	DBEst	1615078
AA076291	DBEst	1616160
AA078508	DBEst DBEst	1837982 1623371
AA080864 AA083345	DBESt	1625405
AA083693	DBEst	1625753
AA085497	DBEst	1628765
AA086463	DBEst	1629080
AA093935	DBEst	1639528
AA100291	DBEst	1646582
AA101207	DBEst	1647860
AA102403	DBEst	1647188
AA111856	DBEst	1663943
AA115174	DBEst	1670371
AA122134	DBEst	1678255
AA122291	DBEst	1678547
AA125780	DBEst	1685521
AA127322	DBEst	1686638 1691715
AA130432	DBEst DBEst	1691715
AA131801 AA132445	DBEST	1693290
AA134109	DBESt	1691321
AA135924	DBEst	1697110
AA136322	DBEst	1697597
AA143034	DBEst	1712411
AA150057	DBEst	1721279
AA151651	DBEst	1720206
AA156335	DBEst	1727969

PCT/US00/24199

TABLE 1-1

ACC NUM	DATABASE	GI NBR
AA157333	DBEst	1728942
AA158987	DBEst	1733823
AA165439 AA165632	DBEst	1741455
AA165618	DBEst DBEst	1741665 1745207
AA172067	DBEst	1745207
AA172007 AA173031	DBEst	1754310
AA178870	DBEst	1760393
AA181874	DBEst	1765359
AA195194	DBEst	1784884
AA203206	DBEst	1798916
AA203289	DBEst	1799038
AA204768	DBEst	1802618
AA206621	DBEst	1802009
AA213914	DBEst	1812716
AA218919	DBEst	1832993
AA224050	DBEst	1844591
AA224244	DBEst	1844769
AA227596	DBEst	1849140
AA229018	DBEst	1851983 1851090
AA229161 AA236445	DBEst DBEst	1858734
AA236680	DBEst	1860973
AA243537	DBEst	1874328
AA252436	DBEst	1887407
AA252869	DBEst	1885537
AA256330	DBEst	1891867
AA262700	DBEst	1898112
AA278358	DBEst	1921666
AA287076	DBEst	1934137
AA291551	DBEst	1939545
AA293273	DBEst	1941423
AA295982	DBEst DBEst	1948378 1954018
AA301675 AA301722	DBESt	1954065
AA301722 AA302964	DBEst	1955294
AA303199	DBEst	1955604
AA304927	DBEst	1957254
AA305042	DBEst	1957368
AA305635	DBEst	1957960
AA315030	DBEst	1967520
AA315943	DBEst	1968272
AA317144	DBEst	1969699
AA326060	DBEst	1978315
AA327358	DBEst	1979623 1988636
AA336387 AA346413	DBEst DBEst	1998651
AA352580	DBESt	2004900
AA363162	DBEst	2015480
AA375754	DBEst	2028074
AA399230	DBEst	2053028
AA400249	DBEst	2054315
AA401629	DBEst	2055827
AA402885	DBEst	2056782
AA406401	DBEst	2064402
AA421682	DBEst	2100499
AA422057	DBEst	2100890
AA424445	DBEst	2103415
AA424901	DBEst	2107006 2107137
AA424984 AA425182	DBEst DBEst	2107137
AA428607	DBEst	2112800
AA446099	DBEst	2158764

PCT/US00/24199 WO 01/18542 73

ACC NUM	DATABASE	GI NBR
AA446403	DBEst	2159068
AA447735	DBEst	2161405
AA449054	DBEst	2163074
AA449205	DBEst	2162668
AA449520	DBEst	2163270
AA452273	DBEst	2165942
AA455007	DBEst	2177783
AA455104	DBEst	2177880
AA459527	DBEst	2184434
AA460226	DBEst	2185042
AA461287	DBEst	2186407
AA464526	DBEst	2189410
AA468398	DBEst	2194932
AA469135	DBEst	2195669
AA469453	DBEst	2194248
AA470690	DBEst	2197999
AA479427	DBEst	2207983
AA480336	DBEst	2208487
AA483454	DBEst	2212267
AA487669	DBEst	2217833
AA488423	DBEst	2215854
AA488635	DBEst	2216066
AA488843	DBEst	2218445
AA489772	DBEst	2220656
AA503972	DBEst	2238939
AA508506	DBEst	2246009
AA513550	DBEst	2251962
AA513783	DBEst	2252204
AA514989	DBEst	2254589
AA516400	DBEst	2253762
AA520993	DBEst	2261536
AA521110	DBEst	2261653
AA523639	DBEst	2264567
AA523697	DBEst	2264625
AA528106	DBEst	2270175
AA528190	DBEst	2270259
AA528226	DBEst	2270295 2279083
AA534830	DBEst	22/9083
AA548722	DBEst	2319004
AA551236 AA551243	DBEst DBEst	2321488
AA551243 AA558778	DBESt	2329255
AA563834		2335473
AA576432	DBEst DBEst	2353932
AA580069	DBESt	2355396
AA580294	DBEst	2355621
AA582588	DBESt	2359948
AA584304	DBEst	2368913
AA588772	DBEst	2402503
AA593075	DBESt	2402303
AA595585	DBEst	2410935
AA601895	DBEst	2436048
AA628700	DBESt	2541087
AA630326	DBEst	2552937
AA630642	DBEst	2553253
AA631178	DBEst	2553789
AA631218	DBESt	2553829
AA633550	DBEst	2556764
AA634808	DBESt	2558022
AA639199	DBEst	2562978
AA639791	DBEst	2563570
AA644273	DBEst	2569491
AA648897	DBEst	2575326

ACC NUM	DATABASE	GI NBR
AA664732	DBEst	2619345
AA677550	DBEst	2658072
AA687308	DBEst	2675499
AA705002	DBEst	2714920
AA706685	DBEst	2716603
AA708266	DBEst	2718184
AA713687	DBEst	2725961 2732717
AA719618	DBEst	2732717
AA719674	DBEst	2736707
AA720572	DBEst DBEst	2737814
AA721752 AA723612	DBEst	2741319
AA730571	DBEst	2751775
AA742282	DBEst	2784282
AA748437	DBEst	2788395
AA749187	DBEst	2789145
AA761602	DBEst	2810532
AA768355	DBEst	2819370
AA769127	DBEst	2820365
AA774030	DBEst	2825919
AA774247	DBEst	2825545
AA779631	DBEst	2838962 2878153
AA808747	DBEst	2879260
AA809854	DBEst DBEst	2880470
AA810859 AA825673	DBEst	2898985
AA825768	DBESt	2899080
AA826517	DBEst	2898339
AA827331	DBEst	2899772
AA827764	DBEst	2901323
AA829511	DBEst	2902610
AA831603	DBEst	2904702
AA836991	DBEst	2912190 2912453
AA837254	DBEst DBEst	2932620
AA846480 AA846840	DBESt	2932980
AA853515	DBEst	2940254
AA883212	DBEst	2992742
AA886885	DBEst	3001993
AA889485	DBEst	3016364
AA897461	DBEst	3034081
AA902582	DBEst	3037705
AA902644	DBEst .	3037767
AA909144	DBEst	3048549 3052673
AA913281	DBEst DBEst	3056148
AA916756 AA922420	DBEst	3069729
AA922420 AA927283	DBEst	3076180
AA933075	DBEst	3087008
AA935979	DBEst	3093136
AA937947	DBEst	3096058
AA948295	DBEst	3109548
AA969131	DBEst	3144311
AA971881	DBEst	3147171 3148199
AA973019	DBEST	3148199
AA988923	DBEst DBEst	3174829
AA989465	DBESt	3180568
AA994023 AB002310	GenBank	2224564
AB002310 AB002330	GenBank	2224604
AB002330 AB007944	GenBank	3413911
AB012911	GenBank	3062802
AB017019	GenBank	4512256

ACC NUM	DATABASE	GI NBR
AB018266	GenBank	3882166
AB018305	GenBank	3882244
AB018347	GenBank	3882328
AB019568	GenBank	3885371
AB023158	GenBank	4589525
AB028976	GenBank	5689442
AB029005	GenBank	5689500
AC28164	N/A	N/A
AD001528	GenBank	2198556
AF000231	GenBank	2149974
AF006088	GenBank	2282041
AF006516	GenBank	2245670
AF012072	GenBank	2895096
AF026947	GenBank	2736255
AF028832	GenBank	3287488
AF030424	GenBank	2623155
AF031379	GenBank	4894208
AF035287	GenBank	2661040
AF035309	GenBank	2661070
AF038197	GenBank	2795918
AF038404	GenBank	2707904
AF043431	GenBank	3452280
AF044670	GenBank	4191318
AF044958	GenBank	4164447
AF047184	GenBank	2909859
AF052164	GenBank	3360475
AF052496	DBEst	3090893
AF052578	GenBank	2967847
AF054990	GenBank	3005703
AF059524	GenBank	4091867
AF070561	GenBank	3387928
AF070626	GenBank	3283892
AF070655	GenBank	4454685
AF070674	GenBank	3978243 3377580
AF075040	GenBank GenBank	4689107
AF077030 AF078847	GenBank	5531808
AF080246	GenBank	3406799
AF081282	GenBank	4336324
AF081484	GenBank	3420928
AF084523	GenBank	3550342
AF086163	GenBank	3483508
AF095791	GenBank	3777595
AF100756	GenBank	5410297
AF107406	GenBank	5531905
AF119297	GenBank	4633508
AF131858	GenBank	4406705
AF132940	GenBank	4680650
AF151857	GenBank	4929666
AI028733	DBEst	3246042
AI031901	DBEst	3250113
AI033739	DBEst	3254692
AI040324	DBEst	3279518
AI051172	DBEst	3306706
AI076805	DBEst	3404634
AI087005	DBEst	3425428
AI089913	DBEst	3428972
AI092007	DBEst	3427205
AI127326	DBEst	3595840
AI147251	DBEst	3674933
AI148933	DBEst	3677402
AI149846	DBEst	3678315
A1167855	DBEst	3701025

ACC NUM	DATABASE	GI NBR
AI183965	DBEst	3734603
AI189258	DBEst	3740467
AI220148	DBEst	3802351
AI224374	DBEst	3807087
AI240095	DBEst	3835492
AI246677	DBEst	3842074
AI248538	DBEst	3843935
AI266582	DBEst	3884740
AI268864	DBEst	3888031
AI270183	DBEst	3889350
AI271795	DBEst	3890962
AI273008	DBEst	3895276
AI273841	DBEst	3896109
AI274756	DBEst	3897030
AI275528	DBEst	3897802
AI283096	DBEst	3921329
AI298059	DBEst	3957795
AI335653	DBEst	4072580 4075904
AI338977	DBEst	4076873
AI339946	DBEst	4152898
AI373032	DBEst	4174944
AI374954	DBEst DBEst	4174944
AI374954 AI380539	DBESt	4190392
A1380539 A1417583	DBESt	4261087
A1417563 A1432644	DBEst	4283347
AI432544 AI433157	DBEst	4287209
A1457792	DBEst	4310661
AI469112	DBEst	4331202
AI471114	DBEst	4333204
AI471534	DBEst	4333624
AI473927	DBEst	4326972
AI479305	DBEst	4372473
AI499243	DBEst	4391225
AI525796	DBEst	4439931
AI525843	DBEst	4439978
AI537677	DBEst	4451812
AI541029	DBEst	4458402
AI560129	DBEst	4510470
AI583108	DBEst	4569005
AI584068	DBEst	4569965
AI587208	DBEst	4573649 4598915
AI589867	DBEst	4619843
AI610676	DBEst	4681692
A1630362	DBEst DBEst	4684336
A1633006	DBEst	4685773
AI634443 AI635096	DBEst	4686426
A1682105	DBEst	4892287
A1682105 A1683338	DBEst	4893520
A1684800	DBEst	4896094
A1684991	DBEst	4896285
A1689369	DBEst	4900663
A1689617	DBEst	4900911
AI689883	DBEst	4901177
AI693745	DBEst	4971085
AI701001	DBEst	4988901
A1733038	DBEst	5054151
AI735638	DBEst	5057162
AI741506	DBEst	5109794
AI742722	DBEst	5111010
AI742738	DBEst	5111026
AI743552	DBEst	5111840

ACC NUM	DATABASE	GI NBR
A1753784	DBEst	5132136
A1754296	DBEst	5132560
A1754256 A1754652	DBEst	5132916
A1754652 A1754732	DBEst	5132916
A1765975	DBEst	5232484
	DBESt	5236479
AI769970		
AI819225	DBEst	5438304
AI820563	DBEst	5439642
AI827818	DBEst	5448489
AI828682	DBEst	5449353
A1830067	DBEst	5450738
AI861989	DBEst	5526096
AI887129	DBEst	5592293
AI887632	DBEst	5592796
AI890281	DBEst	5595445
AI924046	DBEst	5660010
AI924096	DBEst	5660060
AI924823	DBEst	5660787
AI963471	DBEst	5756184
AI963604	DBEst	5756382
AI972556	DBEst	5769302
AI979048	DBEst	5804078
AI984656	DBEst	5811933
AJ010442	GenBank	3954884
AJ132694	GenBank	4454210
AJ224442	GenBank	2911586
AL036299	DBEst	5405889
AL042979	DBEst	5422409
AL047305	DBEst	4727252
AL049247	GenBank	4499985
AL049313	GenBank	4500086
AL049381	GenBank	4500168
AL049932	GenBank	4884176
AL050041	GenBank	4884283
AL050161	GenBank	4884375
AL050265	GenBank	4886440
AL050268	GenBank	4886442
AL050367	GenBank	4914600
AL079286	GenBank	5102746
AL079312	GenBank	5102890
AL079314	GenBank	5102893
AL080113	GenBank	5262540
AL110164	GenBank	5817069
AL117412	GenBank	5912102
AL117612	GenBank	5912188
AL119009	DBEst	5924908
AW014693	DBEst	5863450
AW014985	DBEst	5863742
AW021794	DBEst	5875324
C01521	DBEst	1433751
D01096	GenBank	220128
D13119	GenBank	285909
D13627	GenBank	286010
D13630	GenBank	286000
D13639	GenBank	285990
D13665	GenBank	393318
D14530	GenBank	414348
D21260	GenBank	434760
D25278	GenBank	434780
D26361	GenBank	452516
D3 0 6 5 5	GenBank	485387
D50310	GenBank	1183161
D51497	DBEst	951733

ACC NUM	DATABASE	GI NBR
D53031	DBEst	954928
D62116	DBEst	965892
D63878	GenBank	961447
D78611	GenBank	1655421
D82348	GenBank	1311461
D83032	GenBank	1374697
D85433	GenBank	1841371 1665768
D87437	GenBank	1620019
D87667	GenBank	2780747
D89092	GenBank GenBank	219413
D90041	GenBank	2170856
E02628	GenBank	2173919
E05732 F00551	DBEst	707254
H08920	DBEst	873742
H25080	DBEst	893979
н30306	DBEst	901216
H44647	DBEst	920699
н81376	DBEst	1059465
н93521	DBEst	1099849
н94496	DBEst	1102129
J03464	GenBank	179595
J03799	GenBank	186840
J04027	GenBank	950413 179729
J04177	GenBank	180391
K01228	GenBank GenBank	187721
K01566	GenBank	190218
L07395	GenBank	307374
L09159 L11315	GenBank	403386
L1313 L13806	GenBank	306554
L15702	GenBank	291921
L16510	GenBank	291887
L24804	GenBank	438651
L25931	GenBank	438638
L28809	GenBank	454151
M10036	GenBank	339840 182696
M10905	GenBank	184092
м11353	GenBank GenBank	189328
M12267	GenBank	180248
M13536	GenBank	339692
M14483 M14630	GenBank	339690
M17885	GenBank	190231
M18366	GenBank	179131
M21575	GenBank	1311702
M23254	GenBank	511636
M24194	GenBank	187701
M24486	GenBank	190785
M26512	GenBank	177796
M28372	GenBank	643575 183115
M31159	GenBank	186619
M32220	GenBank	178984
M36341	GenBank GenBank	338285
M36693	GenBank GenBank	1048988
M38690	GenBank	180154
M58485	GenBank	182591
M59849 M62831	GenBank	182260
M64241	GenBank	190813
M69043	GenBank	187290
M77142	GenBank	339700
M77830	GenBank	4689438

ACC NUM	DATABASE	GI NBR
м86667	GenBank	189066
M88108	GenBank	189499
M93651	GenBank GenBank	338038 184271
M95542 N43970	DBEst	1182498
012759	N/A	N/A
014635	N/A	N/A
R11045	DBEst	763780
R76376	DBEst	851058
R84450	DBEst	942856
S74728	GenBank	797409
S82081	GenBank	1488412
T07459	DBEst	318608
T19883	DBEst	597628
T21168	DBEst	2596291
T22605	DBEst DBEst	2597187 621222
T37405 T67129	DBEst	676569
T69703	DBEst	680851
T78615	DBEst	697124
T89937	DBEst	718450
U03851	GenBank	433307
U12404	GenBank	531170
U14967	GenBank	550014
U14971	GenBank	550022
U20659	GenBank	929920
U25789	GenBank	808089
U30825	GenBank	1049077 9027566
U47077 U49844	GenBank GenBank	1235901
U63846	GenBank	1480921
U65928	GenBank	1549382
U72516	GenBank	1673521
U79282	GenBank	1710254
U90716	GenBank	1946350
U90904	GenBank	1913882
U94364	GenBank	2618769
V20437	N/A	N/A
V24305 V81394	N/A N/A	N/A N/A
V81394 V84510	N/A N/A	N/A
W19427	DBEst	1295328
W65357	DBEst .	1373499
W75963	DBEst	1386337
W80525	DBEst	1391689
X01630	GenBank	28871
X04098	GenBank	28338
X04408	GenBank	31914
X06700	GenBank	30053 30057
X14420	GenBank GenBank	52697
X51742 X60111	GenBank	34768
X69398	GenBank	396175
X72755	GenBank	311375
X74979	GenBank	400462
X76180	GenBank	452649
X78627	GenBank	607129
X79067	GenBank	483524
X80910	GenBank	531475
X87949	GenBank	1143491
Y00052	GenBank GenBank	30308 34275
Y00062 Y00282	GenBank	36048
10000		555.0

ACC NUM	DATABASE	GI NBR
Y00503	GenBank	34038
Y15286	GenBank	2584788
Y17171	GenBank	3093333
Z13009	GenBank	31072
Z24724	GenBank	505034
229083	GenBank	435654
Z29331	GenBank	483539
Z46606	GenBank	575250 693936
Z48501	GenBank DBEst	1436925
AA001460 AA001543	DBESt	1437008
AA001545 AA001792	DBEst	1445606
AA001792 AA004925	DBEst	1448503
AA010897	DBEst	1471994
AA017162	DBEst	1479361
AA019019	DBEst	1482429
AA022980	DBEst	1487079
AA024595	DBEst	1489500
AA024940	DBEst	1489864
AA024996	DBEst	1489901 1491134
AA025750	DBEst	1491134
AA026598	DBEst DBEst	1496712
AA029271 AA029725	DBEst	1497138
AA029725 AA029930	DBEst	1496355
AA033832	DBEst	1505650
AA035471	DBEst	1507128
AA035616	DBEst	1507426
AA036752	DBEst	1509790
AA037377	DBEst	1512540
AA039778	DBEst	1516057
AA039948	DBEst	1516243 1517002
AA040688	DBEst DBEst	1517002
AA040820	DBEst	1517683
AA041259 AA043477	DBEst	1521333
AA044209	DBEst	1522066
AA044233	DBEst	1522109
AA044791	DBEst	1522994
AA045054	DBEst	1523256
AA045147	DBEst	1523487
AA045768	DBEst	1525870
AA046848	DBEst	1524747
AA053021	DBEst	1544277 1545775
AA053316	DBEst DBEst	1544863
AA053919 AA054069	DBEst	1545012
AA055479	DBEst	1547884
AA055591	DBEst	1547956
AA055637	DBEst	1547976
AA057243	DBEst	1550096
AA058712	DBEst	1551520
AA059128	DBEst	1552146
AA065169	DBEst	1559064
AA069850	DBEst	1577210
AA071167	DBEst	1578528 1615214
AA075158	DBEst	1615214
AA075515	DBEst DBEst	1615533
AA075663	DBEst	1616448
AA076397 AA076421	DBEst	1616290
AA076421 AA078387	DBEst	1837861
AA078570	DBEst	1838051
121010010		

PCT/US00/24199

ACC NUM	DATABASE	GI NBR
AA078872	DBEst	1617825
AA079480	DBEst	1618390
AA080889	DBEst	1623378
AA081073	DBEst	1622991
AA081608	DBEst	1623666
AA081834	DBEst	1623893
AA081917	DBEst	1623975
AA082258	DBEst	1624341
AA082441	DBEst	1624498
AA083270	DBEst	1625391
AA083345	DBEst	1625405
AA083522	DBEst	1625582
AA083573	DBEst	1625633
AA083638	DBEst	1625697
AA083774	DBEst	1625832
AA088318	DBEst	1633822
AA088344	DBEst	1633856
AA088351	DBEst	1633889
AA088693	DBEst	1634214
AA088783	DBEst	1634295
AA088829	DBEst	1634323
AA090106	DBEst	1636590
AA096032	DBEst	1641617
AA099819	DBEst	1645918
AA099923	DBEst	1646071
AA099976	DBEst	1646109
AA100764	DBEst	1647117
AA101010	DBEst	1647531
AA102013	DBEst	1645759
AA102564	DBEst	1647756
AA102830	DBEst	1648675
AA112186	DBEst	1664473
AA112645	DBEst	1665346
AA113305	DBEst	1665010
AA115218	DBEst	1670047
AA115315	DBEst	1670632 1679269
AA121656	DBEst DBEst	1679447
AA121718 AA125809	DBEst	1688020
AA125009 AA125939	DBEst	1687931
AA126452	DBEst	1686119
AA126718	DBEst	1686236
AA127436	DBEst	1686832
AA127666	DBEst	1686935
AA128063	DBEst	1687342
AA128636	DBEst	1688579
AA128641	DBEst	1688584
AA130778	DBEst	1692444
AA130982	DBEst	1692473
AA131827	DBEst	1693380
AA132056	DBEst	1693545
AA132163	DBEst	1693672
AA132574	DBEst	1694081
AA132992	DBEst	1694561
AA133351	DBEst	1690319
AA133474	DBEst	1690442
AA134460	DBEst	1692042
AA134527	DBEst	1692092
AA134589	DBEst	1695586
AA135696	DBEst	1696707
AA137017	DBEst	1698226
AA142941	DBEst	1712319
AA143001	DBEst	1712506

ACC NUM	DATABASE	GI NBR
AA143074	DBEst	1712578
AA143074 AA143746	DBESt	1713134
AA146900	DBEst	1716290
AA147200	DBEst	1716573
AA147247	DBEst	1716883
AA147781	DBEst	1717161
AA148027	DBEst	1717451
AA148136	DBEst	1717510
AA149810	DBEst	1720917
AA150377	DBEst	1721908
AA150837	DBEst	1722412
AA150928	DBEst	1722439
AA151274	DBEst	1719600
AA151594	DBEst	1720081
AA151755	DBEst	1720310
AA152476	DBEst	1718704
AA155754	DBEst	1727371
AA156066	DBEst	1727700
AA157163	DBEst	1728787
AA157993	DBEst	1732804
AA158738	DBEst	1733549
AA159110	DBEst	1733921
AA159576	DBEst	1735127
AA161003	DBEst	1735290
AA161076	DBEst	1735364
AA161467	DBEst	1735906 1741344
AA164193	DBEst	1741344
AA164473	DBEst DBEst	1740889
AA164729 AA164873	DBEst	1741032
AA165027	DBEst	1740273
AA165068	DBEst	1740296
AA165087	DBEst	1740315
AA165174	DBEst	1740402
AA165282	DBEst	1740510
AA165293	DBEst	1740521
AA165638	DBEst	1741671
AA166618	DBEst	1745207
AA167041	DBEst	1745434
AA167750	DBEst	1744900
AA171630	DBEst	1750889
AA173506	DBEst	1753638
AA174097	DBEst	1754302
AA179187	DBEst	1760556
AA180137	DBEst	1761403
AA180224	DBEst	1761553
AA180383	DBEst	1761692 1764592
AA181075	DBEst	1764785
AA181258	DBEst	1765213
AA181684	DBEst DBEst	1766238
AA182415 AA182540	DBEst	1766256
AA186577	DBEst	1774676
AA187817	DBEst	1774011
AA188045	DBEst	1774295
AA188140	DBEst	1774332
AA188384	DBEst	1775418
AA188826	DBEst	1775853
AA190873	DBEst	1779393
AA191422	DBEst	1780101
AA192094	DBEst	1782111
AA193308	DBEst	1782719
AA194577	DBEst	1784338

TABLE 1-1

AA195246 DBEST 1784946 AA195865 DBEST 1791530 AA196424 DBEST 1791999 AA196982 DBEST 1792573 AA204867 DBEST 1802927 AA204867 DBEST 1801958 AA206991 DBEST 1801246 AA206991 DBEST 1801246 AA219665 DBEST 1801460 AA219665 DBEST 1837452 AA223121 DBEST 1843680 AA223820 DBEST 1844662 AA224109 DBEST 1844668 AA224407 DBEST 1845029 AA2229325 DBEST 1851167 AA2229325 DBEST 1851167 AA2239325 DBEST 1851608 AA233833 DBEST 1855951 AA233843 DBEST 1856920 AA23407 DBEST 1856920 AA234337 DBEST 1856856 AA234092 DBEST 1856920 </th <th>ACC NUM</th> <th>DATABASE</th> <th>GI NBR</th>	ACC NUM	DATABASE	GI NBR
AA196424 DBEst 1791999 AA196982 DBEst 1792573 AA203691 DBEST 1799458 AA204867 DBEST 18019958 AA204867 DBEST 18019958 AA206991 DBEST 18019958 AA206991 DBEST 1801246 AA216753 DBEST 1801246 AA216753 DBEST 18017460 AA213820 DBEST 1843680 AA223321 DBEST 1843680 AA223121 DBEST 18443680 AA2234109 DBEST 18443680 AA224407 DBEST 1844568 AA224407 DBEST 1845029 AA229325 DBEST 1845029 AA229325 DBEST 1851668 AA223935 DBEST 1851668 AA233835 DBEST 1851668 AA233835 DBEST 1855951 AA233835 DBEST 1856920 AA234092 DBEST 1856920 AA234092 DBEST 1856818 AA236776 DBEST 1856818 AA236776 DBEST 1856818 AA242338 DBEST 1856818 AA242338 DBEST 1856920 AA234092 DBEST 1858618 AA243338 DBEST 1856920 AA234092 DBEST 1858618 AA243338 DBEST 1856920 AA234092 DBEST 1858618 AA24671 DBEST 1874149 AA244442 DBEST 1874149 AA244442 DBEST 1874189 AA2455502 DBEST 1874149 AA2455502 DBEST 187419 AA26299 DBEST 1879783 AA26299 DBEST 1892106 AA278642 DBEST 1892106 AA278642 DBEST 199962 AA278642 DBEST 199962 AA278642 DBEST 199961 AA278642 DBEST 199961 AA278642 DBEST 199961 AA278643 DBEST 199961 AA278644 DBEST 199961 AA278640 DBEST 199961 AA286699 DBEST 1992758 AA286699 DBEST 1992758 AA286699 DBEST 1992758 AA286699 DBEST 1992764 AA286699 DBEST 1992768 AA286699 DBEST 1992768 AA286699 DBEST 1992768 AA286699 DBEST 1993501 AA286917 DBEST 1993501 AA28917 DBEST 1993501 AA28917 DBEST 1993501 AA28917 DBEST 1993501 AA28917 DBEST 1993501 AA2991313 DBEST 1994075		DBEst	
AA196982 DBEst 1792573 AA203691 DBEST 1799458 AA204867 DBEST 1799458 AA204867 DBEST 1802927 AA206578 DBEST 1801958 AA204671 DBEST 1801958 AA2046578 DBEST 1801958 AA2046578 DBEST 1801958 AA2046578 DBEST 1801958 AA206991 DBEST 1807460 AA216753 DBEST 1817452 AA219665 DBEST 1817452 AA219665 DBEST 1817452 AA219665 DBEST 1843680 AA223121 DBEST 1844366 AA2234109 DBEST 1844366 AA2234109 DBEST 1844366 AA224109 DBEST 1844366 AA224109 DBEST 1844668 AA224118 DBEST 1845802 AA227118 DBEST 1845802 AA229325 DBEST 1851608 AA232959 DBEST 1851608 AA233843 DBEST 18556950 AA233843 DBEST 1856856 AA233843 DBEST 1856856 AA2334092 DBEST 1856856 AA234092 DBEST 1856868 AA242985 DBEST 1856868 AA242985 DBEST 1856818 AA242985 DBEST 1856818 AA2442985 DBEST 1873177 AA249154 DBEST 1873177 AA249154 DBEST 1879783 AA2455502 DBEST 1879783 AA256591 DBEST 1892130 AA262939 DBEST 1892406 AA256591 DBEST 1892130 AA262939 DBEST 199962 AA278642 DBEST 199968 AA278642 DBEST 199978 AA284555 DBEST 19927582 AA288028 DBEST 19927582 AA288029 DBEST 19927582 AA288029 DBEST 19927582 AA288020 DBEST 19927582 AA288020 DBEST 19927582 AA288470 DBEST 19933325 AA28719 DBEST 19933325 AA28719 DBEST 19933321 AA28915 DBEST 19933321 AA28915 DBEST 19933321 AA289171 DBEST 19933323 AA289173 DBEST 19933323 AA289173 DBEST 19933323 AA293333 DBEST 1994750			
A203691 DBEST 1799458 A204867 DBEST 1802927 A206578 DBEST 1801958 A2066991 DBEST 1801246 A216753 DBEST 1807460 A216753 DBEST 1817452 A223121 DBEST 1837722 A223121 DBEST 1843680 A2223820 DBEST 1844668 A2224409 DBEST 1843680 A2223820 DBEST 1844668 A2224407 DBEST 1845029 A227118 DBEST 1845029 A227118 DBEST 1845029 A227211 DBEST 1851608 A222407 DBEST 1855029 A2229325 DBEST 185167 A222931 DBEST 1855951 A233835 DBEST 1855951 A233835 DBEST 1855951 A233843 DBEST 1856856 A2224092 DBEST 1856856 A2234092 DBEST 1856856 A2234092 DBEST 1858618 A2336776 DBEST 1858618 A2336776 DBEST 1858618 A243338 DBEST 1858618 A243338 DBEST 1857971 A242955 DBEST 1877780 A243442 DBEST 1879783 A255502 DBEST 1892177 A242954 DBEST 1897973 A252509 DBEST 1892177 A262939 DBEST 199962 A278462 DBEST 199962 A278465 DBEST 199961 A278642 DBEST 199962 A278464 DBEST 199963 A27845 DBEST 199963 A278465 DBEST 199961 A278664 DBEST 199961 A228991 DBEST 199961 A228967 DBEST 1993511 A228971 DBEST 1993511 A229973 DBEST 1994077 A229334 DBEST 1994077			
A204867			
AA206578 DBEST 1801958 AA206991 DBEST 1807460 AA216753 DBEST 1817452 AA221665 DBEST 1817452 AA223121 DBEST 1843680 AA22320 DBEST 1843680 AA224109 DBEST 1844668 AA224407 DBEST 1845029 AA227118 DBEST 1845029 AA227118 DBEST 1845029 AA227118 DBEST 1845029 AA227118 DBEST 1851167 AA229325 DBEST 1851167 AA229325 DBEST 1851668 AA223407 DBEST 1851608 AA232959 DBEST 1855656 AA233835 DBEST 1855656 AA233843 DBEST 1856656 AA234092 DBEST 1856668 AA234092 DBEST 1858618 AA236776 DBEST 1858618 AA236776 DBEST 1858618 AA236776 DBEST 1873780 AA242985 DBEST 1873780 AA24338 DBEST 1873780 AA243442 DBEST 1873780 AA243444 DBEST 1879783 AA255502 DBEST 1879783 AA255502 DBEST 1892406 AA25699 DBEST 1892130 AA261990 DBEST 199962 AA278445 DBEST 199962 AA278462 DBEST 1999782 AA278462 DBEST 1999782 AA278464 DBEST 1999782 AA278956 DBEST 1999782 AA28990 DBEST 1999782 AA28959 DBEST 1999783 AA28959 DBEST 1999783 AA28959 DBEST 1999783 AA28959 DBEST 1999783 AA28959 DBEST 1999782 AA28959 DBEST 1999783 AA299333 DBEST 19940750			
AA206991 DBEst 1801246 AA209508 DBEST 1807460 AA216753 DBEST 1817452 AA219665 DBEST 1833722 AA223820 DBEST 1843668 AA223820 DBEST 1844668 AA224109 DBEST 1844668 AA224109 DBEST 1844668 AA22407 DBEST 1845029 AA227118 DBEST 1845029 AA227118 DBEST 1845029 AA227118 DBEST 1845029 AA227118 DBEST 1851667 AA229611 DBEST 1851668 AA232959 DBEST 1851668 AA233835 DBEST 1856856 AA233843 DBEST 1856856 AA233843 DBEST 1856856 AA233843 DBEST 1856856 AA233843 DBEST 1856856 AA2344092 DBEST 1856856 AA2344092 DBEST 1856856 AA234307 DBEST 1856856 AA234307 DBEST 1856818 AA244925 DBEST 1874149 AA242955 DBEST 187780 AA243338 DBEST 1874149 AA242955 DBEST 187780 AA243338 DBEST 1875177 AA249154 DBEST 1879783 AA243402 DBEST 1879783 AA255502 DBEST 1879783 AA255502 DBEST 1879783 AA255502 DBEST 1879783 AA262939 DBEST 1897971 AA262939 DBEST 1899679 AA278445 DBEST 1919782 AA278446 DBEST 1919782 AA278446 DBEST 1919787 AA264939 DBEST 1919782 AA278446 DBEST 1919782 AA27845 DBEST 1919782 AA278462 DBEST 1919782 AA278464 DBEST 1920757 AA280099 DBEST 1920757 AA280099 DBEST 1920758 AA280828 DBEST 1921759 AA280828 DBEST 1927581 AA280829 DBEST 1927582 AA280828 DBEST 1927582 AA280828 DBEST 1927582 AA280828 DBEST 1927582 AA280828 DBEST 1927582 A			
A209508 A216753 A2216753 DBEST A3217665 DBEST A323121 DBEST A323121 DBEST A323680 A223820 DBEST A323820 A224109 DBEST BA44668 AA224407 DBEST A3224109 DBEST A322325 DBEST A346672 AA229325 DBEST BA46672 AA229325 DBEST BA46672 AA229325 DBEST BA33722 BBEST BA46672 AA229325 DBEST BA33673 DBEST BA33673 DBEST BA33673 DBEST BA33673 DBEST BA33835 DBEST BA33843 DBEST BA33843 DBEST BA33843 DBEST BA33676 DBEST BA33676 DBEST BA324307 DBEST BA3244342 DBEST BA3244342 DBEST BA3244342 DBEST BA3244344 DBEST BA3244344 DBEST BA32464 BA326590 DBEST BA326990 DBEST BA32642 DBEST BA32642 DBEST BA32642 DBEST BA32642 DBEST BA32642 DBEST BA3278445 DBEST BA3278445 DBEST BA3278461 DBEST BA328099 DBEST BA328099 DBEST BA3280099 DBEST BA3280621 DBEST BA3280699 DBEST BA3280691 DBEST BA3280601 BBEST BA3393 BBEST BA3393 BBEST BA34911 BBEST BA34911 BA346601 BBEST BA34911 BBEST BA34911 BA32806 BBEST BA34911 BA32806 BBEST BA3491 BA3280 BA3280 BBEST BA3280 BA3280 BBEST BA3280 BA3280 BA3280 BA3280			
AA216753 DBEst 1817452 AA219665 DBESt 1833722 AA223121 DBEST 1843680 AA223320 DBEST 1844362 AA224109 DBEST 1844362 AA224109 DBEST 1844362 AA224107 DBEST 1845029 AA227118 DBEST 1845029 AA227118 DBEST 1845676 AA229611 DBEST 1851608 AA232959 DBEST 1851608 AA233835 DBEST 1856856 AA233843 DBEST 1856856 AA233843 DBEST 1858686 AA234092 DBEST 1858618 AA242985 DBEST 1858618 AA242985 DBEST 1858618 AA242985 DBEST 1873780 AA24338 DBEST 1873780 AA24338 DBEST 1873780 AA24338 DBEST 1873780 AA24338 DBEST 1873780 AA243402 DBEST 1873780 AA2439154 DBEST 1879783 AA256591 DBEST 1892130 AA261990 DBEST 1892130 AA261990 DBEST 1892130 AA261990 DBEST 1892130 AA262939 DBEST 1892130 AA262939 DBEST 1892130 AA2642 DBEST 1919782 AA278642 DBEST 1919782 AA278642 DBEST 1919782 AA278643 DBEST 1919782 AA278644 DBEST 1919782 AA28687 DBEST 1919782 AA28687 DBEST 1919782 AA28687 DBEST 1927573 AA280009 DBEST 1927573 AA280009 DBEST 1927584 AA286670 DBEST 1927684 AA286699 DBEST 1927684 AA286670 DBEST 1927684 AA286699 DBEST 1927684 AA286699 DBEST 1927684 AA286670 DBEST 1927684 AA286699 DBEST 1927684 AA286670 DBEST 1927684 AA28470 DBEST 19233325 AA28717 DBEST 1933331 AA28171 DBEST 1933331 AA28171 DBEST 1933331 AA291333 DBEST 1941173 AA293273 DBEST 1941173 AA293273 DBEST 1941775			
AA219665 AA223121 DBEST AA223120 DBEST 1843680 AA224109 DBEST 1844668 AA224407 DBEST 1844668 AA224407 DBEST 1844668 AA224109 DBEST 1844668 AA2227118 DBEST 1848672 AA229325 DBEST 1851167 AA229325 DBEST 1851167 AA229325 DBEST 1855951 AA233835 DBEST 1855951 AA233843 DBEST 1855951 AA234092 DBEST 1858897 AA234092 DBEST 1858897 AA23407 DBEST 1858897 AA234307 DBEST 1858897 AA234342 DBEST 1858618 AA236776 DBEST 1860841 AA242985 DBEST 1873780 AA24342 DBEST 1873780 AA24342 DBEST 1875177 AA249154 DBEST 187917 AA269154 DBEST 1892406 AA255501 DBEST 1892406 AA256591 DBEST 1892406 AA256591 DBEST 1892406 AA261990 DBEST 1892130 AA261990 DBEST 1898659 AA278445 DBEST 1898659 AA278642 DBEST 1919801 AA278642 DBEST 1919801 AA278642 DBEST 1919801 AA278645 DBEST 1919801 AA278646 DBEST 1919801 AA278646 DBEST 1920577 AA280029 DBEST 1920577 AA280221 DBEST 1921759 AA280828 DBEST 1921759 AA280828 DBEST 1923508 AA284670 DBEST 1923508 AA284670 DBEST 1927581 AA284670 DBEST 1927582 AA284870 DBEST 1927582 AA284870 DBEST 1927582 AA284870 DBEST 1927582 AA284966 DBEST 1927582 AA284671 DBEST 1927582 AA284670 DBEST 1927582 AA2847815 DBEST 1927582 AA2847815 DBEST 1927582 AA287815 DBEST 1933335 DBEST 1933325 AA287815 DBEST 1933932 AA28773 DBEST 1941173 AA293273 DBEST 1941173			
AA223121 DBEst 1843680 AA224109 DBEst 1844362 AA224109 DBEst 1844668 AA224407 DBEst 1845029 AA227118 DBEST 1845029 AA229325 DBEST 1851167 AA229611 DBEST 1851608 AA232383 DBEST 1856856 AA233843 DBEST 1856856 AA233843 DBEST 18586920 AA234092 DBEST 1858618 AA234307 DBEST 1858618 AA234307 DBEST 1858618 AA234338 DBEST 1858618 AA234338 DBEST 1873780 AA243338 DBEST 1873780 AA243338 DBEST 18774149 AA24985 DBEST 1877783 AA244342 DBEST 1879783 AA255502 DBEST 1897971 AA249154 DBEST 1892406 AA256591 DBEST 1892406 AA256591 DBEST 1892406 AA261990 DBEST 1897971 AA262939 DBEST 1897971 AA262939 DBEST 1897971 AA262939 DBEST 1997872 AA278445 DBEST 1919801 AA261990 DBEST 1997872 AA278462 DBEST 1919801 AA261990 DBEST 1997873 AA278956 DBEST 1919801 AA278956 DBEST 1919801 AA278956 DBEST 1920577 AA280099 DBEST 1920577 AA280099 DBEST 1921779 AA280099 DBEST 1921779 AA280099 DBEST 1921779 AA280828 DBEST 1921779 AA280828 DBEST 1921779 AA2804670 DBEST 1921779 AA284671 DBEST 1923861 AA284670 DBEST 1927581 AA284670 DBEST 1927581 AA284670 DBEST 1927581 AA284671 DBEST 1927581 AA284670 DBEST 1927581 AA284671 DBEST 1927581 AA2846699 DBEST 1927581 AA284671 DBEST 1927581 AA284671 DBEST 1927581 AA284671 DBEST 1927581 AA284671 DBEST 1927448 AA284671 DBEST 1927581 AA284671 DBEST 1927581 AA284671 DBEST 1927484 AA284671 DBEST 1927581 AA2847815 DBEST 1927581 AA2847815 DBEST 1927484 AA284671 DBEST 1927581 AA291485 DBEST 1933525 AA2815 DBEST 1933531 AA292334 DBEST 1933531 AA293333 DBEST 1933531 AA293333 DBEST 1934177 AA293333 DBEST 1934177 AA293333 DBEST 1941177 AA293273 DBEST 1941177 AA293273 DBEST 1941775			
AA223820 DBEst 1844362 AA224109 DBEst 1844668 AA224407 DBESS 1845029 AA227118 DBESS 1848672 AA229325 DBESS 1851608 AA223959 DBESS 1851608 AA232959 DBESS 1855951 AA233843 DBESS 1856920 AA234092 DBESS 1856920 AA234092 DBESS 1856920 AA234092 DBESS 1858618 AA2336776 DBESS 1858618 AA234307 DBESS 1858618 AA243388 DBESS 1858618 AA243389 DBESS 1873780 AA24338 DBESS 1873780 AA24338 DBESS 1873787 AA255502 DBESS 18779783 AA255502 DBESS 18779783 AA255502 DBESS 18979783 AA261990 DBESS 1897971 AA262939 DBESS 1897971 AA262939 DBESS 1997972 AA262939 DBESS 1997972 AA278445 DBESS 1997978 AA278445 DBESS 1997972 AA278642 DBESS 199787 AA278642 DBESS 19919782 AA278642 DBESS 19919782 AA278642 DBESS 1992057 AA28099 DBESS 1992057 AA28099 DBESS 1992057 AA28021 DBESS 1992057 AA28021 DBESS 1992057 AA280221 DBESS 1992057 AA280221 DBESS 1992057 AA280221 DBESS 19921573 AA280221 DBESS 19921759 AA280220 DBESS 19921759 AA280221 DBESS 19921759 AA280220 DBESS 19921759 AA280221 DBESS 1992173 AA293333 DBESS 1993173 AA293333 DBESS 1993173 AA293333 DBESS 1994173 AA293333 DBESS 1994173 AA293333 DBESS 1994175			
AA224109 DBEst 1844668 AA224407 DBEst 1845029 AA227118 DBESS 1845029 AA227118 DBESS 1851167 AA229325 DBESS 1851167 AA229611 DBESS 1851167 AA22959 DBESS 1855951 AA233835 DBESS 1856856 AA234092 DBESS 1858897 AA234092 DBESS 1858618 AA234338 DBESS 1858618 AA234338 DBESS 1858618 AA234338 DBESS 1873780 AA244985 DBESS 1873780 AA244985 DBESS 1873780 AA2449154 DBESS 1879783 AA249154 DBESS 1879783 AA265591 DBESS 1897973 AA261990 DBESS 1897971 AA262939 DBESS 1897971 AA262939 DBESS 1897971 AA262939 DBESS 1997972 AA278445 DBESS 1997972 AA278446 DBESS 1997973 AA26099 DBESS 1997872 AA278842 DBESS 1997872 AA278956 DBESS 199605 AA278956 DBESS 1996057 AA280099 DBESS 192573 AA280099 DBESS 1925750 AA284334 DBESS 1925750 AA284334 DBESS 1925750 AA284370 DBESS 1925750 AA284370 DBESS 1925750 AA284370 DBESS 1925750 AA284870 DBESS 1927581 AA284870 DBESS 1927581 AA284870 DBESS 1927582 AA284870 DBESS 1927581 AA291485 DBESS 1927484 AA28455 DBESS 1927582 AA287313 DBESS 1934173 AA293273 DBESS 1941173 AA293273 DBESS 1941173 AA293286 DBESS 1941775			
AA224407 DBEst 1845029 AA227118 DBEst 1848672 AA229325 DBEst 1851167 AA229611 DBEst 1851167 AA229611 DBEst 1855951 AA233835 DBEst 1856856 AA233843 DBEst 1856856 AA2334092 DBEst 1858897 AA234092 DBEst 1858618 AA234070 DBEst 1858618 AA236776 DBEst 1860841 AA24985 DBEst 1875177 AA249154 DBEst 1875177 AA249154 DBEst 1879783 AA255502 DBEst 1892406 AA256591 DBEst 1892406 AA256591 DBEst 1892406 AA256591 DBEst 1892130 AA261990 DBEst 1892130 AA261990 DBEst 1991962 AA278642 DBEst 1919782 AA278642 DBEst 1919782 AA278642 DBEst 1919782 AA278642 DBEst 1919801 AA278642 DBEst 1919787 AA280099 DBEst 1920577 AA280099 DBEst 1920577 AA280099 DBEst 1921573 AA28021 DBEst 1921573 AA280828 DBEst 1921573 AA280828 DBEst 1923508 AA282915 DBEst 1923508 AA282916 DBEst 1927581 AA284670 DBEst 1927581 AA284670 DBEst 1927581 AA284670 DBEst 1927582 AA284870 DBEst 1927581 AA284870 DBEst 1927581 AA284870 DBEst 1927582 AA284870 DBEst 1927581 AA284870 DBEst 1927582 AA284870 DBEst 1927582 AA284870 DBEst 1927581 AA284870 DBEst 1927581 AA284870 DBEst 1927582 AA284870 DBEst 1927581 AA29488 DBEst 1933581 AA291438 DBEST 1933514 AA291333 DBEST 1940027 AA29334 DBEST 1940027 AA29334 DBEST 1941173 AA293373 DBEST 1940750			
AA227118 DBEst 1848672 AA229325 DBEst 1851167 AA2295611 DBESE 1851608 AA232959 DBEST 1855951 AA233835 DBEST 18569520 AA2334092 DBEST 1856826 AA233407 DBEST 1856827 AA234092 DBEST 18568618 AA236776 DBEST 1860841 AA242985 DBEST 1873780 AA243338 DBEST 1873780 AA243338 DBEST 1873780 AA243340 DBEST 1875177 AA249154 DBEST 1875177 AA249154 DBEST 1879783 AA255502 DBEST 1892406 AA256591 DBEST 1892406 AA256591 DBEST 1892406 AA262939 DBEST 1899791 AA262939 DBEST 1898659 AA278445 DBEST 1919782 AA278442 DBEST 1919782 AA278642 DBEST 1919782 AA278642 DBEST 1919801 AA278642 DBEST 1919962 AA278643 DBEST 1920495 AA278956 DBEST 1920495 AA278956 DBEST 1920495 AA27845 DBEST 1920495 AA278640 DBEST 1921759 AA280099 DBEST 1921759 AA280291 DBEST 1921759 AA280291 DBEST 1921759 AA280291 DBEST 1927884 AA284670 DBEST 1927884 AA284671 DBEST 1927884 AA284671 DBEST 1927884 AA284670 DBEST 1927884 AA284670 DBEST 1927882 AA284870 DBEST 1927884 AA284671 DBEST 1927884 AA28470 DBEST 1927882 AA288715 DBEST 1933581 AA291438 DBEST 1933581 AA291438 DBEST 1933514 AA291438 DBEST 1933521 AA291438 DBEST 1933521 AA291333 DBEST 1941173 AA293335 DBEST 1941173 AA293335 DBEST 1941173			
AA229325 AA22951 AA22951 AA23835 DBEst AA233835 DBEst AA233843 DBEst AA233843 DBEst AA233847 DBEst AA234092 DBEst AA234097 DBEst AA24985 DBEst AA24338 DBEst AA243442 DBEst AA27863 DBEst AA29015 AA261990 DBEst AA255502 DBEst AA261990 DBEst AA261990 DBEst AA27845 DBEst AA278482 DBEst AA278482 DBEst AA278642 DBEst AA278642 DBEst AA278645 DBEst AA278646 DBEst AA279048 DBEst AA279048 DBEst AA279048 DBEst AA279048 DBEst AA280099 DBEst AA280099 DBEst AA280021 DBEst AA284670 DBEst AA284670 DBEst AA284670 DBEst AA284670 DBEst AA284671 DBEst AA284671 DBEst AA284670 DBEst AA284671 DBEst AA284671 DBEst AA284670 DBEst AA284671 DBEst AA284719 DBEst AA29448 DBEst AA29448 AA284719 DBEst AA29448 DBEst AA29448 AA284719 DBEst AA29448 DBEst AA29448 AA284719 DBEst AA294744 AA28455 DBEst AA29448 AA284719 DBEst AA29448 DBEst AA29448 AA284719 DBEst AA29448 AA284719 DBEst AA29448 AA284719 DBEst AA29448 DBEst AA29448 AA284719 DBEst AA294748 AA294733 DBESt AA29336 DBEST AA293373 DBEST AA2933			
AA229611 DBEst 1855951 AA232959 DBEst 1855951 AA233843 DBEst 1856856 AA233843 DBEst 1856820 AA234092 DBEst 1858897 AA234307 DBEst 1858897 AA234307 DBEst 1860841 AA242985 DBEst 1873780 AA243338 DBEst 1873780 AA243338 DBEst 1874149 AA244342 DBEst 1875177 AA249154 DBEst 1879778 AA255502 DBEst 1892406 AA256591 DBEst 1892406 AA256591 DBEst 1892130 AA261990 DBEst 1897971 AA262939 DBEst 1897877 AA24845 DBEst 1919782 AA278445 DBEst 1919782 AA278446 DBEst 1919782 AA278482 DBEst 1919962 AA278642 DBEst 1919962 AA278956 DBEst 1920495 AA2789049 DBEst 1920577 AA280029 DBEst 1920577 AA28021 DBEst 1921573 AA280221 DBEst 1921573 AA280221 DBEst 1921573 AA280221 DBEst 1923508 AA284334 DBEst 1923508 AA284334 DBEst 1923508 AA284300 DBEst 1927581 AA284670 DBEst 1927581 AA284671 DBEst 1927581 AA284670 DBEst 1927582 AA284870 DBEst 1927582 AA286699 DBEst 1927582 AA286699 DBEst 1927584 AA286699 DBEst 1933581 AA28672 DBEst 1933581 AA28672 DBEst 1933581 AA28673 DBEst 1933581 AA28133 DBEST 1933593 AA287219 DBEST 1933593 AA287219 DBEST 1933594 AA291438 DBEST 1933594 AA291438 DBEST 1933594 AA291333 DBEST 1941075			
AA232959 DBEST 1855951 AA233835 DBEST 1856820 AA233843 DBEST 1856920 AA234092 DBEST 1858897 AA234307 DBEST 1858618 AA236776 DBEST 1858618 AA236776 DBEST 1858618 AA242985 DBEST 1873780 AA243338 DBEST 1874149 AA244342 DBEST 1875177 AA249154 DBEST 1892406 AA255502 DBEST 1892406 AA256591 DBEST 1892406 AA256591 DBEST 1892130 AA261990 DBEST 1897971 AA262999 DBEST 18998659 AA278445 DBEST 1919782 AA278482 DBEST 1919802 AA278482 DBEST 1919802 AA278642 DBEST 1919802 AA278642 DBEST 1919802 AA278009 DBEST 1920495 AA279048 DBEST 1920495 AA279048 DBEST 1921573 AA280221 DBEST 1921573 AA280828 DBEST 1921573 AA280434 DBEST 1925910 AA284334 DBEST 1925910 AA284334 DBEST 1925910 AA284334 DBEST 1927881 AA284670 DBEST 1927881 AA284671 DBEST 1927881 AA284670 DBEST 1927881 AA293333 DBEST 1933333			
AA233835 DBEST 1856856 AA233843 DBEST 1856826 AA234092 DBEST 1858897 AA23407 DBEST 1858897 AA234307 DBEST 1858618 AA236776 DBEST 1860841 AA242985 DBEST 1873780 AA243338 DBEST 1873780 AA243338 DBEST 1874149 AA244342 DBEST 1875177 AA249154 DBEST 1879783 AA255502 DBEST 1892406 AA256591 DBEST 1892406 AA256591 DBEST 1892406 AA256591 DBEST 1897971 AA262939 DBEST 1897971 AA262939 DBEST 1897871 AA262939 DBEST 1898659 AA278445 DBEST 1919782 AA278445 DBEST 1919782 AA278445 DBEST 1919782 AA278642 DBEST 1919962 AA278642 DBEST 1919962 AA278656 DBEST 1920657 AA280099 DBEST 1920577 AA280099 DBEST 1920577 AA280099 DBEST 1921573 AA280221 DBEST 1921573 AA280221 DBEST 1921573 AA280221 DBEST 1921573 AA280221 DBEST 1921573 AA28024334 DBEST 1921578 AA284670 DBEST 1927581 AA284455 DBEST 1927684 AA284670 DBEST 1927684 AA284906 DBEST 1927644 AA28455 DBEST 1927684 AA284571 DBEST 1927684 AA284572 DBEST 1927644 AA284579 DBEST 1927644 AA284579 DBEST 1927646 AA28470 DBEST 1927646 AA28470 DBEST 1927646 AA284906 DBEST 1927640 AA284906 DBEST 1927600			
AA233843 DBEst 1856920 AA234092 DBEst 18588618 AA236776 DBEst 1860841 AA242985 DBEst 1873780 AA234338 DBEst 1873780 AA243338 DBEst 1875177 AA244342 DBEst 1875177 AA249154 DBEst 1892406 AA256591 DBEst 1892406 AA256591 DBEst 1892130 AA261990 DBEst 1897971 AA262939 DBEst 1897872 AA278445 DBEst 1919782 AA278445 DBEst 1919782 AA278462 DBEst 1919801 AA278642 DBEst 1919801 AA278642 DBEst 1919801 AA2780099 DBEst 1920577 AA280099 DBEst 1920577 AA280291 DBEst 1921573 AA280221 DBEst 1921573 AA280828 DBEst 1921573 AA280828 DBEst 1923508 AA282915 DBESt 1923508 AA284570 DBESt 1927484 AA284670 DBESt 1927882 AA284670 DBEST 1927882 AA284670 DBEST 1927882 AA284670 DBEST 1927582 AA284870 DBEST 1927582 AA284906 DBEST 1927582 AA284870 DBEST 1927582 AA284870 DBEST 1927582 AA284870 DBEST 1927584 AA284555 DBEST 1927584 AA284555 DBEST 1927584 AA284570 DBEST 1927582 AA284870 DBEST 1927582 AA284870 DBEST 1927582 AA284870 DBEST 1927582 AA284870 DBEST 1927584 AA284555 DBEST 1927584 AA2845699 DBEST 1927584 AA284575 DBEST 1933514 AA291438 DBEST 1933514 AA291438 DBEST 1933514 AA291438 DBEST 1933514 AA291438 DBEST 1934177 AA293133 DBEST 1941173 AA293273 DBEST 1941173 AA293273 DBEST 1941177 AA293353 DBEST 1941177 AA293353 DBEST 1941177		DBEst	
AA234307 AA236776 DBEst AA236776 DBEst AA242985 DBEst 1873780 AA243338 DBESt AA243338 DBESt AA249154 AA249154 DBESt AA256502 DBESt AA256591 DBESt AA261990 DBESt AA261990 DBESt AA278445 DBESt DBESt AA278445 DBESt AA278462 DBESt D		DBEst	1856920
AA236776 AA242985 DBEst AA24338 DBEST AA24338 DBEST AA24338 DBEST AA24338 DBEST AA243442 DBEST AA249154 DBEST AA255502 DBEST AA255502 DBEST AA261990 DBEST AA261990 DBEST AA262939 DBEST AA278445 DBEST AA278445 DBEST AA278445 DBEST AA278462 DBEST AA278642 DBEST DBEST AA278956 DBEST AA278956 DBEST AA278956 DBEST AA278956 DBEST AA278956 DBEST AA278956 DBEST AA278957 AA280099 DBEST AA280099 DBEST AA280221 DBEST AA280221 DBEST AA280221 DBEST AA280434 DBEST AA284334 DBEST AA284334 DBEST AA284334 DBEST DBEST AA284455 DBEST AA2844570 DBEST AA284670 DBEST AA284671 DBEST AA284870 DBEST AA29464 DBEST AA284870 DBEST AA29464 ABBEST AA294687 DBEST AA294687 DBEST AA29464 AA28455 DBEST AA294687 DBEST AA29408 AA287615 DBEST AA29408 AA291971 DBEST AA291438 DBEST AA291448 DBEST AA291473 DBEST AA293333 DBEST AA293353 DBEST AA293353 DBEST AA293353 DBEST AA293353	AA234092	DBEst	1858897
AA242985 AA243338 DBEst AA244342 DBEST AA244342 DBEST AA249154 DBEST AA255502 DBEST AA265591 DBEST AA2626591 DBEST AA262939 DBEST AA278445 DBEST AA278445 DBEST AA278445 DBEST AA278446 DBEST DBEST AA278482 DBEST AA278482 DBEST AA278956 DBEST AA278956 DBEST AA278956 DBEST AA2789048 DBEST AA280099 DBEST AA280099 DBEST DBEST DBEST DBEST DBEST AA280021 DBEST AA280421 DBEST AA280444 DBEST AA280645 DBEST AA280646 DBEST AA280646 DBEST AA280647 DBEST AA280648 DBEST D	AA234307	DBEst	1858618
AA243338 DBEST 1874149 AA244342 DBEST 1875177 AA249154 DBEST 1879783 AA255502 DBEST 1892406 AA256591 DBEST 1892130 AA261990 DBEST 18997971 AA262939 DBEST 1896659 AA278445 DBEST 1919782 AA278442 DBEST 1919782 AA278482 DBEST 1919801 AA278642 DBEST 1920495 AA278956 DBEST 1920495 AA279048 DBEST 1920577 AA280099 DBEST 1921573 AA280221 DBEST 1921573 AA28021 DBEST 1921573 AA28021 DBEST 1927581 AA284334 DBEST 1927581 AA284355 DBEST 1927581 AA284670 DBEST 1927581 AA284670 DBEST 1927581 AA284670 DBEST 1927581 AA284670 DBEST 1927464 AA284500 DBEST 1927464 AA284500 DBEST 1927464 AA284500 DBEST 1927448 AA286699 DBEST 1933581 AA2866872 DBEST 1933581 AA287219 DBEST 1933581 AA287612 DBEST 1933514 AA291485 DBEST 1933514 AA291485 DBEST 1939506 AA291971 DBEST 1939506 AA291971 DBEST 1939506 AA293133 DBEST 194173 AA293133 DBEST 194173 AA293133 DBEST 194173 AA293353 DBEST 1940750	AA236776		
AA244342 DBEst 1875177 AA249154 DBEst 1879783 AA255502 DBEst 1892406 AA256591 DBEst 1892130 AA261990 DBEst 1897971 AA262939 DBEst 189659 AA278445 DBEst 1919782 AA278446 DBEst 1919801 AA278642 DBEst 1919962 AA278956 DBEst 1920495 AA279048 DBEst 1920577 AA280099 DBEst 1921573 AA280221 DBEst 1921759 AA28028 DBEst 1921759 AA280434 DBEst 1921759 AA280434 DBEst 192577 AA280640 DBEst 192577 AA280460 DBEst 1927884 AA284670 DBEst 1927581 AA284670 DBEst 1927581 AA284670 DBEst 1927582 AA284870 DBEst 1927582 AA284870 DBEst 1927582 AA284870 DBEst 1927464 AA284669 DBEst 1927464 AA284555 DBEst 1927464 AA284550 DBEst 1927464 AA284569 DBEst 1933932 AA287219 DBEST 1934280 AA287219 DBEST 1933932 AA287219 DBEST 1933932 AA287219 DBEST 1933932 AA287219 DBEST 1933932 AA287219 DBEST 1934280 AA293438 DBEST 1933932 AA293438 DBEST 1933936 AA293439 DBEST 1941167 AA293133 DBEST 1941173 AA293133 DBEST 1941173 AA293353 DBEST 1941775 AA293353 DBEST 1940750			
AA249154 AA255502 DBEst AA256591 DBEst AA261990 DBESt AA262939 DBESt AA278445 DBESt AA278445 DBESt AA278482 DBESt AA278462 DBESt DBE			
AA255502 DBEst 1892406 AA256591 DBEst 189771 AA261990 DBEst 1897771 AA262939 DBEst 1898659 AA278445 DBEst 1919782 AA278482 DBEst 1919801 AA278642 DBEst 1920495 AA278956 DBEst 1920577 AA280099 DBEst 1921573 AA280291 DBEst 1921573 AA280221 DBEst 1921573 AA280221 DBEst 1921759 AA280328 DBEst 1923508 AA282915 DBEst 1923508 AA282915 DBEst 1925910 AA284334 DBEst 1925910 AA284334 DBEst 1927484 AA284670 DBEst 1927581 AA284671 DBEst 1927581 AA284671 DBEst 1927582 AA284870 DBEst 1927582 AA284870 DBEst 1927582 AA284870 DBEst 1927464 AA2846699 DBEst 1927464 AA286699 DBEst 1933581 AA286699 DBEst 1933581 AA286672 DBEst 1933581 AA287219 DBEst 1933581 AA287642 DBEst 1933514 AA291438 DBEst 1933514 AA291485 DBEst 1933514 AA291485 DBEst 1933514 AA291485 DBEst 1933514 AA291477 DBEst 1939506 AA293133 DBEst 1940027 AA293133 DBEst 1940750			
AA256591 DBEST 1892130 AA261990 DBEST 1897971 AA262939 DBEST 1898659 AA278445 DBEST 1919782 AA278445 DBEST 1919801 AA278482 DBEST 1919801 AA278642 DBEST 1920495 AA278956 DBEST 1920495 AA280099 DBEST 1921573 AA280021 DBEST 1921573 AA280221 DBEST 1921573 AA280221 DBEST 1921579 AA280828 DBEST 1923508 AA282915 DBEST 1925910 AA284334 DBEST 1925910 AA284555 DBEST 1927484 AA284670 DBEST 1927581 AA284671 DBEST 1927581 AA284671 DBEST 1927581 AA284670 DBEST 1927484 AA284670 DBEST 1937582 AA287815 DBEST 1933581 AA286699 DBEST 1933581 AA286699 DBEST 1933581 AA286672 DBEST 1933581 AA287815 DBEST 1933514 AA291438 DBEST 1933514 AA291438 DBEST 1933514 AA291438 DBEST 1933514 AA291438 DBEST 1939506 AA291971 DBEST 1939506 AA291971 DBEST 1940027 AA293333 DBEST 1940137 AA293353 DBEST 1941173 AA293273 DBEST 1941173 AA293273 DBEST 1941377 AA293353 DBEST 1941377 AA293353 DBEST 1940750			
AA261990 AA262939 DBEST AA278445 DBEST AA278445 DBEST AA278482 DBEST AA278642 DBEST AA278956 DBEST AA279048 DBEST AA280099 DBEST AA280021 DBEST			
AA262939 AA278445 AA278482 DBEST AA278482 DBEST AA278642 AA278956 DBEST AA279048 DBEST AA280099 DBEST AA280221 DBEST AA280221 DBEST AA280221 DBEST AA2802915 DBEST AA284334 DBEST DBEST DBEST DBEST AA284370 DBEST		_ _	
AA278445 AA278482 AA278482 DBEST AA278642 DBEST AA278956 DBEST AA280099 DBEST AA280099 DBEST AA280221 DBEST AA280281 DBEST DBEST AA2802915 AA284334 DBEST DB			
AA278482			
AA278642 DBEst 1919962 AA278956 DBEst 1920495 AA279048 DBEst 1920577 AA280099 DBEst 1921573 AA280221 DBEst 1921759 AA280828 DBEst 1923508 AA282915 DBEst 1925910 AA284334 DBEst 1926614 AA284555 DBEst 1927581 AA284670 DBEst 1927582 AA284671 DBEst 1927582 AA284870 DBEst 1927582 AA284870 DBEst 1927582 AA284870 DBEst 1927464 AA284590 DBEst 1927464 AA285290 DBEst 1927468 AA286699 DBEst 1933581 AA286672 DBEst 1933581 AA28672 DBEst 1933581 AA287219 DBEst 193325 AA287642 DBEst 193325 AA287815 DBEST 193325 AA287815 DBEST 193325 AA287815 DBEST 1933514 AA291438 DBEST 1933514 AA291438 DBEST 1939417 AA291485 DBEST 1939506 AA291971 DBEST 1940027 AA292334 DBEST 1940027 AA293133 DBEST 1941173 AA293273 DBEST 194177 AA293353 DBEST 1941377 AA293353 DBEST 1941377 AA293353 DBEST 1941377			
AA278956 AA279048 DBEST AA280099 DBEST AA280221 DBEST AA280828 DBEST AA280828 AA282915 DBEST AA284334 DBEST AA284555 DBEST AA284670 DBEST AA284671 DBEST AA284870 DBEST			
AA279048			
AA280099 AA280221 DBEST AA280228 DBEST A280828 AA282915 DBEST A284334 DBEST A284555 DBEST A284670 DBEST A284671 DBEST DBEST DBEST A284870 DBEST			
AA280221 DBEST 1921759 AA280828 DBEST 1923508 AA282915 DBEST 1925910 AA284334 DBEST 1928614 AA284555 DBEST 1927484 AA284670 DBEST 1927581 AA284671 DBEST 1927582 AA284870 DBEST 1927464 AA284906 DBEST 1927464 AA284906 DBEST 1927448 AA285290 DBEST 1929600 AA286699 DBEST 1933581 AA286672 DBEST 1933581 AA286872 DBEST 1933932 AA287219 DBEST 1934280 AA287642 DBEST 193325 AA287645 DBEST 1933514 AA291438 DBEST 1933514 AA291438 DBEST 1939417 AA291485 DBEST 1939506 AA291971 DBEST 1940027 AA292334 DBEST 1940314 AA293127 DBEST 1940173 AA293133 DBEST 1941173 AA293273 DBEST 194177 AA293353 DBEST 1940750		DBEst	1921573
AA282915 AA284334 DBEST DBEST 1928614 AA284555 DBEST AA284670 DBEST AA284671 DBEST AA284870 DBEST AA284906 DBEST D	AA280221	DBEst	
AA284334 DBEST 1928614 AA284555 DBEST 1927484 AA284670 DBEST 1927581 AA284671 DBEST 1927582 AA284870 DBEST 1927464 AA284906 DBEST 1927448 AA285290 DBEST 1929600 AA286699 DBEST 1933581 AA286872 DBEST 1933932 AA287219 DBEST 1933932 AA287219 DBEST 1934280 AA287642 DBEST 193325 AA287815 DBEST 1933514 AA291438 DBEST 1933514 AA291438 DBEST 1939417 AA291485 DBEST 1939506 AA291971 DBEST 1940027 AA292334 DBEST 1940027 AA293133 DBEST 1941173 AA293127 DBEST 1941173 AA293273 DBEST 1941173 AA293286 DBEST 1941776 AA293353 DBEST 1940750	AA280828	DBEst	
AA284555		DBEst	
AA284670		DBEst	
AA284671 DBEST 1927582 AA284870 DBEST 1927464 AA284906 DBEST 1927448 AA285290 DBEST 1929600 AA286699 DBEST 1933581 AA286872 DBEST 1933932 AA287219 DBEST 1934280 AA287642 DBEST 1933325 AA287815 DBEST 1933514 AA291438 DBEST 1939417 AA291485 DBEST 1939417 AA291485 DBEST 1939506 AA291971 DBEST 1940027 AA292334 DBEST 1940027 AA293133 DBEST 1941167 AA293133 DBEST 1941173 AA293273 DBEST 1941423 AA293286 DBEST 1940750			-
AA284870			
AA284906 DBEst 1927448 AA285290 DBEst 1929600 AA286699 DBEst 1933581 AA286872 DBEst 1933932 AA287219 DBEst 1934280 AA287642 DBEst 1933325 AA287815 DBEst 1933514 AA291438 DBEst 1939417 AA291485 DBEst 1939506 AA291971 DBEst 1940027 AA292334 DBEst 1940027 AA293133 DBEst 1941173 AA293273 DBEst 194123 AA293286 DBEst 1940750	· -		
AA285290 DBEst 1929600 AA286699 DBEst 1933581 AA286872 DBEst 1933932 AA287219 DBEst 1934280 AA287642 DBEst 1933325 AA287815 DBEst 1933514 AA291438 DBEst 1939417 AA291485 DBEst 1939506 AA291971 DBEst 1940027 AA292334 DBEst 1940027 AA293133 DBEst 1941173 AA293173 DBEst 1941173 AA293273 DBEst 1941377 AA293353 DBEst 1940750			
AA286699 DBEst 1933581 AA286872 DBEst 1933932 AA287219 DBEst 1934280 AA287642 DBEst 1933325 AA287815 DBEst 1933514 AA291438 DBEst 1939417 AA291485 DBEst 1939506 AA291971 DBEst 1940027 AA292334 DBEst 1940027 AA293133 DBEst 1941167 AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1940750			
AA286872 DBEst 1933932 AA287219 DBEst 1934280 AA287642 DBEst 1933325 AA287815 DBEst 1933514 AA291438 DBEst 1939417 AA291485 DBEst 1939506 AA291971 DBEst 1940027 AA292334 DBEst 1940027 AA293127 DBEst 1940314 AA293127 DBEst 1941167 AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1941377 AA293353 DBEst 1940750	- · · ·		
AA287219 DBEST 1934280 AA287642 DBEST 1933325 AA287815 DBEST 1933514 AA291438 DBEST 1939417 AA291485 DBEST 1939506 AA291971 DBEST 1940027 AA292334 DBEST 1940027 AA293127 DBEST 1940314 AA293127 DBEST 1941167 AA293133 DBEST 1941173 AA293273 DBEST 1941423 AA293286 DBEST 1941377 AA293353 DBEST 1940750			
AA287642 DBEst 1933325 AA287815 DBEst 1933514 AA291438 DBEst 1939417 AA291485 DBEst 1939506 AA291971 DBEst 1940027 AA292334 DBEst 1940314 AA293127 DBEst 1941167 AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1941377 AA293353 DBEst 1940750			
AA287815 DBEst 1933514 AA291438 DBEst 1939417 AA291485 DBEst 1939506 AA291971 DBEst 1940027 AA292334 DBEst 1940314 AA293127 DBEst 1941167 AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1941377 AA293353 DBEst 1940750			
AA291438 DBEst 1939417 AA291485 DBEst 1939506 AA291971 DBEst 1940027 AA292334 DBEst 1940314 AA293127 DBEst 1941167 AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1941377 AA293353 DBEst 1940750			
AA291485 DBEst 1939506 AA291971 DBEst 1940027 AA292334 DBEst 1940314 AA293127 DBEst 1941167 AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1941377 AA293353 DBEst 1940750			
AA291971 DBEst 1940027 AA292334 DBEst 1940314 AA293127 DBEst 1941167 AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1941377 AA293353 DBEst 1940750			
AA292334 DBEst 1940314 AA293127 DBEst 1941167 AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1941377 AA293353 DBEst 1940750			
AA293127 DBEst 1941167 AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1941377 AA293353 DBEst 1940750			
AA293133 DBEst 1941173 AA293273 DBEst 1941423 AA293286 DBEst 1941377 AA293353 DBEst 1940750	AA293127	DBEst	1941167
AA293286 DBEst 1941377 AA293353 DBEst 1940750			
AA293353 DBEst 1940750			
AA293572 DBEst 1941239			
	AA293572	DREST	1941239

ACC NUM	DATABASE	GI NBR
AA293629	DBEst	1941280
AA293759	DBEst	1941542
AA293804	DBEst	1941727
AA296780	DBEst	1949277
AA297402	DBEst	1949735
AA298505	DBEst	1950908
AA299640	DBEst	1951971
AA301062	DBEst	1953433
AA301800	DBEst	1954133
AA303461	DBEst	1955795
AA303568	DBEst	1955901
AA306718	DBEst	1959046
AA306862	DBEst	1959190
AA306876	DBEst	1959204
AA307198	DBEst	1959526
AA307325	DBEst	1959653
AA308065	DBEst	1960394
AA308274	DBEst	1960673
AA308744	DBEst	1961143
AA310739	DBEst	1963088
AA310771	DBEst	1963242
AA311228	DBEst	1963628
AA311460	DBEst	1963786
AA311571	DBEst	1964055
AA311801	DBEst	1964150
AA311848	DBEst	1964177
AA311905	DBEst	1964306
AA312218	DBEst	1964618
AA312240	DBEst	1964578
AA312435	DBEst	1964763
AA313108	DBEst	1965456
AA313223	DBEst	1965552
AA313653	DBEst	1965983
AA313994	DBEst	1966555
AA314431	DBEst	1966760
AA314872	DBEst	1967221
AA315363	DBEst	1967742
AA315379	DBEst	1967707
AA317243	DBEst	1969570
AA317393	DBEst	1969772
AA318969	DBEst	1971371 1979467
AA327201	DBEst	1979467
AA331991	DBEst	1984234
AA332672	DBEst	1985601
AA333358	DBEst	1987516
AA335273 AA336666	DBEst DBEst	1988905
	DBEst	1989429
AA337192 AA337489	DBEst	1989954
AA338793	DBEst	1991103
AA339957	DBEst	1992224
AA340341	DBEst	1992579
AA341446	DBEst .	1993684
AA341446 AA341465	DBEst	1993733
AA342969	DBEst	1995205
AA343629	DBEst	1995868
AA344084	DBEst	1996321
AA345329	DBEst	1997564
AA346393	DBEst	1998631
AA346698	DBEst	1999168
AA347887	DBEst	2000122
AA350059	DBEst	2002398
AA351507	DBEst	2003827
		

ACC NUM	DATABASE	GI NBR
AA355003	DBEst	2007559
AA356682	DBEst	2009000
AA357574	DBEst	2009894
AA358887	DBEst	2011207
AA359705	DBEst	2012096
AA364352	DBEst	2016692
AA367451	DBEst	2019769
AA367773	DBEst	2020090
AA368542	DBEst	2021085
AA369400	DBEst	2021719
AA373230	DBEst	2025550
AA374754	DBEst	2027074
AA375312	DBEst	2027642
AA375815	DBEst	2028133
AA393525	DBEst	2046493
AA394115	DBEst	2047129
AA398443	DBEst	2051755
AA398585	DBEst	2051827
AA398739	DBEst	2051861
AA399165	DBEst	2052960
AA399628	DBEst	2052642
AA401329	DBEst	2053554
AA401334	DBEst	2053559
AA402191	DBEst	2056138
AA402289 AA402775	DBEst	2056202 2056528
AA403319	DBEst DBEst	2056820
AA404613	DBEst	2058825
AA405124	DBEst	2063536
AA406239	DBEst	2064220
AA410580	DBEst	2069686
AA410982	DBEst	2070088
AA411021	DBEst	2070171
AA411252	DBEst	2068793
AA411764	DBEst	2070352
AA417794	DBEst	2079604
AA419263	DBEst	2078976
AA419284	DBEst	2079014
AA420751	DBEst	2094630
AA420758	DBEst	2094637
AA421248	DBEst	2100135
	DBEst	2100499
AA422060	DBEst	2100893
AA422143	DBEst	2101011
	DBEst	2107073
	DBEst	2106322
	DBEst	2107249
	DBEst	2113001 2110974
AA430436	DBEst DBEst	2110974
	DBESt	2115136
	DBEst	2138902
	DBEst	2141229
	DBEst	2141325
	DBEst	2155699
	DBEst	2162785
	DBEst	2165448
	DBEst	2167547
	DBEst	2177444
	DBEst	2177729
	DBEst	2177738
	DBEst	2178021
AA455785	DBEst	2178561

PCT/US00/24199 WO 01/18542 86

- 00 NTM	DATABASE	GI NBR
ACC NUM		2179030
AA456454	DBEst	2179030
AA456557	DBEst	2179133
AA457255	DBEst	21/99/3
AA457579	DBEst	2184074
AA459167	DBEst	
AA459210	DBEst	2184117
AA459527	DBEst	2184434
AA460570	DBEst	2185690
AA460816	DBEst	2185936
AA461005	DBEst	2186125
AA468657	DBEst	2195191
AA469447	DBEst	2194242
AA469453	DBEst	2194248
AA476522	DBEst	2204733
AA477018	DBEst	2205229
AA477567	DBEst	2206201
AA477973	DBEst	2206607
AA478230	DBEst	2206864
AA479646	DBEst	2205532
AA479648	DBEst	2205534
AA479848	DBEst	2205734
AA481078	DBEst	2210630
AA481710	DBEst	2211262
AA482430	DBEst	2210108
AA482432	DBEst	2210110
AA482779	DBEst	2211624
AA483258	DBEst	2212071
AA483726	DBEst	2212539
AA483858	DBEst	2212671
AA484181	DBEst	2212994
AA486047	DBEst	2216263
AA486859	DBEst	2217023
AA488141	DBEst	2215572
AA488385	DBEst	2215816
AA488517	DBEst	2215948
AA489323	DBEst	2218925
AA489380	DBEst	2218982
AA489382	DBEst	2218984
AA491204	DBEst	2220377
AA492143	DBEst	2221705
AA493371	DBEst	2223212
AA494321	DBEst	2224108
AA494552	DBEst	2224339
AA501657	DBEst	2236624
AA502136	DBEst	2237103
AA505780	DBEst	2241917
AA512933	DBEst	2251356
AA514395	DBEst	2253995
AA514974	DBEst	2254574
AA515143	DBEst	2254743
AA516376	DBEst	2253738
AA521006	DBEst	2261549
AA523522	DBEst	2264234
AA524748	DBEst	2265676
AA524950	DBEst	2265878
AA525141	DBEst	2266069
AA526028	DBEst	2268097
AA527275	DBEst	2269344
AA527557	DBEst	2269626
AA533506	DBEst	2277602
AA534349	DBEst	2278602
AA534586	DBEst	2278839
AA534608	DBEst	2278861

PCT/US00/24199 WO 01/18542 87

ACC NUM	DATABASE	GI NBR
AA535496	DBEst	2279749
AA541651	DBEst	2288085
AA548056	DBEst	2318338
- AA548600	DBEst	2318882
AA550854	DBEst	2321106
AA550855	DBEst	2321107
AA551351	DBEst	2321603
AA551391	DBEst	2321643
AA554437	DBEst	2324976
AA554735	DBEst	2325274
AA555102	DBEst	2325641
AA564272	DBEst	2335911
AA564870	DBEst	2336509
AA565420	DBEst	2337059
AA568936	DBEst	2341990
AA569816	DBEst	2343796
AA569851	DBEst	2343831
AA569916	DBEst	2343896
AA573761	DBEst	2348276
AA573787	DBEst	2348302
AA577537	DBEst	2355011 2357065
AA578881	DBEst	2357775
AA579591	DBEst DBEst	2355217
AA579890 AA580835	DBESC	2358607
AA580835 AA582093	DBEst	2360771
AA582866	DBESt	2360226
AA583055	DBEst	2360415
AA583498	DBEst	2368107
AA583567	DBEst	2368176
AA583773	DBEst	2368382
AA584921	DBEst	2367701
AA586755	DBEst	2397569
AA587140	DBEst	2397954
AA587315	DBEst	2398129
AA587873	DBEst	2402048
AA593983	DBEst	2409333
AA594366	DBEst	2409716
AA595624	DBEst	2410974
AA595771	DBEst	2411121
AA599454	DBEst	2433079
AA600227	DBEst	2433852
AA600771	DBEst	2434396 2434797
AA601172	DBEst DBEst	2436373
AA602395 AA602871	DBESt	2436805
AA602871 AA603125	DBEst	2436986
AA603125 AA603177	DBEst	2437038
AA604324	DBESC	2445233
AA604324 AA604853	DBEst	2445717
AA610279	DBEst	2458707
AA610476	DBEst	2458904
AA610734	DBEst	2459162
AA614482	DBEst	2466678
AA628536	DBEst	2540923
AA628547	DBEst	2540934
AA630611	DBEst	2553222
AA631326	DBEst	2553937
AA633909	DBEst	2557123
AA634260	DBEst	2557474
AA634298	DBEst	2557512
AA640505	DBEst	2565755
AA641289	DBEst	2566539

TABLE 1-1

100 100		
ACC NUM	DATABASE	GI NBR
AA644625	DBEst	2569843
AA648944	DBEst	2575373
AA651720	DBEst	2583372
AA652478	DBEst	2584130
AA652505	DBEst	2584157
AA653775	DBEst	2589929
AA658374	DBEst	2594528
AA663005	DBEst	2616996
AA669154	DBEst	2630653
AA677560	DBEst	2658082
AA677750	DBEst	
AA678185	DBEst	2658272
AA678251		2658707
	DBEst	2658773
AA687495	DBEst	2675686
AA703208	DBEst	2706321
AA703667	DBEst	2713585
AA703907	DBEst	2713825
AA704208	DBEst	2714126
AA706347	DBEst	2716265
AA714010	DBEst	2726284
AA715984	DBEst	2728258
AA716651	DBEst	2728925
AA719530	DBEst	2732629
AA721642	DBEst	2736625
AA729381	DBEst	2750740
AA731946	DBEst	2753897
AA736817	DBEst	2768051
AA742713	DBEst	2782219
AA743278	DBEst	2782784
AA744681	DBEst	2783445
AA745953	DBEst	2785939
AA759195	DBEst	2807058
AA767779	DBEst	2818794
AA769697	DBEst	2820935
AA773998	DBEst	2825887
AA775058	DBEst	2834392
AA776593	DBEst	2835927
AA777384	DBEst	2836715
AA778672	DBEst	2838003
AA779949	DBEst	2839280
AA781487	DBEst	2840818
AA788907	DBEst	2849027
AA806278	DBEst	2875028
AA806735	DBEst	2875485
AA808769	DBEst	2878175
AA810149	DBEst	2879555
AA811609	DBEst	2881220
AA813604	DBEst	2882289
AA826307	DBEst	2899619
AA833766	DBEst	2908534
AA833900	DBEst	2907499
AA837457	DBEst	2912656
AA843531	DBEst	2930049
AA845737	DBEst	2931877
AA846698	DBEst	2932838
AA846856	DBEst	2932996
AA852896	DBEst	2939635
AA856902	DBEst	2945204
	DBEst	2946126
AA857882	DBEst	2946184
AA861665	DBEst	2953805
	DBEst	2958236
AA868529	DBEst	2963974

ACC NUM	DATABASE	GI NBR
AA873271	DBEst	2969393
AA877189	DBEst	2986266
AA884922	DBEst	2994903
AA886453	DBEst	3001561
AA906652	DBEst	3042238
AA906865	DBEst	3042109
AA918993	DBEst	3058883
AA926926	DBEst	3075823
AA928934	DBEst	3078291
AA932501	DBEst	3087282
AA933987	DBEst	3090255
AA935947	DBEst	3093104
AA937302	DBEst	3095413
AA937773	DBEst	3095884
AA947835	DBEst	3109088
AA954939	DBEst	3118634
AA962587	DBEst	3134751
AA962632	DBEst .	3134796
AA972525	DBEst	3145289 3152281
AA976489	DBEst	
AA983380	DBEst	3161905 3163111
AA984586 AA992596	DBEst DBEst	3179352
AB002305	GenBank	2224554
AB002305 AB002330	GenBank	2224534
AB002330 AB002357	GenBank	2224658
AB002337 AB002806	GenBank	2780782
AB003476	GenBank	2081606
AB004066	GenBank	2308996
AB006077	GenBank	2564010
AB006534	GenBank	2924619
AB006755	GenBank	2979417
AB007867	GenBank	2662094
AB007900	GenBank	2662160
AB007916	GenBank	6683704
AB007923	GenBank	3413869
AB007957	GenBank	3413931
AB011103	GenBank	3043585
AB011143	GenBank	3043665
AB011151	GenBank	3043681
AB011166	GenBank	3043711
AB014533	GenBank GenBank	3327079 3327097
AB014542 AB014560	GenBank	3327037
AB014560 AB015630	GenBank	4586837
AB015856	GenBank	3953530
AB013838 AB018281	GenBank	3882196
AB018284	GenBank	3882202
AB018285	GenBank	3882204
AB018289	GenBank	3882212
AB018305	GenBank	3882244
AB018327	GenBank	3882288
AB018331	GenBank	3882296
AB018337	GenBank	3882308
AB019409	GenBank	4587128
AB019563	GenBank	3885366
AB019568	GenBank	3885371
AB019691	GenBank	5051742
AB020682	GenBank	4240238
AB020718	GenBank	4240310
AB021288	GenBank	4038732
AB023154	GenBank	4589517
AB023219	GenBank	4589647

TABLE 1-1

ACC NUM	DATABASE	GI NBR
AB024704	GenBank	4589928
	GenBank	6172222
	GenBank	4996095
	GenBank	5103045
	GenBank	5689428
	GenBank	5689462
	GenBank GenBank	5689490
	Genbank GenBank	5689498 5689546
	N/A	3689346 N/A
	N/A	N/A N/A
	GenBank	3153911
	GenBank	2232135
AF001893	GenBank	2529723
	GenBank	3041872
	GenBank	2674061
	GenBank	2852610
	GenBank	2852629
	GenBank GenBank	2865251
	Genbank Genbank	2393946 3153208
	Genbank Genbank	2318114
	GenBank	2316114
	GenBank	2353176
AF016507	GenBank	2909776
	GenBank	2367668
	GenBank	2501872
	GenBank	3510461
	GenBank	2460207
	GenBank GenBank	2460317
•	GenBank GenBank	2809382 4103447
	GenBank	2815605
	GenBank	4090928
	GenBank	2612967
	GenBank	2598967
	GenBank	2606093
	GenBank	4426566
	GenBank	2661038
	GenBank GenBank	2661070
-	Genbank GenBank	2661075 2906012
-	SenBank	3132897
	GenBank	2828109
	GenBank	4104738
-	GenBank	2809399
_	SenBank	2804783
	GenBank	3493528
	GenBank	2828148
	GenBank	7770717
	GenBank GenBank	2865520
	SenBank	3417598 3335131
	GenBank	2921872
	enBank JenBank	3005586
_	enBank	5668577
	lenBank	2961556
	enBank	4164453
· · · · · · · · · · · · · · · · · · ·	enBank	3360431
	enBank	3360444
	_	3360459
		3360475
AF052169 G	enBank	3360480

PCT/US00/24199

ACC NUM	DATABASE	GI NBR
AF052180	GenBank	3360492
AF052514	GenBank	3510662
AF054183	GenBank	4092053
AF054187	GenBank	4092059
AF054840	GenBank	2997744
AF055012	GenBank	3005735
AF055033	GenBank	3005763
AF057299	GenBank	5739040
AF059252	GenBank	3372629
AF061258	GenBank	3108092
AF062318	GenBank	3152814
	GenBank	4731856
AF063611		3347856
AF064019	GenBank	4321975
AF068235	GenBank	
AF068846	GenBank	3201999
AF070523	GenBank	3764088
AF070537	GenBank	3387894
AF070555	GenBank	3387920
AF070561	GenBank	3387928
AF070596	GenBank	3387973
AF070600	GenBank	3387979
AF070626	GenBank	3283892
AF070649	GenBank	3283923
AF070662	GenBank	4454699
AF070672	GenBank	3978239
AF071202	GenBank	3335172
AF071219	GenBank	3288867
AF071593	GenBank	3249712
AF073298	GenBank	3641537
AF075587	GenBank	3319325
AF077030	GenBank	4689107
AF077045	GenBank	4689137
AF077200	GenBank	4679013
AF077202	GenBank	4679017
AF077207	GenBank	4679027
AF081192	GenBank	3420798
AF081484	GenBank	3420928
AF083190	GenBank	3599414
AF085355	GenBank	5114044
AF086003	GenBank	3483348
AF086116	GenBank	3483461
AF086178	GenBank	3483523
AF086205	GenBank	3483550
AF086207	GenBank	3483552
AF086336	GenBank	3483681
AF086517	GenBank	3483862
AF087135	GenBank	3641297
	GenBank	3523196
AF087990 AF088036	GenBank	3523242
	GenBank	3859989
AF091076		
AF092563	GenBank	3851583
AF095287	GenBank	3766235
AF095791	GenBank	3777595
AF097709	GenBank	3777616
AF100741	GenBank	5138992
AF100756	GenBank	5410297
AF100928	GenBank	4323586
AF104222	GenBank	3983426
AF104913	GenBank	3941723
AF104923	GenBank	4680483
AF107405	GenBank	5531903
AF120334	GenBank	4191615
AF124438	GenBank	4838431

TABLE 1-1

ACC NUM	DATABASE	GI NBR
AF124439	GenBank	4838433
AF125525	GenBank	4689281
AF131799	GenBank	4406628
AF131814	GenBank	4406648
AF139461	GenBank	4894945
AF139658	GenBank	4894940
AF144755	GenBank	5006628
AF147331	GenBank	4761682 5020252
AF150962 AF151832	GenBank GenBank	4929616
AF151832 AF151868	GenBank	4929688
AF151898	GenBank	4929748
AF151990 AF151907	GenBank	4929766
AF152097	GenBank	4929772
AF159295	GenBank	5714635
AF176702	GenBank	6103642
AF190744	GenBank	6176531
AI004664	DBEst	3214174
AI004915	DBEst	3214425
AI016073	DBEst	3230409
AI016323	DBEst	3230659
AI016791	DBEst	3231127
AI018451	DBEst	3232970
AI018625	DBEst	3233144
AI022779	DBEst	3238020
AI023799	DBEst DBEst	3238843 3241777
AI026164 AI027516	DBEst	3246446
A1027316 A1031636	DBEst	3249848
A1031030 A1033037	DBEst	3253990
AI034115	DBEst	3255068
AI037859	DBEst	3277053
AI041670	DBEst	3280864
AI042034	DBEst	3281228
AI042290	DBEst	3281484
AI051971	DBEst	3307962
AI056917	DBEst	3330706
AI057124	DBEst	3331000
AI066419	DBEst DBEst	3367121 3412449
AI078041 AI081116	DBEst	3417908
A1081116 A1081472	DBEst	3418264
A1081472 A1081913	DBEst	3418705
AI082244	DBEst	3419036
AI082648	DBEst	3419440
AI084731	DBEst	3423154
AI085381	DBEst	3423804
AI087291	DBEst	3425714
AI087819	DBEst	3426852
AI088178	DBEst	3427256
AI089981	DBEst	3429040
AI090524	DBEst	3429583
A1090623	DBEst	3429682
AI091425	DBEst DBEst	3430484 3431947
AI092971 AI095477	DBESt	3434453
A1095477 A1123229	DBEst	3538995
A1125229 A1125642	DBEst	3594156
AI125042 AI125874	DBEst	3594388
AI127013	DBEst	3595527
AI127515 AI127556	DBEst	3596070
AI140291	DBEst	3647748
AI141130	DBEst	3648587

TABLE 1-1

`

ACC NUM	DATABASE	GI NBR
AI141847	DBEst	3649304
AI143899	DBEst	3665708
AI144100	DBEst	3665909
AI148251	DBEst	3675933
AI149429 AI149592	DBEst DBEst	3677898 3678061
A1149592 A1186028	DBESt	3736666
A1186028 A1186042	DBEst	3736680
AI190341	DBEst	3741550
AI192367	DBEst	3743576
AI192629	DBEst	3743838
AI198930	DBEst	3751536
AI216969	DBEst	3789623
AI217003	DBEst	3789657
AI223292	DBEst	3805495
A1241706	DBEst	3837103
AI251743	DBEst	3848272
AI252466 AI253330	DBEst DBEst	3848995 3850451
A1253330 A1253335	DBEst	3850451
A1253333 A1253338	DBEst	3850459
A1253375	DBEst	3850496
AI253379	DBEst	3850500
AI253436	DBEst	3850391
AI262380	DBEst	3870583
AI263674	DBEst	3871877
AI267162	DBEst	3886329
AI267185	DBEst	3886352
AI267209	DBEst	3886376
AI267289 AI267307	DBEst DBEst	3886456 3886474
A1267307 A1267321	DBESt	3886488
A1267454	DBEst	3886621
AI267502	DBEst	3886669
AI268293	DBEst	3887460
A1269060	DBEst	3888227
AI269369	DBEst	3888536
AI270183	DBEst	3889350
AI270472	DBEst	3889639
AI271786 AI272827	DBEst DBEst	3890953 3895095
A1272027 A1274047	DBEst	3896315
AI274047 AI276341	DBEst	3898615
AI276839	DBEst	3899113
AI278611	DBEst	3916845
AI280022	DBEst	3918255
AI283548	DBEst	3921781
AI288965	DBEst	3931274
AI290565	DBEst	3933339
AI291683	DBEst	3934457
AI292286	DBEst	3935060
AI298472 AI298941	DBEst	3958208 3958595
A1304857	DBEst	3988546
A1304657 A1308959	DBEst	4003830
AI312552	DBEst	4018157
AI333055	DBEst	4069614
AI333116	DBEst	4069675
AI335249	DBEst	4072176
AI336326	DBEst	4073253
AI345325	DBEst	4082531
AI366549	DBEst	4126238
AI366549	DBEst	4126238

TABLE 1-1

ACC NUM	DATABASE	CT MDD
AI367850	DBEst	GI NBR 4137595
AI375624	DBEst	
AI375624	DBEst	4175614
AI376561	DBEst	4175614 4186410
AI399636	DBEst	4242723
AI417384	DBEst	4242723
AI421720	DBEst	4267651
AI424841	DBEst	4207031
AI431507	DBEst	4303669
AI433180	DBEst	4287371
AI434084	DBEst	4293703
AI434401	DBEst	4295922
AI436016	DBEst	4307232
AI436448	DBEst	4281781
AI446503	DBEst	4295666
AI453199	DBEst	4308687
AI459028	DBEst	4311607
AI469237	DBEst	4331327
AI492520	DBEst	4393523
AI492769	DBEst	4393772
	DBEst	4395347
	DBEst	4438075
	DBEst	4438812
	DBEst	4452817
	DBEst	4489422
	DBEst	4511601
	DBEst	4526440
	DBEst	4533089
	DBEst	4565667
	DBEst DBEst	4569108
	DBESt	4569467
	DBEst	4598349 4606986
	DBEst DBEst	4600986
_	DBESt	4617754
	DBEst	4618135
	DBEst	4618360
	DBEst	4618448
	DBEst	4648735
AI628689	DBEst	4665489
AI636635	DBEst	4687965
	DBEst	4734816
	DBEst	4738075
	DBEst	4763815
	DBEst	4834027
	DBEst	4834858
	DBEst	4874793
	DBEst	4888334
-	DBEst	4888885
	DBEst	4889226
	DBEst	4889503
	DBEst	4893322
	DBEst	4893520
TT III II	DBEst	4893975
	OBEst OBEst	4900092
	DBESt	4970206
	DBEST DBEST	4971427 4984719
	DBEst	4984/19
	DBEst	5056446
	DBEst	5056668
	DBEst	5101318
	DBEst	5101318
		525250

ACC NUM	DATABASE	GI NBR
	DATABABE	GI NDA
A1743595	DBEst	2111883
AI743691	DBEst .	5111979
AI750198	DBEst	5128462
AI750909	DBEst	5129173
	DBEst	5129306
AI751364	DBEst	5129628
A1751565	DBEst	5120020
	DDESC	5123023
AI752319	DBEst	2130263
AI752553	DBEst	2130817
AI752929	DBEst	2131133
AI753108	DBEst	5131372
AI753671	DBEst	5131935
AI754437	DBEst	5132701
AI755181	DBEst	5133445
AI758869	DBEst	5152594
AI761927	DBEst	5177594
AI763126	DBEst	5178793
A1791906	DBEst	5339622
	DDESC	5339022
AI793120	DBEst	5340636
AI799521	DBEst	5364993
AI804346	DBEst	2369818
AI808109	DBEst .	5394597
AI811021	DBEst	5397587
AI811845	DATABASE DBEST DBEST	5398411
AI814139	DBEst	5425354
AI814674	DBEst	5425889
AI815868	DBEst	5431414
A1822030	DBEst	5441109
A1827641	DBEst	5448312
A1859619	DBEst	5513235
	DBEst	5528687
A1864580		5553017
A1878968	DBEst	
AI879179	DBEst	5553228
AI879367	DBEst	5553416
AI879992	DBEst	5554041
AI888377	DBEst	5593464
AI911704	DBEst	5631559
AI911997	DBEst	5631852
AI912084	DBEst	5631939
AI916284	DBEst	5636229
AI916584	DBEst	5636439
AI923224	DBEst	5659188
A1924096	DBEst	5660060
A1928185	DBEst	5664149
		5665783
AI929819	DBEst	
AI936748	DBEst	5675618
AI950087	DBEst	5742397
A1955808	DBEst	5748118
AJ001258	GenBank	2769648
AJ002030	GenBank	2570006
AJ006026	GenBank	3127893
AJ011001	GenBank	4456466
AJ011915	GenBank	3757675
AJ012499	GenBank	5441359
AJ223183	GenBank	3925598
	DBEst	5927582
AL035802		5405617
AL035987	DBEst	
AL036801	DBEst	5927917
AL037646	DBEst	5928237
AL038985	DBEst	5408101
AL039150	DBEst	5408232
AL041780	DBEst	5421127
AL044019	DBEst	5432247

TABLE 1-1

ACC NUM	DATABASE	GI NBR
AL046804	DBEst	5434866
AL049055	DBEst	4728364
AL049227	GenBank	4499957
AL049229	GenBank	4499961
AL049296	GenBank	4500057
AL049464	GenBank	4500256
AL049953 AL049954	GenBank GenBank	4884201
AL049955	GenBank	4884203 4884205
AL049959	GenBank	4884205
AL049987	GenBank	4884238
AL049999	GenBank	4884252
AL050011	GenBank	4884080
AL050089	GenBank	4884107
AL050141	GenBank	4884352
AL050171	GenBank	4884383
AL050187	GenBank	4884402
AL050198	GenBank	4884436
AL050217	GenBank	4884458
AL050392	GenBank	4914613
AL080062 AL080186	GenBank	5262466
AL080186 AL080235	GenBank GenBank	5262664
AL080233 AL096857	GenBank	5262728 5541862
	GenBank	5541864
	GenBank	5817115
	GenBank	5817176
	GenBank	5834563
AL117499	GenBank	5912003
	GenBank	5912062
	DBEst	5924898
	DBEst	5924984
	DBESt	5925056
	DBEst DBEst	5874009
	DBEst	5904643 6073454
	DBEst	1434324
	DBEst	1571593
	DBEst	1580488
	GenBank	219909
D00022	GenBank	219653
	GenBank	220080
	GenBank	219941
	GenBank	220063
	GenBank	520586
	GenBank	285909
	GenBank GenBank	496370
	GenBank GenBank	393318 433410
	GenBank	285948
	GenBank	285964
	GenBank	559324
	GenBank	285968
D15049	GenBank	475003
	GenBank	598955
	GenBank	598856
	GenBank	598702
	GenBank	598899
	GenBank	2335046
		457407
		434752
		432358 662389
~~~~~		VUL307

WO 01/18542 PCT/US00/24199 .. **97** 

ACC NUM	DATABASE	GI NBR
D28759	GenBank	633074
D29677	GenBank	473938
D31767	GenBank	505091
D31784	GenBank	974184
D31883	GenBank	505093
D31890	GenBank GenBank	505107 1019367
D37991 D38491	GenBank	559327
D38583	GenBank	560790
D38383 D43948	GenBank	603950
D43950	GenBank	603954
D45248	GenBank	1008914
D45887	GenBank	665587
D45915	GenBank	1483130
D49489	GenBank	1136742
D49547	GenBank	710654
D50310	GenBank	1183161
D50371	GenBank	2605591
D55192	DBEst	957089
D55649	GenBank	1132478
D56120	DBEst	970603
D59253	GenBank GenBank	1060898 1228048
D78586	DBEst	1180177
D79826 D79983	GenBank	1136383
D79986	GenBank	1136389
D79997	GenBank	1136409
D80006	GenBank	1136427
D80012	GenBank	1136437
D80087	DBEst	1177964
D80253	DBEst	1178130
D81635	DBEst	1179512
D82128	DBEst	1183520
D82348	GenBank	1311461
D83197	GenBank	3893154
D83327	GenBank	2687860 1663695
D83784 D86227	GenBank GenBank	2081619
D87437	GenBank	1665768
D87442	GenBank	1665772
D87470	GenBank	1665822
D87666	GenBank	1620016
D87667	GenBank	1620019
D87682	GenBank	1663699
D87735	GenBank	1620021
D87969	GenBank	1694636
D89052	GenBank	1694672
D90226	GenBank	219946
D90373	GenBank	219477
E00882	GenBank	2169143
E01650 E01797	GenBank GenBank	2169903 2170049
E01797 E01813	GenBank	2170045
E01813	GenBank	2170079
E01979	GenBank	2170227
E02628	GenBank ·	2170856
E02651	GenBank	2170879
E03569	GenBank	2171785
E06721	GenBank	2174903
E07218	GenBank	2175359
F28779	DBEst	4814405
F30276	DBEst	4815902
F31082	DBEst	4816708

TABLE 1-1

ACC NUM	DAMADA GE	
H03854	DATABASE	GI NBR
H03834 H05412	DBEst	866787
H03412 H08994	DBEst	868964
H13339	DBEst	873816
H16426	DBEst	878159
H39960	DBEst	881246
H48742	DBEst	916012
H59372	DBEst	988582
H60722	DBEst	1012204
H69238	DBEst DBEst	1013554
H72481	DBESt	1030614
H75695	DBEst	1044297
H78517	DBEst	1049638
H79084	DBESt	1056606 1057173
H84729	DBEst	1057173
н85709	DBEst	1063923
Н89654	DBEst	1087288
J00269	GenBank	186699
J02621	GenBank	184229
J03005	GenBank	183183
J03040	GenBank	338312
J03171	GenBank	184645
J03191	GenBank	190385
J03210	GenBank	180670
J03464	GenBank	179595
J03473	GenBank	337423
J03799	GenBank	186840
J04080	GenBank	179645
J04164	GenBank	177801
J04177	GenBank	179729
J04765	GenBank	189404
J05013	GenBank	182417
J05021	GenBank	340216
J05192	GenBank	178026
J05633	GenBank	186504
K00558 K01566	GenBank	340020
K02765	GenBank	187721
L00160	GenBank GenBank	179664
L02547	GenBank	189904 180598
L05092	GenBank	388031
L05186	GenBank	182394
L07633	GenBank	186512
L11066	GenBank	307322
L11932	GenBank	307423
L12711	GenBank	388890
L13848	GenBank	307382
L14599	GenBank	348238
L19161	GenBank	306899
L19184	GenBank	440305
L19597	GenBank	306467
	GenBank	507251
	GenBank	414316
	GenBank	799328
	GenBank	452059
	GenBank	452047
	GenBank	454151
	GenBank	521214
	GenBank	500848
	GenBank	551596
	GenBank	1220373
	GenBank	790816
L42024	GenBank	804748

		DATABASE		NBR
		GenBank	899	
				8859
	<del>-</del> ·			6416
			339 182	
			182	
L43575       GenBank         L44349       DBEst         L54057       GenBank         M10036       GenBank         M10119       GenBank         M1146       GenBank         M13573       GenBank         M14983       GenBank         M14483       GenBank         M14630       GenBank         M14631       GenBank         M15182       GenBank         M15800       GenBank			182	
L43575       GenBank         L44349       DBEst         L54057       GenBank         M10036       GenBank         M10119       GenBank         M10905       GenBank         M11146       GenBank         M13573       GenBank         M14083       GenBank         M14483       GenBank         M14630       GenBank         M14631       GenBank         M15182       GenBank         M15800       GenBank         M16247       GenBank			189	
			186	
			189	
M144	83	GenBank	339	692
M146	30	GenBank	339	690
M146	31		183	
			183	
	· ·		187	
			178	
M165		GenBank	339	
M166		GenBank GenBank	184 184	
M169 M175		GenBank	340	
M178		GenBank	190	
M203		GenBank	189	
M221		GenBank	337	
M223		GenBank	190	
M225		GenBank	179	_
M229		GenBank	189	
M229	20	GenBank	189	021
M236	13	GenBank	189	
M241		GenBank	187	
M252		GenBank	340	
M260		GenBank	188	
M261		GenBank		0968
M263		GenBank GenBank	186 339	
M279 M279		GenBank	187	
M283		GenBank	609	
M311		GenBank	183	
M312		GenBank	188	
M318	99	GenBank	182	178
M321	10	GenBank	189	
M327		GenBank	180	
M327		GenBank	180	
M333		GenBank	340	
M340		GenBank	416	
M375		GenBank GenBank	184 189	
M554		GenBank	189	
M555		GenBank	183	
M584	<del>-</del> -	GenBank	180	
M604		GenBank	181	
M608		GenBank	338	446
M624		GenBank	184	<b>B15</b>
M628	10	GenBank	188	563
M642	41	GenBank	190	
M674		GenBank	182	
M691			641	
M740		GenBank	178	
M751			1840	
M767			1899	
M781: M817:			2738 337	
M832			189	
M847		<del>-</del>	1798	

ACC NUM         DATABASE           M87503         GenBank           M88279         GenBank           M92357         GenBank           N20576         DBEst           N34255         DBEst           N35187         DBEst           N35421         DBEst           N39717         DBEst           N40823         DBEst           N40852         DBEst           N67927         DBEst           N76180         DBEst           N7080         DBEst           N84497         DBEst           DBEst         DBEst           DBEst         DBEst           DBEst         DBEst           DBEst         DBEst		GI NBR
	GenBank	184652
		186389
		306463
	· — — — —	1125531
		1155397
		1156329 1156563
		1163262
		1164420
N40852		1164449
	DBEst	1220052
		1238758
		1239255
		1239658
N84497 N86776	DBEst	1260122
N91638	DBEst	1439978 1263947
N92086	DBEst	1264395
N99205	DBEst	1270661
Q37741	N/A	N/A
Q48043	N/A	N/A
Q65676	N/A	N/A
Q90526	N/A	N/A
R06046 R17092	DBEst DBEst	756666
R47228	DBESt	770702 808115
R55150	DBEst	824379
R55398	DBEst	824693
R68132	DBEst	841649
R72676	DBEst	846708
R73306	DBEst	847338
R78333 R92367	DBEst	853443
R93637	DBEst DBEst	959907 967803
R99649	DBEst	986250
S41458	GenBank	252252
S42303	GenBank	253482
S54005	GenBank	264772
S66431	GenBank	435777
S70154 S70290	GenBank	546900
	GenBank GenBank	546602 1195555
S82076	GenBank	1488423
T02792	DBEst	319308
T24119	DBEst	523315
	DBEst	651174
	DBEst	655339
	DBEst	660634
	DBEst	673605
	DBEst DBEst	675157 724073
	DBEst	724073
	GenBank	405049
_	GenBank	507157
	GenBank	460624
	GenBank	469048
	GenBank	478884
	GenBank	532312
	GenBank GenBank	577169 562073
	~	606922
		606943
		565079

TABLE 1-1

ACC NUM	DATABASE	GI NBR
U14966	GenBank	550012
U15008	GenBank	600747
U16306	GenBank	608514
U17104	GenBank	609307
U17496	GenBank	596139
บ19769	GenBank	924600
U20896	GenBank	1046220
U22431	GenBank	881345
U22815	GenBank	930340
U24105	GenBank	1638873
U24153	GenBank	780807
U27768	GenBank	1216372
U33760	GenBank	995823
U33833	GenBank	1517815
U34877	GenBank	1143231
U39361	GenBank	1066081
U41515	GenBank	1209723
U46570	GenBank	1688073
U50733	GenBank	1255187
U51586	GenBank	1809247
U56255 U59305	GenBank GenBank	1399688 1695872
U60975	GenBank	5030423
U61083	GenBank	4097430
U61397	GenBank	1518693
U63846	GenBank	1480921
U67784	GenBank	1617516
U68723	GenBank	2114391
U68727	GenBank	2052384
U68758	GenBank	4097815
บ70735	GenBank	2360944
บ77085	GenBank	1684789
บ79258	GenBank	1710211
U79274	GenBank	1710240
บ79278	GenBank	1710247
U80213	GenBank	1857418
U81234	GenBank	4098960
U82130	GenBank	1772663
U86602	GenBank	1835785
U87309	GenBank	1842092 2745975
U90028	GenBank GenBank	
U90441	GenBank GenBank	2439984 1913880
U90902 U90917	GenBank GenBank	1913898
U94831	GenBank	2276459
V00478	GenBank	28244
V00503	GenBank	30123
V05728	N/A	N/A
V11636	N/A	N/A
V57903	N/A	N/A
V59662	N/A	N/A
V59746	N/A	N/A
V84428	N/A	N/A
V86232	N/A	N/A
V87930	N/A	N/A
W07215	DBEst	1281217
W19127	DBEst	1294870
W19407	DBEst	1295308
W19441	DBEst	1295361
W25547	DBEst	1303421
W26197	DBEst	1306608
W38952	DBEst	1320872
W56388	DBEst	1358278

ACC NUM	DATABASE	GI NBR
W68015	DBEst	1376884
W73140	DBEst	1383275
W73168	DBEst	1383322
พ76204 พ87522	DBEst	1386429 1401728
W87891	DBEst DBEst	1401728
x00351	GenBank	28251
X00497	GenBank	32130
X01742	GenBank	35324
X01924	N/A	N/A
X03084	GenBank	29537
X04098	GenBank	28338
X04408	GenBank	31914
X04470	GenBank	28638
X05276	GenBank	37201
X05908	GenBank	34387
X06700 X07819	GenBank GenBank	30053
X13425	GenBank	35798 31590
X14420	GenBank	30057
X15729	GenBank	38317
X15880	GenBank	30029
X16869	GenBank	31091
X17206	GenBank	34391
X24068	N/A	N/A
x37385	N/A	N/A
x37509	N/A	N/A
X40178 X51466	N/A	N/A
X53505	GenBank GenBank	31105 36145
X54304	GenBank	34755
X54941	GenBank	29976
X55110	GenBank	35086
X55885	GenBank	34030
X56932	GenBank	23690
X56998	GenBank	37564
X56999	GenBank	37568
X57766 X62744	GenBank GenBank	456256 36062
X63432	GenBank	28335
X66360	GenBank	36616
X67698	GenBank	37476
X68277	GenBank	29980
X68880	GenBank	31141
X69398	GenBank	396175
X69838	GenBank	287864
X70340 X71087	GenBank GenBank	37089
X73608	GenBank	288396 793844
X73902	GenBank	452754
X74039	GenBank	456192
X74801	GenBank	671526
X74979	GenBank	400462
X76013	GenBank	531595
X76180	GenBank	452649
X78627	GenBank	607129
X81109	GenBank	535057
X82676 X84939	GenBank GenBank	3929753
X85373	GenBank	695548 806565
x93036	GenBank	1085025
X93207	GenBank	2462486
X94323	GenBank	1213612

ACC NUM	DATABASE	GI NBR
X94754	GenBank	1702931
X97324	GenBank	1806039
x99920	GenBank	1694827
Y00503	GenBank	34038
Y00757	GenBank	23910
Y00815	GenBank	34266
Y09188	GenBank	2230868
Y11435	GenBank	2910996
Y12065	GenBank	2230877
Y13247	GenBank	2117158
Y13286	GenBank	2853173
Y15286	GenBank	2584788
Y17114	GenBank	4160551
Z18538	GenBank	28711
Z18954	GenBank	396706
Z19054	GenBank	38519
Z21507	GenBank	38521
Z26317	GenBank	416177
Z29093	GenBank	732799
Z31696	GenBank	479156
Z32564	GenBank	473235
Z36531	GenBank	535184
Z37986	GenBank	780262
Z46629	GenBank	758102
Z47087	GenBank	860989
Z74615	GenBank	1418927

Accession Ave-Normal expression-of-
Number expression 28 Ma
104.38 104.38 104.38
N54508 1784 1784
1148.01
N95249
2 8.17 94.05
T69346 2.44
R01281 4.04 21.40
0.87 4.57
H65066 12.82 75.35
9 19.83 101.81
W05628 16.34
R02373 17.70 142.15
T62491 10.11
AA029418 1.91 18.11
32.04 420.31
N54598 16.00 2255.66
1 R83836 12.68
T67005 5.59 37.42
H42679 13.99 179.31
6 55.22
AA481758 52.79 372.83
H73590 3.21
AA412053 100.19 1601.71
18.52 118.34
AA453823 6.53 92.09
173 8.44 51.73
AA449118 11.47 64.12
44.36
1.08
AAAA9504 44 54 54 54 54 54 54 54 54 54 54 54 54
W20276 11.01 64.88
T66828 6.08 46.49
N76276 22.03 125.65
T98244
T98320 10.70 57.20
H91281 33.92 209.27
H60588 5.62 35.13
R91137 9.71 48.79
H90997 8.74 60.87
R08220 41.86 295.18
R277730 7.77 48.63
1.27
W92594 25.09 125.47
8 R38459 6.31 35.24
T66907 541.40 3318.74
R63523 8.74 100.81
W01048 6.03 102.30
T97119 6.40 46.50
10.74 60.32
R78513

_
ò
-
0
~
•
8
Δ.

Other LID not found	200	oPlacenta	Other	LID not found	Ovary	LID not found		LID not found	Pool	Other	1	Musca Other	Eva By	LID not found		LID not found	Colon	ž česk	LID and for ind		1 Other	1 Other			Prostate	Other	d Other	d Other	Whole embryo	UD not found	Office and	Pal	d Other	UD not found	LID not found	d Other	Tall O	a Ciner	Adrenal oland		Parathyroid	Parathyroid	Neural	Muscle	Whole embryo		Lavex
LID not found Other Pool	Roact	Whole embryoPlacenta	LID not found Other	Placenta	Pool	Pool		Pool	CNS	LID not found		Inyroad I D not found	Muscle	Pool		Pool	Testis	Ear Cervi	LID ROL TOUR	2	LID not found Other	LID not found Other		į	Pool Prosts	LID not found Other	LID not found Other	LID not found Other	Pool	<u>8</u> 8	t ID not fraind Other	Foreskin	LID not found Other	P. 20	Brain	LID not found Other	LID not sound Other	בוום חמל זמנים	Lind	D.	m Thyroid		Thymus	Parathyrold	Uterus		Stomach
75.41 Pool Placenta	Prolect	253.8 Pooled	183.65 Pool	Pooled	374.98 Tonsil	14.49 Pancress	225.9	Aorta	54.46 Breast	475.18 Placenta	208.56	127.40 Gall pladder	212 02 Pancreas	539.64 Kidney		Parathyroid	Smooth musc Testis	107.84	130.30 P001	240.08	Pool	174.05 Pool	307.47	590.63	Tests	3 8	8	148.31 Pool	547.88 Pooled	222.36 Heart	85 25 Prol	67.01 CNS		Ovary	P80	361.71 Pod	227.19 P00	184.27 P000	Over O		247.33 Synovial mem Thyroid	151.95 Smooth musc -	317.31 Spleen	Eye	490.87 Esophagus		98.87 Escobacus
-		4	7		<b>50</b>	7	21	;	Ξ:	<b>9</b>	<b>6</b>	٥	20	y y			,	- g	3	=		-	-	-				1	~	5		=	12		;	δ.	<u>.</u>	2	'n		5	60	×		4		-
8 8 8 8	8 8	8 8	80	0.00	9.00	0.0	0.0	8	0.0	6.5	0.00	9 6	90.0	2.00	0.0	0.00	8.6	9.6	9 6	8 6	3.8	1.00	1.00	8 3	0.00	800	00.1	4.00	0.00	0.0	8 8	8 6	0.00	0.00	2.00	5.00	9.5	8.6	8 8	9	8	000	000	0.00	0.00	0.4	8
5.00 00.5	8 5	90.50	2.00	1.00	3.00	5.00	6.00	8	8.	3.00	8 8	8.6	8 0	6.00	1.00	2.00	5.00	9.0	8.6	8 8	800	0.0	5.00	8 6	2.69	200	00.4	1.00	1.00	8 8	8 6	9 00	1.00	2.00	9:	00.9	90.5	2.00	00.6	8	8	9.1	1.00	<b>5</b> .8	2.00	8	5
6.98	15.40	8 8	7.08	5.07	8.01	5.43	9.25	6.55	8.05	6.05	7.03	0.30	9 6	98:39	6.59	9.93	13.17	B. 13	20.0	20.51	8.45	5.30	8.81	12.09	7.28	6.12	7,60	7.07	81.80	96	7.59	2.6	5.84	7.95	9.20	20.44	200	12.53	10.19	5.62	535	5.28	6.80	15.44	15.00	8.38	11 15
185.68	40.07 a. c.	5005	78.19	14.73	25.58	38.50	237.06	165.76	126.20	1094.00	348.37	45.101.	9197	702.93	24.17	32.05	41.15	114.03	90.00	307.62	83.74	135.80	122.97	105.10	308 84	18.86	131.78	14.68	154.54	298.59	132.42	22.61	59.26	53.36	354.88	376.08	256.49	116.99	60.93	374 82	32.14	103.50	36.08	78.05	723.83	106.43	AG 78
26.60		202	8	2.90	3.19	7.10	25.64	25.31	15.68	180.89	49.58	19.24	15.36	78.47	3.67	3.23	3.12	12.49	5. O	2 5 5	*	25.61	13.88	8.69	93.73	3.08	17.34	2.08	1.89	37.51	17.45	3.18 19	10.15	6.71	38.58	18.40	40.82	21.5	8 9 8	68.75	6.01	19.59	5.31	5.08	48.24	12.73	7.78
T98484 R39745	K38/45	R26798	138511	R37884	R06362	R10185	T96529	T67652	T67022	R25464	R08153	VV86653	N76944	N99839	R97154	N72510	AA461521	AA010158	WU1484	T89996	N63753	H48360	R70462	W87752	N74360	N54036	T81574	W02824	H04382	R92962	N74385	T84084	H54622	N76735	R06642	R93007	186081	H50747	T8/1031	H98812	AA434487	H67988	H80129	H17882	H73080	R01428	AA410285
122126	558051	132569	122170	137647	126234	128833	123065	68753	66550	132323	127173	416633	246074	294255	200031	245489	795856	430153	206741	110503	292968	201030	141768	417251	296149	247 194	111054	296141	149373	196222	29898	111264	203227	244350	126438	196636	111634	194307	116102	282063	770868	211206	233457	50182	234907	123790	789343
247	047	254	255	256	259	281	263	382	288	268	278	278	283	287	289	290	292	98.2	) A C	305	38	309	311	316	317	7.00	339	342	83	343	3 5	355	357	362	383	369	25	373	7 F	3 8	392	403	412	4	419	\$	121

į
AA053051 9.68 52.00
43.21
103.88 1436.31
8.95 49.81
51.39 322.04
AA485626 76.01 443.38 5.
74.83 486.06
125.76 1238.62
12.79 94.86
4,18 40.44
4.62 76.81
7.00 35.19
6.25 125.76
691.72 4078.06
198.25 1429.49
92.09 537.51
37.77 303.69
5.26 28.23
4.86 41.62
13.87 336.68
139.34 975.12
3.59 30.07
4.96 43.50
4.03 23.97
30.01
31.25 254.39
19.67
20.42 148.44
21.73 297.33
6.32 33.06
3.00
19.78 104.65
48.05 391.53
18.22 258.47
55.50 308.70
11.48 113.13
22.61 144.53
16.46 171.30
5.33 66.65
83.42 442.60
56.83 430.88
38.62 249.43
4.10
28.39 259.36
105.95 601.68
7.42 60.23
44.34 286.04
34.89 197.48
5.08 60.21
17.47 105.55
28.47

ge 3 of 91

	Uterus	Spleen	100		JD not found	Aorta		Colon	Other	Lymph	Liver	Blood	Parathyroid	Other	Piacenta	ikh	JID not found	Germ Cell	Brain	Other	Liver	Breast	Pool	Parathyroid	Breast	CNS	Placenta	Colon	Colon	Germ Cell	Stomach	Sall bladder	Pancreas	CNS	Placenta	Cerx	olo.	Testis	Sich	Ovary	Thymus	Synovial membrane	Pool	Ovany	CNS	Testis	Colon	LID not found	Pool	UD not found	Whole embryo	Breast	UD not found	
	78			•	_	Spleen			200			Colon	Small intestine Gall bladder P	LID not found C	Pooled	iat mem tei	_	yroid		LID not found	Adipose	Gem Cell B	_	_	Stomach			ate	_	_	Skir	mAdrenal gland (			Ę	200			5		MOLLE		Liver	Muscle		ambayo	Breast (					Lung		
	451.92 CNS Germ C	129.27 Peripheral ne	473.39 Pooled	534.21 Cervix	Tonsil	Thyroid	245.08	CNS	P00	Bone	235.26 Synovial mem Germ Cell	lgnore	238.33 Small intestin	530.17 Pool	119.56 Eye	Ignore	Prostate	745.7 Adrenal glan	Aorta	<u>8</u>	67.01 Gell bladder	Brain	423.35 Ovary	130.74 Thymus	631.73 Pancreas	43.68 Eye	345.45 Bone marrow Pooled	Cervix	274.67 Ovary	Whole embryoPlacenta	191.81 Adipose	539.01 Synovial mem Adrenal gland Gall bladder	655.1 Parathyroid	270.14 Parathyroid	449.88 Adipose	ZZO. /9 Inymus	200	Whole embroBrain	17.79 Cerytx	671.26 Adipose	47.11 Lymph	Liver	644.55 Gall bladder	563.64 Head and nec Muscle	111.22 Adrenal gland Thyroid	471.64 CNS	Liver	357.99 Eye	217.02 Thyroid	7.79 Placenta	Eye		291.14 Breast	32.1
	4	ŧ,	e	17			×				=		×	^	o,			-			=		•	8	S	12	×		61		-	-	7	2	<b>~</b> ;	2			•	· <del>-</del>	- 21		4	æ	7	₽		σ	<del>4</del>	4		60	6	-
<b>(</b> )	0.00	8.	00.0	0.00	1.00	0:00	0.00	0.00	0.00	5.00	0.0	0.00	00.0	8.8	0.00	0.0	8.	8.0	8.0	28	8.	0.0	8.1	1.00	0.0	90.1	0.00	0.0	1.00	0.00	0.00	1.00	1.00	0.00	00.0	2.00	3 8	8 6	80	000	2.00	8	000	000	000	2.00	1.00	0.00	0.0	000	3.00	0.00	0.00	0.00
<b>47</b> 000 0	9.5	2.00	1,00	8.	0.00	5.00	2.00	9.00	9.00	6.00	3.00	8. 8.	<b>5</b> .80	8	9.	2.00	0.00	1.00	9.00	3.00	10.00	5.00	8.	0. 80.	2.00	0.1	2.00	2.00	15.00	1.00	5.8	0.00	3.00	8	8	9.6	9 6	8 5	8 8	10,00	0.00	000	1.00	2.00	0.0	0.00	0.00	2.00	1.00	2.00	8	1.00	3.00	8.
	5.80	7.	5.64	6.11	5.02	7.02	10.51	8.55	7.50	14.01	7.27	11.83	6.54	8.44	5.74	11.12	5.01	6.81	10.84	9.78	46.84	11.83	7.50	5.12	7.69	6.74	6.80	33.57	104.82	18.64	47.75	5.23	24.30	6.00	5.56	11.83	9.0	, c	5.28	33.25	10.69	9.37	5.68	7.70	80.5	7.74	5.12	7.90	5.50	87.8	6.57	6.05	6.98	5.56
	17.78	10.20	18.96	28.10	7.13	39.10	1074.94	46.58	76.85	549.46	143.45	33.33	99.17	103.51	6.46	105.15	206.27	177.95	39.80	457.50	244.53	68.54	237.99	411.33	23.49	29.07	38.73	78.39	396.88	33.71	488.78	252.69	58.07	194.29	64.47	198.15	25.40	29.5	6187 71	360.36	370.01	375.69	31.38	311.58	936.24	23.48	19.90	402.17	695.78	29.44	200.44	671.93	616.50	83, 13
	3.07	1.35	3.01	4.27	1.42	5.57	102.29	5.45	10.25	39.23	19.74	2.82	15.17	12.28	1.12	9.45	£.38	26.14	3.67	46.78	5.22	5.80	31.75	80.28	3.06	4.32	5.84	2.34	3.79	1.81	10.24	48.30	2.39	32.41	6.10	16.75	7.7	4 - 4	1172 13	10.84	34.50	40.11	5.52	40.44	185.04	3.03	3.89	50.91	126.61	5.08	30.49	111,11	88.91	14.95
	R09873	AA484970	AA458869	R65573	AA620346	AA458959	N90470	AA491302	H89795	N58163	W47350	AA037410	AA425655	N86001	AA284292	AA464962	H90946	AA459853	AAD22601	H80355	H25546	H51481	N68565	R10896	AA102670	AA479981	H83934	R32852	AA454743	T64905	AA410587	R76283	N90246	T47229	N39161	AA458801	707050	10/030	A4410517	AA434115	AA487634	R93124	172422	AA447774	R52654	AA448015	T68351	T84382	T67093	R25641	N52880	AA281189	766930	N91198
	128260	810104	810888	139376	1030928	810843	292812	824659	240318	247635	324225	321271	773220	293847	327247	810083	240674	795798	364555	241355	181458	179534	282613	129146	563598	754031	209137	135221	809784	66731	754479	144777	305608	75923	243816	838373	708077	#0000#	753882	770212	841332	196992	86220	813830	40017	784876	83231	111204	66562	132848	244205	711857	86400	292416
	869	669	002	702	8	704	902	707	8	110	1	719	723	729	738	740	741	748	78	765	798	000	808	916	836	843	844	848	851	854	858	178	872	878	893	8	8 8	2 6	923	928	827	828	2	3	848	95	926	981	883	88	698	973	974	888

age 4 of 91

					7	2			70			10	ō					<b>.</b>																			τ.	2		2													
Foreskin		Olber		d Other	Adrenal gland	LID not found	d Ofher	d Other	LID not found	d Other	d Other	LID not found	LID not found	Skin	d Other		d Other	LiD not found	Breast	d Other		Placenta	Placenta	d Other	d Other	Blood	d Other	c Nose	d Other	d Other	d Other	Testis		d Other	d Other			Testis		LID not found	Pool	Brain	Breast	d Other	d Other	Nose		d Other			Breast		Pool
Eva		I ID not found Other		LID not found Other	Spleen	<u>Poo</u>	LID not found	LID not found Other	Ovary	LID not found	LID not found Other	Pool	Brain	Adipose	LID not found Other		LID not found Other	Placenta	Tonsil	LID not found Other	LID not found	5	cord Uterus	LID not found Other	UD not found	Cervix	LID not found	Small intestineSmooth musc Nose	UD not found	LID not found (	LID not foun	Colon		LID not found	Up not found	LID not found		Tonsi	LID not found	Heart	Ovary	CNS	Placenta	LID not found	LID not found	ineAdipose	LID not found	LID not found		LID not found	Hear		Placenta
490.05 Prostate		Placenta		Pod	4 Thyroid	4 Testis	Pod	Po		1 Pod	Pool	6 Placenta	Pod	Layra	Placenta		P.00	2 Pooled	S Germ Cell		Pool	Blood	Umbilical	<u>8</u>	5 Pool	9 Breast	2 Pool		<u>8</u>	Lung		1 Blood		P 00		D 100	Breage trease	Ulerus		6 Pool	Heart	3 Aorta	6 Heart	6 Pool	Placenta	Small intest	<u>8</u>	7 Pool	90	<u>8</u>	4 Lymph	60	711.38 Testis
490.0	372 88	9	71.14		140.84	23.4			521.82	150.81		157.6				197.02		82.52	430.49	245.08		82.52	40.26		61.75	111.69	429.02	47.11				48.71			000	26.83			473.2	350.76		468.83	119.16	551.66		482.73		334.17	578.78		41.44	450.16	711.3
4	- 2-	•	23		17	<b>6</b> 0			^	9		t				e		6	en :	×		6	4		n	-	1	5				6				4 2	:		2	4		~	-	~		9		∞	S		=	4	-
0.00	900	8 8	0.0	0.0	000	8	0.00	0.00	0.00	8	0.0	0.00	0.00	5.00	0.0	0.0	3.00	<u>-</u> 8	8	8	8	0.0	800	000	0.00	8	5.00	9.	3.00	0.00	0.0	0.0	8	0.0	9.6	9 6	3 5	000	000	3.00	0.00	0.0	9.	0.00	2.00	0.0	0.0	0.00	0.00	2.00	0.0	0.0	0.00
90.4	9	00 6	2.00	1.00	3.00	1.00	2.00	3.00	8	800	1.00	9.	3.00	4.00	9.00	3.8	0.0	8.	8:	2.8	8.0	5.00 5.00	2.00	3.00	3.00	3.00	6.00	9.	8	500	8.9	8.	3.00	2.00	9.6	8 6	8 5	00.	6.00	3.00	1.00	8.	6.00	9.1	2.00	0.1	1.00	1.00	1.00	3.00	2.00	5.00	1.00
8.46	7 08	52	6.52	89	7.52	2.	5.52	7.55	6.92	8.50	7.03	7.27	6.25	7.42	9.25	7.55	5.90	6.69	7.46	6.64	11.73	6.44	8.25	8.05	6.11	9.27	22.64	11.28	6.61	10.25	8.66	4 4	7.05	6.40	5.32	9.80	13.98	5.55	9.26	8.49	9.51	5.66	18.95	5.13	6.65	8.86	5.76	5.15	5.87	12.27	7.69	7.18	5.54
175.16	333.08	678.64	641.84	32.07	1375.47	41.19	15.59	282.46	24.49	33.50	40.72	76.10	219.10	437.88	169.98	325.87	41.05	214.24	13.27	409.70	209.29	43.43	199.56	49.63	234.45	40.15	626.95	66.15	112.20	20.07	200.6	10.32	51.41	18.35	94.24	107.05	178.03	129.45	175.65	512.31	23.11	17.94	56.67	18.73	287.22	12.57	465.59	93.56	37.80	113.38	186.77	129.78	43.88
27.12	47.05	9 9	88.44	5.35	182.88	4.36	2.62	37.43	3.54	3.94	5.79	10.47	35.06	59.04	18.37	43.18	6.95	32.01	1.78	61.67	17.84	6.75	24.19	6.16	38,35	4.33	27.69	5.86	16.98	1.96	57.86	1.63	7.30	2.87	7.7	12.23 55.18	12.74	23.32	18.96	60.37	2.43	3.17	2.88	3.26	43.22	1.45	80.83	18.15	6.44	9.24	24.28	18.08	7.92
R91710	T99145	R26813	86266N	T99150	R92352	T98972	H77533	R99288	T99011	R53024	T99617	R26931	N75729	H69048	R53860	T90360	N92085	RZ6855	H16746	R53900	R07998	R08297	R53910	R06936	R01277	WZ4055	N77203	H96213	W02639	T65770	R83153	R02036	N72852	H94978	W03050	N77272	R 16769	W03052	H75490	N74942	N76803	N62328	R83758	R94893	R39705	AA460003	N91330	W04369	R82609	R94212	N55492	R94601	H51056
195458	122384	132623	294133	122359	196148	122702	233347	201207	122684	154312	123354	133225	244329	212634	138168	110980	293437	133333	50214	138165	127076	127243	138189	126638	123720	306808	245413	251351	296199	80384	197051	124271	291459	242644	296330	24556	128795	296334	230637	295527	245836	287843	187616	188583	136874	795604	292568	295321	196282	198339	246144	198028	194155
688	8	988	986	688	500	1001	101	1013	1015	1016	1017	1020	1021	1023 23	1024	1029	<u> </u>	039	1038	8	Ē	1045	1048	2	1051	1054	1057	1060	1062	1063	1065	1067	1068	1069	0,01	1074	1075	1078	1081	1093	108	<u>=</u>	Ξ	1113	115	<del>1</del> 20	1121	1126	1127	123	를 왕	1137	1139

age 5 of 91

8	
7	
9	
8	
õ	

	Prostata	LID not found	LID not found	Blood	oPancreas	Blood	LID not found	•	Lung	ם ומאנטו ניי		Colon			Fve	Forestin	Aorta	Germ Cell	Lum	Testis	LID not found	n Pancreas	Brain	Breast	Liver	Pooled	Pooled	Germ Cell	Tonsi	Bran		57.5	Colon Colon	Candir	Gall hladder	Kidnev	Ovary	Pool		Thyroid	Breast	Placenta	Cdo	d Other	UD not found	Piacenta	d Other	Pancreas	10 to	e come	Other	LID not found	
	Testis	Pool	Pool	Bone	Whole embryoPancreas	Tonsil	Hear	Clomon	Stomach	Synower mem inyroid	4	Drostata	Coll bladder	000	Prestate	Pooled	Adinosa	Head and nec	Ovar	Lymph	Luna	Synovial mer	Pooled		Muscle	Pancress	Tonsil	Skin		င် ပိ	9	City and round Other	a Cerax	) Herris	Pancreas	Uterus	Torsi	Foreskin		Ovary	Tonsil	Bone	Geral Cel	UD not found (	Brain	Hone Piacer	LID not foun	Germ Cell		LID not roun	בייים אפר יביי	Pool LID not	
	143.55 Colon	458.69 Kidney	Brain	24.51 Adipose		422.37 Lymph	Pool		460.32 Celva	233.13 Nose		Sol.us spiecn	320.23 Ear	See 46 1 ives	307.80 Far	71.55 Gall hladder	Gall hladder	lanore	Brain	E W	619.04 Pool	61.77 Larynx	145.79 Eye	Bone marrow	607 Adipose	538.34 Stomach	216 Stomach	236.87 Larynx	Adrenal gland	253.29 Aorta	307.47	512.91 Pool	25.02 Periphera ner Cervx	Cerm Cell	Lavar	436 69 Lymph	Placenta	340.31 Eye	87.96	255.21 Epididymis	732.12 Thymus	356,29 Nose	Bone		395.98 Pool	Stomach	- B	299.63 Spieen	00.00	245.06 700	188	Lung Lung	
	-	တ		11		n		9	<u>e</u> 9	£ 4	₽ >	<	>	۲,	a t	. 4	•				v	16	5		~	-	<del>6</del>	2		<b>=</b> !	÷ '	າ ເ	2 '	า		•		က	7	8	က	×		,	7		;	. α	٠,	<	•	D	
Table 2A	0.00	9.7	3.00	0.00	0.0	<del>1</del> .00	0.0	0.00	9 6	8.	0.6	8 8	3 8	3 6	8 8	8 6	8 8	8 5	900	00.0	0.00	00.0	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	8:	8.6	900	900	8 5	000	0.0	1.00	2.00	1.00	0.00	0.00	0.00	0.00	00.0	4.00	8 8	8 8	9.6	8 6	3	8 8	
Tabl	8.4	8.8	1,00	9.1	5.00	2.00	2.00	9 6	2.00	8 8	9 6	8 6	8.6	8 8	3 5	5 6	3 5	8 9	8	8	001	2.00	2 00	2.00	1.8	3.8	<del>.</del> 8	0.00	8	9.	0.00	9 9	8.6	8 8	8 6	8 8	1.00	0.0	0.00	21.8	00.	1.00	2.00	1.00	3.00	9.00	8.6	2.00	9.6	2.00	3 6	4.00	
	8.21	6.69	8.68	5.52	5.61	6.42	5.47	0	87.8	7.39	5.0	) (	2.33	9 9	0 4	7 28	2.4.5	) v	47.4	888	5.82	7.24	19,25	8.71	5.33	9.04	6.08	5.56	7.61	6.79	6.28	5.33	12.23	2. A	9 6	14 S	5,05	5.88	5.28	280.58	7.48	5.64	7.52	5.85	6.41	8.48	6.78	6.37	0.00	9.60	a ( )	7.29	
	28.76	140.00	235.66	1974.00	10.29	37.88	68.30	73.75	1858.11	211.73	76.587	73.60	33.30	202.30	75.00	782.42	03 15	945.89	97.81	582.63	17.85	141.71	82.85	330.90	704.71	98.61	284.97	104.91	34.79	43.89	128.31	136.35	73.00	38.03	521.05	8150	191.67	105.27	687.71	4927.42	59.98	78.52	23.17	43.58	704.54	145.62	964.40	358.42	00.00	25.50	CC.B12	245.63	
	3.50	20.92	27.14	357.49	1.83	5.80	12.50	123.44	224.35	98 S	DE ST	2 6	20.02	64.40	115.33	107.40	50.00	26 17	2 0.4	87.23	3.07	19.56	4.30	37.99	132.17	12.27	46.90	18.85	4.57	6.48	20.42	18.05	14.14	6.27	102 68	9	37.95	17.89	130.33	17.56	8	13.92	3.08	7.33	109.88	17.17	142.25	56.28	4.7	10.03	E (5)	33.68	
	AA431988	W03672	H53156	H75531	H95141	AA424575	N70349	K48/96	AA112660	R21614	K52/89	079894	N324/4	1120047	A 4 5 5 2 3 3	NESSOS	MINOSEE	NA1467	W24420	AA477514	N48137	AA486138	AA018482	AA487797	WC3677	AA292676	AA504351	AA456878	AAS04710	R11236	AA443351	K85780	AA388884	H61978	AA284668	AA131406	AA455082	H99544	AA448261	AA451904	W02558	N51018	H50229	R10159	R84407	R66924	H74032	R07684	2/4012	H53038	KORGEZ	R16484	
	782217	297411	202357	230370	256515	767163	296998	154015	563444	130153	41341	212640	244 169	001880	233/21	246070	206720	285680	30804	74002	243399	840788	363086	840493	297421	713782	826478	815526	825577	129392	783729	199251	89/68	10002	714106	503617	812266	263200	782811	786875	296072	244147	179232	128503	194656	140301	214858	125788	/10971	202339	126560	128627	
	1140	1142	1149	1151	1152	1164	1166	1174	2	1191	6	B 5	707	3 5	5 50	5	1770	277	533	1236	1240	1249	1250	1261	1264	1288	1271	1273	1279	1284	1289	1292	1299	300	2 5	13.19	1320	1330	1331	1335	1338	1345	1348	1350	1352	1356	1380	1365	200	1369	2 !	1372	

	Stomach	Other	LID not found	Other			Pool	Testis	Other	Germ Cell	Tonsil	Other	Whole embryo	Other	Other	LID not found	<u>8</u>	Other	Bone	P80	Pool	LID not found	Pool	CNS	Other	LID not found	CNS	Pool		Ovary	Other	Stomach	Head	Placenta	CIO not round	Breask IID and found		Throid	Other	Uterus	CNS	LID not found	Tonsil	Thyroid	Other	Pool		Other	CNS	Малом	Blood	d Lymph node	Adrenal gland	Colon
	Placenta	LID not found Other	8	LID not found Other			Ulerus	Color	LID not found Other	Uterus	Kidney	UD not found Other	Aorte	LID not found Other	LID not found Other	<u>8</u>	Foreskin	LID not found	Thyroid	Germ Ce	Testis	Prostate	Kidney	Stomach	LID not found	<u>P</u>	Ovary	Prostate			LID not found Other		Germ Cell	CNS	8	er Cung Discosta	IID not found	Thomas com	LID not found (	Luna	Teatis	Brain	CNS		_	yoHeart	Kidney	LID not found	Liver	rd Muscle	ic Tonsil	Synovial mem Umbilical cord Lymph node	rd Brain	•
	142.19 Foreskin	73.91 Pool	Breast	Parathyroid				269.7 Kidney		528.2 Pencreas	Ovary	712.78 Pool	.07 Parathyroid	225.9 Pool	81.8 Pool	65.51 Placenta	637.68 Placenta	442.68 Pool	71.09 Adipose	Blood	513.74 Blood		615.41 Foreskin		500.36 Pool		266.41 Esophagus	Muscle	70.67	77,18 Placenta	109.76 Pool	631.89 Smooth musc	711.92 Stomach	245.08 Aorta	247.56 lons#	Pempheral ner		230 18 Parimharal pay		400.71 Thymus	148 92 Stomach	416.26 Pool		Gall bladder	193 Prostate	538.71 Whole embryoHeart	Muscle	629.01 Pool	682.13 Ear	356.2 Umbilical cord Muscle	35.68 Smooth musc Tonsil	138.3 Synovial me	528.17 Umbilical cord Brain	421.53 Liver
	142.	52	•		292.28		27	28		22		712	286.07	22	8	92	637	442	7		513	222	615		200		200		2	7	5	631	71	245	747	346	, (4)	970	513	400	148	416				638		828	682	35	35	5	226	421
	15	6	:		Ξ		6	1		S		-	5	5	18	5	*	9	6		7	n	^		S		5		8	4	-	7	<del>-</del> ;	× ;	=	>	≺	ţ	5 5	: 2	g	÷			2	7		Œ	^	7	6	23	^	κŋ
Table 2A	0.00	0.00	2	8 8	0.00	9.00	2.00	0.00	0.00	00:0	5.00	000	000	00:0	000	2.00	1.00	8.4	0.00	0.0	0.00	0.00	0.00	1.00	0.00	4.00	0.00	0.00	0.00	1.00	0.00	0.00	80	00.0	000	000	8 6	3 6	88	8 0	000	900	900	8	8.	9:00	0.00	000	0.00	0.00	0.00	00:0	0.0	000
Tabl	1.00	001	6	3 5	3.00	6.00	1.00	8.	9.00	3.8	3.00	4.00	1.00	9.00	4.00	9.00	0.00	3.00	4.00	2.00	1.00	00.4	1.00	00.4	4.00	3.00	6.00	1.00	2.00	3.00	8.	8.8	8	3.00	8.8	8.6	8.5	3 5	3 8	3 6	5	8 6	8 5	8	8	3.00	2.00	8:	0.1	2:00	5.00	6.	1.00	<b>9</b> .9
	5.35	88.8	} \	5 Z	8.90	21.65	5.99	6.80	8.34	6.74	5.91	8.05	5.18	8.68	9.41	11.64	6.38	10.24	6.23	6.48	999	7.93	90.9	42.58	7.68	9.63	21.81	8.86	6.65	10.81	9.06	6.67	5.95	6.31	6.92		0.00 4	27.5	4 6	5 5	9	848	80.8	5	6.47	7.38	7.93	5.72	5.36	<b>8</b> .9	6.21	5.52	6.94	8.74
	803.04	31 49	10.87	90.05	665.11	600.51	407.57	23.16	605.29	114.43	64.99	176.10	25.54	967.64	165,11	182.89	32.70	650,81	199.57	39.02	12.41	289.85	459.67	545.92	293,84	332.54	115.80	8.2	232.53	1320.42	36.83	417.41	8.22	670.95	88.73 5.73	34.07	308.64	00.14	591.69	707	26 75	261.52	42.28	382 14	792.85	489.47	28.41	1010.53	45.76	7077.92	119.66	32.20	85.06	98.58
	150.20	5 57	200	25.5	74.76	27.74	68.02	3.51	72.54	16.98	1.80	21.87	8.	111.54	19.67	15.71	5.13	63.56	32.03	8.02	1.87	36.65	90.85	12.82	38.28	3.5	5.31	6.10	24.96	122.18	4.06	62.55	1.38	106.28	14.27	6.22	53.63	9 6	102.74	1.38	20.4	20.04	8.32	69 42	122.58	68.29	3.58	176.78	8.53	648.75	19.25	5.83	12.26	11.05
	R98677	REA738	00.461	WA1784	R68514	H93619	N71457	R84636	R68245	R63735	R89157	T81988	R07313	T90369	H47297	R68381	H56655	H47335	R02528	H65481	R16800	H90477	H64938	W15283	H90490	N91317	R54560	H64972	R01566	AA434382	H65044	T80942	AA026030	N30838	H91353	AA463972	H91216	120C87	A65830	AA156251	MARTOR	N69674	D78499	AA485373	N54803	N77096	AA284285	N57964	H59820	W15277	199639	AA083831	R25521	150788
	200883	2008040	123845	130630	137760	242010	294916	274932	137787	139354	195720	110282	126864	110987	193481	137885	203918	183200	123079	210494	129600	241475	210431	322537	241497	292542	39874	210501	123546	770935	210525	109049	385685	257823	240769	810864	241274	967861	2,0564	505414	270300	203510	143756	811028	244323	246276	325380	247281	207288	322561	123400	365945	35271	78284
	1382	1384	200	800	1398	1400	1401	1402	2	1406	1416	1418	1419	1422	1424	1428	1430	1432	1438	1441	1442	1445	1449	1452	1453	1454	1456	1457	1468	1472	1	1474	1479	1484	1485	1495	1501	200	5 5	1507	450	95	1678	15.28	153	1533	1535	1548	1552	1558	25	1566	1567	1570

age 7 of 91

	_	Nose Foreskin				Adipose Calon		Blood Colon		E GE		Skin Blood	Pancras	Poorts Andre				моша		Foreskin Pancreas	Userus Brain	Adrenal gland Pooled	Cervix Esophagus		biadder			Pancreas Brain	LID not round Giner	tuell special			of found	Tonsil Brain		Testis Pancreas	LID not found Other	Control of the Contro	Lymph		found	LID not found Other	Germ Cell Brain		punoj lot	Pool Brain		Pool LID not found	LID not found Other		UD not found Other -	רום וימן וסתים
	99.75 Spleen	40.71 Smooth musc Nose	385.82 Germ Ced	228.96 Eye	269.17 Umbitical cord Nose	671.44 Esophagus	86.55	Synovial memBlood	Cervix	123.04 Peripheral ne	317.13 Adrenal gland Muscle	78.13 Neural	429.61 Lympn node	78.05 Traches	384.36 Gall bladder	252.9 Pancreas	Germ Cell	373.41 Omentum	471.03 Overy	217.43 Aorta	317.36 Cervix	387.63 Muscle	39.19 Umbilical cord Cervix	114.01	345.25 Small intestir	528.48 Bone	219.19 Stomach	67.5 Tonsi	104.97 POO	(3.14 KT Mhole emhaceDlements	555.07 VW10/B BITTER	Co. Co.	P8	471.75 Tostis	Foreskin	17.69 Adipose	506.62 Pool	746 De Brain	Placenta	Pool	271.39 Pool	<u>8</u>	596.66 Foreskin	Brain	Pool	580.91 Prostate	130.31	Testis	134.94 Pool	292.64	Pool	こうきょうこう つきようき
	w	7	œ	Ξ	6	-	5		1	R;	<u>-</u> :	₽;	= "	. E	-	=	:	=	16	52	5	S	ω	23	×	ဖ	<b>2</b> 2 :	<b>6</b> 5	2 5	2 -	-			5		a	8	>	•		Ξ	:	S			~	2		4	o	ç	2
Table 2A	9:0	0.00	0.00	0.00	0.00	3.00	0.00	0.0	00.0	0.00	9.5	8.6	00.0	8.6	800	0.00	0.00	0.00	00.0	0.00	0.00	0.00	0.00					8.6				8 8						8 6				00.0						0.00		0.0	0.0	0.00
Ta	1.00	1.0	1.00	8.8	2.00	22.00	8	5.0	8.9	8	8	8 8	8 8	8 5	8 8	00	100	2.00	5.00	7.00	5.	1.00	1.8	9.	9.1	0.0	8	8 8	8.8	9 6	3 8	3 5	8	8.	3.00	2.00	9.6	9 6	8 6	8 6	300	5.00	9.	5.00	3.8	5.00	8.8	5.8	300	8.6	8.8	3
	5.22	6.97	10.24	8.27	8.41	110.73	5.12	8.35	12.37	9.88	6.00	80.0	, ,	5.63	825	13.60	8 92	9.47	9.56	23.61	7.43	6.33	5.62	80	5.48	5.59	6.87	88.	5.31	20.2	0.4°C	5.05	7.37	9.83	6.38	8.68	2.	8/:9 2	14.78		8.26	10.06	5.96	8.69	7.41	6.86	11.85	7.32	6.76	6.27	.43 65.63	77'A
	111.69	129.10	10.96	399.66	617.76	284.38	1440.73	95.99	427.57	2198.58	409.18	218.20	200.06	250.07	34.82	67.25	56.93	320.07	416.62	509.40	18.67	72.35	57.27	254.18	63.56	992.01	45.88	28.02	30.08	87.18	26.33	282.47	478.95	43.60	211.85	1376.11	115.32	172.76	112.75	31.53	103.73	761.78	276.67	112.46	358.85	23.62	163.65	23.26	102.18	88.52	368.38	200.00
	21.38	18.52	1.07	48.32	96.33	2.57	281.52	11.48	2	222.88	68.14	24.00	E 5	5.00	65.9	78 7	6.38	33.81	48.69	21.58	2.24	11.42	10.20	31.61	11.60	17.3	89.9	¥.	5.66	14.97	75.0L	55.90	8.8	4.38	33.18	205.87	15.09	27.6	7 63	5. 5	18.57	75.72	46.44	12.95	48.43	3,44	13.81	3.18	15.11	14.11	48.58	70.07
	N69672	T98559	R44864	H84113	R02348	AA433851	AA477893	AA421687	AA598863	AA589177	H90415	AA461554	AA487/00	103324	AA459286	AA143436	W95346	AA504943	AA432030	AA456888	AA113331	AA460480	AA424833	AA489555	AA491225	AA598794	H94949	N43830	H52098	/L/86N	H9321/	195234 R02188	T95238	H89637	W03972	R98295	R99685	1852/4	R28287	N76675	WD4411	N80622	170429	T95160	T98894	08806H	179084	T95462	R02710	R92641	R15715	Helbuo
	283696	123117	33478	223098	124261	770910	739801	739126	897982	949938	241474	815285	841841	80108	814465	591907	358162	839736	782513	815542	583465	785965	768168	843312	824070	898092	242578	276547	197474	246/05	241824	124719	120631	240199	297155	206816	201322	291021	134719	245319	285283	292207	67070	120124	122913	240838	113488	120823	124090	195947	66423	TANAR.
	1571	1590	1600	1608	1610	1816	1636	1639	946	1652	653	1655	1808	7701	1679	1687	1691	1692	1696	1698	1699	1700	1701	1703	1714	1716	1720	1721	1728	2	2	1739	1747	1751	1753	1758	1941	1/63	1773		1781	1785	1786	1789	1791	1792	1793	1795	1797	1801	1802	1805

age 8 of 91

.

	Other	LID not found		Breast	Officer Officer		Olber	LID not found	1 Other	J Olher	į	og e	office 10 mg ferring			Other	Adrenal gland	Torisi		d Other	d Other	Other	of Other	oge o	8 6			Parathemid		d Other	d Other	Lung	d Other	Placenta		Pancress		_	_	Kidney			Parathyroid	Dictor Control	Call diagood	1	Hear			Placenta
	LID not found Other	<u>8</u>		Lymph	LID not found Other		Lib not found Other	P8	LID not found Other	LID not found Olher	!	LID not found Other	LID not round Cine		UD not found Other	UD not found Other	Ear	Colon		LID not found Other	LID not found	Ovary		Chic not found	Correll intestine Call Madder	Adinase	LID not found Other	LID not found Other	Smell IntestineThymus	LID not found Other	-	LID not round	Call bladder	Pooled	Kidney			Placenta	Gall bladder	Spieen	Spide	Adiposo	Esobuadas	Placenta	רמכמוום	RVED TISSUES				
	P. 90	727.12 Heart	339.39	Pooled		100 L 1 1 100 I	Pool	254.53 Lung	726.84 Pool	Pool		124.02 Pool	247.58 Pool	TOTAL	27.3 Pool	49.43 Pool	353.54 Bone	Muscle	92.32	<u>8</u>		495.48 Pool	8	155.48 Pool	93.95 Muscle	340.75 Pool	84.53 Pool	Solida Inying	-13 12 Thyrold	Pool	62.35 Pool			501.96 Pancreas	001	248 ne Tonsii			54.22 Foreskin	27.23 Gall bladder	357.93 Uterus	203.26 CNS	356.85 Aorta	istro i	-13.12 Thyroid	MUSCIB	130.31 Aorta	40.65 Liver	111.21 NO OBSERVED TISSUES	215.58 Uterus
		-	8		•	7		72	•			e (	£	ţ	2 -	· 10	S		×			9		ត្	×	- ;	27	-	Ę	2	6	•		'n	9	2 -	=	60	73	œ	7	7	2	•	₽	•	2 4	<b>2</b> 5	· <del>-</del>	7
Table 2A	0.00	00.0	0.00	0.00	000	8 8	8 5	8	0.0	0.0	0.00	00.0	8 6 6	8.0	8 6	90.9	000	1.00	0.00	9.0	9.00	0.00	2.00	0.00	0.00	2.00	0.00	9 6	3 8	8 8	00.00	00.0	3.00	0.0	9.00	8 8	8 8	1.00	0.00	2.00	8:0	0.0	0.0	96.	8 8	8 3	00.0	8 8	80	0.00
Tab	5.00	1.00	2.00	3.00	8	8 5	8 6	800	1.00	1.00	1.00	2.00	3.00	9.6	8.6	809	2.00	0.00	1.00	2.00	1.00	8	9.00	6.8	2.00	3.00	8 6	8 8	3 5	8 6	4	8.	3.00	8 6	2.00	8 8	3 2	2.00	1.00	8.00	5.00	2.00	8 8	0.00	0.5	1.00	9.4	9.6	00.1	1.00
	8.57	6.36	6.45	11.84	5.22	13.27	9.60	9 5	5.88	6.59	6.28	6.51	6.36	0.7	0.22	15.67	7.41	5.31	5.49	6.68	8.42	9.87	8.85	7.60	7.63	7.49	6.53	21.21	9.4	6 6	7.51	5.85	9.25	7.30	5.87	39.	5.0	12.65	8.54	14.96	6.62	8.75	10.31	5.15	7.27	1.72	13.41	8. 6. C. 6.	5.20	9.35
	161.83	24.88	558.21	42.17	22.12	98.17	424 11	61.62	154.92	177.11	622.47	33.31	515.27	268.88	204.00	512.12	25.32	23.63	1460.54	1272.50	113.02	50.15	266.28	219.15	288.23	358.75	48.35	14.391	07.10	160.5	488.83	651.16	103.85	1340.02	320.43	682.72	52.33	93.08	176.15	37.43	28.78	299.05	233.09	30.58	1549.07	41.98	259.81	243.29	7.95	51.37
	18.90	3.91	86.58	3.56	4.24	8. 58 5. 58	5.5	12.32	28.35	26.87	99.41	5.12	81.01	23 E	20.02	32.68	3.41	4.45	265.96	190.44	13.42	5.08	29.74	28.85	37.79	47.88	7.40	36.63	12.03	17.87	65.07	111.37	11.23	183.58	\$4.55	\$9.10	0. A	3.8	20.62	2.50	4.35	44.28	22.60	283	212.94	4	19.37	29.87	; E	8
	H81037	T95693	H53732	H25019	R15709	R84808	/00ccN	N77643	H53224	T85990	N52911	R94810	N77652	K91033	H33202	R94840	AA621150	H22171	H53878	R00688	H53553	N59494	H58838	H53920	R09890	H73321	R95819	N78301	K/0/82	R95851	H78482	W88967	· R95869	H79363	H53964	R70361	AA457158	AA478279	AA458853	N78083	H78484	AA001444	AA464525	H65034	R28423	R11490	H66158	W96268	AA058857	AA233079
	208789	120173	236129	160628	66430	198578	24545	247833	202492	112409	244652	198582	247859	194872	50502	275834	1046522	160573	202704	123448	202703	246824	205417	202802	128290	232586	189229	248688	243/90	199220	233579	417711	189243	229330	202785	155201	323917	740925	813428	248261	233583	361943	810213	210522	133178	128159	234011	361639	181812	968685

Page 9 of 91

		Tonsil	Brain	Musde	Lymph	Dogg	Dea State	200	Pogled	Ear	Skin	UD not found		Other	- Other	Placente	Other	P00	Whole embryo	dMuscle	Cher	2 S		P 400	l vary		Thyroid	Parathyroid	Placenta	d Foreskin	d Other	d Other	Prostate		Rigney	1000		Placenta	Ovary	d Other	נייז <u>.</u>	d Other	Š .	i	Umbilical cord	d Other	d Other	Uterus	Foreskin	Aorta	Testis
		Germ Cett	Placenta	Skin	Spleen	Poreskin	Thursid	Ear	dSkin	Laynx	Placenta	Pool		LID not found Other	LID not found	Uterus	LID not found		Testis	Umbilical cord Muscle	LID not found Other	Breast Pool		in sol found Other	Nos	3	Ear	Cervix	Bresst	Adrenal gland Foreskin	LID not found Other	LID not found Other		LID not found	Userus	-	LID not found	yoPool	Pooled	LID not foun	Kidney	בונט הפל לפעה	rancies.		Cervix	LID not found Other	LID not found	Eye	Germ Cell	Skin	Eye
	121.9	17.28 Blood	455.24 CNS	113.12 Larynx	-5.34 Ignore	253.29 Adrenal gland Foreskin	87.54 252 77 Hambilinal cord Thursid	69 22 Tonsil	53.69 Umbilical cord Skin	117.99 Omentum	84.81 Thymus	271.39 Colon	17.75	529.34 Pool	P80	110.31 Parathyroid	102.82 Pool	Umbilical cord	277.06 Inyroid	336.98 Aorta	356.18 Pracents	96.57 CNS	243.00 Nightly	726 84 Pool	241 3 Ovan	66.84	215.11 Adipose	55.14 Liver	43.96 Blocd	427 Aorta	<b>8</b>	117.99 Pool	141.89 Breast	8	112.35 - Call Modder	137.73 Pool	357.75 Pool	Whole embryoPool	Thymus	192.57 Pool	404.02 Germ Cell	474.68 Pool	241.04 Spicen		400 27 Rone	Foreskin	469.28 Foreskin	103.38 Germ Cell	180.89 CNS	Thymus	671.44 Skin
	n	۳ د	^		2		<u>.</u>	- 67				Ξ	19	w		ហ	4	:	<u>.</u>		<b>a</b>	<u>د م</u>		,	. Ĉ	ā 6	. <del>2</del> 5	12	•	8		Φ.	m	;	4	ø	NO.			7	17	<b>0</b> ;	<u>.</u>		cr	•	ĸ	60	80		-
e 2A	0.00	1.00	1.00	0.00	0.00	8 6	8 8	8 6	8 8	000	000	000	0.0	0.0	0.00	5.00	9.0	0.1	0.0	8:	0.0	8.6	8 6	9 6	8 6	900	00.0	0.00	00.0	0.00	0.00	8.0	0.0	0.0	90.0	3 6	8	0.00	0.00	00.0	0.00	8 6	3 6	8 8	8 8	00.0	000	0.00	3.0	8.0	0.00
Table 2A	3.00	0.00	00.0	1.90	1.00	2.00	8 6	8 5	8 8	200	8	1.00	9.	5.00 1.00	2.00	4.00	5. 8.	0.00	2.00	9.5	8.6	9.60	3 8	3 5	3 6	8 8	00.	00.1	1.00	1.00	2.00	2.00	2.00	5.00	8.6	8 6	5.00	3.00	2.00	3.00	8.	5 8 8	3 5	3 5	3 5	9	8.	2.00	2.00	8	8.8
	6.22	7.27	53.18	5.93	5.56	6.76	6.17	7.30	28.50	7.64	7.53	5.29	9.8	7.33	6.11	10.80	8.79	7.28	6.33	8.28	5.77	8.29	50 W	9 6	0.30	14.91	17.7	96.9	9.08	5.31	7.52	7.04	6.73	83	7.51	16.30	7.00	8.54 47.54	6. 53	6.72	5.12	5.67	7.5¢	5.06 07.01	9.45	8.34	5.08	5.72	8.38	7.23	6.38
	63.47	32.04	457.65	108.93	266.65	51.15	177.40	54.33	501.66	109.00	35.01	204.15	101.22	179.74	22.41	80.27	294.33	44.92	511.71	46.63	34.36	265.95	1282.55	750.57	770.85	83.97	359.21	110.38	112.24	67.31	43.03	333.87	415.93	53.74	340.79	278.25	176.76	1144.60	13.96	367.61	10.16	28.44	30.40	43.63	42.08	103,45	337.04	628.25	265.18	1183.85	109.48
	8	4.41	8.61	16.36	47.97	5.05	21.72	30.58	85.67	14.27	4.85	38.62	10.48	24.52	3.67	7.43	33.47	6.18	80.87	5.63	283	32.09	144.43	90.0	8	5.50 5.60 5.60 5.60 5.60 5.60 5.60 5.60	46.22	15.86	12.35	12.68	5.72	47.39	61.78	8.21	45.38	17 13	25.24	133.97	2.17	54.68	1.98	5.02	2.07	. e.	3 4	12.40	65.63	109.79	31.64	163.85	17.17
	AA031284	R31395	R52797	AA485401	AA460756	W55997	AA064715	AA400049	B19156	AA487837	AA025778	AA088745	R65622	H47475	R17054	R68897	H47542	T72691	T90374	N64431	R69798	H78855	K69934	876.74L	1304031 1004031	R38133	R07695	N89539	R70140	W60845	H48115	196731	R70318	190794	R92412	H47883	H93842	N71385	AA427782	H66442	W68559	H48389	AA456598	V447576	Hearon	N72008	N24581	AA454745	W15465	N54244	N91202
	470379	135608	41650	840333	796888	340712	525566	8445.30	24415	841340	368341	511816	140354	193586	129853	141453	193533	108651	111004	294310	141785	233289	142387	19391	276286	137387	125799	294973	142532	341805	193713	121275	155128	111510	198190	193724	242084	294127	771133	229651	342522	206986	809552	324342	242780	290893	267241	809788	322723	247582	292424
	2034	2036	2043	2046	2053	2056	2061	2002	2070	2081	2084	2085	2082	2120	2127	2132	2136	2138	2142	2145	2148	2152	2156	20.7	1917	2180	2171	2178	2180	2183	2184	2189	2198	2198	2109	2208	2213	2214	2216	2217	2223	2228	7577	223	3245	2247	2251	2222	2254	2255	2257

Page 10 of 91

.:

Whole embryo	Spleen	Other	LID not found	P80	Other	LID not found	Other	Parathyroid	LID not found	Lung	Gall bladder	Muscie	Other		0	Muscio	Bone	Heart	Brain	Tonsil	Paralhyroid	Brain	Lymph	Ovan	Breast	Tonsi	Germ Cell		Skin	Paramyroid	Adipose 110 not found	Pancreas		. 3	Kidney	Brain	Heart	Breast			CIO POI DUNG	Bone Coll Modder	Call Galder	LID not found	Foreskin		Forestún	
1 Aorta	Liver	LID not found	Pool	Colon	LID not found Dither	P.00	CID not found Other	Hear	8	Whole embryoLung	reNeural		UD not found Other	2 2 2	rear	E 020	T Lymph	d Pancreas	Lymph	Muscle	n Tonsil	Aorta	Head and nec Umbilical cord Lymph	Smooth muse synowial men brain	c Pooled	Ulerus	Skin		Thymas	Kidney Coll Floddor	Call plander	Nose		Tonsil	Muscle	Pancreas		er Adipose			Uterus	Synoval mem Ombircal cod bone	Benin	Tonail	Bone	mLymph	Pooled	Š
Umblical cord Aorta	636.05 Gall bladder	28	428.53 Placenta	358.65 Pancreas	315.78 Podi	Foreskin	70.87 Pool	83.08	171.71 Brain	Ulerus		102.5/ Synowal mem-	80	Pool	racenta	45.38 Epidiaymis	43.64 Synovial mem Lymph	Adrenal gland Pancreas	Pancreas	184,45 Foreskin	130.57 Synovial mem Tonsil	343.57 Parathyroid	291.28 Head and ne	357.49 Smooth mus	276.5 Head and nec Pooled	894.79 CNS	Ignore	46.67	79.91 Liver	387.37 Stomach	373.32 Liver	538.46 Stomach	170.18	Placenta	48.49 Foreskin	701.75 Pooled	Eye	726.84 Peripheral ner Adipose	19.39	250.6		727.12 Synowaime	Selection of the control of the cont	3 8	88.82 Ear		Adipose Pooled	Cada
	969		428	358	315				•						•	<b>.</b>	. 4			- -	130								~									27			•	2						
	4		7	G	7		8	<b>*</b>	₽		ē.	2			5	Ď. ĸ	•			₽	Ξ	-	<u> </u>	2 5	. 4			22	- '	N ;	= =		92	,	- +	2 "		•	9	₽	,				×			
0.0	00.00	0.00	0.00	0.00	00.00	2.00	8.9	0.00	0.00	8	8 8	0.00	9.0	000	8 8	8 8	1.00	0.00	0.00	1.00	8.	2.00	8 8	8.8	8 0	0.00	0.00	0.00	0.00	0.0	8 6	0.00	0.00	0.0	8 8	88	800	0.00	0.00	0.0	8.0	9 9	8 8	8 8	800	8.0	0.0	8
1.00	5.00	3.00	3.00	2.00	6.00	2.00	3.00	3.00	9.6	0.00	3.00	3 3	1.00	5.00	9.6	8.5	8	3.00	7.00	1.00	2.00	8.00	8 8	3 5	8	0.00	2.00	8.00	9.0	8 8	8.5	22.00	7.00	2.00	8.6	9 60	1.00	1.00	3.00	5.00	2.00	9 9	9 6	3 8	00.9	9.	7.00	200
5.39	9.22	8.73	6.21	5.28	8.92	7.74	6.85	6.05	6.18	5.92	5.50 5.50	2 5	7.29	8. 6 0. 3	<b>3</b> 7		5.10	8.S.	14.59	5.81	24.34	10.86	89 G	20.5	6.86	8.67	7.23	33.43	12.18	23.47	6. F.	78.68	12.94	5.86	5.61	11061	5.59	12.15	26.69	7.52	7.57	20.00	19.1	7.24	23.15	5.99	23.29	7 66
616.99	383.46	965.51	135.46	36.98	37.73	165.74	931.91	93.16	73.87	118.63	145.08	48.81	25.42	293.21	72.7	76.85	181.59	30.39	28.40	382.27	152,12	67.88	868.28	20.12	148.28	93.80	98.50	529.35	230.89	78.08	66.33 66.48	778.31	670.76	27.22	98.21	135.62	23.81	320.35	369.35	307.34	125.68	40.07	24.4	134.53	80.80	11.57	169.22	64.61
114.39	41.59	109.92	21.82	7.03	4.23	21.41	95.30	15.39	11.96	19.96	26.38	7.48	3.49	35.34	6.81 5.55	42.49	35.60	3.56	1.85	65.76	6.25	6.25	151.11	9. E	21.8	10.81	13.62	15.83	19.00	3.33	15.261	68.6	51.83	4	17.50 2.33	1 23	4.26	28.37	13.84	40.85	18.60	97.7	<u> </u>	2 85	3.49	1.83	7.27	77 8
H94043	H91121	W86376	H70120	H94262	H66856	N24645	H68719	AA284258	167261	AA148641	AA026686	AA454741	H94578	H73013	AA055629	H37774	AA487452	AA418846	H30688	H23021	AA464644	H39187	N38959	77.879	AA457114	R69749	AA402879	T67053	171284	W88899	D 80402	AA488073	T94293	AA279147	N71853	851912	AA054358	H15842	N67034	195657	K10007	K40970	962290	R08083	R42852	T95804	N28268	TORDAG
242797	241179	415948	213496	242698	210744	268960	211859	325150	68678	503083	366579	810613	243199	235173	37/58/	190491	841357	768031	184038	51737	810521	175103	243343	7.007	810444	201727	741841	66560	85128	417508	105712	840687	118914	104020	295137	39590	380737	159608	285838	120681	128775	28083	9000	127118	31251	120695	234376	120413
2261	2262	2263	2266	2269	2270	2271	2278	2279	2280	2282	2299	2300	2301	2302	2303	2306	2316	2327	2335	2348	2358	2367	2376	2383	2413	2421	2423	2424	2444	2446	2440	2450	2451	2452	2453	2478	2479	2493	2487	2499	2501	2002	2007	200	2514	2515	2518	2518

age 11 of 91

1.00 0.00 13 74 1.00 0.00 13 74 1.00 0.00 13 74 2.00 0.00 13 74 2.00 0.00 10 13 75.18 2.00 0.00 10 13 75.18 2.00 0.00 10 13 75.18 2.00 0.00 10 12 246.56 4.00 0.00 10 12 246.56 4.00 0.00 10 12 246.56 4.00 0.00 10 12 246.56 4.00 0.00 10 12 246.56 4.00 0.00 10 12 246.56 4.00 0.00 10 12 246.56 1.00 0.00 10 11 250.51 2.00 0.00 11 130.77 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51 1.00 0.00 11 250.51			90 2300	à	S	Table 2A	<b>8</b>	:	404 40 Shansah	Sector language	Acet
1.00 0.00 13 74 Torsis Pedi Pedi 1.00 0.00 1.00 1.00 1.00 1.00 1.00 1.0	ROZERS 4.04	22.65		3 40		90	9 6	:		Total Bridge	LID and found
100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100   100	H65569 4 01 20 77	20.52		. v.		8 6	8 6	5		8 8	Libert found
2.00 15 362.16 Breast 0.00 1.00 1.00 1.00 1.00 1.00 1.00 1.0	N88390 4.69 23.56	23.56		5.03		001	000	0	- 276.55 Whole amb	NoGerm Cell	Pancreas
56.78   Proof   LID rate found	H68724 12.97 78.72	78.72		6.07		2.00	2.00	5	85.4 Pool	LID not found	
100   1   58.78   Small intestineTonsis	R55184 4.36 66.52	68.52		15.27		9.00	0.00	16		Breast	Heart
0.00 13. Small intestineTonsil 1.00 13. 107.1 Pool	128355 R05544 30.98 206.48 6.67 122899 R00151 20.06 156.02 7.88	206.48 158.02		7.68		3 60 0 00 0 00	8 8		<u>0</u>	LID not found	Olber
0.00 13 107.1 Pool Lung 0.00 12 457.4 Pool LID not found 0.00 12 456.56 Placenta LID not found 0.00 13 426.56 Placenta LID not found 0.00 14 286.56 Placenta LID not found 0.00 17 448.84 190.7 Heart Lung 0.00 18 130.77 Heart Lung 0.00 19 367.64 Ovary Breast 0.00 11 130.77 Heart Lung 0.00 11 1256.51 Pool LID not found 0.00 11 256.59 Pool LID not found 0.00 11 256.59 Pool LID not found 0.00 11 256.59 Pool LID not found 0.00 12 44 Muscle Heart 0.00 13 10.17 Pool LID not found 0.00 13 10.17 Pool LID not found 0.00 14 495.89 Pool LID not found 0.00 17 48.59 Pool LID not found 0.00 18 48.59 Pool LID not found 0.00 17 652.18 Parethyroid Liver 0.00 18 48.59 Pool LID not found 0.00 17 652.19 Parethyroid Liver 0.00 18 436.47 Pool LID not found 0.00 19 438.47 Pool LID not found 0.00 11 652.19 Pool LID not found 0.00 0.00 14.7 Pool LID not found 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.	R63407 4.74 38.34	38.34		7.67		5.00	0,0	-	56.78		
5.00         1,00         13         107.1 Pool         Lung           5.00         0,00         12         457.4 Pool         LID not found           5.00         0,00         12         246.56 Pacenta         LID not found           4.00         0,00         17         246.56 Pacenta         LID not found           4.00         0,00         17         246.56 Pacenta         LID not found           4.00         0,00         17         246.56 Pacenta         LID not found           3.00         0,00         17         448.84         Adjoin           3.00         0,00         17         448.84         Adjoin           5.00         0,00         17         448.84         Brain           1.00         0,00         1         150.77 Heart         Lung           5.00         0,00         1         150.78 Pool         LUng	H95823 94.16 624.13	624.13		8.75		5.00	8.0			theTonsil	Pool
3.00         0.00         5         318.73 Blood         Pool           5.00         0.00         12         246.56 Placenta         LID not found           5.00         0.00         17         246.56 Placenta         LID not found           3.00         0.00         10         478.84         Thymus         Adipose           4.00         0.00         14         281.08         Adipose         LID not found           3.00         0.00         10         17         448.84         Pool         LID not found           3.00         0.00         10         17         448.84         Pool         LID not found           1.00         0.00         1         130.77 Heart         LID not found           2.00         0.00         1         130.74 Heart         LID not found           2.00         0.00         1         130.77 Heart         LID not found           2.00         0.00         1         130.74 Heart         LID not found           2.00         0.00         1         130.74 Heart         LID not found           2.00         0.00         1         10.78 Blood         LID not found           2.00         0.00         1	R14602 28.54 256.66	258.66		8.78		5.00	1.00	₽ ·	107.1 Pool	Lung	LID not found
5.00         0.00         12         456.56 Placenta         LID not found           3.00         0.00         12         246.56 Placenta         LID not found           4.00         4.00         17         363.66 Placenta         LID not found           3.00         0.00         17         363.66 Placenta         LID not found           3.00         0.00         17         363.66 Placenta         LID not found           3.00         0.00         17         448.84         Adjose           3.00         0.00         1.00         Liver         Pool           1.00         0.00         1         130.77 Heart         Lung           5.00         0.00         1         130.77 Heart         Lung           6.00         1.00         1         100.853.60 <t< td=""><td>196035 3.62</td><td>70.03</td><td></td><td>14.15</td><td></td><td>3.00</td><td>8.6</td><td>n (</td><td>3/8./3 51000</td><td>8 9</td><td>CID not found</td></t<>	196035 3.62	70.03		14.15		3.00	8.6	n (	3/8./3 51000	8 9	CID not found
3.00         0.00         12         246.56 Pacenta         Placenta         LID not found           4.00         4.00         17         246.56 Pacenta         LID not found           4.00         4.00         17         363.86 Pacenta         LID not found           3.00         0.00         17         448.84         Thymus         Adjose           5.00         0.00         1         428.16         Pool         Lib           1.00         0.00         1         448.84         Pool         Lib           2.00         0.00         1         495.86         Pool         Lib         Pool           3.00         0.00         1         1         250.51         Pool         Lib ont found           4.00         0.00         1         1         250.58         Pool         Lib ont found           2.00         0.00         1         246.39         Pool         Lib ont found	190201 19.24 196.49 TREAT 6.36 64.49	136.43		7.01	_	8. 6	8 8	· ·	100 F		
4.00 4.00 10 426.56 Thymus Adipose 10.00 0.00 17 448.84 10.00 0.00 7 448.84 10.00 0.00 7 448.84 10.00 0.00 7 448.84 10.00 0.00 7 448.84 10.00 0.00 1.00 1.00 1.00 1.00 1.00 1.	R31426 137.52 1087.72	1087,72		7.91		8 8	800	- 12	246.56 Placenta	LID not found	
4.00         0.00         17         363.86 Placenta         LID not found           3.00         0.00         14         281.08         Liver         Pool           3.00         0.00         1.00         Liver         Pool         Ling           5.00         0.00         1         130.77 Heart         Lung         Pool           1.00         0.00         4         495.88 Pool         Brissat         Pool           1.00         0.00         4         495.88 Pool         Brissat         Pool           1.00         0.00         4         495.88 Pool         LID not found         Pool           2.00         0.00         11         24.47 Muscle         Heart         Pool           3.00         0.00         17         486.39 Pool         LID not found           4.00         0.00         17         486.39 Pool         LID not found           2.00         3.00         0.00         17         486.39 Pool         LID not found           2.00         3.00         0.00         13         225.88 Forestin         Ear           4.00         0.00         13         225.88 Forestin         Ear           4.00         0.00	AA026562 51.89 513.37	513.37		9.69		8	8.9	<b>.</b> 5	426.56 Thymus	Adipose	
3.00 0.00 7 448.84 3.00 0.00 1.00 7 448.84 5.00 0.00 1.00 1 130.77 Heart Pool 1.00 0.00 0.00 1 130.77 Heart Pool 1.00 0.00 0.00 4 495.89 Pool Brain 1.00 0.00 0.00 1 1 235.5 Pool 1.10 not found 2.00 0.00 1 1 235.5 Pool 1.10 not found 3.00 0.00 1 1 235.5 Pool 1.10 not found 4 102.82 0.00 0.00 1 1 235.5 Pool 1.10 not found 6.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 235.5 Pool 1.10 not found 7.00 0.00 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	R38239 127.60 877.81	677.81		6.87		4.00	0.00	11	363.86 Placenta	LID not found	Other
3.00         0.00         7         448.84           0.00         1.00         Thymus Skin           5.00         0.00         1         130.77 Heart Lung           6.00         5.00         9         367.64 Overy Breast           1.00         0.00         4         495.88 Pool         Breain           1.00         0.00         4         495.88 Pool         LUng Pool         LUng Pool           2.00         0.00         10         316.17 Pool         LID not found         Color         Color         Color         Color         Color         LID not found         LID not found         Color         LID not found         LID not	N62685 400.94 2154.88	2154.88		5.37		3.00	0.0	4	281.08		
5.00         1.00         Thymus         Skin           5.00         0.00         1 130.77 Heart         Lung           6.00         5.00         9 367.64 Overy         Breast           1.00         5.00         9 367.64 Overy         Breast           1.00         5.00         1.00         4 455.89 Pool         Lung           1.00         0.00         4 455.89 Pool         LlD not found           2.00         0.00         111         250.51 Pool         LlD not found           3.00         0.00         111         250.51 Pool         LlD not found           1.00         0.00         111         250.51 Pool         LlD not found           2.00         0.00         17         486.39 Foreskin         Earth           2.00         0.00         17         486.39 Foreskin         Earth           2.00	T96215 25.88 185.98	185.98		7.19		3.00	0.00	7	448.84		
5.00         0.00         1 130.77 Heart         Lung         Pool           1.00         5.00         9 36.64 Overy         Breast         1.00           2.00         5.00         6 315.52 Pool         LID not found         1.00           2.00         5.00         11 250.51 Pool         LID not found         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00         1.00 </td <td>N72540 13.52 83.07</td> <td>83.07</td> <td></td> <td>6.14</td> <td></td> <td>0.0</td> <td>1.00</td> <td></td> <td>Thymus</td> <td>Skin</td> <td>Aorta</td>	N72540 13.52 83.07	83.07		6.14		0.0	1.00		Thymus	Skin	Aorta
1.00 0.00 1 130.77 Heart Lung 6.00 5.00 9 367.64 Overy Breast 6.00 0.00 4 495.68 Pool Brain 1.00 0.00 0.00 4 495.68 Pool Brain 1.00 0.00 0.00 11 250.51 Pool 1.10 not found 1.00 0.00 1.00 1.00 1.00 1.00 1.00 1.0	H57242 36.75 344.96	344.96		9.39		5.00	0.00		Liver	Pool	LID not found
6.00 5.00 9 367.64 Overy Breast F 1.00 0.00 4 495.85 Pool Lung Pool LU	R00608 4.31 47.67	47.67		=	40	8.	0.00	-	130.77 Heart	وسا	Pool
1.00 0.00 1.00 1.00 1.00 1.00 2.00 2.00	H77797 40.13 537.54	527.54		13.40	_	6.90	9.00	o,	367.64 Ovary	Breast	Pool
1.00 0.00 4 4.95.88 Pool Brain 1 2.00 0.00 6 315.52 Pool LID not found 5.00 0.00 11 2.50.51 Pool LID not found 6.00 0.00 11 2.50.51 Pool LID not found 7.00 0.00 1.00 1.11 2.50.51 Pool LID not found 6.00 0.00 1.00 1.00 1.00 1.00 1.00 1.00	W03793 2.97 15.00	15.00		š		8.	0.00			<u>P</u> 8	LID not found
3.00         0.00         6         315.52 Pool         LID not found           5.00         0.00         11         250.51 Pool         LID not found           5.00         0.00         11         250.51 Pool         LID not found           3.00         0.00         17         486.39 Pool         LID not found           2.00         0.00         17         486.39 Pool         LID not found           2.00         1.00         17         486.39 Pool         LID not found           4.00         2.00         13         226.88 Foreskin         Ear           4.00         2.00         13         226.88 Foreskin         Ear           4.00         2.00         10         510.78 Pool         LID not found           7.00         2.00         17         68.81 -         Pool           1.00         0.00         17         63.64 Thyroid         LiD not found           2.00         0.00         1	H83760	22.83		5.89		90	0.0	4	495.88 Pool	Brain	LID not found
2.00         0.00         10         310.17 Pool         LID not found           3.00         0.00         11         250.51 Pool         LID not found           3.00         0.00         4         102.82         LID not found           3.00         0.00         4         102.82         LID not found           2.00         0.00         17         485.39 Pool         LID not found           2.00         3.00         7         583.56         Prosite         LID not found           2.00         0.00         7         583.58         Prosite         LID not found           4.00         2.00         13         225.88 Foreskin         Ear         Prosite           1.00         2.00         13         225.88 Foreskin         Ear         Prosite           1.00         2.00         13         225.88 Foreskin         Ear         Prosite           1.00         2.00         13         225.88 Foreskin         Ear         LID not found           2.00         2.00         17         68.81         Prosite         LID not found           4.00         2.00         17         68.81         Prosite         LID not found           2.00	R86208 25.79 220.20	220.20				8 6	8 8	9	315.52 Pool	LID not found	ğ. Ö.Bğı
3.00 0.00 11 250.51 Pool LID not found 3.00 0.00 11 250.51 Pool LID not found 3.00 0.00 11 250.51 Pool LID not found 4.00 0.00 1.00 1.00 1.00 1.00 1.00 1.00	FL3/88U 102./8	5,00.02		6.13		9 5	B 6	;	Money Control	1001	
3.00 0.00 6 24.7 Muscle Heart B 3.00 0.00 6 1.00 4 102.82 2.00 0.00 6 1.00 8 3.4.7 Muscle Heart B 1.00 0.00 1.00 8 3.4.3 Pool LID not found 1.00 0.00 7 583.56 - Prostate B 1.00 0.00 7 583.59 Pool LID not found 1.00 0.00 1.00 1.00 1.00 1.00 1.00 1.0	N46139 20.50 142.2/	17.74		. a		8 8	9 9	2:	350.55 Pool		
3.00         0.00         4         102.82           2.00         0.00         17         486.39 Pool         Prostate           1.00         1.00         900         Pool         LID not found tound           2.00         0.00         7         593.58 - Pool         Prostate           4.00         2.00         13         278.38 Pool         LID not found           1.00         2.00         13         278.38 Pool         LID not found           1.00         2.00         13         278.38 Pool         LID not found           1.00         2.00         10         510.78 Pool         LID not found           1.00         2.00         17         68.81 - Pool         Pool           1.00         0.00         17         621.82 Testis         Pool           1.00         0.00         7         621.82 Testis         Pool           1.00         0.00         7         621.82 Testis         Pool           1.00         0.00         0.00         Whole embryobool           1.00         0.00         0.00         436.84 Thyroid         Earthroad           2.00         0.00         0.00         0.00         H.7. Pool         LID no	N72321 28.63 201.79	201.79		6.8		8 8	9 9	- œ	24.47 Mtscle	Head	
2.00         0.00         17         486.39 Pool         Prostate           1.00         1.00         3.00         Pool         LID not found           2.00         0.00         7         \$93.56 - Prostate         Prostate           4.00         0.00         7         \$93.56 - Prostate         Prostate           1.00         2.00         13         278.98 Pool         LID not found           1.00         2.00         13         278.98 Pool         LID not found           1.00         2.00         10         \$10.78 Pool         LID not found           1.00         0.00         17         \$21.82 Pool         LID not found           1.00         0.00         17         \$21.82 Pool         LID not found           1.00         0.00         17         \$21.82 Pool         LID not found           1.00         0.00         0.00         \$6.51.82 Pool         LID not found           1.00         0.00         0.00         \$436.84 Thyroid         Earnbryood           1.00         0.00         \$6         \$436.84 Thyroid         Earnbryood           2.00         0.00         \$6         \$436.84 Thyroid         Earnbryood           2.00	R91215 78.02 697.42	697.42		8.94		3.80	00.0	4	102.82		
1.00 1.00 Small intestine Forestin C 2.00 3.00 Pool LID not found C 2.00 0.00 7 593.58 - Pool LID not found C 1.00 0.00 7 593.58 - Pool LID not found C 1.00 0.00 13 225.88 Forestin Ear C 1.00 0.00 10 17 68.81 - Pool LID not found C 2.00 0.00 17 621.82 Festis Pool LID not found C 2.00 0.00 17 621.82 Festis Pool LID not found C 2.00 0.00 17 621.82 Festis Pool LID not found C 2.00 0.00 0.00 6 436.84 Thyroid Ear P 2.00 0.00 6 137.43 Pool LID not found C 2.00 0.00 6 137.43 Pool LID not found C 2.00 0.00 6 137.43 Pool LID not found C 2.00 0.00 6 137.43 Pool LID not found C 2.00 0.00 6 137.43 Pool LID not found C 2.00 0.00 10 0.00 10 0.00 Pool LID not found C 2.00 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00	H72388 3.49 19.26	19.26		5.5	•	5.00	0.00	11	486.39 Pool	Prostate	LID not found
2.00         3.00         Pool         LID not found           2.00         0.00         7         \$83.56 - Prostein         Prostein           4.00         2.00         13         225.88 Foreskin         Ear           1.00         2.00         13         225.88 Foreskin         Ear           4.00         2.00         10         510.78 Pool         LID not found           7.00         2.00         10         510.78 Pool         LID not found           7.00         2.00         17         621.82 Testis         Pool           1.00         0.00         7         621.82 Testis         Pool           1.00         0.00         6         436.84 Thyroid         Liver           2.00         0.00         6         436.84 Thyroid         Ear           2.00         0.00         6         436.84 Thyroid         LiD not found           2.00         0.00         6         436.84 Thyroid         LiD not found <td>T83829 7.44 39.45</td> <td>39.45</td> <td></td> <td>5.3</td> <td>_</td> <td>0.1</td> <td>1.00</td> <td></td> <td>Small inter</td> <td>stineForeskin</td> <td></td>	T83829 7.44 39.45	39.45		5.3	_	0.1	1.00		Small inter	stineForeskin	
2.00         0.00         7         \$93.56         LID not found           4.00         0.00         13         226.88 Foreskin         Ear         Prostate           1.00         0.00         13         226.88 Foreskin         Ear         LID not found           1.00         2.00         10         \$10.78 Pool         LID not found           7.00         2.00         17         68.81         Pool         LID not found           7.00         0.00         7         63.81         Pool         LID not found           1.00         0.00         7         63.81         Pool         Liver           1.00         0.00         7         63.51         Parathyridd         Liver           1.00         0.00         7         63.51         Parathyridd         Liver           1.00         0.00         6         436.84         Thyrid         Ear           2.00         0.00         6         436.84         Thyrid         Ear           2.00         0.00         6         436.84         Thyrid         Ear           2.00         0.00         6         14.7         Pool         LID not found           2.00 <td< td=""><td>H54423 60.77</td><td>453.86</td><td></td><td>~</td><td>=</td><td>5.00</td><td>3.00</td><td></td><td>Pool</td><td>LID not found</td><td>d Other</td></td<>	H54423 60.77	453.86		~	=	5.00	3.00		Pool	LID not found	d Other
4.00 0.00 7 \$83.84 - Prostate 1.00 0.00 1.3 226.88 Forestin Ear 4.00 0.00 1.3 226.88 Forestin Ear 4.00 2.00 1.3 226.88 Forestin Ear 4.00 2.00 1.0 25.00 1.0 1.0 not found 1.0 not found 2.00 0.00 1.7 68.81 - Pool 1.0 not found 1.0 not found 2.00 0.00 7 621.62 Testis Pool 1.0 not found 1.0 not found 2.00 0.00 8 436.84 Thyroid Eiver 1.00 0.00 8 436.84 Thyroid Eiver 1.0 not found 2.00 0.00 6 137.43 Pool 1.0 not found 2.00 0.00 1.0 1.0 not found 1.0 not found 2.00 0.00 1.0 1.0 not found 2.00 0.00 1.00 1.0 not found 2.00 1.00 1.00 1.0 not found 2.00 1.00 1.00 1.00 Pool 1.0 not found 2.00 1.00 1.00 Pool 1.0 not found 2.00 Pool 1.0 not found 2.00 Pool 1.0 not found 2.00 1.00 Pool 1.0 not found 2.00 Pool 1.0 not found 2.0 not 2.00 Pool 1.0 Pool 1.0 not found 2.0 not 2.0	N91231 41.37 242.75	242.75			<u>-</u>	8	000	1		LID not found	Other
1.00 2.00 1.1D not found 1.10 not fo	R96436 3.81 22.55	22.55		S.	5.92	<b>4</b> .00	8.0	_	583.58 -	Prostate	<u>8</u>
1.00 0.00 13 255.88 Forestin Ear 1.00 0.00 1.00 1.00 1.00 1.00 1.00 1.0	N92136 62.21 373.00	373.00		80 1	! و	9:	5.00	!	Pool	LID not found	
4.00 2.00 10 S10.78 Pool LID not found 7.00 10.00 17 621.82 Pool LID not found 7.00 17 621.82 Testis Pool LID not found 10.00 0.00 17 621.82 Testis Pool LID not found 10.00 0.00 7 625.1 Parethyroid Liver 1.00 0.00 8 436.84 Thyroid Ear 2.00 0.00 6 137.43 Pool LID not found 2.00 0.00 18 14.7 Pool LID not found 2.00 0.00 18 14.7 Pool LID not found 2.00 0.00 10 0.00 18 14.7 Pool LID not found 2.00 0.00 10 0.00 10 0.00 Pool LID not found 2.00 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00 10 0.00	N29914 3,14 56,77	56.77		20.	<b>=</b>	8 :	0.00	<u>.</u>	226.98 Foreskin	Ž.	
1.00 2.00 10 510.78 Pool LID not found 7.00 0.00 17 68.81 Pool LID not found 4.00 0.00 7 621.62 Tests Pool Liver 10.00 0.00 7 621.62 Tests Pool Liver 10.00 0.00 7 623.1 Parathyroid Liver 10.00 0.00 8 436.84 Thyroid Ear 2.00 0.00 6 137.43 Pool LID not found 2.00 0.00 110 14.7 Pool LID not found 5.00 0.00 1.00 11.00 11.00 found 10.00 1.00 1.00 1.00 1.00 1.00 1.00 1.	H54609 21,94 135,43	135.43		69		9.9	2.8	eo (	478.59 Pool	LID not foun	
4.00 0.00 17 521.82 Tsuis Pool 1.00 0.00 7 521.82 Tsuis Pool 1.00 0.00 7 651.82 Tsuis Pool 1.00 0.00 7 651.82 Tsuis Pool 1.00 0.00 7 655.1 Parathyridd Liver 1.00 0.00 8 436.84 Thyroid Ear 2.00 0.00 6 137.43 Pool 1.1D not found 2.00 0.00 18 14.7 Pool 1.1D not found 2.00 1.00 81.03 Thyraus Colon 4.00 0.00 81.13 Thyraus Colon 1.00 1.00 1.00 Pool 1.1D not found 2.00 0.00 1.00 Pool 1.1D not found 2.00 0.00 Pool 1.1D not found 2.00 1.00 Pool 1.1D not found 2.00 Pool 1.1D not found 2.00 Pool 1.1D not found 2.00 1.00 Pool 1.1D not found 2.00 Pool 1	60.271 67.7cm	1100.55		0.78		00.1	97.0	2 !	510.78 POOL	LID not tour	•
4.00 0.00 7 655.1 Parethy of Liver 10.00 0.00 7 655.1 Parethy of Liver 1.00 0.00 7 655.1 Parethy of Liver 1.00 0.00 8 436.84 Thyroid Ear 2.00 0.00 6 137.43 Pool LiD not found 2.00 0.00 1.00 1.00 Pool LiD not found 5.00 0.00 1.00 81.13 Thyrous Colon 1.00 1.00 1.00 Pool LiD not found 6.00 0.00 1.00 Pool LiD not found 7.00 0.00 1.00 Pool LiD not found 6.00 1.00 1.00 Pool LiD not found 6.00 1.00 Pool LiD not found 6.00 Pool LiD not found	07:147 FR. 21 COUNTY	241.70		7.0		9.	9 9	<b>-</b> '	66.61	ē ;	UD not found
1.00 0.00 7 625.1 Parathyrod Liver 1.00 0.00 8 436.84 Thyroid Ear 2.00 0.00 6 137.43 Pool LiD not found 2.00 0.00 1.00 1.00 1.00 1.00 1.00 1.00	K86262 14.89 100.26	100.26		, c	_ •	9.00	9.0	~ 1	521.52 1850\$		בווט אסג זסניים
1.00 0.00 Aoria Pancrass 1.00 0.00 6 436.84 Thyroid embryobod 1.00 0.00 6 436.84 Thyroid Ear 2.00 0.00 6 137.43 Pool LID not found 2.00 0.00 18 14.7 Pool LID not found 2.00 0.00 18 14.7 Pool LID not found 2.00 0.00 1.00 81.13 Thyrius Colon 4.00 0.00 1.00 81.13 Thyrius Colon 1.00 1.00 Pool LID not found 2.00 0.00 Pool LID not found 3.00 0.00 Pool LID not found	N90246 2.25 30.08	20.08		3.5	_	00.00	0.00	_	655.1 Paramyron		Pancreas
1.00 0.00 6 436.94 Thyroid Ear 2.00 0.00 6 137.43 Pool LID not found 2.00 0.00 18 14.7 Pool LID not found 2.00 0.00 1.00 Pool LID not found 3.00 0.00 1 61.13 Thyrnus Colon 4.00 0.00 61.00 1.00 Pool 1.00 1.00 Pool IID not found 2.00 0.00 1.00 1.00 Pool 2.00 0.00 Pool IID not found 3.00 0.00 Pool IID not found	H73329 5:33 28:12	28.12		5.28		1.00	0.00		Aorta	Pancreas	Heart
0.00 6 436.84 Thyrbid Ear 0.00 137.43 Pool LID not found 0.00 18 14.7 Pool LID not found 0.00 Pool LID not found 0.00 1 81.13 Thymus Colon 0.00 Eye Pool 0.00 Pool LID not found 0.00 Pool LID not found 0.00 Pool LID not found	W02016 2.84 15.44	15.44		5.45		1.00	8.0			bryoPool	LID not found
0.00 6 137.43 Pool LID not found 0.00 18 14.7 Pool LID not found 0.00 Pool LID not found 0.00 1 61.13 Thymus Colon 0.00 Pool LID not found 0.00 Pool LID not found 0.00 Pool LID not found	AA458846 57.11 348.14	348.14		6.10		5.	8.	•	436.84 Thyroid	Ear	Bone
2.00 0.00 18 14.7 Pool LID not found 2.00 0.00 1.00 Pool LID not found 3.00 0.00 1.00 81.13 Thymus Colon 1.00 1.00 Pool LID not found 1.00 1.00 Pool LID not found 2.00 Pool LID not found 3.00 Pool L	H54811 3.70 34.01	<b>%</b>		9.18		2.00	0.00	90	137.43 Pool	LID not foun	
2.00 0.00 Pool LID not found 2.00 1.00 Pool IID not found 6.00 1.00 Pool IID not found 6.00 0.00 1.00 Eye Pool IID not found 7.00 1.00 Pool IID not found 6.00 Pool IID not found 6.00 0.00 0.00 Pool IID not found 6.00 0.00 Pool IID not found 6.00 0.00 0.00 Pool IID not found 6.00 0.00 Pool IID not found 6.00 0.00 0.00 Pool IID not found 6.00 0.00 Pool IID not found 6.00 0.00 0.00 DOIL IID not found 6.00 DO	R99287	1072.08		6.75		2.00	0.00	18		LID not foun	a Other
2.00 1.00 Pool LID not found 5.00 0.00 1 61.13 Thymus Colon 4.00 0.00 Eye Pool 1.00 1.00 Pool LID not found 5.00 0.00 Pool LID not found 5.00 0.00 Pool LID not found 5.00 0.00 Pool LID not found 6.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	R96561 1.99 18.66	18.66		9.37		2.00	0.00		Pool	LID not foun	
5.00 0.00 1 81.13 Thymus Colon 4.00 0.00 Eye Pool 1.00 1.00 Pool LID not found 2.00 Pool LID not found 6.00 0.00 0.00 Pool LID not found 6.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	H52623 78.26 525.41	525.41		6.7	_	2.00	1.00		P001	LID not found	Other
4.00 0.00 Eye Pool ILD not found 2.00 Pool ILD not found 4.00 Pool ILD not fou	N38801 16.16 256.25	258.25	•	15	. 45	00 5	000	-	At 13 Thomas	Color	
1.00 1.00 Pool LID not found of 2.00 0.00 Pool LID not found of 2.00 LID not found of 2.00 LID not found of 2.00 not fou	R96586 13.16 92.70	92.70		2 ~	7.05	8 8	800		2000 AV	Pod	LID not found
2.00 0.00 Pool	N91731 41.14 280.22	280.22		9	6.81	8.	6:1		. <u>18</u>	LID not foun	Other
	N59838 169.54 1068.24	1088.24		80	2	2.00	0.00		Pool	LID not foun	- Page
	VA7408 80 00 00 00 00 00 00 00 00 00 00 00 0	487.00		; è	::	} {	, (		3		B 50 0

Page 12 of 91

nd Other	LID not found		Pool	i		Oppose		Blood		w Neural	Sall bladder Stomach	nyoSpleen	Tonsil Breast	Stomach	Pool	TAPATA CEIL		Lund de	ابره	Breast		Pooled		Pancreas	Thymid	Muscle	Pool		CNS		Aorta		Thomas		Whole embryo	Aorte	Tonsil	Tonsil	and Other	Head and nec Macenta	Tastk	LID not found	Brein		Whole embryoTonsil	ID not found Other	Lib not found Other	
LID not found Other	<u>8</u>	CNS	Overy	:	Foreskin	Hean	Misch	Escophagus	P80	c Bone marrow Neural	Gall bladde	Whole emb	Tonsil	Skin	Eye	Aorta	Calar	808	Whole embryo-	Brain	Gall bladder	Bone	Gall bladde	Cervix Pand	בוט חסת זסט בי לואימיני	or mymus	yoBrain	LID not found	erEar	LID not found	Nose	Splean	Ulerus od Gall Medder	Skin	Heart	Heart	Breast	P 00		2		2 A	Pod		Whole em			
8	96.76 Ear	631.68 Ignore	192.45 Marrow	371.29	57.43 Thyroid	701.1 Germ Cell	AR B1 Formskin	585 14	308.36 Kidney	390 Head and ne	Pooled	138.07 Eye	Thymus			107.37 Ignore	-10.3) Eye	58.38 Germ Cell	Foreskin	Liver	250.6 Liver	280.97 Tonsil	414.87	24.9 Ovary	Placenta LIU not I	458.37 Small intestine constin	144,44 Whole embryoBrain	249.3 Pool	Peripheral ner Ear	Placenta	362.25 Bone marrow Nose	199.83 Aorta	147.41 CNS 819.8 Umbilical conf	Thymus	245.8 Aorta	Esophagus	432.9 Adipase	Germ Cell		190.04 Small intesti	264 32 Topeil	378.6 Prostate	362.64 Testis		Breast	635.65 Pool	8 1	0100000
	~	~	8	Ξ	50	- ;	<u>7</u> a	۰ ۱	· <b>-</b>		,	vo		^	- •	<b>.</b>	3 :	<u>.</u>	•		19	4	ĸņ	16	Ş	2 5	5 E	9			2	φ ;	ნ -	_	2		16		•	~ .	2 1	2 2	5			4		
3.00	8	0.00	8:8	0.0	8	5.00	8 6	8 6	80	2.00	00	00.0	2.00	0.0	0.00	0.0	8.8	8 6	2.00	8	0.0	1.00	00.00	0.00	0 0 0 0	9 5	000	0.00	0.00	2.00	1.00	1.00	0 0	8 8	8	0.00	1.00	0.00	0.00	8 8	3.8	8 8	000	0.00	0.00	3.00	8	2
9.00	9.1	1.00	4.00	1,00	<b>1</b> .00	9.0	0.00	8 5	2 62	16.00	3.00	7 00	0.0	3.00	3.00	9.00	8	8.6	8 8	8	9.	0.0	1.00	8.00	8 8 8	8 8	8 8	8	5.00	3.8	8.	8	5 0 0 0 0 0 0	3 8	8 8	1.8	0.0	3.00	÷.	<u>5</u> 5	8 8	3 6	2.00	3.0	2.00	<b>6</b> .00	9.	•
66.9	5.24	5.40	11.06	5.98	8.25	6.43	81.21 44.24	(S. 7	6.32	69.69	12.52	7.34	7.03	5.94	8.46	55.06	6.21	6.25	46.68	10,58	5.31	5.06	6.83	35.33	8.12 2.02	8.8	5.26	5.10	31.13	5.70	6.77	5.83	6.01	07.0	5.91	5.79	5.21	5.83	6.13	6.05	9.00	3.6 70.8	7.81	6.22	5.84	10.45	7.42	***
193.16	45.30	929.50	151.89	1146.72	74.88	117.14	1116.13	148.00	306.49	446.78	1099.65	63.58	148.31	76.40	96.21	255.68	18.54	52.08	45.07 620.78	49.41	30.52	134.44	288.07	337.36	156.71	4603.26	25.65	40.67	465.42	86.08	710.68	849.43	38.61	43.3/	620.12	426.01	16.09	119.71	66.23	25.20	32.70	20.162	1082.50	20.05	157,44	101.79	110.80	***
27.64	8.85	172.08	13.74	191,71	9.08	18.22	91.58	5. E	48 48	6.39	87.81	8.66	21.08	12.86	11.37	7	2.88	9.33	3.85 OF 61	4.68	5.75	26.57	42.21	9.55	19.30	653.05	4 88	7.97	14.85	16.85	81.01	145.69	4.82	27.00	104.96	73.56	3.09	20.55	10.81	4.17	4.91	47.97	142 18	3.22	26.97	9.74	14.93	-
N49439	R96694	W19461	H60119	N99553	W49563	T87341	H59915	AA406242	K32342 T9886	AA401137	A4459519	T80232	H24707	AA028963	AA456695	N49629	H17975	AA490688	108218	R72075	171888	AA450869	AA291163	AA488406	R36175	H48420	H22856 R55130	R91296	175041	R23089	AA278759	T74608	H70099	AA460479	N77515	AA034213	AA281616	R00395	R08109	H93550	R71414	W32731	SPOON	T77812	R72681	H60503	R08275	-
243428	199709	305227	207448	294995	324815	115443	204335	153775	13084	741497	810801	24642	160793	470178	813149	243741	50413	823859	41565	155718	85509	815503	700527	843028	136602	207029	51702	195200	22731	131365	703581	84820	212772	814054	246543	471186	712023	123408	127096	242687	142733	327506	207642	108830	156270	207890	127216	
2678	2681	2882	2685	2686	2687	2688	2695	86 E	20/2	27.50	27.14	27.77	2731	2743	2755	2756	2759	2760	2762	27.79	2783	2780	2799	2802	2812	2813	2815	2820	2821	2824	2829	2830	2832	2838	2852	2860	2866	2882	2883	2888	2882	2893	2002	2898	2908	2920	2923	441

Page 13 of 91

Other	Gem Cel	1 Other	1 Other	1 Other	Muscle	Other	Other	d Other		LID not found	Brain	LID not found	Esophagus	d Liver	d Other	8 6				2000	Total	110 not found	Pool	LID not found			Pooled	d Other	d Other	LID not found	3		d Other		Pool	LID not found	yolher		Small intestineLymph node	Bressi	Thymus	Ionsil	44/100	Adipose Pogl	3	Tonsil	Smooth muscle	Pool	Muscle		Heart
LID not found Other	Breast	LID not found Other	LID not found Other	LID not found Other	Foreskin	LID not found	LID not found Other	LID not found Other		Testis	Pod	Pool		Umbilicat cord Liver	LID not found Other	Breast	City and found City	בים ויסו יסו	LID not round Other	Head and next	Mische	Tong	Ulenis	Kidney		LID not found	Ovary	LID not found	LID not found Other	Foreskin	3	Ē	LID not found Other		Breast	Pod	Whole embryoLiver		Small intest	Testis	Nose	Pool	1007	SON .	1981	Brain	Thymus	Spleen			DIOJĆI D
Breast	Parathyroid	264.87 Pool	Pool	366.2 Pool	208.72 Podled	85.46 Pool	227.78 Pod	88.89 Pool		675.72 Spleen	94.68 Eye		643.74 Smooth musc	446.88 Nose		158.34 Mutde	<u> </u>	8	910,96 P00	447 OB Moca		191 53 Whole emhoorTonsil	49 13 Fve	835.64 Pool	Hear	322.97 Pool				283.86 Eye	10.86	754.93	Prostate	227.19	216.37 Thyroid	460,37 Adrenal gland Pool	188.13 -		422.9 Epididymis	87.89 Germ Cell	Adpose	Adrenal gland Pool	199.30	236 P. Dang merran	228.23	192 44 Germ Cell				of CO Administration	25.02 Adrenal gland Thyroid
		19		ur,	7	-	en :	×		^	-	<b>a</b>	n	က		ıo.		•	n	ď	, ,	4 6	, 2	4		17		е	∞	<del>-</del> ;	17	9	!	5	4	11	9		~	23		>	٠ -	- ;	<u>2</u> >	٠ -	- vc	) <del>-</del>	6	;	71
0.00	0.00	0.0	0.0	0.00	0.00	000	5.00	0.00	0.00	9.80	0.00	0.00	0.00	0.00	8.	000	3.00	3.5	9.6	8 8	8 8	8 8	8 6	2.00	00 %	0.00	1.00	0.00	8.	0.00	8.8	9.00	3.00	8.	0.00	0.00	0.00	8.0	0.0	0.00	8	0 6	9.6	9 6	8 6	8 6	3 6	800	000		00.0
1.00	3.00	3.00	9.00	3.00	9.8	2.00	9.00	9.00	8.9	5.00 5.00	2.00	2.00	3.00	3.8	8.	8	0.6	8	3.00	0.5	3 5	9 6	8 5	90	9	5.00	3.00	8.	1.00	6.00	5.00	3 8	8	5.00	9.1	4.00	2.00	7.80	5.00	8.	1.00	9.6	3 3	9.5	8.5	5	8 6	00.1	00		00.
5.80	2.8	7.89	11.92	6.59	12.52	8.48	13.11	6.42	6.24	12.94	5.47	9.63	6.09	6.26	6.53	6.63	7.32	4.0	7.90	0 0	0.22	0.50	8.53 8.53	10 03	12.42	9.63	9.28	6.44	6.78	7.71	8.21	8 r	104	6.62	6.03	7.88	5.55	12.10	5.24	5.37	5.52	00.7	9.0	5.83	1.09	43.63	14.42	5.51	507	5 6	E
44.90	62.63	150.41	143.03	233.77	70.96	587.51	325.60	1244.58	74.15	155.50	146.11	216.48	478.38	224.01	14.15	492.35	50.95	37.09	38.31	18.24	173.02	145.29	264.66	1617.25	136.03	229.49	197.78	289.06	43.04	20.02	446.37	263.90	474.67	394.91	687.63	98.69	582.10	212.01	648.70	58.73	33.11	37.09	102.85	24.78	19.90	400.23	43B 10	308.72	95.85	3	58 41
7.81	8.70	19.07	12.00	35.47	6.87	69.25	24.84	193.76	11.89	12.01	26.69	22.48	78.49	35.76	2.17	74.27	98.9	5.76	4.85	2.5	ro. /2	15.20	8 2	161.20	08.01	23.34	21.29	46.42	6.35	9.18	54.37	3.80	67.41	59.66	113.95	12.84	104.92	17.51	123.77	10.94	6.00	5.30	17.79	4.25	3.40	7 30.27	2 2	5. 5. 5. 5.	18.80	3 5	7.63
H24616	H80423	R12267	R90957	R08690	H96634	H90603	R91004	H67666	N52394	R91031	N80361	R08761	R68721	H73661	W95104	W05000	N77198	H68932	H95044	WZ3541	AAA30011	H/ 1/0/	0.7404F1	195086 H95086	H78650	H71224	AA457728	N76873	N77321	N34751	H77897	H27733	H69653	N26072	AA018134	R06284	N55012	R88764	AA115919	AA490680	H69582	N72452	H80215	H74265	00060	H62418	A A 48 6 6 2 7	7899EW	WASSES	2000	184153
160730	241171	128331	194906	127768	251250	241539	194935	211202	246116	195037	292482	127409	139226	214614	415178	295389	245401	212098	243245	295497	100000	233419	730776	241317	239711	214563	810754	245784	245534	27 1378	233399	134537	212712	268951	352894	126277	245409	195034	548957	823884	213138	245296	240766	228365	207784	1240000	CP/07/1	246764	446833	2001	240249
2932	936	938	¥	ž	949	35	9	196	962	998	970	176	386	8	191	8	26	ត្ត	8	8 3	= ;	4 4	D P	2 5	2 2	ន្ត	124	22	33	5	33	38	2 5	222	2	983	88	1.0	084	8	9	102	9	ર્કે ક	2	8 2	2 5	2	2 6	2	A DA

age 14 of 9

FIGH	testine	7250		191.31 Prostate CNS Lung			Synovial mem skin	Thymus Skin		118.59		CNS Thyroid	99.33 Tonsi Lymph	546,17 Adipose	11.08 Lymph Adrenal gland	Cvary	Poor Programme Annual Control of the	Total	380.27 Pool LID not found	246.56		mta Prostate	Pool LID not found Other	Thymus Tonsil	411.43 Pool LID not found Other	i		188.44 Placenta Pool	531.65 Whole embryo-	980		245.06 Pool	- '	32.59 Precenta Heart	430.65 Placenta Aorta	3 732.12	121.9		Piacenta 244 64 Disease	24-01 Pieceiga Lympa 567-49		-	Eye	25.86 Pool	439.12 Pool LID not found	373.94	Section of the sectio	
-	60	-		18	;	4		ø	0	ø	7		91	7	ୡ		:	•	82	7				<b>6</b>	<b>₽</b> 3	×τ	, E	7	60	4	;	×	•	- 6	*	60	e	••	4	<u> </u>			1	0	æ.	n •	•	
1.00	800	8	8.	0.0	8	8	8	8	1.00	0.00	8.	9.0	0. 0.	8	1.00	86	9 6	8 6	9 8	8	000	9. 8.	0.0	1.00	80	0.00	9 0	0.00	0.00	0.00	0.00	8 S	8 6	2 6	0.00	0.00	1.00	00.0	2.00	8 8	200	3.00	0.00	0.0	3.00	800	8 8	
0.00	3.00	8	9.0	2.00	13.00	8.9	9.	2.00	1.00	7.00	0.0	<b>5</b> .00	1.00	<b>0</b> .00	0.0	9.9	00.4	8 6	8 8	2.00	4.00	8:	3.00	8	2.00	3.00	8 8 8 8	8	8	9.	8.9	8 8	3 5	8 8	5.0	3.00	3.00	8.5	8 8	3 5	8 8	0.00	1.00	7.00	9.9	2.0	8 6	3
5.48	898	5.63	16.97	9.59	39.37	20.34	5.55	8.80	5.28	16.74	5.21	6.14	5.32	6.37	7.88	8.71	 	20.0	22.c	7.24	2	6.44	<b>3</b> 9.6	7.61	5.80	6. 60 60 6	7.31	6.52	5.04	7.90	7.14	æ ;	5 5	5. 35 5. 35	5.04	6.52	8.65	9.05	5.87		6.89	5.49	5.15	8.29	18.71	6.8	٠ م	2
458.26	217.93	158.75	136.70	19.14	632.20	94.33	230.99	206.43	284.92	279.39	567.02	44.04	103.99	1065.64	257.47	115.35	34.92	26.30	36.13 157.22	2229.97	552.40	22.15	44.43	128.34	454.30	1165.32	20.82	691.48	11.35	83.44	311.39	98.20	97.90	60.30	163.64	458.49	71.20	. 883.38	32.68	38.4/	105.16	74.38	418.18	54.17	1040.08	541.43	17.55	
85.13	24.32	28.18	8.08	2.00	16.08	2	41.59	31.29	53.87	16.69	108.93	7.17	19.55	167.19	32.66	13.25	3.03	5.00	12.55	307.87	72.28	3,44	4.61	16.60	76.98	188.14	28.50	106.10	2.25	10.58	43.61	12.00	0.50	80.9 81.4	29.01	70.32	8.23	85.79	5.57	 	5.28	13.55	81.26	6.53	55.60	25 th	3.41	
AA450227	AA459318	R13434	AA497051	R67147	AA598508	AA 160852	AA496837	AA442964	N73030	T63324	AA419108	AA418564	AA490920	AA487560	AA448755	AA074677	H52361	TOTOGE	195/08 R92577	H48502	N55583	R31965	R00528	196780	N58424	R00648	195870 H65775	R62241	T95503	R62288	196909	196919	W83346	W21482 R71190	N24268	H58884	AA031398	R32751	R62653	K32/54	T97076	R32839	R96358	N66843	H55897	W04231	A2043484	
789232	814306	28475	823590	42373	897770	592801	897594	809598	247816	80108	755506	767345	624547	841664	786057	544639	202158	130051	121239	207098	246073	134229	123506	121355	292452	123617	211024	139764	120544	138635	121412	121415	358162	147884	261567	207379	470379	135450	138999	135454	121206	135200	197933	295600	204098	295324	467819	
3203	3207	3209	3214	3217	3220	3222	3231	3234	3241	3242	3245	3247	3250	3252	3258	3284	3265	2500	12.6	3272	3273	3276	3279	3283	3285	3287	3281	3286	3301	3304	3307	3315	3317	3320	3322	3323	3329	3332	333		3347	37.8	3363	3361	3365	888	3366	7

age 15 of 91

Ξ
9
ъ
8
-
9
Ω,
6

	8										· <b>S</b>														9		Whole embryo		_	hyroid			<b>.</b>	0	9	883				Cell	1888	nte			*	Gall bladder		LID not found	<u> </u>	Adrenal gland			•	
	Pancress	Heart	Hear	Other	Uterus		Breast		<u>8</u>		Foreskin	Other	S Other	Eye		1 Other		Ovary		o Cher	d Other		d Other	Testis	Prostate		Mag	d Other	Breast	Parathyroid	P 80	Tonsi	Lymb.	Muscle	riacenta			B. E.	Nose	Id Germ	Pancreas	Placenta	Aorta	Liver	sc Kidne	Gall	d Lung	5	Kidney	Adre	<u>8</u>	er Nose	Liver	yoEye
	Bone	Eye	Colon	LID not found	Heart	LID not found	Testis	LIO not found	Ovary	LIO not found	Stomach	LID not found Other	LID not found Other	: Thymus		LID not found Other		rvous system		LID not found Other	LID not found Other		LID not found Other	Hear	d Foreskin	LID not found	Tonsil	LID not found Other	Skin	eThyrold	Umbilical cord Pool	oLiver	Blood	Kidney	Heart	Smooth musc Umbucal cord Pancless	Tonsi	Bone	Adipose	Adrenal gland Germ Cell	80	Pool	Lymph node	CNS	Small intestineSmooth muse Kidney	Foreskin	Adrenal gland Lung	Tonsil	Ovary	Stornach	Tonsil	Peripheral ner Nose	90	Whole embryoffye
	101.92 Ignore	Foreskin	Pancreas	P001	347.35 Gall bladder	461.06 Pool	Adipose	272.44 Pool	Marrow	263.15 Pool	Ce <b>P</b> six	178.79 Pool	-8 	44.57 Head and nec Thymus	193	106.8 Pool		466.93 Peripheral nervous system		P00	Pool		134.94 Pool	Larynx	Umbilical cord Foreskin		500.87 Blood	P00 .	Bone marrow Skin	695.02 Smail IntestineThyrold	152.22 Thyroid	325.76 Whole embryoLiver	26.14 Cervix				130.14 CNS	132 58 Foreskin	142.59 -	490.28 Larynx	524.57 Smooth muscle				671.11 Smal intesti	680.68 Thymus	Parathyroid	249.05 Placenta		96.5 Gal bladder			155.62 Small intestine	Bone
	₽				Z	46		27.		Ŕ		7		\$		7		₹					ţ				ŝ			69	5	32	~	•	,	9 6	2 5	: 5	4	48	52	40	7	35	67	8		*				4	*	
	6				7	က		7		\$		2		4	8	7		~					4				7			•	7	1	ā		4 (		- 0	• -	-	9	s	^	20	×	ო	ი		•		1		80	s	
Table 2A	000	000	000	8:	00.0	3.00	0.0	1.00	0.0	5.00	8.0	0.00	0.1	0.00	0:00	000	0.0	0.00	0.00	1.00	0:00	2:00	0.00	9.	0.00	0.80	0:00	0.0	8.0	1.00	0.00	9.0	8:	8.5	8.5	9.0	8 5	00.0				1.00									2.00		8.0	8.0
Ta	7,0	100	8	2.00	1.00	0.00	3.0	8.00	5.0	6.00	1.8	9.	8.7	1.00	3.0	8	5.00	9.	9.	000	3.00	9.00	3.8	8.00	4.00	1.0	1.8	3.00	3.00	6.	<u>5</u>	2.00	8	8 9	8 6	8.8	8 8	3 5	8 8	8	000	1.00	5.8	6.	9.	1.00	2.0	3.00	5.	9.0	1.00	3.00	1.0	2.00
	17.09	5.46	8.26	6.46	8.27	9.74	10.25	6.94	6.10	20.69	6.29	7.03	<b>9</b> 6	8.20 8.20	6.13	7.14	5.71	5.49	s.30	5.27	7.21	12.35	8.29	36.91	6.90	6.26	5.88	6.13	10.99	17.83	8.47	6.84	<b>8</b> . 10	5.10	102.48	90.0	7.50	80.5	10.08	9.54	5.15	7.41	12.77	5.0	11.68	5.81	11.00	9.09	9.07	5.91	5.83	5.80	6.62	5.79
	45.06	428.36	704.79	90.85	8.98	228.54	15.29	98.25	136.79	285.33	178.78	200.93	31.43	59.37	593.71	17.91	111.09	148.08	36.19	17.83	369.39	156.14	357.35	102.48	47.02	163.02	232.23	263.42	384.82	430.88	25.64	48.64	22.95	207.56	1008.01	1000.90	25.55	93 93	195.07	7.92	71.52	48.64	572.27	105.51	107.94	231.92	146.85	197.39	157.35	168.38	140.54	307.36	1242.18	176.68
	2.64	78.50	112.51	14.08	8.1	23.48	1.49	14.15	22.41	12.82	28.42	28.60	89 89	9.57	<b>86.8</b> 2	2.51	18.48	28.97	6.83	3.34	51.27	12.65	43.11	2.78	6.82	26.05	39.52	42.09	35.02	24.16	3.03	7.11	2.84	40.70	20.	198.87	24.33	15.52	19.44	0.63	13.90	98.9	44.83	20.82	9.24	39.89	13.35	21.72	25.94	28.51	24.97	52.98	187.57	30.52
	N94385	N87041	W73782	H80958	W69471	R97234	T70850	H56424	N48213	NS4893	H38088	H56438	N91997	AA404288	N92034	H56879	W01893	R32944	H95358	H94571	H56981	R98074	W03686	W73140	W24161	N92035	HGG611	H57017	H45617	R31168	AA418251	AA438406	AA485021	R28294	R33154	H15707	N62620	B26070	AA406551	N27227	AA026631	AA410591	R97066	W01240	R98851	AA085597	AA486836	H12312	N91428	T99688	T67139	AA489261	AA070228	AA496810
	309515	298010	344133	230341	343646	200418	108330	203605	243460	245386	190940	203850	293128	758356	283356	203858	294167	135220	234469	243194	204558	206781	297437	344588	310034	293358	228580	204624	183476	134270	767638	756480	810083	134748	136188	49518	224404	111122	753467	261971	366558	754509	199945	296880	200814	562927	841278	148421	292731	122822	112865	842863	530814	697669
	3384	3386	3387	3390	3391	3393	3385	3397	3398	<b>2</b> 6	3404	3405	3409	3412	7 7	3421	<b>8</b>	3427	3429	2433	3437	24	3442	344	3446	<b>3</b> 2	3451	3453	3463	3467	3470	3472	3475	3480	3482	7 2	3484	3400	15.13	3514	3516	3522	3526	3530	3538	3544	3556	3561	3576	3580	3588	3584	3603	3605

	vany	Breast	Blood	LID not found	Testis	LID not found			Kidney	ther		ther	Testis	ther	ther	ther	ther	Lung	Other	ther	Kidney	LID not found	ther	Prostate	Spieen		Testis	Placenta	ther	ther	ther	UD not found		Breast	CIU not round	CNS	Foreskin	Placenta	Aorta	Other		ther	Brain	Other	Umbilical cord	Foreskin	Other	Umblical cord	Lung	Lung	LIO not found	LIU not found	olon ther
	Nose	Blood		Pool		Brain (1)				LID not found		LID not found Other	Pool	LID not found Other	Pool	LID not found O	LID not found Other	Pool		LID not found Other	Breast P.	ρġ			Lung	LID not found Other	LID not found Other	found	Colon		Heart B				Cell	Pooled A	Ø	Parathyroid -	found		found			LID not found	Adipose	_	Hyroid			Germ Cell Color			
	Lymph node	67.65 Prostate	353.84 Thymus	132.75 Eve	413.63 Tonsil	Uterus	295.51 Breast		Whole embryo-	101.49 Pool	313.88	354.68 Pool	569.13 CNS	283.63 Pool	378.75 Pool	327.26 Pool	<b>P</b> 80	Bone	248.15 Pool		Pooled	Placenta	<u>8</u>	562.73 Esophagus	Thyroid	424.67	Fareskin	Breest	71.96 Pool		251.63 Pod	P80	550.79	Pracenta	Ionsii 477 to Damthunid	650.88 Adrenal pland Pooled		Blood	Thymus	Pool	Poded		143.47 Peripheral ner Uterus	20	Pancreas	320.82 Umbilical cord Cervix	Pool		539.65 Stomach		334.32 Prostate	Adipose	474.57 Pool
		9	8	~	<b>ā</b>		7			<del>1</del>	17	5	ø	24	6	œ			-					-		7			73	4	4	•	m		ç	ō ru	Ν.						ឧ			ត		5	-	ā.	4		5
<b>(</b>	0.00	0.00	1.00	0.0	8.0	2.00	0.00	0.00	0.00	0.00	1.00	0.00	00.0	5.00	0.00	4.00	0.0	0.00	00. <del>*</del>	0.0	0.00	0.0	0.00	9.	2.00	0.00	0.00	2.00	0.00	0.00	0.00	0.0	80.0	8.6	9.6	2 6	00.0	0.00	0.0	0.00	0.0	0.00	0.00	8.0	0.0	8.5	00.0	0.00	800	0.00	0 6	8 6	8 8
	1.00	2.00	9.4	3,00	3.00	0.00	1.00	2.00	5.00	2.00	1.00	5.00	00. <del>4</del>	<b>9</b> .00	3.00	2.00	4.00	3.00	9.00	2.00	5.00	8.4	2.00	17.00	2.00	6.00	3.00	2.00	3.00	3.00	3.00	3.00	9.5	8.6	8 8	00.00	2.00	3.00	2.00	8.	8.	<b>5</b> .8	9.	2.00	8	8 8	3.00	1.00	8	2.00	8 8 8 8	3 5	3 <b>9</b>
	5.78	7.33	10.25	11.42	5.95	9.11	5.00	7.88	10.13	29.63	5.58	9.78	7.35	16.81	6.97	7.23	7.78	8.13	10.21	7.12	7.33	6.87	9.89	34.82	6.13	8.43	7.56	6.2	5.46	823	6.46	6.58 6.58	9 9	9 7	. e. e.	10.44	5.97	5.85	7.07	10.57	5.58	20.	6.01	8.09	5.92	5.18	10.20	5.45	7.57	8.76	6.28	2.5	5.13 5.13
	54.67	103.31	123.11	27.91	265.36	19.23	14.84	31.30	239.05	140.02	85.85	287.96	376.88	188.27	325.72	57.99	273.00	170.05	645.51	120.58	165.90	28.71	255.51	150.87	235.67	113.53	110.68	180.51	1358.00	4.65	29.41	647.47	155.53	300.38	10.33 516 61	143.05	522.40	330.01	50.26	57.99	76.55	27.39	18.21	126.08	5.58	69.57	27.75	81.86	25.89	20.83	265.08	06.33	101.45
	9.45	14.10	12.01	2.44	44.57	2.11	2.88	3.97	23.61	5.7	15.40	29.51	51.27	11.20	46.71	8.03	35.08	20.92	63.22	16.94	22.65	4.18	25.92	4.33	38.48	13.46	14.65	28.02	248.83	7.18	4.55	98.35	27.36	1.4.7	60 B7	13.70	87.50	55.38	7.10	5.49	13.77	4.12	2.70	15.47	0.84	13.48	2.5	15.02	3.42	3.11	42.19	20.11	14.24
	T51182	AA490881	AA459588	T99191	N59786	AA027964	T84998	RB3354	R89539	H59056	T96523	R68999	H95238	R91821	R08868	R89218	R08883	N75715	H93319	T78571	T84381	R22088	R89285	W25368	R09153	R22113	T79129	R22085	N58198	N91290	K89471	K08498	AAU23041	K22238	N30708	R27505	R86333	N77006	W84612	N64285	AA024866	H71314	AA133167	N78306	AA004671	N73611	14774	AA485443	N63846	N34967	M72280	A84143	H72259
	78869	824568	814526	122345	248535	469762	111884	275612	185358	207813	121072	195381	234318	185553	127514	195546	127542	244299	242011	113431	111200	130758	195784	308989	127943	130791	113538	130801	247710	292498	182588	01//21	470ds1	130624	267701	132871	194524	246194	356635	247486	365177	228997	490755	248698	428788	296095	800512	811056	292770	27.7003	213698	400004	213535
	3626	3629	3639	3649	3652	3653	3654	3657	3664	3666	3870	3672	3674	3688	3891	3896	3699	3700	3704	3706	3710	3711	3712	3713	3715	3719	3722	3727	3730	3732	3738	37.28	37.4	2776	3747	3750	3755	3758	3780	3766	3788	3769	3772	3774	3779	3783	3/83	3788	3790	3792	3780	0 0	3601

age 17 of 91

Page 18 of 91
Pag

	LID not found	Other	Spleen		Other	Other	Heart	Brain	Parathyroid	Parathyroid	Lonsi	Textis	CNS	<u>8</u>				Blood	SSS	Breast	Kidney	eSkin	Adrenal gland Whole embryo	Whole embryo	Kidney	Thyrold		Sp	Pooled Pooled	Thyroid	Esophagus	Breasi	Parathyrod	Cabical cod	Placenta	Other	ormo/	Noney	, Joe	UD not found	Tonsil	Kidney	a Skin		Pancreas	Lug	Heart	d Other	Germ Cell	Whole embryo	d Other	d Other	Tetto p	d Other
	Pool	LID not found Other	Umbilical cord Spleen		LID not found Other	UD not found Other	Brain	<u>ا</u>	Lymph	Breast	Kidney	Stomach	Gall bladder	Placenta				Nose	eStomach eStomach	Brain	Germ Cell	Small intestineSkin	Adrenal gland	Thymus	Uterus	Nose	QCNS	Gall bladder	Head and nec Adrenal gland Pooled	Spieen	c Larynx	c Stomach	Ea	c Placenta	Blood	LID not found Other	Whole embryoung		Š	Placenta	d Placenta	Piacente	Synovial mem Skin		Germ Cell		e Pooled	LID not found Other	Aorta	Colon	LID not found Other			
	Adipose	P80	Stomach					P80	CNS	Eye	630.42 Stomach	Thyroid	Epididymis	15.07 Blood		_	m	263.4 Synovial mem Nose	Small Intestin	Ignore	7 Stemach	31.44 Thyroid	294.09 Ear	Ē	675.52 Placenta	Pancreas	339.21 Umbilical cord CNS	Pancress	Head and ne	634.12 Thymus	843,74 Smooth musc Larynx	7 Smooth musc Stomach	368.81 Thyrold	8 Smooth musc Placenta	6 Stomach		Placenta	See. 83 Pracenta	Brass	71 Brain	560.21 Adrenal gland Placenta	12 Parathyroid	Neural	21	457.37 Placenta	19 Pool	15 Head and nec Pooled	Placenta	Pooled	Bone	Pod			Placenta
		485.73	283.38			175.49	66.07		344.83	293.98 Eye	630.42		247.44	15.07	278.45	827.13	170.16	263.4	426.02		247.7	31.4	294.0		675.5		339.2			634.1	643.7	149.77	368.8	401.58	588.76	650.84		900		355.71	560.2	180.72		301.3	457.3	64.49	42.15					636.07	422.24	
		5	, vo			ឧ	<del>5</del>		<u>5</u>	ଷ	-		-	-	7	~	9	15	2		7	80	-		-		-			ø	0	Ø	ss ·	9	- (	8	,	-		٩	6	6		4	9	6	9					-	4	
\$ 2A	0.00	8	000	00.0	4.00	2.00	0.00	8	0.00	0.00	8	0.00	0 0 0	0.0	0.00	8	0.0	0.0	0.00	0.0	0.0	0.0	0.0	0.0	0.00	0.00	00.0	6.9	8	8	0.0	0.0	80.0	9.	8	0.0	0.00	00.0	8 8	8 0	000	8	2.00	0.0	0.00	0.0	0.00	8.0	0.00	3.00	2.00	2.00	0.00	0.00
Table 2A	8.00	3.00	200	001	9.1	8.	1.00	0.00	00.₩	€.00	0.00	1.00	1.00	8.	11.00	8.	6.9	2.00	8.	8.	8.	2.00	8.8	9.1	6.00	8.	1.00	22.00	2.00	9.6	6.00	8.	1.00	0.00	2.00	0.1	2.00	8 9	9 9	8 5	2.00	2.00	2.00	8	9.	1.00	3.0	2.8	3.00	5.00	3.00	6.00	8.	8.
	7.53	6.45	7.63	906	6.94	5.69	5.02	10.49	9.01	9.82	39.25	10.83	5.20	7.16	105.08	6.45	8.26	7.51	5.48	8.00	5.18	7.17	7.78	5.15	378.45	12.75	10.51	27.84	6.11	22.22	37.70	6.07	8.27	9.92	8.24	5.43	9.42	9.74	6.30 F.	3 6	6.27	8.10	10.15	5.28	6.25	68.9	15.88	10.00	7.16	18.8	7.23	9.8	8.16	10.63
	138.39	234.35	198 78	96.38	64.38	756.41	178.79	28.50	39.67	897.64	169.71	63.29	877.18	23.62	2000.27	354.12	466.48	169.89	37.19	16.94	51.18	550.84	99.79	33.28	1338.88	276.61	177.19	195.43	47.44	483.45	447.40	33.51	41.69	64.26	8.2	10.78	16.20	45,25	38.45	51.40	28 58	47.56	257.17	403.17	172.23	74.59	52.65	63.99	101.19	253.22	87.60	124.60	61.45	1600.38
	18.39	36.38	25.78	10.64	9.28	133.02	35.59	2.53	4.40	91.43	4.32	5.84	168.72	3.16	19.04	54.89	56.45	22.62	6.79	2.82	9.88	76.84	12.88	8.48	3.54	21.70	16.86	7.02	7.7	21.75	11.87	5.52	50.0	6.48	7.53	1.86	1.72	79.	9.4	7 9	3 5	5.87	25.34	78.85	27.55	10.66	3.32	6.40	14.14	25.56	12,11	12.68	7.53	150.48
	N95107	H71854	D04456	NR0252	N80384	N48130	N70072	H70554	W31675	N50014	AA453774	AA393408	N79669	R90744	N92646	AA453650	T94293	AA487346	W24248	R22306	W07798	AA588950	R31701	AA017528	T46924	AA488699	AA490256	AA489246	AA456888	AA405000	H54629	AA114226	W32272	T53628	H78053	T97080	R62926	R68537	R01348	1/0/N	23.265	R63137	N59057	W81582	N95381	R99573	R68101	R63295	R33570	R66533	T97309	T97427	R33699	R39730
	203836	244833	40026	294740	292559	243385	297919	212620	320712	243675	813707	727792	289502	167280	289337	813714	119914	841470	310105	130843	301061	898035	134783	381204	70827	841679	823775	825085	815501	712341	203132	564050	321386	69672	235155	121214	138051	137793	124128	106/47	13611	137889	247216	2478.87	308082	201301	140197	138579	135999	141209	121501	121808	135853	136909
	2808	0000	2000	3822	3828	3828	3830	3834	3840	3848	3852	3876	3887	3902	3908	3912	3919	3940	3942	3944	3945	3948	3981	3977	3981	3987	3989	<b>6</b> 03	4010	4015	4018	4025	4027	4028	4032	4035	4040	4043	404	4048	9 6	408	4067	808	4070	4078	4085	4088	4092	4086	4099	4107	4116	4124

	Brain	Other	Pencreas	Uterus	Testis	Pool	Gall bladder	Esophagus	Pool	<u>8</u>	Blood	Other	Foreskin	Other	Uterus	Blood	Other		_	Heart	Utens	Skin	Pancreas	UD not found	Lung	Uterus	Pooled		Stomach	Other	Other	Other	Utenus	Other	Other		Kidoo:	Charley	o diber	Uterus	Prostate	Placenta	Testis	Prostate	Esophagus	Kidney		Skin	Ovary	Kidney	Breast	Placenta	CNS
	Ę	LID not found Other		Placenta	Whole embryoTestis	Lung	aCervix	, Lanynx	Testis	Muscle	Colon	LID not found	Smooth musc Adrenal gland Foreskin	LID not found	c Placenta		LID not found	Breast	LIO not found	P00		-	Germ Cell	Germ Cell	Tonsil	Peripheral nervous system	Umbilical cord Thymus	LID not found	Cervix	LID not found	LID not found Other	LID not found	Kidney	LID not found Other	LID not found	4	Siles Coll	Librar farm Other	LID not found			Bone		Ovary	dLaryrx	Eye	LID not found	Ovary	Bone	Brain	Blood	Say	Pool
	45.1 Ulerus	159.67 Pool	121.68 Colon	258.67 Foreskin	276.5 Pcol	432.99 Heart	Small intestineCervix	Bone merrow Larynx	439.93 Heart	494.74 Placenta	160,78 Cervix			289.86 Pool	211.28 Smooth musc Placenta	255.63 Pcoled	16.25 Pool	434.43 Kidney		198.24 Thyroid	77.59 Lung	235.02 Gall bladder	Aorta	Fcreskin		39.26 Peripheral n	615.85 Umbilical co	Pod		473.63 Placenta	117.11 Pool	96.76 Lung		78.97 Pool	Pool	1000000	64 47 Branel		318.41 Pool			587.59 Eye		333.71 Germ Cell	351.63 Umbilical cord Larynx	371.63 Lung	271.57 Brain	272.9 Thymus		334.7 Ear	Marrow	262.87 Cervix	78.13 Pooled 146.12 Spieen
	5	11	6	15	7	01			0	۲.	8	10	<b>€</b>	11	3	•••	5	<b>5</b>		<b>6</b>	-	<b>5</b>				7	-			in (	50	8	,	₩		•	•	•	ěn C	1		29	12	23	11	17 3	15 2	=	20	~	;		2 -
ZA	0.00	0.00	0.00	3.0	5.00	1.00	2.00	0.00	0.00	8	0.0	9.00	0.00	2.00	0.00	0.00	0.00	0.00	90.	0.00	6.	9.	0.00	0.00	0.00	0.00	0.0	0.0	8	0.1	9.80	8	8:	8	8.8	8 8	8 8	3 8	8 8	1.00	0.00	0.00	0.00	0.00	8.	1.00	8.0	8	0.00	2.00	00.0	0.00	0.00
Table 2A	1.00	8.	1.00	0.00	4.00	0.00	0.00	3.00	3.00	8.	8.	4.00	2.00	8	1.00	9.	9.	1.00	5.00	1.00	0.00	1.00	1.00	8.	2.00	9.	1.00	2.00	000	0.5	9.00	8.	2.00	0.00	3.00	B 6	8 6	3 5	8 8	12.80	13.00	9:	8	10.00 00.01	8.0	8	8.	0.0	17.00	11.00	8.5	9.5	8 8
	7.63	6.26	6.05	5.36	11.60	16.29	6.31	6.93	5.67	8.30	5.11	1.96	6. 15.	7. 7.	5.89	6.32	5.37	5.37	8.83	7.72	5. E	12.43	8.4 4	12.24	6.39	. 23	15.69	9.6	6.20	5.81	8.80	7.43	12.64	5.21	8 8 8	4 t	4 5 4 5	49. E	2.59	207 75	23.89	5.83	7.81	12.35	8.46	5.35	5.02	9.75	64.45	274.41	7.57	104.63	5.64
	16.91	131.91	29.05	40.56	145.94	150.41	81.78	116.75	53.97	42.80	35.65	91.50	47.35	287.13	46.42	2	169.79	18.09	107.52	32.30	3.66	1082.48	32.51	44.57	59.63	134.35	354.24	262.10	106.94	628.68	289.99	63.82	67.51	100.72	120.05	3.3	363.85 74.81	87.48	85.81	1316.45	114.71	41.92	67.92	53.22	1902.38	5,31	334.70	1045.68	243.17	781.29	40.76	19.176	55.59
	22	21.08	8.4	7.57	12.58	6. 23.	12.97	16.86	9 53	5. 16 5	6.98	7.68	7.03	9.16	7.76	3.74	31.62	3.37	12.17	4.18	8	97.06	5.97	3.84	9.38	18.58	22.57	27.18	20.57	107.78	29.59	8.59	5.34	19.32	12.54	2.48	3.60 2.60	10.72	8.67	40.0	4.84	7.07	8.70	4.31	224.97	0.99	68.69	107.26	3.77	2.85	5.38 6.38	70 C	9.85
	AA053285	R98107	W30810	T85668	R98191	AA488072	H98856	AA447569	H57111	R27412	. AA129089	H94849	AA044662	H57273	W72621	AA284234	H58001	R10043	H65231	H64095	AA434160	AA464588	N94060	N29986	H77736	AA46839	AA621342	R98591	R21425	R36070	H58574	H12777	R16134	K98805	N84274	STROPIN STROPIN	071303	D08013	H58834	AA031513	AA126115	W58032	AA401693	AA398334	AA143201	N99243	H44958	T52435	AA402207	AA227594	W74377	K4635	751350
	488019	206849	309685	120701	200780	840683	261836	782635	204814	132789	586898	230191	488422	204688	345751	324712	204444	128632	209468	209381	770593	810558	293500	268211	234647	783697	1048810	201334	130120	136780	204489	148743	66491	206882	283675	27.738	165073	206805	207370	470393	511428	341310	727292	725680	589115	309161	163200	72050	741139	667482	346552	50151	71727
	4125	4129	4130	4134	4137	4139	4140	4144	4149	4150	4151	4153	4156	4157	4158	4164	4165	417	1	4174	4175	4176	4178	4180	4.69	5	4182	4 193	4195	4199	202	4204	208	687	4210	2125	4215	4217	723	4228	4228	4235	4244	4248	4250	4255	4256	4260	4275	4282	5 5	7154	4321

Page 19 of 9

; :

					Table 2A	2A					
48873	H28922	080	6.47	7.18	8.	0.00	5	329.7 Synovial mem Adipose	ovial mem.A	dipose	Breast
787861	AA452376	7.02	48.04	28.0	1.00	0.00	5	277.88 Smc	ooth muse A	lorta	Muscle
124052	R02800	2.92	23.38	10.9	1.00	0.00		Pool		LID not found	Other
132142	R26164	7.18	68.24	9.54	8.	0.00	-	152.54 Placenta		Aorta	Eye
120343	197139	3.59	22.14	6.17	<u>5</u>	0.00	:	Pooled		Bone	Pod
625923	AA186901	23.06	164.27	7.12	00.0	8.5	<b>2</b> 9	18.43		Adiposo	Agronal giand
809464	AA443093	6.07	108.14	17.82	8.8	8.8	2 \$	A26 46 Head and new Stomach	d and nor	Stomort	Braset
161992	H26176	45.02	247.82	0.00	3.5	3 8	2 -	AS 95 Gall Fladder	Pladder	Foreskin	Parathyroid
787016	AA463565	21.12	19.97	5.03 0.03	8.6	3 8	- =	240.08			,
110503	10201	51.23	503.35 508.87	0.5.9	000	3 6	. 6	170.16 Neural	lear	Smooth musc Placenta	Placenta
840940	AA486626	282.98	7043.38	24.88	2.00	8	60	439.33 Ear			Head and nach
140515	R66057	30.54	455.14	14.90	8.00	3.00			enta	Pool	LID not found
361974	AA001449	12.23	323.96	26.48	3.00	0.00	7	624.62 Ear		Adrenal gland Parathyroid	Parathyroid
72391	T51689	7.94	161.34	20.33	13.00	0.00					
248624	N78283	2.18	13.50	6.24	0.0	1.00	5	167.89 Ear		Muscle	<u>8</u>
139189	R68705	96.86	677.35	6.89	3.00	0.00	=	272.02			,
209583	H97748	20.35	173.21	8.51	3.0	0.00	61	250.6 Pool	_	LID not found Other	Other
198961	H83233	55.12	382.12	6.83	1.00	0.00	8	198.38 Testis	ris sti	<b>D</b>	Whole embryo
139250	R68738	28.75	502.50	17.48	8.8	9.00		Brain	. <u>c</u>	Prostate	Placenta
184670	R89862	5.87	30.28	5.16	<del>1</del> .8	0.00		<b>8</b>	_	LID not found	Oibe
210898	H66877	7.36	39.07	5.31	0.0	1.00	O		Thyroid	Pooled	Eye
128118	R08870	2.91	14.79	5.08	8	0.00	80	327.75 Pool	_	LID not found Other	Other
211319	H66650	9.03	91.86	10.18	2.00	3.00	-	367.28 Pool	_	LID not found	Other
293417	N92134	130.10	916.66	7.05	3.00	0.00		•		Pod	LID not found
194921	R91060	4.37	32.72	7.48	2.00	8		Pool		LID not found	
251461	H98001	<b>3</b> .00	50.74	5.32	9:0	8.0	•	, i		Tonsil	Pancreas
292833	N90491	\$	188.93	13.47	9	000	- (	81.13 IN	Inymus Guis	Colon	Dreast
144852	R78527	121.99	615.16	2	8	000	7	228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 228.2 2 2 2		Pooled	Whole empry
195052	R91176	31.62	652.86	20.65	6.00 6.00	8.8				200	Lung emply
470348	AA029361	53.50	897.06	16.77	8 8	8.8			Albeig ombos	Didasi	T 4/1
296783	W01171	41.02	270.05	6.58	2.00	9.0		Šá	or emory	Lib on family	
1172	T91088	1.95	11.52	5.90	8.	0.00		8	в ;		
130572	R22420	6.40	32.82	5.14	8	0.00		<u>.</u>	1013	Hear	Cympn Compa
741841	AA402879	13.06	100.83	7.72	5.00	t.00		6	gnore	oken Distriction	
195091	R91244	22.28	407.93	18.31	9	2.00			<b>5</b>	CID not round Caner	
248308	N78103	19.14	157.51	8.23	2.00	0.00	m •			Greast	5 2
195139	R91271	26.88	380.59	14.16	8.8	8.6	<b>o</b> (		5 7	LID not round Other	
210923	H70862	11.51	63.48	5.52	8.5	8.6	Ð	568.45 P00	2	Dingerit	Droetote
130977	R22926	50.11	300.5	5.20	3.5	8 8		åå	Pool	Kidney	1 10 pot found
128993	K10311	8.7. E	726 40	5.03 50.4	3 5	8.6		2	ē		
670111	104003	32.44	277.98	6.9 8.43	3 5	000		ď	Pool	LID not found Other	Other
#UPE9C	NAGATE	177.13	1055.80	5.88	3.00	000	60	565.78			
296041	W02424	41.53	500.26	12.05	4.00	5.00	4	558.69 Fo	Foreskin	<u>P</u>	LID not found
127221	AA284305	2.43	13.32	5.47	1.00	0.00			Heart	LID not found Other	d Other
232723	H72700	56.50	462.62	8.19	2.00	00.0	-	705.71 Pc	Pool	LID not found	
235026	H73304	55.65	308.83	5.56	0.1	0.00	17	322.28 O	Ovary	P00	LID not found
126239	R06372	10.28	64.93	6.32	1.00	0.00	=	220.06			
504300	AA148640	2.93	15.54	5.31	1.00	0.00	t .	63.11			
296162	W02630	6.55	33.19	5.07	5.0	000	33 W	422.75 Bi	Blood	I SUO I	Manda ambox
341588	W58368	8.33	254.68	30.58 4 74	3 6	5.00	n		Pool	LID not found	Whole sunory
P10087	252248	13.40 4 90	47.96		3 8	90	80	150.71 BJ	Blocd	Placenta	Pool
135/52	N54401	12.56	101.24	8 8	8.6	8.8	· <b>so</b>	391.02 Bc	Bone	Eye	Foreskin
5	-			;	:						

Page 20 of 91

		LiD not found	LID not found	d Other	Plecenta	Pancreas	Parathyroid	Breast	Bone	Aorte	Smooth muscle	LID not found	Uterus				Pool	Cervix	Parathyroid		LID not found	Ovary	Placenta	CNS	Heart	Foreskin	Ear	Pancreas	<u>P</u>	Blood	Pooled	Parathyroid	d Colon	a Giber	Placenta		BC OKIN	Note	Pooled	Adipose	Adrenal gland	Garm Cell	Cerytx	Stomach	Umbilical cord Placenta	Breast	d Other		d Other	d Other	Uterus	Blood	d Other	P001
		Pog		LID not found	Tonsil	Lymph	Testis	CNS	nEye	Colon	d Aorta	<u>8</u>	Brain				. Testis	Thyroid	Uterus		Testis	Placenta	dAorta	Ovary	Pancreas	o£ye	Heart	Thyrold		c Thyroid	Muscle	Nose		LID not found Other		1	nead and nec okin - Tarii		Parathyroid	Pool	Blood	Liver	Bone	Eye	Umbilical co	Pancreas	LID not found Other	Lung	LID not foun	LID not found	Lung	Tonsil	LID not found	Germ Cell
		192.96 Prostate	Luna	<u>8</u>	Pooled	Germ Cell	Bone	Eye		Thymus	592.98 Adrenal gland Aorta	Tonsil	Pooled				Smooth musc Testis	CNS	Pancreas		Brain	Lymph		Esophagus	Foreskin	Small intestinoEye	Muscle	Larynx	Adipose	Head and nec	Bone		Smooth musc		Skin		Surynx Cross			Ear		Pancreas	Brain	Gall bladder	Ear	Skin	Pool	Placenta	Pool	Placenta	Foreskin	Ear	Placenta	Kidney
	297.84	192.96	207.23	695.13			141.89	410.91	258.04		592.98		20.09	357.64	129.58				221.51	249.31	461.79		405.59	268.41	411.33	266.38		16.54	740.99	225.28	240.98	223.76	293.34	154.71	127.63	200.00	21.122	9	215.71	42.01	45.84			337.8	585.19		545.17	189.11		359.62	510.43	304.52	625.84	67.03
	5	<b>*</b>	<b>±</b>	-			က	ø.	5		-		^	S	•				Ξ	7	m		7	5	16	-		9	-	= :	7	<u> </u>	R, S	27	- :	=	י ב	•	77	80	22			υ	~		7	9		ø	~	~	~ :	7
Table 2A	5.00	0.00	5.00	00.0	0.00	000	0.0	0.00	0.00	0.00	0.00	3.00	5.00	0.00	7.00	2.00	8.0	0.0	0.00	3.00	00'0	000	8.	0.00	0.00	9.1	8.6	0.00	0.00	8	0.00	8.	8.6	8 8	88	8 6	9.6	8 6	000	00.0	3.00	0.00	00.0	0.0	9.6	0.00	2.00	8.0	8.	0.00	0.0	00.4	80.0	90.0
Tab	6.00	9.00	00.9	5.00	1.00	3.80	1.00	2.00	4.00	0.0 0.0	1.00	1.00	<b>6</b> .00	3.8	1.00	6.00	1.00	<b>5</b> .00	1.00	2.00	1.00	1.00	0.00	5.00	3.00	0.00	2.00	1.00	8.	3.00	5 1 1 1 1 1 1 1	00'.	2.90	8.8	8 8	3 5	3 6	8 8	9	2.00	5.00	3.00	6.00	8.	1.00	3.00	4.00	3.00	0.00	2.00	8.9	8	0.7	2.00
	20.14	6.73	19.96	7.68	5.45	6.70	6.04	5.46	33.66	15.02	6.20	5.78	11.54	5,39	6.51	17.96	8.47	8.12	8.0g	9.42	22.51	5.32	5.72	22.26	12.85	7.30	.5. 25.	5.66	5.72	7.95	57.5	27.49	9.72	. 15 20 10 10 10 10 10 10 10 10 10 10 10 10 10	(S. 2)	, . ;		9.67	7.92	5.78	16.37	7.45	27.15	11.69	5.49	8.81	8.65	6.36	10.90	6.80	87.98	10.45	7.	6.94
	197.97	858.30	914.31	583,30	18.00	346.25	296.34	28.00	130.14	78.40	91.74	408.97	262.62	153.65	96.09	636.95	83.67	31.84	47.80	367.80	151.19	28.30	366.28	183.05	118.85	399.64	1028.72	144.29	91.14	141.22	32.71	12/1.89	1/8.65	1453.55	150.27	200	43.44 146.40	384.90	256.88	49.78	207.32	65.64	356.01	285.25	67.84	104.95	370.44	389.12	83.96	18.25	223.42	205.86	284.91	47.00
	88.	127.45	45.80	73.34	3.30	51.70	49.03	4.76	3.87	27.52	14.81	70.98	22.78	28.48	9.36	35.47	8.80	3.82	7.89	39.06	6.72	5.32	63.99	7.32	90.6	7.12	185.57	25.47	15.94	17.78	5.71	46.27	37.24	203.37	105 70	200	1.84	40.21	32.42	8.61	12.86	8.81	13.11	23.89	12.35	11.91	42.80	60.69	5.87	2.68	2.54	19.71	38.27	6.77
	AA461108	R19406	N78558	N95656	R62339	W00899	T97257	N49224	AA454702	W81128	N34362	H69471	H79130	H74330	N45384	W69791	AA458882	W02258	AA155695	R00822	AA069596	AA427667	R22412	AA480851	AA425556	AA235332	AA458931	AA486275	N74383	AA056148	AA460827	AA459039	AA480906	AA250771	M56873	A 4 4 0 5 0 7	AA460330	AA464250	AA452866	AA448599	AA598817	R95740	AA410207	R54050	AA496804		H77772	R63342	N92048	R65963	N74882	R63782	K33780	R00332
	796198	130027	301678	293990	139558	296180	121420	280288	809694	347038	271038	212408	235008	230180	243989	344141	810809	286678	582243	123561	382787	770014	130541	810761	173301	687397	638568	842836	296198	360851	796268	8143/8	00000	724378	20/358	507540	70577	810131	788566	785975	897956	199180	754436	39808	897655	781362	214165	138592	293380	140057	298600	139331	136288	122982
	4550	4557	4558	4561	4562	4565	4566	4567	4571	4573	4579	4586	4590	4593	4605	4606	4807	4612	4626	4638	4642	4674	4694	4700	4708	4715	4716	4722	473	4734	4742	16/4	00,	10/4	4763	4754	4785	4782	4771	4772	4774	4778	4786	4795	4796	4798	4803	4806	4807	4808	4813	4816	4820	4821

Page 21 of 91

RR4408 45.31 RR2452 258.83 R03526 12.19 R84449 63.35 R03380 2.85 H81404 53.35 R03380 2.85 H81404 53.35 R03380 2.85 R34013 88.80 R34013 88.90 R34013 88.90 R34010 80.65 R34013 88.90 R3540 80.64 R3540 80.64 R3540 80.64 R3540 80.65 R3551
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Page 22 of 91

÷

	Other	UD not found		Other	Testis	Esophagus	Germ Cell	Adrenal gland	Spleen		Stomach	Muscle	Spleen	P80	Germ Call	Skin	Whole embryo	Colon		Skin	oPool	Lymph	Whole embryo	Thyroid	Tonsil	Heart		Heart	nCervix	Parathyroid	Cervix	Bone	Ovany	Pod	Parathyroid	Adipose	BIODO	roraskin	8 6	O Paris		Whole emboo	7000						Blood 110 pol found		Other	Parathyroid		- Ciner Heart
	LID not found Other	Brain		LID not found Other	Pancreas	neSkin	Synovial mem Germ Cell	m Blood	Ovary		Adipose	Breast	Lymph	Stomach	CNS	Ear	Heart	Head and nec Colon		c Placenta	Whole embryoPool	Ovary	Gern Cell	ignore	er Blood	Soleen		Foreskin	Synovial mem Cervix	CNS	Parathyroid	Muscle	Tonsa	Muscle	Breast	S Blood			LID oot family	In not found Other	Lib not found Other		300	TO SO found	TO not found Other	Table found Oller		10000	Larynx	SAPORA	LiD not found Other	Placerta Pool	3 :	Colon Head
	50.93 Pool	160.11 CNS	2	Heart	475.57 Kidney	408.29 Small IntestineSkin		404.41 Synovial mem Blood	27 Eye	246.83	671.23 Breast	35.88 Eye	153.69 Eye	24.07 Laryrix	193.03 Ear	529.52 Cervix	504.31 Placenta	254.9 Laryrix		Smooth musc Placenta	Spleen	301.16 Marrow		133.9 Epididymis	Periphenal ner Blood	151.92 Pooled		141.14 Perathyroid		567.39 Omentum	85.4 Ulerus	350.47 Cervix		494.74 Placenta		213.91 Smooth muse Blood			340.31 Eye	444.33 Broom		2 20		535.51 Fidualita	./* 016331 Dl	F00 607 47 Bool			123.91 Ellophagus			450.11 Uterus Kidney	χο. Ο	Pool
	15 50	3 160	~		7 475	16 408	3	17 404	-	12 248			5 153			10 629		20 25				9 301		22 13		14 151	9 417	13		2 587	×	5 350					200			2				9 0	ś	¥	3	ç	<u>;</u>	,	2 212	g g		
(4 ) (a)	0.00	0.0	0.0	2.00	0.00	8.	8.0	1.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.0	2.00	0.0	9.1	0.00	1.0	<b>5</b> .	0.00	000	0.00	000	000	0.00	0.0	0.0	0.0	0.00	9. 9. 9.	8.0	o. 8	8	8.5	3 5	8 5	3 6	3 6	9.00	9 6	8 8	3 8	8 6	8 6	} ?	3 6	9 6	8. 60 60 60 60 60 60 60 60 60 60 60 60 60 6	9 6	3 6	8 6
3	1.00	1.00	4.00	0.00	9.00	8.00	5.00	8.9	2.00	6.9	2.00	1.00	8.	2.00	9.1	4.00	000	6.00	9.00	8.00	000	8.6	2.00	1.00	2.00	1.00	8	8.8	8	8.	1.00	2.00	2.00	4.00	1.8	8	8.6	9 6	900	8 6	8.8	3 5	8 6	8 8	3 6	9 6	8 5	3	3 8	3 3	8 8	8 5	3 6	8 8
	7.74	5.07	7.7	9,15	24.25	23.00	6.43	19.85	22.75	12.12	6.37	5.25	14.99	18.20	10.09	21.58	23.94	19.47	16.20	16.24	5.46	114.81	9.85	7.10	5.66	5.50	7.22	11.78	7.58	5.27	5.30	8.70	10.34	8.54	5.71	13.67	6.07	200	7.67	00.0	8 9	0 C	9.6	7.30	7.45	4.0	10.0	2.4	60.7	2.83	20.12	7.82	0.0	3.52
	æ.æ	11.77	539.39	21.23	79.35	586.14	268.53	2893.05	75.85	95.88	195.58	107.67	73.61	63.27	234.52	90.82	330.56	156.62	118.02	90.47	44.17	301.01	31.08	238.64	20.52	38.09	952.94	3218.30	280.94	97.87	309.18	1317.86	220.91	51.98	35.89	14.57	55.80	136.01	93.74	67.71	20.00	47.6	200	97.00	47.071	21.04	206.32	3 t	40.69	90.81	198.27	28.85	7.007	73.07
	4.45	2.32	69.70	2.32	3.27	25.48	41.35	145.78	3.33	7.91	30.70	20.53	4.91	3.48	23.25	4.21	13.81	7.99	7.18	5.57	8.09	2.62	3.12	33.32	3.62	6.93	131.96	273.12	2.8	18.58	58.37	151,56	21.38	60.9	6.29	1.07	9. 70 5. 50	5.03	12.17	- F - F	- 9	., r 5 6	3 6	53.80 13.53	8	4.01	9 4 6		- 2.0	9	9.85	. <u>.</u>	9.5	13.24
	H59670	N52350	H56033	AA063574	AA455911	H97778	H06113	AA478436	W76376	H24688	AA486471	W58658	N64882	AA417654	W01011	AA456160	T98152	AA430504	AA497051	AA453816	H65526	AA598572	AA451891	T49539	AA480859	AA011320	H79888	T64625	AA453105	R99423	AA151486	AA486524	AA455062	N53177	AA489714	AA489017	N59542	NSAZBO NSASS	80512N	87011V	Te 4860	D2206E	2000	207.00	080774	5/800A/3	Te0719	00.70	K81904	KK308	H84244	K31831	194965	R91557
	207293	284479	203551	360029	813256	251019	44255	741087	345586	160838	811162	341248	293325	752631	296529	809464	121722	769921	823590	813757	210317	897822	786872	67654	814546	359781	233365	80500	789091	201986	503097	843133	812266	246789	624393	824922	248649	244684	494697	105.021	00000	44046	200	190001	107701	7,6907	176801	00000	500981	131388	210822	134948	20/111	196522
	1981	1984	4985	4988	9	966	2005	200	5	5015	5016	020	220	3024	503	5032	5048	5051	570	5080	5084	5089	2030	5093	960	5097	5108	5111	5118	5124	5125	5130	5131	5138	5139	5147	6164	9/16	20.5	7010	8 8	200		200	3136	200	2000	3070	5202	2	2208	5213	5214	5216

age 23 of 91

Table 2A

.;

	٠	,	
	4	¢	
	•		
		¢	
	•		
	1	١	į
		ı	
		ė	
		ì	į
	1	3	ı

		Hear	Coton	Olher	Other	Other		<u> </u>	rica d	Toetie	Exis	I D not found	Pool	i i	2 de 10	Char	o page			Dancease	Tankeas 10 ag fama	2000 Marie	Boos	Dool	3 6	Misch	Pool			Bone	Whole embryo	UD not found	Other	Other	Heart	Heart	Whole embryoLID not found	Pool	Placenta	Case	CNS	Kidae	Heat	LID not found	Heart	UD not found	Whole embryo	Blood		Kidney	Synovial membrane	Pancreas ⁻	
1				LID not found (	LID not found (	LID not found (			Chapta		2 2			7		Total	4	Cmall intesting	I D and found Other	Don't de			dder		Dancrase	SECOND I		ncell Breis	5	Ear	Brain	8	LID not found Other	LID not found Other	Kidney	Ear			Foreskin	CD not round Other	Formelin	rulesulli ProSploon	Blood	Pool	Color	Pod	ordCNS	Placenta		Colon	ow Neural	use CNS	
	Z50.6 Pracenta	66.29 Adipose	484.53 Kidney	Pool		322.57 Pool		131.70 7001	Design of	Poorte	457.51 PURGES	Discenta	588 48 Anda		5 6	00.0	Š	1001	124 OB Popl	24.00 Look	14.04 Cervix	247 Contact	346.4 DIBIR	33.14 CM	M0508	Too!	18101	A4COS CNC	35.65	140 47 Mouth	107 Acrta		Pool	413.5 Pool	53.56 Neural	86.88 Placenta	403.14 Pod	450.31 Parathyroid	Blood	8 3	10.07 rock	SES 16 Manual combane Colors	Dans Oran	5 5	300.43 Foreskin	84.78 CNS	14.64 Umbilical cord	338.92 Pooled	318.41	115.72 Blood	582.84 Bone marrow Neural	557.85 Smooth muse CNS	
,	<u> </u>	₽ :	12			11	:	2		;	2 5	2	-						n <b>;</b>	- "	n	9	2 ;	2	•	•	r	٠ ،	7	^	. 55	1		7	6	×	•	5		1	9 9	Þ.	2		~	2	<b>.</b>	11	7	^	-	-	
•	000	8 :	3.00	3.8	0.0	3.8	0.0	8 6	8.8	8.8	8.6	8 8	8 5	3 5	9.0	9.00	8.5	20.5	9.6	3 6	9.5	8 8	8.8	8.5	8.6	8 8	8.8	9.5	3 6	8 6	00 0	00.0	5.00	0.00	0.00	0.00	8.0	5.00	8	0.00	8.	3 8	3 8	8 8	8	8	80	0.00	000	000	0.00	0.00	1.00
	8.8	9.	6.00	3.00	<b>4</b> .00	1.00	8	9 9	9. 2	9.00	8 8	3 5	3 8	3 5	3 8	9.00	8 9	50.6	9 6	3.6	8.8	3 8	9.0	2.00	8.6	3 5	8.5	8 8	3 5	3 5	9 5	8 8	9	00.	9.1	6.0	8.	2.00	8.0	2.00	8.8	8 8	8 8	3 8	8 0	000	8	2.00	4.00	9.	9.	1.00	0.0
	5.5 <b>4</b>	39.13	14.45	6.85	6.59	291.89	6.90	5.03	10.82	7.07	9	9.10	0.4	0.00	9.32	16.30	6.93	80 G	583	16.47	6 6 6 6	0.64	6.13	6.26	21.90	3.72	3, 3	16.89	er o	07:5	15.47	60.38	6.41	5.20	5.97	19.45	5.88	5.79	5.17	5.85	9 6	5.63	8.80	13.50	2 2	6.71	6.00	29.13	6.15	9.61	5.74	10.98	7.49
	1040.36	413.19	486.27	73.24	455.30	2019.02	29.98	18.88	308.99	58.16	581.16	20.21	35.33	84.TOL	283.75	752.28	133.41	775.83	1357.48	20.000	40.16	20.28	02.212	105.73	571.38	23.50	99.10	215.41	18.61	15.00	19 of	88.66	184.18	249.31	50.96	75.90	280.39	1077.98	61.49	117.13	216.51	25.03	276.82	45.0	68.37	177 29	55.98	36.62	36.04	32.94	672.25	158.57	311.01
	187.72	10.58	33.68	10.69	8.8	6.92	¥.3	3.75	28.55	9.71	70.95	8.73 3.73	51.6	16.26	30.46	46.14	19.07	65.35	228.73	R.	7.49	3.5	2.51	16.89	26.02	4.09	20.0	12.75	3.17	9.00	, c	2.4	28.74	47.92	8.53	3.90	47.71	186.09	11.90	20.02	37.37	4.ZB	31.68	3.12	3.5	28.48	8.33	1.26	5.86	3.43	117.19	14.47	41.53
	N52408	W76603	H53693	T97616	H36088	H66312	R97050	N99519	H37846	R26094	N75669	K92032	K33041	H80358	H14894	R92285	R21785	R19183	AA025807	78778H	AA427732	H73606	AA485365	R26929	H77714	AA040269	H72932	N26802	N48375	HB2532	14/58347	HTONAG	T83394	NABBBB	R66945	AA004664	N99803	N49895	R22262	N74059	186603	AA126825	R07594	A4485663	AACAKOK7	B82163	AAABABOS	H02340	T67549	AA497085	AA453831	H09914	AA453728
	246143	345670	202740	121661	203772	210873	201562	294968	191508	132159	244154	195314	136218	239682	129567	185820	130371	129922	366389	195621	770838	232055	811010	133236	233446	376058	213871	257011	280388	720077	15581	222710	111070	879272	140635	428773	294150	243656	130835	296749	115223	202062	125685	811128	376883	106487	812975	150702	66982	897497	813673	46697	813841
	27.72	5227	5228	5230	5232	5233	5244	5248	5252	2222	5262	5264	6026	2266	5287	5272	5273	5275	2277	2280	5288	2284	2296	\$298	2302	2308	2308	5310	5317	53.19	2228	9250	6118	241	5342	534	5345	5348	5350	5353	5354	2360	5366	5387	25.5	27.5	5383	A384	5390	5392	5395	5396	<b>\$4</b> 08

						p _i o								bryo			<b>-</b>				ord vein																	o.c.		2	<u>!</u>							2	oku					
		Color	200	P 20	1 Thyroid	Umbilical cord	Blood	Kidney	Slomach	Thyroid	Brain	Brain	Breast	Whole embryo	Testis	Spleen	Parathyroid	CNS	Calon	Blood	Umbilical cord vein	Gem Cell	Musde	CNS	CNS	Ear P	Stomach	Blood	Prostate	Ulerus	Blood		Breast		Lymph	Stomach	Pancreas	vinose embryo	Other	110 and found	Prostate	CNS	O Sec	Foreskin	Tonsil	Thymus	Other	UD not found			Kidney	Heart	Pooled	Pool
	<b>8</b>	_		Kidney	ec Umbilical con	Skin	Foreskin	Liver	Adipose	_		CNS	Germ Cell	Breast	Eye	Umbilical cord Spleen		Kidney	Lymph	Cervix	Muscle	Breast	Brain	Tonsil	Brain	Stomach	Small intestineBone marrow	Lymph	Liver	Heart	Ovary		Foreskin	Heart	Parathyroid	ec Thymus	Solo	e Lion	LID not found Other	Pool	Whole embryoProstete	Eye	Torsi	Parathyroid	Muscle	neEar	LID not found Other	Brain	rd Prostate	LID not found	Placenta	Breast	Germ Ced	Brain
	Liver		87 RS Neural	462.18 Lymph	366.4 Head and nec Umbijical cond Thyroid	345.1 Adipose	57.43 Thyroid	333.71 Adipose	309.46 Skin	237.93 Trachea	248.73 Adrenal gland	-7.15 Adipose	118.53 Jgnore	117.94 Pooled	150.71 Brain	100.33 Thyroid	697.15 Smooth musc	419.76 Bone	280.44 Larynx		727.92 Omentum	Tonsil	Blood	59.86	46.69 Eye	471.03 Ovary	250.6 Small intesti	340.59 Thymus	Kichey	Pancreas	353.84 Thymus	347.86	270.03 Ear	73.6 Muscle	221.18 Blood	195.03 Head and m	238.39 P0000	142 59	421.71 Pool	740.99 Liver	601.45 Placonta	184.61 Thyroid	19.44 CNS	384.33 Pancreas	260.03 Ear	Small intestineEar	391.73 Pool	629.01 CNS	361.74 Umbilical cord Prostate		•	261.25 Placenta	371.25 Blood	Ovary
		2	; 5	5 9	က	17	20	50	17	F	51	က	80	9	ဖ	60	-	•	တ		<b>-</b>			12	11	16	2	-			8	₽	8	<b>:</b> :	= 8	8 ;	= >	٠,	. 6	-	7	4	7	•	Ξ		νo	9	9	01		=	-	
Table 2A	0.00	900	000	9.1	000	00:0	8	8	8.8	0.00	0.00	8.	9.	0.00	00.0	8	0.00	1.00	9	00.0	0.00	8.	8.0	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	1.00	0.0	2.00	0.00	8 6	8.6	8 8	0.00	0.00	0.00	1.00	0.0	3.00	0.0	8.0	2.00	0.00	0.00	3.00	00.0	0.00	0.00	0.00
Tab	2.00	9	100	00.0	1.00	3.00	9.	900	5.00	8.00	8	8	000	8	8	80	2.00	8	8	8	2.00	8	8	1.0 0.1	2.00	5.00	8	8.	8	1.00	8:0	0.00	6.0	0.0	8 8	3 8	3 5	900	1.00	8.9	1.00	0.00	3.80	9.	2.00	9.	8.8	9.	4.00	3.00	6.00	3.8	8	5.0
	8.50	12.11	13.87	6.07	5.78	7.67	7.63	14.11	10.21	8.78	6.23	7.12	5.66	5.57	5.27	6.99	6.80	5.77	8.33	9.79	7.76	27.35	10.98	14.88	5.84	11.79	5.98	10.51	28.27	5.58	12.93	6.37	5.32	3.60	0. A	5 c	3.20 6.75	7.35	5.65	11.10	5.23	5.35	1.4	7.86	8.23	6.04	11.69	5.51	6.35	6.76	10.28	8.54	5.10	7.93
	20.42	381,99	414.75	32.79	739.00	52.68	39.43	29.83	57.99	137.58	16.41	87.57	230.95	11.67	4.60	67.53	14.74	3.1	315.88	59.83	292.78	111.12	57.32	50.52	614.30	815.43	1373.76	48.76	77.76	10.03	58.09	182.95	302.27	325.27	40.24	120 54	20.00	49.29	13.82	61.58	60.78	72.53	181.17	233.68	66.55	492.14	215.95	37.14	245.26	53.74	122.49	729.64	72.90	17.82
	2.40	31.54	29.90	5.40	127.85	6.87	5.17	2.11	5.58	15.68	2.83	12.29	75.10	2.10	0.87	90.0	SA'D	7	37.0	6.11	37.73	90.4	5.22	3.39	105.24	69.15	229.90	4.64	2.75	1.80	4.49	74.72	56.78	3 75	2 62	7.83 7.83	2002	6.70	2.45	5.55	11.61	13.57	15.84	29.72	8 8 8 9	81.49	18.48	6.74	38.59	7.95	11.93	65.42	14.30 5.30	522
	H70473	AA459197	N91890	H57180	H71868	R41839	H22563	AA405/69	1909/N	H02158	H48839	K40400	VO/323	A45533	H165/3	AA453410	ואווצא	HZ318/	845867/B	AA485983	AA026609	AA463693	AA461506	AA278883	H14841	AA48478	H75547	AA132080	H62162	AA026112	A4459566	40.4300	AA44/098	MO1385	AA504817	A4478543	N59718	T97889	R02718	R99311	R35253	R02820	177847	N68497	R10015	N77205	198075	174714	N45244	R68994	T98615	K36161	NSOGBI	R05837
	212849	810873	293104	204897	211780	31842	51916	745062	981847	150623	153008	2/18/	20000	788387	49,00	60100	01440	50000	200000	\$5055	Trease	70000	785827	704459	48799	782513	232873	504228	208413	469281	914320	79197	818497	306013	825583	785283	248703	121981	124091	201264	138775	124079	108422	294040	128785	245428	121736	22711	243617	140334	122178	130001	86/292	124822
	<b>\$408</b>	2	5428	<b>8</b>	2440	5443	9446	X :	2	3 3	200	2460		2 5	247	200	200	808	5	0000	AOCC V		9216	5524	5533	2230	<b>X</b>	5540	2222	250	0000	000	7000	556.4 556.4	5567	888	5570	5578	5583	5590	2236	5598	2805	5610	5815	5617	5619	2829	2630	5632	8	2044	2040	2

Page 25 of 91

<b>B</b> rain	400.33 Ear	=	0.00	18.00	26.18	240.93	8.20	AA424516	767069
InerCNS	576.3 Periphera	-	0.00	9.00	18.02	119.62	7.47	H20872	51447
bryoPool	71.09 Whole em	6	0.00	3.00	7.87	105.49	13.41	H15634	45509
	Ear		0.00	3.00	80°8	15.26	1.89	AA100296	511066
Smoot	116.56 Marrow Smooth	φ	1.90	1.00	11.95	13.72	1.15	AA480815	810724
	•								

Page 26 of 91

	Prostate	Other		Other	Other	Other	Other	Whole embryo	Other	Gra	Placente	Olher	je je	Foreskin	Ciner	Other	Of her	CID not found	ğ g	- - -		Breast	Other	Other		Blood	Placenta	Brain	Uterus	Other	Other		00 1		P00			i di	Contract	Other	Parathyroid	Parathyroid	Tests	Head and neck	LID not found	LID not found		Muscle	Ovary	: Larynx	1 Tonsil	Kidney	Blood	
	Placenta	UD not found Other		LID not found (	UD not found	LID not found	LID not found Other	Aorta	LID not found Other	CID not found Uther	CNS	LID not found Other		Gall bladder	CID not found	LID not found Other	LID not found Other		LID not found Other	Placenta		Sary	LID not found	LID not found Other				Eye	Germ Cell	UD not found	LID not found	LID not found	Aorta	LID not found	Tonsi		LID not found	tio not found	CO no lour	LID not found	Uterus	Small intestineGall bladder	CNS	Nose	Lung	Brain		Prostale	Skin	Smooth musc Larynx	Umbilical cord Tonsil	yoPool	erCNS	erain
	46.9 Blood	Pool	284.08		243 Pool	8	•	384.54 Tonsil	236.72 Pool	544.88 Pool	345.68 Eye		8		220.59 Pool		506.5 Breast	Adrenal gland	P8	35.68 Pooled		227.6 Parathyroid	Pad	Pool	673.59				453.05 Placenta	- S	8		64.01 Placenta	P00			66.06 P001	8 3	POOL OF POOL		1	238.33 Small intest			70.89 Prostate	frag	108.91	Bload	412.17 Thyroid	116.56 Marrow	Ea.	71.09 Whole embryoPool	576.3 Peripheral nerCNS	400.33 Ear
	က		19 2		15			<b>6</b>			2 ;			,	15		~		,	<del>1</del> 9	-	=			4	=	<b>5</b>	vo ·	<b>.</b>			•	_		;	6	~		;	=		×	12		Ø		8		'n	φ		<del>1</del> 9	- ;	F
ζ	00:0	1.00	1.00	0.00	0.00	3.00	2.00	1.8	0.00	000	000	8	000	2.00	5.00	0.00	1.00	000	1.00	0.00	0.00	9.	2.00	8.0	0.00	4.00	0.00	0.00	8.0	9.	0.00	8	8:	0.00		1.80	8 8	8.9	3.5	8 6	200	000	000	4.00	0.0	0.00	1.00	0.00	3.00	1.00	0.00	0.00	000	20.0
ania	8.	8.	8	1.00	3.00	2.00	4.00	2.00	8.00	6.00	90	5.00	2.00	2.00	2.00	2.00	1.00	8	5.00	2.00	2.00	0 0 0	6.00	8.	8.	6.00	8	8	9.	8.	8	2.00	8	8.9	6.00	0.1	8 8	8.8	3.8	8 8	2	100	1.00	8.00	1.00	1.00	1.00	1.00	10.00	1.00	3.00	3.00	6.00	999
	5.45	6.62	7.46	5.62	7.64	9.04	13.82	6.47	12.55	8.74	16.80	6.36	7.56	18.46	17.83	6.49	1.26	6.34	6.30	6.52	7.13	5.46	15.08	9.9	36.70	6.95	5.71	5.88	5.47	6.70	5.75	6.58	99.9	6.80	10.29	16.97	6.81	6.14	6.82	80.0 F. 80.	7.33	5.51	14.73	28.72	6.32	8.17	5.91	5.78	19.68	11.95	8.08	7.87	16.02	26.18
	17.67	77.84	62.36	42.69	131.41	98.74	685.43	50.67	44.23	132.58	61.83	282.25	145.45	97.00	180.28	626.99	58.47	471.73	202.68	12.53	22.83	82.07	206.53	507.63	385.12	174.78	19.20	12.37	32.43	862.04	64.31	436.73	99.87	44.63	527.18	12.86	20.28	12.75	16.03	162.03	80.08	139.90	63.77	303.63	12924.63	89.80	203.01	39.24	288.69	13.72	15.26	105.49	119.62	240.83
	3.24	11.75	8.36	7.60	17.21	10.93	49.61	7.83	3.52	15,17	3.68	<b>1</b> .8	19.24	5.53	10.11	101.25	5.01	74.43	32.18	1.92	3.51	15,02	13.71	73.17	10.49	29.39	3.36	2.11	5.83	128.72	11.19	86.30	14.89	9. 9.	51.22	0.78	2.93	9 6	7 S	2.5	78.10	25.40	4.33	10.58	2048.09	10.99	34.32	6.79	14.67	1.15	1.89	13.41	7.47	8.20
	T98098	R08301	R68634	H48445	H48467	N71585	H80317	R36006	W01645	H50491	R68272	W02401	H60523	N35301	R99386	W02591	H23963	H60688	R99682	R78580	R24258	AA464202	R99690	W00793	N51521	H65052	T60848	AA013240	R32406	H69576	R99938	W01026	H78097	H61684	W04152	AA460168	H75690	189674	H48318	N/6193	700071	R40784	R39484	AA458684	N91584	H08936	T96783	H46663	AA405891	AA480815	AA100296	H15834	H20872	AAA24516
	121776	127636	138496	200545	200604	295044	207881	137139	295106	207668	138444	285580	207952	271952	201229	296094	159725	208984	201314	144880	131239	810403	201317	286559	281476	210548	109314	360075	135688	213118	201784	298802	240430	208940	295918	795893	211351	122787	201618	766407	223846	28012	23932	810813	303048	46356	122274	157771	742101	810724	511066	48209	51447	767069
	\$653	2857	2680	5685	5673	5674	5677	5678	2882	5688	5887	2630	<b>2693</b>	<b>2636</b>	2897	2638	5703	5709	5713	5715	5719	5720	5721	5722	5724	5725	5726	<b>\$728</b>	5731	5733	6737	5738	5739	6741	5747	5748	5749	5750	5753	5757	220	5783	5787	5788	5790	5791	5784	5796	2804	5812	9820	5824	5826	2827

Table 2A

- ;

·į

	Pool	Adimse	Rein	Cervic	Thyroid	Foreskin	d Esophagus	Eye	Breast	Lymph	Cervix	Other	Bone		Germ Cell	Foreskin	Lymph	Неал	Umbilical cord		Blood	Other	Thyroid	Ovary	LID not found	Pool	LID not found	Pool	Whole embryo			Other	Other	Torsi	Heart	Torrail	Pancreas	Other	Pool	Stomach	Other			Other	;	Parathyroid	Uterus	Coton		Other	oPerathyroid	Other	Eye	Whole embryo	
	oAorta.	Skin	dEva	Eve	Tonsil	Aorta	Umbilical cord Esophagus	Smooth musc Gall bladder	Kidney	Thyroid	Nose	LID not found	Pancreas		Tonsil	Pooled	Foreskin	<u>8</u>	Gall bladder		Tonsil	LID not found	ePooted	Lung	<u>8</u>	Placenta	<u>8</u>	Uterus	Heart	LID not found		LID not found Other	LID not found	Pooled	Perathyroid	Colon	CNS	UD not found	Еув	Thyroid	LID not found Other			LID not found Other		Eye	Prostate	Tonsi		LID not found Other	Whole embryoPerathyroid	LID not found Other	Brain	Aorta	
	320.28 Whote embryoAorta	118 71 Thymus	457.01 Adrenal cland Eve	252.33 Placenta	701.95 Kidney	311.24	384.44	382.93 Smooth mus	119.23 Perethyroid	239.99 Skin	132.5 Stomach	Pool	351,05 Blood		223,55 Neural	51.16 Larynx	138.23 CNS	345.1 Placenta	601.35 Nose		257.7 Lymph node	292.92 Cervix	114.61 Small intestinePooted	CNS	Breast	Pooled	Brain	Testis	545.1 Foreskin	Pod		338.83 Placenta	508.28 Pool	243.99 Placenta	Eye	592.98 Dvary	Placenta		536.56 Liver	470.33 Muscle	8	430.63	27	85.38 Pool	247	144.63 Gall bladder	104.03 Lymph node	<u>8</u>		463.92 Pool	Spleen	678.51 Pool	477.99 Pool	CNS	
	17	. 6	4	7	<u>ج</u>	12			22	19	9		ਲ ×		7			17			=	-	22 1						7			5 %	10			-			10	4		eo -			₩ ;		¥			⊕ *¥			8		
Table 2A	8	0	000	1.00	0.0	9.	0.00	0.0	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	8	8.	0.00	0.00	0.00	80	8	0.0	8.	8.	0.0	00.0	\$.00 \$	5.00	0.00	8	8	0.00	0.00	000	00.00	0.00	0.00	000	0.00	000	000	0.00	9 9	5 6	5.00	00.00	0.00	0.00	0.00	3.00	0.00	<b>0</b>	3.00
Tabl	8	909	00.1	000	6.00	0.00	2.00	- 0. 1.00	1.0	1.00	<del>.</del> 8	8	8.	3.00	3.8	5.00	9.	0.0 0.0	8.	2.00	1.00	8	0.0	5.00	3.00	1.00	6.00	2.00	6.00	9.	3.00	2.00	4.00	5.00	6.00	1.00	806	3.00	5.00	8.8	00.	2.00	9.00	9.5	8.8	3 8	8 8	500	8	2.00	9.	8	1.00	0.0	0.00
	30.25	8.16	5.14	13.44	8.43	6.70	8.70	2.06	s S	7.31	5.07	5.25	5.27	5.32	15.41	5.95	5.31	5.94	8.42	5.74	6.43	7.57	6.75	20.67	7.27	5.41	12.55	6.35	18.12	8.57	9.62	6.70	19.06	8.10	9.68	5.94	17.99	9.40	6.18	10.98	6/2	6.42	40.	8.60	10.25	3 6	9.40	12.82	13.61	10.50	5.01	8.30	9.37	90.9	7.36
	151.45	297.75	39.39	10.38	73.88	259.23	5862.61	303.58	232.69	28.18	41.31	8.88	222.37	167.01	135.51	144.22	40.03	35.89	459.40	1241.33	58.83	999.77	123.46	71.40	507.82	33.31	3	481.07	253.22	201.82	157.40	25.27	258.46	542.83	233.28	16.92	86.83	1124.58	79.88	1332.25	187.20	121.28	325.85	136.54	1073.86	240.34	6.0.2	53.48	756.70	32.78	25.73	41.59	34.93	37.08	82.07
	5.0	36.49	7.67	0.77	8.76	38.68	673.78	60.04	46.12	3.85	8.15	1.69	42.16	31.42	6.79	24.28	7.54	6.04	54.57	216.08	9.15	132.07	18.29	3.45	69.82	6.16	7.53	75.77	13.98	30.71	16.35	3.77	13.56	66.99	24.08	2.85	4.83	119.58	12.93	121.53	5	18.90	30.44	16.11	104.75	<u>}</u>	77.77	4.17	22:73	3.12	4	5.01	3.73	7.33	11.15
	AA426311	AA458472	175436	R35665	AA598652	AA258396	AA486305	AA048411	AA010609	AA481277	AA521346	H65280	AA459380	R08755	AA521243	AA292995	H14804	R82485	A4486367	AA608548	AA481547	R89083	H57830	AA458533	181281	R25980	H36148	H50871	R92310	199881	H94163	R23952	N54407	R31154	R92347	R82435	R74357	K92545	H52534	K92455	N39323	164956	12121	K16431	X83017	Nagora Postoria	/2600M	101081	10100	H63223	164861	H94236	H76863	N64671	H94934
	769028	809598	23173	137017	897906	667883	842784	380057	430318	815239	826135	209518	610942	127408	827144	725503	49117	196444	840691	850607	815294	195753	205445	811600	109271	132630	191518	184351	195853	122889	242700	131448	244781	134235	196125	186303	143322	198350	202209	196345	243770	66813	15051	129342	196185	243784	49704	120097	293083	0/6807	7000	242070	233316	290054	230247
	5831	5839	5847	5856	5857	5859	5861	2866	5877	5878	5683	288	5891	2685	2901	36	2908	5911	5913	5921	5923	5927	2834	5942	5954	2965	5964	2962	2868	5970	5972	5975	5976	5983	5984	0009	6007	909	6014	9109	2 2	200	270	/700	8779	200	700	200	6000	2 5	1500	8038	6039	9	6042

age 27 of 91

11 277.15 Blood 6 503.11 Place	
0 0 0 0 0	
5.00 5.00	
6.17 10.00	
153.48	
1.46	
467839 AA004415	

Page 28 of 91

	Whole embryo	Brain	Lung		Kidney			Poloco	rocied Conit	CONIX	UD not found	Prostate		Other	Whole embryo	Odber	Other	Tonsi	Other	Teslis	LID not found	Cervix	LID not found	LID not found	LID not found		Other	Ear	Breast	Overy	Office	Certain Certain	LID not found	Other	Skin	Tonsil	Other	Brain	Other	1 Other		Lung	Placente	UD not found	Pooled	LID not found	Otner		Brain		Naney	, see	Prostate
	Foreskin	Ovary	Heart		Breast			Clamach	Someon	Esobusdus		: Pooled		LiD not found Other	Breast	LID not found Other	LID not found Other	Uterus	LID not found Other	Germ Cell	Pool	Uterus	Pool	Pool	Ovary		LID not found Other	Bone	Kidney	Stomach	Liturion tound Cirrer	Coard Certification Characteristics		110 not found Other	Ear	Thyroid	LID not found Other	Pool	LID not found Other	LID not found Other		Testis	Eye	Foreskin	Parathyroid	Heart	UD not found Other		Hear	LID not round	200	Forestin	Parathyroid
	268.06 Gall bladder	406.09 Parathyroid	425.84 Placenta		CNS	134.37		10.201	AOTIB	Loreston		215.71 Smooth musc	243.11	94.41 Foreskin	354.55 Thymus	Ovary	558.69 Pool	275.71 Ovary	Pool	Prostate	Foreskin	64.16 Germ Cell	Pancreas	Prostate	gun)	28.08	271.02 Pool	Adipose	Larynx	377.24 Thyroid	8	Flacenta	3 8	243 19 Pool	252.77 Liver	Pooled	<u>8</u>	260.52 Foreskin	53.22 Pool	260.52 Placenta	150.31	Piacenta	Foreskin	N080	357.99 Nose	415.54 Foreskin	Foreskin	383 60 6	242.02 CNS	P801	99.65 Placenta	24.00 Rightow	503.11 Placenta
	768	406	426			Š	į	ě				71	24	<b>み</b>	35		35	27				Φ																58	~	*	=										_ a	· ·	- 10
	=	1	=			12	,	2				<b>~</b> :	₹ <u>.</u>	7	7		7	×				9				-	19			<b>.</b>				,	. a	•		7	12	7	•					2		•	12	•			
3 ZA	0.00	0.0	9.	5.00	0.00	1.00	0.00	8 8	8.6	000	8	8	8	0.0	8.0	8.0	8.	8.	3.00	0.00	0.00	0.00	0.00	8.	60.4	0.0	0.00	0.0	8.	0.	00 0	0.0	9 6	9 5	9 6	000	00.0	0.00	0.00	0.00	5.00	2.00	3.00	8.	8	1.00	0.00	8.8	0.0	0.00	3 6	3 6	800
Table 2A	2.00	1.00	0.00	8.00	2.00	8.	3.00	3.9	2.00	3.00	0.00	0.00	8	5.0	200	4.00	8.4	9. 0.	2.00	3.00	8.	8.	3.00	0.00	7.00	2.00	2.00	1.00	1.00	1.00	3.00	0.0	9 6	8 8	8 5	8 8	8	8	2.00	1.00	5.00	8.0	2.00	7.80	16.00	8	3.00	8.6	2.00	9:0	9.5	3 6	3 68
	6.19	7.19	5.18	22.30	6.40	5.95	S. 83	6.28	S. 3	11.42	5.51	14.43	6.96	5.77	10.63	10.97	9.10	5.43	7.38	9.76	5.77	6.07	18.57	5,15	8.38	8.55	5.68	7.36	17.86	6.93	8.67	æ.	/R.0	7 44		9.51	8.02	12.17	18.17	9.87	7.36	7.87	9.00	7.98	19.4	6.05	9.52	6.03	15.45	5.05	15.22	ų. a	10.00
	23.26	15.80	12.87	1326.43	58.31	92.37	15.53	494.97	1072.03	82.05	15.83	45.78	977.85	106.59	844.48	48.88	321.13	420.72	118.61	44.76	64.46	37,53	91.61	33.87	39.05	843.44	423.77	30.64	218.85	838.42	67.75	29.32	247.28	45.67	37.27	54159	96.41	38.73	42.87	33.60	55.44	43.00	1362.44	90.12	60.77	60.79	70.52	15.47	57.93	14.62	45.29	46.50	153.40
	276	2.20	2.48	59.47	9.11	15.54	2.64	78.79	202.10	8.06	2.87	3.17	140.53	18.46	60.64	4.46	35.31	77.49	16.11	4.58	11.16	6.18	5.53	6.58	4.65	98.69	74.60	4.16	12.25	120.65	10.16	4.82	27.36	6.38	<u>5</u> 8	8.0	1.87	3.02	2.38	3.40	3.	5.46	151.34	11.29	3. 13	9.40	7.41	55 138 138	3.75	2.89	2 38	2 2	1.46
	H55968	W02483	R25114	N49231	N49774	AA431972	H79813	197590	N95217	H93393	W86660	N52254	H55784	N23753	H25846	AA464517	N52535	AA031770	H80336	AA448484	W90001	N73555	W86466	N72384	AA427978	H77506	H80724	AA046424	AA434390	AA464739	R16656	AA427521	N73227	K89381	17623	M69628	NS3167	W80749	N52978	R31218	T67223	R26396	R67903	N21592	W38022	AA046112	N35892	R26456	W93682	197650	W93847	AA431/21	AA004415
	203514	285741	131824	280122	282404	782203	240138	121611	307314	241847	416856	284341	203474	268000	161988	810203	244722	470648	241097	782537	417305	295992	416611	245062	77 1023	233299	241507	488202	770868	810609	129618	771058	246478	1953/0	230303	212638	246766	418289	244201	134312	96856	132217	140267	266161	322223	376843	272548	133192	357285	121649	357396	782233	428431
	6043	6044	6047	6048	8052	8035	8057	6058	6083	909	6067	6909	6071	6075	6079	6083	6085	808	6809	6092	6095	6097	6609	6101	818	6110	6113	6115	6116	6119	6122	6124	6125	6127	21.0	05.50	2 5	8136	6137	6138	6140	6143	6144	6148	6156	6160	6168	6171	6191	6194	628	1129	6215 6219

6220 213850	H72368	20.72	218.92	10.56	0.00	<del>1</del> .00	=	131.77 Whole embryoOvary	nbryoOvary	Kidney
_	T90971	3.27	17.94	5.48	0.1	0.00				
•	N81017	2.89	24.88	8.31	5.00	00.0	5	400.44 Spleen	Tonsil	Foreskin
	H68542	23.67	137.85	5.82	8.1	0.0	~	743.9		
••	AA284287	2.86	17.03	5.98 	9.1	0.0		Heart	UD not found Other	nd Other
	N69908	44.42	830.09	18.68	3.00	0.00		Lung	Testis	LID not found
-	A4454710	4.39	33.40	7.61	2.00	0.00	<del>6</del>	68.86 Bone ma	Bone marrow Head and nec Placenta	ec Placenta
	AA009677	2.47	22.30	9.01	0.4	0.00	5	549.86		
59 154769	K55630	6.94	49.19	7.09	0.1	8.0	-	32.1		
	HOAATB	104.48	1043.38	B (6)	8.	8 8	;	10505	8	LID not found
	AA284307	11.58	84.71	9.00	8 9	8.6	₽ (	115.51 Heart	LID not found Other	d Other
080986	AA028686	27.63	139.08	5.03	8.5	000	<b>o</b> ;	417.73 Ear	Teo L	E
	RZDOCH	73.57	2457.62	13.5	90.5	90.0	2	84.71		
	909074	77.707	91.916.1	6.02	8 5	0.00	•	1	,	
871178	W02/53	4.38	40.08	25 T	8	0.00	-	165.69 Heart		LID not found
	AA284249	15.86	91.15	5.73	8:	8 9		Prostate		Kidney
	40000N	25.65	140.20	5.47	8 3	8 3		8	UD not found Other	יפקט פר
320495	W16659	3.54	34.61	8.83	00.0	0.0	,	Ear	Umbilical cord Aorta	ord Aorts
	164150	66.781	1297.51	6.80	2.00	3.00	2	714.07		
.,	W32303	11.36	57.93	5. 10	8	0.00	8	467.75		
	AA156030	13.06	70.29	5.38	1.8	00.0	'n	154.93 Head an	Head and nec Stomach	Umbilical cord
••	AA022949	4.71	164.27	34.90	2.8	3.00	ĸ	633.32 Lung		Ovary
	AA 151285	3.80	28.82	7.65	3.00	0.0		Germ Cell	_	Utarus
Ī	AA011347	11.40	61.38	5.39	8.1	1.00	2	94.72 Cervix	Umbilical cord Pooled	and Poorled
	W89170	4.	44.98	9.11	8.	0.00	7	110.66 Pooled	Hear	
	H86518	8.08	56.97	7.05	1.00	0.0		Eye	UD not found	other
_	AA128005	19.13	114.62	5.00	9.	0.00		Uterus	Lymph	Lung
24 207636	H59063	35.97	228.38	6.35	2.00	3.00				
	W74254	3.42	20.51	00 0	8	8		Lymph	Heart	
	AA038/09	<b>3</b>	32.31	7.45	90.0	8 8	:	Parathyroid	Did Blood	Uterus
	AA128362	23.BD	150.03	9 6 8 6	90.	0.00	9	394.98 Head an	Head and nec Uterus	Brain
	AA625915	2.38	17.53	7.36	00.	80		Adrenal	Adrenal gland Blood	Lye.
	AA112979	8.24	41.48	5.04	9:0	0.00	<b>4</b> :	280.52 Nose	Stomach	Lymph
	AA058323	478.17	3249.59	6.80	2.00	00.0	=	18.88 Nose	Skir	Adipase
6352 65384	171965	52.98	317.62	60.0	00.0	80.0	-	145.6 Thyroid	Liver	Adrenal gland
	AAG00685	3 4	300		2.00	8 6				ě
	A A 4 7 5 9 0 4	0.00 0.00 0.00	10,58	0.0	8 8	8 8	•	Teor Cent		5 6
	H61243	2 23	621.89	28.53	20.00	3 5	2 :	268 69 Smooth miss Soloss	Colon Soloon	a facility
	T61938	10.07	193.22	17.61	8 6	8 6	-	708 84 Adioosa	Condition	Daramanid
	AA54444B	7.62	75.32	5 6	90.5	900		93 22 Periotheral ner Rone	al per Bone	le Camer
	AA626787	×	47.69	5.72	00.1	000	•			
	AA291556	2.25	12.42	5.52	2.00	80		Marrow	Esophagus	
	R43605	2.94	40.75	13.86	8.	80	12	427.01 Liver	Brain	Testis
	AAB34464	9.24	58.62	6.35	1.00	0.00	e	156.88 Unblical cord	Umbilical cord Brain	Blood
	AA479691	23.06	118.87	5.15	0.00	1.00	7	357.89 Lymph n	esoN ebo	Gall bladder
	AA412064	6.23	34.41	5.52	1.00	0.00		Adrenal	Adrenal gland Heart	Lung
	T62552	6.67	131.55	19.71	9.00	0.00	11	475.65 Eye	Storrach	Breast
•	AA400186	10.93	58.95	5.36	1.00	0.0		Spleen	Tonsil	Ovary
_	T49238	15.29	78.34	5.12	1.00	0.00	4	427.9 Tonsil	Eye	Placenta
Ĭ	R52794	3.33	35.58	10.70	1.00	0.00	20	229.43 Muscle	CNS	Brain
19 252663	H88329	9.76	210.92	21.61	2.00	1.00	ထ	425.57 Ear	Kidney	Germ Cell
_	T49309	39.48	225.30	5.71	0.00	1.00	Ξ	276.98 Blood	Foreskin	Prostale
	162849	12.81	77.90	<b>8</b> 0.9	001	00.0	-	221.51 Saleen	Kidnou	Toosi
	******									3

Page 29 of 91

::

٠		•
€	1	þ
7	į	
¢		١
¢	۰	ı
1	į	þ
1	ĺ	l
C	١	Ī

Germ Cell		Ouner University	Umbilical cord		CLO not round	Admin's	Agrenal grand	LID not tound	ברים ברים	<b>P80</b>	Heart	Other	Adrenal gland	Thyroid	Eye	Muscle		Eye	O Per	Skin	Other	Brain	Other	Lung	Tonsil	Prostate		Bone	Colon		Testis	Other	Brain	- 700 -	Foreskin	Gall bladder	Messe				Other			Whole embryo	Parathyroid	Eye	Heart	Placenta	Colon	Parathyroid	LID not found .		n Blood
Aorta	Cerva	LID not tound	Stomaco	LID not found	8 1	00000	Stomach	Hear	Breast	Prostate	Ulens	LID not found	Lymph	Parathyrold	Blood	Bone		Adrenal gland	LID not found	Thyroid	LfD not found	Bone	LiD not found	Uterus	Foreskin		Ulens	Ear Bone	Smooth musc		Placenta	LID not found	Heart	Foreskin	Kdney	Adipose	600		rooi come cito not toure. Small imestine Thomas	200	LID not found	Skin		Heart	Blood	CNS	Muscle		ਲ	Tonsil	Pool		sc Synovial mer
240.08 Pancreas	194.42	19.4 Brain	347.25 EBr	223.28 Brain	419.22	SAC.13 Umbiscaro	96.5 Gall bladder	291.03 Brain	Brain	323.38 Breast	199.75 Parcress	644.77 Brain	121.59 Cervix	237.93 Trachea	387.03 CNS	674.5 Gall bladder	271.02	638.73 CNS	524.72 Brain	477.69 CNS	Foreskin	556.38 Ear	240.78 Brain	-6.83 Foreskin	317.39 Breast	840.65 CNS	Pooled	489.94 Mouth	86.18 Ignore	221.61	93.95 Breast	<b>8</b>	46.83 Tonsil	Parathyroid	274.89 -	575.4 Esophagus	77.44 Ovary	470.7 Gel Decue	117 94 Small imesti	77 77 Arteral cland Crary	204 36 Pool	118 71 Thymus		Bone	E,	650.68 Stomach	107.16 Omentum	Pooled		52.62 Placenta	Uterus		32.75 Smooth musc Synovial mem Blood
= :	× '	<b>3</b> 0 (	<b>m</b>	7	<b>→</b> (	s i	<u>,</u>	2		S	n	so.	ю	=	60	-	61	-	9	9		10	15	19	=	7		7	22	Ξ	×		1,		vo (	r (		•	α	, ţ	4 E	. «	•			-	22		7	80			60
1.00	2.00	2.00	00.	8	9:	3	0.00	2.5	00.0	8.	0.0	1.00	2.00	0.00	2:00	8.0	0.0	1.80	8.0	1.00	2.00	00'0	1.00	1.00	8.0	0.00	0.0	<b>8</b> '0	0.00	6.90	0.00	8.0	0.00	8.6	8 9	8.6	8 8	8 8	3 6	8 5	8 6	8 6	8	00.0	0.00	0.0	0.00	0.0	0.00	0.0	0.00	0.00	5.00
0.00	8 9	00.	000	0.00	11.00	8 9	0.5	8	9	0.0	4.00	0.0	00.0	5.00	00.00	1.00	2.00	0.00	5.00	0.00	0.00	2.00	5.00	2.00	2.00	3.00	4.00	8.	3.00	3.8	3.00	8	8	8	8	8 6	9 6	2.00	3 5	3 5	3 5	9	8	2.00	8.	14.00	4.00	2.00	2.00	2.00	8.	1.00	0.00
5.92	13.51	5.93	5.78	5.83	19.49	6.61	7.41	6.48	5.45	5.67	12.27	6.12	5.18	7.90	8.30	5.69	7.05	31.34	19.46	6.17	8.08	6.93	8.09	7.45	6.46	7.62	20.56	6.90	10.81	10.77	7.16	6.34	6.72	60.9	5.22	6.35	6.61	87.11	5.73		20.0	0.00	7.67	823	5.81	23.95	9.37	19.79	18.71	80. 80.	13.48	8.46	5.99
168.58	155.33	392.88	417.09	13.13	80.65	160.39	37.12	888.45	14.14	1149.89	483.21	29.81	861.50	616.12	83.28	1007.34	10587.00	162.57	21.25	190.53	920.08	433.10	764.45	309.91	230.40	50.49	124.83	269.43	47.45	363.84	1824.02	27.01	1123.88	239.91	318.27	1020.03	83.33	140.16	14.//	50.757	33.00	19150	89.65	728.09	126.14	119.62	111.11	46.54	70.07	32.08	37.03	<u>4</u>	501.27
28.46	11.50	66.21	72.21	2.33	4.14	24.25	5.01	137.13	2.59	202.82	38.38	4.67	166.23	77.96	10.03	170.96	1502.29	5.19	1.09	30.89	113.94	62.53	94.50	41.62	35.68	8.63	8.07	39.07	4.39	33.80	254.56	4.28	187.30	39.36	60.99	160.67	14.13	12.41	2.56	6.80	8 6	25.00	11.69	117.00	21.72	4.99	11.86	2.35	3.55	3.89	2.74	4.65	63.64
AA074222	AA633577	R44850	AA432108	H16989	N53031	AA148213	N30258	R44955	R44717	H15296	AA159578	R43721	AA630628	AA400234	H15696	AA678021	AA486072	H08862	H10983	N66750	N73448	H11718	R52522	AA088214	WB7714	N38891	R10875	W93067	W80688	AA043790	R85841	AA007276	AA083588	N35156	W46629	N73309	AA456629	AA046/00	AA033991	A44007.58	AA480450	A 660066	T51530	AA025248	N91145	AA017544	AA176581	AA115761	AA625855	N92699	AA138666	AA453485	N33274
383175	658535	34070	784174	50130	246430	569069	270589	20064	33817	49916	592594	32598	856167	743230	49204	431803	640753	45852	47358	284908	291653	47580	39973	488271	416851	280000	128515	414994	347220	487151	199196	429210	365955	271830	324148	292082	809585	487371	429932	851110	A9900/	170074	12705	365425	302897	381323	611443	490718	745343	306420	490970	795358	273546
6426	6427	6440	6443	8445	6430	6452	6455	6456	6464	6469	6479	8480	6482	6490	6497	88	8206	8509	6521	6523	6524	6525	6528	6532	6546	6554	6582	6570	6575	8228	6591	6598	6298	8602	<b>6</b> 60 <b>4</b>	6608	6822	625	6833	3	3 3	200	64.0	6873	6874	6878	999	6683	288	6691	6883	6694	9639

	Heart			Heart	Lymph	Other	Tonsi		Whole embryoulD not found	Testis			Pancreas	Pooled	Other	Ear	LID not found	Skin	<b>Brain</b>	LID not found	Blood	Other	Thymus	Testis	Placente	Other	Other	Other	Adrenal gland	Pooled	CNS	Pool	Testis	Skin .	Foreskin		Paralhyrod	ordin Sabra	Forestin		Prostate	Testis		Foreskin	Brain		Thyrold	Oiher		Testis	Testis	Other	Brain	Umbilical cord
	Foreskin			Lymph	Pooled	LID not found Other	ineLymph		Whole embryo	P80			Placenta	Breast	LID not found Other	Adipose	Testis	Umbilical cord Umbilical cord Skin	Whole embryoBrain	Brain	Gall bladder	LID not found Other	Parathyroid	8rain	Stomach	LID not found Other	LID not found (	LID not found	-		Ea	Brain	Lung	Small intestineSkin	Thymus			Brain	Kidney	LID not found	Adipose	Kidney	Pos	Eye	Bone			LID not found Other		Spleen	Brain	LID not found Other	Spleen	m Pooled
	440.23 Muscle		397.57	230.36 Uterus	Liver	24.02 Brain	Small intestinelymph		-6.08 Brain	Spleen	570.96	377.78	545.17 Stamach	234.91 Colon	238.91 Brain	Neural	134.61 Brain	46.24 Umbilical co	41.9 Aorta	241.89 Prostate	Esophagus	40.6 Brain	177.49 Ignore	359.28 CNS	Skir	Brain	Brain	316.21 Brain	Thymus	Gall bladder	85.21 Aorta	446.85 Testis	116.7 Brain	143.7 Ignore	-3.15 -		19.41	Source Com Deli	537 56 Panriese	277.24 CNS	Ęve	Brain	454.98 Foreskin	385.82 Nose	132.56 Foreskin		102.83 Cervix	566.66 Brain	162.35	Eye	230.92 Ovary		250.4 Pooled	483,28 Synovial mem Pooled
	60	•	12	15		4			4		-	9	8	19	15		5	60	က	15		80	21	2				<b>#</b> 0			∞	2	15	φ.	-	•	- 4	n	-	. 52			m	17	-		-	8	ო		2		\$	4
Table 2A	0.00	2.00	8	8	0.00	3.00	2.00	0.00	0.00	0.00	0.00	9.1	6.5	0.00	3.00	0.00	5.00	3.00	1.00	0.00	0.00	1.00	0.00	0.0	0.00	3.00	2.00	1.00	9.	3.00	0.00	1.8	o. 0	00'0	000	9 6	8 8	3 5	8 8	8	0.00	2.00	0.00	1.00	0.00	0.00	1.00	3.00	0.00	0.00	0.00	4.00	0.00	<b>1</b> .00
Tab	200	8	2.00	0.00	9:	2.00	0.00	6.00	<del>-</del> 8	2.00	9.	8.0	11.00	<b>9</b> .00	00.0	13.00	3.00	3.00	0.0	<b>6</b> .0	<del>1</del> .8	0.0 0.0	9.1	1.0	1.00	4.00	2.00	0.0	0.00	3.00	9	00.0	9.0	8 6	9.60	9 6	3 5	8 8	8	00	1.00	5.00	8.	0.0 0.0	8.	8.	0.00	8	8	1.00	9	1.00	8	8
	7	5.85	8.89	6.20	6.72	9.16	7.41	7.49	5.85	71.83	5.98	5.47	11.68	16.97	7.90	22.50	10.25	12.61	5.40	7.55	8.78	6.62	7.22	5.25	5.41	9.40	10.41	5.86	5.61	15.71	10.11	6.32	6.18	7.99	25.73	20.0	0 0	17.73	517	6.59	5.12	10.23	7.40	7.76	5.51	5.13	5.70	6.23	9.58	7.92	7.19	7.46	5.28	5.52
	735.67	309 09	1484.29	167.68	1963.30	88.35	83.60	48.98	10.99	449.41	44.72	358.58	108.65	147.36	244.90	323.40	441.17	78.77	78.43	20.39	209.55	74.60	23.10	15.20	60.40	365.96	245.83	5.74	77.41	213.43	172.52	39.60	19.28	102.08	245.62	31.48	45.65	40.76	14.48	43.68	1138.84	88.81	2000.42	105.83	110.16	167.52	380.33	362.11	631.29	92.19	32.34	63.24	51.53	109.53
	11245	51.96	166.58	27.04	295.35	9.65	11.29	6.54	1.86	6.26	7.48	65.53	9.30	8.68	30.98 30.98	14.37	43.05	6.25	14.53	2.70	23.89	11.27	3.20	2.89	11.17	38.56	23.60	98.0	13.32	13.56	17.06	4.76	3.11	12.71	9.50 9.00	1.01	20.07	9 6	2.80	6.63	222.27	8.68	270.30	13.63	19.98	32.67	66.78	43.97	65.89	11.65	4.50	8.48	9.76	19.84
	N28175	AA702422	AA443587	AA454098	W45688	R44930	AA460838	AA487543	R54034	AA496149	H08210	T82459	H13688	R52030	T82481	AA291749	R44840	H11003	R59197	H15114	AA150500	T87226	AA629707	R44530	H08226	H11454	T88939	H15153	AA012839	R27615	R39111	R\$4073	H15288	AA487218	AA458878	000771	U20413	H18832	AA160870	N62914	AA178819	R52681	N36130	R10823	R58885	T55897	AA102053	R53258	AA487070	AA600184	AA428603	H08206	R56100	AA454713
	269433	447568	771241	768256	323500	34008	796278	841396	40009	757222	45607	22374	146225	154172	22376	725321	33860	47359	41789	49567	491751	22383	884462	33694	45512	47460	22334	49588	380240	133637	26588	41495	49810	841314	510801	7070		51599	692728	278857	611324	41842	272816	128020	41345	73244	510790	40449	841185	950355	781442	45801	41070	809738
	6698	8712	6718	8720	6721	6728	6730	673	8738	6753	6759	6764	6770	6771	6772	6774	8776	6782	6784	6785	6787	6788	6788	8792	6796	880	6804	6808	8809	8813	4 5	8815	6818	6817	802	200	2200	6829	6830	6834	6835	6840	6842	6844	6845	6849	6851	6856	6828	6863	6865	6989	6875	6878

ide 31 of 91

		Неал	Foreskin	LiD not found	Foreskin	Ovary	Other	Proetate	Sezix	LID not found	LID not found	Placenta	LID not found	Parathyroid	Pool	Kidney	Olher	Pancreas	Other	Ovary	LID not found	Other	Breast	LID not found		LID not found	Adipose		Pool	Brain	Kidney	LID not found		Parathyroid	Placenta	Directorio	Tonsil	LID not found	Other	Pooled	Colon	Lymph	:	LiD not found	Placenta	Larynx	Pacenta	Storing found		Forestin	Testis	o Testis	Pooled
		Brain	Pool	Lung	Eye	Cervix	LID not found	Aorta	Parathyroid	Pool						Placenta	LID not found Other	Cervix	LID not found Other	Colon	P.00	LID not found	Germ Cell Breas	Brain		Pool	Cervix		Ovary	Colon	Foreskin	8	LID not found	Prostate	Dancton	***************************************	Breast	Lung	LID not found	Parathyroid Poole		Foreskin		8	Uterus	, i	Aidney	o i nyrou	8 1	Tigger 1	Lung Lung	Whole embry	Parathyroid Pooled
			Thyroid		Spleen			Colon		Brain	382.37 Adipose	Pooled	Placenta	101,7 Blood	143.33 Bone	101.87 Foreskin	Pool	9.28 Aorta	162.18 Pool	8.34 Breast	Foreskin	24.47 Pool	Neural	Placenta	7.26	Foreskin	257.89 Head and nec Cervix	27.2	9.95 Brain	Uterus	334.11 Tonsil	3.53 Lung	00	Kidney	SUB.ZB Poreskin	Lone	Aorta	Spleen	8	Nose	287.05 Pencreas	31.52 Gall bladder	£6.58	Kidney	130.57 CNS	74.16 Umbilical cord	Sroad Aldrey	Ornalical Co	39.74 Penciess	43 08 -	Prostate	58 41 Pooled	17.79 Ovary
	2 568	8 118		2 48(		333			×		8			19	×	8		12 6	31	-		8			9		20 28	7	2 51		2	11 36		,	й 2						\$	٠ ٣	12 24	:	= '	7		•		- `	•	13 20	4
2A	3.00	1.00	8	3.00	2.00	0.00	1.00	8.8	0.00	0.00	0.00	0.00	8.0	0.00	0.00	0.00	0:00	0.00	1.00	0.00	0.00	0.00	0.00	0.0	9.1	1.00	0.00	0.00	0.0	0.0	0.00	0.00	2.00	3.50	8 6	8 6	000	1.00	5.00	3.00	0.00	1.00	0.00	8	0.0	0.00	00.0	8 6	3.00	8.8	000	00 1	0.00
Table 2A	00.00	000	000	2.00	8.	2.00	0.00	1.00	1.00	2.00	1.00	3.00	3.00	1.00	1.00	00.9	1.00	2.00	0.00	1.00	1.00	1.00	1.00	9:	0.0	0.00	2.00	3.00	<del>.</del> 8	1.00	8.	8	9:0	8.00	2.00	8 8	8 8	000	2.00	9.00	7.00	0.00	5.00	2.00	1.00	1.90	8 6	9 6	00.6	8 6	8 6	000	1.00
	5.40	6,53	5.50	7.05	12.25	5.34	5.13	5.04	6.93	7.70	8.18	5.56	5.93	21.42	9.83	10.86	5.65	15.92	9.00	5.32	6.01	5.21	5.27	7.17	7.11	00.9	6.89	8.89	7.47	10.06 80	2.90	6.16	6.01	18.02	Z, F	2.5	6.6	6.25	89	18.89	12.08	7.01	6.97	99.9	8.25	5.23	73.72	3.62 11.65	CO.1.		848	7 19	5.03
	244.57	399.60	71.13	113.46	682.13	190.20	105.24	1135.07	8.8	23.17	151.19	80.6	44.19	20.21	16.48	102.30	20.08	66.73	335.56	42.08	57.27	202.03	169.82	35.81	51.54	27.76	104.59	55.78	72.55	77.01	5.72	14.14	1373.17	132.81	514.11	20.83	114 54	30.57	903.67	98.20	24.85	198.48	1126.96	85.35	68.89	9089.75	552.19	95.887	1407.02	2.3	41.43	169 43	53.49
	45.26	61.16	12.94	16.09	55.70	35.63	20.51	225.23	6.50	3.01	24.45	1.63	7.46	0.94	6.49	9.42	3.56	4.19	55.96	7.92	9.52	38.74	32.23	4.99	7.25	4.63	15.18	6.27	9.72	7.65	0.97	2.30	228.40	7.37	- E	77.0	17.26	4 89	131,17	5.20	2.06	28.30	181.71	12.82	14.22	1739.50	7.49	23.26	120.80	12.41	39	23.55	10.64
	H17034	H17513	AA496871	R55673	T47625	T57359	AA121697	AA443089	172336	R44714	T96605	N51838	R27975	N57858	N72228	N29918	R95867	R28660	H79538	AA459278	N32502	R05293	AA404278	R31262	N72976	N25798	W46433	N71028	AA005219	AA088820	H59618	N93721	R01448	W72972	N30008	AA2844.00	WATER	N70553	H60514	W37680	AA425900	N23454	R73661	W87801	AA134111	AA625632	W72294	N54456	H90296	VV81504	AA676840	N70759	AA428959
	50477	50615	897576	40491	71312	74738	564514	809455	88160	33814	121256	281870	133860	247089	291290	271078	199241	133864	239615	810890	270889	125118	758338	134011	291827	268478	323988	294535	428756	489800	207275	307138	123811	344854	268258	334333	324333 121888	289182	207932	321908	769600	250883	143145	417059	503334	877827	345034	245174	240878	347613	460114	298104	769712
	6880	8885	8890	8898	6897	6901	8902	6903	6969	6912	6914	6915	6931	6939	6944	6948	6950	6963	6972	6982	6984	6986	6990	6895	7000	7007	7010	7012	7014	7017	1020	202	7038	7037	2043	9 5	40,4	7057	2060	7081	7064	7072	7075	7076	7079	7080	7087	260	7092	2007	7086	7007	7108

Page 32 of 91

Pool		d Other	d Blood	Umbilical cord	1	неап	Inyrod	Ovary	Pancreas	77700	ig Pooled		r Greakin	200		d Other	d Other	LID not found	CN3	d Other	d Other	LID not found	d Other	Kidney	Kidoev	Other	m Kidney	Lung	se Thyroid	LID not found	d Other	Andle embryolito not found	Nation forms	Blood	Parathyroid	nd Other	Testis		1	Aora	CNS	od Other	nd Other	Plecenta	nd Other	Pool	LID not found	yoCervix	Lung	6
Piacenta		LID not found Other	Umbilical cord Blood	er Cervix		Kidney	S C S C S C S	e i	Pacenta	-	Agrenal gland Pooled	er Grain	Skin reason Smooth must find	Spleen Spleen		LID not foun	LID not found Other		_	LIO not found Other	LID not found Other	ineColon	LID not found Other	Placenta	CID not round Carer	11D not found Other	Synovial mem Kidney	Brain	and Smooth muse Thyroid	Brain	LID not found Other	Whale embi	Testis	em Thyroid	Placenta	LID not found Other	Skin			Cerm Cell	Blood	LID not found	LID not found	Spicen Placer	LfD not four	Uterus	Color	Whole embryoCervix	lineThymus	
347.76 Uterus		29.67 Brain	Pancreas	Peripheral nar Cervix	283.96	333.71 CNS	Parathyroid	24.51 Neural	239.66 Blood	424.13		511.27 Perpheral ner Brain	SKIN 108 21 Cumuial me	251 Liver	619.07	Brain	246.56 Placenta	264.5 Testis	Parathyroid	175.36 Brain	21.93 Brain	433.96 Small intestineColon	CNS	289.5 Uterus	Brain Page 32 Cac	277 88 Brain	580.59 Eve	558.61 Pool	326.36 Umbilical oc		542.07 Brain	Liver	Prostala	562.43 Synovial m	74.7 Ear	P86	Thymus		469.78	POOR POOR	Bone	334.17 CNS	728.84 Brain	172.31 Nose		740.99 CNS	Pool	165.42 Nose	118.49 Small intestineThymus	
18		ъ			6 (	50	!	17	∓ '	~ (	7 1	~	d	. <b>4</b>	-	•	5	-		4	B	60		-	u	ı, Ç	i v	4	•		S.	;	=	-	8			9	12	ų.	2	80	B	9	7	-		9	80	,
1.00	0.00	0.0	8.	2.00	8 8	2.00	8 9	8	8 3	0.0	5.00	8 8	8 8	800	200	8 8	2.00	2.00	9.0	9.7	0.00	2.00	2.00	9.6	9 8	<b>7</b> .	0.00	1.00	1.00	2.00	1.00	00.0	0.00	90.5	5.00	0.00	0.00	080	8 8	8 8	3 8	8 8	0.00	1.00	0.0	0.0	<b>4</b> .00	0.0	800	,
0.00	2.00	1.00	9.	2.00	1.00	8 9	8	0.00	00.	8 6	8 9	9	8.6	3 8	4 00	8 8	0.00	8.0	<b>6</b> .00	0.0	÷	9.00	8	8.	8 8	8 8	8 8	1.0	0.00	8.	0.0	8.6	9 6	8 8	3.00	5.00	1.00	8	9	8 8	3 8	8	8	10.00	3.00	8	8	2.00	300	
9.56	5.50	8.82	5.42	10.56	5.73	66.11	5.25	5.7	8.85	5.4	6.98	5.80	D (0	5.05	13.29	10.23	6.37	6.27	16.25	8.12	5.16	10.48	6.27	7.41	6.12	 	57.17	8.33	5.23	11.52	8.38	6.59	7.61	5.23	8.11	8.14	5.57	6.01	5.13	11.52	2 9	11.85	5.20	29.09	5.78	7.00	8.00	8.08	13.28	
72.88	18.27	19.97	12.38	161,47	1030.55	470.67	235.92	4.13	51.01	309.75	35.84	37.80	77.62	15.91	319.47	147.95	314.59	80.68	45.22	628.19	10.70	892.20	257.30	625.57	8.03	404.02	1750.51	17.94	237.63	1367.55	13.28	28.10	107.28	171.37	129.35	315.39	107.04	43.02	1086.74	351.39	30.68	210.46	2222.49	277.32	571.85	28.48	71.11	868.70	883.56	*****
7.62	3.32	2.28	2.28	15.29	179.73	7.12	44.82	0.72	5.70	60.57	5.13	6.52	14.64	10.10	25.52	14.47	49.42	14.47	2.78	77.36	2.07	85.14	41.02	94.42	1.31	20.07 88 -	30.62	2.15	45.43	118.71	2.09	3.96	6.80 8.80	2 2 2	15.95	51.41	19.20	7.18	211.90	30.51	7 7	17.77	427.45	9.53	98.79	3.78	8.89	107.45	85.02	11:55
T49530	AA701081	H10981	N20338	T49802	H23081	W3473	150041	T64216	R80779	T62577	AA682815	H17115	T50121	N58558	151290	R66415	T40688	R52635	H22956	R53442	H19417	AA088861	N48899	R42698	H19217	W465//	AA684180	H24347	AA621256	R56432	R54558	T41032	VV4/362	198628	AA010557	W91885	AA458486	N62273	N34637	W90323	H/0603	N62080	H49517	AA457718	R99293	AA147654	AA004652	H48251	AA664195	*****
67625	397495	47355	264646	68836	51743	344430	70152	80228	146868	79743	450453	51070	77193	2/8412	71783	41548	60882	40108	51939	40036	51397	511909	279577	32095	51103	524122	855523	52066	744565	40768	39770	61638	324715	122163 810567	430264	415250	809608	290231	271280	416279	234127	289867	178656	810727	201217	505597	428749	201855	855547	
7108	7110	7111	7114	7132	134	7139	7148	7152	7153	7159	7165	7167	7172	7107	7108	7209	7215	7216	7221	7232	7245	7246	7247	7248	7253	7254	7278	7285	7287	7288	7289	7292	7	2 28	2308	7314	7322	7324	7332	7335	7338	7340	7363	7366	7367	7368	7370	7383	7418	>

Page 33 of 91

•	-
- 0	Þ
-	_
•	٥
	Ξ
- 2	٨
•	4
4	п
-	1
- 0	Ĺ
	_

		6 358.74 Brain Foreskin Colon	tin Heart		Pool LID not found Other	10 499.96 Umbilical cord Thyroid Ear	13 136.15 Lymph Blood Heart	LiD not found	3 18.86 Foreskin Heart Pool	9 416.03 Ovary Whole embryoProstate	14 123.72 Small intestineHead and nec Esophagus	Eye	Placenta Pod	reas Pocied	Colon	iye i	2	LID not found		2 487.92	8 399.21 Brain Kidney LID not found	Blood	Adrenal gland		CNS Brain	- ·	Brain LID not found	16 365.99 Brain Breast Prostate		Piacenta	Eligan Lesits Lung		Placenta Pancreas	Prostate	Brain LID not found	Skin Pooled	5 5/6.31 Appose Signach Prostate	Brain LID not found		Brain LID not found Other	Umbilical cord vein	Ovary Blood	CNS	US CNS	Ey0	Ear Muscle	CNS Testis	8	Acrta . Whole embryo	.!	1 31.2 Eye Cervix Blood 8 407.58 Colon LID nol found Other
Table 2A	1.00	0.00	0.00	1.00	Ī	1.00				4.00						2.00	8.6			2.00				2.00 5.00			0.00		1.00				2.00								1.00								0.00		1.00
	5.12	7.97	14.23	5.89	5.83	6.14	34.56	30	5.62	22.82	5.01	8.78	17.21	17.05	5.67	6.24	97.6	6. 8. 87. 8.	27.03	26.73 26.50 26.50	11.82	6.43	5.90	9.62	10.87	7.87	6.10	17.20	5.62	5.87	5.21	6.26	6.10	7.35	12.58	5.57	33.80	6.73	6.21	5.45	5.78	9.04	5.28	5.85	5.76	6.36	8.87	9.14	7.89	9.72	7.18
	533.03	137,53	518.88	761.43	74.51	1175.82	512.53	53.81	366.58	159.54	219.10	47.59	66.74	141.98	41.29	312.68	127.97	63.48 60.08	9.50	000	\$6.00	128.48	1768.94	224.14	66.28	175.16	8.25	72.19	106.74	106.23	94.86	110.72	8.53	579.47	15.84	103.70	799.59	1025.58	613.02	81.94	1286.36	280.13	445.79	1997.97	169.43	96.55	139.39	328.24	169.22	26.43	339.43
	·		36.46			_		9.71		6.89					7.28									23.31			1.02				18.22						23.68				.,								21.48		47.31
	AAD41396	AA569689	AA016234	N63943	W86521	H65478	W73144	AA448167	N36123	AA402883	AA630328	N52136	N30553	AA001432	R39069	AA055585	AA455521	H09064	111063	178CH	H17322	AA430875	AA427889	H17484	R42894	AA405800	T89084	R66139	AA630320	148692	R52796	R81539	R31562	AA405901	H29245	AA425318	N73101	H22846	N56372	H28738	R54177	NS1705	95965H	T52652	172915	AA176867	AA426113	H17046	AA479913	R20862	AA490249 AA099748
																																																			840062
	7427	7432	74.24	7440	7449	7455	7458	7482	7486	7468	7480	7482	7484	7488	7480	7493	7484	4 4 8 6	3	1 2	7516	7517	7523	7532	7533	7534	7540	7541	7546	7551	7554	7555	7557	7571	7576	7579	7582	7892	7595	7600	7601	7603	7612	7621	7824	7627	7831	7833	7646	7657	7880

	Whole embryol.ID not found	LID not found Other	Tonsil Whole embryo	. <b>⊆</b>		Germ Cell Placenta	LID not found Other			•	Muscle Lung			Post	LID not found Other	Pool LID not found		Placenta Germ Cell				Proctate 110 pot found		3			Ovary Blood	gland	Breast Heart		<b>М</b> ћоја етљуоРод	CNS		Spleen Brain		Pool LID and facing	ate		LID not found Other	LID not found Other	Lymph Placenta	LID not found Other	100		Soleen	cs	p	Blood Kidney
	540.74 Brain	Brain	Parathyroid	145.04 Eye	271.02		95.03 Foreskin			0.43 CEI	364 06 Earestin	223.68 Rhod	Placenta	584.18 Pool		250.29 Prostate		365.61 CNS	46.33 Foreskin	253.29 Aorta	220.12 CN3	108 t 1 Pool		17.4 Uterus		Uterus	Adipose	Hear	108 17 Pool	17.11	Tonsit			CNS	592.45 Tonsii	599 98 Colon	Ovary	Smooth musc	Pool		87.87 Blood	Poot	11000		726.84 Fronhagus	Pooled	116.59 Liver	
	σ,			5	19		~	₩ 1	- ;	<u>.</u>	~ >	ς <u>σ</u>	)	vī	'n	5		Ξ	15	= ;	7	•	•	12		-	eo .	- 1		2	ł	11	S	•	_	2		22			-	•	n		•	, <del>E</del>	<b>.</b>	50
Table 2A	0:00	3.00	8	000	0.00	0.00	8 6	8 6	8 8	8 8	8 6	8 5	200	000	000	9.1	0.00	0.00	8	8 8	8 8	8 8	8	0.0	3.00	0.00	8	8 6	8 8	8 8	80	0.00	5.00	8 6	8 8	8 8	000	000	3.00	0.00	00.0	6 6 6 6	8 8	8 6	000	80	0.0	00.0
Tab	8.	8	8	8	8.	8.	8 8 8	8 8	3 5	3 5	8 8	3 8	8 6	3.00	8	0.00	9.	2.00	1.00	8.6	8 5	8 8	80.00	1.00	3.00	1.00	9.00	2.00	8 8	8 6	9	1.00	0.0	5.6 8.6	8 8	8 6	9.	2.00	4.00	5.00	2.00	8 8	3 5	8 8	2 60	58	5.00	2.00
	5.32	10.38	5.01	5.00	5.71	2.8	7.27	5.51		) c	5 C	9 45 8 45	68.5	6.71	8.96	6.59	5.28	7.62	6.03	6.73 6.83	20.0	5.30	60.12	7.25	8.17	5,53	8 i	<u>.</u>	9 2 6 4	8 75	6.38	6.53	8.54	80.0	6.80 6.51	17.10	80.0	8.41	13.28	1.21	8.20	18.39	2.5	8 64	20	5.83	11.68	6.22
	35.10	633.49	78.21	400.02	1849.12	49.53	1603.13	130.74	52.08	92.00	30.34	67.44	12.19	43.25	6.25	67.94	22.29	43.43	121.67	65.40	66.63	43.93	359.44	7.22	344.25	620.11	191.72	27.97	100.47	68.51	12.09	8.69	3163.12	52.36	165.70	120.70	303.66	526.71	104.35	25.03	450.82	732.45	41.88	1038.8R	1085.12	1043.98	599.25	41.17
	6.80	61.03	15.21	79.93	324.08	7.07	220.65	23.7	2.0	11.83	4 t 4	11.92	2.14	4	0.92	10.31	4.22	5.70	20.17	9.30	20.00	8.29	5.98	1.00	42.15	112.19	21.22	3	17.5	10.15	1.90	1.33	482.02	9.38	27.00	2 2	51.66	62.61	7.86	3.47	7273	5.5	7 08	123.03	135.03	179.06	51.32	5.01
	H09759	R56789	H08734	N20577	H98780	R33037	H99394	N35889	AA480202	AA00431	N27145	AA443105	AA063573	W93147	AA010819	AA011678	AA001983	N59219	AA039857	K17086	44001359	AA011480	W80701	AA136049	N68738	AA151111	AA454864	A5707N	AA035/45 N54157	AA041293	R86970	AA133194	H66670	N63949	/ * O . O . O	H66710	AA464728	W90128	N74625	AA464140	N32811	N63848	Wa1521	F99847	T51582	H68885	AA401441	T\$1995
	46565	41103	45318	284105	281687	133108	282334	272531	705730	386763	289787	809487	360025	415111	430336	428728	427931	288741	375853	129862	427893	429499	415562	502593	293097	505183	810002	298082	247482	378333	197265	490784	211367	289428	177671	211865	810263	417867	296452	810320	259017	283110	357138	201071	72426	212115	741977	72616
	7672	673	1491	689	700	707	208	21.7	77.19	7 2 2	2 2 2	22.	127	7740	77.42	7748	7750	7751	7752	797	77.77	7780	1877	98	7804	8	7814	7816	2007	7821	7827	7833	7836	7840	7807	7844	7846	7847	7852	7854	7858	7850	7867	7867	7878	8787	7883	900

Page 35 of E

9
63
o
8
Ž
ä

						ound	o(Lagr		_							found	lound	Synovial mombrane			found		found				7	פתחפ						side			il mombrane		Bone marrow Synovial membrane		Zell		gand				found	tound	LID not found	75	Whole embryo		•	
	CNS		Kidney	Uters	Cervix	LID not found	Whole embryo	yornue	Foreskin	Ear Ear		74 Blood		Heart	d Other	LID not found			Uters	other Other	LID not found		LID not found	d Other		. 1	Tonsil	בורות ביי	od Omer		8 6		Brain a	Esophagus	nd Other	Brain	oc Synovia		JW Synovie	nd Other	Germ Cell	Ç	Whole embryoAdrenal gland	:	Heart	၌ (၁)	UD not found	LID not found	E D	Gera Cell	Whole	8 8	<u>8</u>	Lympa
	Foreskin		Placenta	Ovary	: Thymus	Cun	Gern Cell	Whole embryoLung	Larynx	eSmooth mus		Umbilical cord Blood		Overy O	LID not found Other	Brain	Pool	Esophagus	CNS	LID not found Other	8rain	,	Lung	LIO not found Other	į	Skin	Prostate	Macenta	LID not tound Other	בים של יים	Consult format Other	Lib not found Office		, Ski	LID not found Other	Uterus	Small intestincheed and noc Synovial membrane	Breast	Bone marr	LID not found Other	Heart	Prostate	Whole emt		CNS:	Uterus	P09	CNS		Breast	. ;	CNS	Sol	Š
	414.52 Thyroid	193.03	Pancreas	Brain	Head and nec Thymus		151.73 Pooled	Uterus	Smooth muse Larynx	488.43 Small intestineSmooth musc Ear		344.82 Thyrold		61.79 Ear	489.95 Brain	Pancreas	553.94 Brain	719.03 Stomach	672.97 Eye	Brain	60.19 Placenta	67.29	Spleen	459.29 Brain	92.81	449.6 Adipose	443.43 Parathyroid	Inyroid	49.6 Bran	336.3 Brain	Adipose	74 60 0 00 07	841 15 Prestate	228 02 1 avnx	Testis	59.14 Foreskin	546.7 Smell intesti	471.03 Thyroid	Marrow	P. 00		557.51 Pool	Aorta		Brain G	245.32 Eye	460.48 Ignore	Sp/een	251.6 CNS	Lymph node	17.11 Heart	20.5 Ovary	CNS	258.32 Ovary
	18	18					-			<b>8</b> 0		S		<b>6</b>	S		-	~	4		17	Ø		ო	-	n	φ		- 1	7		•	٠.	. 5	:	œ		91			×	7			;	₹	17		-		23	=		12
Table 2A	0.00	90.0	0.0	9.1	9.1	8.4	3.00	9.	2.00	8:	9.	2.00	8	0.00	9.	2.00	2.00	3.00	0.0	3.00	<b>9</b> .0	5.00	0.00	8.	3.00	2.00	0.00	000	8	8	8 8	8 8	8 5	8 6	8 8	200	8 8	0.00	0.00	. 80	0.0	3.00	0.00	0.00	0.0	8	00'0	0.00	3.00	0.00	0.00	8.0	8	0.00
Tabl	8.	5.00	8	7.00	0.00	0.00	1.00	0.00	0.00	<b>5</b> .00	0.00	<b>6</b> .00	000	2.00	2.00	2.00	8.	0.00	1.00	5.00	4.00	5.00 7.00	5 8 7	0.0 0.0	5 8 8	8,	8	5.00	8.8	8	8 8	8 8	3 6	8 6	8 6	00 2	8	8.	8	9.9	2.00	8	8	5.00	8	9. 8	1.00	3.00	0.00	8.	9.	1.00	1.00	3.00
	18.76	5.89	8.54	16.93	5.33	8.02	7.77	12.00	9.11	6.35	69.6	11.73	583	7.92	6.65	5.38	6.75	13,48	13.88	7.84	16.84	10.10	5.71	6.20	6.16	6.92	9.26	11.83	8. 15	10.94	6.49	97.6		2 5	10.61	8 18	5.48	6.93	13.51	6.63	8.80	7.59	5.89	6.19	9.74	15.35	6.89	4.7	7.62	5.01	60.9	6.18	5.58	17.59
	317.86	38.06	28.83	61.73	1000.39	520.69	759.02	457.85	859.21	161.66	39.06	82.60	323.37	207.08	14.37	64.81	31.48	1442.59	421.81	124.19	49.37	22.85	162.69	13.55	48.47	66.65	39.56	3420.38	41.26	1055.20	105.82	821.16	493.46	78.00	170.63	1731 38	307.25	797.22	287.53	142.66	3348.21	188.28	212.50	180.89	18.37	135.78	186.67	141.62	165.68	19.07	43.55	128.21	13.17	75.03
	16.94	6.35	88	3.65	187.62	64.91	19.78	38.17	94.28	25.48	4.03	4.48	54.33	26.16	2.16	12.04	4.66	106.98	30.40	15.84	2.93	2.28	28.48	2.18	8.03	9.63	6.32	289.13	90.9	96.43	16.30 50.50	8.8	3 5	40.04	15.78	211.47	11.95	115.08	21.28	16.54	507.22	22.16	27.34	29.21	2.87	8.85	27.11	19.02	21.75	3.80	7.16	20.92	236	4.27
	WB3749	R43271	R73584	H23265	T54144	T70032	R83277	R59167	T52325	AA683102	AA689732	H94471	T71578	R44538	R44584	H10226	H09620	AA476294	AA504858	H24327	R52786	H15250	T48011	H18456	H17063	T61888	H23482	T48649	H17981	H09317	AA412509	H19312	K44210	711440	AA150332	L15653	AA426049	AA460304	AA485730	AA011598	AA024832	W87710	N91962	H\$1050	AA011100	AA043092	H51271	NS1961	N71147	W92233	AA029703	AA485424	N48700	AA427733
	342181	32517	141495	52220	69164	80912	194236	41358	72016	970613	433307	243159	85224	33999	34014	46919	46287	770704	839688	51747	41850	49687	71591	50895	50240	78736	52543	69890	50860	45999	730288	51020	4994	4/432	705837	A0204	77.7446	795758	811138	429685	365004	416945	306921	194156	359684	486885	194023	282315	288936	358936	366783	811038	279392	770840
	7915	7816	7922	7927	7930	7936	7937	7938	7940	7949	182	1961	1968	787	7985	7992	7993	7994	7995	7897	900	8005	8012	8013	8021	8023	8025	8028	8038	8032	8038	8045	8055	200	8008	500	808	8070	808	8087	9008	8098	8089	8103	9104	8108	8111	8112	8116	8118	8119	8122	8127	8128

							ode									pund			pund	punc		nbryo	pund	<b>\$</b>						משם		1	2																				
d Parathyr	Othar			Pool	Color		rd Lymph n	d Other	rd Foreskin	CNS	w Pooled	Uterus			O Pe	LID not found	Breast	Pancreas	LID not found	L1D not found	Kidney	Whole embryo	LID not found	Lymph node	d Other		Cervic	Testis	Procenta	. LID not found	8	A ton Cl			Solo	Lymph	Pancreas	d Other		<u>8</u>		<b>B</b> rain	Prostate	•	Brain	S O			Brain	Kkiney	Uterus	dCNS	E G
Adrenal oland Parathyroid	110 and found Other	Adrenal pland CNS	B B B B B B B B B B B B B B B B B B B	Colon	Ovary		Umbilical co	LID not found Other	Umbilical cord Foreskin	Blood	Bone marrow Pooled	Adipose			LID not found Other	Pool	Thyroid	Germ Cell	Kidney	Lung	<b>Parathyroid</b>	Prostete	Ovary	Omentum	LID not found	1	Eye	Uterus	Foreskin	8 .	Lung	مامل			Syary Syary	Blood .	Blood	LID not found Other	LID not found	Foreskin	LID not found	SUS	Brain	Brain	ž Š	LID not found			Pool	Muscle	Eye	Umbilical co	Kidney
CNS	Pod	200	3	Ulenus	Blood		Synovial mem Umbilical cord Lymph node	Pool	Sall Maddor	Spleen	Trachea	Adrenal gland Adipose			Pool	Colon	Gall bladder	Peripheral ner Germ Cell	Uterus	Uterus	Testis	Esophagus	Poof	Colon	Pool		Stomach	Ovary	Thymus	Prostate	Foreskin	37.19 300.04 Servil Industrian Cales	Gindi Intesur		524.94 Whole embryoOvary	Gall bladder Blood	Head and nec Blood	Brain	Brain	Whole embryof oreskin	Brain	Whole embryoCNS	gnore	Germ Cell	Eye.	Brain			Breast	Bone	Stomach	Smooth muse Umbilical cord CNS	Breast
	474.75		626.75		_			466.22			71.41			576.51		_		272.85		_			<b>2</b> 0.44	227.72					387.3			37.18	200.5	3	524.94	26.78	253.83	151.92		336.84		467.91		411.77			126.76			355.29	211.115	••	154.22 Breast
	œ	•	ĸ	•		6	9	4		12	=			-			-	49				2	7	2		<u>5</u> ،	n	_	<b>8</b> 0		8	3 :	- <b>t</b>	2	1	00	=	7	7	12		7		m			=			LO.	=		ம
8	000	8 8	800	000	0.00	1.00	0.00	0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8	8.	8	0.00	0.0	80	8.	8.0	0.00	5.00	8	8	0.0	8.0	00.0	8.0	8 6	8 6	8 6	00.0	1.00	0.00	3.00	0.00	1.90	0.0	0.00	0.00	9:	8	0.00	0.00	8.0	5.00	0.0	0.00	0.0	0.00
200	3 00	8 5	2.00	8	1.00	0.00	6.00	5.00	1.00	1.00	9.	1.00	2.00	8	8	3.00	0.00	5.00 5.00	<b>9</b> .00	3.00	1.00	2.00	1.00	9.00	000	2.00	8.	8	2.00	6.00	8 8	8.8	8 8	8 8	00.1	2.00	3.00	8.4	1.00	0.00	2.00	1.0	9:	10.00	500	9.	2.00	3.00	0.0	0.0	1.00	8.	8.
12.42	10.04	2. v	6.07	5.93	5.69	6.41	36.21	10.47	5.78	5.82	216.92	6.26	12.60	5.44	5.50	9.04	2.97	5.38	± 8	8.05	10.66	20.38	13.91	13.69	7.56	13.58	10.07	5.29	7.7	85.71	5.64	12.69	2 6	8.30	5.03	25.95	9.77	10.37	5.46	5.03	7.67	5.59	20.5	21.80	7.68	19.74	6.37	20.68	7.14	10.61	5.24	5.64	5.05
64.81	580 30	30.74	502.00	36.83	6826.70	46.71	168.95	939.12	813.47	118.12	665.15	22.09	111.24	28.09	196.63	263.98	219.77	30.05	23.52	47.94	46.86	78.59	68.38	1550.11	42.82	29.98	57.70	101.19	1413.03	325.08	922.84	2363.91	. S	295.93	63.65	27.77	27.65	332.56	9.54	17.97	20.09	51.58	55.83	64.43	49.22	53.38	204.40	87.39	357.26	522.50	36.19	496.57	236.81
5.22	58 77	28.5	82.67	6.21	1200.45	7.29	4.67	89.68	140.67	19.94	3.07	3.53	6.83	10.67	<b>8</b>	29.29	36.83	5.58	1.9.	5.30	4.40	3.86	4.92	113.25	5.68	2.21	5.73	19.13	183.22	18.49	155.42	186.31	9.58	35.63	16.63	1.07	2.83	32.06	1.75	3.57	2.62	9.23	9,49	2.86	6.41	2.70	32.08	4.73	50.03	49.22	6.91	88.06	46.90
N91003	H83858	NA0917	N70848	AA136869	AA430629	W51985	AA629897	N53360	AA427778	N40952	AA677706	AA043800	AA455013	K68106	AA001884	N55355	W81135	AA429681	AA115328	AA127965	AA460313	AA629189	H60298	AA664179	AA010000	W15318	AA017379	AA455128	R88992	W88/25	N67810	H41144	AA679907	N72210	AA434411	AA052932	N40945	H29276	R55658	N20108	H10413	R37566	AA496334	HZ9227	H45976	R54212	AA670155	AA700322	H09601	W72437	AA122287	AA461098	AA404585
306066	209189	277134	288609	491097	770969	325641	884644	283968	771142	277187	460487	487317	811612	138369	427697	245688	347035	780947	501479	501854	795755	1035889	207838	855521	430073	322641	361122	809857	195357	417/61	29182	192198	869375	291241	770896	510002	277186	49953	40277	263118	47400	24061	755228	22704	177772	41835	845663	460688	46383	345525	490819	796176	772377
8144	8154	8182	8163	8185	9166	8172	8176	8178	8162	818	916	6169	8191	8192	8193	35	6195	98	6197	6205	8208	8208	8215	8216	8217	6219	8220	8228	8231	8233	6234	8228	8248	8250	8254	8257	8258	8263	8264	9285	8272	8276	8278	9280	8289	8292	9314	6317	8320	8329	8340	8353	6329

Page 37 of 91

.

Brain	LID not found	Breast	oKidney		Eye	Parathyroid	Pool	Gall bladder	Brain	Whole embryo	Colon	Gall blødder	Whole embryoParathyroid		SIS	Kidney	ES	Comercia	200	Herrs	Head	O T	LID not found	CNS	Whole embryoGerm Cell	Umbilical cord	Colon		Colon	Testis		2 2	Hear	d Other	Prostate	LID not found	yoBrain	UD not found	Lung	Acres grant grant	I ID and for the		vol uno	Pool	<u>8</u>	d Other	Placenta	d Other	d Other	Whole embryo	Pool
Lung	Pool	Heart	Whole embryokidney		Blood	Liver	Lymph	sc Laynx	Tonsi	Blood	Germ Cell	ec Cervix	Whole embry		Bone	Foreskin	E y0	Phod Sund Cines	3	Smooth mire: Stomach	Project	LID not found Other	Pool	Foreskin	Whole embry	em Breast	Lung		Testis	657		Breast	Someth	LID not foun	Parathyroid	Tonsil	Whole embryoBrain	P 6	Pooled	Spage Page		200	Whole embryol und	Eve	Prostate	LID not found Other	Еув	LID not found (	LID not foun	Testis	Placenta
Aorta	Testis	Uterus	194.82 Prostate	245.06	78.76 Noso	62.6 Ear	Çezi,	61.75 Smooth musc Larynx	127.04 Spleen	164.58 Stomach	163.57 Bone	277.72 Head and nec Cervix	66.18 Placente	:	401.76 Foreskin	436.1 Ear	697.77 Inyroid	156.43 FOOT	128.27	137 65 Smooth mu	13.47 Far	892.03 Pool	372.61 Lung	31.46 Ear	53.48 Aorta	Synovial mem Breast		28.83	Tonsil	510.24 Eye	410.63	-8.01 Foreskin	460 B3 Adinose	232.44 Pool	Germ Cell	Ovary	442.79 Pool	ခ် ပ	Ovary 19 7 Still	15.7 OKIN	•	Deford Broked	143 02 Pooled	553.7 Placenta	235.13 Liver	20	Pooled	443.85 Pool	•	•	237.77 Adipose
			4	×	14 2	s		n	2	±	5	12	19	,	œ ·	æ (	,	- ·			, «		16		17		n	20		œ (	ָי פּ	<u>-</u> :	2 6	· =			9		;	2		>	( 6	,	61			4			<b>=</b>
8.	80	000	0.00	1.00	000	0.00	3.00	9.0	0.0	0.00	8.0	1.00	8.	8	0.00	5.00	8 8	8 6	8 8	8 5	200	900	0.00	0.00	00'0	0.00	9:1	0.0	0.00	0.00	000	0.00	3 6	3 0	0.00	00.00	0.00	8.0	0.0	3.5	8 8	8 8	9 6	000	8	3.8	0.00	0.0	0.00	0.00	00.0
1.00	4.00	80 9	2.00	8.	3.00	2.00	8.0	1.00	1.00	8	2.00	0.00	00.1	2.00	9	2.00	5.00	0.00	9 6	3 6	8 5	00.0	8	8	8.	2.00	2.00	3.0	<del>.</del> 8	8.	8.5	5 8 8	3 5	00.8	1.00	1.00	4.00	1.00	6.00	0.00	8.8	3 5	8 6	8 6	00.0	2.00	3.00	1.00	2.8	2.00	2.00
9.87	98	29.78	17.74	6.90	6.48	6.01	7.06	5.08	8.33	9.24	8.55	5.05	5.39	6.70	6.25	7.90	9.8	B 5	66.01	7 28	6.23	6.55	8.71	8.90	5.34	6.13	7.47	9.87	5.43	<b>8</b> .	5.16	10.17	9.5 2.5 7.0	12.16	5.12	5.36	8.37	5.08	10.94	5.62	6.27	10.44	4.13	6.43	7.87	10.18	6.51	6.80	6.88	10.69	17 74
7.06	40.52	288.81	147.99	490.54	103.37	44.00	111.34	417.75	56.21	221.39	689.29	530.01	713.23	969.36	86.75	3025.83	205.57	124.13	63.62	25.44	46.00	2. y	1059.74	453.45	284.46	284.35	226.02	131.27	77.12	68.22	554.40	72.02	93.86 87.50	87.44	205.61	24.67	149.22	20.02	56.93	283.41	513.18	4075	130.73	60.33	27.78	495.61	43.28	89.28	48.79	3155.68	118.24
0,72	4.33	02.6	9.34	71.11	15.96	7.32	15.77	82.25	6.75	79,62	103.96	104.93	132.31	128.38	10.51	382.95	29 :	19.15	20.80	2 6	3.4	1 2 4	157.82	75.56	53.29	46.41	30.25	13.30	14.21	7.88	107.53	8 6	9 C	5 Z	40.12	4.60	17.83	<b>3</b> 6	85. 186.	4	81.88	27.60	16.38	A 40	28.87	48.67	6.65	13.13	7.09	285.30	8.66
AA443706	AA448281	AA045524	H15695	H29303	AA489975	AA446864	AAD11637	AA483516	T54672	AA496247	AA608572	AA211459	AA460965	T47971	H19307	AA46887	AA425302	AA010247	M17143	744473	14117	N42332	N93740	AA054722	AA142842	NS7950	N70059	H91615	AA448182	N79989	N72882	AA455509	N30000	R89105	H54263	AA443594	AA676888	HS8806	AA457137	AAGESTS10	AA284265	AA4/8030	W443040U	4401021	AA004525	H73628	R31783	R12679	AA2B4261	AA284164	H87459
784017	782843	487727	49203	52618	730439	784212	429640	787038	73785	796887	950700	626068	796127	71557	51015	784229	773073	430172	5000	288033	375	253733	307157	487881	504372	247261	297899	241648	782794	302180	291558	809731	258242	2011040	203008	771257	454083	204478	810457	853368	325544	2000 C	44663	410015	428507	234855	134897	129320	325169	324220	242491
8382	936	8174	8376	8377	8378	8384	8386	8388	8392	8395	8399	8402	8405	<b>8</b>	84 16	8410	8422	8426	3 3	5	2 4	0440	8485	8488	8495	8438	8502	6508	<b>8</b> 510	8516	8228	8531	6532	0 CP	8547	8558	8560	8563	8584	8268	8573	9 2	2000	8000	8491	8596	862	8604	8605	8606	8610

Page 38 of 91

	Foreskin	Тһутиѕ		Brain	Pool	50	aColon -	Pool	LID not found	ŝ	red C		Hear	Tonsil	<u>8</u>	Pancreas	2000 C	Adrenal dand	Cervix	Placenta		Placenta	Adimase	LID not found		Other	UD not found	18 FO	Poole	}	oBlood	Other	LID not found	Umbilical cord		<u>8</u>	Other	Parathyroid	Adrenal gland	Serie Cell	Other	Thyroid	Other	CNS		Parathyroid Germ Cell
	Kldney	Adipose		Lung	Kidney	Placenta	Whole embryoColor	Placenta	Pool	мода	LID not found Other		CNS	d Blood	Ovary	Breast	I ID not found	Thyroid	Foreskin	Adrenal gland Placenta		c Parathyroid	c Foreskin c Cervix	Testis		LID not found Other	Brain	Synchronia	Brain Pool		Whole embryoBlood	LID not found Other	Brain	Eva Eva	·	Placenta	LID not found Other	CNS	Brain	Whole embroderm Cell	UD not found Other	,	LID not found Other	Adipose	LID not found	Parathyroid
	165.83 Aorta	276.5 Cervix	103.36	•	Placenta	102.62 Pooled	Muscle	231.75 Cervix	250.6 Germ Cell	501.44 GBII DISQUET	Pool	3	Blood	Adrenal gland Blood	Civer	424.99 Larynx	414.35 Liver Brain	412.13 Brain	230.42 Pencreas		400.09		267.89 Head and nec Cervix	Splaen	144.63		114.88 Eye	24 SE Capit	368.42 Fue	300.46	554 Brain	652.25 Brain	Z10.44 Kigney	orain 97.57 Placenta			422.79 Brain	Gall bladder	59.74 Musde	S S S	Brain	102.83 Cervix	Spleen	Ear	350.62 Brain	628.88 Ear
	9	<b>2</b>	80		,	-	;	×	B (	3 v	•				,	~ !	=	=	Ξ		<b>o</b> ;	6 ,	< 8	ì	23	4	Φ	ģ	ē ¢	: 8	5	7	92	2	• ▼	က	4	•	13			-			×	က
8.	8.0	8.1	2.00	0.00	8.6	0.00	0.0	0.0	0.00	3.5	8 8	1.00	0.00	9.	0.00	B. 5	8.6	00.0	2.00	0.0	0.00	0.00	000	3.00	1.00	1.00	0.00	8 8	3 5	00.0	0.00	00.0	9.6	8 8	5.00	0.00	5.00	0.0	900	8 8	000	1.00	3.00	0.0	0.00	5.0
8.0	2.00	0.00	1.00	2.00	00.0	2.00	8	8 6	2.00	2.00	00.4	8	9:	0.00	1.00	22.00	3 8	5.00	0.0	5.00	0.1	0.0	8 6	8.0	0.0	0.0	8.6	3 5	3 6	5.00	2.00	3.00	8.6	3 8	8.	8.	2.00	8 8	8 8	8 8	8.8	000	8.	8.	8.5	0.0
8.74	9.60	19.05	9.80	9.35	9.41	6.93	16.41	7.87	6.04	6.78	10.92	5.32	6.71	8.15	5.24	35.05	9.09	33.88	5.98	13.55		7.28	9.79	9.66	5.17	26.81	ខ្លួ	, r	. e	5.57	6.19	8.71	7 6		10.35	6.81	7.16	29.00 40.00	10 K	10,32	8.88	9.38	9.22	5.71	5.92	5.31
54.87	1055.36	1511.88	282.39	690.33	334.34	123.40	53.80	46.40	1387.97	267.24	330.73	48.75	91.23	108.73	39.88	162.53	45.85	90.53	690.52	153.67	75.79	160.52	168,15	778.76	19.19	59.44	120.24	300	23.25	64.17	66.03	17.07	30.50	148.76	228.61	16.77	1147.64	926.81	17.62	42.44	3069.48	878.52	392.08	121.09	12.35	302.36
8.14	109.91	79.37	47.84	73.80	35.54	17.82	3.28	5.90	97.42	39 43	30.29	8.79	13.60	17.36	7.62	3.21	7.40	2.67	115.38	11.34	14.15	2.2	26.13	79.02	3.72	2.22	16.40 26.53	11.07	3.65	11.52	10.67	1.98	153.24	21.84	22.09	2.46	160.22	155.92	334.58		341.33	93.83	42.52	21.21	5.08 5.08	56.93
AA114966	AA008593	AA864040	N32832	AA284281	H77494	AA437113	AA010188	AA677308	190446	N63598	AA010406	AA700419	AA680407	AA412217	172068	AA43Ubbb	R53527	H49511	AA630794	T53431	174586	AAB77185	M52110	AA668527	AA630016	H24352	R44353	AA488413	H16701	AA045074	AA489470	H17511	97750	AA186605	H11270	H10204	H17625	N67816	AA666180	AA456139	H20757	AA486761	T52375	H15436	H24018	H10893
490023	365517	855788	259066	324046	233277	810446	430188	454440	110903	289060	430320	460584	433111	731433	85804	7,0388	39843	178825	856454	68818	84695	454872	197520	859807	884690	52186	705.20	BATOMB BATOMB	49275	487165	897427	50613	1040	625623	47225	46907	50593	291618	859422	796357	51542	841070	72083	49240	51485	47 149
8613	8615	8624	8625	8827	8628	8	8631	8632	8633	8636	8639	8645	8654	8655	8656	000	8678	8681	8683	8684	8688	8698	8 29 20 20 20 20 20 20 20 20 20 20 20 20 20	8713	8717	8720	8727	8743	8745	8747	8750	8753	1018	8768	8769	8773	9776	6779	8780	8791	8792	8794	8796	8797	9800	8809

Pege 39 of 91

	Page 40 of 91
•	

	Adipose	Prostate	Other	Prostate			Whole embryo	Other	Other	Brain	Other	Pool	Kidney		LID not found	Eye	LID not found	Other	LtD not found	Нвал	ornu	LID not found	Brain	LID not found	Tonsil		LID not found	Testis	Germ Cell	n Prostate	Cleras 10 of free	Ditter aging	Chear	Sen Cell	Breast	100	Testis	LID not found	Adrenal gland		LiD not found	•	Testis	LID not found	Pancreas	Brain	Uterus	Pancrass	Brain	Heart	Eye	Liver	•	Pool
	Spleen	Ovar	LID not found Other	Whole embryoProstate			CNS	LID not found Other	LID not found Other	Heart	LID not found Other	Colon	Eye		Brain	Liver	Pool	LID not found Other	Pool	Breast	Whole embryolung	mLung	Uterus	Pool	Breast		Brain	Foreskin	Blood	Synovial mem Prostate			Liver				Brain	Colon	Stomach		8	CNS	Ovary	Brain	Uterus	Blood	•	ineSkin	Foreskin	Tonsi		Cervix		Aorta
	545.68 Thymus	CNS	227 19 Spleen	205 02 Shleen		215.11	_	P86	CNS	Kidney	113.68 Pool	334.46 Kidney	188.88 Pooled		254.48 Pool	647.14 CNS	-10.98 Prostate	Pool	455.8 Cervix	438.5 Stomach	Ovary	615.42 Synovial me	-14.62 Ovary	570.71 Eye	462.78 Uterus	19.86	137,28 Pool	Thyrold	591.02 Tonsil		481.U. Cerwx	BIRISOLA I	430 30 Enichania	Action of property of the prop	436 32 Gall bladder	Kidney	117.56 Eva		289.73 Neural		Kidney	242.45 Muscle	Pooled	CNS	553.7 Skin	-13.58 Larynx	45.2 Blood	165,69 Small intestineSkin	331.21 Pancreas	674.5 Pooled	247.55 Neural	266.24 Esophagus	576.82	127.97 Skin
	-		35			15					91	-	9		=	7	81		vo	<b>6</b> 0		4	<b>e</b> 0	w	7	0	×		۲.		n		\$	7	•	•	=	:	×			7			-	s	7	-	ю	-	12	21	-	=
\$	0.00	8	8 8	8 5	000	2.00	0.00	1.00	0.00	1.00	0.00	2.00	8.	9.0	0.00	0.00	8.0	9.0	0.0	0.0	0.00	00.0	8.0	<b>4</b> .00	0.00	0.00	0.00	0.00	0.00	00.0	00.0	0.00	9.0	3 8	8.5	3 5	00.0	0.0	0.00	0.00	0.0	0.00	0.00	0:00	8.	0.00	1.00	0.0	0.00	00.4	1.00	8:	8	8.8 8
lable 24	8.	000	8 8	8 8	200	3.00	2.00	3.00	1.00	1.00	1.00	9.00	2.00	1.00	3.00	8.	8.	8.	3.8	7.8	2.00	1.00	8.	4.00	5.00	5 8 9	2.00	1.00	1.00	8 3	2.00	9.0	9 6	9 6	8 6	8 8	3 5	1.00	10.00	1.00	4.00	9.	7.00	9.	0.00	1.00	0.00	2.00	3.00	2.00	0.00	1.00	1.00	1.00
	7.28	900	0.70	- 1	2 4	8.60	12.38	6.79	6.11	6.60	5.30	42.05	19.5	6.23	5.83	5,15	5.39	5.57	15.78	8.93	10.87	6.31	7.33	8.25	5,56	6.46	6.33	5.16	5.90	7.29	8.7	5.89	6.44	0.70	7.48	90.00	7.85	8.68	95.10	6.61	6.72	20.28	77.40	5.25	6.84 8.84	9.00	8.70	9.58	8.20	6,23	5.71	10.67	10.87	8.83
	345.61	78 677	50.00	380.00	790.01	1622.27	1092.05	244.91	79.23	187.51	354.07	180.46	113.28	153.94	499.68	121.21	588.83	12.32	51.45	18.88	1591,08	67.63	33.08	526.49	115.22	1020.30	570.88	40.81	146.03	307.87	74.61	65.89	234.14	20.010	8:2	97.00	24.57	32.59	687.41	115.28	948,35	78.47	392.62	85.58 85.58	351.95	81.63	41.81	23.15	31.82	641.75	473.20	280.51	62.20	718.01
	47.65	41.40	77.60	60.60	93.15	183.04	88.19	36.08	12.98	28.40	66.75	6.29	9.48	24.70	85.64	23.52	109.26	2.21	3.28	2.11	146.42	10.72	4.51	63.81	20.73	157.87	90.21	7.87	24.74	42.21	10.36	11.55	36.34	141.83	4.45		6.6	88.8	7.23	17.44	141.05	3.87	5.07	3.	51.45	16.31	6.26	2.42	3.88	103.13	82.83	26.28	5.72	80.75
	T65736	4464700	754679	1346/2	A4610040	H28231	H17506	W80361	8446N	W81603	AA004719	W91879	AA457138	H56640	H90767	W86630	N7 1080	H57060	H57130	W74802	AA454881	N59270	AA429398	W92514	AA053296	R69225	WB3024	AA447553	N30372	W60057	AA676404	W93382	AA448271	K//283	A4443837	200777	P95982	AA058711	AA454582	AA436187	AA007283	AA055979	AA486539	H24308	N84014	H07934	R56251	H09076	H19227	H15089	AA418759	AA430367	H08720	H15685
	80338	2000	61023	13/8/	103204B	52917	50508	415447	276920	347772	428011	415229	810459	203888	240509	416627	299465	204596	204661	345081	808883	289606	771128	381840	468054	195547	418435	782622	260035	342008	882459	415085	782840	145112	771301	100040	BOSCA!	488149	809503	754406	429211	377671	755881	51842	293950	45587	40871	46166	51210	49555	731308	769857	45417	48410
	8818		000	0799	9823	8824	8829	8842	8844	8863	8864	8871	8875	9879	8883	1688	6900	8903	8911	8915	8838	8960	8983	8964	8968	2969	8968	8982	8984	8988	8888	8883	888	8 8	9001	2008	9 6	506	9014	9016	9023	9024	8028	8028	8028	9047	9053	90%	8069	9060	1906	9070	9071	9075

			Breast	ID not found Other	Colon	Whole embryoPlacenta	of found Other		LID not found		Imbilical cord Foreskin	ID not found Other	ξ		kin CNS		c Code				Umbilical cord Colon		Testis		Prostate	JD not found Other		CNS Nose	of found Other			Whole embryo	LID not round	ID not found Other	Germ Cell			cal cord				Air vendre emaryo	Bone			agus Lymph node		E mer	LID not found		
			ach Bone	_	_	_	_			_	_		_	Aorta			Nguey	Ö	•	•		cal cord	Brain		_	_				•	Kidney		_	_				<b>)</b>		•	5	LOGISKI	Cerix			Small intestineEcophagus				Poofex	
		413.5	Stornach	486.84 Brain	179.77 Placenta		515.79 Brain	Skin	482.73 Brain	269.09 Larynx	400.44 Skin	Brain	414.93 Brain	671.54 Pooled	634.12 Ear	599.45 Splean	Oranus Con 43	74 66 10400	and of Control	255.55	48.77 Overv	137.48 Umbil	553.28 CNS	24.02	Pance	726.88 Brain		Thymus	300.98 Brain	250.6 Parathyroid	333.71 CNS	FORESKIN	440.8/ FORESUN	201.54 Foreskin	255.2 Poole	515.7 Breast	423.24	71.09 Overy	629.85 Ear	674.22 Placenta	Nomaca Conference	180.34	101.44 Skin	Thymus	163.73			389.93 Lymph	416.73 Placenta	41.87 Ear	400.35
		7		e	19		60		S)	Ξ	16	1	~ ·		φ.	<b>1</b>	•	•		2	17	<b>.</b> თ	9	4		-			Φ,	<b>6</b>	R	ţ	<u> </u>	, w	· =	, <b>150</b>	69	<u>5</u>	-	-	\$	2 5	; °		-			=	ß	-	2
Table 2A	1.00	8.4	0.00	1.00	<del>.</del> 8	9.0	8.	0.00	3.00	8	0.00	1.00	8.5	0.00	0.00	8.8	3 6	8 6	8.5	8 8	100	3.00	0.0	1.00	1.00	1.00	8.	1.00	000	2.00	90.	9 6	8 6	8 00 S	000	000	5.00	0.00	1.00	8 6	8 8	8 8	00.0	00:0	9:00	1.00	00.0	0.00	1.00	8.	0.00
<u>∓</u>	0.0	8.	1.00	00.0	3.8	2.00	0.0	1.0	3.00	8	.00	000	8 :	1.9	9.60	8 8	9 6	9 6	8 6	8 8	22.00	4.00	1.00	8.0	0.00	0.0	0.00	1.00	1.00	2.00	9.00	8.	9 5	0.00	1.00	2.00	4.00	9.5	0.00	2.00	0.00	5 6	2.00	3.8	2.00	0.00	3.	<del>.</del> 8	8 8	8	1.00
																																											11.12					5.51	5.28	5.70	6.41
	5403.58	308.50	17.76	26.07	103.84	49.89	9.65	113.52	157.02	276.03	37.78	23.77	200.00	98.39	266.24	206.33	101.03	050 70	53.46	1581.09	906.98	328.15	20.94	742.68	492.06	168.48	257.84	146.60	6.71	322.45	83.72	13064	93.57	152.51	193,03	1408.06	139.16	305.85	68.90	1037.80	10.10	320.54	3968.32	203.64	237.22	2311.00	301.14	38.60	39.06	34.78	92.22
	•					3.50						3.02	BC.1.2											105.89	93.70	30.46	39.57																356.77			310.41	57.31	7.01	7.40		
	AA626698	H09325	AA046525	H08322	T54121	H08730	R42823	W69954	H28590	AA292074	AA187148	H12081	100000	A4611/4	5677/M	151116	AA488423	D56234	AAA88781	T49633	AA487488	T52700	R44173	T55197	T63520	R44163	T56013	N84617	R43168	R3/026	ARCESONA Maren	N35922	N89873	H97868	AA457108	N75569	H91245	AA485357	AA431433	AAA29367	NAMEDA	H79319	W42587	AA670107	H94474	AA629592	R75639	AA055946	AA010222	W74337	AA009840
	745138	•	•	46105	Ŭ	•		343867	-,		624754	•						4086		67735	-	_	•	•	•	••	•	•				•	305677	. , ,		209332			٠.	176954		• ••		_	•	~	143535	377560	430233	346292	430092
	9081	8082	88	96	9102	9103	2	9105	9108	8	910	5 5	2 6	913/	9140	9149	0163	2 6	2	216	9183	9184	9189	9192	9193	9196	9200	9203	8 8	9216	222	9248	9258	9260	9267	9275	9276	9296	9	9310	3 5	93.16	9322	9338	9340	9352	9353	9380	9361	9364	9365

-
Ò
₹
~
4
•
ğ
œ
ο.

	d neck	5															-	10		ovder	forms		<b>=</b>			,	o Cugura		SOC										j	<b>8</b>								夏	٠	
	Head and neck	2000	8	P. aconta	8		Gral Gral	Brain	8	Other	Oher	(Lung	Uterus	Testis	<u>8</u>	E G	S S S S S S S S S S S S S S S S S S S		2	Whole embryo	UD not found	Calon	Germ Cell	Pooled	Heart	Kidney	Whole emplyo	Spien	Esophagus	d Other	Breast		o De la		Brain	Lung			ey e	Pancreas	CNS			Cervix	yoBrain	d Other	Eğ.	Germ Cell	yoBrain	Prostate
	Thymus	Specied S	rogeo	ceopragus	LOPEKIN		Testis	Hear	Brain	LID not found Other	LID not found Other		Aorta	Brain	Parathyroid	Stomach	Adrenal gland Cvary	Dinetate	Mead	Soleen	Brain	Eye	Lymph	Spleen	Tonsil	Testis	Colon Whole	Pooled rough	Nose	LID not found Other	Prostate		UD not found Other	בים נסי חום	Heart	Foreskin		LID not found	Adipose	רק E אין ב	Lymph	Tonsi Port		Pancress	Whole embryoBrain	LID not found Other	9	Cervix	Whole embryoBrain	Colon
	424.26 Peripheral ner Thymus	Peripinata ner	apone .	Larynx	TTO SE MUSICIO		Pooted	Tonsil	58.78 Uterus		Pool	Spleen	Placenta	Breast	Colon	675.52 Synovial mem		Stomach	47 SS Breast	Imbigoal cond Solean	345.1 Neural	Thymus	236.8 Parathyroid	Skin	597.27 Smooth musc Tonsil	66.5 Heart	Biood Biood	276.32 CNS	Smooth musc Nose	542.05 Brain	572.03 Pooted		454.26 Brain	26.23 P00	Colon	Parathyrold		Brain	:		Thyroid	Solven		Stomach	290.72 Tonsil	Lung	347.4 Small intestine	CNS	Splean	Bone
-13.12	424.26	07:474		7.28	110.83	27.19	695.02	419.83	56.78	452.42			720.63	117.87		675.52	2/6.45	28.82	47 FF	3	345.1		236.8		597.27	60.0		276.32	117.99	542.05	572.03	139.45	454.28	20.62	89.67	182.99	278.24	355.78	740.99	166.48			694.44	55.7	290.7		347.	192.65	32.97	419 74
18	7		•	7 (	~ ;	5	-	60	-	1			~	×		~	*	:	: :	2	11		7		<b>-</b> ;	=	ı	D >	ω .	· <del>-</del>	S	7	လ (	2	17	9	<del>4</del>	<b>6</b>	<b>-</b> !	5			2	4	9		11	2	Φ	ø
0.00	00 0	8 9	8.5	0.0	0.00	8.0	8.0	8.	0.00	5.00	0.0	0.00	1.00	1.00	0.00	0.00	0.00	8 6	8 6	90.6	1.00	2.00	0.00	00.	9.	0.0	0.00	9.00	000	8.8	2.00	1.00	8.6	8 6	0.7	2.00	1.00	1.00	9.5	000	8 8	9 6	00.	5.00	4.00	0.0	0.00	0.00	<del>.</del> 8	300
3.00	9	3.6	9.6	8.5	2.00	2.00	9.	7.00 7.00	8.	2.00	1.00	2.00	1.00	0.00	1.00	9.0	7,00	8.5	8 8	3 5	00.0	0.00	1.00	0.00	0.0	0.0	2.00	8 5	8	8 8	0.00	1.00	8.6	9.00	9 6	000	7.00	2.00	00.0	9.0	9.00	8 5	8 6	00.0	00.0	<b>8</b> :	1.00	1.00	0.00	000
7.40	6 13	2 6	20.0	6.22	7.28	5.70	5.33	5.98	6.00	8.59	17,18	9.08	6.85	8.21	5.28	5.40	9.78	51.6	10.0	7.24	5.77	5.86	5.70	5.1	44.	10.39	8. S	8 °	19.97	9.76	18.68	7.19	17.38	2.5	13.51	14.85	14.34	6.03	8.80	7.05	15.14	8 6	64.8	5.86	6.76	5.37	5.24	6.63	98.9	6.33
491.18	263.01	10.50	124.44	118.33	3017.05	1599.25	96.16	285.07	288.22	1009.81	10.01	487.36	3242.42	37.95	69.07	29.93	145.68	60.40	3 5	553.64	25.62	258.70	28.77	98.88	172.26	51.68	132.19	10.24	1075.17	381.56	111.01	239.68	422.45	62.56	22.55	63.37	4461.25	525.84	444.59	1279.28	856.15	192.99	27875	85.23	337.10	50.30	171.68	61.69	40.69	155 29
66.35	42 92	78.7	21.05	19.03	414.27	280.66	18.03	49.32	48.04	117.56	0.58	60.45	473.01	4.62	13.08	<b>3</b>	18.58	11.78	5.0	42.03	5.83	43.37	4. 5.	19.33	26.76	4.97	17.18	30.49	53.84	43.58	6.65	33.35	24.31	80° C	18.48	5.81	311.21	87.14	50.55	181.35	58.55 5.55 5.55 5.55 5.55 5.55 5.55 5.5	2 2	50.41	15.97	58.66	9.37	32.78	8.31	5.85	24 54
H87153	AAATAIR7	A443418/	AA032221	AA074511	N35250	N32281	W93378	W56753	AA157017	R88003	N63768	AA485731	AA150487	R48320	R44357	R39520	AA485427	AA821535	4 40000	755407	H11938	R38635	AA668726	T55704	W88906	R44496	AA610086	R52682 T50007	AA634028	R38652	H90431	R44048	H19415	W33370	AA055350	H98694	H58540	H16761	AA598781	H08753	AA088258	K42671	100015	R84175	H18428	T57848	AA412738	AA495387	H10403	AAAAAAA
252278	77051B	8160//	375682	525926	271926	272658	415089	340542	502561	201609	283013	811142	491727	153541	34405	23903	811046	1034776	1000	780//6	47783	22786	854284	73608	344243	33028	1031076	1043	RERATO	23114	241489	33076	51395	415086	177252	261580	253009	50018	898076	45645	511091	32186	49944	276237	50863	80699	730833	897595	47188	811000
389	77.4	93/4	9375	9376	9377	9385	9386	9389	9391	9393	9396	9407	<u>z</u>	9414	51 26	9418	£21	22.53	275	57.50	33	9456	9457	9460	9461	8464	9470	9472	8478	9480	9483	9467	948	9493	8 8	9501	8502	8509	0512	9513	9514	515	9537	9838	9539	9540	9544	9552	9553	25.55

48631	H29257	196.31	1278.87	6.51	3.00	2.00			Whole embryoBrain	ograin	lonsii
249755	H85476	88.89	455,14	5.12	00.1	0.00	12	105.23			
530237	AA111979	19.99	101.13	5.06	00.1	80			Muscle		Pancreas
428544	AA004868	38.91	211.86	5.44	000	2:00			Pool	LID not found Other	Other
593537	AA165410	5.71	110.06	19.20	0.00	1.00	7	478.93	Spleen	Ovary	Whole embryo
429333	AA007502	27.49	174.35	6.34	2.00	2.00				LID not found Olher	Olher
587398	AA130351	129.23	778.20	6.03	2.00	0.00	<b>5</b>	362.75		Colon	
46508	H09143	1.38	120.19	10.55	4.00	5.00	19	32.33		CID not found Other	Other
346889	W79834	1.87	18.22	9.74	1.00	9			Lymph	Hear	CID not found
416095	W85890	63.88	532.08	8.33	3.00	5.00				LID not found Olher	Olher
204442	H58000	17.82	101.92	5.72	<b>4</b> .00	0.0	=	339.45	Aorta	Pool	LID not found
248232	NS8473	153.16	1000.45	6,53	3.00	0.00	6	359.28			
283268	N45301	9.75	57.26	5.87	0.0	8.			CNS	LID not found	Other
428529	AA004846	3.43	17.42	5.09	1.00	8.	-	674.22	Parathyroid	Pool	Prostale
244305	N54793	4.23	23.65	5.59	0.1	0.0	18	57.88			
359135	AA010128	10.84	75.58	6.97	0.00	1.00	7	80.08	Pooled	Bone	Colon
489220	AA056734	4.36	32.29	7.41	2.00	0.00	12	-9.21	Pooled	Brain	Uterus
384352	AA022496	4.13	35.98	8.70	1.00	00.0	12	474.54	Kidney	Perethyroid	Hear
357298	W93688	5,5	61.48	6.02	1.00	00.0	=	274.11	Germ Cell	Prostate	Неап
283919	N50797	27.04	162.73	6.02	2.00	000	9	104.03		Synovial mem Ceryb	Centr
191858	H40351	1.36	8.01	60 50	8	000		198 24		LID not found Other	S C C
277747	N46096	4.19	96.43	23.02	200	90	ļ		CNS	Kidney	Pool
279164	N48321	44.10	338 03	7 82	1 00	000			Far	Imblical cord Toosil	Tonsil
247781	NSRODO	2.74	13.80	90	5				l Berns	100	Diacento
124895	R06123	25.73	179.55	6.98	3 00	000	6	269.05		8 8	LID not thund
294281	N84428	2.54	16.64	6.56	8	000	22	86.07		LID not found	
126449	R06706	5.86	31.28	5 34	8	000				Pool	Breast
782668	AA447593	25.28	162.18	6.42	8	00.0	-	115.45		Testis	Liver
263995	N53378	9.86	44.55	5.03	1.00	0.00	5	19.85		Eye	Tonsil
207826	H60560	6.24	37.40	6.00 6.00	2.00	0.00	S	467.02	Pool	LID not found	_
489169	AA056580	18.08	105.60	5.54	0.0	90.1			SKi.	Pooled	CNS
205239	H60824	4.17	27.32	6.56	3.00	00.0	2	46.94	Thyroid	Lymph	Heart
303180	N92764	6.00	35.21	5.87	8.	0.00			Muscle	Brain	Eye
755301	AA496360	5.63	33.79	9.00	3.00	0.0	ಣ	181.89	Lymph	Ovany	Breast
292223	N62464	96.86	533.08	5.50	9.1	0.00	12	469.78	459.78 Foreskin	Tonsti	Blood
22895	R35640	3.92	172.21	43.91	3.00	0.00	8	105.9	Brain	Lung	Pool
427750	AA001897	2.61	14.52	5.57	0.1	0.00	-	568.94	Pool	Bone	LID not found
120929	T96107	4.41	29.74	6.74	1.00	0.00			Brain	Pool	LID not found
434833	AA703141	6.24	151.91	24.34	0.00	5.00					
280970	N50854	21.51	144.48	6.72	9.1	2.00	12	40.87	40.87 Germ Cell	CNS	Tonsil
296448	N74623	16.41	2386.92	145.45	3.8	0.00	=	16.42			
359009	W92134	1.85	21.18	4.11	8.8	0.00	ĸ	561.51	561.51 Head and nec Esophagus	<b>Esophagus</b>	Skin
795315	AA454172	96.40	574.13	5.96	2.00	9.0			Еув	Germ Cell	Pancreas
795564	AA459674	5.70	28.83	9.09	1.00	0.00			Pooled	Thyroid	Testis
428338	AA005153	5.39	48.88	9.07	7.00	0.00	-	165.59	Blood	Parathyrold	Pool
795614	AA450005	1.08	9.91	9.34	1.00	0.0			Testis	Pool	LID not found
212347	H88286	26.95	237.69	6.82	1.00	0.00	G	22.34		Testis	Brain
428832	AA004528	43.79	246.10	5.62	2.00	0.00					
243068	N39542	24.58	125.89	5.12	8.	9.0			Lung Burn	Pool	LID not found
375857	AA037810	8.39	45.30	5.40	00.0	1.00	<b>\$</b>	223.96	Head and nec Cervix	Cervix	Synovial membrane
504431	AA151245	1.50	20.77	13.83	2.00	0.0				Ulerus	Brain
755599	AA419251	64.15	1420.22	22, 14	2.8	0.00	F	18.88	18.88 Nose	Skin	Adipose
810700	AA457688	25.28	141.61	5.80	2.00	0.00	=	228.96	Ovary	Brain	LID not found
155768	R72097	1.88	32.64	17.33	20.5	60	=	10.400	1	ě	
				}	3	3	=	0.72	<b>Esophagus</b>	Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signage Signag	Hreas!

ige 43 of 91

Ovary	CNS	LID not found	Prostate	Whole embryo	Heart	Parathyrold	Pooled	oKidney	d Lung			Pool		a Umer Proetate	TER.	LID not found	d Other	Brain	CNS	Placenta	Brain	d Aorts		d Olber	Whole emboro	LiD not found	Germ Cell	Lymph			Brain	LtD not found	LID not found		yolung	Tonsil	Parathyroid	Bose	200	Aorta	ambrane		Adrenal gland	Muscle	Whole embryoGerm Cel	Cervix	Whole emboo	VYIMIG GILLERY
Heart	c Stomach	Pool	Pancreas	Blood	n Neural	Placenta	Ovary	Whole embryokidney	Adrenal gland Lung			Brain	d Testis	Ribod Burge	Head and ner Far	Brain and In	LID not found Other	Lung	voPancreas		Pool	Adrenal gland Aorta		LiD not tound Other	2 d	Brain	Cervix	CNS	. !	LID not found	Foreskin	Uterus	Brain	Lung	Whole embryol ung		Brain	Synovial membiood		Brain			E S	CNS	Whole emb	SE Skin	yodrain	i di
404.08 Blood	421.81 Smooth musc Stomach	Brain	Parathyroid		165.67 Synovial mem Neural	398.69 CNS	363.47 Marrow	434.49 Brain	439.11	578.76		131.57 CNS	Adrenal gland Testis	472 27 Brain	131 31 Stoffach	Some	697.57 Brain		147.98 Whole embryoPancreas	611.54 Gall bladder	Testis	740.99 Esophagus		204.51 Brain 97.87 Brain	-9 1 Forestin	Pool		538.57 Eye	236.57 Brain		485.65 Neural Foreski	Liver	97.53 CNS	675.88 Germ Coll	228.05 Brain	654.42 Smooth musc	584.16 Larynx	Sec. 2 Neural	Brain mou	CNS CNS	194.85 Lymph node		120.56 Thymus	639.63 Adipose	91.28 Foreskin	442.4 Synovial mem Skin	Whole embryobrain	556.54 CZII
æ	5			eo	•0	<b>1</b>	5	40	4	<b>10</b>	Ø	=	;	کا د	, <del>t</del>	2	•	5	13	-		<b>-</b> -	•	<b>5</b> °	4 4	,	12	-	Ξ:	₽'	~ «	•	1	7	8	wo t	vo c	»			16		13	-	Φ	€	Ç	:
0.00	0.00	4.00	0.00	0.00	0.00	0.00	1.00	2.00	0.00	0.0	5.00	2.00	00.1	8 8	3 8	8 6	2 00 2	00.0	0.00	0.00	0.00	0.00	1.00	0.00	9 6	000	1.00	0.00	8	00.0	8 5	8 6	1.00	3.00	8:	0.00	0.0	8 8	3 6	800	000	0.00	1.00	0.00	0.00	0.00	8 8	3.
8.1	3.8	0.00	1.00	8.	1.00	1.00	0.00	1.00	5.00	9.	3.00	0.00	8.0	8 8	3 5	3 5	3 6	1.00	1.00	1.00	2.00	2.00	8.5	8 5	3 5	8 6	0.00	3.00	.8	00.	5 5 5 6 6 6	8 6	0.0	1.00	9.	1.00	9. S	8.5	8 8	8.8	8 8	3.00	0.00	1.00	9.	1.00	0 0	20.0
17.72	42.72	6.73	5.16	5.34	26.81	6.48	5.75	7.07	7.89	5.07	1.71	9.80	5.18	25.5		 	6.5	7.38	7.49	7.08	7.17	7.65	5.43	5.90	9 6	7.10	6.37	7.07	5.01	5.93	6.28	88	26.79	9.16	5.54	5.48	21.35	11.68	20.0 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 2	931	\$ \$	7.69	5.43	5.78	14.30	9.95	89. e	17.0
61.13	428.49	284.50	7.33	106.31	16.98	219.53	49.69	97.07	101.37	62.28	1246.09	56.83	135.05	14.61	1360 48	32 83	30.59	19.31	96.96	29.01	28.80	162.81	140.68	15.79	115.07	24.72	224.01	14.07	48.18	10.41	16.23	1425.87	49.89	73.87	136.75	71.96	47.37	9.76	20.03	18.68	30.82	391.93	298.40	270.05	197.65	1782.73	2 2 2 2 8 2 8	26.26
3.45	10.03	42.30	1.42	19.92	0.63	33.68	<b>5</b> .0	13.72	12.69	12.28	161.57	5.81	26.06	1.33 2.33	3.63	4.59	75.0	2.61	12.95	4.11	4.01	21.29	25.78	2.68	2 4	3.48	35.14	1.89	8. 28.	1.75	2.58	243.52	8	8.07	24.68	13.12	22	9.00	402.03	4.0 7.0	3	50.97	55.00	46.62	13.82	170.13	3.31	3
AA464518	N63988	H18953	AA157499	AA427891	N32514	AA025275	H18472	H11038	R45939	AA284954	H29566	R43352	AA446482	187235	0.000	H17800	H18936	R44193	N90783	AA680136	R43486	N62244	AA700556	H17055	H1506/	R39066	H91691	T52330	AA129171	R56397	R43896	T68113	H08203	R38369	R41730	AA400229	H10939	AA450353	000000	H18927	WAREE	R12808	N50079	AA487115	H09757	AA600214	K43543	110464
810205	289498	51508	590774	773478	270917	364834	51218	47378	33837	713974	52577	32150	781047	22600	05/20	80083U	51808	<b>3</b> 260	303109	433155	32496	287745	432651	50132	46684	24915	241736	72003	586725	40649	33510	83158	45500	23586	31818	743224	47234	796078	90000	51498	346671	25384	282720	841226	46581	949988	32683	2000
9790	9792	9804	9805	6086	9813	9818	9820	9824	9828	9830	9831	9632	9837	9844	200	2843	0000	9860	1986	9862	9864	9865	9870	9871	2/86	9876	9881	9884	9885	9888	9892	2000	6086	9913	9921	9923	9925	8286	0000	9640	200	986	9966	9970	9973	9874	9980	1986

	Ostate	Skin	Other	05	Other	ID not found	Sreast	200	<b>6</b> 811	Heart		Pool	Uterus	Parathyroid	Olher	Ped	8		earl	iye.	Cidney	lear	Pancress	Amole embryo	Other	CNS	Eye	Breest	ID not found			LID not found	ther	ther	Breast	Pool	Germ Cell	Umbilical cord	Other	Pancreas	Heart	Whole embryo	whole embryo	c g	8		MUSCIB	Z day		DO not found	Brain	Foreskin	Giler I Giler	Tonsil Lung
		Cock	Paris d	Breast L	UD not found O		_			CNS		Placenta P		Foreskin P	LID not found 0	Testis P			_	_	_	_	Neural	_	5	Eye	_	w	_			Pool	LID not found Other	LID not found Other	Liver				found	Kidney	Eye .	Aorta	e conse	Lung	Whole embryol.	isuo:		500	•		Pool	Spleen	Dring	Splean T
	98.48 Parethyroid	217.43 Larvax	Pool	22.69 Colon	141.89 Foreskin	287.53 Pool	298.2 CNS	198.24 Breast	420.51 Whole embryoPool	218.02 Slomach		CNS	579.1 Colon	404 Bone	128.87 Pool	45.1 Foreskin	Foretkin	119.23	576.51 Ear	154.34 Neural	164.31 Adipose	Prostate	270.8 Epididymis	14.91 CNS	Foreskin	69.98 Thymus	116.81 Foreskin	CNS	•		120.34	354.33 Placenta	289.88 CNS	52.66 Brain	264.9 Skin	Ear	Tonsil	140.92 Foreskin	Heart	Неал	Foreskin	Z10.4 Heart	cours olerus	Ses :	Hear Force	343.87 EBI	+1.12 Neural	Pancreas	102	5/6.38 ACT8	Kidney	Umbifical cord	650.09 Brain	684.31 CNS Breast
	-		i	16	ຕ	×	×	က	4	<del>6</del>			4	<b>6</b> 0	2	5		22	_	21	က		8	4		en	80				2	16	'n	6	-			7			,	- 5	2		٠	۰ ۲	=	•	<b>9</b> (	N		•	<b>»</b> «	
9 2A	0.00	900	000	000	0.00	000	0.00	2.00	3.00	0.00	2.00	8.0	8.0	0.0	0.00	0.00	0.00	9.0	1.00	0.00	0.00	0.00	0.00	0.00	2.00	5.00	0:00	0.00	3.00	1.00	9.	0.00	4.00	0.00	8.	0.00	0.00	1.00	8	8.0	0.00	8.8	8.6	8 6	8 8	8 8	8.8	3.5	9.6	0.00	8.5	8.8	8.	2.00
Table 2A	200	8	2.00	9:	1.00	1.00	2.00	2.00	3.00 0.00	1.00	2.00	1.00	1.00	3.00	1.0	<del>-</del> 80:	1.00	3.00	0.00	5.00	1.00	2.00	1.00	8.9	6.0	0.00	2.00	1.8	0.0	1.00	8.	1.00	0.0	1.00	8.0	2.00	1.00	8.0	3.80	0 :	8 8	9 6	3 6	9 6	3.5	8.5	9 9	00.0	8 8	3 3	8 6	8 8	9.0	0.00
	6.39	7.52	9.52	5.82	5.93	5.15	7.08	6.67	8.46	9.83	5.77	6.46	6.71	8.56	5.89	6.92	5.85	7.65	5.77	8.85	<b>8.6</b> 9	7.71	6.03	10.10	00.9	9.51	8.39	9.83	9.0	5.86	11.01	8.05	6.67	5.08	5.22	6.21	6.70	8.58	<b>18</b> .23	6.29	10.28	0.20	6.0	9 6	3.32	90.5	20.00	0.04	3.5	F. 5.	,	7.14	ָה ה ה ה	9.20 6.75
	672.71	293.81	54.41	26.38	279.16	17.48	1134.59	449.02	114,47	97.80	282.84	14.52	23.21	141.89	27.01	38.72	122.51	1082.71	230.36	178.23	1632.70	19.63	122.45	47.81	652.50	348.61	1366.82	95.69	204.61	200.17	92.76	27.21	75.96	21.50	168.49	639.40	95.93	390.24	23.42	39.11	1604.38	04.70	40.00	704.02	42.05	, co e	7.00	8.5	5,00	35.40	36.12	1113.27	18/U.B3	149.69
	105.30	39.05	5.72	4.53	47.05	3.40	160.27	51.78	13.53	9.85	49.05	2.25	4.07	16.58	4.59	5.59	20.94	141.55	39.91	20.15	286.70	2.55	20.31	4.73	108.68	38.68	213.91	9.73	33.89	34.17	8.42	3.38	11.39	4.23	31.92	102.91	14.33	45.48	1.29	6.21	180.45	13.0	5 6	13.54	- 0	8 5	3 5	8 8	7 6	3 5	20.5	155.02	364.00	22.18 81.18
	W15542	AA457119	R02329	N91589	N33555	W84774	AA131530	T95650	N92404	AA007370	T83864	N49577	W87292	W37447	AA004796	N36172	N26714	T95909	W02102	W72666	H98201	AA055052	AA569545	N39572	N36994	AA022561	N72307	N624B7	W63785	AA700604	N28906	R62384	N49276	H46254	N45240	W85423	AA149226	R15785	AA009484	AA040387	RALZEN	00164480	2010100	74404000	AA40497	AA 12881	197740		K45065	002600	AA019320	157834	26747	R46202
	320201	810454	124229	303049	270277	415806	503725	120678	306216	429299	113193	277714	343387	321900	42910B	272677	286250	120924	327337	345743	261163	377363	856796	277042	273652	364510	291417	288748	342208	433350	257248	139840	280387	177967	279091	416539	504623	53092	365575	376080	175717	40300E	90000	377468	267.100	631087	121664	100171	26027	58214	363055	80692	90100	152453
	9866	10003	1001	1001	10020	10022	10027	10030	10034	10038	10042	5	8	10052	10058	900	2000	10078	10081	10084	10089	10095	10096	10099	10105	10112	10113	10115	10117	8	10124	10128	10129	10136	10139	10140	10143	4	10149	10157	20101	10103	200	2010	27.0	2	10101		6016	70101	CALOL	10180	20101	10205

1ge 45 of 91

=
æ
•
5
m
\$
-
•
쨞

LID not found		LID not found	LID not found	LID not found		CID not found	regone	d Cine		£ .	₽ OF		Breast	Foreskin	Lung	Uterus	Color		d Ciner	Stomach	LID not found	Brain	id Other	Brain 9.	d Office	Managaran	Adrenal aland	od Other	P8		Prostate			nd Other	nd Other	Breast	nd Other	Anna City	Eva Fva	Olber	iyaPool	Parathyroid	Brain	nd Other	Foreskin	nd Other	nd Other	
8	Lymph	Brain	Colon	P 2	00 .	Prain	Small intestinetione	LID not found Other	Small imesunemeural	Lye Smot	, m	Adrenal pland Colon	Eye	Ear	Uterus	Luno	Placenta	LID not found o	Can the room	2 C	Colon	Heart	LID not found Other	Testis	LID not found Other	Aorte Torlis	resus neCervix	of ID not four	Brain	Parathyroid	Lung Prosts		Blood F Pool	LID not found Other	LID not found Other	Pooled	LID not found Other	ć	Foreskin	LID not found Other	Whole embryoPool	Ovary	Colon	LID not found Other	Synovial mem Placenta	LID not found Other	LID not found Other	
542.11 Spleen	31.43 Ulerus	335.43 CNS	Testis	443.96 Brain	621.98 Adipose	613.3 Thyroid	421.71 Aoria	413.37 Brain	245.27 Ignore	286.50 100.50 286.50 (mnnm	24.02 Lymnh	309.17 Thyraid	438.11 Brain	368.23 CNS	Ear	51.33 Heart	599.41 Naural	43.25 Heart	473.03 Dran	354.2 Codiy	Adrenal gland Colon	122.42 Nose	Brain	143,76 Kidney	283.1 Brain	139.88 CNS	Small intestineCervix	248.29 Whole embryof, ID not found Other	281.57 Tonsil	384.33 Pancreas	436.1 Testis	245 OR FLOR	45.27 CNS	308.54 Pool	Parethyroid	Aorta	Brain	7007	64 68 Germ Cell	185.89 Brain	Tests	217.43 Cervix	511.07 CNS	253.65 Brain	Synovial me	309.06 Eye	354.11 Brain	Description of
ω,	8	-		4	-	φ ;	우 '	<b>*</b> ;	5 '	7 7	4	. ñ	• •	40		-	e ;	∓ '	7 9	2 ×	ς	e		유 :	×	n		8	w	ø	<b></b>	n ‡	<b>- 9</b>						œ	<u> </u>		12	w	5		6	2	
3.00	000	000	3.00	8.0	00.0	8 :	0.0	000	8.5	8.8	8 5	2 8	00.	1.00	0.0	2.00	2.00	8.8	90.4	8 5	2.00	4.00	0.00	5.00	0.00	6.00	9.60	8,4	1.00	2.00	8.8	8 8	8 8	0.0	2.00	0.00	0.00	0.00	8 6	00°5	3.00	2.00	1.00	2.00	1.00	2.00	2.00	:::
8.	5.00	8.	2.00	2.00	8.	2.8	8	8:	0.00	8 6	9.5	800	80	0.00	3.00	<b>1</b> .8	000	00.0	96.	9.00	8 0	9.	0.1	5.00	8.5	90.9	8 8	8 0	8	4.00	88	8 8	90.6	8	1.00	4.00	1.00	3.00	8.6	90.5	000	0.00	2.00	5.00	0.00	2.00	3.00	
6.25	27.84	8.17	9.27	5.38	5.33	10.67	8.63	7.52	5.24	6.25	1.30	7.76	7.80	8	7.46	6.04	11.78	5.33	11.87	9.00	8.76	7.70	5.04	12.92	19.68	8.06	7.44	7.03	6.43	¥.	5.20	4 5	7.41	5.02	8.68	14.40	6.53	7.96	6.4 7.7	10.1	6.07	7.76	9.05	24.09	7.05	8.22	10,13	
332.42	230.57	19.79	352.82	21.50	112.40	318.81	4715.07	19.30	325.37	28.74	11.4	777.83	43.90	217.12	60.75	505.47	596.34	51.42	558.85	29.97	1094 78	226.19	32.69	620.10	64.15	645.84	69.52	228.15	25.58	402.97	54.16	119.59	33 88	343.88	1389.36	62.27	22.55	8 8 8	7.97	2. 2. 2. 3.	89.26	237.42	13.64	22.97	9.28	1842.03	23.90	
53.18	8.28	2.42	38.08	3.59	21.09	89.83	546.62	2.57	62.10	4.76	2.13	20.58	5.56	30.83	7.85	83.72	50.72	9.85	47.70	11.67	16.9	29.38	6.48	48.00	4.27	80.09	5.54 as as	28.77	3.98	61.65	10.42	3.63	32.02 4 57	08.53	208.05	4.33	3.60	4.07	1.24	, e	14.71	30.61	1.51	0.95	1.32	199.76	2.36	
157221	T95113	R43646	AA400262	R38069	AA007899	H09769	AA834006	R56148	AA156461	R38274	190668	AA629558	H10079	AA078280	T58129	N94820	R39555	AA041300	R54797	AA402812	AA088430	H09664	R43456	R53980	R43678	H10661	AA608555	AA460366	R45284	H11016	AA487898	K53446	PSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS	AA034059	W35416	R56123	R38546	W72881	T50995	A4409047	AA429573	AA458473	R42695	R54109	R23735	AA489768	R38018	
73222	120600	32825	742635	23218	429448	46360	868304	41405	505491	23554	121406	434710	48949	432042	79240	306575	23728	376358	40352	742038	541808	46438	32483	40150	22845	46238	950676	795084	23063	47059	840576	40038	8385/B	429938	321751	41391	23822	345262	16647	0,000	781461	809600	32092	41825	131626	839807	24237	
10201	10210	10218	10223	10224	10225	10232	10235	10240	10246	10248	10253	10201	10264	10286	10268	10269	10272	10275	10278	10282	10288	10293	10294	10297	10302	10309	10312	10315	10316	10317	10319	10321	10323	10326	10327	10329	10340	10342	10344	1034	10351	10355	10356	10361	10362	10363	10364	

Bone	Pool	Cervix	Stomach	Other			Uterus	Eye	Testis	CID not found		Lymph	Foreskin	Officer	Eye	Thymus	Pool	Gem Cell	lens.	Whole embon	Nose	Pooled	Foreskin	Ovary	Whole embryo	Ē	Prostate	CNS	LID not found	Lung	Ulerus	Orestate	200	j	Pool	Pancreas		•	Umblical cord	E .	Brain	Pancress	Gerra Cell	Other		Bone	1 Placenta	7
Parathyroid	Kidney	nec Aorta	Heart	LID not found		LID not found	Placenta	Gall bladder	Hear .	lestis 2	Ē	Adrenal pland Lymph	Placenta	LID not found	Pooled	Noso	Lung	Cervix	0000	CNS not sound	Head and one Nose	ec Adrenal gland	Lymph	Cervi Cervi	Eye		Ovary	Aorta	Pool	Uterus	Pooled	Whole emboy Prostate	d Bone		Testia	Ovary		LID not found	yopooled	MUSCA	Speed	2	Pooled	LID not found		cord Germ Cell	Adrenal gland Placenta	I Day of
95.89 Cervix	Cymph	2	252.02 Musde	62.25 Pool			629.23 Pooled	Foreskin	SNS	SNS	730 79	194 Thyroid	Germ Cell	316.62 Pool	22.79 Blood	199.9 Aorta		440.23 Esophagus	nyraig 2007	152 58 Bone	Esophagus	Head and nec	_	561.65 Breast	Blood	63.7	Adioose	Blood	103.51 Brain		444.77 Stomach	Head	403 27 Artranal cland Rone	-10.43	Overy	274.87 Larynx	44.66	183.74 Pool	335.81 Whole embryoPooled	BLOG .	250.4 Pooled	137 5 Cervix	46.48 Thymus	208.92 Brain	591.55	Umblical	57.07 CNS	
9			15	8			-				•	» ~		12	91	<b>=</b>		<b>m</b> 0		5	•		5	<b>80</b>	•	* 6	:		7	•0	4		5	ັດບ		19	9	Ξ:	9	•	19		. 12	70	S		Ξ	•
2.00	<b>6</b> .00	0.00	0.00	0.00	0.00	0.00	0.00	00.0	00.0	0.00	8 8	8 8	000	000	0.00	90.0	8	8 6	9 6	9 0	8 6	9:	9:1	00'0	8 8	90.0	8 6	00.0	0.00	8.0	8.5	8 6	8 5	8 8	0.00	1.00	1.00	8 :	8.8	3.5	0.0	8 8	001	0.00	2.00	8.	8	
5.00	8	3.00	1.00	2.00	5.00	3.00	7 8 8	1.00	4.00	9.0	3 5	8 8	4.00	1.00	1.00	5.00 0.00	2.00	8.00	00.6	8 5	9 6	000	0.00	7.00	0 0	8 5	2.00	5	8.	2.00	8.6	8.5	3 5	8 8	3.00	13.00	8	2.00	0.0 0.0 0.0	9.5	9.5	000	000	1,00	1.00	00.0	1.00	
8.49	9.82	8.81	5.12	9.88	6.08	7.40	7.15	6.88	6.01	5.30 0.30	0.00	20.5	15.17	5.27	5.31	9.77	8.91	11.40	9.6	9.03	5.54	6.79	11.17	17.71	0.90	0 40 0 40	5.54	5.38	5.01	6.67	5.69	16.35	20.0	16.25	8.54	68.60	7.41	6.38	S. 3.		6.01	5.0	12.23	7.35	6.93	5.97	110.14	
993.99	241.73	230.85	235,75	117.38	449.48	41.33	30.97	4.65	37.03	15.02	70.07	98.66	208.51	78.31	37.61	82.30	10375.29	246.82	025.00	303.60	1553.70	133.85	678.41	309.86	143.51	55.44	72.85	81.51	17.87	724.53	38.83	37.27	106.83	20.88	31.42	560.56	117.88	167,78	77.50	67.6	55.32	1256.57	147.97	60.13	<b>3</b>	114.79	1683.19	
117.10	34.79	26.21	48.08	11.78	73.91	5.58	4.33	0.68	6.16	2. 2. 2. 2.	11.63	5 5 5 5 5	13.74	14.87	7.08	6.43	1165.06	21.64	05.71	4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	237.84	19.71	60.74	17.49	20.78	¥ 5	11.15	15.19	3.57	63.53	6.83	973	10.10	3.13	3.68	8.17	15.91	28.39	13.30	8A.7	9.20	138 10	12.10	8.18	7.81	19.22	15.28	
AA486410	R06746	AA448285	R87122	R07128	R89104	R89828	R21408	AA013260	AA053815	N62213	AA 140303	N73705	AA453495	AA005428	H77729	AA485377	N91165	AA406020	21686088	N50350	AA157813	AA074596	AA419177	AA464963	W86199	WE2790	AA464694	AA459681	W84867	AA135868	AA150263	AA102068	WASSA4	H70887	AA010600	AA459401	AA045658	R94491	AA150777	AA440003	AA005140	AA629909	AA071486	R56044	H09618	AA629262	86060H	
842879	128513	782851	197374	128739	195801	194669	130078	360155	360065	290182	909900	289287	795378	428492	234623	811015	301817	742132	3/0452	28820	588915	386041	755578	810089	415699	344134	810230	785561	415715	502917	481644	376043	121402	223949	430291	810960	489208	198311	504826	187131	429060	884655	631319	40873	46896	744047	46173	
10368	02001	10374	10395	10418	10427	10435	10438	1044	0446	84 6	200	10460	0462	0465	0467	9468	27.	872 872	3 5	2 2	0488	0493	98	0501	3 3	513	212	10522	0525	0530	0531	10533	1550	243	55	920	10550	0553	<b>3</b>	200	10558	26.00	988	0567	0571	10573	0575	

Table 2A

9
ซ
8
96

Other	رسع	LID not found	Uterus	Prostate	Uterus	LID not tound	Prostate	Ovary	E S E	Brain	Colon	Kidney	Whate embryo	CNS	Brain	LID not found	Pooled	Muscle	Eye	Lung	Bone	CNS	LID not found	Stomach	Pool		Kidney	Testis	Bleod			Parathyroid		Muscle	CID not round		Brain	Testis	Heart	Testis	Heart	Other	Kigney	Prostate	Pool	1 Other	LID not found		Ulerus	1 Olher	1 Other	LID not found	1 Oiher
LID not found Other						Tests		Liver						Pooled	Ovary	Brain	Малом	Splean	Germ Cell	Foreskin	nEye	Pooled	oBrain	Parathyroid	Brain		Parathyroid	Breast	Prostate	Placenta	Adrenal gland	Placenta	CID not found	CCGCAX	Rain		Pool	Torsil	Synovial mem F	Breast	CNS	LID not found	Muscle	Adipose	Germ Cell	LID not found	Pool			LID not found Other	LID not found Other	Heart	LID not found Other
	323.97 Brain	259.81 Brein	141.38 CNS	Pool	143.12 Lung	466.05 Brain	Ovary	426.08 Gall bladder	130.67 -	468.83 Aorta	229.15 Pancreas	Gall bladder	21.38 Foreskin	97.77 Brain	471.33 Adronal gland	91.11 Spleen	601.67 Neural	268.7 Gall bladder	Brain	194.06 Brain	258.04 Synovial memEye	97.77 Brain	278.4 Whole embryoBrain	340,31 Neural	32.28 Uterus	214.41	278.42 Brain	162.94 Ear	276.85 Foraskin	24.9 Lymph	188.25 CNS	56.88 Gall bladder	227.31 CNS	262.8 Head and nec Cervix	Prostato	Ac. 76	229.15 Ovary	Eva	307.17 Lavax		109.9 Spieen		529.52 Nose	57.93 Neural	141.87 Ear	Pool	167.66 Prostate		284.58 Aorta	Pool	112.49 Foreskin	123,72 Pool	592.27 Pool
7	^	=	^		e	7		•	-	^	21		<u> </u>	7	7	n	_	-		8	5	7	19	17	13	19	5	5	=	16	12	7	4	4	;	=		i	11		22	2	<b>.</b>	7	٣		4		13		19	4	2
3.00	0.00	1.90	000	0.0	1.00	9.00	8	5.00	8.	0.00	8.0	0.00	0.00	8.	0.00	0.00	2.00	0.0	0.00	5.00	000	0.1	2.00	8.	0.00	5.00	8.0	9.	1.00	000	9.1	0.0	8	000	00.0	90.0	8 6	000	000	000	8	00.0	00.0	80	00'0	3.00	3.00	3.00	0.00	1.00	0.00	000	9.0
2.00	8.	9.1	1.00	8.	8	8.9	3.00	21.00	5.00	1.00	2.00	1.00	2.00	0.0	8.00	1.00	0.00	0.1	7.00	4.00	6.00	1.00	7.00	0.0	2.00	1.80	2.00	0.0	0.00	3.00	8.0	8.	<u>.</u>	2.00	8.6	8 6	00.6	8 5	8 6	2 00	000	8	8 2	1.00	90.	3.00	3.00	1.00	1.00	0.00	8	6.5	8.
9.03	9.26	6.37	5.41	39.01	22.17	8.94	9.60	117.56	7.80	7.28	7.47	6.10	9.76	5.51	15.69	8.83	6.87	96.44	39.51	15.52	19.49	6.97	12.07	11.45	8.20	11.67	6.11	9.03	7.20	69.6	5.20	10.55	5.37	8.89	16.48	10.96	15.78	5.43	8 8	58.5	7 28	5.87	10.38	6.89	28.75	6.47	9.68	6.33	1.76	5.80	5.33	5.68	5.29
136.25	62.58	39.97	28.84	234.02	151.10	627.73	710.43	372.02	66.85	112.35	20.43	38.68	65.74	23.78	188.01	18.33	119.79	70.39	79.05	385.27	100.31	7.37	195.37	132.27	428.97	819.70	40.85	67.74	158.85	39.90	103.13	25.74	20.36	133.33	41.18	70.78	82 18	48.75	247 95	567.57	29 73	17.38	235 73	36.47	117.55	289.72	57.72	60.93	39.49	211.40	607.20	26.13	40.24
15.09	6.76	6.28	5.33	9.00	6.82	70.18	74.03	3.16	8.47	15.43	5. 5.	6.34	6.73	4.32	11.98	2.07	17.44	6.73	2.00	24.63	5,15	1.06	16.19	11.55	82.53	70.24	6.69	8.73	22.05	4.03	19.84	2.44	3.78	15.00	2.50	8.3	\$ 50 50 50 50 50 50 50 50 50 50 50 50 50 5	3.22	20.00	81.64	200	8	25 25	4.10	4.39	34.20	5.96	9.62	5.08	36.44	114.02	4.60	7.60
H10047	H08582	H09959	H09078	AAG78335	AA036881	H17620	H23228	H86554	H09082	AA670430	H11728	AA682293	H15408	R20639	AA419229	H16733	R44078	AA629603	H28734	R37108	AA421218	R54105	R37696	H72030	R44214	H23529	H09164	N69091	AA173926	H18834	AA589085	AA486780	N46354	AA431887	H20747	H23225	66164847	M30224	AA406878	M30702	Wansan	NOBLEG	Nesota	N92895	N3030B	AA004321	T96309	AA005355	AA137073	AA004353	N35025	W90067	N32623
46829	45877	46367	46266	430966	472008	50587	51991	223350	46273	878838	477.88	461727	49227	26505	755612	50004	33715	884783	49987	25838	739193	41720	25520	214985	34468	\$1907	46411	287468	595109	51604	850428	841094	279308	773639	51433	51988	606.407	183137	603603	367096	417976	259072	30626	309081	25,8028	428652	121028	429196	491186	428697	271471	418081	280022
10584	10587	10598	10603	10813	10614	10616	10620	10622	10623	10626	10827	10629	10632	10635	10637	10639	10640	10641	10642	10644	10648	10651	10652	10653	10660	10665	10877	10688	10711	10716	10718	10721	10735	10737	10740	10741	10/44	27.07	10764	4075	10763	2000	10764	10767	10772	10778	10782	10798	10799	10802	10808	10814	10816

_
8
6
8
훘
ے

Bone		Other	Pool	Lymph	Parathyroid	LID not found		Parathyroid	Pool	LID not found	Eye		Prostate	:	Parathyroid	Kidney	Colon	Geral Cell	Stomach	Parathyroid	Prostate		Gerra Cell	Kidney		Umblical cord	Eye	lestis Other	Mische	Tookil	LID not found		Ear	Breast	Spleen	Esophagus	LID not tound	OKIN	41	Lymba mde		Braast	LID not found	Testis	Other	Bone	Foreskin	Pooled	Other	Gall bladder	Brain
<b>₹</b>	Color	found	Uterus	100		Pool		Stomach	Breast	Pool	CNS		CNS	;	Gerra Cell			Loreskin	Smooth musc Stomach	Spleen	Spleen		Foreskin	Adrenal gland Kidney	i	1		Lymph		T T T T T T T T T T T T T T T T T T T	Line	P	Bone		Lymph	Head and nec Esophagus	Brain	• F		- Ambh	į	Heart	Testis	Heart	LID not found Other	Brain	Nose	Adipose	LID not found Other	Esophagus	Eye.
74.71 Ignore	499.89 Foreskin	Pool	Heart	383.51 Thyroid	387.37 Stomach	Heart		253.29 CNS	603.72 Lymph	-10.76 Ovary	Laynx	135.17	481.98 Parathyroid	99.75	111.13 Thymus	709.74 Foreskin	Bone	Parathyroid	Lymph node	42.89 Esophagus	682.97 Thyroid	94.62	554.22 Skin	464.97 CNS	:	675.72 Smooth musc Skin	126.92 Small intestmer arathyroid	Biood	The said	inyidin	, To	540.8	Skin	Kidney	Blood	387.82 Larynx	525.98 Breast	236.07 Synovial mem -	200.01	662 74 Thomas	567 74 Broin	558.38 Muscle	Spleen	44.83 Brain	Brain	61.44 Ignore	185.79 CNS	299.02	Brain	21.67 Laryax	416.74 Cervix
ß	9	?		æ				Ξ	7	G)		15	^	9	<b>6</b>	2				12	-	1	-	9		۰,	0					9				Ξ	~ ;	<u>د</u> و	<b>.</b>	9 4	٠,			12		5	19	6		<b>ā</b>	0
0.00	000	90	90	100	000	000	2.00	0.00	0.00	5.00	0.00	1.00	0.00	3.00	9.	6.	0.00	0.0	0.00	0.00	6.	1.00	1.00	0.00	00.0	8	000	9 9	9.6	8 8	8 8	8 8	0.0	0.00	0.00	8	000	9 9	8 6	3 8	3 8	3 6	2.00	000	0.00	0.00	0.00	0.00	3.00	8.	2.00
3.00	8	9 0		8	2.00	200	800	200	3.00	200	9.	0.00	2.00	2.00	0.00	0.00	1.00	2.00	4.00	5.00	9.	0.00	0.00	1.00	2.00	9.	5.00	8 9	9.5	9.00	8 5	00.	5.00	8.4	60.4	2.00	8	8.8	3 6	00.	8.	3.5	000	2.00	5.00	8	8.	1.00	1.00	0.00	60
16.26	6.83	86.8	2 20	98.6	9,46	7.11	8.05	7.12	89.86	12.56	16.58	9.06	98'6	7.83	5.88	4.04	8.68	7.83	6.51	7.38	9.81	6.58	7.97	5.03	7.88	7.29	6.50	5.71	0 0		7.0	13.78	13.97	7.72	10.36	19.27	5.14	9:50 1:50	9.	5.05 67.05	0.21	9.69	5.58	8.02	6.19	5.19	5.05	5.17	8.80	5.73	7.18
27.95	27.99	58.48	617.65	34.18	56.94	1010.78	63.17	49.81	317.54	399.27	46.17	95.38	2560.65	96.29	31.80	58.65	37.41	132.95	545.96	39.13	40.08	280.02	224.85	18.70	27.56	172.64	153.71	123.01	24.22	347.75	194 04	256.87	458.69	146.94	46.81	97.13	10.64	105.91	405.04	1167.94	138.70	19.48	67.66	28.46	16.26	8 48	37.68	167.02	25.76	599.29	1271 R7
1.72	4 10	5 65	111 80	111	8.82	142 07	10.44	7.00	3,53	31.79	2.78	15.74	257.16	12.30	5.32	4.18	4.31	16.99	83.84	5.30	<b>4</b> .00	42.55	28.20	3.72	3.50	23.68	23.64	21.53	4.32	£ 6. 1.	13.13	18 62	32.83	19.03	4.52	5.04	2.07	20.33	2 2	231.06	12.57	2.76	12.12	3.55	2.63	12.48	7.45	32.28	3.22	104.55	177 53
AA459389	N67832	TARR18	00000	Names	886242	W72892	H92865	R32334	R91570	H92974	N51357	H93050	N52554	AA011383	N92924	N36174	AA48270	N92502	N57577	AA476255	H61758	W04713	N25240	AA454218	N62086	AA457153	W90705	N93438	W76169	AA459286	Section 1	WR6518	AA669750	H12338	AA047478	AA055486	H24350	H15718	K38349	N56053	12616N	K38364	T\$9016	R42433	R44754	H29521	N47443	AA434139	172533	H54417	DASAG
810937	201590	400053	10300	25.85.E.R	194515	345838	241995	134942	196543	242001	283190	241946	244798	428505	307687	272690	782838	304686	278999	770681	236155	320455	267458	785522	287528	810496	418004	307249	346899	810911	30/304	416744	684283	146469	487988	377275	52071	49318	23579	283984	306841	23897	74518	30175	34041	17465	280697	770588	21920	203003	10330
10819	10820	07001	07001	0.00	10842	10848	10852	10855	10858	10860	10867	10868	10875	10876	10889	10890	10895	10897	10899	10903	10901	10905	10908	10911	10916	10917	10918	10929	1093	10935	10837	1090	10950	10951	10953	10054	10960	10983	10968	10974	108/19	10304	1098	1000	11008	11011	11011	11018	11024	11030	

5	
ö	
င္တ	
8	
α.	

	CNS	Prostate	Other	Ovary	Other			Other	Placenta	Other	Lymph	LID not found		Ovary	Umbilical cord	LID not found	Kidney	Prostate	Gall bladder	Gern Cell	Parathyroid	Stomach		Whole embryo	Germ Cell		Other	Overy	Other	LID not found	LID not found	Pancreas	Lymph	LID not found	Foreskin		Placenta	Aorta	Bone	Cae		ŝ	o age	Brain		e SCIS		8	Oiner	LID not found	nEye	Other	Heart	Ovary .	Ovary
	ğ	CNS	LID not found Other	Prostate Ovary	LID not found			orng orng		LID not found Other		Pool		d Eye	Muscle	<u>P</u> 00	Gerra Cell	Aorta	Thyroid	Parathyroid	Thyroid	Çez <u>i</u>		Tonsil	Lung		LID not found Other	Gem Cell	LID not found Other	Brain	<b>8</b>	Pooled	Pooled	Brain	Lymph	LIO not found	Breast	Eye	yoSpleen	CID not found		mroreskin	LID not found	Kidney	LID not tound	Placenta		- oreskin	UD not found Other		Synovial mem Eye	LID not found Other	Colon	Pancreas	Placenta
	118.94 Ear	242.83 Ovary	37.32 Brain	Breast	Pool		118.71	Brain	75.1 Smooth musc Thymus	151.38 Brain	53.59 Adrenal gland Pooled	373.9 Heart	52.28	Adrenal gland	Lymph	214.06 Erain	338.35 Colon	416.03 Kidney	309.19	Cervix	Gall bladder	38.6		455.53 Breast	711.38 Breast	644.94	4.6 Brain	CNS	28.06 Brain	Eye	Brain	45.2 Ignore	245.32 Neural	740.99 Pool	508.5 Poded	8	295.61 Lymph	Bood		287.91 Brain	e cye	101.74 Synoviel mem-oreskin	157.88 Brain	139.45 Ear	272.22 Pool	roreskin			653.71 Pool		339.79 Bone	P80	CNS	CNS	442.17 CNS
	12	=	œ				9		15	€0	12	5	۲			6	-	œ	ø			20		5	-	4	ĸ		พ			5	15	-	5		=		,	15	;	72	21	7	7		•	ומו		ıo į	11				~
<b>§</b>	1.00	0.00	3.80	0.00	6.9	8.0	0.00	5.8	1.00	5.00	9.1	3.00	8.8	0.00	1.00	8.	0.00	0.00	0.00	0.00	2.00	8.	6.9	2.00	0.00	5.00	0.00	2.00	0.00	0.00	9.0	0.00	0.00	2.00	3.00	4.00	8	0.00	9.	0.00	8	8 6	8	8.	000	2.00	0.0	000	9:0	0.00	0.00	5.00	0.00	0.00	0.00
	1.00	8.	0.00	2.00	2.00	8	3.00	4.00	9.0	2.00	0.0	2.00	2.00	1.0	2.00	0.00	1.00	2.00	1.00	2,00	2.00	9.0	4.00	0.00	5.00	0.1	0.1	0.00	2.00	9.	1.00	3.00	5.00	0.0 0.0	3.00	9.7	0.00	8	8	2.00	9.80	8	3.00	1.00	3.00	22.00	3.00	00.4	00.0	8	1.00	<b>4</b> .00	9.	<del>.</del> 8.	9.
	16.45	9.14	9.75	5.57	11.29	9.13	2.00	9.58	5.32	10.24	8.67	8.51	15.41	5.27	6.62	5.83	7.59	10.57	6.37	11.43	12.23	5.82	8.21	69.9	6.07	6.83	5.64	6.18	10.18	5.84	6.62	14.37	8. 14	5.32	6.65	19.93	8.08	6.75	5.20	7.78	14.70	18.21	7.60	9.86	7.78	9.	7.55	8.13	6.75	6.13	6.62	8. 8.	3.6	7.09	6.07
	282.19	28.59	62.33	41.20	432.24	43.84	464.36	110.09	200.68	311.46	34.87	363.47	1385.32	417.11	194.37	120.73	45.92	34.80	3656.31	157.20	216.14	628.67	208.08	322.62	69.53	2058.98	38.79	202.83	31.21	35.72	88.88	72.42	843.57	40.01	650.07	265.62	163.64	69.80	73.75	7.86	143.60	820.58	5.31	335.05	263.80	1138.23	91.10	59.71	116.36	64.88	83.89	199.18	1345.02	40.59	737.87
	17.14	3.13	9.40	7.40	38.27	4.81	66.35	11.47	37.75	30.41	4.02	42.73	89.80	79.16	29.35	20.69	9. 9.	3.28	574.04	13.75	17.67	108.04	25.11	48.24	11.46	301.59	6.88	32.64	3.07	6.12	5.13	5.04	103.58	7.52	97.71	13.33	27.02	12.16	14.17	0.98	9.77	50.61	0.70	33.88	2.02	8.8	12.07	7.35	22	10.58	12.69	21.32	155.59	5.72	121.50
	T60081	AA402891	R43867	R54193	R00046	AA401397	AA457543	H28985	N70520	R37615	H15533	W57872	AA419143	AA457485	AA191019	H09790	AA134985	R43318	AA669674	AA195463	H16793	AA186327	R38944	H16785	R54822	AA629987	H16832	AA599140	R56130	R17747	H17308	N90281	N24024	R39926	H17634	R20755	AA053411	AA113291	AA417307	R37410	AA169372	AA164819	R56898	149355	R92011	N33083	R08164	N32285	W88497	R92448	N92415	W80635	N48057	N50904	N63034
	81318	741958	33486	41822	123085	743113	638732	49922	299059	25029	49264	340994	755581	838287	627040	46667	568057	32863	856981	627226	50562	628531	25061	50585	40384	884500	50786	950497	41186	25396	60421	302832	268795	25355	50805	26196	510060	526945	731121	25983	609743	595078	41214	67440	195274	270385	127230	272708	417730	198325	308238	415535	281681	281045	278875
	11036	11038	11039	11041	11043	11046	11047	11053	11056	11060	11061	11067	11074	11075	11078	11079	11080	1081	11062	11083	11085	11086	11092	11093	11097	11098	11101	11103	11105	11108	11109	11114	11115	11116	11117	11118	11120	11122	11123	11124	11126	11127	11128	11133	11139	11150	1154	11163	11170	11171	11174	11188	11188	11191	11200

					48					oid Did	PG.													orug	orno orno							pond					puno			prino		onud										
Tonsi	Char	Other	Pool	S C	Pancreas		Testis	Foreskin	Testis	Parathyroid	Parathyroid	Prostate	Testla	Heart	Prostate	Ulerus	Blood		Kidney	Breast	Hear		Hear	LID not found	ED PG	į	Olber G	d Other	SZKE		Total	11D not found	Eye Sye	Tonsil	d Other	Brain	LID not found	Blood		LID not found	Heart	LID of		ביים היים				Tage of	8	Skin	Hans	1
Uterus	110 miles		Lima	LID not foun	Muscle		Pancreas	Tonsil	Brain	_		Muscle	Lymph	Kidney	Testis	Lymph	Ovary		Pooled	Germ Cet	Pool		Pancress	Неал	Testis	:	LID not found Other	LID not foun	Chair resu	Solog -	Placente	Pool	Pooled	er Lymph Tonsil	UD not foun	Foreskin	Brain	Stomach		Placenta	Brain	Brain	Placenta	Liver	Topsil	Total Modern	Aoda Gaudel	10 post found		Spleen	Stomach	
165.7 Brain	0	123.62 CNS	508.52 Tonsil	567 03 Pool	SAS	}	548.99 Cervix	343.84 Thyrold	Overy	632.4 Adrenal gland	238.08 Lung	305.6 Adipose	160.78 CNS	Bood	Tonsil	Germ Cell	522.77 Foreskin		•	8	252.49 Liver	472.48	20.42 Germ Cell	Testis	675.72 Spleen	688.26	251.52 Pool	345.44 Pool	31.44 Inyroad	on of Donby	108 BR Adimes	883 89 Colon	568 CNS	Peripheral no	18.92 Brain	201.24 Pooled	591,57 -	81.46 Nose	546.17	765.21 Brain	49.48 Muscle	35.63 Pooled	Muscle	236.58 CNS	Adipos	acoding to ove	611 42 Parathomid	ATOM Besington	155.48	272.16 Larynx	aroun	B 200 00 00
5		7	. ~	1 62	•		80	45		-	15	11	ო				\$			;	12	m	12	ı	-	ຕ :	×	ın e	0	a	2 0	. "	~		2	တ	-	2	~	-	ı,	8	;	× 4	ס	÷	- 4	* *	- 5	×		•
80		800	200	000	8	8	2.00	0.00	9.	0.00	0.00	00.0	0.0	00.0	0.0	0.00	0.00	000	5.8	000	0.0	5.00	8.	8	8	0.00	0.00	8 8	9.6	9 6	9 9	800	000	1.00	0.00	8.4	2.00	1.00	8	3.00	8.	00.0	8.	8 8	8 8	8 6	8 8	9 6	8 6	8	900	3 8
2.00	00	2.00	8	00.	100	900	00.4	3.00	8.0	8.8	8.6	1.8	<del>2</del> .	2.00	4.00	1.00	6.00	8	8	8	3.00	0.0	8	<del>-</del> .00	2.00	9:0	6.00	9.6	5.00	3 5	3 5	8	8 5	0.00	2.00	4.00	5.00	9. 9.	8	9.5	0.00	8	000	3.0	3 5	8 8	8 5	8 8	8 6	000	9	)
14.39	7.70	12.85	14.50	5 08	10.11	8.43	47.20	9.23	6.57	15.98	16.76	5.89	5.52	8.01	9.07	6.87	7.51	7.20	12.55	24.53	11.79	7.36	6.45	8.55	8.24	8.38	15.70	5.83	20.0	98 6	200	5.52	10.82	5.35	9.54	13.07	6.92	6.84	9.59	7.56	5.07	7.55	5.32	15.31	6 87	2	2 5	2 2	5.5	12.75	10.85	
32.71	75 77	53.38	887.19	100 34	3	20.49	145.25	220.28	68.40	290.55	70.39	1560.18	24.23	31.10	89.02	47.17	88.78	538.79	524.80	115.70	909.87	85.13	111.75	42.66	32.74	168.22	588.61	88.43	1065.53	07.71	90.90	170.86	45.89	103.64	20.79	912.86	407.74	99.97	1281.57	753.04	55.53	16.69	28.20	47.72	328.03	446 70	247.87	746.53	229 88	479.89	14 83	
2.27	3.17	4.15	81.18	19 70	6.31	2.43	3.08	23.86	10.41	18.18	4.20	264.67	4.39	3.83	9.82	6.87	11.82	74.78	41.81	4.72	77.17	11.57	17.31	6.51	3.97	20.12	37.49	15.17	1/6.99	65.6	(8 G)	30.93	4.24	19.38	2.18	69.85	56.91	14.61	131.51	99.60	10.95	2.21	5.30	3.12 2.00	47.73	90 94	38.81	30.01	8 8 8	37.64	1.38	
AA005254	HASAN	N62846	N92947	W92798	AA135888	R23727	AA447522	H57308	AA485432	AA453474	AA498630	AA454610	N53512	AA453588	R74478	AA136080	AA044814	W85927	AAD69372	AA025434	AA455528	N69393	W74602	AA454022	AA453470	W84780	N38787	H98487	W47.178	AA127744	BA0234	R98849	AA018457	W86860	R55367	H29820	H29771	R42685	AA055835	H18790	H10417	H23213	R70505	N62394	Banara Banara	990779	W73474	BAARO7	R73570	AA485442	AA869272	
428828	210554	278759	307740	418400	502674	131589	782575	204740	811033	795185	755751	811604	284160	785207	143450	490060	488584	418154	382564	365707	809829	292736	346698	795278	785171	415630	244012	201172	324205	40133	147075	201090	362409	416390	40598	52865	52647	32289	377461	50559	47074	\$1775	141852	288663	25636	976378	24433	33003	156437	811064	854138	
11208	1207	1208	1210	1218	1220	11222	11237	11242	11246	11254	11256	11258	11282	11265	11287	11269	11283	11287	11288	11289	1280	11295	11296	11297	1288	1301	11303	11309	71811	1321	1324	1327	130 081	11333	11344	11347	11348	11349	1350	11351	1325	1360	1361	11362	295	900	27.5	11378	71377	11389	11390	

Page 51 of 91

Page 52 of 91

	•		Brain		Pancreas		Foreskin		LID not found	LID not found Other	nec Spleen		Slomach			Esophagus	Whole embryo	Whale embryo	Pancreas	LID not found Other	Utens	Synovial mem Adipose	Gall bladder	Stomach	InerEar	UD not found	Bood	LID not found Other	Whole embryoUterus	LID not found Other	:	LID not found	Ovary	LIU net reuna	Companie Civer	-	Dool fand Other		LID not found	الساع	Synovial membrane	Aorta	LID not found Other	Whole embryoPool	Overy	000	Lagr	Adrenda gland			CIC not found		Colon LID not found Other	
	Uterus		Germ Call	tomy.	Brain		Brain		Pool	LID not fo	Synovial mem Head and nec Spleen		Adipase		Brain	ordSkin	Ear	Brain	Tonsil	LID not fo	Smooth muse Germ Cell	Synovial	Spleen	Head and nec Thyrold	Peripheral ner Ear	Eye	SS	LID not fo	Whole en		,	Eye	Head and nec Adipose	8 .	Economics				Pod	Eye	Nose	usc Brain	LID not fo	Whole en	Foreskin	6 m	Oterus	Brain	estis	בים הסו ומנוחם	Poor	raraunyie Calab		
	Germ Cell	189.84	•	VevO	Pooled		108.17 Skin	346.22	Hear	<u>8</u>	Synovial m		508.83 Larynx	413.37	157.1 Stomach	123.72 Umbilical cord Skin	504.23 Muscle	130.88 Tonsil	399.44 Blood	Brain	Smooth mu	Ignore	373.42 Liver	Head and n	745.31 Omentum	8rain	281.08 Kidney	215.15 Brain	352.69 Ear	485.02 Brain	248.09	Brain	Head and r	eran Gran	22.84 Brain	277 24 Brain	Rein	421.53	Heart	276.54 Aorta	70.89 Neural	355.54 Smooth musc Brain	458.69 Brain		373.32 Marrow	Brain	27.41 Pancreas	327.21 Bone	Z C	e k	lestis	CASE Deal	511.5 Pool	
		80	•				-	Φ					7	60	თ	7	8	5	<b>9</b>				=		8		8	60	2	<b>2</b>	8			•	n	•	•	S		12	6	8	9	;	=	;	9	£			8	3 "	n 4	r
Table 2A	2.00	80	8	8 8	000	0.00	0.00	1.00	0.0	0.00	8.0	0.00	1.00	0.00	0.00	0.00	8.0	2.80	9.	3.00	0.0	0.00	00.0	0.0	0.00	8.	0.0	1.00	0.0	8	0.0	8 :	8 8	8.6	8 6	3 8	88	8	2.8	8.	3.00	8.0	2.00	0.0	4.00	0 0	00.0	00.0	9.5	8 6	9 9	3 6	8 6	>
Tat	0.0	8	8	3 5	2 00	6.	5.00	0.00	9.	3.00	1.00	1.00	0.0	9.	1.00	1.00	9.0	9.6	0.0	3.00	2.00	1.00	8	1.00	7.00	13.00	5.0	9.	8	<u>.</u>	8	8	8.5	8 9	8 6	8 8	3 5	8	000	8.	8	9.	9.	8.5	8.9	8 8	9.4	8	8.6	9.6	8 8	3 5	8 8	} •
	15.53	5.77	9	10.53	80	7.83	8.56	7.12	8.31	9.85	27.53	16.14	5.04	5.34	5.72	5.12	8.72	5.78	10.17	8.84	11.47	5.05	5.38	10.75	8.15	65.33	5.53	6.88	6.75	7.36	6.53	5.24	5.05	6.06	6.05	9 4		13.12	9.16	34.65	8.55	5.07	6.81	8.54	6.48 6.48	7.08	4.4	10.84	5.32	18.60	7.47	13.00	5. S.	e P
	79.80	488.50	25.52	58.38 38.38	8.5	44.52	32.12	302.25	92.30	115.02	63.41	548.03	136.32	170.13	23.57	1212.18	<b>3</b> .50	123.48	303,93	825.31	258.14	54.72	84.82	29.30	78.19	498.55	57.12	37.16	29.41	11.58	639.36	11.87	40.97	14.45	13.48	25.30	2.5	599.97	279.50	100.79	961.14	58.22	38.52	70.82	734.17	11.63	74.01	31.19	55.55 55.65	480.86	58.38	10.110	288.78	22.20
	5.14	80.88	2 BS	4 v	2 5	5.61	3.75	42.44	11.11	11.68	12.15	33.95	27.08	31.87	4.12	236.75	5.14	21.34	29.89	93.34	22.51	10.84	15.77	2.73	9.60	7.60	10.34	5.40	4.36	1.57	97.97	2.23	8.11	2.38	2.23	8.3	, 5, 7, 8, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13	45.73	30.51	2.91	146.68	11.49	5.65	8.30	113.34	Z :	33.5	2.88	10.28	25.86	7.81	05.70	118 78	;
	AA047190	N27829	W62190	4443131	AA481745	AA041254	N86139	N51499	W90748	AA002091	N75473	AA427715	W86282	N47717	W49494	AA644234	AA176957	T72562	AA458838	R15794	W58771	AA677083	R97710	AA629686	T40541	H50114	H18950	R38678	AA131238	H09616	AA683520	H24020	AA419088	H10/08	H10228	20030403	P19804	H20828	AA053982	R55809	AA487885	R41972	R56045	R20670	AA101155	H11895	AA158244	H23524	AA190834	AA505003	A4400013	K36134	AA121158 H23230	204041
	489047	270038	126181	323363	610772	378308	278504	282108	418297	428124	299162	710997	415851	281039	324927	845519	611586	22144	814353	53103	340857	454190	200263	884436	60565	179163	51408	25153	503579	46183	378813	51585	755517	47262	46921	20002	78787	51548	364839	40908	840575	32050	40771	26520	583592	47451	292802	51799	627105	839784	742541	781187	511718	9
	1649	11652	11687	200	11878	11679	11682	11684	11685	11686	11695	11697	11704	11711	11713	11723	11726	11728	15731	11735	11757	11761	11763	11773	11774	11778	11782	11784	11789	11792	11795	1800	11805	11808	11809		11011	11821	11822	11825	11827	11828	11833	11836	1840	196	1842	1045	184	11651	285	1185/	11859	3

Page 53 of 91

22.08 5.21 1.1 3.0.06 14.09 34.13 5.54 114.04 14.09 114.04 14.09 114.04 14.09 22.10 6.53 22.10 6.53 22.10 6.53 22.10 6.53 117.7.73 118.04 6.53 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05 118.05	4.23 22.08 5.21 1.00 6.05 34.13 5.06 14.08 2.00 6.05 34.13 5.06 14.08 2.00 6.05 34.13 5.06 14.08 2.00 6.08 5.31 114.04 34.44 6.00 177.57 1301.83 7.22 1.00 6.08 5.31 1.00 6.08 5.31 1.00 6.08 5.32 1.00 6.08 5.32 1.00 6.08 5.32 1.00 6.08 6.32 1.00 6.08 6.32 1.00 6.30 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1.00 6.32 1	H29188
22.08 5.21 1.1 3.0.06 14.09 34.13 5.54 114.04 34.44 1101.83 7.22 22.10 8.41 120.88 8.90 114.04 6.97 115.56 19.80 6.63 6.97 115.56 19.80 6.63 6.97 115.56 19.80 6.63 6.97 115.56 19.80 6.90 12.24 6.90 12.22 46 12.25 10.04 18.55 10.04 18.55 10.03 18.56 5.39 18.56 5.39 18.57 10.23 18.58 5.39 18.59 10.33 18.51 10.33 18.51 10.33 18.51 10.33 18.52 10.04 18.52 10.04 18.52 10.04 18.52 10.04 18.52 10.04 18.52 10.04 18.52 10.04 18.52 10.04 18.52 10.04 18.53 10.03 19.35 10.03 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.34 10.35 10.34 10.35 10.34 10.35 10.34 10.35 10.35 10.35 10.35 10.35 10.36 10.35 10.36 10.35 10.37 10.39 10.38 13.39 10.40 13.33	4.23 22.08 5.21 1.1 5.13.95 72.82 5.22 1.1 6.05 34.13 5.64 1.09 6.05 34.13 5.64 1.1 6.09 51.27 8.41 17.857 1301.83 7.23 13.30 238.88 7.23 13.30 238.88 7.23 13.30 238.88 7.23 13.30 238.88 7.23 13.30 238.88 7.23 13.30 238.88 7.23 13.30 238.88 7.23 13.30 23.88 6.00 6.82 6.3 6.3 1.25 1.6 6.3 6.3 1.25 1.6 15.26 1.30 1.57 18.05 1.57 18.05 1.57 18.05 1.57 18.05 1.57 18.05 1.57 18.05 1.57 18.05 1.57 18.05 1.57 18.05 1.57 18.05 1.57 18.05 1.57 18.05 1.58 1.50 1.57 18.59 1.57 18.59 1.57 18.59 1.57 18.59 1.57 18.59 1.58 18.51 1.58 18.52 6.74 1.59 114.41 6.39 1.59 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.52 6.74 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 7.50 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 116.55 1.50 11	22.08 5.21 1.1 30.08 14.09 2.2 34.13 5.64 1.1 639.13 1.64 6.1 114.04 34.44 6.6 114.04 34.44 6.6 130.83 7.22 2.10 6.63 6.97 1.1 130.46 28.33 1.1 130.46 28.33 1.1 150.28 19.80 0.0 150.28 19.80 0.0 150.28 19.80 0.0 150.28 19.80 0.0 150.28 19.80 0.0 150.28 1.1 150.28 1.1 150.28 1.1 150.28 1.1 150.28 1.1 150.28 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.29 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20 1.1 150.20
	4.23 6.06 6.06 6.06 6.06 6.06 6.06 6.06 6.0	H29188 H29265 H29534 H29534 H29535 H29533 H295333 H29533 H29533 H29533 H29533 H29533 H29533 H29533 H29533 H295333 H295
		H29188 H29285 H29285 H29285 H29285 H10045 H10045 H10045 H10045 H10045 H10045 H10045 H10045 H29285 H44477 AA488341 H39179 H39198 H67707 H89322 H67707 H89322 H67707 H89328 H68708 H68708 H68938

Page 54 of 91

	Colon	d Other		d Other	LID not found	Thymus	i	Blood	LTD not found	Adipose	LID not found	Brain	neOvary	LID not found	Ovary	Ovary	LID not tound	LID not found	CNS	d Other	Aorta	d Other		Poot	Prostata	Breast	Lymph	d Other	d Other		yoTonsil	Pooled	Uterus	Stomach	Hear		Esophagus			200	Too do	LtD not found	Synovial membrane	wagrain	d Other	Stomach		Gall bladder	Foreskin	d Other			Hear	Placenta
	Spleen	LID not found Other		LID not found Other	Pool	<b>Esophagus</b>		Bone	Prostate	nec Cervix	Brain	Uterus	Small intestineOvary	Testis			Grain	Bone	Small intestineSkin	LID not found Other	Umbilical cord Adipose	LID not found Other		Lymph	Testis	Brain	Muscle Lymph	LID not foun	LID not found Other		Whole embryoTonsil	Head and nec Blood	Tonsil	I nymus	Eye	LID not found		SE CRS	Small miestimeorain	THE STATE OF THE S	Teel	lund	Small intestine Dymis	Whole embryoBrain	LID not found Other	Umblical cord Skin	LID not found		Liver	LID not found				Spleen
	680.88 Ovary	Uterus	463.25	27.41 Uterus	292.28 Neural	564.08 Laryrx	358.9	62.05 Skin	142.57 Uterus	267.89 Head and nec Cervix	Testis	15.89 Muscle	460.31 Breast	Uterus	298.79 Bone	147.26 Gall bladder	Ovary	568.94 Pod	200,17 Small inte	Uterus	68.19 Umbilical	328.81 Uterus	271.02	Spleen	247.37 Brain	175.36 Hearl	Pooled	Liver	173.21 Brain				337.33 CNS	606.38 Larynx		90.1 Brain	154.77 Ignora	Paramyron	Marie 8.762	278 45	10 48 Brain	313.32 Pool			Liver				140.54 Pooled	258.93 Brain	115.67 Adrenal gland	248.09 Tonsil	Adipose	349.48 Stomach
	7		ø	<b>5</b>	=	œ	ĸ	₹ ;	53	8		-	<b>\$</b>		12	ŧ		<b>-</b>	<b>6</b>		5	60	61		7	4			-		11	8	×	_	- ;	₽ (	R	¢	<b>.</b>	. 4		· ÷	2 ^	- 6	•	18	51	-	o	-	×	=		5
Table 2A	0.00	900	0.0	0.0	0.00	0.00	0.00	0.0	0.00	0.00	800	0.00	9.	9.	000	000	0.00	0.00	0.00	0.00	0.00	0.00	000	00.1	1.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	000	000	0.00	0.00	0.00	00.0	8.6	3 8	8 8	8 5	8 6	8 6	000	1.00	0.00	0.00	3.00	5.00	0.00	0.00	8.0	1.00
Tab	6.00	2.00	3.00	3.00	1.00	6.00	8.	1.00	6	2.00	3.00	<b>4</b> .8	000	2.00	2.00	1.00	0. 0.	6. 8.	2.8	2.8	8.	8.	5.00	5.00	0.0	2.00	2:00	1.00	1.00	1,00	1.80	2.00	1.00	1.00	10.00	9:	0.5	8.	9.6	8 8	6	8 8	8 6	8 5	300	1.00	2.00	3.00	3.00	3.00	1.00	5.00	<del>.</del> 8	0.00
	7.07	6.31	9.0	8.19	5.38	10.64	6.26	5.96	11.48	6.47	7.33	12.68	6.02	8.54	7.24	5.58	9.01	7.41	9.68	6.47	5,19	9.30	18.78	9.79	5.41	5.77	63.88	6.41	6.10	7.36	6.98	7.66	6.17	5.49	31.92	6.20	o; ;	15.29	40.50	10.30	10.88	89	11 80	5.7	8.45	7.88	11.57	7.27	11.51	9.45	5.38	6.95	35.45	7.47
	123.68	15.90	69.89	557.11	55.37	391.66	613.80	404.61	33.04	155.77	36.48	445.08	205.23	23.99	37.49	68.39	50.48	23.48	6.24	15.89	677.23	45.82	8999.87	403.09	19.99	17.62	224.15	14.80	6.60	73.68	29.77	189.33	280.10	508.27	119.61	10.11	437.30	118.71	2.60	3034 57	47.46	17.40	100.17	125.84	351.19	1789.14	26.81	98.24	1275.71	770.47	160.20	43.41	766.95	90.48
	17.48	2.82	10.21	67.89	10.29	36.84	90.06	16.79	2.88	24.09	4.98	35.10	34.08	2.81	5.18	12.26	9.60	3.17	9.0	2.47	130.40	4.93	536.48	41.18	3.69	3.06	3.50	2.31	1.08	10.02	4.26	25.04	45.38	82.22	3.75	.63	46.83	7.78	1.82	2 2	444	45.45	25.04	17.53	41.58	227.17	2.32	13.50	110.82	81.8 22.5	29.77	8.25	21.63	12.11
	R01094	AA150198	W47552	AA128008	AA005108	AA630094	M58250	N67487	AA138052	AA156793	AA459937	AA127017	AA457700	AA128017	AA427621	N92478	AA427522	H52379	AA630604	AA152299	AA155913	AA131469	R78521	T40725	H10030	H18958	H07920	140927	H18017	AA699427	H10012	R70685	N48355	T71991	AA291484	R44949	AA134871	HZ2854	K37411	697191	700000	AA668060	764700	DAA006	T58775	AA663986	H10641	AA634109	T88440	R42922	N93505	AA628028	N92901	H1 1088
	124447	491311	324323	501876	429165	854696	204536	291880	502618	502333	795687	502634	810711	501890	770789	301867	771060	202194	856135	491244	580284	503749	144925	61044	46931	51511	45578	81462	50983	433253	46716	141815	279790	85409	724888	34321	502367	51700	25984	11877	25,000	10000	10046	24443	77538	855755	46328	868380	83345	32331	307471	745019	307660	47428
	12046	12049	12051	12053	12054	12058	12059	12060	12061	12063	12066	12069	12071	12073	12077	12085	12086	12087	12088	12089	12092	12093	12094	12103	12104	12108	12113	12119	12120	12122	12123	12129	12130	12131	12134	12136	12138	12139	12140	12143	2000	12140	20.21	1012	12153	12154	12160	12162	12163	12164	12168	12169	12170	12171

Page 55 of 91

6
ō
8
90
å

	đun:	Brain	Tonsil	Other	5un1	Other	Whole embryo	Blood	Breast	Heart	Prostate	Splaen	Other	Head		Lymph		Cerxix	Laryux		Grain	Aorta		Other	Parathyroid	Tonsil	Colon	Thyroid	Other		CID not roung	roreskin	orain Marin contract	Verigie embryo	•	Lune	Breast	Kidney	Brain	Umbifical cord	Testis	Other	Other	Ed Ed	Whole embryo	Parathyroid	:	Inyroid			lestis		Colon	LID not found
	_	CNS	Lymph T	found		ot found	_	Gall bladder B	Blood	.ş	Liver	Liver	t found	Testis +		Blood			Omentum			Placenta /		of found		2		Foreskin	LID not found Other			_		ğ		Ear	Brain	Tonsil	Colon	Lymph	Parathyroid	LID not found	LID not found Other	Umblical cord Lymph	Parathyroid	Prostate	:	Parathyroid	LID not found Ulher		Whole embryo estis	E 78	Tonsil	8
	674.22 CNS	Bone	43.37 Thyroid	597.06 Brain		55.98 Brein	116.08 Pooled	Esophagus	268.89 Lymph	62.76 Germ Cell	Smooth musc	634.21 Gall bladder	Brain	667.01 Thyroid	71.09	88.36 Gall bladder		137.52 Thymus	319.26 Testis	341.89	552.2 Ear	Stomach	630.22	382.31 Brain	89.33 Foreskin	737.83 Thyroid	63.62 Testis	Larynx	483.92 Brain		348.63 Cervix	720.56 Inymus	245.00 VATOR emoryonesm	Thems	502 5A	610.47 Thuroid	20.17 Heart	Stomach	Kidney	Ear	Germ Cell	Lung	450.37 Lung			170.13 Tonsil		249.52 Trachea			75.05 Parathyroid	lonsal	Clerus	Cobn
	-		မှ	-	57	17	w		19	4	×	4		-	19	13		ro 1	17	11	w		-	o	€	-	16		6	;	۶ ،	- >	<		ā	ōκ	9	:					4	5	4	5		Ξ	•	- ;	7			
2A	0.00	000	00.0	1.00	0.00	00.0	1.00	00.0	0.0	4.00	0.00	0.00	00.0	1.00	8.4	0.00	2.00	1.00	2.00	0.00	0.00	2.00	9.0	2.00	2.00	0.00	0.00	9.0	0.00	0.00	8 8	0.00	8.8	8 8	8.8	8 8	8 6	9:	0.00	1.00	8:	2.00	3.00	8:	8.	0.0	0.00	00.0	500	0.00	1.00	0.0	8.	5.00
Table 2A	2.00	8.	00,	00,	2.00	1.00	0.00	2.00	8.	2.00	8.9	2.00	2.00	0.0	0.0	2.00	0.00	0.00	90.	2.00	3.00	1.00	5.00	4.00	0.00	1.00	1.00	00.0	2.00	9.00	00.0	2.00	8.6	9 8	8.8	8 8	8 8	00	9.1	0.00	0.00	2.00	2.00	1.00	0.00	4.00	2.00	6.00	4.00	2.00	1.00	1.00	0.00	0.0
	9.56	6.15	7.27	6.17	5.11	5.90	14.76	8.87	5.21	15.10	8.12	5.93	5.29	5.08	12.15	6.74	8.20	9.41	80.9	7.12	38.92	10.42	8.41	19.8	6.42	5.14	5.19	6.15	9.67	23.20	5.87	12.89	12.75	9.50	- C		200	5.02	13.74	6.54	7.79	7.71	7.60	7.00	5.51	11.40	12.77	14.22	12.84	11.32	19.27	5.29	5.05	<b>B.41</b>
	35.78	19.91	93.26	27.6	56.82	8.81	382.06	148.77	55.57	546 94	134.75	47.51	155.76	220.08	2024.13	75.15	1230.98	1108.01	482.96	451.49	118.26	633.37	55.60	50.71	60.55	137.22	96.67	741.07	33.77	219.72	30.81	27.87	2394.83	61.66	490.61	014.00	27.72	40.62	67.50	563.46	27.56	501.31	1303.92	280.98	104.47	110.92	316,35	2378.38	114.36	6799.12	161.74	83.20	133.72	666.72
	3.74	3.24	12.83	1.53	11.13	1.49	25.69	16.77	10.67	36.21	16.69	8.01	29.43	43,33	166.62	11,14	198.52	117.75	79.39	63.42	30.0	60.77	6.61	7.60	9.43	26.70	18.64	120.52	3.49	9.47	5.25	2.16	187.84	11.64	72.17	80.08 24.78	2 ×	60.00	4.81	88.20	3.55	65.05	171.56	40.13	18.96	9.73	24.77	167.30	8.91	600.52	9.39	15.71	26.49	79.29
	R54590	W72051	AA111969	H15427	T82854	H17325	AA421819	AA478785	AA676453	R43595	T68445	174257	R37620	AA481769	H10372	T49652	AA428182	AA488391	AA489324	AA055656	H15677	AA480722	R38196	H10679	H73640	AA460848	AA156597	AA598468	R38543	H29783	AA179600	AA457566	R38613	AA416684	K36297	K39179	H10072	AA421266	H17463	N67366	W04509	N70756	N93967	AA446865	H97366	AA085042	N32072	AA053185	N94488	N32847	W37683	AA169202	R08548	AA055404
	40100	345826	530185	49443	79585	50443	739155	740604	431655	325.87	83358	84713	25132	838829	46977	627759	773556	643008	842946	510464	49303	796760	23774	46553	234977	796285	602277	897761	22762	52755	612809	838774	22773	731270	136799	23116	4843	731023	50266	286503	320209	298091	309388	784214	251147	525478	260170	510273	309895	259275	321805	594323	127368	510380
	12172	12173	12174	12176	12179	12180	12181	12185	12190	12102	12193	12201	12202	12210	12213	12217	12218	12219	12221	12235	12237	12240	12244	12245	12247	12250	12254	12259	12260	12261	12266	12267	12268	12	2727	9/27/	(0771	12283	12285	12286	12280	12300	12304	12306	12307	12316	12319	12322	12328	12343	12344	12351	12358	12382

Heart	Foreskin	Breast	Adrenal gland	Breast		Pool	Eye	Olher	oLung	Whole embryo	Other	Other	S S S S S S S S S S S S S S S S S S S	Colon	Prostate	Prostate		1 Parathyroid		I to not found	Other	Other	Kidney	LID not found		200	Other	Other	Brain	P 90	P 25	Thymus	1 Other	Heart	Other	E COLO	Other	Brain	1 Other	1 Other	Other	3 Other	Other	Other	Whale embryo	Ciner	Kidney
Foreskin	Tonsi	Aorta	Ear	Muscle		tung	Ovary	LID not found Other	Whole embryolung	Prostate	LID not found Other	LID not found	LID not found Other	Toneil	Ear	Tonsil		Adrenal gland Parathyroid		Pool	LID not found Other	LID not found Other	Parathyroid	yokdney	Tonsil	and Change Other	LID not found Other	UD not found Other	Placenta	Brain	LiD not found Other			Kidney	LID not found Other	Bone Tours	LID not found Other	Hear	LID not found	LID not found Other	LID not found Other	LID not found Other	UD not found Other	LID not found Other	Blood	LiD not tound Other	Heart Mana
139.88 Blood	385.71 Musde	276.96 Carvix	Thyroid	Pooled		Aorte	Ear	84.81 Colon	Thyroid	689.84 Ear	Testis	509.69 Heart	Parathyroid	381.57 45.1 Kirtney	Head and nac Ear	Cerk		Еат		490 86 Head		Pool	Testis	280.52 Whole embryokidney	Pooled	457.63 M. scrie	301.58 Brain	Testis		666.75 Stomach	177 24 Overv	79.75 Smooth musc	380.7 Brain	Pancreas	Testis	722 7 Ensekin	143,33 Testis	194.39 Tonsil	320.68 Brain	82.43 Spleen	Pancreas	Spleen	151.82 Ovary	377.31 Pool	200.16 Pancreas	Testis	484.87 Germ Cell
3 138								٠		1 68		50 50 50		10						49				14 26	4	2	11 30			- 8	7.	9 9	8		9	0 -	-	20 19	•				14 15	37	12 20	•	5
9.0	1.00	8	8	8	2.00	0.00	1.00	0.00	1.00	0.00	0.00	1.00	3.00	8.8	8 5	9.0	1.00	0.00	9.5	9.0	8 8	80	0.00	2.00	8 6	9.6	8 8	3.00	2.00	1.00	0.00	0.00	1.00	0.1	8 2	9 6	8 6	000	2.00	00'0	0.00	3.00	2.00	000	2.00	2.00	0.00
1.00	0.00		000	8	000	2.00	0.00	1.00	00.0	9.0	1.00	1.00	000	8 8	8 5	8 8	0.00	2.00	0.00	8 8	3 8	8	1.00	0.00	8 8	8 8	90.4	0.0	0.00	0.0	8.6	8.6	00.0	0.00	8 8	8 6	8 6	9	2.00	<del>1</del> .0	6.	0.00	0.0	2.00	0.0 0.0	00.0	<del>-</del> 8
5.91	5.78	9 49	65 53	21.70	7.18	6.37	9.43	6.70	16.44	10.23	5.75	6.65	8.42	5.18 7.28	8 91	5.38	7.42	8.24	15.74	 	50.0	11.24	5.16	6.55	5.25	14.51	95.6	9.14	6.79	7.91	10.93	5.82	5.26	6.86	8.45	E F	11.10	6.19	9.23	5.02	86 66	9.37	7.31	10.52	13.44	7.19	5.36
4011.17	563.39	27.8.70	181 50	78.41	671.66	21.88	353.93	32.83	51,61	91.05	21.93	92.16	502.87	650.44	200 63	183.71	165.43	288.35	319.06	140.70	2 8.8	88.94	38.53	788.29	4.42	188.46	217.30	77.75	750.61	50.11	74.79	107.33	36.33	370.29	508.50	398.04	48.95	88.83	313.65	5802.59	60.40	560.69	627.56	427.64	312.81	871.57	10.11
678.82	97.45	5	20 20	1.52	83.80	3.44	37.55	5.76	3.14	8.90	3.81	13.85	59.74	126.17	3 5	8 X	22.29	38.21	20.27	24.84	3,70	. 6.	7.47	120.27	0.84	12.99	3 6	8.51	110.55	<b>8</b> .9	6.81	18.45	6.9	\$4.00	60.21	51.47	4.41	14.35	33.98	1156.15	6.05	59.85	85.63	40.64	23.27	121.20	1.89
H98967	N72113	N75058	AAKOA\$46	AA425214	06756N	N70837	N67305	AA088005	N80764	AA608531	AA400492	N93197	N95073	AA404288	A 4 4 3 6 0 8	AA191548	AA400422	AA487934	AA101878	AA437094	AA284112	H93318	AA406048	AA461084	W42996	T83646	M69100	AA609485	R31933	H12105	AA609744	AA453420	H04795	AA609749	AA609585	K39360	A 4 60 95 99	AA424950	R45567	T55238	AA159356	T55437	AA165116	AA454668	R45292	AA609628	R48700
261408	291082	200705	950803	773393	308446	298236	286566	511302	300815	950594	743314	304868	305408	758343	207716	626716	743297	840530	489833	757327	374363	242009	742830	796166	323251	113257	2020447	1031599	134297	48142	1031807	788705	43840	1031919	1031719	41899	1031748	768260	35366	74283	593026	73472	593972	811927	35626	1031767	36491
12363	12384	1000	2374	12382	12384	12387	12395	12397	12402	12404	12406	12411	12419	12420	12421	12441	12444	12449	12481	12463	12466	12468	12470	12471	12475	12476	17457	12483	12485	12488	12489	2483	2486	12487	12498	12504	12507	12511	12512	12517	12518	12525	12526	12527	12528	12531	12535

Page 57 of 91

Pool	Other	Other	Thyroid	LID not found	CID not found	Brain		CNS	Parathyroid	Pooled	LID not found	Brain	Pool	Cogn	Head and neck	Prostate	Lung	Sem Cell	Thyroid	Kidney	Muscle	Kidnev	Placenta	Other	Other	Lib not found		Breast	Brain		Tonsil	Pancings	Other	Ear	Prostate	Other	Erain Co.	Color	LID not found	Parathyroid	LID not found	LID not found	CIO not todio	Other	8	3
Colon	LIO not found	LID not found	Adipose		8 8	Placenta	UD not found	Blood	Tonsil	Adrenal gland Pooled	P001	Testis	Bran	. (	Resign	coUterus	Testis	Whole embryoGerm Cell	dAorta	Foreskin	Testie	Whole embrookidney	Pancreas	LID not found Other	LID not found	Kirtner	LID not found	Uterus	Thyroid	LID not found	Lung	Esopragua	L1D not found Other	Foreskin	Hear	LID not found Other	er Eye	Bone	Testis	,	P.00	8 8	Superiol men Thyroid	Synovial mean	Testia	
682.76 ·	413.49 Overy	193 Testis	511.76 Nose	Ovary	Sign	27.42 Thyroid		422.79 Adipose	599.98 Foreskin	317.73 Adipose	339.35 Foreskin	419.03 Colon	358.39 Testis		295.78 Ignore	214.37 Whole embryoUterus	Brain	Storrach	Umbilical cord Aorta	412.17 Prostate	293.34 Umbilical cord Pool	256 34 Foreskin	76.13 Adpose	P80	Pool	CNS	49.89 Heart	343.85 Aorta	527.16 Neural	443.2 CNS	Heart	131 82 Liver	Head	45 Aorta	Lung		103.66 Peripheral ner Eye	16505 515.69 Far	Colon		209.39 Tonsil	Tonsi	nenon George	E sobredas	Gerin Ced	
7	ທ	50	'n			22	2	4	2	×	Ξ	е .	18	₹;	× g	2 7	!			7	a	<b>,</b> a	. ē				9	Ξ	so.	7	•	o -	•	9			9	•	•		-					
1.00	<b>4</b> .00	8.4	2.00	8 6	9 6	000	100	0.00	0.00	0.0	1.80	0.4	8	1.00	9 9	900	00.0	0.00	2.00	2.00	0 0	9.0	00.0	0.00	0.00	00.0	8 8	0.00	0.00	2.00	88	8 8	2.00	1.00	0.00	2.00	1.00	8 8	0.0	0.00	2.00	8.6 8.6	8 6	8.8	000	3
0.00	8.0	0.0	0.00	8 8	8 8	3 5	900	8 6	2.00	1.00	0.00	0.00	8	8 8	8 8	8 5	3 8	7.8	0.0	0.0	8 8	3 5	9.9	1.00	9.6	8 6	3 8	2.00	2.00	2.00	8.5	8 8	800	8	1.00	3.00	8.5	8 8	8.8	2.00	1.00	8 8 8	3.00	3.6	3 8	3
9.52	7.97	15.17	8.17	203	11.79	888	2 47	98	24.41	5.22	6.09	11.37	16.68	10.21	5.04	7.28	7.86	23.41	5.56	7.88	11.78	9.0	9.48	8.89	5.21	12.13 g gg	3 7	14.80	7.3	5.00	11.48	5.43	8.85	5.09	23.01	88.6	6.57	5.97 7.84	. v	8.	8.21	9.67	6.27	13.82	38.63	3
9313,38	595.57	469.68	7138.07	1526.80	500.01	R2 28	30.03	95.74	1348.92	195.86	61.46	30.89	401,19	56.58	2629.07	104 77	25.00	110.99	91.22	1173.53	255.92	28.80	166.98	180.87	29.15	47.69	269.53	264.79	97.79	620.25	75.47	401.27	43.64	241.38	220.63	83.02	5.23	42.95	30.64	6022.66	1483.88	622.10	95.82	94.50	212.28	4.40
978.67	74.70	30.95	730.67	305.00	42.40	20.5	8 8	89.05	55.25	37.55	10.09	2.72	24.05	30.00	521.50	14.39	3.18	4.74	16.42	148.86	21.70	10.87	17.62	21.49	5.60		25 55 57 55	17.89	13.40	106.13	6.58	73.48	6.28	47.43	9.59	8.40	7.49	7.19 8 .5	5.64	854.32	180.84	64.99	15.24	9.78	67.6	
R49144	AA169488	AA609648	R40208	AA169535	AA609695	AA194983	D43535	AA417950	AA417956	N47312	AA417982	R51305	H04828	N31585	AA886148	AAASORAA	H05939	AA49944	AA410298	R51836	AA418728	H06194	AA878576	AA418743	W93108	AA401376	WB7193	AA149051	AA172188	N48181	W58266	AA159600	W69435	AA136551	W69774	W94247	AA457570	AA150459	AA454016	W46832	NS4783	N71483	N63696	AA1/3430	AA427978	21077
38816	594176	1031785	27515	594226	1031839	18676	33775	767690	767706	280507	787721	38883	43966	271744	1492104	785542	43679	785585	754449	39147	767823	44154	1492426	767843	415042	742679	343381	504959	610883	281970	342497	593164	343569	564771	343930	358699	838761	491712	795284	324154	244300	294915	293444	595238	758271	1 /700 /
12549	12550	12555	12557	12558	12563	12567	2007	12581	12589	12592	12597	12603	12607	12608	12820	2070	12631	12638	12641	12659	12661	12663	12668	12669	12680	12682	12692	12694	12706	12715	12732	12734	12748	12754	12756	12760	12762	12769	12782	12783	12784	12768	12786	12797	12800	70071

Page 58 of 91

AA588179 14.30 AA160780 43.19 AA160780 43.19 AA438008 5.11 H66005 20.97 AA425665 301.81 AA43582 4.00 AA425665 301.81 AA43589 2.51 AA43589 2.51 AA436837 1.12 AA436837 1.13 AA436837 21.36 RR3099 47.36 RR3099 67.36	237.38 237.38 237.38 237.38 203.41 26.45 2179.31 381.81 117.4 111.90 277.80 5.67	5.86 5.02 5.51	2.00	00.0	ω .	21.48 Pooled	Gall bladder	
		5.02			)			CNS
		5.51	3	1.00		Cervix	P80	LID not found
			0.00	1.00		Pancreas	LID not found Other	Other
		9.	8.	0.8		Tests	UD not found Other	Other
		9.70	0.00	2.00	į	8	UD not found Other	Other
		6.57	8.5	00:0	Φ (	510.58 Germ Cell	Pancreas	lestes
		777	8 8	200	n -	474 62 Cmall integrine	ryobrain	Stomach
		7.08	8 8	8 8	•	Testia Inden	Gem Cell	Whole embryo
		13.89	6.0	8 9		Head	- B8	LID not found
		15.78	2.00	0.00	4	682 Testis	LID not found	
		5.07	1.00	000	4	350.78 Germ Cell	P80	UD not found
10 - 1		7.23	4.00	00.0		<u>8</u>	Uterus	Brain
		11.78	1.00	0.00	n	726.84 Peripheral ner Adipose	ner Adipose	Breas(
		5.35	1.00	0.00	က	726.94		
		6.55	2.00	0.00		Certix	Umbilical cord Ovary	dOvary
		5.52	0.00	5.00	Ξ	59.6 Foreskin	LID not found Other	Other
		5.10	8	0.0		8	LID not found Other	Other
		6.80	2.00	0.00	2	288.35 Testis	8	LID not found
~		5.03	1.00	00.0		Cterus	Lung	8
		9.25	2.00	8.0		Nose	LID not found	Other
		7.53	9	8		Testis	LID not found Other	Other
		6.13	8	0.00		Whole embryoPool	nyoPool	LID not found
H06195 58.56		5.29	000	8	7	640.65 CNS	Heart	Bone
		7.13	0.	3.00	•		Whole embryorod	20.00
		6.70	8 9	2.00	<u> </u>	245.31 Colon	8 :	CLD not found
		142.87	00.6	8.8		436.11 Bram	Eye Breas	Break
VA608364 24.34		57.0	90.4	9 6	9	Sussilia 306 11 Omorbina	Muscle	omer.
		9.00	3 8	8 5	2	386.48 Utanis	Foreskin	. 6
			8 5	8 6	: 3	15 73 Famphania		Cervix
2.55 N24969 2.86		5.62	00	00.0	55	16.86 Stomach		Foreskin
		6.18	8	00.0			aryol.1D not found	
		11.20	00.4	8		Larynx	Esophagus	Blood
		6.63	2.00	00.00		Bone	Liver	Adrenal gland
AA454854 11.58	1193.03	103.05	12.00	0.00	-	305.09		
		5.51	0.0	9.5	<u>6</u>	156.84 Thyroid	Ovary	Aorte
		7.38	3.00	8 6	- (	143.55 Colon	Lestus Coll Madde	Prostate
		70 CT	8 8	3 8	e C	89 05 Gall Madde	_	
_		7.07	3 8	3 5	1 9	4 to 78 Thursid	-	Coll Modder
•		2.2	3.5	3 5	•	200 P		Tonail
•		, e	3 5	800		ovar Ovar	Germ Cell	Luna
		9 6	000	1 00		Pooled	Blood	Germ Cell
R39325 8.08		9 9	3.00	000	7	182.05 Adipose	Brain	Perathyroid
		6.45	3.00	000	9	269.06 Pool	Whole embryoPlacenta	yoPlacenta
4		10.96	800	8.	5	318.05 Stomach	Uterus	
		6.29	2.00	0:1		P8	LID not found Other	d Other
		7.06	<del>,</del>	000	7	260.52 Bone	Brain	LID not found
AA190871 6.10		5.68	<b>5</b> .8	8.0	64	719.37 Cervix	LID not found Other	d Other
		6.39	8.	8.0	5		Adrenal glan	d CNS
		7.56	0.0	8	o.	307.02 CNS	Uterus	Whole embryo
98		5.15	8	000		Thyroid	SS	Lymph
342871 2.18		7.14	1.00	0.0	18	477.68 Testis	Brain	LID not found

8 of 6 of 9

ò
5
_
8
8
8
۰

	Lymph	her	Her	lher	CNS	Foreskin	Enug	ann Tair	whote emoryo	1	בינט וופר ופונים		Germ Cerr	b 1	10 m	# 15 E		<b>1</b>	B	2		104	Gall Phodogo	- TO		, ma		Oner form	TO DOLLOGIS	July or an	7000		Other	Ī	Ovary	Bons	Kidney	Other	Brain	Whole embryo	Pool	3	501	to out found	שוויים וייון סון	Outer	vende emoryo	ie in constant	Umer	LID not tound	ing.		. Selection	5
	CNS Ly	LID not found Other	LID not found Other	LID not found Other				D D	Placenta			2		LID not found Other	Paragone -	IID act found Other	C period to City	CID not found Other		The act for an Other	LID not found Other	LID not lowed Other		P		משפע זמ			Lang Lines Chors	LiD not found Other			1 to not found Other	Prostate		CNS	Foreskin	t found		C S	CNS		65	1000	1		Z daley	CID not round	or found	eran.	UD not found Other			100 E
		529.87 Foreskin	Foreskin	93.95 .	Cervix	Cervix			120.51 Stomach	377.63	2 1	11891		11.15 PdSi		Toetir	ense.	Eye	67.34 FOIL CONTRACTOR	83.17 Whate emplyo	5	Eye	332.38 rddl 340.43 E=444 =1464 Iime	Jean Moone Care	8	100 F 20.20	534.94 ICSUS	62.43 700	<b>2</b>	אפים ווייוו	21.8	2	ě,	501.89 Brain	440.43 Blood	157.53 Brain	Tons	567.28 Pool	278.14 Small intestineHeart	245.08 Aorta	171.28 Heart		73.17 Brain	245.UD Toetie	10000	roreskin	5/6.44 POOIBO	152 Brain	278.48 Pool	Germ Cell	528.52 Lung	1	Parathyroid	256.24 Brain
	15	2		×				e i		11				<b>.</b>	,			ç	2	. í	7	•	, .	=	;	= :	0	-		2	ç	3		^	. 60	60		7	=	×	<b>-</b>	•	N 3	κ		•	 N 1		ю		9		•	æ
2A	3.00	2.00	8	2.00	1.00	00.0	1.00	0.5	8.	2.00	9 6	00.5	8 8	00.0	3 8	8 6	9 6	90.5	8.5	8.6	8.6	0.00	8 6	9.0	6.90	3.90	9.5	0.00	0.00	9.69	8 6	8 8	8 6	000	0.00	0.0	00:0	5.00	9.	0.00	0.00	8 9	00.0	8 8	3 6	8 8	00.0	8	8.9	80	9.5	8.8	0.00	3.00
Table 2A	0.00	000	2.00	00.1	0.00	2.00	1.00	80	2.8	8	8 8	0.00	8.5	8.5	8 9	9.60	9.6	0.00	2.00	8 5	8.5	8.5	8.8	9.1	0.00	0.0	0.00	2.00	3.00	2.00	9.0	3 5	3 5	8 8	200	5.00	3.00	0.00	8.0	8	8	18.00	2.00	8 8	3.5	0.00	4.00	4.00	000	0.0	000	0.00	200	6.00
	5.74	80	27 6	60	5.77	8.07	<b>10.06</b>	5.49	8.68	5.35		9.76	29.5 20.5	5.03	6.72	5.10	9.0	5.00	4.0	6.09	0.0	7.36	5.57	6.46	8.10	12.37	5.9B	9.43	6.67	5.79	9.0	90.04	2 2	28.50	10.12	7.23	6.37	8.62	8.62	6.26	7.48	21.55	6.33	6.72	6.61	7.25	6.12	9.60	8.97	5. 89.	7.18	5.20	7.71	108.17
	108.80	142 22	127.57	1041 01	268.84	1099.47	121.41	90.90	108.06	549.68	33.58	450.94	33.57	1123.34	30.27	56.27	21.13	55.58	270.63	21.65	263.32	94.65	392.13	172.32	210.34	1386.49	370.06	244.04	40.57	1733.60	137.42	1713.70	10.41	246.40	74.50	78.95	396.07	229.65	280.27	4171.04	304.93	348.36	20.01	1853.58	58.24	91.65	108.95	22.48	408.68	13.02	<b>32.</b>	5.24	53.89	261.02
	18,60	22 12	13.47	177 72	8.56	136.16	12.07	14.72	12.45	102.71	5.13	48.21	5.91	23.17	4.51	2. 5	3.59		31.94	3.55	30.52	12.87	70.37	26.68	25.68	112.11	81.91	25.89	6.08	289.52	20.51	19:007		13.73	7.38	10.92	62.15	26.65	42.32	60.999	40.77	16.18	2.40	275.74	6.0	12.65	13.42	2.29	45.55	5.58	47.58	10.1	6.9	2.41
	N83575	N72288	N72300	N98513	AA191336	AA190313	N74106	AA599104	AA488183	N74958	N34895	W70342	AA192435	H75778	AA621201	AA176413	AA406210	AA481789	H62011	AA479928	H65832	AA481729	H78999	AA487527	W90105	H81083	AA405690	H70163	AA489791	AA489826	W92738	AA489840	N4/200	AA490040	44169379	AA406231	N73477	N73571	R15832	N73807	AA456289	N48698	R43017	N73846	AA609861	H86229	AA447692	R49045	N74042	H06508	N76101	AA218033	AA398264	R60170
	278243	201385	201418	310501	627272	627428	298369	950451	642762	299498	276712	345847	627555	233246	744391	611209	742867	838855	209179	772938	210531	838518	233644	641366	418113	241241	742952	213575	639545	839837	356940	839855	200412	438884	42003	753248	291700	296022	53110	289402	813154	279388	31869	296574	1031027	260273	813611	37539	296710	44073	289412	629863	728703	42824
	13058	900	2005	1307	13102	13106	13118	13118	13122	13132	13151	25.5	13157	13160	13184	13165	13186	13167	13168	13171	13178	13183	13184	13185	13194	13200	13214	13216	13223	13231	13235	13239	13245	13247	7575	13255	13258	13266	13272	13274	13276	13279	13280	13282	13283	13286	13287	13288	13290	13312	13314	13334	13335	1338

	Lung	Lymph	oTestis	LID not found	1 Other	oGerm Cell	Kidney	LID not found	oProstate	Lung	Parathyroid	oBrain	1 Other	Kidney	Foreskin	LIO not found	LID not found	1 Other	Other		Неал	LID not found	Uterus	1 Other		Parathyroid	Other	Heart	Poo	1 Other	8	Heart	1 Other	Other	Foreskin	CID not found	8		LID not found	Lib not found	CIO not round	8	LID not found	Cung	Placenta	E SE SE	Pool	LID not found	Kidney	Thyroid	Prostate	Еув	Lymph	Brain	Pod
	Brain	Smooth muse Lymph	Whole embryo Tests	Pool	LID not found Other	п Whole ешблу	Testis	Prostate	Whole embryoProstate	oKidney	Brain	Whole embryoBrain	LID not found Other	Heart	Blood	<b>P</b>	Brain	LID not found	LID not found Other		Brain	Pool	Breast	LID not found Other		Blood	LID not found	roOvary	Неал	LID not found	•	Lung	LID not found Other	LID not found Other	Muscle	0 1	lesis	Pancreas	/oPod	/oPool	00	Saga	Pancreas	Ovary	Uterus	d 700 eq	Uterus	Overy	Ovary	Parathyroid	Cervix	Ovary	Muscle	Uterus	Placenta
	4 Germ Cell	453.51 Neural	Pooled	Foreskin	5 Brain	590.63 Synovial mem Whole embryoGerm Cell	5 Parathyrold	Testis	CNS	Whole embryokidney	S Breast	17 Cervix	Brain	9 Germ Cell	S Muscle	628.88 Parathyroid	2 Liver	Brain	6 Brain	rō.	Pooled	Germ Cell	4 Placenta	Testis	gn	5 Pancreas	CNS	Whole embryoOvary	Eye		Germ Cell	Pooled	Heart			Kidney			Whole embryoPod	Whole embryoPool	6208	9000	Blood	Ear	Aorta	19 Umblical cord Pooled	24 Adipose	2 Pool	29 Tonsu	474.57 Foreskin	9 Larynx			Qvan	19 Ovany
	628.0	453.5			438.5	690.6	276.5				46.35	63.37		380.79	65.25	628.8	481.92		521.56	554.85			118.74		185.79	277.15				422.58				564.37	78.88		0	282.48							•	15.39	192.24	521.6	112.29	474.	136.79	52.19	101.7		146.89
	11	4			60	~	7				φ	60		11	ო	n	~		~	~			-		19	=				m				~ ;	Ø		;	4							•	٠.	- 1	-	9	₽	22	5 .	7		Ç
W aige	0.00	000	000	2.80	5.00	1.00	9	0.00	0.00	1.00	3.00	0.00	0.00	0.00	2.00	2.00	0.0	€.00	8.	1.90	0.00	000	1.00	4.00	000	1.00	5.00	0.0	2:00	0.00	8.	0.00	2.00	0.0	8.6	8. 6	8 8	8	9:1	8.5	2.00	2.00	0.00	0.4	00.0	000	0.0	000	200	0.00	9.9	3.00	1.00	3.00	0.00
_	2.00	8.00	9	000	2.00	0.00	1.8	1,00	2.00	0.00	0.00	1.0	4.00	9.1	0.00	00.0	1.00	0.0	1.00	0.00	2.00	1.00	00.0	0.0	1.8	8.0	8.	5.	8.0	8.	8	8	8	4.00	8 8	8.6	8 8	8	00	8 8	8	8.0	<del>-</del>	0.00	2.00	1.00	8	1.00	8	1.00	0.0	0.0	0.0	0.0	1.0
	6.15	68.25	10.80	5.59	8.18	8.55	6.25 53	5.20	89.6	5.57	13.07	6.51	11.35	90.9	5.18	5.53	8.20	6.15	8.93	5.33	6.70	7.70	11.27	6.17	10.25	8.33	68.68	8.47	6.74	5.	5.76	6.32	6.72	6.21	5.06	98.08	6.9	E .	5.61	55.74	8.03	7.4	9.54	12.66	6.14	6.93	18.27	11.12	<u>-</u>	8.78	7.78	8.40	4.	7.80	5.70
	4.78	346.78	43.91	238.54	470.44	89.98	19.61	36.98	37.45	23.93	32.65	22.87	188.06	23.98	597.95	67.84	21.68	679.62	136.40	85.66	43.58	34.80	6.37	476.55	23.55	221.88	819.40	98.29	649.98	29.48	29.28	3.20	327.02	78.05	48.02	252.46	527.31	29.46	64.3	358.22	410.59	2073.78	122.27	1264.57	2124.21	235.51	184.20	72.09	510.35	45.23	573.11	1092.90	105.81	217.85	30.87
	0.77	5.08	4.07	42.71	57.51	11.31	3.18	7.11	3.66	4.30	2.50	3.51	16.57	3.96	115.41	10.43	4.17	110.56	15.27	16.07	6.50	4.52	0.57	77.18	2.30	26.65	11.93	15.18	128.17	5.74	5.08	0.51	48.66	12.58	9.48	28.11	2 2	78.2	11.48	6.39	51.11	291.83	12.82	99.85	345.70	33.98	10.08	6,48	58.02	5.4	73.63	130.11	8	27.95	5.41
	R60328	AA878880	AA449329	AA410190	R52347	AA757351	AA844124	AA398112	R54444	AA449332	H06525	R51361	H06377	AA855158	H06385	AA84447	R51186	H11968	H11987	R51631	H11780	AA418747	AA449686	AA397918	H11631	AA890663	N56888	W70242	W94363	N62817	W70264	AA062985	W94620	N62969	AA463206	Wastus	AA486427	AA160692	AA425700	AA425749	AA453823	AA102223	AA160484	AA127385	H99704	AA186460	AA151775	AA454595	AA159605	W45453	AA486185	AA428179	AA443290	T96986	R26531
	42271	1493160	785693	754485	39288	1326920	1388373	726551	39191	785699	44387	39311	44300	1389018	44409	1390860	30336	47916	48238	39453	48033	768018	785760	726595	48060	1405689	277487	344010	358800	278516	2482	366209	358872	289742	796916	415182	842885	29145/	773189	773392	185456	510906	592523	584567	262827	SE9529	566383	811572	593174	328889	642765	773548	784005	120273	132392
	13344	13348	13358	13381	13363	13384	13368	13370	13371	13374	13375	13379	13383	13384	13391	13488	13403	13407	13415	13419	13423	13429	13430	13434	13439	13440	13443	13444	13448	13455	13460	13468	13480	13487	13490	13504	13512	1353/	13538	13546	355	13552	13553	13560	13563	3565	13568	13574	13585	13591	13592	13594	13596	13600	13604

Page 61 of 91

56
ō
62
8
G.

	3one	Lung		Lung	į	Cine	Other	Germ Cell	LID not found	LID not found	Placenta	Other	Foreskin	Germ Cel	Pool	Heart	Prostate	Other	Adrenal gland		Pod	Other	Testis	Muscle	CID not found	8 8	e de	Lympa Lympa	NGTBy CNC	CNS	Cerytx	Pancreas	Whole embryo		Lung	CNS	•		Cervi	SES	Coary	Pancreas	Book	9000		100	Cell Cell	Adipose		Agrenal grand	Chron	Sales Sales	200
	Umbilical cord Bone	Ovary		Cervix		LID not found Other	LID not found				*	found	Ear	Pooled	Brain	Pool	Nose	LID not found Other	Tonsil		Brain	5	Germ Cell	Foreskin	Foreskin	Cerix	LID not found Other	Synovial mem Foreskin	Manage emphanolist	nd Brain	nd Muscle	Brain	Foreskin		Pancreas	Parathyroid	nyoBlood	:	Pioréi :	Foreskin	2 0	rooled	Voncie embrydrod	•		40.00	Small mestinestomach	LINE	Č	Ріасепта	land bash		
	689,77 tgnore	Aorta	415.29	Ignore	:	252.9 Foreskin	226 9R Pool	Synovial mem Skin	104.49 Foreskin	CNS	675.52 Parathyroid	384.62 Foreskin	438.89 Adipose	117.99 CNS	Uterus	714.15 Stomach	321.66	553.91 Nose	391.24 Adipose		319.19 Tonsil	Whole emb	105.89 Ear			615.42 Ear	Testis	Synovial m	Thomas	500 78 Adrenal gland Brain	Adrenal cland Muscle	173.12 Podled	14.91 CNS	404.08	Musde	Placenta	Whole embryoBlood	326.68	160.11 Larynx	-13.35 Ignore	Aone	287.82 Poreskin	362.35 CNS	352.44 Lanynx			242.21 Small inter	Š		750.96 CKIN	40.66 56 54 1 Terbiling and Dool	30.14 Original	Perenyion
	-		9		,	Ξ	5	:	9	!	4	5	5	9		60	17	-	m		Ξ		5	1	2	4			ć	n (	•	4	<b>.</b> 4	80				20	F	22	;	<b>8</b> 2 :	2 :	=		i	13		,	- 8	2 5	,	
\$	2.00	00.0	0.0	2.00	9.9	9.0	8.5	8 6	000	000	000	2.00	000	0.00	0.00	0.00	0.00	00.0	1.00	0.00	0.00	1.00	1.00	0.00	2.00	00.0	0.0	00.0	8 8	8 8	8 6	8 6	8 8	00.0	2.00	2.00	0.00	2.00	00.0	0.0	8 9	2.00	8 8	3.5	8.6	8 6	8 9	8 9	0.00	0.00	0.00	3 8	3
lable 2A	8	8:	9:	0.00	8.0	80	8.8	8 8	8 6	200.	8	3.00	2.00	1.00	1.00	9.1	3.00	2.00	0.00	1.00	1.00	0.0	0.0	<b>6</b> .0	0.00	2.00	2.00	2.00	8 8	3 5	20.0	8	9	9	000	1.00	1.00	0.00	3.00	0.5	0.00	0.0	00.5	9.6	0.00	2.00	2.00	8.00	<b>5</b> 0.5	8 9	8 8	8 5	3
	9.39	5,88	5.13	6.91	10.94	7.05	5. C	7.18	9 6	28.85	5.30	14.18	6.72	5.22	10.50	7.37	13.37	5.59	7.66	5.64	5.17	5.18	6.33 St. 0	6.94	6.82	5.94	5.44	5.90	9.12	7.04	3.50	48.4	25.75	6.29	8.23	9.80	5.13	5.52	21.97	10.81	9.68	11.53	11.55	15.63	6.07	9.41	12.94	10.69	33	5.27	9.60	89°	70.0
	27.051	91.96	1066.14	320.60	1329.27	208.24	97.59	92.49	402	216.16	57.49	135.88	40.35	77.18	61.85	1259.80	687.44	219.99	78.89	224.58	48.96	5090.11	281.64	21.70	92.80	79.78	10,63	134.85	57.78	0.00	40.0	15.74	239.92	15.40	201.16	344.69	917.74	91.50	467.98	39.16	145.97	75.47	100.11	254.33	81.61	664.97	176.48	639.22	27.09	63.85	30.17	334.46	322.51
	15.59		207.98		•		17.04	Ī						14.78												13.43											_		•			6.55					13.64			•		45.23	•
	80105108	AA166695	N69962	AA191437	H89505	N24829	AA609422	AA406248	NOABAB	N51682	AA406363	N25920	AA459944	AA406373	AA417940	AA194833	AA406233	N27366	R43755	AA411656	AA194941	AA443719	AA478106	H06249	N29817	AA424754	AA621224	AA452572	AA876021	AA443284	N66104	044762	A4452801	AA256176	R43008	AA452818	AA452822	R43020	AA402915	AA425664	AA452824	AA456093	AA452877	W51794	AA456635	AA773894	W72140	AA676466	AA773883	R44336	AA469383	AA149117	W04685
	417714	293690					743536																											681891								813513									843386		
	3000	13617	13627	13829	13832	13633	13636	2000	2000	286.	1364B	196.0	13655	13656	13667	13668	13872	13681	13687	13688	13892	13698	13699	13707	13713	13715	13726	13730	13732	13735	27.70	27.40	13754	13755	13758	13762	13770	13774	13775	13783	13786	13789	13794	13800	1380	1380	13808	13815	13820	13822	13823	13826	13832

Blood	Other	Other	Jung Buntle	Heart	UD not found	CID not lound	Manay Manay	Normely Other	Other	Luno	Breast	LID not found	Other	Other	,	CID not round	# F C	9	Other	LID not found	LID not found	CNS	Other	Caler	Kidney I ID an found	Other	Pancreas		Ovary	Pool	Sum :	Crug	Gall bladder	Brain	E ST	Other	Other		Other	Brain	Other	Other	O de c		Office for the factory	CID not round	Other	5 5
Pooled	LID not found Other	_	Whole embryolung		<u>8</u>			7	LID not found Other	Placenta		_	LID not found Other	LID not found Other	Ğ				LID not found Other	Pool		kin	LID not found Other	LID not found	Kidney	Whole embryoLID not found Other	ec Ear		Tonsil	yoColon	500	нови	Adinose		al cord	LID not found Other	_		LID not found	_	LID not found Other	LID not found Other	LD not found Other	LID not found Other		Long LD not found	LID not found Other	2
191,21 Stomach	Parathyroid	202.63 CNS		Pooled	245.05 Lung	Trostate	41 EE Company		522.76 Pool	277.57 Pooled	537.66 Nose		Testis	Eye	88.45	Otenus	Orerus	504.31	E, Se	347.96 Uterus	646.75 Uterus	7	76.07 Uterus	02.33 P00	Lymph	Whole embr	428.78 Head and nec Ear	529.13	Spleen	121.06 Whole embryoColon	71.14 Overy	240.37 Overy 162.07	575.4 Esophagus	Eye	316.2 Eye	Testis	Parathyroid	459.05	126.05 Brain	Parathyroid	743.9 Lung	229.98 Brain		ense.	40.00	495 58 Pool	455.09 Brain	
16		5			×		Ç	=	ø	. 5	n				-			N.T	•	15	4	12	×	£	Ā	?	5	s		<b>6</b>	77 5	2. <b>E</b>	m		₽			n	-		~	12				œ	. 67	•
0.00	3.00	2.00	1.00	0.00	00.0	8.5	8 5	3.5	000	8	00.0	0.00	0.00	000	6 6 8	9.5	3 5	8 8	00.0	1.00	0.00	0.00	3.00	8.6	8 8	0.0	0.00	4.00	0.00	8.6	0.00	0.00	2.00	0.00	0.0	0.0	2.00	1.00	8.	8.	8	8 8	3 5	3 5	3 5	3 8	0.00	•
9:	0.0	0.00	0.00	5.00	2.00	8 8	8 8	8 8	8 8	8	1.00	2.00	9.1	0.4	8 8	8 6	8.5	8 6	3.00	00'0	3.00	1.8	000	9.5	8.6	2.00	1.00	0.00	1.00	1.00	2.00	8 6	0.00	8.00	2.00	1.00	0.00	0.0	0.1	87	8.0	8 8	3 8	8 8	8 8	88	8	
6.01	8.09	6.20	5.69	23.85	8.97	0.70	6.03	20.0	80.8	7.81	8.62	8.12	6.17	8.53 5.53	6.53	5 44 8 44		32.5	6.21	9.0g	48.25	5.43	ر ال	0.10	9.47	5.99	5.22	9.27	6.83	13.68	4 5	13.85	8	12.83	8.0 20.0	5.48	6.67	5.28	6.22	125.57	5.99	7.65	9 6	11.87	7.5	89.0	11.40	
132.95	103.45	323.77	58.41	63.69	1879.75	98.20	108 48	22.25	41.85	1651.17	70.09	1402.32	5.95	77.47	153.04	014.04	148.88	57.25	24.42	54.09	254.25	1064.67	588.75	20.05	1093.12	5263.63	84.13	971.77	59.00	204.49	01.787.10	90.24 6608.43	962.04	38.08	26.83	44.32	449.68	157.14	33.82	920.13	1489.62	515.85	20.00	19. E	755.21	740.08	45.19	
22.14	12.79	52.25	10.26	99	209.53	67.03	21.60	22.60	8.20	211.35	8.13	172.73	8 0	80 G	23.43	187.46	21.41	10.77	3.93	8.89	5.27	185.98	<u>5</u>	34.21	118 80	878.64	16.12	88.89	9.79	14.97	86.12U	473.66	159.16	2.87	8.	9.11	67.43	29.77	5.44	7.33	248.86	67.40	2 2	18.25	20.52	78.46	3.96	3
AA152340	W16425	N34833	N76133	W20462	192200	AA 198281	AA009738	W23581	AA005135	AA487192	N23885	AA132524	AA406061	AA490058	N51030	AAD44741	AA012911	N53456	AA013353	AA121271	AA122079	AA485886	AA121518	N5/833	AA148978	AA460376	AA161161	AA487233	AA484522	AA126958	164604	N25650	AA424586	R42312	AA459983	AA609955	N90595	AA452125	H05535	R49597	N92804	R43026	940018	T96935	N98238	T89043	R40835	3000
566466	322447	276861	299459	327480	118049	927833	165508	327732	429050	841280	255285	587430	743030	839903	244194	487018	360177	245324	360355	490188	480434	840503	489931	26032	447,000	796095	592630	841474	810209	511833	22750	267864	767206	29920	796448	1031162	306276	786550	43532	37310	308820	3/8/8	1032046	121154	309119	122752	26737	
13842	13848	13855	3860	3880	13882	1888	3494	3896	13914	3916	13824	13825	13826	13927	13928	11046	13947	13952	13955	13957	13959	13983	13965	2060	13970	13980	13986	3968	3996	14005	976	4018	14028	14040	14047	14051	14058	14068	14072	4080	4082	14088	7007	14101	14108	4109	14112	

Page 63 of 91

*:*:

ì	i		
٠	į		
•	4		
4	۱		۱
Ì	Č		
	á	5	į

Tonsil	Prostate	Germ Cell	Piacenta	Ear	LID not found	. 🤄	Bloom White	Tonail	E CE	Olber Olber	Other	Kidney	Other	LID not found	LID not found		Other	Aorta	LID not found	Lung	Whole embryo	okidney	DID not round	Calga	Muscle	Other	1 Other	1 Other	Other		1 Diber	d Other	Teslis	d Other	d Osher	Dine.		LID not found	d Other			_	Right	Colon	d Other	d Oither	Library factories
Blood	P864		Liver	d Pancreas	Kidney	Cung .	Thurst in esture	Forestin	- Creskii	I Dank found Other	LiD not found Other	CNS	LID not found (	Kidney	Brain		Whose emeryoung	Umbilical cord Aorta	Heart	Aorta	Pooled	Whole embryokidney	000	Whole embroColon	Blood	LID not found Other	200	LID not found Dither	UD not found Other	Prostate	LID not found	LID not found	UD nos rouns	LID not found	Pool	LID not found	LID not found	Lung	. LID not found	is on	Head	LID not tound	LID not found Other	2			
	168.31 Parathyroid		395.51 Pooled	Salivary gland Pancreas	592.03 Pancreas			323.4/ CNS	Negot Contract Contract	145 08 Brain			Brain	Pool	410.63 Breast		MUSCH 957 OO LOOM		Kidney	504.11 Brain	83.98 Ear	Heart	SAS CNS	Sr4:08 Eye Pooled	200.65 Eye		CNS	37.19 Heart	Pool	190.28	Cy6 Testic	P. 00	Musdo	349.65 Eye	14.4 Pool	GEON GB	Eva Fva	Testis	57.43 Eye	250.6 Testis	120.04 Colon		121.77 Stomach	Sir.	Pool	245.06 Testis	
17	•	n	eo		^	,	~ ;	ç				•			6		đ		,	2	×		ç	2	e			22	;	5				4	₹ £	23			S	19	20	;	×			×	
0.0	80	00.0	0.0	800	0.00	200	8.6	8 8	8 6	9 6	8 6	8 6	800	2.00	3.00	98.0	8 8	8 8	00.0	0.00	1.00	0.00	8.6	3.00	00.0	8	0.00	0.00	8.	0.0	3 6	0.00	3.00	0.00	2.0	0.00	3.00	9.0	3.00	2.00	0.00	0.00	8 8	8 8	000	00.0	
<del>1</del> 8	700	9	1.00	8.00	2.00	86	20.5	8.8	8 8	8 8	8 8	8 8	8	0.0	0.0	8	8 8	8 5	8	8.	1.00	9.	0 0	8 5	8 8	0.0	<del>.</del> 8	8.	5.00	8.8	8 8	200	8.0	1.00	8.6	9 6	3 8	8 8	90.0	0.00	3.00	3.00	8 6	8 8	001	00.	
5.61	15.90	5.29	8.24	51.11	33.42	6.68	25,19	5.13	20.78	20.36 6 86	7 73	20.5	16.80	5.73	6.52	7.7	90.0	8.5	6.08	11.61	7.67	70.7	5.30	, o	. 4 4 - 4	5.27	22.72	6.21	5.36	1.25	9.04	6.16	10.37	5.46	9.22	6.88 6.48		5.85	9.74	5.40	10.13	7.39	19.6	6.74	6.4	5.72	
37.93	39.09	236.76	204.98	392.52	164.96	27.03	87.84	457.43	200	276.04	7.88	104.27	29.89	467.39	1424.49	9.56	1414.66	3930.43	43.30	71.52	83.68	35.24	542.72	1473.86	179.30	29.22	131.13	1041.92	189.93	19.6	102.0/ 44.05	48.95	103.98	182.38	301.43	1509.71	1472.70	68.92	556.26	82.28	12.98	51.88	231.39	920.17	41.25	921.82	
9.76	2.46	25. 24	32.83	7.68	4.84	8.0	3.49	69.12	0.75	10.64	20.0	20.80	1.79	81.52	218.35	1.24	155.88	307.67	7.12	. 8. 1. 8.	11.91	4.88	102.34	192.85	27.95	11.24	5.77	167.79	35.43	0.78	20.15	7.95	10.03	33.42	32.70	219.53	272.32	11.63	57.11	15.24	1.28	7.02	8	136.48	6.43	161.02	
AA406311	R66438	AA406201	AA406320	AA844818	AA844831	AA411204	AA844864	AA449362	AA411607	AA449481	F16096	A449490	H16179	AA424944	H16725	AA777551	AA132867	VV92313	W72870	AA129217	AA598640	W72920	N51585	AA467297	AA459964	N63516	N50702	W73597	AA002228	N73083	198355	T99243	AA426026	AA458674	H90407	N27837	AA459403	AA459649	AA167589	AA458689	AA133554	AA169173	AA047275	R06754	AAMARM AAMARM	AA459851	
754582					1412245							785913												838099																							
4129	4131	4137	14145	14156	14164	14169	14172	14174	14177	86	14191	14.19.8	14199	14205	14207	14208	14222	14232	14236	14238	14242	14244	14251	14254	14274	14295	14299	14300	14304	14307	14316	14324	14325	14328	14328	14331	14334	14357	14345	14350	14352	14353	14355	14356	14787	14374	

					Adrenal gland				Umbilical cord		<u>*</u>		<u>*</u>	-					_	_	Pancreas				_		_	tate					18	_		_	1081	LID not found	Pancreas	_		akin		c '	<b>u</b>			<b>&amp;</b>			72	-		Paramyroid	
	Office	Other	Other	Other		Other		<u>8</u>		Other	Kidney	Other	Kidney	Tons		o a	Aorta	Brain	Other	Othe	Pan	9	SS	9	0	C Brair	o o	Prostate	900			8	d Poor	000		8	Pag :	9	Par		9	Foreskin	SKI	5000	Broast			E E		,	Tous	Brain	Ovary	5	
	LID not found	UD not found	LID not found	LID not found	Gall bladder	LLD not found	LID not found	Heart	Skin	LID not found	Pancreas	LID not found	Liver	Ovany		LID not found Other	P801	Thyroid	LID not found	LID not found Other	Pooled	LID not found Other	Pooled	LID not found Other	LID not found Other	Head and nec Brain	LID not found Other	Blood	LID not found Other	Germ Cell		Brain	Umbilical cord Pooled	LID not found Other		Whate embryoLID not found Other	Umbilical cord Pancreas	Brain	Head and nec Esophagus	Head and nec Adrenal gland Brain	Pancreas		r Spleen	ver Tonsil	Gall bladder		:	Foreskin			Pooled	Parethyroid	Prostate	P)	
	697.77 Eye	Pop	75.2 Pool		589.13 Nose	CNS	Testis	Colon	Larynx	Testis	477.99	CNS	Brain	Pancress	19.39	355.78 CNS	247.58 Placenta	527.16 Neural	372.38 Pool	Overy	118.58 Thyroid		20.28 Thymus	450.16 Pool		271.39 Eye		472.27 Brain	628 Pool	639,11 Pooled		470.89 Uterus	84.72 Cervix	82.24 Brain	250.29	-	628.88 Adipose	Colon	Head and r	675.52 Head and n	37.19 Foreskin		422.75 Gall bladder		562.82 Adipose			217.43 CeNix			Neural	626.75 Eye		294.33 CNS	194.51
	e		7		-						•				9	ø	61	9	5		15		e	4		Ξ		ო	-	4		80	7	4	2		m			7	ឧ	8	œ	×	4		į	52				w	,	7	7
Table 2A	1.00	00.0	80	2.00	2.00	00.0	0.00	0.00	0.00	2.00	0.00	0.00	1.00	1.00	00.00	000	1.00	000	000	0.00	2.00	000	0.00	3.00	3.00	0.00	00.00	0.1	0.1	0.0	0.0	8.9	5.00	0.0	1.00	0.00	3.00	0.00	90.0	0.00	3.00	00'0	000	8	1.00	0.0	8:	000	00.0	2.00	8.	8	0.00	2.00	0.00
Tabl	8	4.00	0.1	8.	0.00	1.00	3.0	9.0	\$.00	0.00	2.00	8	8.00	8.00	1.00	1.00	00.0	00.1	8	1.00	000	2.00	1.00	0.00	00.	3.00	2.00	9.1	1.00	8	3.00	0.0	3.00	2.00	0.00	9.	<b>2</b> 7	8	3.00	8	0.00	5.00	9:	1.00	1.00	1.00	18.00	3.00	9	0.00	0.00	9.00	9:	0.00	2.00
	8	12.07	8.17	6.19	6.03	5.78	5.15	5.77	12.34	6.37	9.04	5.74	20.82	17.94	6.01	5.02	14.11	5.75	5,18	6.02	702	12.22	5.28	5.85	7.45	7.53	5.40	96 6	5.65	B. 15	12.59	6.91	19.10	44.61	5.31	6.83	79.13	6.62	7.22	8.86	6.54	12.07	5.67	7.81	.8.21	6.52	90.45	6.41	6.42	8.40	6.53	10.30	5.99	6.35	6.93
	2265.82	23.21	34.05	346.97	1681.08	31.91	26.38	282.39	71,10	163.18	183.14	32.63	96.62	107.04	53.68	830.04	132.05	45.38	21.75	665.02	731.42	82.04	203.49	180.33	72.82	79.67	4.90	15.24	2822.94	7.17	105.02	156.78	87.39	140.88	188.88	68.23	735.73	24.36	24.03	115.35	173.44	356.01	192.07	52.07	282.70	1482.41	1900.75	56.95	43.53	1387.94	132.57	258.12	78.61	1488.72	726.20
	374.87	8	5.52	56.06	278.83	5.5	5.12	48.96	5.78	25.62	22.78	5.72	4.75	5.97	8.83	185.50	9.38	7.80	4.20	110.50	104.16	6.71	38.85	32.56	9.78	10.58	0,91	1.53	499.66	0.88	8.34	22.68	4.57	3.15	35.57	8.89	9.30	3.74	3.33	13.03	28.52	29.49	32.72	6.67	84.48	227.49	21.01	88.8	6.78	165.20	20.32	24.85	13.11	234.02	104.73
	AA218047	N34042	R93409	AA219230	N30557	N52876	AA621294	AA195318	AA454654	AA453494	AA478596	N52935	AA455988	AA411685	AA194993	NS2938	R96522	R45517	N33610	AA454616	AA418603	AA455130	AA185080	N54061	AA478717	AA412417	AA457576	R4447	N54274	R59473	AA449832	AA256464	AA187143	R44409	AA458854	AA449847	AA181023	R44428	AA598507	W72310	AA459949	R45114	AA026605	AA455882	AA055440	AA778392	AA775618	AA455980	AA708301	AA709143	AA455994	R43798	AA165313	AA483249	AA488646
	629885	244050	197102	629907	257170	283819	744611	665316	811907	795376	753633	283682	812074	753376	665379	283888	199635	33329	243477	811503	752636	809883	685445	247285	753596	731469	838776	34869	247898	37823	788641	682072	624744	34745	811983	788687	625011	34866	897768	345077	796395	34901	366518	812012	377468	378955	378461	812053	1155071	385003	812069	32300	594693	797057	643251
	14389	14395	14.386	14397	14401	14421	14422	14428	14431	14434	14435	14437	14439	1444D	14444	14445	14445	14463	14465	14466	14467	14474	14478	14477	14480	14486	14480	14491	14493	14495	14498	14499	14500	14502	14505	14506	14308	14510	14511	14512	14522	14528	14528	14529	14536	14544	14552	14569	14580	14584	14585	14590	14600	14818	14820

Page 65 of 91

2	
ъ	
8	
8	
æ	

Other	Parathyroid Whole embryo		LID not found	Prostate	Other		•	LID not found	Parathyroid	Whole embryo	Hear	Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Office Of	5	Q.ber		Uterus	Other	Other	Other	Forestan	Testis	Brain	Whole embryo	Aorta	Pancress	Pool	Whole empryo	200	1 Other		UD not found	d Other	Other	LID pot forms	Other	d Other	Gall bladder	LID not found	d Other	Hear	I ID not found	d Other	Foreskin	Brain	d Other	d Other	LID not found	Pancreas .
LID not found Other	Parathyroid		Pod	Pooled	LID not found	eThyroid	LID not found	Foreskin	Muscle	Foreskin	Colon Heart	Lib not found Other		LID not found Other		Prostate	LID not found Other	LID not found Other	LID not found	Pooled	Uterus	Dog.	Kidney	Blood	Prostate	Ovary	105(15	Brod	LID not found Other		Testis	LID not found Other	LID not found Other	Drain	LID not found Other	LID not found Other	пеАфрозе	Prostate	LID not found Other	Muscle Heart	Pancraae	LID not found	Placenta	Pancreas	LID not found Other	LID not found Other	P80	Dem Cell
Pancreas	433.36 Esophagus	246.58	148.92 Lung	Stomach	<b>8</b>		98.66 Lung	ran i	173.27 CNS		123.62 Placenta	545.25 CNS		Testis			Pung	Lung	Colo	330. t9 CNS	Cer <del>z</del>	Çeve	654.24 CNS	277.15 Cervix	327.49 Skin	Testis	Mense	22 62 Pancrese	149.53 Lung	719.04	Muscle	347.4 Heart	Hs.163751 Pool	o de activado	esorte .	385.62 Pool	110.93 Small intestineAdipose	Brain	200	151.92 Foreskin Toelie	21 19 Rrain	Foreskin	840.93 Perathyroid	96 Parathyroid	CNS	Pod	88.95 Brain	Pooled
	က	12	7				22	1	es :	×	<del>,</del>	<b>.</b>	0							12			e	=	8			=	m	-			680.45 H			a	2		;	<b>*</b>	•	•	រេ	4			7	
2.00	5.00	0.00	2.00	0.00	0.00	0.00	0.00	8	0.00	8	0.6	0.00	3 5	8 0	0.00	0.00	0.00	0.0	0.00	0.00	0.00	9 6	8	1.00	0.00	0.00	8.8	8.6	8	2:00	0.00	90	0.0	3.5	3 8	3.00	2.00	0.00	2.00	5.00	8 8	3 0	000	00.0	0.0	8.	0.00	000
1.00	0.00	1.00	0.00	9.00	9.	1.00	8.	2.00	2.00	9.	0.00	8.8	9 6	8 8	8	8.1	2,00	2.00	2.00	8.1	6.00	9.5	8	00.0	4.00 00.4	2.00	0.00	00.4	8.8	1,00	<del>.</del>	0.00	8.8	9 6	8 8	000	0.00	1.00	0.00	000	2.00	200	8	2.00	1.00	0.00	1.00	8
17.72	8.47	6.40	10.49	21.76	6.11	6.09 9	5.18	5.78	7.82	5.72	5.01	200	. c	90.9	11.62	5.23	7.32	7.61	5.29	6.54	13.36		5.62	6.48	7.38	10.85	9.86	22.62	5.11	19.8	5.69	6.78	5.24	0.10	2.75	6.92	5.97	6.55		ន្ត	0.20	8 6	11.20	32.25	5.55	6.14	5.91	10.03
216.57	1953.21	3028.61	398,16	426.06	111.38	193.81	55.94	1407.07	45.88	1763.62	140.21	132.91	93.04	33.55	179.89	172.99	45.03	1177.04	130.91	65.30	61.72	59.84	49.54	150.88	337.10	45.21	56.30 20.00	75.85	128.29	1531.72	239.38	342.75	1258.08	62.04 4.05 4.05 4.05	540 10	211.52	1025.19	26.62	1211.40	1740.75	32.30	2126 96	61.73	354.13	45.40	449.88	22.23	70 KK
7.82	230.65	473.36	37.94	19.58	21.78	31.84	10.71	243.53	5.87	308.13	27.97	24.91	10.20	5.55	15.48	33.07	6.15	154.78	24.74	9.99	4.62	8.14	8.82	23.27	45.68	4.24	9,45	20.39	25.12	177.91	42.08	50.53	240.13	12.17	59.73	30.57	171.67	4.06	207.89	211.56	3.5	300 1R	7.30	10.98	8.17	73.32	3.78	707
W31919	AA432081	AA608729	AA128462	AA120868	AA47476	AA173411	T94556	N84145	AA437089	N35894	AA151917	N39603	T07034	A4435988	AA443978	AA056484	AA485869	AA485969	AA053682	AA598983	AA488604	191098	AA128318	AA172039	R81831	AA412443	AA460669	AA487501	AA486858	R00130	AA609310	W23441	R06860	W32192	K455/9	R08260	N25657	R49650	N54925	W58308	MAD21/01	NOSTA	R27619	R42056	N40180	R16983	R59355	NAMON TO
328287	784142	950924	565110	490965	784272	595200	119330	285760	757337	272552	566501	277083	121580	730742	757205	489109	840470	840514	510397	897722	843056	111735	564898	594946	147834	731445	786227	839C3	841016	122872	1031580	327748	126549	321310	124111	127192	267865	37367	244859	340737	1030633	265845	133647	31564	276387	128777	37814	236470
14624	14628	14636	14644	14654	14659	14662	14666	14875	14679	14684	14686	14687	14504	14702	14704	14715	14719	14727	14729	14731	14735	14736	14749	14755	14760	14766	14770	14772	14775	14784	14793	14794	14797	14802	14808	14613	14814	14816	14817	14818	44614	14824	14826	14832	14833	14837	14840	44845

Other	<del>GPe</del>	Whole embryo	<u>8</u>	į	Caper	8	5 E E	Testis	8		Eye	Other		LID not found	Esophagus	Kidney	Ovary		Colon	Other	Cervix	CID not found	Other	Other	Foreskin	oPod		Ovary	O the	Prostate	e de	Tonsi	CID not round	OCVBRY	S S		Olher		Other	Whole embryo	Other	Other	Prostate	Other	Hear	Other		LID not found	Pancreas	Other	Testia	Breast	
LID not found Other	LID not found Other	Pancreas	Невп		CIU not tound Other	estis	/oHeart		CNS	;	Tonsi	LID not found Other		50	Smooth muse Esophagus	Pool	Synovial mem Overy		Brain	LID not found Other	Blood	Brain	LID not found Other	LID not found Other	Pooled	Whole embryoPool		Placenta	LID not found Other	Testis	LID not found Other	Prostate	Hear	Whole embryoOvary	Lib act found Other	I ID not found Other	LID not found Olhe		LID not found Other			LID not found Other	Ear	LID not found Other	Colon	LID not found	LID not found	Eye	Colon	LID not found Other	Overy	Testis	
CNS	Testis	231.66 Thyroid	Uterus		lesus	Brain	357.95 Whole embryoHeart	12 Thyroid	683.81 Gall bladder	,	SNS	29.21 Brain		<b>8</b>	276.5 Marrow	Parathyroid	319.81 Esophagus		Testis		Layux	Testis	Brain	309.19 Brain	Adipose	23 Musde		39 Lung	Testis	Germ Cell	8	SNO		440.21 Cervix	Tage 7	Heart	482.18 Pool		CNS	05 Smooth muse	S6 Nose	Pool	461.43 Eye	128.34 Ovary	53 Pancreas	37 Eye	09 Pool	426.28 Tonsil	Stomach	Testis	Cerx	Cerx	
		231.6		245.08			367.8	577.82	683.6			29.			276		319.8			43.69				8		209.23		53.69				, ,	182.95	246.021	210.03	,	482			366.05	445.66		461	128	98.53	301.37	627.09	428					
		4		×		•	on (	~	^			~			7		×			4				ø		m		†				:	<u> </u>	m >	< 5	2	17	:		17	4		က	7	17	4	90	16					
8:	0.00	9.1	0.00	0.00	8.5	0.00	000	00.0	8	000	8	8	8	2.00	2.00	9.	0.0	0.00	0.00	0.00	8	0.00	0.00	0.00	8.	9.	0.00	0.00	8:	0.0	0.0	0.00	200	8.8	8 8	8 8	000	0,1	1.00	1.0	000	000	0.00	1.00	0.00	2.00	0.00	0.00	2.00	1.00	0.00	0.00	000
0.00	9.	0.00	7.00	2.00	8.0	3.00	00.	<del>.</del> 8	1.00	<b>5</b> .8	8	8:	5.00	8	8	0.00	200	3.00	2.00	8	0.00	5.00	1.00	8.	000	00.0	5.00	4.00	2.00	3.00	5.00	9 6	0.00	9.6	3.5	8 8	8	2.00	000	0.00	1.00	2.00	1.00	0.00	2.00	0.00	1.00	2.00	16.00	0.0	3.00	<del>.</del> 8	28
5.70	98.9	12.29	80 96.94	7.60	8	8.24	6.48 84	2	6.90 6.90	6. 16	6.69	5.23	6.60	10.28	14.59	5.28	5.89	6.19	6.02	5.01	58.58	7.02	5.56	5.25	6.32	5.08	8.94	9.26	6.89	7.43	7.15	6.05	6.32	5.80 5.93	13.03	5.46	7.40	6.18	50.0	9.80	6.74	8.14	6.05	8.0	5.54	7.60	5.13	6.23	19.86	5.02	11.73	8. 8.	8.28
89.85	43.04	101.29	67.51	4144.44	69.08	16.57	59.24	62.82	59.29	35.34	179.72	586.02	366.48	124.06	495.07	41.85	224.00	16.03	21.44	171.71	280.19	272.37	14.11	3511.35	66.32	16.48	89.27	105.55	879.81	43.08	1430.28	57.47	156.07	1540.53	145.78	33.18	118.08	1984.75	151.32	207.35	6391.17	2.4	19.72	185.56	117.03	237.88	3660.65	729.33	166.58	32.60	233.32	61.19	184 56
15.78	6.27	8.24	7.55	545.65	7.78	2.01	9.14	9.44	10.04	5.74	26.86	114.02	55.57	12.07	33.94	7.93	37.40	2.59	3.56	34.27	4.95	38.81	2.54	668.79	10.49	3.25	8.83	11.40	127.67	5.80	200.05	9.51	24.68	265.59	8 9	2 8	15.86	321.40	30.08	21.18	947.84	5.52	3.26	36.84	21.11	31.32	713.98	88.62	8.38	6.49	19.89	5 8	22 22
N63520	AA820359	T86932	W67536	W67368	AA620669	R51514	AA449321	N48050	AA448853	AA704255	AA398365	R61700	AA707321	AA424537	AA694557	AA424534	AA857131	AA778919	AA388267	R61187	AA857101	AA199668	R61231	R61297	AA495835	AA448855	AA705112	AA424562	AA398285	W72671	AA001879	N50740	W74257	AA588947	W35636	W73904	AA001924	H69691	N64198	AA446661	N23717	AA004887	AA491457	AA169840	AA143467	AA219172	H72232	AA481788	AA171760	AA431210	AA172056	AA621291	H72279
278137	1030959	115277	343174	343235	1049168	38887	785694	281659	786053	450574	726695	42302	451504	787113	1416762	767128	1434948	452588	726709	42330	1434905	647444	42860	42452	768417	788154	482595	767178	726731	345761	427677	283744	348368	898050	35821/	261824	427897	212784	277871	784183	255295	428592	639527	594063	591814	629994	213484	638853	594684	782171	594758	744605	214AR2
14849	14851	14852	14858	14868	14867	14872	14976	14878	14902	14904	14906	14907	14912	14913	14916	14921	14924	14828	14830	14931	14932	14935	14947	14955	14857	14958	14988	14969	14970	14982	14984	14987	14998	14998	15004	1501	15018	15038	15039	15040	15046	15048	15055	15073	15084	15085	15087	15101	15113	15114	15121	15133	15140

Page 67 of 91

705057	4 4 4 5 0 4 4 7	0 8.3	£1 1;	CC 3	2	٤		•	oction .		
2000	740044	9 6		9 6	3 8	3 8	•	33 4 6	Supposite Dans	Dooled	Breact
345711	W/1884	18.21	753.65	0	3	3	-		yroylal man	B :	בומפות
290227	N62271	86.33	506.21	5.46	8.8	000		U	CNS	Tonsil . L	LID not found
609950	AA174106	5.49	30.43	5.54	5.8 8.8	0.00		ш	Eye	LID not found	Other
782489	AA431771	62.94	340.33	5.41	9.	0.0		-	Testis	LID not found Other	Other
288961	N62712	27.25	139.37	5.11	9.	00.0	7	424.67 C	CNS	LID not found Other	Other
566440	AA148862	21.48	150.63	7.01	2.80	0.00	7	487.5 S	tomach	Uterus	Musde
838478	AA457517	38.98	285.88	7.93	2.00	0.00	•	437.97 \$	salivary gland	Adipose	CNS
897422	AA489463	24.33	173.86	7.15	0.00	1.00	4	85.75 C	SNS	Spleen	Lung
27404	R40031	3.13	16.85	5.42	2.00	0.00	7	672.07 G	672.07 Germ Cell Eye	Eye	
753626	AA478952	11.24	57.94	5.15	1.00	8.0	81	96.61 P	pajoo	Foreskin	P80
796328	AA461317	128.49	683.48	5.32	000	1.80	×	245.06 C	CNS	Whole embryo	Whole embryol ID not found
814286	AA458993	8.18	43.55	5.32	1.00	800	-	15.07 N	Neural	Pooled	Placenta
753388	AA410345	18 00	85.86	5.37	100	000		14.		Pancreas	Kidney
245883	N55361	140.20	742.30	5.29	100	000	v	337.25		CNS	Tonsil
753684	AA408588	17.20	93.81	5.45	000	8	Ξ	339.35 Placenta		Parathyroid	Foreskin
813169	AA456318	14.56	80.68	3	9	000		_		Kidney	
752825	AA419608	24 BB	180.85	727	9	8	60	65.2 F	65.2 Parathymid	Nose	CNS
241747	NABBED	27.02	192.04	7.11	000	901	4	179.2 Pool	boot	LID not found	
22222	1157403		1 2 2		\$	2		16467	N.C.	Pund too CI	Ş
175117	705/CN	77.	1.5.7	36.0	3 8	3 6	,		200		5
76/082	AA424511	7.82	77.44	900	3 6	9.6			5 9		5 6
277039	N38577	8	329.80	2	0.00	3.5	,		2	בישפו זפת כוט	j :
665385	AA195021	55.28	280.51	5.07	0.00	8	17	403.8	Pancreas	Cervix	Umbilical cord
726483	AA389269	38.53	317.18	8.23	0.0	8.		_	Jens	Pool	LID not found
247177	N57506	14.34	133,20	9.29	1.00	8.		_	lool	Pool LID not found Other	Q.her
788155	AA461090	200.57	1105.18	5.51	5.00	2.00		-	Whole embryo	ALID not found	Q, Per
812098	AA456001	7.45	89.03	11.96	2.00	0.00		-	Cidney	Germ Cell	Qan
187814	R83757	9.04	76.31	8.44	3.8	000	4	623.42	Umbilical cord Germ Cell	Germ Cell	Foreskin
1091543	AA599311	325.85	2096.08	6.43	8	8.0	9	349.34	Skin	Cervix	Bone
35147	R45550	10.94	67.12	6.14	8	1.00	7	554.03	Brain	LID not found	
813719	AA453779	12.45	1464.63	117.63	11.00	8.		-	Muscle	Heart	estis
35812	R45627	242.87	1224.71	5.04 40.0	8	0.00	×	246.7	Brain	Lung	LID not found
768421	AA49583B	21.43	159.27	7.43	0.00	2.00		_	<u>8</u>	LID not found	Qhe.
35729	R45692	4.13	25.72	6.23	1.00	0.00	-	633.69	Lung	Brain	LID not tound
1459234	AAB65729	11.33	137.74	12.15	1.0	0.00	×	83.98	Skin	Germ Cell	Colon
812172	AA456036	10.8	50.35	6.29	8.	0.00			Tonsil	Testis	<u>8</u>
813748	AA453802	0.73	8.15	11.15	8.	0.00					
812175	AA456044	9.40	73.50	7.82	9.	<b>4</b> .00			Foreskin	Pool	LID not found
214006	H70775	16.72	138,19	8.26	3.8	0.00	æ	104.03			
626348	AA188853	11.81	225.11	19.06	3.00	1.00	~	653.71 Cervix	Cervix	Placenta	Pancreas
266697	N22897	248.28	1302.54	5.25	2.00	0.00		_	Foreskin	LID not found Other	Other
300024	N78903	16.17	26.19	5.07	0.00	1.00	-	174.53	174.53 Umbilical cord Ear	Ear	Thymus
321958	W37733	122.09	1402.23	11.48	0.0	5.00	<b>\$</b>	102.24	102.24 Parathyroid	LID not found Other	Other
289168	N68970	56.84	462.61	8.14	0.00	2.00	×	245.08	CNS	LID not found Other	Other
841670	AA487563	14.61	95.54	6.54	0.00	4.00			Lung	Tonsil	LID not found
627401	AA190825	6.03	115.98	19.22	9.8	0.00	S	481.83	481.83 Lymph nods	Head and nec CNS	CONS
254562	N23651	9.45	74.55	7.89	1.00	0.0			Nose	Aorta	Heart
291691	N73011	28.77	302.80	10.53	0.00	8	19	157.82	157.82 Foreskin	Spleen	Adrenal gland
322926	W45025	480.32	2443.33	5.00	0.0	9.	60	474.75		Whole embry	Whale embryoLID not found
488499	AA047462	34.02	205.07	6.03	0.00	9.	5	460.41	460.41 Placenta	CNS	Bone
592771	AA15994	8.15	37.15	6.04	1.00	0.00			Larynx	Pancreas	Blood
282475	N49850	31.20	235.84	7.54	8.0	8.	•	670.02 CNS	CNS	<u>P</u> 00	LID not found
323269	W42746	6,70	34.87	5.20	0.0	1,00			CNS		Ovary
305481	N88912	67.0	67.03			•				•	
		2	0	200	00.0	3			Parathyroid	<u>₹</u> 85	Hear

Page 68 of 91

-
œ
ซี
8
986

	LID not found Other	ole embryoUterus	Pancreas Parathyroid	P	LID not found Other	576	Uterus LIID not tound	LID not found Other	CIO POST SQUIPE COLORER			Foreskin Whole embryo	_		ses		0	yrogo	Brain Breast	Heart IIO not found	formal	D not found Other	estis Pool	found t	Brain Testis	5	Lung Breast	ID not found Other	CONTROL OF STATE OF S	Control of the Contro	LID not found Other	LID not found Other	ID not found Other	forug	Breast Urenus	ID oof found Other	LID not found Other	Adrenal gland Eye	<u>c</u>	Ear Cervix	Parathernia Luna				8	=	Ē	Testis LID not found	Testis Eye	LID not found Other
	142.28 CNS LID	201.92 Adrenal gland Whole embryoUterus	Colon Pan	_	Eye		Aorta	Lung		CNC Hear		Aorta	Parathyroid	356.18 Pool Brain	Adipose	е ешблуо		Hreast		SOLUTION NO. 1	•	-	2	_	Germ Cell		Brain		100 FOC.	l look	8	s	_			245 TB Prod	Lung		Ignore		Lestis Lit	•	Anda		Esophagus	CNS	247.78 Skin Ac	Lung		CNS
	-	4		7		6		₽ '	n		;	<u>-</u> ×	:	æ		×			<b>∞</b> (	0	. •	-		9	ø		ର :	=	٤	3 \$	:		-		;	<u>.</u> ≻	; <del>5</del>	-		~				×	. 22	į	8		4	
Table 2A	1.00	8	000	8 0	2.00	0.00	2.00	0.00	2.00	8 8	8 8	900	1.00	3.00	0.00	0.0	1.00	8	0.0	00.5	90.0	8 6	86	200	0.00	0.00	0.00	8 5	00.4	9.5	300	00.0	1.00	2.00	0.0	B 8	8.8	1.00	1.00	0.00	0.0	3.6	8 6	0.0	000	8.	8.	000	1.00	1.00
Tak	000	000	9 6	200	0.00	8.	8.8	2.00	0.0	8 8	9 6	3 8	8 8	8	2.00	1.00	9.0	9.	8	8 8	3 6	9.0	8 6	8	8	1.00	1.0	9.5	0.00	8 8	8 8	8	0.00	1.00	8 8	2.00	8 8	0.0	5.00	5.00	8.8	0.0	8 6	3 8	9	8 8	8	8	0.0	0.0
	5.37	4	2 5		7.49	6.48	10.14	10.14	7.71	7.19	, .	÷ ;	6 4 95	11.30	7.31	5.74	7.42	5.45	6.48	E .	9.40	7.00	0.0	7	7.13	7.09	5.38	5.08		90.9	7.81	6.24	6.38	7.63		6.17	2 99	9.24	10.29	5.49	6.11	7.48	11.11	35.00 cr a	12.38	11.68	7.59	9.86	5.78	5.75
	281.82	30 62	27.74	418.62	62.29	164.28	212.25	59.67	587.63	205.12	131.83	26.52	96.90 P 97	1539.66	255.97	2.97	75.93	6957.63	209.42	229.05	255.62	803.60	30.44	123.02 RSG 78	25.47	576.55	38.27	4242.62	442.67	173.65	320 75	8.88	300.26	107.83	69.74	2400.79	582.11	85.92	77.58	235.28	1202.45	168.50	23.83	457.14 38.88	117.89	102.95	38.68	200.56	36.00	290.69
	141 95 7						20.94		_			95.6				0.52							B0.01								20.54						93.00		7.54			22.33	2.15	13.06	6.67	8.82	80.5	20.35	6.22	50.58
	NAROOT	N50001	AA131240	AA413407	AA487301	R33363	AA131450	AA133385	AA056383	AA598515	W73781	AA487505	AA133390	B01179	AA158352	AA446866	H60899	AA166743	R61377	N68389	W81229	R58013	K99082	VV80185	R42143	H91680	H06380	R91401	R00311	AA233070	VV33407	AA620783	N93853	AA620794	AA436460	R97240	19/8/A	R60981	AA916728	AA424675	AA206914	AA418402	R81886	AA418392	K61003	AA418408	R61289	AA131315	AA398341	N51601
	00,4000	676087	503383	98008	839009	135811	503675	565683	509463	897773	344108	839048	911216	127735	591116	784216	208686	583838	37671	292389	347472	138281	201422	416309	30459	241705	44303	195988	123326	666492	415163	106937	309224	1055487	753038	200417	108102	42415	1473690	767236	648046	767259	43065	767262	71877	767273	43080	567055	726821	281545
	16466	200	200	2450	2 2	15472	15475	15477	15481	15484	15487	15503	15509	15674	15531	15533	15536	15547	15568	15569	15570	15573	15577	155/8	15592	15583	15600	15613	15617	15623	15625	15627	15630	15635	15636	15637	15645	15675	15678	15689	15695	15697	15699	15713	15723	15729	15733	15735	15738	15783

	Other	Placenta	LID not found		Other	Germ Cell	Other	Other	Office		LID not found	Whole embryoLID not found	Whale embryoLID not found	Tonsi	LID not found	LID not found	Musde	Other	Nose	Other	LID not found	Cervix	LID not found	Kidney	Eye	Tonsil	Testis		LID not found		Lýmpn Lýmpn		SNA	Adrenal gland	LID not found	<u>8</u>	Uteres		. (		LID not found	LID not found	Other	Other	Parathyroid	Aorta	ocoion	Stomatic Control	Storing	Testis	Other	Brain	Stomach
	LID not found Other	Colon	Breast	Quid	LID not found Other	Eye	LID not found Other	LID not found Other	LID not found Other		oPool	Whole embry	Whole embry	CNS	Неал	Ovary	Bjood	LID not found Other		LID not found Other	Colon	Synovial mem Cervix	Eye	Pooled	d CNS	yoTestis	Muscle	Foreskin	Prostate	CIU not found		Kidooy			Testis	CNS	Placenta		CNS	LID not found Ulber	SC CNS	Pool	LID not found Other	LID not found Other	Pooled		Whole embryocolon	Dogogo	randeas	CNS	LID not found Other	Testis	Pancreas
	Pool	300.32 Cervik			283.48 Eye	114.62 Tonsii	CNS	CNS	Pool	188.13	Whole embryoPool	Muscle	162.07 Blood	45 Kidney	Cervix	732.12 Parathyroid	Pooled	-2.94 Eye	118.59 Adrenal gland	Pool		17.22 Thymus	Cenix	Skin	Adrenal gland CNS	Whole embryo Testis	Bone	217.43 Thyroid	219.18 Testis		43/.61 Spieen	Coon	810.42 Gall bladder		Lung		438.03 Spleen	133.06		355.Z9 P00	Smooth muse CNS	Testis	Pool	Pool	Ear	Slomach	Parathyroid	222.80	206 78 Whole embookideeu	88.99 Colon	Pod	500	Poded
		•	۰ ۵	I	vo	€0				9			91	5		n		9	9		<del>1</del> 9	<b>‡</b>					į	5 3	14	,	•	ų	<u>.</u>	•		×	-	7	,	n							;	=	>	< ×	c		
¥2	000	86	9	2.00	0.00	0.0	5.00	0:00	0.00	0.00	0.00	<del>1</del> 00	28	1.00	0.00	2.00	0.0	0.00	0.00	5.00	2.00	8.	2.00	0.00	0.00	0.00	0.00	00 1	8	8.5	0.00	0.00	8 6	2.00	3.00	0.00	0.00	0.00	0.00	0.00	2.00	0.00	8.8	3.00	9.	5.00	8:0	3 6	8 6	3 8	8	3 8	9.6
Table 2A	100	8 6	800	8	5.00	2.00	2.00	1.00	3.00	2.00	9.	0.00	1.00	0.00	2.00	0.00	1.00	2.00	1.00	0.00	0.00	0.00	0.0	0.0	9.1	1.00	9:	0.00	8	8	2.00	6.00	9 5	8 8	0.0	6.00	1.8	1.00	3.00	2.00	00.0	1.00	0.00	0.00	0.0	0:00	8.6	3 6	9.6	00.0	8 6	60.0	14.00
	5.62	20.4	7.07	66.5	6.16	6.65	11.91	5.13	8.89	5.73	10.23	17.10	5.82	5.73	9.15	6.24	5.32	6.47	18.68	13.14	5.83	6.46	8.28	6.70	6.16	5.35	25.10	5.77	8.04	5.46	6.65	21.31	9.0	5.58	6.47	13.89	5.97	5.13	11.68	5.75	5.96	6.40	69.9	7.67	8 8	5.38	7.45	9.5	9.75	87.78 E0.8	S 93	, e	29.75
	301.85	201.02	282.31	802.08	500.26	101.73	250.86	36.46	44.59	125.16	105.79	147.49	890.95	124.24	1467.32	251.92	88.22	2332.06	121,39	667.01	1721.92	107.12	139.16	146.53	74.83	86.33	185.46	406.39	937.30	48.09	35.15	9928.18	25.67	1685 70	578.60	189.67	89.67	3258.35	495.61	489.82	377.14	68.83	<b>94.75</b>	275.50	71.01	252.45	196.86	20.22	244.02	34.58	137.42	148.71	189.68
	53.69	AB 20	39.65	133.96	81.15	15.29	21.06	7.10	5.01	21.85	10.34	8.83	153.08	21.67	160.45	40.35	16.60	360.37	7.28	50.76	287.42	16.59	16.80	21.89	12.17	16.15	7.39	70.39	116.62	4	5.29	465.83	76.13	30.186	89.47	13.56	15.03	635.67	42.42	85.25	63.28	10.75	14.17	35.90	13.41	47.10	26.41	3.85	37.70	67.7 88.6	25.80	24.00	6.71
	AAMOTROB	AAAABEG	WB7424	N52039	H85434	H64793	N52337	N64762	AA010611	N49717	AA463221	AA176506	AA443695	N56892	AA179392	AA464972	AA609473	AA434482	N22033	T95320	W15284	AA443958	AA191493	AA435985	N48593	AA461091	AA620697	AA809463	AA437124	T98287	AA410383	AA100874	AMBZUBBB	AA488658	AA620628	AA193579	AA417994	AA621381	AA479362	NS8276	N40211	AA608824	N68578	H77814	AA478982	AA453435	AA452802	R459/0	AA863464	K303U3	AA455041	AA425418	AA872020
	429447																																	843276																86707			1475859
	15788																																												16008	16019	16031	16046	16055	10000	18085	46067	16071

Page 70 of 91

	Foreskin			bring found	Foreskin		LID not found		Blood	LID not found Dither	a Lymph	Whole embryoPool	LIO not found Other			CID not loung		Whole embro	Pool	Whole embryoParathyroid	LID not found		Kidney	Kidney	found Other	Lung		In mat foring Other	10 not found Other	Hear	LID not found Other	LID not found Other	o de		8 5	LID not found	.ID not found Other	n Whole embryo	LID not found Other	Adrenal gland Tonsil	mbryoUterus	CID room round	CID not round Other		found Other	found Other	found Other	found Other	ID not found Other	
	vroid Placenta		2	Hrain Arain	1		Brain		Calon	LID not		Whole e	_		Serm Cell	100			Color		mbryo	d Placenta		Gall bladder Testis			Esophagus			. –	_	_			_	Pool	_			ğ		rdmy.				LID not found	LID not found	_	TID UOT	
	197.2 Parathyroid	499.2 Brain	4:50	511.72 Parcress	162.89 Blood		Tonsil		374.6 Ear	333.64 Nose	Pooled	CNS	45.93 Parathyroid	•	111.13 Таутиз	. Č	14 94 Pooled	146 O1 Anda	358.37	703.17 Thymus				108.43 Gall b	CNS	Uterus	44.4 Neural	245.07 245.08 Tocie	32.73 Pool	Ulerus	379.83 Poot	316.02 Coton	390.78 Ear		167.12 Pandeas	263.38 Tonsil	103.38 Testis	Aorta		102.53 Gall b	233.5 Pooled	Eye	8 1	10 to Testis	Pool	227.19 Pool	271.02	130.93 Brain	153.98 Pool	74.75 Breast
	8	4	•	7	. ~				11	<b>4</b>			<b>=</b>		•		8	-	. 60	8		11	8	w		•	φ •	- >	٠ -	•	5	11	₩	•	- •		· 40			11	7			ď	•	5	6	7	-	×
90.0	000	8 8	3 5	8 5	1.00	00.0	0.00	0.0	0.00	0.00	0.00	1.00	1.00	0.00	000	9.0	8 6	00 6	9 4	0.00	0.00	1.00	2.00	2:00	0.00	0.00	0.00	8 6	8.0	00.1	3.00	1.00	0.0	0.00	8 8	8 8	8.9	0.00	1.8	0.0	800	8 6	3.00	8 6	8 5	2.00	0.0	1.00	0.0	1.00
1.00	-	• •			000				1.0						8 :						•	0.00										0.00														8 6				800
8.78		•					-									54.7		A 28									5.63									32 6.10							6.11						92 5.16	
83.64					-					_					69.65	·											649.50		8034					0 854.15		48.28		••					3274.86							
	200				4 25.90					231.79						·			72 117.75			12.54										50 6.24											8.5				322.08			
AA70194					AA49704	AA70297													AA132172													AA132660				R86198	AA4014;	W93544	H78411	AA0648	AA461490	A44817	R00835	1001444	TAARGE	R89471	W42450	R42218	H63241	H04789
7 435934		·		•		0 447167																										892.288				081187 SI					13 796871				74 68734		323041	••		51 43733
1607	16079	9		9 6	16117	1812	1612	1812	1613	1613	1613	1614	1614	1615	161	101	101	1810	1620	1620	162	1620	1621	162	162	162	162	201	16.24	1626	1626	16269	162)	162)	162	16283	162	163	1630	<u>1</u> 83	2	9	16316	3 6	18324	<u> </u>	16326	3	\$	18351

5
ð
2
99
_

			λυν σ					punc	bring				oid						puno			ž	3		_		прпуо		Duno				found			7		ğ										
Other	Oher	<u>8</u>	LID not found	Other	Lung	Kldney	Brain	LID not found	LID not 1	Other	Prostate	Pool	Parathyroid	8 8	Pacel	Brain	Brain	_	LID not found	Bone	8 6	Darathumid	Foreskin	P 80	Foreskin		Whole embryo	Hear	LID not found	Other	Coto	Brain	OLID not	- Po	000 1	P80    15 m		Paralhyroid	Ovary	Other		Kdney				Blood	Placente	. Other
LID not found Other	LID not found	מית	arPool	LID not found Other	Pool		ner Adipose	Pool	Whole embryoLID not found	LID not found Other	Whale embryoProstate	Brain	Foreskin	Lung	Probled	Whole embryoBrain	Spleen	LID not found	Pool	SNS.	Lung Pool	Solomon Country	yoColon	gun	Pooled	LID not found	Testis	Prostate	Lestis	L1D not found	Tonsil	Colon	Whole embryoLID not found	Heart	Stomach	Breast	Dog.	Thyroid	Eye	LID not found	Qvary	Parathyroid	Dan ferral	Eve inc.	i i	Pancreas	<b>UneAorta</b>	LID not found
101.02 Pool	449.86 Brain	Colon	Peripheral ner Pool	8	92,24 Placenta	714.07 Foreskin	Pertpheral	421.53 Heart	Eye	Brain	485.68 Pooted	Kidney	39.72 Thyroid	143.02 Thyroid	IOUSII 47 03 Ear	Luno	201.74 Foreskin	Tesús		282.85 Ear	Kidney	Contract	Whole embryoColon	Pancreas	42.61 Skin	443.42 Pocl	144.58 Pancreas	Color	Colon lestis	209.24 Pool	Testis	191.7 Kidney	Colon	875.72 CNS		105.6 Lung	S F	427.01 Eye	Biood	361.52 Pool	Marrow	Spleen	15.76 Pooled	545 43 CNS	201.71		391.77 Small intestine Aorta	340.75 CNS
-	0				5	8	~	'n			e		æ	n	,	•	7			5					17	5	~			2	ı	-		7	,	•		12		40		,	٠ ;	<u> </u>	4	5	n	-
2.00	000	000	00	2.00	2.00	1.00	0.00	0.00	1.00	0.00	2.00	0.00	0.00	0.00	9 6	8 8	8 2	0.00	0.00	9.0	8.8	8 6	20.5	3.00	0.00	4.00	0.00	0.00	8 8	8 8	000	00.0	0.00	8	8	9 6	9 6	0.00	0.00	0.00	0.00	0.00	8.5	9.5	0,1	00'0	8.	2.00
0.00	5.8	1.00	1 00	000	1.00	00.0	2.00	2.00	0.00	8.	0:00	2.00	1.00	8:	8 6	8 8	800	1.00	1.00	4.00	8.5	8 8	3 8	8	2.00	0.00	1.00	9:0	8 8	8 8	8	9.	1.00	3.00	0.00	9.5	9.6	0.0	1.00	2.00	9.00	2.00	8 8	8 8	8	3.8	0.00	0.0
6.03	5.62	5.71	10.80	5.28	6.31	6.37	5.62	6.41	6.13	5.88	8.21	6.48	5.47	5.73	6.14 4.14		5.42	98.9	<b>6</b> .08	87.85	5.48	13.36	9 60	7.70	9.58	8.48	8.58	47.84	6.26	10.42	5.30	8.60	5.58	6.61	8.77	7.12	_ «	5. 5 16	6.75	5.77	12.13	13.12	8.24	0.0	6.96	29.62	12.80	5.42
487.59	378.58	48.45	728.00	842.34	89.83	25.85	20.46	58.99	111.38	18.33	1224.89	50.13	129.22	97.62	17.38 27.38	67.80	63.87	241.60	31.53	148.03	15.78	78.61	564 13	813.61	68.47	359.85	70.07	257.50	48.12	145.88	32.75	74.17	74.39	58.86	448.96	72.54	334.37	44.26	106.92	3692.85	99.35	116.50	42.86	27.76	176.24	336.28	224,18	1299.90
80.90	67.34	848	67.42	159.60	14.23	4.06	364	9.20	18.17	3.29	149.27	7.74	23.63	17.05	2.63		11.78	38.84	6.19	1.68	2.88	9.67	81.87	105.64	7.15	42.58	8.18	6.41	7.37	00.45	6.17	7.72	13.38	16.8	51.18	10.19	30.86	8.58	15.85	639.84	8.19	8.83	5.20	15.34	25.24	12.54	17.51	240.04
H66122	R61821	R45832	AA002258	H81938	H06282	H99362	R60014	AA425056	AA452118	R60135	AA452130	AA598594	AA452134	R60044	AA810225	AA45750	AA588625	AA398355	AA425543	R61372	190789	AA388430	AA386879 AA481318	N53670	AA460961	W86445	N62652	AA055788	AA 100283	NR2474	AA412047	AA088231	AA443712	H82435	AA464698	AA487468	W84656	AA486538	AA427737	N83777	AA443140	AA496884	AA151621	KO1246	R23270	AA426025	R92801	N46353
233942	42331	35820	42777R	238943	44092	262262	42803	768596	786534	42807	786537	898204	788545	42816	1367900	78853	898227	726858	768961	37980	111489	728889	796330	247840	786117	416644	292531	510578	51 1080	202122	729956	511117	784032	240148	810217	641621	415/12	840837	770854	293058	796723	897 587	503234	280010	131452	757244	197056	279308
16357	16375	18400	16402	16405	16408	16409	16415	16421	16430	16435	16438	16439	18454	16467	16472	27.70	16479	16482	16485	16499	16500	16508	16514	16547	16562	16588	16611	16612	16815	18810	16620	16821	16634	16638	16637	16638	16644	16851	16655	16859	16669	16678	16879	16684	16899	16701	16703	18713

100   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0					۰										0																	_																					
MACRISTATION         66.21         44.93.99         6.4.4         0.00         3.00         CHARSAN           AAF17812         16.24         4.93.99         16.45         1.00         0.00         CATTIC           AAF17812         16.30         16.35         17.75         1.00         0.00         7         6.14.90           AAF17812         16.30         17.35         1.00         0.00         7         6.16.49         CATTIC           AAF4181         11.98         1.32.75         1.00         0.00         7         6.16.49         CATTIC           AAF4182         11.98         5.37         1.00         0.00         7         7         6.16.49         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00	1 Other	Othor	ies o	Other		d Other	Bone		1 Other	<b>B</b>	Other	Heart	Other	OLID not found	Whole embry	Other		Breast	Pool	Tonsi		Other	oPool	P80	Lung	Breast	Other	LID not found	į	Other	Eve a	Whole embry	Gall bladder	Parathyroid	Testis	Other	:	LID not found	e ka	למיומי לימי כון ו	Colon	LID not found		Muscle	Whole embryo	Testis	Kidney		LID not found	LID not found	250	ja 1	S. Par
AMATORIS 1         64.2   438.99         6.45   100         0.00         7         616.49           AMATORIS 2         6.8   6.84   488.99         6.45   100         0.00         7         616.49           AMATORIS 3         6.86   6.80   118.23         1.77   10.00         0.00         7         616.49           MAATORIS 3         6.84   6.90   10.00         0.00         0.00         0.00         7         616.49           AAATORIS 3         6.84   6.90   10.00         0.00         0.00         0.00         0.00         0.00           AAATORIS 3         6.18   6.91   10.23         1.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00	LID not found	I ID not found	L'O not tour	היים זים ניים	Heart	LiD not found	Pancreas	Prostate	LID not found	yoTestis	LID not found	Lymph	LID not found	Whole embry	Bone	LID not found		roBrain	Heart	Broast		LID not found	Whole embry	Foreskin	Blood	Brain	LID not found	<u>8</u>		LID not found	Germ Cell	Pooled	d Germ Cell	CNS	Kidney	LID not found		8 8	of them is	Testis	Pancress	Testis			n Perathyroid		Testis	LID not found	Heart	Kidney	LIC not round	CIU POLISUIS	LID not found Other
AAGD0823         64.21         438.98         6.45         0.00         3.00           AAAGD0823         10.34         438.98         6.45         1.00         0.00           AAAGD0823         10.34         118.25         1.00         0.00         0.00           AAAGD083         118.35         11.25         2.00         0.00         0.00           AAAGD08         4.34         1.00         0.00         0.00         0.00           AAAG1801         5.32         1.13         2.00         0.00         0.00           RAAAG1801         5.18         2.33.77         1.00         0.00         0.00         0.00           RAAAG1807         5.18         2.00         0.00         0.00         0.00         0.00         0.00           RAAAG200         2.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00	Testis	CNS	2 0	ž Če Če	Adipose	6.49 CNS	0.52 Ear	1.89 Brain	Eye			0.72 Pancress	Brain	Neural	7.29 Thyroid			4.01 Whole embry	5.35 Kidney	4.38 Placenta		Brain	Brain	Kidney	50.5 CNS	3.05 Germ Cell		Kidney		vos orain						Brain			3.56 Synovial mer	Hear	.96 Testis	CNS	.03					ъ. 6	ē,	lests Pool			Testa
AA608923         68.21         439.89         6.45         0.00           AA7197344         69.6         10.34         183.72         1.70         AA7197344         69.6         118.63         13.25         1.00           AA7197243         6.96         118.63         13.25         2.00           AA478913         10.36         6.36         5.91         1.00           AA478923         1.03         6.34         5.91         1.00           AA478924         1.21         4.71         2.22         1.00           HORZ66         1.21         4.00         1.028         2.00           R46354         4.74         2.4.86         5.21         1.00           R46357         4.74         2.4.86         5.21         1.00           R46357         4.74         2.4.86         5.51         1.00           R46357         4.74         2.4.86         5.27         1.00           R46357         4.74         2.4.86         5.27         1.00           R46357         4.74         2.4.86         5.27         1.00           R46357         4.74         2.4.86         6.8         1.00           AA470336         4.35 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>ନ -</td> <td></td> <td>2 7</td> <td></td> <td></td> <td></td> <td></td> <td>3 12</td> <td>1 17</td> <td></td> <td>7</td> <td>3 15</td> <td>0</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>ç</td> <td>67 71</td> <td></td> <td>2 741</td> <td></td> <td>36\$ 9</td> <td></td> <td>_</td> <td></td> <td>_</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								ନ -		2 7					3 12	1 17		7	3 15	0									ç	67 71											2 741		36\$ 9		_		_						
AA608923         68.21         439.89         6.45         0.00           AA7197344         69.6         10.34         183.72         1.70         AA7197344         69.6         118.63         13.25         1.00           AA7197243         6.96         118.63         13.25         2.00           AA478913         10.36         6.36         5.91         1.00           AA478923         1.03         6.34         5.91         1.00           AA478924         1.21         4.71         2.22         1.00           HORZ66         1.21         4.00         1.028         2.00           R46354         4.74         2.4.86         5.21         1.00           R46357         4.74         2.4.86         5.21         1.00           R46357         4.74         2.4.86         5.51         1.00           R46357         4.74         2.4.86         5.27         1.00           R46357         4.74         2.4.86         5.27         1.00           R46357         4.74         2.4.86         5.27         1.00           R46357         4.74         2.4.86         6.8         1.00           AA470336         4.35 <td>8</td> <td>8</td> <td>8 8</td> <td>3 3</td> <td>8 8</td> <td>8 :</td> <td>8:</td> <td>8 :</td> <td>8</td> <td>2</td> <td>8</td> <td>8</td> <td>8</td> <td>8</td> <td>9</td> <td>2</td> <td>2</td> <td>2 2</td> <td>2 2</td> <td>2 2</td> <td>. 8</td> <td>8</td> <td>Q</td> <td>2</td> <td>9</td> <td>2 9</td> <td>2 9</td> <td>2 9</td> <td>. 0</td> <td>9</td> <td>Q</td> <td>9</td> <td>0</td> <td>0</td> <td>0</td> <td>0 (</td> <td><b>.</b></td> <td><b>.</b></td> <td><b>.</b></td> <td><b>.</b></td> <td></td> <td></td> <td>0</td>	8	8	8 8	3 3	8 8	8 :	8:	8 :	8	8	8	8	8	8	8	8	8	8	8	2	8	8	8	8	9	2	2	2 2	2 2	2 2	. 8	8	Q	2	9	2 9	2 9	2 9	. 0	9	Q	9	0	0	0	0 (	<b>.</b>	<b>.</b>	<b>.</b>	<b>.</b>			0
AA608923         68.21         438.88         6.45           AA197244         68.40         488.88         117.76           AA197249         8.96         118.83         13.25           AA478678         8.96         118.83         13.25           AA478673         8.36         11.88         5.67           AA478673         10.80         63.85         5.91           AA481801         51.84         259.87         22.23           AA481801         51.84         259.87         22.23           AA6527         2.20         12.08         5.51           R65537         2.20         12.08         5.51           R40357         2.20         12.08         5.51           R40357         2.20         12.08         5.51           R40377         35.87         23.63         5.27           R40377         35.87         23.63         5.27           R40377         35.87         23.63         5.27           R40377         35.87         24.86         6.06           R40377         35.87         24.86         6.06           R40377         35.87         24.33         5.27           R408																																																					
AA608923         68.21         439.89           N46845         10.34         183.72           AA197844         89.6         118.83           N63528         A.36         14.13           AA478619         8.96         118.83           NA478623         4.36         118.83           AA478639         10.80         63.85           AA47865         12.14         100.01           N64024         53.28         74.13           R85537         4.74         24.86           R40552         2.20         12.08           R405537         4.20.29         2362.88           R405537         4.20.29         2363.89           AA4786537         4.20.29         2363.89           AA4786537         4.20.29         2363.89           R405537         4.20.29         2363.89           AA4786537         4.20.29         2363.89           AA4786537         4.20.29         2363.89           AA4786537         4.20.29         2363.89           AA470352         8.36         37.54           AA470352         8.16         4.20           AA470350         8.16         3.03           AA4				•																																																	
AA608923 A66.21 AA6845 AA1848 AA1844 86.40 AA478618 8.96 N63528 A.36 R4443 11.88 AA481801 51.84 H08266 12.14 N64024 4.74 R49552 2.20 R40357 420.29 R40357 420.29 R40357 420.29 R40357 15.3 H1884 5.2 R40867 8.16 AA777637 35.87 R40868 AA48899 AA776339 81.62 AA777637 10.81 AA65829 4.23 AA683602 66.53 H19687 8.16 AA68899 11.62 AA68899 11.62 AA68899 11.63 AA68999 11.63 AA68999 11.63 AA68899 11.63 AA6889		•																																																			
AA608923  M46845  M46845  AA478618  N63528  AA478623  R54443  AA478623  R64443  AA48624  R40357  R40367  R40367  R40967  R409633  AA486984  AA486993  AA704922  AA419492  AA419492  AA419492  AA419492  AA416541  AA416442  AA416442  AA416442  AA416442  AA416444  AA416441  AA41644  AA416441	•																																																				
10305 27817 827817 27810 27810 28308 33030 18017 18017 18017 18039 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 2800 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28030 28																																																					
16728 16739 16739 16739 16739 16739 16739 16830 16830 16850 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859 16859																																																			-		

1ge 73 of 91